<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>BioLens — Biopharma Intelligence</title>
<link href="https://fonts.googleapis.com/css2?family=DM+Sans:wght@400;500;600;700&family=Fraunces:wght@600;700&display=swap" rel="stylesheet">
<style>
:root{--bg:#f7f9fc;--surface:#fff;--border:#dfe4ed;--text:#1a1e2e;--text-muted:#6b7280;--accent:#2563eb;--accent-light:#eff4ff;--money-green:#0d7c5f}
*{margin:0;padding:0;box-sizing:border-box}
body{font-family:'DM Sans',sans-serif;background:var(--bg);color:var(--text);line-height:1.5}
.header{background:linear-gradient(135deg,#1e3a5f 0%,#2d5f8a 40%,#3b7cb8 100%);color:#fff;padding:28px 40px 24px}
.header h1{font-family:'Fraunces',serif;font-size:26px;font-weight:700;letter-spacing:-.5px}
.header p{font-size:13px;opacity:.7;margin-top:4px;max-width:960px;line-height:1.6}
.controls{padding:16px 40px;display:flex;flex-wrap:wrap;gap:10px;align-items:center;border-bottom:1px solid var(--border);background:var(--surface)}
.search-box{flex:0 1 220px;min-width:140px;padding:9px 13px;border:1.5px solid var(--border);border-radius:8px;font-size:13px;font-family:inherit;background:var(--bg);transition:border-color .2s}
.search-box:focus{outline:none;border-color:var(--accent)}
.stats{margin-left:auto;font-size:12px;color:var(--text-muted);font-weight:500;white-space:nowrap}
.reset-btn{padding:8px 14px;border:1.5px solid #e5383b;border-radius:8px;background:#fff5f5;color:#c62828;font-size:11px;font-weight:600;font-family:inherit;cursor:pointer;transition:all .15s;white-space:nowrap}
.reset-btn:hover{background:#fde8e8;border-color:#c62828}
.msel{position:relative;display:inline-block}
.msel-btn{padding:8px 28px 8px 10px;border:1.5px solid var(--border);border-radius:8px;font-size:12px;font-family:inherit;background:var(--bg) url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='12' height='12' fill='%236b7280'%3E%3Cpath d='M2 4l4 4 4-4'/%3E%3C/svg%3E") no-repeat right 8px center;cursor:pointer;white-space:nowrap;user-select:none;transition:border-color .2s;max-width:200px;overflow:hidden;text-overflow:ellipsis;display:block}
.msel-btn:hover,.msel-btn.open{border-color:var(--accent)}
.msel-btn .cnt{display:inline-block;background:var(--accent);color:#fff;border-radius:10px;font-size:9px;font-weight:700;padding:1px 5px;margin-left:4px;vertical-align:1px}
.msel-drop{display:none;position:absolute;top:calc(100% + 4px);left:0;z-index:500;background:var(--surface);border:1.5px solid var(--border);border-radius:10px;box-shadow:0 12px 32px rgba(0,0,0,.12);min-width:240px;max-height:380px;overflow:hidden;flex-direction:column}
.msel-drop.open{display:flex}
.msel-search{padding:8px 10px;border-bottom:1px solid var(--border)}
.msel-search input{width:100%;padding:6px 8px;border:1.5px solid var(--border);border-radius:6px;font-size:11px;font-family:inherit;background:var(--bg)}
.msel-search input:focus{outline:none;border-color:var(--accent)}
.msel-actions{display:flex;gap:0;border-bottom:1px solid var(--border);font-size:11px}
.msel-actions button{flex:1;padding:7px;border:none;background:none;cursor:pointer;font-family:inherit;font-size:11px;font-weight:600;color:var(--accent);transition:background .15s}
.msel-actions button:hover{background:var(--accent-light)}
.msel-actions button+button{border-left:1px solid var(--border)}
.msel-list{overflow-y:auto;flex:1;max-height:300px;padding:4px 0}
.msel-item{display:flex;align-items:center;gap:8px;padding:5px 12px;cursor:pointer;font-size:12px;transition:background .1s;user-select:none}
.msel-item:hover{background:#f7f9fc}
.msel-item.hidden{display:none}
.msel-cb{width:16px;height:16px;border-radius:4px;border:1.5px solid var(--border);display:flex;align-items:center;justify-content:center;flex-shrink:0;transition:all .15s;font-size:10px;color:#fff}
.msel-item.checked .msel-cb{background:var(--accent);border-color:var(--accent)}
.msel-label{flex:1;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}
select.filter{padding:9px 28px 9px 10px;border:1.5px solid var(--border);border-radius:8px;font-size:12px;font-family:inherit;background:var(--bg) url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='12' height='12' fill='%236b7280'%3E%3Cpath d='M2 4l4 4 4-4'/%3E%3C/svg%3E") no-repeat right 8px center;-webkit-appearance:none;cursor:pointer;max-width:190px}
select.filter:focus{outline:none;border-color:var(--accent)}
.pager{display:flex;align-items:center;justify-content:center;gap:6px;padding:16px 40px;border-top:1px solid var(--border);background:var(--surface)}
.pager button{padding:6px 14px;border:1.5px solid var(--border);border-radius:6px;background:var(--surface);cursor:pointer;font-family:inherit;font-size:12px;font-weight:500;transition:all .15s}
.pager button:hover:not(:disabled){border-color:var(--accent);color:var(--accent)}
.pager button:disabled{opacity:.35;cursor:default}
.pager button.active{background:var(--accent);color:#fff;border-color:var(--accent)}
.pager-info{font-size:12px;color:var(--text-muted);margin:0 8px}
.pager select{padding:5px 8px;border:1.5px solid var(--border);border-radius:6px;font-size:12px;font-family:inherit;background:var(--bg);cursor:pointer}
.table-wrap{padding:0 40px 0;overflow-x:auto}
table{width:100%;border-collapse:separate;border-spacing:0;margin-top:12px;font-size:13px}
thead th{position:sticky;top:0;background:var(--surface);padding:11px 10px;text-align:left;font-weight:600;font-size:10.5px;text-transform:uppercase;letter-spacing:.5px;color:var(--text-muted);border-bottom:2px solid var(--border);cursor:pointer;white-space:nowrap;user-select:none;z-index:10}
thead th:hover{color:var(--accent)}
thead th .sa{margin-left:3px;font-size:9px}
tbody tr{transition:background .15s}
tbody tr:hover{background:#f5f7fb}
tbody td{padding:9px 10px;border-bottom:1px solid #eef1f6;vertical-align:middle}
.cc{display:flex;align-items:center;gap:6px}
.cn{font-weight:600;font-size:13px;color:#1e3a5f;max-width:180px;overflow:hidden;text-overflow:ellipsis;white-space:nowrap;cursor:pointer;text-decoration:underline;text-decoration-color:transparent;transition:text-decoration-color .2s}
.cn:hover{text-decoration-color:#1e3a5f}
.li{display:inline-flex;align-items:center;justify-content:center;width:18px;height:18px;border-radius:3px;background:#0a66c2;color:#fff;font-size:9px;font-weight:700;text-decoration:none;flex-shrink:0;transition:background .15s}
.li:hover{background:#004182}
.badge-e{display:inline-block;padding:1px 5px;border-radius:3px;font-size:8px;font-weight:700;background:#eff4ff;color:#2563eb;text-transform:uppercase;letter-spacing:.3px;vertical-align:2px;margin-left:3px}
.tag{display:inline-block;padding:2px 6px;border-radius:4px;font-size:10px;font-weight:600;white-space:nowrap;margin:1px 1px}
.tc{max-width:170px;line-height:1.8}
.tt{background:#f0edff;color:#5b4fc4}
.tm{background:#e8f4fd;color:#1a6eac}
.td2{background:#fef3e2;color:#b45309}
.money{font-weight:600;color:var(--money-green);white-space:nowrap}
.mn{color:var(--text-muted);font-size:11px}
.date{font-size:11px;color:var(--text-muted)}
.pb{font-size:10px;padding:2px 6px;border-radius:4px;font-weight:500;white-space:nowrap}
.phl{background:#e0f5ef;color:#0d7c5f}
.phm{background:#fff8e1;color:#f57f17}
.phe{background:#fafafa;color:#757575}
.loc{font-size:12px;color:var(--text-muted);white-space:nowrap}
.dc{cursor:pointer;border-radius:4px;transition:background .15s;position:relative}
.dc:hover{background:#f0f3f8}
.dh{display:none;position:absolute;bottom:0;right:3px;font-size:7px;color:#ccc;font-style:italic}
.dc:hover .dh{display:block}
.po{display:none;position:fixed;top:0;left:0;width:100%;height:100%;background:rgba(0,0,0,.35);z-index:1000;backdrop-filter:blur(3px)}
.po.a{display:flex;align-items:center;justify-content:center}
@keyframes su{from{opacity:0;transform:translateY(20px) scale(.97)}to{opacity:1;transform:translateY(0) scale(1)}}
.pp{background:var(--surface);border-radius:16px;box-shadow:0 25px 60px rgba(0,0,0,.2);max-width:640px;width:92vw;max-height:85vh;overflow-y:auto;animation:su .25s ease}
.ph{padding:24px 28px 16px;border-bottom:1px solid var(--border);display:flex;align-items:flex-start;justify-content:space-between;gap:16px;position:sticky;top:0;background:var(--surface);border-radius:16px 16px 0 0;z-index:2}
.pt{font-family:'Fraunces',serif;font-size:22px;font-weight:700}
.ps{font-size:13px;color:var(--text-muted);margin-top:4px;line-height:1.5}
.px{width:32px;height:32px;border-radius:8px;border:none;background:var(--bg);font-size:18px;cursor:pointer;display:flex;align-items:center;justify-content:center;color:var(--text-muted);flex-shrink:0}
.px:hover{background:#eee;color:var(--text)}
.pa{display:flex;gap:8px;margin-top:10px;flex-wrap:wrap}
.pl2{display:inline-flex;align-items:center;gap:5px;padding:7px 12px;border-radius:6px;background:#0a66c2;color:#fff;font-size:11px;font-weight:600;text-decoration:none}
.pl2:hover{background:#004182}
.pl2 svg{width:13px;height:13px;fill:#fff}
.pw2{display:inline-flex;align-items:center;gap:5px;padding:7px 12px;border-radius:6px;background:var(--accent);color:#fff;font-size:11px;font-weight:600;text-decoration:none}
.pw2:hover{background:#1d4ed8}
.pse{padding:16px 28px}.pse+.pse{border-top:1px solid #eef1f6}
.pst{font-size:11px;text-transform:uppercase;letter-spacing:.5px;font-weight:600;color:var(--text-muted);margin-bottom:10px}
.meta-grid{display:grid;grid-template-columns:1fr 1fr;gap:8px 20px}
.meta-item{font-size:12px}
.meta-label{color:var(--text-muted);font-size:10px;text-transform:uppercase;letter-spacing:.3px}
.meta-val{font-weight:600;margin-top:1px}
.pi{display:flex;align-items:center;gap:10px;padding:6px 0;border-bottom:1px solid #f5f7fb}.pi:last-child{border-bottom:none}
.pn{font-weight:600;font-size:12px;flex:1;min-width:0;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}
.pind{font-size:11px;color:var(--text-muted);flex:1;min-width:0;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}
.di{padding:8px 0;border-bottom:1px solid #f5f7fb}.di:last-child{border-bottom:none}
.dhl{font-size:12px;font-weight:500;line-height:1.4}
.dm{font-size:11px;color:var(--text-muted);margin-top:3px}
.fi{display:flex;align-items:center;gap:12px;padding:6px 0;border-bottom:1px solid #f5f7fb}.fi:last-child{border-bottom:none}
.fa{font-weight:600;color:var(--money-green);font-size:13px;min-width:70px}
.fd{font-size:12px;color:var(--text-muted)}
.fv{font-size:11px;color:var(--text-muted);margin-top:2px;line-height:1.3}
.tr{display:flex;flex-wrap:wrap;gap:5px}
.mb2{display:none;position:fixed;z-index:1001;background:var(--surface);border-radius:12px;box-shadow:0 12px 40px rgba(0,0,0,.18);max-width:420px;width:90vw}
.mb2.a{display:block;animation:bp .2s ease}
@keyframes bp{from{opacity:0;transform:scale(.92)}to{opacity:1;transform:scale(1)}}
.mbh{padding:14px 18px 10px;border-bottom:1px solid var(--border);display:flex;justify-content:space-between;align-items:center}
.mbt{font-weight:700;font-size:13px}.mbc{font-size:11px;color:var(--text-muted)}
.mbx{width:24px;height:24px;border-radius:6px;border:none;background:var(--bg);font-size:14px;cursor:pointer;display:flex;align-items:center;justify-content:center;color:var(--text-muted);flex-shrink:0}
.mbx:hover{background:#eee}
.mbb{padding:12px 18px 16px;max-height:300px;overflow-y:auto}
.mbe{font-size:12px;color:var(--text-muted);font-style:italic;padding:8px 0}
.mscrim{display:none;position:fixed;top:0;left:0;width:100%;height:100%;z-index:1000}.mscrim.a{display:block}
@media(max-width:768px){.header,.controls,.table-wrap,.pager{padding-left:16px;padding-right:16px}.ph,.pse{padding-left:20px;padding-right:20px}}
</style>
</head>
<body>
<div class="header">
  <h1>BioLens <span style="font-family:DM Sans;font-weight:400;font-size:14px;opacity:.5;letter-spacing:1px;vertical-align:3px">BIOPHARMA INTELLIGENCE</span></h1>
  <p>2,433 US companies &middot; Preclinical+ &middot; 293 with deal &amp; financing intel &middot; Click any company to explore</p>
</div>
<div class="controls">
  <input type="text" class="search-box" id="search" placeholder="Search company...">
  <div class="msel" id="mselTA"></div>
  <div class="msel" id="mselDG"></div>
  <div class="msel" id="mselMod"></div>
  <select class="filter" id="fPhase">
    <option value="">All Phases</option>
    <option value="marketed">Marketed / Approved</option>
    <option value="late">Late (Ph III+)</option>
    <option value="mid">Mid (Ph I–II)</option>
    <option value="early">Early (Preclinical)</option>
  </select>
  <select class="filter" id="fMoney">
    <option value="">Any Funding</option>
    <option value="financed">Has Financing</option>
    <option value="deals">Has Deals</option>
    <option value="both">Both</option>
    <option value="enriched">Enriched Only</option>
  </select>
  <div class="msel" id="mselState"></div>
  <div class="msel" id="mselCity"></div>
  <button class="reset-btn" id="resetBtn" title="Reset all filters">&#x21BA; Reset</button>
  <div class="stats" id="stats"></div>
</div>
<div class="table-wrap">
<table>
  <thead><tr>
    <th data-col="company" data-dir="asc">Company <span class="sa">&#x25B2;</span></th>
    <th data-col="_ta" data-dir="asc">Therapeutic Areas <span class="sa"></span></th>
    <th data-col="_dg" data-dir="asc">Disease Focus <span class="sa"></span></th>
    <th data-col="_mod" data-dir="asc">Modalities <span class="sa"></span></th>
    <th data-col="mostAdvanced" data-dir="asc">Phase <span class="sa"></span></th>
    <th data-col="nProducts" data-dir="desc">Pipeline <span class="sa"></span></th>
    <th data-col="totalRaised" data-dir="desc">Financing <span class="sa"></span></th>
    <th data-col="latestFinDate" data-dir="desc">Last Fin. <span class="sa"></span></th>
    <th data-col="totalDealValue" data-dir="desc">Deal Val. <span class="sa"></span></th>
    <th data-col="latestDealDate" data-dir="desc">Last Deal <span class="sa"></span></th>
    <th data-col="state" data-dir="asc">State <span class="sa"></span></th>
    <th data-col="city" data-dir="asc">City <span class="sa"></span></th>
  </tr></thead>
  <tbody id="tbody"></tbody>
</table>
</div>
<div class="pager" id="pager"></div>
<div class="po" id="popupOverlay"><div class="pp" id="popup"></div></div>
<div class="mscrim" id="miniScrim"></div>
<div class="mb2" id="miniBubble"></div>
<script>
const DATA=[{"company": "1200 Pharma LLC", "city": "Pasadena", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "UCT-000445", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=1200%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "13therapeutics Inc.", "city": "Portland", "state": "OR", "country": "United States", "diseaseCats": ["Infectious", "Inflammation", "Otologic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "P13", "phase": "Preclinical", "indication": "Otitis media"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.13therapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=13therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "180 Therapeutics L.P.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "adalimumab", "phase": "Phase II", "indication": "Dupuytren disease"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.180therapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=180%20Therapeutics%20L.P.", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "2m Biotech L.P.", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Macrocycle", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CBR-2092", "phase": "Phase I", "indication": "Bacterial infection"}, {"name": "P7C3A20", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.2mbiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=2m%20Biotech%20L.P.", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Neurodegeneration / NMD"]}, {"company": "2x Oncology Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "2X-111", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://2Xoncology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=2x%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "4d Molecular Therapeutics Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Ophthalmic", "Pulmonary"], "modalityGroups": ["Gene Therapy"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "4D-150", "phase": "Phase II", "indication": "Diabetic macular edema (DME)"}, {"name": "4D-125", "phase": "Phase I/II", "indication": "Retinitis"}, {"name": "4D-310", "phase": "Phase I/II", "indication": "Fabry disease"}, {"name": "4D-710", "phase": "Phase I/II", "indication": "Cystic fibrosis (CF)"}, {"name": "4D-110", "phase": "Phase I", "indication": "Blindness"}, {"name": "4D-175", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "4D-725", "phase": "Preclinical", "indication": "Alpha-antitrypsin (AAT) deficiency"}], "ceo": "David H. Kirn, MD", "employees": 227, "founded": 2013, "website": "http://www.4dmoleculartherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -99804362.63, "evFmt": "", "ticker": "FDMT", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0.0, "totalDealFmt": "", "latestDealDate": "2024-01-03", "recentDeals": [{"headline": "4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases", "date": "2024-01-03", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=4d%20Molecular%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Ophthalmology", "Rare / Genetic"]}, {"company": "4m Therapeutics Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "4MT-01", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "4MT-02", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "4MT-03", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.4mtx.net/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 1400000.0, "totalRaisedFmt": "$1M", "latestFinDate": "2022-03-08", "latestFinType": "Seed financings", "nRounds": 1, "recentFinancing": [{"type": "Seed financings", "amount": "$1M", "date": "2022-03-08", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=4m%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "60 Degrees Pharmaceuticals Inc.", "city": "Washington", "state": "DC", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Arakoda", "phase": "Marketed", "indication": "Malaria"}, {"name": "60P002", "phase": "Phase II", "indication": "Dengue fever"}, {"name": "60P001", "phase": "Phase I", "indication": "Dengue fever"}], "ceo": "Geoffrey S. Dow, PhD, MBA", "employees": 3, "founded": 2010, "website": "http://www.60degreespharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 9186964.9, "evFmt": "$9M", "ticker": "SXTP", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-04-08", "recentDeals": [{"headline": "Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health", "date": "2025-04-08", "value": ""}, {"headline": "Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention", "date": "2024-12-23", "value": ""}], "totalRaised": 1755000.0, "totalRaisedFmt": "$2M", "latestFinDate": "2022-05-19", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$2M", "date": "2022-05-19", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=60%20Degrees%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "7 Hills Pharma LLC", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "7HP349", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.7hillspharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=7%20Hills%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "7 Oaks Phamaceutical Corp.", "city": "Easely", "state": "SC", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Bensal HP ointment", "phase": "Marketed", "indication": "Wounds"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.7oakspharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=7%20Oaks%20Phamaceutical", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "858 Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ETX-19477", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "858 Therapeutics-ADAR1-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "858 Therapeutics-METTL3-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "858 Therapeutics-QPCT/L-unknown", "phase": "Preclinical", "indication": "Atherosclerosis"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://8five8tx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 50000000.0, "totalRaisedFmt": "$50M", "latestFinDate": "2024-06-26", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$50M", "date": "2024-06-26", "investors": "Avidity Partners, Insight Partners, Mirae Asset Capital, Alexandria Venture Investments LLC, Versant Ventures, New Enter..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=858%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Solid Tumors (General)"]}, {"company": "9 Meters Biopharma Inc.", "city": "Raleigh", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune", "Gastrointestinal"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "NM-003", "phase": "Phase I/II", "indication": "Short bowel syndrome"}, {"name": "NM-004", "phase": "Phase I", "indication": "Ulcerative colitis"}], "ceo": "Jason Thomas Serrano", "employees": 0, "founded": 2012, "website": "https://9meters.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "NMTR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=9%20Meters%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "A2 Biotherapeutics Inc.", "city": "Agoura Hills", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "Tmod program 3", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "A2B530", "phase": "Phase I/II", "indication": "Colorectal cancer"}, {"name": "A2B694", "phase": "Phase I/II", "indication": "Mesothelioma"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.a2bio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=A2%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "A28 Therapeutics Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Peptide"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AT-101 (EP-100)", "phase": "Phase II", "indication": "Ovarian cancer"}, {"name": "AT-201 (EP-200)", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "AT-301 (EP-300)", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "AT-401 (EP-400)", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://a28therapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=A28%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "A2a Pharmaceuticals LLC", "city": "Chappaqua", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AA-001", "phase": "Preclinical", "indication": "Gram-negative bacterial infection"}, {"name": "AA-002", "phase": "Preclinical", "indication": "Gram-negative bacterial infection"}, {"name": "AO-002", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.a2apharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=A2a%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)"]}, {"company": "A6 Pharmaceuticals", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "A6-5188", "phase": "Preclinical", "indication": "Respiratory distress syndrome (RDS)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.a6pharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=A6%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Aardvark Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "ARD-101", "phase": "Phase III", "indication": "Genetic disorders"}], "ceo": "Tien Li Lee, MD", "employees": 22, "founded": 2017, "website": "https://aardvarktherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "AARD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aardvark%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Aavogen Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Musculoskeletal"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AVGN7", "phase": "Preclinical", "indication": "Cachexia"}, {"name": "AVGNF", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://aavogen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aavogen", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Obesity / Metabolic"]}, {"company": "Abata Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "ABA-101", "phase": "IND", "indication": "Multiple sclerosis (MS)"}, {"name": "ABA-201", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://abatatx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abata%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "MS / Neuroimmune"]}, {"company": "Abbott Laboratories", "city": "Abbott Park", "state": "IL", "country": "United States", "diseaseCats": ["Cardiovascular", "Diagnostic", "Endocrine/Metabolic", "Gastrointestinal", "Infectious", "Neurology"], "modalityGroups": ["Combination", "Diagnostics", "Digital / Device", "Other", "Protein / Biologic", "Small Molecule"], "nProducts": 93, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Abbott ESA Chagas", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "Abbott HBV Sequencing", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "Abbott PRISM Chagas test", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "Abbott Prism HCV test", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "abbott prism hiv o plus assay", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "Abbott Prism HTLV-I/HTLV-II test", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "Abbott RealTime HBV assay", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "Abbott RealTime HCV assay (HCV PCR test", "phase": "Marketed", "indication": "Infectious, Diagnostic"}], "ceo": "Robert B. Ford, MBA", "employees": 0, "founded": 1900, "website": "http://www.abbott.com", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "ABT", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abbott%20Laboratories", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Abbreos Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ABB-201", "phase": "Preclinical", "indication": "Respiratory distress syndrome (RDS)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.abbreos.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abbreos", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Abbvie Inc.", "city": "North Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dental", "Dermatology", "Diagnostic", "Endocrine/Metabolic", "Gastrointestinal", "Genitourinary", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Ophthalmic", "Other", "Pulmonary", "Renal", "Transplant"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Cell Therapy", "Combination", "Diagnostics", "Digital / Device", "Macrocycle", "Other", "Peptide", "Protein / Biologic", "Small Molecule", "Undisclosed"], "nProducts": 215, "mostAdvanced": "Phase IV", "hasOrphan": true, "pipeline": [{"name": "veligrotug (VRDN-001", "phase": "Registration", "indication": "Thyroid eye disease"}, {"name": "apimostinel (AGN-241660", "phase": "Phase II", "indication": "Depression"}, {"name": "navocaftor (ABBV-3067)", "phase": "Phase II", "indication": "Cystic fibrosis (CF)"}, {"name": "zelquistinel (AGN-241751", "phase": "Phase II", "indication": "Depression"}, {"name": "Kaletra", "phase": "Phase IV", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Nimbex", "phase": "Phase IV", "indication": "Respiratory distress syndrome (RDS)"}, {"name": "Actonel", "phase": "Marketed", "indication": "Osteoporosis"}, {"name": "Acular LS (acuvail 0.45%", "phase": "Marketed", "indication": "Inflammation (unspecified)"}], "ceo": "Robert A. Michael, MBA, CPA", "employees": 0, "founded": 2013, "website": "http://www.abbvie.com", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "ABBV", "exchange": "NYSE", "nDeals": 8, "totalDealValue": 1440000000.0, "totalDealFmt": "$1.4B", "latestDealDate": "2025-05-14", "recentDeals": [{"headline": "AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas", "date": "2025-05-14", "value": ""}, {"headline": "Sionna Therapeutics Expands Pipeline with Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement with AbbVie", "date": "2024-07-16", "value": ""}, {"headline": "AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies", "date": "2024-01-04", "value": "$1.4B"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abbvie", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease", "Musculoskeletal", "Ophthalmology", "Other Inflammation", "Psychiatry / Behavioral", "Rare / Genetic", "Respiratory / Allergy"]}, {"company": "Abcuro Inc.", "city": "Newton", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "ulviprubart (ABC008)", "phase": "Phase II/III", "indication": "Inclusion body myositis"}, {"name": "ABC015", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.abcuro.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abcuro", "hasDealsFin": false, "diseaseGroups": ["Other", "Solid Tumors (General)"]}, {"company": "Abeille Pharmaceuticals Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Transdermal granisetron patch (AB-1001", "phase": "Phase III", "indication": "Emesis"}, {"name": "AB-3001", "phase": "Preclinical", "indication": "Metabolic syndrome"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.abeillepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abeille%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other", "Supportive / Other"]}, {"company": "Abelzeta Pharma Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious"], "modalityGroups": ["Cell Therapy", "Nanoparticle / Delivery"], "nProducts": 11, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "AZD7003", "phase": "Phase I/II", "indication": "Liver cancer"}, {"name": "C-CAR039", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "C-CAR066", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "Re-Join", "phase": "Phase II", "indication": "Osteoarthritis"}, {"name": "AFP TCR-T", "phase": "Phase I", "indication": "Liver cancer"}, {"name": "CAR T CD19 CD20 BICAR", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "CAR-T CD20 (CBM-C20.1", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "CAR-T CD22", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.cellbiomedgroup.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abelzeta%20Pharma", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Musculoskeletal"]}, {"company": "Abeona Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Dermatology", "Endocrine/Metabolic", "Neurology", "Ophthalmic", "Other", "Pulmonary"], "modalityGroups": ["Gene Therapy", "Nanoparticle / Delivery", "Small Molecule"], "nProducts": 9, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Mucogard", "phase": "Marketed", "indication": "Mucositis"}, {"name": "ProctiGard", "phase": "Marketed", "indication": "Poisoning"}, {"name": "Zevaskyn", "phase": "Approved", "indication": "Epidermolysis bullosa"}, {"name": "rebisufligene etisparvovec (UX111", "phase": "Phase III", "indication": "Mucopolysaccharidosis"}, {"name": "ABO-401", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}, {"name": "ABO-503", "phase": "Preclinical", "indication": "Retinal detachment"}, {"name": "ABO-504", "phase": "Preclinical", "indication": "Stargardt disease"}, {"name": "ABO-505", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "Vishwas Seshadri, PhD, MBA", "employees": 136, "founded": 2013, "website": "http://www.abeonatherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 153628507.42, "evFmt": "$154M", "ticker": "ABEO", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-07-11", "recentDeals": [{"headline": "Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications", "date": "2024-07-11", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abeona%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Ophthalmology", "Rare / Genetic", "Supportive / Other"]}, {"company": "Abintus Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ABIN-19", "phase": "Preclinical", "indication": "Lymphoma"}, {"name": "Abintus Bio-in vivo CAR-NK-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Abintus Bio-in vivo CAR-T-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://abintusbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 13652623.0, "totalRaisedFmt": "$14M", "latestFinDate": "2022-08-15", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$14M", "date": "2022-08-15", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abintus%20Bio", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Abpro Holdings Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Ophthalmic"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 4, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "ABP-300", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "ABP-100", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "ABP-102 (CT-P72)", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "ABP-201", "phase": "Preclinical", "indication": "Diabetic macular edema (DME)"}], "ceo": "Jin Wook Suk", "employees": 6, "founded": 2007, "website": "http://www.abpro.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 42788844.468114, "evFmt": "$43M", "ticker": "ABP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 1999998.0, "totalRaisedFmt": "$2M", "latestFinDate": "2022-04-06", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$2M", "date": "2022-04-06", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abpro%20Holdings", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "Diabetes", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Abvance Therapeutics Inc.", "city": "Reno", "state": "NV", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "insulin and glucagon\u200b (ABV100)", "phase": "Preclinical", "indication": "Hypoglycemia"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://abvancetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abvance%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Abvc Biopharma Inc.", "city": "Fremont", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ABV-1504", "phase": "Phase II", "indication": "Depression"}, {"name": "ABV-1505", "phase": "Phase II", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "ABV-1601", "phase": "Phase I/II", "indication": "Depression"}, {"name": "BLEX 404 for MDS (ABV-1702)", "phase": "IND", "indication": "Myelodysplastic syndrome (MDS)"}, {"name": "BLEX 404 for NSCLC (ABV-1519)", "phase": "IND", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "BLEX 404 for pancreatic cancer (ABV-1703)", "phase": "IND", "indication": "Pancreatic cancer"}, {"name": "BLEX 404 for TNBC (ABV-1501)", "phase": "IND", "indication": "Breast cancer"}], "ceo": "Uttam Yashwant Patil, PhD", "employees": 19, "founded": 2016, "website": "https://abvcpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 8660647.2, "evFmt": "$9M", "ticker": "ABVC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Abvc%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Hematologic Cancers", "Lung Cancer", "Psychiatry / Behavioral"]}, {"company": "Acadia Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Nuplazid", "phase": "Marketed", "indication": "Psychosis"}, {"name": "ACP-204", "phase": "Phase III", "indication": "Alzheimer's disease"}, {"name": "ACP-211", "phase": "Phase I", "indication": "Depression"}, {"name": "ACP-271", "phase": "Preclinical", "indication": "Huntington disease (HD)"}], "ceo": "Catherine Owen Adams", "employees": 654, "founded": 1993, "website": "http://www.acadia-pharm.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2348744700.0, "evFmt": "$2.3B", "ticker": "ACAD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acadia%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD", "Psychiatry / Behavioral"]}, {"company": "Accent Therapeutics Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Accent Therapeutics-METTL3-unknown", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "ATX-295", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "ATX-559", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "Accent Therapeutics-ADAR1-unknown", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "Accent Therapeutics-XRN1-unknown", "phase": "Preclinical", "indication": "Head and neck cancer"}, {"name": "ATX968", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.accenttx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Accent%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Head & Neck Cancer", "Hematologic Cancers"]}, {"company": "Accolade Pharmaceuticals LLC", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Dermatology", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Zafi3", "phase": "Registration", "indication": "Rhinitis"}, {"name": "Zafi1", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "Zafi2", "phase": "Phase II", "indication": "Allergic conjunctivitis"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.accoladepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Accolade%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Ophthalmology", "Respiratory / Allergy"]}, {"company": "Accuitis Inc.", "city": "Cumming", "state": "GA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ACU-D1", "phase": "Preclinical", "indication": "Rosacea"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.accuitis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Accuitis", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Accuronix Therapeutics Inc.", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ACXT-3102", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://accuronix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Accuronix%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Accutar Biotechnology Inc.", "city": "Cranbury", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AC0676", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "AC0699", "phase": "Phase I", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.accutarbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Accutar%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers"]}, {"company": "Acelink Therapeutics Inc.", "city": "Newark", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Other", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "AL1211", "phase": "Phase II", "indication": "Fabry disease"}, {"name": "AL0804", "phase": "Preclinical", "indication": "Gaucher disease"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://acelinktherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acelink%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Acella Pharmaceuticals LLC", "city": "Alpharetta", "state": "GA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Loutrex Topical Cream", "phase": "Marketed", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.acellapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acella%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Acepodia Inc.", "city": "San Mateo", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ACE1831", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "ACE-NK-HER2 (ACE1702)", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "ACE1708", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "ACE1975", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "ACE2016", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "ACE2023", "phase": "Research", "indication": "Liver cancer"}], "ceo": "Sonny Hsiao, PhD", "employees": 0, "founded": 2016, "website": "https://www.acepodia.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 125885090.017364, "evFmt": "$126M", "ticker": "6976", "exchange": "TPEx", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 100000000.0, "totalRaisedFmt": "$100M", "latestFinDate": "2023-06-06", "latestFinType": "Series D rounds", "nRounds": 1, "recentFinancing": [{"type": "Series D rounds", "amount": "$100M", "date": "2023-06-06", "investors": "Digital Mobile Venture, Existing Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acepodia", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Aceragen Inc.", "city": "Exton", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Other", "Pulmonary"], "modalityGroups": ["Cell Therapy", "Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Pivotal", "hasOrphan": true, "pipeline": [{"name": "tilsotolimod (IMO-2125)", "phase": "Pivotal", "indication": "Melanoma"}, {"name": "ACG-701 (sodium fusidate)", "phase": "Phase II", "indication": "Bacterial infection"}, {"name": "EMD 1201081", "phase": "Phase II", "indication": "Head and neck cancer"}, {"name": "TLR7 agonist", "phase": "Phase I", "indication": "Adjuvant"}, {"name": "TLR8 agonist", "phase": "Phase I", "indication": "Adjuvant"}], "ceo": "John Clayton Taylor", "employees": 0, "founded": 1989, "website": "https://www.aceragen.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "ACGN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aceragen", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer", "Infectious Disease", "Skin Cancer / Melanoma", "Supportive / Other"]}, {"company": "Acesis Holdings Corp.", "city": "Centennial", "state": "CO", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ACE-167 (IAS-167A)", "phase": "Preclinical", "indication": "Hypogonadism"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://acesisbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acesis%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Aceto Corp.", "city": "Port Washington", "state": "NY", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "ciprofloxacin ophthalmic solution 3%", "phase": "Marketed", "indication": "Bacterial infection"}, {"name": "diclofenac sodium ophthalmic solution 0.1%", "phase": "Marketed", "indication": "Pain"}, {"name": "levofloxacin ophthalmic solution 0.5%", "phase": "Marketed", "indication": "Bacterial infection"}], "ceo": "Chen Schor, MBA, CPA", "employees": 152, "founded": 1947, "website": "http://www.aceto.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -74541489.53, "evFmt": "", "ticker": "ACET", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aceto", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Pain / Migraine"]}, {"company": "Achelios Therapeutics Inc.", "city": "Chapel Hill", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Topofen (ELS-M11)", "phase": "Phase I/II", "indication": "Migraine"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.achelios.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Achelios%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Achieve Life Sciences Inc.", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "cytisinicline", "phase": "Phase III", "indication": "Substance use disorders"}], "ceo": "Richard Alistair Balfour Stewart", "employees": 25, "founded": 1991, "website": "http://achievelifesciences.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 88488433.92, "evFmt": "$88M", "ticker": "ACHV", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Achieve%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Aclaris Therapeutics Inc.", "city": "Wayne", "state": "PA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Leqselvi", "phase": "Approved", "indication": "Alopecia areata"}, {"name": "ATI-1777", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "ATI-2231", "phase": "IND", "indication": "Breast cancer"}, {"name": "Aclaris-ITK/TXK/JAK3-unknown", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "ATI-2138", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "Neal S. Walker, PhD, MBA", "employees": 64, "founded": 2012, "website": "https://www.aclaristx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 80699729.2, "evFmt": "$81M", "ticker": "ACRS", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-11-18", "recentDeals": [{"headline": "Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline", "date": "2024-11-18", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aclaris%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Dermatology", "IBD / GI Inflammatory"]}, {"company": "Aclipse Therapeutics LLC", "city": "Radnor Township", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "M102", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.aclipsetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aclipse%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Acorda Therapeutics Inc.", "city": "Ardsley", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Musculoskeletal", "Neurology"], "modalityGroups": ["Antibody", "Other", "Protein / Biologic", "Small Molecule"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Inbrija", "phase": "Marketed", "indication": "Parkinson's disease"}, {"name": "Qutenza", "phase": "Marketed", "indication": "Diabetic neuropathy"}, {"name": "Selincro", "phase": "Marketed", "indication": "Substance use disorders"}, {"name": "Zanaflex", "phase": "Marketed", "indication": "Spasticity"}, {"name": "SYN120", "phase": "Phase II", "indication": "Parkinson's disease"}, {"name": "Timolumab (BTT1023", "phase": "Phase II", "indication": "Primary sclerosing cholangitis"}, {"name": "cimaglermin alfa (GGF2", "phase": "Phase I", "indication": "Heart failure"}, {"name": "CVT-427", "phase": "Phase I", "indication": "Migraine"}], "ceo": "Ronald Cohen, MD", "employees": 102, "founded": 1995, "website": "http://www.acorda.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 179279000.0, "evFmt": "$179M", "ticker": "ACORQ", "exchange": "Pink", "nDeals": 1, "totalDealValue": 144000000.0, "totalDealFmt": "$144M", "latestDealDate": "2023-05-08", "recentDeals": [{"headline": "Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide Inbrija in Greater China", "date": "2023-05-08", "value": "$144M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acorda%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Liver Disease", "Musculoskeletal", "Pain / Migraine", "Parkinson's", "Psychiatry / Behavioral"]}, {"company": "Acorn Biomedical Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Hematology", "Ophthalmic"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ACN-1052", "phase": "Preclinical", "indication": "Glaucoma"}, {"name": "ACN-8337", "phase": "Preclinical", "indication": "Neutropenia"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.acornbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acorn%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Ophthalmology"]}, {"company": "Acova Inc.", "city": "Plymouth", "state": "MN", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "VAP-1 (PRX167700)", "phase": "Phase II", "indication": "Osteoarthritis"}, {"name": "USL311", "phase": "Phase I/II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acova", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Musculoskeletal"]}, {"company": "Act Biotech Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "telatinib (EOC315)", "phase": "Phase II", "indication": "Gastric cancer"}, {"name": "ACTB1003", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.actbiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Act%20Biotech", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Actinium Pharmaceuticals Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Transplant"], "modalityGroups": ["Antibody", "Radiopharmaceutical"], "nProducts": 7, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "apamistamab (Iomab-B", "phase": "Phase III", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Actimab-A", "phase": "Phase II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Actimab-MDS", "phase": "Phase II", "indication": "Myelodysplastic syndrome (MDS)"}, {"name": "lintuzumab-ac225 (Actimab-M)", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "Actimab-P", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "ATNM-400", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "HER3-ARC", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Sandesh Seth, MBA", "employees": 37, "founded": 2000, "website": "http://www.actiniumpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -33442764.72, "evFmt": "", "ticker": "ATNM", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Actinium%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Actinobac Biomed Inc.", "city": "North Brunswick", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Leukothera", "phase": "Preclinical", "indication": "Crohn's disease"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.actinobac.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Actinobac%20Biomed", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Actio Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Genitourinary", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "ABS-0871", "phase": "Phase I", "indication": "Incontinence"}, {"name": "ABS-1230", "phase": "Preclinical", "indication": "Epilepsy"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://actiobio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Actio%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other Specialties"]}, {"company": "Actithera Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Actithera-FAP-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Actithera-Target B-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.actithera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-10-14", "recentDeals": [{"headline": "Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications", "date": "2025-10-14", "value": ""}], "totalRaised": 75500000.0, "totalRaisedFmt": "$76M", "latestFinDate": "2025-07-09", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$76M", "date": "2025-07-09", "investors": "Merck Ventures, Hadean Ventures, Sofinnova Partners, 4bio Capital, Bioqube Ventures, Innovestor, Investinor, Surveyor Ca..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Actithera", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Actuate Therapeutics Inc.", "city": "Fort Worth", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "elraglusib (9-ING-41)", "phase": "Phase I/II", "indication": "Hematologic malignancies"}], "ceo": "Daniel M. Schmitt, MBA", "employees": 10, "founded": 2015, "website": "https://actuatetherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 147235191.56, "evFmt": "$147M", "ticker": "ACTU", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Actuate%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Actus Biotechnologies Inc.", "city": "Las Vegas", "state": "NV", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology"], "modalityGroups": ["Macrocycle"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CY-102", "phase": "Preclinical", "indication": "Psoriasis"}, {"name": "HA-102PH", "phase": "Preclinical", "indication": "Scars/wrinkles"}, {"name": "TA-102", "phase": "Preclinical", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.actusbiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Actus%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Actym Therapeutics Inc.", "city": "Berkeley", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ACTM-838", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.actymthera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Actym%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Acumen Pharmaceuticals Inc.", "city": "Charlottesville", "state": "VA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "sabirnetug (ACU193)", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "subcutaneous sabirnetug (ACU193)", "phase": "Phase I", "indication": "Alzheimer's disease"}], "ceo": "Daniel J. O'Connell, MBA", "employees": 61, "founded": 1996, "website": "http://www.acumenpharm.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -38632163.56, "evFmt": "", "ticker": "ABOS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acumen%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Acura Pharmaceuticals Inc.", "city": "Palatine", "state": "IL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Infectious", "Neurology"], "modalityGroups": ["Combination", "Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Nexafed", "phase": "Marketed", "indication": "Infectious (unspecified)"}, {"name": "Oxaydo", "phase": "Marketed", "indication": "Pain"}, {"name": "Vycavert", "phase": "Phase II", "indication": "Pain"}, {"name": "hydrocodone bitartrate/acetaminophen (LTX-03)", "phase": "Phase I", "indication": "Pain"}, {"name": "LTX-04", "phase": "Phase I", "indication": "Endocrine (unspecified)"}], "ceo": "Robert B. Jones, MBA", "employees": 9, "founded": 1935, "website": "http://www.acurapharm.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 28535500.0, "evFmt": "$29M", "ticker": "ACUR", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acura%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other Specialties", "Pain / Migraine"]}, {"company": "Acurastem Inc.", "city": "Monrovia", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AS-202", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://acurastem.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acurastem", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Acurex Biosciences Corp.", "city": "San Carlos", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AcureX - neurology - unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "AcureX - neurology - unknown2", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.acurex.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acurex%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Acurx Pharmaceuticals Inc.", "city": "White Plains", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ACX-375C", "phase": "Preclinical", "indication": "Gram-positive bacterial infection"}], "ceo": "David P. Luci, CPA", "employees": 4, "founded": 2017, "website": "http://www.acurxpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 9450266.924, "evFmt": "$9M", "ticker": "ACXP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acurx%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Acusphere Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Imagify", "phase": "Registration", "indication": "Cardiovascular, Diagnostic"}], "ceo": "", "employees": 0, "founded": 1993, "website": "http://www.acusphere.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "ACUS", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Acusphere", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Adaptin Bio Inc.", "city": "Charlotte", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "APTN-101", "phase": "IND", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://adaptinbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adaptin%20Bio", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Adarx Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Endocrine/Metabolic", "Hematology", "Inflammation", "Neurology", "Ophthalmic", "Renal"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 9, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ADX-038", "phase": "Phase I/II", "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)"}, {"name": "ADX-324", "phase": "Phase I/II", "indication": "Angioedema"}, {"name": "ADX-850", "phase": "Phase I", "indication": "Hypertension"}, {"name": "ADX-626", "phase": "Preclinical", "indication": "Thrombosis"}, {"name": "Adarx/Abbvie-CNS-unknown", "phase": "Research", "indication": "Central nervous system (CNS) disorders"}, {"name": "Adarx/Abbvie-immunology-unknown", "phase": "Research", "indication": "Autoimmune (unspecified)"}, {"name": "Adarx/Abbvie-oncology-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "ADX-CNS1", "phase": "Research", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.adarx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-05-14", "recentDeals": [{"headline": "AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas", "date": "2025-05-14", "value": ""}], "totalRaised": 246000000.0, "totalRaisedFmt": "$246M", "latestFinDate": "2025-02-01", "latestFinType": "Uncategorized venture rounds", "nRounds": 3, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2025-02-01", "investors": "Lg Technology Ventures"}, {"type": "Series C rounds", "amount": "$200M", "date": "2023-08-09", "investors": "Bain Capital Life Sciences, Tcgx, Blackrock Inc., Commodore Capital, Cormorant Asset Management, Hbm Bioventures AG, Inv..."}, {"type": "Series B rounds", "amount": "$46M", "date": "2023-01-20", "investors": "Ascenta Capital, Orbimed Advisors LLC, Sr One Capital Management, Lilly Asia Ventures (\u793c\u6765\u4e9a\u6d32\u57fa\u91d1), Sirona Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adarx%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Brain / CNS Tumors", "Cardiovascular", "Hematology (non-cancer)", "Other Inflammation", "Other Neurology", "Solid Tumors (General)"]}, {"company": "Adcentrx Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ADRX-0706", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "ADRX-0405", "phase": "IND", "indication": "Solid tumors"}, {"name": "ADRX-0314", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://adcentrx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 51000000.0, "totalRaisedFmt": "$51M", "latestFinDate": "2023-12-05", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$13M", "date": "2023-12-05", "investors": "Quan Capital, Partners Investment"}, {"type": "Series A rounds", "amount": "$38M", "date": "2023-04-24", "investors": "Eight Roads Ventures, F-prime Inc. (F-prime Capital Partners), Abio-x, Delta Capital, Trinity Innovation Fund (\u4e09\u4e00\u521b\u65b0\u6295\u8d44), ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adcentrx%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Adcure Bio LLC", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AVID-212", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "AVID-388", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "AVID-448", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "AVID-670", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://adcurebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adcure%20Bio", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Adial Pharmaceuticals Inc.", "city": "Glen Allen", "state": "VA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "AD04", "phase": "Phase III", "indication": "Substance use disorders"}], "ceo": "Cary J. Claiborne, MBA", "employees": 7, "founded": 2010, "website": "https://www.adial.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1149476.87, "evFmt": "$1M", "ticker": "ADIL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adial%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Adicet Bio Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ADI-001", "phase": "Phase I", "indication": "ANCA vasculitis"}, {"name": "ADI-212", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "Chen Schor, MBA, CPA", "employees": 152, "founded": 2014, "website": "https://www.adicetbio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -74541489.53, "evFmt": "", "ticker": "ACET", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adicet%20Bio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "GU / Gynecologic Cancers"]}, {"company": "Adimab LLC", "city": "Lebanon", "state": "NH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MM-151", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "SRK-181", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.adimab.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adimab", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Adipo Therapeutics LLC", "city": "Indianapolis", "state": "IN", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Adipo-T2 Diabetes-unknown", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://adipotherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adipo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Adiso Therapeutics Inc.", "city": "Concord", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Inflammation", "Neurology"], "modalityGroups": ["Oncolytic / Microbiome", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ADS024 (ART24)", "phase": "Phase II", "indication": "Ulcerative colitis"}, {"name": "ADS051", "phase": "Phase I", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "ADS032", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}, {"name": "ADS012", "phase": "Research", "indication": "Neuroinflammation"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://adisotx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 60000000.0, "totalRaisedFmt": "$60M", "latestFinDate": "2022-03-10", "latestFinType": "Seed financings", "nRounds": 1, "recentFinancing": [{"type": "Seed financings", "amount": "$60M", "date": "2022-03-10", "investors": "Morningside Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adiso%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["IBD / GI Inflammatory", "Other Inflammation", "Other Neurology"]}, {"company": "Aditxt Inc.", "city": "Loma Linda", "state": "CA", "country": "United States", "diseaseCats": ["Diagnostic", "Transplant"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Prostate Mitomic Test", "phase": "Marketed", "indication": "Cancer, Diagnostic"}, {"name": "ADI", "phase": "Preclinical", "indication": "Organ transplant"}], "ceo": "Amro Albanna", "employees": 26, "founded": 2017, "website": "https://aditxt.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 14502454.65441, "evFmt": "$15M", "ticker": "ADTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aditxt", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)", "Transplant"]}, {"company": "Adjuvance Technologies Inc.", "city": "Lincoln", "state": "NE", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TQL1055", "phase": "Phase I", "indication": "Adjuvant"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.adjuvancetechnologies.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adjuvance%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Adma Biologics Inc.", "city": "Ramsey", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Hematology", "Infectious"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Asceniv (10% immune globulin liquid", "phase": "Marketed", "indication": "Primary immunodeficiency disease (PIDD)"}, {"name": "Bivigam", "phase": "Marketed", "indication": "Primary immunodeficiency disease (PIDD)"}, {"name": "Nabi-HB", "phase": "Marketed", "indication": "Hepatitis B virus (HBV)"}, {"name": "SG-001", "phase": "Preclinical", "indication": "Streptococcus"}], "ceo": "Adam S. Grossman", "employees": 685, "founded": 2004, "website": "https://www.admabiologics.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4152292291.9, "evFmt": "$4.2B", "ticker": "ADMA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adma%20Biologics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Other Inflammation"]}, {"company": "Adovate LLC", "city": "Charlottesville", "state": "VA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ADO-5030 (PNV-5030)", "phase": "Phase I", "indication": "Asthma"}, {"name": "PNV2", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://adovate.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adovate", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Respiratory / Allergy"]}, {"company": "Advanced Bioadjuvants LLC", "city": "Omaha", "state": "NE", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Adjuplex", "phase": "Marketed", "indication": "Adjuvant"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.advancedbioadjuvants.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Advanced%20Bioadjuvants", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Advanced Cancer Therapeutics LLC", "city": "Louisville", "state": "KY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "3PO (PFK158", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "CK37", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "PU27", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.advancedcancertherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Advanced%20Cancer%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Advanced Innovative Partners Inc.", "city": "Surfside", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Diagnostics", "Other"], "nProducts": 11, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AIP-104", "phase": "Phase I", "indication": "Cancer, Diagnostic"}, {"name": "AIP-107", "phase": "Phase I", "indication": "Cancer, Diagnostic"}, {"name": "AIP-101", "phase": "Preclinical", "indication": "Cancer, Diagnostic"}, {"name": "AIP-102", "phase": "Preclinical", "indication": "Infectious, Diagnostic"}, {"name": "AIP-105", "phase": "Preclinical", "indication": "Cancer, Diagnostic"}, {"name": "AIP-108", "phase": "Preclinical", "indication": "Neurology, Diagnostic"}, {"name": "AIP-109", "phase": "Preclinical", "indication": "Cancer, Diagnostic"}, {"name": "AIP-110", "phase": "Preclinical", "indication": "Metabolic, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.advancedinnovativepartners.com/about-aip", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Advanced%20Innovative%20Partners", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Obesity / Metabolic", "Other Neurology", "Solid Tumors (General)"]}, {"company": "Advanced Life Sciences Holdings Inc.", "city": "Woodridge", "state": "IL", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Macrocycle", "Other"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Restanza", "phase": "Phase III", "indication": "Pneumonia"}, {"name": "IV Restanza", "phase": "Preclinical", "indication": "Pneumonia"}, {"name": "ALS-357", "phase": "Preclinical", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.advancedlifesciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Advanced%20Life%20Sciences%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Skin Cancer / Melanoma"]}, {"company": "Advenchen Laboratories LLC", "city": "Moorpark", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Aitan", "phase": "Marketed", "indication": "Gastric cancer"}, {"name": "lucitanib (AL3810", "phase": "Phase II/III", "indication": "Small cell lung cancer"}, {"name": "anlotinib (AL3818)", "phase": "Approved", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.advenchen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Advenchen%20Laboratories", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Lung Cancer"]}, {"company": "Adverum Biotechnologies Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "ixoberogene soroparvovec (AAV.7m8-aflibercept", "phase": "Phase III", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "AAV.7m8.CaMeRaOpsin", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "AAV.7m8.CFI", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "ADVM-062 (AAV.7m8-L-opsin)", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}, {"name": "ADVM-082", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}, {"name": "LSV1.CFI", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "Laurent Fischer, MD", "employees": 155, "founded": 2006, "website": "https://adverum.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 58395940.0, "evFmt": "$58M", "ticker": "ADVM", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-06-12", "recentDeals": [{"headline": "Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid", "date": "2023-06-12", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adverum%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Adynxx Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Hepatic", "Neurology"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Hepamate", "phase": "Marketed", "indication": "Liver failure"}, {"name": "SilverSeal (hydress + wound care)", "phase": "Marketed", "indication": "Wounds"}, {"name": "Brivoligide (AYX1)", "phase": "Phase II", "indication": "Pain"}, {"name": "AYX2", "phase": "Preclinical", "indication": "Pain"}, {"name": "lidocaine hydrogel patch", "phase": "Preclinical", "indication": "Pain"}], "ceo": "Rick Orr", "employees": 0, "founded": 2007, "website": "http://www.adynxx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "ADYX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Adynxx", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Liver Disease", "Pain / Migraine"]}, {"company": "Aegis Life Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Aegis Life COVID-19 DNA Vaccine", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://aegis.life/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aegis%20Life", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Aegle Therapeutics Corp.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Dermatology", "Transplant"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AGLE-102", "phase": "Phase I/II", "indication": "Burns"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.aegletherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aegle%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Aeolian Biotech Corp.", "city": "Lincoln", "state": "NE", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "iPCV22", "phase": "Preclinical", "indication": "Pneumococcus"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.aeolianbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aeolian%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Aeolus Pharmaceuticals Inc.", "city": "Mission Viejo", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology", "Other", "Pulmonary"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "manganese porphyrin (AEOL 10150)", "phase": "Phase I", "indication": "Mesothelioma"}, {"name": "AEOL 11114", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "AEOL 11207", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "AEOL 20415", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}], "ceo": "John L. McManus", "employees": 0, "founded": 1994, "website": "http://www.aeoluspharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "AOLS", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aeolus%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Lung Cancer", "Rare / Genetic"]}, {"company": "Aeovian Pharmaceuticals Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AV078", "phase": "Phase I", "indication": "Seizures"}, {"name": "AE116", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.aeovian.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aeovian%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other Neurology"]}, {"company": "Aer Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AER-01", "phase": "Preclinical", "indication": "Chronic obstructive pulmonary disease (COPD)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://aertherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aer%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Aerami Therapeutics Holdings Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Pulmonary"], "modalityGroups": ["Digital / Device"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Imatinib (AER-901)", "phase": "Phase I/II", "indication": "Hypertension"}, {"name": "Adagio (Aerami 501", "phase": "Phase II", "indication": "Diabetes"}, {"name": "AER-601", "phase": "IND", "indication": "Diabetes"}, {"name": "Aerami-IPF-unknown", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://aerami.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aerami%20Therapeutics%20Holdings", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Diabetes", "Respiratory / Allergy"]}, {"company": "Aeromics Inc.", "city": "Branford", "state": "CT", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SIM0307", "phase": "Phase I", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 2008, "website": "https://www.aeromics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aeromics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Aether Therapeutics Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LD-6BN", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.aethertherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aether%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Affini-t Therapeutics Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 7, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Affini-T-MCPyV-unknown", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "AFNT-211", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "AFNT-111", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "AFNT-212", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Affini-T-KRAS G12C-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Affini-T-P53 R175H-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Affini-T-PIK3CA-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.affinittx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-04-13", "recentDeals": [{"headline": "Affini-T Therapeutics Announces Licensing Agreement with Leading Comprehensive Cancer Center to Expand Company\u2019s Pipeline of Oncogenic Driver Programs", "date": "2023-04-13", "value": ""}, {"headline": "Affini-T Therapeutics & Metagenomi announce next-generation gene editing partnership to advance cell therapies for solid tumor patients", "date": "2022-06-15", "value": ""}], "totalRaised": 175000000.0, "totalRaisedFmt": "$175M", "latestFinDate": "2022-03-22", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$175M", "date": "2022-03-22", "investors": "Vida Ventures, Leaps by Bayer, Humboldt Fund, Parker Institute for Cancer Immunotherapy, Catalio Capital Management, Age..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Affini-t%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Affyimmune Therapeutics Inc.", "city": "Natick", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AIC100", "phase": "Phase I", "indication": "Thyroid cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://affyimmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Affyimmune%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer"]}, {"company": "Agastiya Biotech LLC", "city": "Temecula", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "PS35", "phase": "Phase III", "indication": "Psoriasis"}, {"name": "AB001", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "ABREV01", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "AVREV02", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.agastiyabiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Agastiya%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Solid Tumors (General)"]}, {"company": "Agenebio Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "levetiracetam (AGB101)", "phase": "Phase II", "indication": "Cognitive dysfunction"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.agenebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Agenebio", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Agenus Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Other", "Transplant"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Cell Therapy", "Other", "Vaccine"], "nProducts": 22, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Prophage", "phase": "Marketed", "indication": "Renal cancer"}, {"name": "QS-21 Stimulon", "phase": "Approved", "indication": "Adjuvant"}, {"name": "balstilimab (AGEN2034)", "phase": "Registration", "indication": "Cervical cancer"}, {"name": "botensilimab (AGEN1181)", "phase": "Phase II/III", "indication": "Colorectal cancer"}, {"name": "zalifrelimab (AGEN1884)", "phase": "Phase II/III", "indication": "Cervical cancer"}, {"name": "INCAGN2385", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "INCAGN2390", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "AGEN1777", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "Garo H. Armen, PhD", "employees": 316, "founded": 1994, "website": "http://www.agenusbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 469707020.0, "evFmt": "$470M", "ticker": "AGEN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Agenus", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "GU / Gynecologic Cancers", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Agios Pharmaceuticals Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Pyrukynd", "phase": "Marketed", "indication": "Anemia"}, {"name": "tebapivat (AG-946)", "phase": "Phase II", "indication": "Anemia"}, {"name": "AG-181", "phase": "Phase I", "indication": "Phenylketonuria"}], "ceo": "Brian M. Goff, MBA", "employees": 488, "founded": 2008, "website": "https://www.agios.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1065518919.3, "evFmt": "$1.1B", "ticker": "AGIO", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-06-09", "recentDeals": [{"headline": "Avanzanite Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders", "date": "2025-06-09", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Agios%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Hematology (non-cancer)", "Rare / Genetic"]}, {"company": "Aiko Biotechnology Inc.", "city": "Portland", "state": "ME", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AIKO-151", "phase": "Preclinical", "indication": "Constipation"}, {"name": "AIKO-152", "phase": "Preclinical", "indication": "Constipation"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.aikobiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aiko%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Aim Immunotech Inc.", "city": "Ocala", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Neurology"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Alferon N Injection", "phase": "Marketed", "indication": "Genital warts"}, {"name": "Ampligen", "phase": "Approved", "indication": "Chronic fatigue syndrome (CFS)"}, {"name": "Alferon LDO", "phase": "Phase II", "indication": "HIV/AIDS"}, {"name": "Intranasal Ampligen", "phase": "Phase II", "indication": "Infectious (unspecified)"}], "ceo": "Thomas Kenwood Equels", "employees": 23, "founded": 1966, "website": "https://aimimmuno.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 10055339.939962, "evFmt": "$10M", "ticker": "AIM", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aim%20Immunotech", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Ainos Inc.", "city": "Amarilla", "state": "TX", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Other"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "low-dose oral interferon-alpha", "phase": "Registration", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Chun Hsien Tsai", "employees": 44, "founded": 1984, "website": "https://www.ainos.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 12440730.808, "evFmt": "$12M", "ticker": "AIMD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ainos", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Airway Therapeutics LLC", "city": "Cincinnati", "state": "OH", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "AT-100", "phase": "Phase I", "indication": "Bronchopulmonary dysplasia (BPD)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.airwaytherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Airway%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Aivita Biomedical Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AV-GBM-1", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "AVOVA-1", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "AV-COVID-19", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "AV-MEL-1", "phase": "Phase I", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://aivitabiomedical.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 6048000.0, "totalRaisedFmt": "$6M", "latestFinDate": "2022-08-30", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$6M", "date": "2022-08-30", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aivita%20Biomedical", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors", "Infectious Disease", "Skin Cancer / Melanoma"]}, {"company": "Aiviva Biopharma Inc.", "city": "Newport Beach", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Genitourinary", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AIV001", "phase": "Phase I/II", "indication": "Skin cancer"}, {"name": "AIV007", "phase": "Phase I/II", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://aiviva.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aiviva%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology", "Skin Cancer / Melanoma"]}, {"company": "Aivo Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AVB-08", "phase": "Preclinical", "indication": "Psychosis"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://www.aivo.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aivo%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Ajax Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AJ1-10502", "phase": "Preclinical", "indication": "Myeloproliferative disorder"}, {"name": "AJ1-11095", "phase": "Preclinical", "indication": "Myeloproliferative disorder"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.ajaxtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ajax%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Akanocure Pharmaceuticals Inc.", "city": "West Lafayette", "state": "IN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AK-1225", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.akanocure.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Akanocure%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Akashi Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "Halofuginone (PCS100", "phase": "Phase I/II", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://akashirx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Akashi%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Akava Therapeutics LLC", "city": "", "state": "", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AKV9", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "NU-9", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://akavatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Akava%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD"]}, {"company": "Akebia Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Vafseo", "phase": "Marketed", "indication": "Anemia"}], "ceo": "John P. Butler, MBA", "employees": 181, "founded": 1998, "website": "https://akebia.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 543581650.2, "evFmt": "$544M", "ticker": "AKBA", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 604000000.0, "totalDealFmt": "$604M", "latestDealDate": "2025-12-01", "recentDeals": [{"headline": "Q32 Bio Sells Complement Inhibitor ADX-097", "date": "2025-12-01", "value": "$604M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Akebia%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Akorn Operating Company LLC", "city": "Lake Forest", "state": "IL", "country": "United States", "diseaseCats": ["Musculoskeletal", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Amrix", "phase": "Marketed", "indication": "Spasticity"}, {"name": "Xopenex", "phase": "Marketed", "indication": "Chronic obstructive pulmonary disease (COPD)"}], "ceo": "", "employees": 0, "founded": 1971, "website": "http://www.akorn.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Akorn%20Operating%20Company", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Respiratory / Allergy"]}, {"company": "Akso Biopharmaceutical Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AB002", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.aksobio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Akso%20Biopharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Aktis Oncology Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Radiopharmaceutical"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AKY-1189", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "AKY-2519", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.aktisoncology.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "AKTS", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-05-21", "recentDeals": [{"headline": "Aktis Oncology Enters Into Strategic Collaboration With Lilly To Discover And Develop Novel Anticancer Radiopharmaceuticals", "date": "2024-05-21", "value": ""}], "totalRaised": 259000000.0, "totalRaisedFmt": "$259M", "latestFinDate": "2024-09-30", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$175M", "date": "2024-09-30", "investors": "Ra Capital Management L.P., Rtw Investments L.P., Janus Henderson Investors, T. Rowe Price Associates Inc., Avidity Part..."}, {"type": "Series A rounds", "amount": "$84M", "date": "2022-08-25", "investors": "Cowen Healthcare Investments, Mrl Ventures Fund, Merck & Co. Inc., Arrowmark Partners, Mirae Asset Venture Investment, T..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aktis%20Oncology", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Alaunos Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Sleeping Beauty Transposed PBL", "phase": "Phase I/II", "indication": "Biliary cancer"}, {"name": "mbIL-15 TCR-T cell therapy", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Holger Weis, CPA", "employees": 1, "founded": 2005, "website": "https://alaunos.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1959385.06, "evFmt": "$2M", "ticker": "TCRT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alaunos%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Alaya.bio S.A.S.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CELTIC", "phase": "Preclinical", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.alaya.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alaya.bio%20S.A.S.", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Alba Therapeutics Corp.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Other"], "modalityGroups": ["Peptide"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "larazotide (AT-1001", "phase": "Phase III", "indication": "Celiac disease"}, {"name": "AT-1004", "phase": "Preclinical", "indication": "Adjuvant"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.albatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alba%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Supportive / Other"]}, {"company": "Aldeyra Therapeutics Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Infectious", "Inflammation", "Ophthalmic", "Other", "Pulmonary", "Renal"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "Reproxalap ophthalmic solution", "phase": "Registration", "indication": "Dry eye"}, {"name": "intravitreal methotrexate 0.8% (ADX-2191)", "phase": "Phase III", "indication": "Lymphoma"}, {"name": "ADX-629", "phase": "Phase II", "indication": "Dermatitis"}], "ceo": "Todd C. Brady, MD, PhD", "employees": 9, "founded": 2004, "website": "http://www.aldeyra.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 210980853.06, "evFmt": "$211M", "ticker": "ALDX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aldeyra%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Hematologic Cancers", "Ophthalmology"]}, {"company": "Alector Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Undisclosed"], "nProducts": 14, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "latozinemab (AL001", "phase": "Phase III", "indication": "Frontotemporal dementia"}, {"name": "AL002", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "Alector AL101", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "AL003", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "ADP009", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ADP012", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ADP016", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ADP017", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Arnon Rosenthal, PhD", "employees": 238, "founded": 2013, "website": "http://alector.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -188326345.47, "evFmt": "", "ticker": "ALEC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alector", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Solid Tumors (General)"]}, {"company": "Aleta Biotherapeutics Inc.", "city": "Natick", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ALETA-001", "phase": "Phase I/II", "indication": "B cell lymphoma"}, {"name": "ALETA-004", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "https://www.aletabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aleta%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Aligos Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Hepatic", "Infectious"], "modalityGroups": ["Other", "RNA Therapeutics", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Aligos Therapeutics-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "ALG-055009", "phase": "Phase II", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "ALG-000184", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "ALG-010133", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "ALG-125755", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "Aligos Therapeutics-chronic hepatitis B virus-unknown", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "Aligos Therapeutics-PD-L1-unknown", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "Lawrence M. Blatt, PhD, MBA", "employees": 70, "founded": 2018, "website": "http://www.aligos.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 200908142.08, "evFmt": "$201M", "ticker": "ALGS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aligos%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Obesity / Metabolic"]}, {"company": "Alivegen USA Inc.", "city": "Thousand Oaks", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Musculoskeletal", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "BIIB110 (ALG-801)", "phase": "Phase I", "indication": "Spinal muscular atrophy (SMA)"}, {"name": "ALG-802", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.alivegen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alivegen%20USA", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Alkeus Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "gildeuretinol (C20-D3-retinyl acetate", "phase": "Phase III", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.alkeus.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alkeus%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Allachem LLC", "city": "Hallandale Beach", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AV4025", "phase": "Phase I", "indication": "Hepatitis C virus (HCV)"}, {"name": "AVR560", "phase": "Phase I", "indication": "Hepatitis C virus (HCV)"}, {"name": "ONC1-0013B", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "AV3208", "phase": "Preclinical", "indication": "Obesity"}, {"name": "AV4203", "phase": "Preclinical", "indication": "Hepatitis C virus (HCV)"}, {"name": "AV5075C", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "AV5080", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "ONC2-13B", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://allachem.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allachem", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Infectious Disease", "Liver Disease", "Obesity / Metabolic", "Solid Tumors (General)"]}, {"company": "Alladapt Immunotherapeutics Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ADP-101", "phase": "Phase I/II", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.alladapt.com/#home", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alladapt%20Immunotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Allara Therapeutics Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CEP-37250", "phase": "Phase I", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2011, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allara%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Allay Therapeutics Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Digital / Device", "Other", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ATX101", "phase": "Phase II", "indication": "Pain"}, {"name": "ATX-201", "phase": "Preclinical", "indication": "Pain"}, {"name": "ATX-301", "phase": "Preclinical", "indication": "Pain"}, {"name": "ATX-401", "phase": "Preclinical", "indication": "Pain"}, {"name": "ATX-501", "phase": "Research", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.allaytx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-12-18", "recentDeals": [{"headline": "Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan", "date": "2023-12-18", "value": ""}], "totalRaised": 57500000.0, "totalRaisedFmt": "$58M", "latestFinDate": "2025-06-05", "latestFinType": "Venture (Debt)", "nRounds": 2, "recentFinancing": [{"type": "Venture (Debt)", "amount": "", "date": "2025-06-05", "investors": "Hsbc Innovation Banking"}, {"type": "Series D rounds", "amount": "$58M", "date": "2025-06-05", "investors": "Lightstone Ventures, Clavystbio Pte. Ltd., New Enterprise Associates, Arboretum Ventures, Vertex Venture Holdings Ltd., ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allay%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Allegis Pharmaceuticals LLC", "city": "Canton", "state": "MS", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Primsol (Brand)", "phase": "Marketed", "indication": "Urinary tract infection (UTI)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://allegispharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allegis%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Allegro Ophthalmics LLC", "city": "San Juan Capistrano", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other", "Peptide"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Luminate", "phase": "Phase II", "indication": "Diabetic macular edema (DME)"}, {"name": "ALG-1007", "phase": "Phase II", "indication": "Dry eye"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.allegroeye.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allegro%20Ophthalmics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Ophthalmology"]}, {"company": "Alleo Labs Corp.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ALO-001", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.alleolabs.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alleo%20Labs", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Allodynic Therapeutics LLC", "city": "North Miami", "state": "FL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "ALLOD-2", "phase": "Phase II/III", "indication": "Migraine"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.allodynic.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allodynic%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Allogene Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Transplant"], "modalityGroups": ["Antibody", "Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ALLO-647", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "ALLO-213", "phase": "Preclinical", "indication": "Small cell lung cancer"}, {"name": "ALLO-819", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "David D. Chang, MD, PhD", "employees": 229, "founded": 2018, "website": "http://www.allogene.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 213229040.28, "evFmt": "$213M", "ticker": "ALLO", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-03-12", "recentDeals": [{"headline": "Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease", "date": "2024-03-12", "value": ""}, {"headline": "Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR Technology", "date": "2022-01-11", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allogene%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Lung Cancer"]}, {"company": "Alloplex Biotherapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SUPLEXA", "phase": "Phase I", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://alloplexbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alloplex%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Allorion Therapeutics Inc.", "city": "Natick", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AVZO-021 (ARTS-021)", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "AVZO-023 (ARTS-023)", "phase": "IND", "indication": "Breast cancer"}, {"name": "Allorion Therapeutics-autoimmune disease-unknown", "phase": "Research", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.alloriontx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 1540000000.0, "totalDealFmt": "$1.5B", "latestDealDate": "2024-01-04", "recentDeals": [{"headline": "Avenzo Therapeutics Announces Global License Of AVZO-021 (ARTS-021), A Potentially Best-In-Class Clinical Stage CDK2 Inhibitor From Allorion Therapeutics", "date": "2024-01-04", "value": "$1.0B"}, {"headline": "Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca", "date": "2024-01-02", "value": "$540M"}], "totalRaised": 50000000.0, "totalRaisedFmt": "$50M", "latestFinDate": "2023-03-09", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$50M", "date": "2023-03-09", "investors": "Ince Capital (\u6e36\u7b56\u8d44\u672c), Qiming Venture Partners (\u542f\u660e\u521b\u6295), Tf Capital, Long River Investments, 3sbio Ventures, Octagon Capital..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allorion%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Breast Cancer"]}, {"company": "Allterum Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "4A10", "phase": "Preclinical", "indication": "Acute lymphoblastic leukemia (ALL)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://allterum.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allterum%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Alltrna Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Nanoparticle / Delivery", "RNA Therapeutics"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Alltrna-liver Gln-TAG-unknown", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "AP003", "phase": "Preclinical", "indication": "Genetic disorders"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.alltrna.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alltrna", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Allysta Pharmaceuticals", "city": "San Mateo", "state": "CA", "country": "United States", "diseaseCats": ["Hepatic", "Ophthalmic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ALY688", "phase": "Phase I", "indication": "Dry eye"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.allysta.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allysta%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Allyx Therapeutics Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "ALX-001", "phase": "IND", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://allyxthera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Allyx%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Alnylam Pharmaceuticals Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Endocrine/Metabolic", "Hematology", "Hepatic", "Infectious", "Neurology", "Ophthalmic", "Renal"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 22, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Amvuttra", "phase": "Marketed", "indication": "Amyloidosis"}, {"name": "Givlaari", "phase": "Marketed", "indication": "Porphyria"}, {"name": "Leqvio", "phase": "Marketed", "indication": "Cardiovascular (unspecified)"}, {"name": "Onpattro", "phase": "Marketed", "indication": "Amyloidosis"}, {"name": "Oxlumo", "phase": "Marketed", "indication": "Hyperoxaluria"}, {"name": "Qfitlia", "phase": "Approved", "indication": "Hemophilia"}, {"name": "cemdisiran (ALN-CC5)", "phase": "Phase III", "indication": "Myasthenia gravis"}, {"name": "zilebesiran (RG6615", "phase": "Phase III", "indication": "Cardiovascular (unspecified)"}], "ceo": "Yvonne L. Greenstreet, MD, MBA", "employees": 2230, "founded": 2002, "website": "http://www.alnylam.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 30086471810.0, "evFmt": "$30.1B", "ticker": "ALNY", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-08-26", "recentDeals": [{"headline": "Scenic Enters License and Research Agreement with Alnylam", "date": "2025-08-26", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alnylam%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Hematology (non-cancer)", "Kidney Disease", "MS / Neuroimmune", "Other", "Supportive / Other"]}, {"company": "Alopexx Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "F598", "phase": "Phase II", "indication": "Bacterial infection"}, {"name": "PNAG Vaccine (AV0328)", "phase": "Phase I", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 2006, "website": "https://www.alopexx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alopexx", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Alora Pharmaceuticals LLC", "city": "Alpharetta", "state": "GA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Dsuvia", "phase": "Marketed", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://alorapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alora%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Alphageneron Pharmaceuticals Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Ankastim", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "Chimeric Antigen Receptor (CAR) NK Cells", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://alphageneron.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alphageneron%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Alphavax Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Gene Therapy", "Vaccine"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CMV alphavaccine (AVX601)", "phase": "Phase I", "indication": "Cytomegalovirus (CMV)"}, {"name": "CEA-expressing VRP vaccine (AVX701)", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "Influenza alphavaccine (AVX502)", "phase": "Phase I/II", "indication": "Influenza virus"}, {"name": "AVX901", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "HIV vaccine (AVX101)", "phase": "Phase I", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.alphavax.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alphavax", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Alphyn Biologics Inc.", "city": "Cincinnati", "state": "OH", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Nanoparticle / Delivery", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Zabalafin Hydrogel (AB-101a)", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "AB-101b", "phase": "Preclinical", "indication": "Epidermolysis bullosa"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://alphynbiologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alphyn%20Biologics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Alseres Pharmaceuticals Inc.", "city": "Auburndale", "state": "MA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Altropane (NAV5001)", "phase": "Phase III", "indication": "Neurology, Diagnostic"}], "ceo": "", "employees": 0, "founded": 1992, "website": "http://www.alseres.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alseres%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Altathera Pharmaceuticals LLC", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Sotalol IV", "phase": "Marketed", "indication": "Fibrillation"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://altathera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Altathera%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Alterome Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AKTI E17K", "phase": "Preclinical", "indication": "Endometrial cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "http://www.alterome.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alterome%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Altesa Biosciences Inc.", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ALT-2023", "phase": "Preclinical", "indication": "Enterovirus"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://altesabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-02-10", "recentDeals": [{"headline": "Altesa BioSciences, Inc., Launches Operations to Develop, Commercialize Drugs for Respiratory Viruses and Global Viral Threats", "date": "2022-02-10", "value": ""}], "totalRaised": 39000000.0, "totalRaisedFmt": "$39M", "latestFinDate": "2022-12-22", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$35M", "date": "2022-12-22", "investors": "Undisclosed Investors"}, {"type": "Seed financings", "amount": "$4M", "date": "2022-02-10", "investors": "Pitango Venture Capital, Gra Venture Fund"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Altesa%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Other"]}, {"company": "Altibio Inc.", "city": "Half Moon Bay", "state": "CA", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ATB226", "phase": "Preclinical", "indication": "Genetic disorders"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.altibio.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Altibio", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Altimmune Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic", "Neurology"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "pemvidutide (ALT-801", "phase": "Phase II", "indication": "Obesity"}], "ceo": "Jerome B. Durso", "employees": 59, "founded": 1997, "website": "http://www.altimmune.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 381682506.79, "evFmt": "$382M", "ticker": "ALT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Altimmune", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Alto Neuroscience Inc.", "city": "Mountain View", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "agomelatine (ALTO-300)", "phase": "Phase II", "indication": "Depression"}, {"name": "ALTO-100", "phase": "Phase II", "indication": "Depression"}, {"name": "ALTO-101", "phase": "Phase II", "indication": "Schizophrenia"}, {"name": "ALTO-202", "phase": "Phase II", "indication": "Depression"}, {"name": "ALTO-203", "phase": "Phase II", "indication": "Depression"}, {"name": "Pramipexole IR (ALTO-207", "phase": "Phase II", "indication": "Depression"}], "ceo": "Amit Etkin, MD, PhD", "employees": 76, "founded": 2019, "website": "https://www.altoneuroscience.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -47218540.0, "evFmt": "", "ticker": "ANRO", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alto%20Neuroscience", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Altpep Corp.", "city": "Mercer Island", "state": "WA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Peptide"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SOBIN-AD", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "SOBIN-PD", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.altpep.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Altpep", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Parkinson's"]}, {"company": "Altravax Inc.", "city": "Fargo", "state": "ND", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Dengue virus vaccine", "phase": "Preclinical", "indication": "Dengue fever"}, {"name": "Therapeutic hepatitis B vaccine", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.altravax.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Altravax", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Altrixbio Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LuCI (AJN 003)", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://altrixbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Altrixbio", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Altrubio Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Transplant"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "neihulizumab", "phase": "Phase II", "indication": "Psoriatic arthritis"}, {"name": "leiolizumab (AbGn-268", "phase": "Phase I", "indication": "Ulcerative colitis"}], "ceo": "", "employees": 0, "founded": 2000, "website": "https://www.altrubio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Altrubio", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "IBD / GI Inflammatory"]}, {"company": "Alucent Biomedical Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AlucentNVS", "phase": "Phase I", "indication": "Peripheral vascular disease (PVD)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://alucentmedical.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alucent%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Aluda Pharmaceuticals Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Pulmonary"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ALD-R491", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Aluda-exosome release inhibitor-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Aluda-I-O STAT3 Potentiators-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Aluda-Methuotics-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Aluda-Th17/Treg balancer-unknown", "phase": "Preclinical", "indication": "Psoriasis"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://aludapharm.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aluda%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Alume Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Bevonescein (ALM-488)", "phase": "Phase III", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://alumebiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alume%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Alumis Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Ophthalmic", "Renal"], "modalityGroups": ["Antibody", "Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "envudeucitinib (ESK-001)", "phase": "Phase III", "indication": "Psoriasis"}, {"name": "izokibep (ABY-035", "phase": "Phase III", "indication": "Ankylosing spondylitis"}, {"name": "VB119", "phase": "Phase I/II", "indication": "Membranous nephropathy"}, {"name": "lonigutamab (VB421)", "phase": "Preclinical", "indication": "Thyroid eye disease"}], "ceo": "Martin Babler", "employees": 168, "founded": 2020, "website": "https://www.alumis.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 170100590.22, "evFmt": "$170M", "ticker": "ALMS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alumis", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology", "Ophthalmology", "Other"]}, {"company": "Alveolus Bio Inc.", "city": "Birmingham", "state": "AL", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AB1000", "phase": "Preclinical", "indication": "Bronchopulmonary dysplasia (BPD)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.alveolusbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alveolus%20Bio", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Alx Oncology Holdings Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "evorpacept (ALX148)", "phase": "Phase II/III", "indication": "Gastric cancer"}, {"name": "ALTA-002", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Jason Lettmann, MBA", "employees": 80, "founded": 2015, "website": "https://alxoncology.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -23646910.32, "evFmt": "", "ticker": "ALXO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alx%20Oncology%20Holdings", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Alxcrypto Holdings Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "ALAN", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "QN-247 (ALAN)", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "QN-302 (SOP1812)", "phase": "Preclinical", "indication": "Pancreatic cancer"}, {"name": "RAS-F", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Kevin A. Richardson, II, MBA; Jiawei Wang", "employees": 0, "founded": 2002, "website": "https://www.qualigeninc.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 6064073.27, "evFmt": "$6M", "ticker": "AIXC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alxcrypto%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Hematologic Cancers"]}, {"company": "Alzamend Neuro Inc.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ALZN002 (AL002", "phase": "Phase I/II", "indication": "Alzheimer's disease"}, {"name": "AL001", "phase": "Phase I", "indication": "Alzheimer's disease"}], "ceo": "Stephan Jackman", "employees": 7, "founded": 2016, "website": "https://alzamend.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -1270909.262248, "evFmt": "", "ticker": "ALZN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alzamend%20Neuro", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Alzheon Inc.", "city": "Framingham", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Musculoskeletal", "Ophthalmic"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ALZ-1903", "phase": "Preclinical", "indication": "Amyloidosis"}, {"name": "ALZ-507", "phase": "Preclinical", "indication": "Amyloidosis"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://alzheon.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Alzheon", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Amaro Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Amaro Therapeutics-TAS2R1-unknown", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.amarotx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amaro%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Amasa Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Amasa-cancer-unknown", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.amasatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amasa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Ambys Medicines Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AMI-918", "phase": "Preclinical", "indication": "Liver disease"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.ambys.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ambys%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "American Biotech Labs LLC", "city": "Alpine", "state": "UT", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "asap antibacterial silver wound dressing gel", "phase": "Marketed", "indication": "Wounds"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.americanbiotechlabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=American%20Biotech%20Labs", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "American Gene Technologies International Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AGT103-T", "phase": "Phase I", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.americangenetechnologies.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=American%20Gene%20Technologies%20International", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Amgen Inc.", "city": "Thousand Oaks", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dermatology", "Endocrine/Metabolic", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Ophthalmic", "Pulmonary", "Renal", "Transplant"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Combination", "Digital / Device", "Oncolytic / Microbiome", "Other", "Peptide", "Protein / Biologic", "Small Molecule", "Undisclosed"], "nProducts": 86, "mostAdvanced": "Phase IV", "hasOrphan": true, "pipeline": [{"name": "azelaprag (BGE-105", "phase": "Phase I", "indication": "Obesity"}, {"name": "sovilnesib (AMG650)", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "NMRA-CK1d", "phase": "Research", "indication": "Alzheimer's disease"}, {"name": "NMRA-GCase", "phase": "Research", "indication": "Parkinson's disease"}, {"name": "Repatha", "phase": "Phase IV", "indication": "Myocardial infarction (MI)"}, {"name": "Actimmune", "phase": "Marketed", "indication": "Chronic granulomatous disease (CGD)"}, {"name": "Aimovig", "phase": "Marketed", "indication": "Migraine"}, {"name": "Amgevita", "phase": "Marketed", "indication": "Ankylosing spondylitis"}], "ceo": "Robert A. Bradway, MBA", "employees": 0, "founded": 1980, "website": "http://www.amgen.com", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 222877020000.0, "evFmt": "$222.9B", "ticker": "AMGN", "exchange": "NASDAQ", "nDeals": 5, "totalDealValue": 1118000000.0, "totalDealFmt": "$1.1B", "latestDealDate": "2026-01-07", "recentDeals": [{"headline": "Disco Pharmaceuticals Enters License Agreement with Amgen to Advance Novel Cancer Surfaceome Targeted Therapies", "date": "2026-01-07", "value": "$618M"}, {"headline": "A-Alpha Bio Collaborates with Amgen to Identify and Validate Ligase-Target Pairs for Molecular Glue Discovery", "date": "2023-09-26", "value": ""}, {"headline": "Amgen grants Volastra Therapeutics an exclusive worldwide license to develop and commercialize sovilnesib", "date": "2023-03-07", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amgen", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Autoimmune / Rheumatology", "Cardiovascular", "Obesity / Metabolic", "Other", "Pain / Migraine", "Parkinson's", "Solid Tumors (General)"]}, {"company": "Amherst Pharmaceuticals LLC", "city": "Basking Ridge", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Zolpimist (zolpidem lingual spray", "phase": "Marketed", "indication": "Insomnia"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://amherstpharmaceuticals.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amherst%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Amicrobe Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Amicidin-Beta", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.amicrobe.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amicrobe", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Amicus Therapeutics Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Gene Therapy", "Protein / Biologic", "Small Molecule"], "nProducts": 13, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Galafold", "phase": "Marketed", "indication": "Fabry disease"}, {"name": "Pombiliti and Opfolda", "phase": "Approved", "indication": "Pompe disease"}, {"name": "Pombiliti", "phase": "Approved", "indication": "Pompe disease"}, {"name": "Opfolda", "phase": "Registration", "indication": "Pompe disease"}, {"name": "AAV9-CLN3", "phase": "Phase I/II", "indication": "Neuronal ceroid lipofuscinosis"}, {"name": "AT-GTX-501", "phase": "Phase I/II", "indication": "Neuronal ceroid lipofuscinosis"}, {"name": "AAV9-CDKL5", "phase": "Preclinical", "indication": "CDKL5 deficiency disorder"}, {"name": "AAV9-CLN1", "phase": "Preclinical", "indication": "Neuronal ceroid lipofuscinosis"}], "ceo": "Bradley Lewis Campbell, MBA", "employees": 499, "founded": 2002, "website": "https://amicusrx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 3060962328.84, "evFmt": "$3.1B", "ticker": "FOLD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amicus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Other", "Rare / Genetic"]}, {"company": "Aminex Therapeutics Inc.", "city": "Kirkland", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AMXT 1501", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "AMX-513", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.aminextx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aminex%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Amivas LLC", "city": "Frederick", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Artesunate IV", "phase": "Approved", "indication": "Malaria"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://amivas.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amivas", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Ammax Bio Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AMB-05X", "phase": "Phase II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.ammaxbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-01-09", "recentDeals": [{"headline": "Ammax Bio enters into an exclusive option agreement with Evopoint Biosciences to license a next generation antibody drug conjugate for the treatment of solid tumors", "date": "2023-01-09", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ammax%20Bio", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Amneal Pharmaceuticals Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Combination", "Other", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Daraprim", "phase": "Marketed", "indication": "Malaria"}, {"name": "Lioresal", "phase": "Marketed", "indication": "Spasm"}, {"name": "Lyvispah", "phase": "Marketed", "indication": "Spasm"}, {"name": "Numient", "phase": "Marketed", "indication": "Parkinson's disease"}, {"name": "Crexont", "phase": "Approved", "indication": "Parkinson's disease"}, {"name": "IPX229", "phase": "Phase III", "indication": "Migraine"}, {"name": "IPX231", "phase": "Phase I", "indication": "Parkinson's disease"}, {"name": "IPX232", "phase": "Phase I", "indication": "Migraine"}], "ceo": "Chintu Patel, PhD; Chirag K. Patel, PhD", "employees": 8300, "founded": 1999, "website": "https://www.amneal.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4986553760.0, "evFmt": "$5.0B", "ticker": "AMRX", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-10-01", "recentDeals": [{"headline": "Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases", "date": "2024-10-01", "value": ""}, {"headline": "Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR (Omalizumab)", "date": "2024-07-01", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amneal%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other", "Pain / Migraine", "Parkinson's"]}, {"company": "Amphastar Pharmaceuticals Inc.", "city": "Rancho Cucamonga", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Infectious", "Neurology"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase IV", "hasOrphan": false, "pipeline": [{"name": "Enoxaparin", "phase": "Phase IV", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Baqsimi", "phase": "Marketed", "indication": "Hypoglycemia"}, {"name": "Intranasal Naloxone (naloxone hydrochloride 2 mg/0.5 ml nasal spray)", "phase": "Marketed", "indication": "Substance use disorders"}, {"name": "Isoproterenol HCl", "phase": "Marketed", "indication": "Cardiovascular (unspecified)"}, {"name": "Phytonadione", "phase": "Marketed", "indication": "Block coagulation"}], "ceo": "Yong Feng Zhang, PhD", "employees": 2028, "founded": 1996, "website": "http://www.amphastar.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2359382540.0, "evFmt": "$2.4B", "ticker": "AMPH", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amphastar%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "Infectious Disease", "Other", "Psychiatry / Behavioral"]}, {"company": "Amphivena Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "AMV564", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.amphivena.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amphivena%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Amphix Bio Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Musculoskeletal", "Neurology"], "modalityGroups": ["Digital / Device", "Peptide", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "AMFX-100", "phase": "Preclinical", "indication": "Bone repair"}, {"name": "AMFX-200", "phase": "Preclinical", "indication": "Spinal cord injury (SCI)"}, {"name": "AMFX-200S", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "Amphix Bio-chronic spinal cord injury-unknown", "phase": "Preclinical", "indication": "Spinal cord injury (SCI)"}, {"name": "Amphix Bio-Parkinson's disease-unknown", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.amphixbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amphix%20Bio", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Neurodegeneration / NMD", "Other Neurology", "Parkinson's"]}, {"company": "Ampio Pharmaceuticals Inc.", "city": "Englewood", "state": "CO", "country": "United States", "diseaseCats": ["Autoimmune", "Diagnostic", "Genitourinary", "Neurology", "Ophthalmic"], "modalityGroups": ["Combination", "Diagnostics", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Zertane", "phase": "Phase III", "indication": "Premature ejaculation"}, {"name": "Optina", "phase": "Phase II", "indication": "Diabetic macular edema (DME)"}, {"name": "AR-300", "phase": "Preclinical", "indication": "Osteoarthritis"}, {"name": "RedoxSYS Diagnostic System", "phase": "Preclinical", "indication": "Neurology, Diagnostic"}, {"name": "Zertane+ED", "phase": "Preclinical", "indication": "Erectile dysfunction (ED)"}], "ceo": "Michael A. Martino, MBA", "employees": 6, "founded": 2008, "website": "http://www.ampiopharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -2154268.35, "evFmt": "", "ticker": "AMPE", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ampio%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Musculoskeletal", "Other", "Other Neurology", "Other Specialties"]}, {"company": "Amplicore Inc.", "city": "Mason", "state": "OH", "country": "United States", "diseaseCats": ["Autoimmune", "Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AM1101", "phase": "Preclinical", "indication": "Osteoarthritis"}, {"name": "AM3101", "phase": "Preclinical", "indication": "Cartilage repair"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.amplicorepharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amplicore", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Amplifica Holdings Group Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Protein / Biologic", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AMP-303", "phase": "Preclinical", "indication": "Androgenetic alopecia"}, {"name": "AMP-506", "phase": "Preclinical", "indication": "Androgenetic alopecia"}, {"name": "AMP-601 (SCUBE3)", "phase": "Preclinical", "indication": "Androgenetic alopecia"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://amplificabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-01-26", "recentDeals": [{"headline": "Amplifica expands pipeline for hair loss", "date": "2023-01-26", "value": ""}], "totalRaised": 11800000.0, "totalRaisedFmt": "$12M", "latestFinDate": "2022-10-24", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$12M", "date": "2022-10-24", "investors": "Sternaegis Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amplifica%20Holdings%20Group", "hasDealsFin": true, "diseaseGroups": ["Dermatology"]}, {"company": "Amplo Biotechnology Inc.", "city": "Pompano Beach", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "AMP-101", "phase": "Preclinical", "indication": "Myasthenia gravis"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.amplobiotechnology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amplo%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Amrixa Pharmaceuticals LLC", "city": "Torrance", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RXA-2", "phase": "Preclinical", "indication": "Inflammatory disease"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://www.amrixapharmaceuticals.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amrixa%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Amygdala Neurosciences Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ANS-858", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.amygns.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amygdala%20Neurosciences", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Amylyx Pharmaceuticals Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Other"], "modalityGroups": ["Peptide", "RNA Therapeutics", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "Albrioza", "phase": "Phase II/III", "indication": "Progressive supranuclear palsy (PSP)"}, {"name": "avexitide (Exendin 9-39)", "phase": "Phase II", "indication": "Hypoglycemia"}, {"name": "AMX0114", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "Josh Cohen; Justin Klee", "employees": 123, "founded": 2014, "website": "https://www.amylyx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 83057357.24, "evFmt": "$83M", "ticker": "AMLX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amylyx%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Neurodegeneration / NMD", "Other"]}, {"company": "Amytrx Therapeutics Inc.", "city": "Nashville", "state": "TN", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Infectious"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AMTX-100 CF", "phase": "Phase I/II", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.amytrx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Amytrx%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "An2 Therapeutics Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "epetraborole (AN2-501971", "phase": "Phase II/III", "indication": "Mycobacterium"}, {"name": "AN2-502998 (AN15368)", "phase": "Preclinical", "indication": "Chagas disease"}], "ceo": "Eric Easom, MBA", "employees": 22, "founded": 2019, "website": "http://www.an2therapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -42455046.74, "evFmt": "", "ticker": "ANTX", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-10-18", "recentDeals": [{"headline": "AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease", "date": "2023-10-18", "value": ""}], "totalRaised": 80000000.0, "totalRaisedFmt": "$80M", "latestFinDate": "2022-01-07", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$80M", "date": "2022-01-07", "investors": "Ra Capital Management L.P., Bvf Partners L.P., Surveyor Capital, Avidity Partners, Monashee Investment Management, Hatte..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=An2%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Anagram Therapeutics Inc.", "city": "Framingham", "state": "MA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Pulmonary"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ANG003 (SNSP003)", "phase": "Phase I", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://anagramtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anagram%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Ananda Scientific Inc.", "city": "Greenwood Village", "state": "CO", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Nantheia (ATL5)", "phase": "Phase II", "indication": "Pain"}, {"name": "Nantheia", "phase": "Phase II", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.anandascientific.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ananda%20Scientific", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Anaptysbio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Infectious", "Inflammation"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Jemperli", "phase": "Marketed", "indication": "Endometrial cancer"}, {"name": "imsidolimab (ANB019)", "phase": "Phase III", "indication": "Psoriasis"}, {"name": "cobolimab (GSK4069889", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "etokimab (ANB020)", "phase": "Phase II", "indication": "Sinusitis"}, {"name": "Rosnilimab (ANB030)", "phase": "Phase II", "indication": "Rheumatoid arthritis (RA)"}, {"name": "ANB032", "phase": "Phase I", "indication": "Inflammatory disease"}, {"name": "CC-90006", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "GSK4074386", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "Daniel R. Faga, MBA", "employees": 136, "founded": 2005, "website": "https://www.anaptysbio.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 359867680.0, "evFmt": "$360M", "ticker": "ANAB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anaptysbio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology", "GU / Gynecologic Cancers", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Anavex Life Sciences Corp.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Oral ANAVEX 2-73", "phase": "Phase III", "indication": "Alzheimer's disease"}, {"name": "IV ANAVEX 2-73", "phase": "Phase II/III", "indication": "Alzheimer's disease"}, {"name": "ANAVEX 3-71", "phase": "Phase I", "indication": "Frontotemporal dementia"}, {"name": "ANAVEX 1037", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "ANAVEX 1066", "phase": "Preclinical", "indication": "Pain"}, {"name": "ANAVEX 1-41", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "Christopher U. Missling, PhD, MBA", "employees": 34, "founded": 2006, "website": "http://www.anavex.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 656499078.3, "evFmt": "$656M", "ticker": "AVXL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anavex%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "GI Cancers", "Pain / Migraine"]}, {"company": "Anchor Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Hematology"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ATI-2341", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.anchortx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anchor%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Androscience Corp.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ASC-J9", "phase": "Phase II", "indication": "Acne"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.androscience.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Androscience", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Anexon Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ANX-042", "phase": "Phase I", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.anexonrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anexon", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Angarus Therapeutics Inc.", "city": "Portola Valley", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AG-3132", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.angarustherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Angarus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Angeles Therapeutics Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 13, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Angeles Therapeutics-BCMA-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Angeles Therapeutics-CD123-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Angeles Therapeutics-CD19-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Angeles Therapeutics-CD19xCD20-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Angeles Therapeutics-CD19xCD20xBCMA-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Angeles Therapeutics-CD19xCD20xCD22-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Angeles Therapeutics-CD19xCD22-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Angeles Therapeutics-CS1-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://angelestherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Angeles%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Angiex Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AGX101", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://angiex.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Angiex", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Angiocrine Bioscience Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "AB-205", "phase": "Phase II", "indication": "Organ damage"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.angiocrinebioscience.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Angiocrine%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Angiogenex Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Idantirx (AGX-51)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Michael Charles Aronstein", "employees": 0, "founded": 1999, "website": "http://www.angiogenex.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "AGGX", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Angiogenex", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Angitia Biopharmaceuticals Ltd.", "city": "Woodland Hills", "state": "CA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Bispecific Antibody", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "AGA111", "phase": "Phase III", "indication": "Cartilage repair"}, {"name": "AGA2118", "phase": "Phase II", "indication": "Osteoporosis"}, {"name": "AGA2115", "phase": "Phase I", "indication": "Osteogenesis imperfecta"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://angitiabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Angitia%20Biopharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Other"]}, {"company": "Angstrom Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Ophthalmic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "A6", "phase": "Phase II", "indication": "Chronic lymphocytic leukemia (CLL)"}], "ceo": "", "employees": 0, "founded": 1996, "website": "http://www.angstrominc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Angstrom%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Ani Pharmaceuticals Inc.", "city": "Baudette", "state": "MN", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Renal"], "modalityGroups": ["Combination", "Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Bio-T-Gel", "phase": "Marketed", "indication": "Hypogonadism"}, {"name": "Purified Cortrophin Gel", "phase": "Approved", "indication": "Multiple sclerosis (MS)"}, {"name": "Pill-Plus", "phase": "Phase II", "indication": "Contraception"}], "ceo": "Nikhil Lalwani, MBA", "employees": 897, "founded": 2004, "website": "http://www.anipharmaceuticals.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1572228040.0, "evFmt": "$1.6B", "ticker": "ANIP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ani%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune", "Other Specialties", "Women's Health"]}, {"company": "Anida Pharma Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Neuroprotectin D1", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://anidapharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anida%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Anika Therapeutics Inc.", "city": "Bedford", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Musculoskeletal", "Neurology", "Ophthalmic"], "modalityGroups": ["Digital / Device", "Other"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Amvisc", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}, {"name": "Cingal", "phase": "Marketed", "indication": "Osteoarthritis"}, {"name": "Hyalofast", "phase": "Marketed", "indication": "Cartilage repair"}, {"name": "Hyalofill", "phase": "Marketed", "indication": "Wounds"}, {"name": "Hyaloglide", "phase": "Marketed", "indication": "Adhesions"}, {"name": "Hyalomatrix", "phase": "Marketed", "indication": "Wounds"}, {"name": "Monovisc", "phase": "Marketed", "indication": "Pain"}, {"name": "Orthovisc", "phase": "Marketed", "indication": "Osteoarthritis"}], "ceo": "Stephen D. Griffin, MBA", "employees": 288, "founded": 1983, "website": "http://www.anikatherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 212610660.0, "evFmt": "$213M", "ticker": "ANIK", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anika%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Musculoskeletal", "Ophthalmology", "Pain / Migraine", "Supportive / Other"]}, {"company": "Anima Biotech Inc.", "city": "Bernardsville", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Anima-cancer-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Anima-lung fibrosis-unknown", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.animabiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anima%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Anivive Lifesciences Inc.", "city": "Long Beach", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GC376", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.anivive.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anivive%20Lifesciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Anixa Biosciences Inc.", "city": "San Jose", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Cell Therapy", "Other", "Vaccine"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Anixa Biosciences-CAR-T-unknown", "phase": "Phase I", "indication": "Ovarian cancer"}, {"name": "Anixa-breast cancer vaccine-unknown", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "Anixa Biosciences-COVID 19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Anixa-Ovarian cancer vaccine-Unknown", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "Amit D. Kumar, PhD, MBA", "employees": 4, "founded": 1982, "website": "https://www.anixa.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 117854020.0, "evFmt": "$118M", "ticker": "ANIX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anixa%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Infectious Disease"]}, {"company": "Anji Pharmaceuticals Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Gastrointestinal"], "modalityGroups": ["Bispecific Antibody", "Macrocycle", "Peptide", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Metformin DR (ANJ900", "phase": "Phase III", "indication": "Diabetes"}, {"name": "AEM-28", "phase": "Phase I/II", "indication": "Hypercholesterolemia"}, {"name": "TTX-564", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "TTX-114", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "TTX-810", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.anjipharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anji%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Hematologic Cancers", "Obesity / Metabolic", "Solid Tumors (General)"]}, {"company": "Ankyra Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "tolododekin alfa (ANK-101)", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://ankyratx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ankyra%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Annexon Inc.", "city": "Brisbane", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology", "Ophthalmic"], "modalityGroups": ["Antibody", "Other"], "nProducts": 3, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "tanruprubart (ANX005)", "phase": "Phase II/III", "indication": "Guillain-Barre syndrome (GBS)"}, {"name": "ANX007", "phase": "Phase II", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "ANX009", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "Douglas Love", "employees": 100, "founded": 2011, "website": "http://www.annexonbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 421838263.85, "evFmt": "$422M", "ticker": "ANNX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Annexon", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Ophthalmology", "Other"]}, {"company": "Annias Immunotherapeutics Inc.", "city": "Chapel Hill", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "PEP-CMV", "phase": "Phase I/II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.anniasimmuno.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Annias%20Immunotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Annovis Bio Inc.", "city": "Berwyn", "state": "PA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "ANVS405", "phase": "IND", "indication": "Shock/trauma"}], "ceo": "Maria-Luisa Maccecchini, PhD", "employees": 8, "founded": 2008, "website": "http://www.annovisbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 50992367.32, "evFmt": "$51M", "ticker": "ANVS", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Annovis%20Bio", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Ansun Biopharma Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Fludase", "phase": "Phase III", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.ansunbiopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ansun%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Anticancer Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "METase", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 1984, "website": "http://www.anticancer.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Anticancer", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Antidote Therapeutics Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Cardiovascular", "Neurology"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "ATI-1013", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "ATI-3009", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.antidotetx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Antidote%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Psychiatry / Behavioral"]}, {"company": "Antipodean Pharmaceuticals Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "MitoQ", "phase": "Phase II", "indication": "Liver disease"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.antipodeanpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Antipodean%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Antiva Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Genitourinary", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ABI-2280", "phase": "Phase I/II", "indication": "Cervical intraepithelial neoplasia (CIN)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.antivabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Antiva%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Aobiome Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Inflammation", "Neurology"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AOB101", "phase": "Phase II", "indication": "Acne"}, {"name": "AOB102", "phase": "Phase II", "indication": "Itch"}, {"name": "AOB103", "phase": "Phase II", "indication": "Rosacea"}, {"name": "AOB201", "phase": "Phase II", "indication": "Rhinitis"}, {"name": "AOB202", "phase": "Phase II", "indication": "Hypertension"}, {"name": "AOB203", "phase": "Phase II", "indication": "Migraine"}, {"name": "B244", "phase": "Phase II", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.aobiome.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aobiome%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Dermatology", "Pain / Migraine", "Respiratory / Allergy"]}, {"company": "Apellis Pharmaceuticals Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Hematology", "Inflammation", "Neurology", "Ophthalmic", "Renal"], "modalityGroups": ["Gene Therapy", "Peptide", "Protein / Biologic", "RNA Therapeutics", "Undisclosed"], "nProducts": 9, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Aspaveli", "phase": "Marketed", "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)"}, {"name": "Syfovre", "phase": "Marketed", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "APL-3007", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "APL-9", "phase": "Phase I", "indication": "Inflammation (unspecified)"}, {"name": "Apellis Pharmaceuticals-brain shuttle-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Apellis Pharmaceuticals-gene therapies-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Apellis Pharmaceuticals-oral alternative pathway inhibitor-unknown", "phase": "Preclinical", "indication": "C3 glomerulopathy"}, {"name": "APL-1030", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "Cedric Francois, MD, PhD", "employees": 710, "founded": 2008, "website": "http://www.apellis.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4010980550.0, "evFmt": "$4.0B", "ticker": "APLS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apellis%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematology (non-cancer)", "Ophthalmology", "Other", "Other Inflammation", "Other Neurology"]}, {"company": "Apertor Pharmaceuticals Inc.", "city": "Alameda", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Apertor Pharmaceuticals-mTORC1/4EBP1 inhibitor-unknown", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.apertorpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apertor%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Apexian Pharmaceuticals Inc.", "city": "Indianapolis", "state": "IN", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "APX2009", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://apexianpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apexian%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Apexqubit Inc.", "city": "Berkeley", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "rnptx-001", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "rnptx-002", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.apexqubit.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apexqubit", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Aphios Corp.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Infectious", "Neurology"], "modalityGroups": ["Combination", "Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "Zindol", "phase": "Phase II/III", "indication": "Emesis"}, {"name": "APH-0812", "phase": "Phase I/II", "indication": "HIV/AIDS"}, {"name": "APH-1104", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 1993, "website": "http://www.aphios.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aphios", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Infectious Disease", "Supportive / Other"]}, {"company": "Apic Bio Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Hepatic", "Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "AMT-162 (APB-102)", "phase": "Phase I/II", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "APB-101", "phase": "Preclinical", "indication": "Hepatic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.apic-bio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apic%20Bio", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Neurodegeneration / NMD"]}, {"company": "Apie Therapeutics Inc.", "city": "Cary", "state": "NC", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Pulmonary", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "APT-101", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}, {"name": "APT-102", "phase": "Preclinical", "indication": "Heart failure"}, {"name": "APT-103", "phase": "Preclinical", "indication": "Metabolic syndrome"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://apie-therapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apie%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Other", "Respiratory / Allergy"]}, {"company": "Apnimed Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "AD109", "phase": "Phase III", "indication": "Sleep apnea"}, {"name": "AD504", "phase": "Phase II", "indication": "Sleep apnea"}, {"name": "AD036", "phase": "Preclinical", "indication": "Sleep apnea"}, {"name": "AD128", "phase": "Preclinical", "indication": "Sleep apnea"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://apnimed.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-04-25", "recentDeals": [{"headline": "Apnimed Expands Portfolio of Oral Pharmacotherapies for Sleep and Breathing Diseases Through Acquisition of Global Rights to Patents Covering Sulthiame, a Differentiated Carbonic Anhydrase Inhibitor, from Desitin Arzneimittel", "date": "2025-04-25", "value": ""}], "totalRaised": 193749932.0, "totalRaisedFmt": "$194M", "latestFinDate": "2025-09-17", "latestFinType": "Venture (Debt)", "nRounds": 4, "recentFinancing": [{"type": "Venture (Debt)", "amount": "$35M", "date": "2025-09-17", "investors": "Undisclosed Investors"}, {"type": "Uncategorized venture rounds", "amount": "$16M", "date": "2025-04-23", "investors": "Undisclosed Investors"}, {"type": "Series D rounds", "amount": "$80M", "date": "2022-12-23", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apnimed", "hasDealsFin": true, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Apogee Biotechnology Corp.", "city": "Hummelstown", "state": "PA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "Yeliva (opaganib", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.apogee-biotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apogee%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Apollomics Inc.", "city": "Foster City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Geptanolimab", "phase": "Registration", "indication": "T cell lymphoma"}, {"name": "benmelstobart (APL-502", "phase": "Phase III", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "APL-102", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "APL-001", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "APL-103 (ES-072)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Hung Wen Chen", "employees": 13, "founded": 2016, "website": "https://www.apollomicsinc.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1145000.0, "evFmt": "$1M", "ticker": "APLM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apollomics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Hematologic Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Apoplogic Pharmaceuticals LLC", "city": "Aurora", "state": "CO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Breceptin (B201)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.apoplogic.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apoplogic%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Apovax Inc.", "city": "Louisville", "state": "KY", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic", "Vaccine"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Apo195", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "ApoVax-104", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.apovax.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apovax", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Solid Tumors (General)"]}, {"company": "Appello Pharmaceuticals Inc.", "city": "Nashville", "state": "TN", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AP-472", "phase": "Phase I", "indication": "Parkinson's disease"}, {"name": "AP-612", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://appellopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Appello%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Neurology", "Parkinson's"]}, {"company": "Applied Biology Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Diagnostic", "Genitourinary"], "modalityGroups": ["Diagnostics", "Oncolytic / Microbiome", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "MRT", "phase": "Marketed", "indication": "Dermatology, Diagnostic"}, {"name": "AB-103", "phase": "Phase III", "indication": "Androgenetic alopecia"}, {"name": "AB-105", "phase": "Phase III", "indication": "Other alopecia"}, {"name": "AB-101", "phase": "Phase I", "indication": "Sexual dysfunction"}, {"name": "AB-102", "phase": "Phase I", "indication": "Other alopecia"}, {"name": "AB-107", "phase": "Phase I", "indication": "Psoriasis"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.appliedbiology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Applied%20Biology", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Other Specialties"]}, {"company": "Applied Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Infectious", "Ophthalmic", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "govorestat (AT-007)", "phase": "Registration", "indication": "Metabolic (unspecified)"}, {"name": "AT-001", "phase": "Phase III", "indication": "Diabetes"}, {"name": "AT-003", "phase": "Preclinical", "indication": "Diabetic retinopathy"}, {"name": "AT-104", "phase": "Preclinical", "indication": "Leukemia"}], "ceo": "Les Funtleyder", "employees": 35, "founded": 2016, "website": "http://www.appliedtherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 42866649.5252, "evFmt": "$43M", "ticker": "APLT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Applied%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Hematologic Cancers", "Obesity / Metabolic"]}, {"company": "Aprea Therapeutics Inc.", "city": "Doylestown", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ATRN-119", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "APR-1051 (ATRN-W1051)", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "APR-DDRi (ATRN-DDRi)", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Oren Gilad, PhD", "employees": 8, "founded": 2003, "website": "http://www.aprea.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -3411181.660665, "evFmt": "", "ticker": "APRE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aprea%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Aprinoia Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Diagnostic", "Neurology"], "modalityGroups": ["Antibody", "Diagnostics", "Undisclosed"], "nProducts": 7, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "florzolotau (18F) (APN-1607)", "phase": "Phase III", "indication": "Neurology, Diagnostic"}, {"name": "APNmAb005", "phase": "Phase I", "indication": "Neurology (unspecified)"}, {"name": "APN-1701", "phase": "Preclinical", "indication": "Neurology, Diagnostic"}, {"name": "Aprinoia Therapeutics-alphaSyn Degrader-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Aprinoia Therapeutics-alphaSyn PET Tracer-unknown", "phase": "Preclinical", "indication": "Neurology, Diagnostic"}, {"name": "Aprinoia Therapeutics-Tau Degrader-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Aprinoia Therapeutics-Tau Modulator-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.aprinoia.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aprinoia%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Apros Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "APR003", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "APR002", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "APR005", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "APR006", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "APR007", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://aprostx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apros%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Liver Disease", "Solid Tumors (General)"]}, {"company": "Apt Therapeutics Inc.", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Cardiovascular", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "APT102", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.apt-therapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Apt%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Aptevo Therapeutics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody", "Other"], "nProducts": 7, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "APVO436", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "ALG.APV-527", "phase": "IND", "indication": "Cancer (unspecified)"}, {"name": "Aptevo-Hematologic-Unknown", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "Aptevo-Solid tumors-Unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "APVO425", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "APVO442", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "APVO603", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Marvin L. White, MBA", "employees": 42, "founded": 2016, "website": "http://aptevotherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -2894849.533448, "evFmt": "", "ticker": "APVO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aptevo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Aptinyx Inc.", "city": "Evanston", "state": "IL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NYX-2925", "phase": "Phase II", "indication": "Pain"}, {"name": "NYX-458", "phase": "Phase II", "indication": "Cognitive dysfunction"}, {"name": "NYX-783", "phase": "Phase II", "indication": "Post-traumatic stress disorder"}], "ceo": "Craig R. Jalbert", "employees": 12, "founded": 2015, "website": "http://www.aptinyx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -11824600.0, "evFmt": "", "ticker": "APTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aptinyx", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Aqualung Therapeutics Corp.", "city": "Tucson", "state": "AZ", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Genitourinary", "Infectious", "Pulmonary"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "ALT-100", "phase": "IND", "indication": "Coronavirus disease (COVID-19)"}, {"name": "ALT-200", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.aqualungtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aqualung%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Aquestive Therapeutics Inc.", "city": "Warren", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Gastrointestinal", "Genitourinary", "Inflammation", "Neurology"], "modalityGroups": ["Other", "Peptide", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Kynmobi", "phase": "Marketed", "indication": "Parkinson's disease"}, {"name": "Zuplenz", "phase": "Marketed", "indication": "Emesis"}, {"name": "Sympazan (AQST-120", "phase": "Approved", "indication": "Seizures"}, {"name": "Anaphylm (AQST-109)", "phase": "Registration", "indication": "Allergy"}, {"name": "Libervant", "phase": "Registration", "indication": "Seizures"}, {"name": "Tadalafil PharmFilm (AQST-119", "phase": "Registration", "indication": "Erectile dysfunction (ED)"}, {"name": "Epinephrine sublingual soluble film (Epinephrine SSF) (AQST-108)", "phase": "Phase I", "indication": "Allergy"}, {"name": "Octreotide buccal soluble film (AQST-305)", "phase": "Phase I", "indication": "Neuroendocrine tumors"}], "ceo": "Daniel Barber, MBA", "employees": 142, "founded": 2004, "website": "http://www.aquestive.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 359137311.16, "evFmt": "$359M", "ticker": "AQST", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aquestive%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other Solid Tumors", "Other Specialties", "Parkinson's", "Respiratory / Allergy", "Supportive / Other"]}, {"company": "Aquilus Pharmaceuticals Inc.", "city": "Winchester", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AQU-118", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://aquiluspharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aquilus%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Araim Pharmaceuticals Inc.", "city": "Tarrytown", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation", "Neurology", "Transplant"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "cibinetide (ARA 290)", "phase": "Phase II", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.araimpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Araim%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Aramis Biosciences Inc.", "city": "Medfield", "state": "MA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "A197", "phase": "Phase II", "indication": "Dry eye"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.aramisbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aramis%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Aravive Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "batiraxcept (AVB-500", "phase": "Phase III", "indication": "Ovarian cancer"}, {"name": "Aravive-cancer and fibrosis-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://aravive.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aravive", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Arbor Biotechnologies Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ABO-101", "phase": "Phase I/II", "indication": "Hyperoxaluria"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://arbor.bio", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 5, "totalDealValue": 0.0, "totalDealFmt": "", "latestDealDate": "2024-03-12", "recentDeals": [{"headline": "Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease", "date": "2024-03-12", "value": ""}, {"headline": "4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases", "date": "2024-01-03", "value": ""}, {"headline": "Arbor Biotechnologies announces expanded strategic partnership with Vertex, now extending to\u00a0precision gene editing using reverse transcriptase", "date": "2023-01-11", "value": ""}], "totalRaised": 73900000.0, "totalRaisedFmt": "$74M", "latestFinDate": "2025-03-18", "latestFinType": "Series C rounds", "nRounds": 1, "recentFinancing": [{"type": "Series C rounds", "amount": "$74M", "date": "2025-03-18", "investors": "Arch Venture Partners, Tcg Crossover, Qatar Investment Authority, Partners Investment, Revelation Partners, Kerna Ventur..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arbor%20Biotechnologies", "hasDealsFin": true, "diseaseGroups": ["Kidney Disease"]}, {"company": "Arbor Vita Corp.", "city": "Fremont", "state": "CA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "A/H7N9 Influenza Rapid Test", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "AVantage A/H5N1 Flu Test (avc dx-2)", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "HPV E6 test (AVC Avantage HPV E6 test", "phase": "Pivotal", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.arborvita.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arbor%20Vita", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)"]}, {"company": "Arbutus Biopharma Corp.", "city": "Warminster", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other", "RNA Therapeutics", "Small Molecule"], "nProducts": 13, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Marqibo", "phase": "Marketed", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "ARB-1467", "phase": "Phase II", "indication": "Hepatitis B virus (HBV)"}, {"name": "Brakiva", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "imdusiran (AB-729)", "phase": "Phase II", "indication": "Hepatitis B virus (HBV)"}, {"name": "AB-161", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "AB-423", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "AB-506", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "AB-836", "phase": "Phase I", "indication": "Hepatitis"}], "ceo": "Lindsay Androski, CFA, MBA", "employees": 44, "founded": 2005, "website": "http://arbutusbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 490436017.98, "evFmt": "$490M", "ticker": "ABUS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arbutus%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers", "Liver Disease"]}, {"company": "Arcellx Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "anitocabtagene autoleucel (anito-cel", "phase": "Phase III", "indication": "Multiple myeloma (MM)"}, {"name": "ACLX-001", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "ACLX-002", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "ACLX-003", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "Rami Elghandour, MBA", "employees": 163, "founded": 2014, "website": "http://www.arcellx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 3574485273.57, "evFmt": "$3.6B", "ticker": "ACLX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arcellx", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Archer Pharmaceuticals Inc.", "city": "Sarasota", "state": "FL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Nilvadipine formulation (ARC029)", "phase": "Phase III", "indication": "Alzheimer's disease"}, {"name": "ARC031", "phase": "Phase I", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.archerpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Archer%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Arcion Therapeutics Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ARC-2022", "phase": "Phase I/II", "indication": "Neuralgia"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.arciontherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arcion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Arcturus Therapeutics Holdings Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic", "Infectious", "Pulmonary"], "modalityGroups": ["RNA Therapeutics", "Vaccine"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Kostaive", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}, {"name": "LUNAR-COV19 (ARCT-021)", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "LUNAR-OTC (ARCT-810)", "phase": "Phase II", "indication": "Urea cycle disorder (UCD)"}, {"name": "LUNAR-CF (ARCT-032)", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}, {"name": "LUNAR-FLU", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "LUNAR-GSDIII (LUNAR-RARE1)", "phase": "Preclinical", "indication": "Glycosphingolipid storage disorders"}, {"name": "LUNAR-NASH", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}], "ceo": "Joseph E. Payne", "employees": 176, "founded": 2013, "website": "http://arcturusrx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 194712003.705075, "evFmt": "$195M", "ticker": "ARCT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arcturus%20Therapeutics%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Obesity / Metabolic", "Rare / Genetic"]}, {"company": "Arcus Biosciences Inc.", "city": "Hayward", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "domvanalimab (AB154)", "phase": "Phase III", "indication": "Gastrointestinal cancer"}, {"name": "quemliclustat (AB680)", "phase": "Phase III", "indication": "Pancreatic cancer"}, {"name": "Etruma", "phase": "Phase II", "indication": "Colorectal cancer"}, {"name": "casdatifan (AB521)", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "AB308", "phase": "Phase I", "indication": "Hematologic malignancies"}], "ceo": "Terry J. Rosen, PhD", "employees": 627, "founded": 2015, "website": "http://www.arcusbio.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 522589000.0, "evFmt": "$523M", "ticker": "RCUS", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arcus%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Arcutis Biotherapeutics Inc.", "city": "Westlake Village", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Zoryve", "phase": "Marketed", "indication": "Psoriasis"}, {"name": "ARQ-252", "phase": "Phase II", "indication": "Vitiligo"}, {"name": "ARQ 255", "phase": "Preclinical", "indication": "Androgenetic alopecia"}, {"name": "ARQ-250", "phase": "Preclinical", "indication": "Alopecia areata"}, {"name": "DS-234", "phase": "Preclinical", "indication": "Dermatitis"}], "ceo": "Todd Franklin Watanabe", "employees": 342, "founded": 2016, "website": "http://www.arcutis.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1566952827.69, "evFmt": "$1.6B", "ticker": "ARQT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arcutis%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Ardelyx Inc.", "city": "Fremont", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Gastrointestinal", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Ibsrela", "phase": "Marketed", "indication": "Irritable bowel syndrome"}, {"name": "RDX013", "phase": "Phase II", "indication": "Hyperkalemia"}, {"name": "RDX022", "phase": "Phase I", "indication": "Hyperkalemia"}, {"name": "RDX002", "phase": "Preclinical", "indication": "Hyperphosphatemia"}, {"name": "RDX009", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "RDX020", "phase": "Preclinical", "indication": "Renal (unspecified)"}, {"name": "RDX98940", "phase": "Preclinical", "indication": "Gastrointestinal (unspecified)"}], "ceo": "Mike Raab", "employees": 395, "founded": 2007, "website": "http://www.ardelyx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1095968939.89, "evFmt": "$1.1B", "ticker": "ARDX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ardelyx", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Kidney Disease", "Other"]}, {"company": "Ares Immunotherapy Inc.", "city": "Cartersville", "state": "GA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Ares Immunotherapy-CD26-unknown", "phase": "Preclinical", "indication": "Mesothelioma"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://aresimmunotherapy.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ares%20Immunotherapy", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Aria Pharmaceuticals Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Hepatic", "Pulmonary", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Aria Pharma- chronic kidney disease-unknown", "phase": "Preclinical", "indication": "Renal (unspecified)"}, {"name": "Aria Pharma-glioblastoma-unknown", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "Aria Pharma-lung cancer-unknown", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Aria Pharma-lupus-unknown", "phase": "Preclinical", "indication": "Lupus"}, {"name": "Aria Pharma-NASH-unknown", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "TXR-1002", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}, {"name": "TXR-311", "phase": "Preclinical", "indication": "Liver cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://ariapharmaceuticals.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aria%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Brain / CNS Tumors", "GI Cancers", "Kidney Disease", "Lung Cancer", "Obesity / Metabolic", "Respiratory / Allergy"]}, {"company": "Arialys Therapeutics Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "ART5803", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.arialysrx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arialys%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Aridis Pharmaceuticals Inc.", "city": "San Jose", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 9, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Salvecin", "phase": "Phase III", "indication": "Staphylococcus"}, {"name": "Aerucin (AR-105)", "phase": "Phase II", "indication": "Pneumonia"}, {"name": "Aerumab", "phase": "Phase II", "indication": "Pseudomonas"}, {"name": "Panaecin", "phase": "Phase I/II", "indication": "Pseudomonas"}, {"name": "AR-201", "phase": "Preclinical", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "AR-401 (KBAB401)", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "AR-701", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "AR-712 (AR-711/AR-713)", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Vu L. Truong, PhD", "employees": 0, "founded": 2003, "website": "http://www.aridispharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "ARDS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aridis%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Arisaph Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ARI-3037MO", "phase": "Phase II", "indication": "Dyslipidemia"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.arisaph.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arisaph%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Armata Pharmaceuticals Inc.", "city": "Marina del Rey", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AP-PA02", "phase": "Phase I/II", "indication": "Pseudomonas"}, {"name": "AP-SA02", "phase": "Phase I/II", "indication": "Bacteremia"}, {"name": "AP-PA03", "phase": "Preclinical", "indication": "Pneumonia"}], "ceo": "Deborah L. Birx, MD", "employees": 60, "founded": 2002, "website": "https://www.armatapharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 184121568.8, "evFmt": "$184M", "ticker": "ARMP", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Armata%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Armatus Bio Inc.", "city": "Columbus", "state": "OH", "country": "United States", "diseaseCats": ["Musculoskeletal", "Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ARM-101", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "ARM-102", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "ARM-201", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "ARM-202", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://armatusbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-03-07", "recentDeals": [{"headline": "Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD", "date": "2024-03-07", "value": ""}], "totalRaised": 3000000.0, "totalRaisedFmt": "$3M", "latestFinDate": "2025-05-06", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$3M", "date": "2025-05-06", "investors": "Solve Fshd Holdings Ltd."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Armatus%20Bio", "hasDealsFin": true, "diseaseGroups": ["Neurodegeneration / NMD", "Other Neurology"]}, {"company": "Armis Biopharma Inc.", "city": "Fort Collins", "state": "CO", "country": "United States", "diseaseCats": ["Dermatology", "Infectious"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Ximycin", "phase": "Phase II", "indication": "Bacterial infection"}, {"name": "Veriox", "phase": "Preclinical", "indication": "Wounds"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.armisbiopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Armis%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease"]}, {"company": "Arms Pharmaceutical (Advanced Research in Microbial Science)", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ARMS-I", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.armspharmaceutical.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arms%20Pharmaceutical%20(Advanced%20Research%20in%20Microbial%20Science)", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Aro Biotherapeutics Co.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "ABX1100", "phase": "Phase I", "indication": "Pompe disease"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.arobiotx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aro%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Aronora Inc.", "city": "Portland", "state": "OR", "country": "United States", "diseaseCats": ["Cardiovascular", "Infectious", "Inflammation", "Neurology", "Renal", "Transplant"], "modalityGroups": ["Antibody", "Protein / Biologic", "RNA Therapeutics"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Gruticibart (AB023)", "phase": "Phase II", "indication": "End-stage renal disease (ESRD)"}, {"name": "proCase", "phase": "Phase I", "indication": "Blood clots"}, {"name": "AB054", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "AB062", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "xisomab (AB022)", "phase": "Preclinical", "indication": "Thrombosis"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.aronorabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aronora", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Infectious Disease", "Other"]}, {"company": "Arrepath Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AP-001", "phase": "Preclinical", "indication": "Urinary tract infection (UTI)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://arrepath.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arrepath", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Arrien Pharmaceuticals LLC", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ARN-0953", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "ARN-1104", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "ARN-3261", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "ARN-4079", "phase": "Preclinical", "indication": "Alopecia areata"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.arrienpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arrien%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Dermatology", "Hematologic Cancers", "Parkinson's"]}, {"company": "Arrivo Bioventures LLC", "city": "Morrisville", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune", "Gastrointestinal", "Inflammation", "Neurology"], "modalityGroups": ["Antibody", "Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "SP-624", "phase": "Phase II/III", "indication": "Depression"}, {"name": "DLX-105", "phase": "Phase II", "indication": "Psoriasis"}, {"name": "DLX-2323", "phase": "Phase I", "indication": "Inflammation (unspecified)"}, {"name": "RABI-767", "phase": "Phase I", "indication": "Pancreatitis"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.arrivobio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arrivo%20Bioventures", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Other Inflammation", "Psychiatry / Behavioral", "Supportive / Other"]}, {"company": "Arrowhead Pharmaceuticals Inc.", "city": "Pasadena", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Endocrine/Metabolic", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Pulmonary", "Renal"], "modalityGroups": ["Other", "RNA Therapeutics"], "nProducts": 25, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Redemplo", "phase": "Approved", "indication": "Hypertriglyceridemia"}, {"name": "zodasiran (ARO-ANG3", "phase": "Phase III", "indication": "Hypercholesterolemia"}, {"name": "GSK4532990", "phase": "Phase II", "indication": "Liver disease"}, {"name": "ARO-CFB", "phase": "Phase I", "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)"}, {"name": "olpasiran (AMG 890", "phase": "Phase III", "indication": "Atherosclerosis"}, {"name": "fazirsiran (ARO-AAT", "phase": "Phase II/III", "indication": "Liver disease"}, {"name": "daplusiran/tomligisiran (GSK5637608", "phase": "Phase II", "indication": "Hepatitis"}, {"name": "ARO-ALK7", "phase": "Phase I/II", "indication": "Obesity"}], "ceo": "Christopher Richard Anzalone, PhD", "employees": 711, "founded": 2003, "website": "http://arrowheadpharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4464992420.0, "evFmt": "$4.5B", "ticker": "ARWR", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 455000000.0, "totalDealFmt": "$455M", "latestDealDate": "2025-08-01", "recentDeals": [{"headline": "Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi", "date": "2025-08-01", "value": "$395M"}, {"headline": "Arrowhead Pharmaceuticals and Vivo Capital launch joint venture aimed at greater China market", "date": "2022-04-25", "value": "$60M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arrowhead%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Hematology (non-cancer)", "Liver Disease", "Obesity / Metabolic"]}, {"company": "Ars Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Inflammation"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "EURneffy", "phase": "Marketed", "indication": "Allergy"}, {"name": "SBT8230", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "Richard E. Lowenthal, MBA", "employees": 160, "founded": 2015, "website": "https://ars-pharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 766243235.4, "evFmt": "$766M", "ticker": "SPRY", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ars%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Respiratory / Allergy"]}, {"company": "Arscience Biotherapeutics Inc.", "city": "Washington", "state": "DC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "COYA 301", "phase": "Preclinical", "indication": "Frontotemporal dementia"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.arsciencebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 100000.0, "totalDealFmt": "$100K", "latestDealDate": "2022-08-23", "recentDeals": [{"headline": "Coya Therapeutics entered into a license agreement with ARScience Biotherapeutics", "date": "2022-08-23", "value": "$100K"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arscience%20Biotherapeutics", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Arsenal Biosciences Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AB-1015", "phase": "Phase I", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.arsenalbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 70000000.0, "totalDealFmt": "$70M", "latestDealDate": "2022-09-27", "recentDeals": [{"headline": "Arsenal Biosciences announces joint discovery collaboration with Genentech to identify features of successful T-cell therapies for oncology", "date": "2022-09-27", "value": "$70M"}], "totalRaised": 545000000.0, "totalRaisedFmt": "$545M", "latestFinDate": "2024-09-04", "latestFinType": "Series C rounds", "nRounds": 2, "recentFinancing": [{"type": "Series C rounds", "amount": "$325M", "date": "2024-09-04", "investors": "Arch Venture Partners, Milky Way Investments Group, Regeneron Ventures, Nventures, Luma Group, T. Rowe Price Associates ..."}, {"type": "Series B rounds", "amount": "$220M", "date": "2022-09-06", "investors": "Softbank Vision Fund, Bristol Myers Squibb Co., Byers Capital, Emerson Collective, Green Sands Equity, Hitachi Ventures,..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arsenal%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Artan Biotechnologies LLC", "city": "", "state": "", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ARTAN-102", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.artan.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Artan%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Artax Biopharma Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AX-158", "phase": "Phase I/II", "indication": "Psoriasis"}, {"name": "AX-194", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://artaxbiopharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Artax%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Other Inflammation"]}, {"company": "Artbio Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AB001", "phase": "Phase I", "indication": "Prostate cancer"}, {"name": "ABA", "phase": "Research", "indication": "Solid tumors"}, {"name": "ABB", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://artbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-11-14", "recentDeals": [{"headline": "ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors", "date": "2024-11-14", "value": ""}], "totalRaised": 245000000.0, "totalRaisedFmt": "$245M", "latestFinDate": "2025-07-29", "latestFinType": "Series B rounds", "nRounds": 3, "recentFinancing": [{"type": "Series B rounds", "amount": "$132M", "date": "2025-07-29", "investors": "Sofinnova Investments Inc., B Capital Group, Undisclosed Investor, F-prime Inc. (F-prime Capital Partners), Omega Funds,..."}, {"type": "Series A rounds", "amount": "$90M", "date": "2023-12-07", "investors": "Third Rock Ventures, Undisclosed Healthcare Fund, F-prime Inc. (F-prime Capital Partners), Omega Funds"}, {"type": "Seed financings", "amount": "$23M", "date": "2023-06-21", "investors": "F-prime Inc. (F-prime Capital Partners), Omega Funds"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Artbio", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Artelo Biosciences Inc.", "city": "Solana Beach", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ART26.12", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Gregory D. Gorgas, MBA", "employees": 6, "founded": 2011, "website": "http://artelobio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1182379.774376, "evFmt": "$1M", "ticker": "ARTL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Artelo%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Artery Therapeutics Inc.", "city": "Danville", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AT5261", "phase": "Preclinical", "indication": "Atherosclerosis"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.arterytx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Artery%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Artielle Immunotherapeutics Inc.", "city": "San Mateo", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "RTL1000", "phase": "Phase I", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.artielle.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Artielle%20Immunotherapeutics", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Artiva Biotherapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AlloNK (AB-101)", "phase": "Phase I/II", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "AB-201", "phase": "IND", "indication": "Gastric cancer"}, {"name": "AB-202", "phase": "Preclinical", "indication": "B cell lymphoma"}], "ceo": "Fred Aslan, MD, MBA", "employees": 89, "founded": 2019, "website": "https://www.artivabio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 73785398.56, "evFmt": "$74M", "ticker": "ARTV", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Artiva%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers"]}, {"company": "Arugula Sciences LLC", "city": "Irving", "state": "TX", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Signature Cord Prime (SIG001)", "phase": "Phase I", "indication": "Osteoarthritis"}, {"name": "SIG002", "phase": "IND", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.arugulasciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arugula%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Aruna Bio Inc.", "city": "Athens", "state": "GA", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AB126", "phase": "Phase I/II", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 2003, "website": "https://arunabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aruna%20Bio", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Arvinas Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "vepdegestrant (ARV-471)", "phase": "Registration", "indication": "Breast cancer"}, {"name": "luxdegalutamide (ARV-766", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "ARV-806", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "bavdegalutamide (ARV-110)", "phase": "Phase I/II", "indication": "Prostate cancer"}, {"name": "ARV-102", "phase": "Phase I", "indication": "Parkinson's disease"}, {"name": "ARV-393", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}], "ceo": "John G. Houston, PhD", "employees": 430, "founded": 2013, "website": "http://www.arvinas.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 348823000.0, "evFmt": "$349M", "ticker": "ARVN", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-10-28", "recentDeals": [{"headline": "PhoreMost enters multi-target collaboration with targeted protein degradation leader Arvinas", "date": "2022-10-28", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Arvinas", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Hematologic Cancers", "Parkinson's", "Solid Tumors (General)"]}, {"company": "Asalyxa Bio Inc.", "city": "Southfield", "state": "MI", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ASX-100", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.asalyxabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Asalyxa%20Bio", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Asana Biosciences LLC", "city": "Lawrenceville", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Inflammation", "Neurology", "Pulmonary"], "modalityGroups": ["ADC", "Other", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ASN008", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "gusacitinib (ASN002)", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "ASN011", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ASN004", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ASN001", "phase": "Phase I/II", "indication": "Prostate cancer"}, {"name": "ASN003", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "ASN007", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "ASN009", "phase": "Preclinical", "indication": "Itch"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.asanabiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-11-29", "recentDeals": [{"headline": "TrialSpark announces acquisition of a clinical-stage immunodermatology portfolio and formation of Libertas Bio", "date": "2022-11-29", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Asana%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Asc Therapeutics", "city": "Milpitas", "state": "CA", "country": "United States", "diseaseCats": ["Hematology", "Transplant"], "modalityGroups": ["Cell Therapy", "Gene Therapy"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ASC-930", "phase": "Phase II", "indication": "Graft-versus-host disease (GvHD)"}, {"name": "ASC-518", "phase": "Preclinical", "indication": "Hemophilia"}, {"name": "ASC-519", "phase": "Preclinical", "indication": "Hemophilia"}, {"name": "ASC-520", "phase": "Preclinical", "indication": "Thalassemia"}, {"name": "ASC-618", "phase": "Preclinical", "indication": "Hemophilia"}], "ceo": "", "employees": 0, "founded": 2008, "website": "https://www.asctherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Asc%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematology (non-cancer)"]}, {"company": "Ascendia Pharmaceuticals LLC", "city": "North Brunswick", "state": "NJ", "country": "United States", "diseaseCats": ["Cardiovascular", "Ophthalmic"], "modalityGroups": ["Macrocycle", "Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ASD-001", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "clopidogrel (ASD-002)", "phase": "Preclinical", "indication": "Acute coronary syndrome"}, {"name": "cyclosporin (ASD-004)", "phase": "Preclinical", "indication": "Dry eye"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.ascendiapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ascendia%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Ophthalmology"]}, {"company": "Ascidian Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology", "Ophthalmic", "Other"], "modalityGroups": ["Gene Therapy"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ACDN-01", "phase": "Phase I/II", "indication": "Ophthalmic (unspecified)"}, {"name": "Ascidian Therapeutics-Genetic diseases-unknown", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "Ascidian Therapeutics-Neuro & neuromuscular-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Ascidian Therapeutics-Neurology-unknown", "phase": "Research", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.ascidian-tx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 1842000000.0, "totalDealFmt": "$1.8B", "latestDealDate": "2024-06-18", "recentDeals": [{"headline": "Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases", "date": "2024-06-18", "value": "$1.8B"}], "totalRaised": 90000000.0, "totalRaisedFmt": "$90M", "latestFinDate": "2023-11-08", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$40M", "date": "2023-11-08", "investors": "Apple Tree Partners"}, {"type": "Series A rounds", "amount": "$50M", "date": "2022-10-12", "investors": "Apple Tree Partners"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ascidian%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Ophthalmology", "Other Neurology", "Rare / Genetic"]}, {"company": "Asclepix Therapeutics Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AXT107", "phase": "Phase I/II", "indication": "Diabetic macular edema (DME)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://asclepix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Asclepix%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Ash Access Technology Inc.", "city": "Lafayette", "state": "IN", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Zuragen (AAT-023)", "phase": "Registration", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 1983, "website": "http://www.ashaccess.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ash%20Access%20Technology", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Asha Therapeutics LLC", "city": "Washington", "state": "DC", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ASHA-091", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "ASHA-624", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://ashatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Asha%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "MS / Neuroimmune"]}, {"company": "Asher Biotherapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "etakafusp alfa (AB248)", "phase": "Phase I", "indication": "Small cell lung cancer"}, {"name": "AB359", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "AB821", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://asherbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Asher%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Ashvattha Therapeutics Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic", "Inflammation", "Neurology", "Ophthalmic"], "modalityGroups": ["Diagnostics", "Nanoparticle / Delivery", "Radiopharmaceutical", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "D-4517.2", "phase": "Phase II", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "OP-101", "phase": "Phase II", "indication": "Inflammation (unspecified)"}, {"name": "Ashvattha Therapeutics-neurology-unknown", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "Ashvattha Therapeutics-plexiform neurofibroma-unknown", "phase": "Preclinical", "indication": "Neurofibromatosis"}, {"name": "D-4559", "phase": "Preclinical", "indication": "Liver cancer"}, {"name": "D6-B483", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "OP-801", "phase": "Development (diagnostic)", "indication": "Neurology, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://avttx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 45000000.0, "totalDealFmt": "$45M", "latestDealDate": "2022-04-27", "recentDeals": [{"headline": "Ashvattha Therapeutics announces up to $45m exclusive license agreement with Huadong to advance hydroxyl dendrimer-based precision medicines", "date": "2022-04-27", "value": "$45M"}], "totalRaised": 119000000.0, "totalRaisedFmt": "$119M", "latestFinDate": "2025-01-13", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$50M", "date": "2025-01-13", "investors": "Tribe Capital, Natural Capital, Existing Investors"}, {"type": "Series B rounds", "amount": "$69M", "date": "2022-04-27", "investors": "Huadong Medicine Co. Ltd., Natural Capital Investment Fund, Plum Alley, Tribe Capital, Undisclosed Biotechnology Fund, A..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ashvattha%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors", "GI Cancers", "Neurodegeneration / NMD", "Ophthalmology", "Other Inflammation", "Other Neurology", "Rare / Genetic"]}, {"company": "Askgene Pharma Inc.", "city": "Camarillo", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ASKB379", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ASKG322", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://ask-gene.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Askgene%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Asklepion Pharmaceuticals LLC", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "L-citrulline", "phase": "Phase III", "indication": "Hematopoietic transplant"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://asklepionpharm.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Asklepion%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Transplant"]}, {"company": "Aspen Neuroscience Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ANPD001", "phase": "Phase I/II", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://aspenneuroscience.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aspen%20Neuroscience", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "Aspera Biomedicines Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "rebecsinib (17S-FD-895)", "phase": "IND", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.asperabiomedicines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aspera%20Biomedicines", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Assembly Biosciences Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ABI-4334", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "ABI-H3733", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "ABI-5366", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}, {"name": "ABI-6250", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "Assembly-hepatitis B virus-unknown", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "Jason A. Okazaki", "employees": 73, "founded": 2005, "website": "http://www.assemblybio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -14238043.2, "evFmt": "", "ticker": "ASMB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Assembly%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Assertio Holdings Inc.", "city": "Forest", "state": "IL", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 11, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Arymo ER", "phase": "Marketed", "indication": "Pain"}, {"name": "Glumetza (metformin", "phase": "Marketed", "indication": "Diabetes"}, {"name": "Indocin", "phase": "Marketed", "indication": "Ankylosing spondylitis"}, {"name": "Otrexup", "phase": "Marketed", "indication": "Arthritis"}, {"name": "Proquin XR", "phase": "Marketed", "indication": "Bacterial infection"}, {"name": "Sprix", "phase": "Marketed", "indication": "Pain"}, {"name": "Zipsor", "phase": "Marketed", "indication": "Pain"}, {"name": "oxycodone (Egalet-002", "phase": "Phase III", "indication": "Pain"}], "ceo": "Mark L. Reisenauer", "employees": 58, "founded": 1995, "website": "https://www.assertiotx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 23202568.017028, "evFmt": "$23M", "ticker": "ASRT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Assertio%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Diabetes", "Infectious Disease", "Other", "Pain / Migraine"]}, {"company": "Astraea Therapeutics LLC", "city": "Mountain View", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AT-121", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.astraeatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Astraea%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Astrocyte Pharmaceuticals Inc.", "city": "Groton", "state": "CT", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AST-004", "phase": "Phase I", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.astrocytepharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Astrocyte%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Asylia Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ASY-77A", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://asyliatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Asylia%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Atara Biotherapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Antibody", "Cell Therapy", "Protein / Biologic"], "nProducts": 9, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Ebvallo", "phase": "Marketed", "indication": "Cancer (unspecified)"}, {"name": "ATA188", "phase": "Phase II", "indication": "Multiple sclerosis (MS)"}, {"name": "ATA2271", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "Autologous ATA190", "phase": "Phase I", "indication": "Multiple sclerosis (MS)"}, {"name": "STM 434", "phase": "Phase I", "indication": "Ovarian cancer"}, {"name": "ATA 842", "phase": "Preclinical", "indication": "Cachexia"}, {"name": "ATA2431", "phase": "Preclinical", "indication": "B cell lymphoma"}, {"name": "ATA3219", "phase": "Preclinical", "indication": "B cell lymphoma"}], "ceo": "Anhco Nguyen, PhD", "employees": 153, "founded": 2012, "website": "http://www.atarabio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 141079280.0, "evFmt": "$141M", "ticker": "ATRA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Atara%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "MS / Neuroimmune", "Obesity / Metabolic", "Solid Tumors (General)"]}, {"company": "Atea Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Combination", "Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "RG6422", "phase": "Phase III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "AT-777", "phase": "Phase I", "indication": "Hepatitis C virus (HCV)"}, {"name": "AT-787", "phase": "Phase I", "indication": "Hepatitis C virus (HCV)"}], "ceo": "Jean-Pierre Sommadossi, PhD", "employees": 56, "founded": 2014, "website": "https://www.ateapharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -170792204.75, "evFmt": "", "ticker": "AVIR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Atea%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Atengen Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Ophthalmic"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Atengen-solid tumors-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Atengen-solid tumors-unknown2", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Atengen-vision diseases-unknown", "phase": "Preclinical", "indication": "Diabetic retinopathy"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://atengen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Atengen", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Solid Tumors (General)"]}, {"company": "Athena Bioscience LLC", "city": "Athens", "state": "GA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Qdolo", "phase": "Approved", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://athenabioscience.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Athena%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Athos Therapeutics Inc.", "city": "Torrance", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "ATH-063", "phase": "IND", "indication": "Crohn's disease"}, {"name": "ATH-001", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "ATH-055", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "ATH-071", "phase": "Research", "indication": "Lupus"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://athostx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 35000000.0, "totalRaisedFmt": "$35M", "latestFinDate": "2024-02-16", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$35M", "date": "2024-02-16", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Athos%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "IBD / GI Inflammatory", "Solid Tumors (General)"]}, {"company": "Atossa Therapeutics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AT-H201", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "endoxifen", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "intraductal fulvestrant", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "AT-301 (nasal spray)", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Steven C. Quay, MD, PhD", "employees": 15, "founded": 2009, "website": "https://atossatherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 47629742.4716, "evFmt": "$48M", "ticker": "ATOS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Atossa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Infectious Disease"]}, {"company": "Atreaon Inc.", "city": "Newton Centre", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Atsttrin", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.atreaon.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Atreaon", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Atricure Inc.", "city": "Mason", "state": "OH", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Synergy Ablation System", "phase": "Marketed", "indication": "Fibrillation"}], "ceo": "Michael H. Carrel, MBA", "employees": 1300, "founded": 2000, "website": "http://www.atricure.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1389059400.0, "evFmt": "$1.4B", "ticker": "ATRC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Atricure", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Atsena Therapeutics Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Ophthalmic", "Other"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "ATSN-101 (SAR439483)", "phase": "Phase I/II", "indication": "Blindness"}, {"name": "ATSN-201", "phase": "Phase I/II", "indication": "Retinal detachment"}, {"name": "ATSN-301", "phase": "Preclinical", "indication": "Usher syndrome"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://atsenatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-11-13", "recentDeals": [{"headline": "Nippon Shinyaku and Atsena Therapeutics enter into an Exclusive Strategic Collaboration for ATSN-101 in the U.S. and Japan", "date": "2024-11-13", "value": ""}], "totalRaised": 174474387.0, "totalRaisedFmt": "$174M", "latestFinDate": "2025-04-02", "latestFinType": "Series C rounds", "nRounds": 2, "recentFinancing": [{"type": "Series C rounds", "amount": "$150M", "date": "2025-04-02", "investors": "Wellington Management, Lightstone Ventures, Sofinnova Investments Inc., Abingworth LLP, Foundation Fighting Blindness, H..."}, {"type": "Uncategorized venture rounds", "amount": "$24M", "date": "2023-08-28", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Atsena%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Ophthalmology", "Rare / Genetic"]}, {"company": "Atterx Biotherapeutics Inc.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "C-1205", "phase": "Phase I", "indication": "Urinary tract infection (UTI)"}, {"name": "GN-4474", "phase": "Preclinical", "indication": "Gram-negative bacterial infection"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://atterx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Atterx%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Attovia Therapeutics Inc.", "city": "Fremont", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology"], "modalityGroups": ["Bispecific Antibody", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ATTO-1310", "phase": "Phase I", "indication": "Dermatology (unspecified)"}, {"name": "ATTO-002", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "ATTO-3712", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.attovia.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-06-20", "recentDeals": [{"headline": "Attovia Therapeutics will receive an exclusive world-wide license to Alamar Biosciences' platform and associated intellectual property and pipeline assets", "date": "2023-06-20", "value": ""}], "totalRaised": 255000000.0, "totalRaisedFmt": "$255M", "latestFinDate": "2025-04-15", "latestFinType": "Series C rounds", "nRounds": 3, "recentFinancing": [{"type": "Series C rounds", "amount": "$90M", "date": "2025-04-15", "investors": "Deep Track Capital, Vida Ventures, Sanofi Ventures, Mirae Asset Capital, Frazier Life Sciences, Venbio LLC, Goldman Sach..."}, {"type": "Series B rounds", "amount": "$105M", "date": "2024-05-09", "investors": "Goldman Sachs Asset Management, Cormorant Asset Management, Nextech Venture, Redmile Group, Ecor1 Capital, Marshall Wace..."}, {"type": "Series A rounds", "amount": "$60M", "date": "2023-06-20", "investors": "Frazier Life Sciences, Venbio LLC, Illumina Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Attovia%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology"]}, {"company": "Attralus Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Diagnostic", "Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Peptide", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Attralus (AT-02)", "phase": "Preclinical", "indication": "Amyloidosis"}, {"name": "Attralus (AT-03)", "phase": "Preclinical", "indication": "Amyloidosis"}, {"name": "Attralus (AT-04)", "phase": "Preclinical", "indication": "Amyloidosis"}, {"name": "iodine I-124 evuzamitide (AT-01", "phase": "Development (diagnostic)", "indication": "Cardiovascular, Diagnostic"}, {"name": "PAR-Peptide + technetium-99m (AT-05)", "phase": "Development (diagnostic)", "indication": "Cardiovascular, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.attralus.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 56000000.0, "totalRaisedFmt": "$56M", "latestFinDate": "2024-02-06", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$56M", "date": "2024-02-06", "investors": "Alpha Wave Ventures, Bristol Myers Squibb Co., Venbio Partners LLC, Surveyor Capital, Vivo Capital, Logos Capital Manage..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Attralus", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Supportive / Other"]}, {"company": "Attune Pharmaceuticals Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ATN-249", "phase": "Phase I", "indication": "Angioedema"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.attunepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Attune%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Atyr Pharma Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Inflammation", "Musculoskeletal", "Pulmonary"], "modalityGroups": ["Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Efzo-Fit", "phase": "Phase III", "indication": "Sarcoidosis"}, {"name": "Resolaris (ATYR1940", "phase": "Phase I/II", "indication": "Muscular dystrophy"}, {"name": "IMod.Fc", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}], "ceo": "Peter Colis, MBA", "employees": 383, "founded": 2006, "website": "http://www.atyrpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "LIFE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Atyr%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Other Inflammation", "Respiratory / Allergy"]}, {"company": "Aug Therapeutics LLC", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "AUG-803 (AVTX-803", "phase": "Phase III", "indication": "Genetic disorders"}, {"name": "AUG-801 (AVTX-801", "phase": "Phase II", "indication": "Congenital disorders of glycosylation"}, {"name": "AUG-802 (AVTX-802", "phase": "Phase II", "indication": "Congenital disorders of glycosylation"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://augtx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aug%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Aum Lifetech Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Neurology"], "modalityGroups": ["Cell Therapy", "Gene Therapy", "RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AUM LifeTech-HIV-unknown", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "AUM LifeTech-lung cancer-unknown", "phase": "Preclinical", "indication": "Lung cancer"}, {"name": "AUM LifeTech-Parkinson's disease-unknown", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.aumlifetech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aum%20Lifetech", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Lung Cancer", "Parkinson's"]}, {"company": "Aura Biosciences Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "belzupacap sarotalocan (AU-011)", "phase": "Phase II", "indication": "Melanoma"}], "ceo": "Elisabet de los Pinos, PhD, MBA", "employees": 106, "founded": 2007, "website": "http://www.aurabiosciences.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 275801945.6, "evFmt": "$276M", "ticker": "AURA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aura%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Auransa Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AU018", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "AU409", "phase": "Phase I", "indication": "Liver cancer"}, {"name": "Auransa-acute myeloid leukemia-unknown", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Auransa-head and neck cancer-unknown", "phase": "Preclinical", "indication": "Head and neck cancer"}, {"name": "Auransa-metastatic prostate cancer-unknown", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "Auransa-triple negative breast cancer-unknown", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.auransa.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Auransa", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Cardiovascular", "GI Cancers", "GU / Gynecologic Cancers", "Head & Neck Cancer", "Hematologic Cancers"]}, {"company": "Aurion Biotech Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AURN001", "phase": "Phase I/II", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://aurionbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aurion%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Aurora Bio Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AUR01", "phase": "Phase I", "indication": "Metabolic, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.aurorabioinc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aurora%20Bio", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Aurora Biopharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AU101", "phase": "Phase I/II", "indication": "Brain cancer"}, {"name": "AU105", "phase": "Phase I/II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.aurora-biopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aurora%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Austin Biosciences Corp.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Gastrointestinal", "Neurology", "Ophthalmic"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ABC-0609", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "ABC-0996", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "ABC-1026", "phase": "Preclinical", "indication": "Emesis"}, {"name": "ABC-1103", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://austinbio.tech/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Austin%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Supportive / Other"]}, {"company": "Autobahn Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ABX-002", "phase": "Phase I", "indication": "Depression"}, {"name": "ABX-003", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "ABX-101", "phase": "Preclinical", "indication": "Central nervous system (CNS) disorders"}, {"name": "ABX-NG", "phase": "Preclinical", "indication": "Central nervous system (CNS) disorders"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://autobahntx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Autobahn%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "MS / Neuroimmune", "Psychiatry / Behavioral"]}, {"company": "Avaliv Therapeutics Inc.", "city": "Naples", "state": "FL", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Avaliv-NASH-unknown", "phase": "Preclinical", "indication": "Hepatic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://avaliv.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avaliv%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Avalon Globocare Corp.", "city": "Freehold", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Inflammation", "Transplant"], "modalityGroups": ["Cell Therapy", "Other", "Protein / Biologic", "Vaccine"], "nProducts": 16, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AVA-001", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "AVA-011", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "Senl_1904B", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "Senl_B19", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "Senl_H19", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "Senl_H19x22P", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "Senl_NS7CAR", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "AVA-101", "phase": "Preclinical", "indication": "Acute lymphoblastic leukemia (ALL)"}], "ceo": "Meng Li", "employees": 5, "founded": 2014, "website": "http://avalon-globocare.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 31536981.64, "evFmt": "$32M", "ticker": "ALBT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avalon%20Globocare", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Avalyn Pharma Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Pulmonary"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Aerodone", "phase": "Phase II", "indication": "Pulmonary fibrosis"}, {"name": "inhaled nintedanib (AP02)", "phase": "Phase I", "indication": "Pulmonary fibrosis"}, {"name": "AP03 (pirfenidone/nintedanib)", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}, {"name": "AP0X", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}, {"name": "inhaled imatinib (AP04)", "phase": "Preclinical", "indication": "Hypertension"}, {"name": "nintedanib dry powder for inhalation (dpi) (AP02-DP)", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://www.avalynpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avalyn%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Respiratory / Allergy"]}, {"company": "Avax Technologies Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "M-Vax", "phase": "Phase III", "indication": "Melanoma"}, {"name": "Ovax", "phase": "Phase I/II", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 1995, "website": "http://www.avax-tech.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "AVXT", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avax%20Technologies", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Skin Cancer / Melanoma"]}, {"company": "Avaxia Biologics Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "AVX-470", "phase": "Phase I", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.avaxiabiologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avaxia%20Biologics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Avelas Biosciences Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AVB-620", "phase": "Phase II", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.avelasbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avelas%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Avencell Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody", "Cell Therapy"], "nProducts": 13, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "GEM333", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "GEM3PSCA (CD3xPSCA", "phase": "Phase I", "indication": "Bladder cancer"}, {"name": "RevCAR-T2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "AVC-101", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "AVC-102", "phase": "Phase I/II", "indication": "Prostate cancer"}, {"name": "UniCAR-T-CD123", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "UniCAR-T-PSMA", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "AVC-201", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://avencell.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avencell%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Avenge Bio Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AVB-002", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://avengebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avenge%20Bio", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Aviceda Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Hepatic", "Neurology", "Ophthalmic", "Pulmonary"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 7, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "AVD-104", "phase": "Phase II/III", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "AVD-1001", "phase": "Preclinical", "indication": "Liver fibrosis"}, {"name": "AVD-1010", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}, {"name": "AVD-302", "phase": "Preclinical", "indication": "Diabetic retinopathy"}, {"name": "AVD-701", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "AVD-801", "phase": "Preclinical", "indication": "Neuroinflammation"}, {"name": "AVD-901", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.avicedarx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aviceda%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Liver Disease", "Ophthalmology", "Other Neurology", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Avidity Biosciences Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Musculoskeletal"], "modalityGroups": ["Other", "RNA Therapeutics"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "delpacibart etedesiran", "phase": "Phase III", "indication": "Myotonic dystrophy type 1 (DM1)"}, {"name": "delpacibart zotadirsen", "phase": "Phase II", "indication": "Muscular dystrophy"}, {"name": "delpacibart braxlosiran", "phase": "Phase I/II", "indication": "Muscular dystrophy"}, {"name": "AOC 1045", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "AOC 1072", "phase": "Preclinical", "indication": "Cardiomyopathy"}, {"name": "AOC 1086", "phase": "Preclinical", "indication": "Cardiomyopathy"}], "ceo": "Sarah Boyce", "employees": 391, "founded": 2013, "website": "http://aviditybiosciences.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1750108560.0, "evFmt": "$1.8B", "ticker": "RNA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avidity%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Neurodegeneration / NMD"]}, {"company": "Avineuro Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AVN-101", "phase": "Phase I", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.avineuro.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avineuro%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Avior Inc. (Avior Bio)", "city": "Cary", "state": "NC", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "nalmefene (TH104", "phase": "Preclinical", "indication": "Itch"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.aviorbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avior%20Inc.%20(Avior%20Bio)", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Avista Therapeutics Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AVST-101", "phase": "Preclinical", "indication": "Retinal detachment"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.avistatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 1007500000.0, "totalDealFmt": "$1.0B", "latestDealDate": "2022-07-19", "recentDeals": [{"headline": "Avista Therapeutics partners with Roche to develop next generation AAV gene therapy vectors for ocular diseases", "date": "2022-07-19", "value": "$1.0B"}], "totalRaised": 10000000.0, "totalRaisedFmt": "$10M", "latestFinDate": "2022-07-19", "latestFinType": "Seed financings", "nRounds": 1, "recentFinancing": [{"type": "Seed financings", "amount": "$10M", "date": "2022-07-19", "investors": "Upmc Enterprises"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avista%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Ophthalmology"]}, {"company": "Avm Biotechnology Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "AVM0703", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "https://avmbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avm%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Avrygen Corp.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal", "Neurology"], "modalityGroups": ["Nanoparticle / Delivery", "Other"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ACTX01", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "ACTX03", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "ACTX06", "phase": "Preclinical", "indication": "Bone repair"}, {"name": "ACTX07", "phase": "Preclinical", "indication": "Musculoskeletal (unspecified)"}, {"name": "ACTX08", "phase": "Preclinical", "indication": "Spinal cord injury (SCI)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.avrygen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avrygen", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Musculoskeletal", "Other Neurology", "Skin Cancer / Melanoma"]}, {"company": "Avstera Therapeutics Corp.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy", "RNA Therapeutics", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "AVS100", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "AVS200", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "AVS300", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://avstera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Avstera%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Axcella Health Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Hepatic", "Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AXA1125", "phase": "Phase II", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "AXA1665", "phase": "Phase II", "indication": "Liver disease"}], "ceo": "Craig R. Jalbert", "employees": 11, "founded": 2008, "website": "http://www.axcellahealth.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 2815510.0, "evFmt": "$3M", "ticker": "AXLA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Axcella%20Health", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Obesity / Metabolic"]}, {"company": "Axelyf Inc.", "city": "Brookline", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["RNA Therapeutics", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "astaxanthin prodrug (AXL-100", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}, {"name": "AXL-003", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "AXL-004", "phase": "Research", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.axelyf.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 2600000.0, "totalRaisedFmt": "$3M", "latestFinDate": "2025-08-19", "latestFinType": "Seed financings", "nRounds": 1, "recentFinancing": [{"type": "Seed financings", "amount": "$3M", "date": "2025-08-19", "investors": "Brunnur Ventures, Omega ehf, Silfurberg"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Axelyf", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Axikin Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AXP1275", "phase": "Phase II", "indication": "Asthma"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.axikin.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Axikin%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Axim Biotechnologies Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Gastrointestinal", "Neurology", "Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 13, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AX-1602", "phase": "Phase II", "indication": "Psoriasis"}, {"name": "CanChew+", "phase": "Phase II", "indication": "Irritable bowel syndrome"}, {"name": "MedChew-1401", "phase": "Phase I", "indication": "Multiple sclerosis (MS)"}, {"name": "AX-1505", "phase": "Preclinical", "indication": "Crohn's disease"}, {"name": "AX-1603", "phase": "Preclinical", "indication": "Glaucoma"}, {"name": "AX-1606", "phase": "Preclinical", "indication": "Dry eye"}, {"name": "CanQuit O", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "MedChew GP", "phase": "Preclinical", "indication": "Neuralgia"}], "ceo": "John W. Huemoeller, II", "employees": 7, "founded": 2010, "website": "http://www.aximbiotech.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7246240.3816, "evFmt": "$7M", "ticker": "AXIM", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Axim%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "IBD / GI Inflammatory", "MS / Neuroimmune", "Ophthalmology", "Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Axonis Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AXN-027", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "AXN-xxx", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://axonis.us/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Axonis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other Neurology"]}, {"company": "Axsome Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Auvelity", "phase": "Marketed", "indication": "Depression"}, {"name": "AXS-07", "phase": "Registration", "indication": "Migraine"}, {"name": "AXS-12 (reboxetine)", "phase": "Phase III", "indication": "Excessive sleepiness"}, {"name": "AXS-09", "phase": "Phase I", "indication": "Central nervous system (CNS) disorders"}], "ceo": "Herriott Tabuteau, MD", "employees": 683, "founded": 2012, "website": "http://www.axsome.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 3941584946.33, "evFmt": "$3.9B", "ticker": "AXSM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Axsome%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Aytu Biopharma Inc.", "city": "Englewood", "state": "CO", "country": "United States", "diseaseCats": ["Neurology", "Other", "Pulmonary"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Adzenys ER (NT-0201", "phase": "Marketed", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "Adzenys XR-ODT", "phase": "Marketed", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "Cotempla XR-ODT (Brand)", "phase": "Marketed", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "Tuzistra XR", "phase": "Marketed", "indication": "Cough"}, {"name": "NT0502", "phase": "Preclinical", "indication": "Drooling"}], "ceo": "Joshua R. Disbrow, MBA", "employees": 83, "founded": 2002, "website": "https://aytubio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 5674841.92, "evFmt": "$6M", "ticker": "AYTU", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aytu%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Other", "Psychiatry / Behavioral", "Respiratory / Allergy"]}, {"company": "Ayurvedic-life International LLC", "city": "Neenah", "state": "WI", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Gymnema sylvestre isolate", "phase": "Marketed", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.ayurvedic-life.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ayurvedic-life%20International", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Azano Pharmaceuticals Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Autoimmune", "Hematology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AZ175", "phase": "Preclinical", "indication": "Lupus"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.azanopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Azano%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Azelon Pharmaceuticals Inc.", "city": "West Conshohocken", "state": "PA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Peptide"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ZT-031", "phase": "Phase II", "indication": "Osteoporosis"}, {"name": "Ostabolin-C inhalation", "phase": "Phase I", "indication": "Osteoporosis"}, {"name": "teriparatide (ZT-034 nasal spray)", "phase": "Phase I", "indication": "Osteoporosis"}, {"name": "teriparatide (ZT-034)", "phase": "Phase I", "indication": "Osteoporosis"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.azelon.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Azelon%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Azevan Pharmaceuticals Inc.", "city": "Bethlehem", "state": "PA", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SRX246", "phase": "Phase II", "indication": "Huntington disease (HD)"}, {"name": "AVN712", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "SRX251", "phase": "Preclinical", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.azevan.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Azevan%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Other Neurology", "Supportive / Other"]}, {"company": "Azitra Inc.", "city": "Branford", "state": "CT", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ATR-04", "phase": "Phase I/II", "indication": "Dermatology (unspecified)"}, {"name": "ATR-12 (AZT-02)", "phase": "Phase I", "indication": "Netherton syndrome"}, {"name": "ATR-01", "phase": "Preclinical", "indication": "Dermatitis"}, {"name": "ATR-05", "phase": "Preclinical", "indication": "Ichthyosis"}], "ceo": "Francisco D. Salva", "employees": 12, "founded": 2014, "website": "http://www.azitrainc.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -2388912.909, "evFmt": "", "ticker": "AZTR", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Azitra", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Azkarra Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Azkarra Therapeutics-multi-PARP inhibitor-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Azkarra Therapeutics-PARG inhibitor-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.azkarrabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Azkarra%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Azome Therapeutics Inc.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AZM-152", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.azometherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-03-06", "recentDeals": [{"headline": "Azome announces exclusive patent license", "date": "2023-03-06", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2024-01-01", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2024-01-01", "investors": "Missouri Technology Corp."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Azome%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Other Inflammation"]}, {"company": "Azora Therapeutics Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AT-177", "phase": "Phase I", "indication": "Ulcerative colitis"}, {"name": "AT-193", "phase": "Phase I", "indication": "Psoriasis"}, {"name": "Azora Therapeutics-dermatology-unknown", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}, {"name": "Azora Therapeutics-gastroenterology-unknown", "phase": "Preclinical", "indication": "Gastrointestinal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.azoratherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Azora%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "IBD / GI Inflammatory", "Other"]}, {"company": "Aztherapies Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Cell Therapy", "Combination", "Other"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "ALZT-OP1", "phase": "Phase III", "indication": "Alzheimer's disease"}, {"name": "ALZT-OP3", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "CAR-Treg", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.aztherapies.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Aztherapies", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Other Neurology"]}, {"company": "Azurity Pharmaceuticals Inc.", "city": "Wilmington", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Gastrointestinal", "Genitourinary", "Hematology", "Neurology", "Pulmonary"], "modalityGroups": ["Digital / Device", "Macrocycle", "Other", "Small Molecule"], "nProducts": 31, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Bretaris Genuair", "phase": "Marketed", "indication": "Chronic obstructive pulmonary disease (COPD)"}, {"name": "Brimica Genuair", "phase": "Marketed", "indication": "Chronic obstructive pulmonary disease (COPD)"}, {"name": "Feraheme", "phase": "Marketed", "indication": "Anemia"}, {"name": "Horizant", "phase": "Marketed", "indication": "Neuralgia"}, {"name": "Hydroxyprogesterone caproate injection", "phase": "Marketed", "indication": "Uterine contractions"}, {"name": "PPC-06 (XP23829)", "phase": "Phase II", "indication": "Psoriasis"}, {"name": "Epaned", "phase": "Marketed", "indication": "Heart failure"}, {"name": "Firvanq", "phase": "Marketed", "indication": "Colitis"}], "ceo": "", "employees": 0, "founded": 2000, "website": "https://azurity.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Azurity%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Dermatology", "Hematology (non-cancer)", "Other", "Pain / Migraine", "Respiratory / Allergy"]}, {"company": "Bacainn Therapeutics Inc.", "city": "Concord", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Inflammation"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AD5051 (BT051)", "phase": "Phase I", "indication": "Ulcerative colitis"}, {"name": "Bacainn-diabetic wounds-unknown", "phase": "Preclinical", "indication": "Wounds"}, {"name": "Bacainn-respiratory inflammation-unknown", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://bacainntherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bacainn%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "IBD / GI Inflammatory", "Other Inflammation"]}, {"company": "Bach Pharma Inc.", "city": "North Andover", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GVT", "phase": "Preclinical", "indication": "Cognitive dysfunction"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.bachpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bach%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Bambusa Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Gastrointestinal", "Pulmonary"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BBT001", "phase": "Phase I", "indication": "Dermatitis"}, {"name": "BBT002", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://www.bambusatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bambusa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Bantam Pharmaceutical LLC", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "BTM-3566", "phase": "IND", "indication": "B cell lymphoma"}, {"name": "BTM-3528", "phase": "Preclinical", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://bantampharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bantam%20Pharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Barofold Inc.", "city": "Aurora", "state": "CO", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Relonsiv (NU100", "phase": "Phase III", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.barofold.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Barofold", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Basking Biosciences Inc.", "city": "Columbus", "state": "OH", "country": "United States", "diseaseCats": ["Cardiovascular", "Hematology", "Neurology"], "modalityGroups": ["Other", "RNA Therapeutics"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BB-031 (DTRI-031)", "phase": "Phase I", "indication": "Stroke"}, {"name": "BB-025 (DTRI-025)", "phase": "Preclinical", "indication": "Bleeding"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.baskingbiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Basking%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Other Neurology"]}, {"company": "Bast Biotechnology", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Bastet 101", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.bastbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bast%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Batu Biologics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide", "Vaccine"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "ValloVax", "phase": "IND", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Hp91", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.batubiologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Batu%20Biologics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer", "Solid Tumors (General)"]}, {"company": "Baudax Bio Inc.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Hematology", "Neurology"], "modalityGroups": ["Cell Therapy", "Other", "Small Molecule", "Undisclosed"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Anjeso", "phase": "Marketed", "indication": "Pain"}, {"name": "Dex-IN", "phase": "Phase II", "indication": "Pain"}, {"name": "Fado", "phase": "Phase II", "indication": "Pain"}, {"name": "BX-1000 (RP-1000)", "phase": "Phase I", "indication": "Neurology (unspecified)"}, {"name": "BX-2000 (RP-2000)", "phase": "Phase I", "indication": "Anesthesia"}, {"name": "TI-168", "phase": "IND", "indication": "Hemophilia"}, {"name": "RP-3000", "phase": "Preclinical", "indication": "Anesthesia"}], "ceo": "Gerri Henwood", "employees": 0, "founded": 2019, "website": "https://www.baudaxbio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "BXRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Baudax%20Bio", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Other Neurology", "Pain / Migraine", "Supportive / Other"]}, {"company": "Baxter International Inc.", "city": "Deerfield", "state": "IL", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Dermatology", "Hematology", "Infectious", "Musculoskeletal", "Other", "Renal"], "modalityGroups": ["Cell Therapy", "Other", "Protein / Biologic", "Small Molecule", "Vaccine"], "nProducts": 17, "mostAdvanced": "Phase IV", "hasOrphan": false, "pipeline": [{"name": "heparin", "phase": "Phase IV", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Actifuse", "phase": "Marketed", "indication": "Bone repair"}, {"name": "ARTISS", "phase": "Marketed", "indication": "Burns"}, {"name": "Brevibloc", "phase": "Marketed", "indication": "Tachycardia"}, {"name": "Certiva", "phase": "Marketed", "indication": "Diphtheria"}, {"name": "Dianeal", "phase": "Marketed", "indication": "Renal failure"}, {"name": "Endoxan", "phase": "Marketed", "indication": "Breast cancer"}, {"name": "Holoxan", "phase": "Marketed", "indication": "Bladder cancer"}], "ceo": "Andrew P. Hider, MBA", "employees": 38000, "founded": 1931, "website": "http://www.baxter.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 26614600000.0, "evFmt": "$26.6B", "ticker": "BAX", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Baxter%20International", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Cardiovascular", "GU / Gynecologic Cancers", "Infectious Disease", "Musculoskeletal", "Other", "Supportive / Other"]}, {"company": "Bcn Biosciences LLC", "city": "Pasadena", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Gastrointestinal", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BCN057", "phase": "Preclinical", "indication": "Pancreatic cancer"}, {"name": "BCN077", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "BCN176", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "BCN512", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.bcnbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bcn%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "GI Cancers", "Solid Tumors (General)"]}, {"company": "Be Biopharma Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hematology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "BE-101", "phase": "Phase I/II", "indication": "Hemophilia"}, {"name": "BE-102", "phase": "Preclinical", "indication": "Hypophosphatasia"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://be.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-04-02", "recentDeals": [{"headline": "MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)", "date": "2024-04-02", "value": ""}], "totalRaised": 304000000.0, "totalRaisedFmt": "$304M", "latestFinDate": "2025-01-15", "latestFinType": "Series C rounds", "nRounds": 3, "recentFinancing": [{"type": "Series C rounds", "amount": "$92M", "date": "2025-01-15", "investors": "Nextech Invest Ltd., Arch Venture Partners, Atlas Venture, Ra Capital Management L.P., Alta Partners, Longwood Fund, Bri..."}, {"type": "Uncategorized venture rounds", "amount": "$82M", "date": "2024-10-22", "investors": "Arch Venture Partners, Atlas Venture, Ra Capital Management L.P., Alta Partners, Longwood Fund, Bristol Myers Squibb Co...."}, {"type": "Series B rounds", "amount": "$130M", "date": "2022-04-14", "investors": "Arch Venture Partners, Bristol Myers Squibb Co., Atlas Venture, Ra Capital Management L.P., Alta Partners, Longwood Fund..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Be%20Biopharma", "hasDealsFin": true, "diseaseGroups": ["Hematology (non-cancer)", "Other"]}, {"company": "Beam Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Hematology"], "modalityGroups": ["Cell Therapy", "Gene Therapy"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BEAM-101", "phase": "Phase I/II", "indication": "Sickle cell disease"}, {"name": "BEAM-201", "phase": "Phase I/II", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "BEAM-301", "phase": "Phase I/II", "indication": "Glycosphingolipid storage disorders"}, {"name": "BEAM-302", "phase": "Phase I/II", "indication": "Alpha-antitrypsin (AAT) deficiency"}], "ceo": "John Evans, MBA", "employees": 483, "founded": 2017, "website": "https://beamtx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1352047598.4, "evFmt": "$1.4B", "ticker": "BEAM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Beam%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Hematology (non-cancer)", "Rare / Genetic"]}, {"company": "Beat Biotherapeutics Corp.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BB-R12", "phase": "Preclinical", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.beatbiotherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Beat%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Beech Tree Labs Inc.", "city": "Providence", "state": "RI", "country": "United States", "diseaseCats": ["Genitourinary", "Infectious"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "BTL-TML-HSV", "phase": "Phase II", "indication": "Herpes simplex virus (HSV)"}, {"name": "UISH001", "phase": "Phase I/II", "indication": "Incontinence"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.beechtreelabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Beech%20Tree%20Labs", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other Specialties"]}, {"company": "Belite Bio Inc.", "city": "San Diego", "state": "", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Hepatic", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "tinlarebant (LBS-008)", "phase": "Phase III", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "LBS-007", "phase": "Phase I/II", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "LBS-009", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "Yue Hsin Lin, MD, PhD", "employees": 25, "founded": 2016, "website": "http://www.belitebio.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1782359651.8, "evFmt": "$1.8B", "ticker": "BLTE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Belite%20Bio", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Hematologic Cancers", "Ophthalmology"]}, {"company": "Bellbrook Labs LLC", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Nudge Therapeutics-cGAS-unknown", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "Nudge Therapeutics-TREX1-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://bellbrooklabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bellbrook%20Labs", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Bellicum Pharmaceuticals Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Musculoskeletal", "Transplant"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Rivo-cel", "phase": "Phase II", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "BCMA-GoCar NK", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}], "ceo": "Dave Maggio", "employees": 13, "founded": 2004, "website": "http://www.bellicum.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 18395300.0, "evFmt": "$18M", "ticker": "BLCM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bellicum%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Belrose Pharma Inc.", "city": "Cranbury", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "ambroxol (BEL-0218)", "phase": "Phase II/III", "indication": "Gaucher disease"}, {"name": "PEG-C1 esterase inhibitor (BEL-0215", "phase": "IND", "indication": "Angioedema"}, {"name": "BEL-0216", "phase": "Preclinical", "indication": "Growth hormone deficiency"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://belrosepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Belrose%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation", "Other Specialties", "Rare / Genetic"]}, {"company": "Benecyte Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Transplant"], "modalityGroups": ["Cell Therapy", "Protein / Biologic", "Vaccine"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CMN-001", "phase": "Phase II", "indication": "Renal cancer"}, {"name": "CAR-CIK", "phase": "Phase I/II", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "sCD-83", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.benecyte.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Benecyte", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Other Inflammation"]}, {"company": "Benevira Inc.", "city": "New York City", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "beta521 (\u03b2521)", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.benevira.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Benevira", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Benitec Biopharma Inc.", "city": "Hayward", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Musculoskeletal", "Ophthalmic"], "modalityGroups": ["Gene Therapy", "Other", "RNA Therapeutics"], "nProducts": 7, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "AXO-AAV-OPMD (BB-301", "phase": "Phase I/II", "indication": "Muscular dystrophy"}, {"name": "RHIV7-shI-TAR-CCR5RZ", "phase": "Phase I/II", "indication": "HIV/AIDS"}, {"name": "BB-102", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "BB-103", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "BB-201", "phase": "Preclinical", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "BB-202", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "BB-501", "phase": "Preclinical", "indication": "Head and neck cancer"}], "ceo": "Jerel A. Banks, MD, PhD", "employees": 19, "founded": 1997, "website": "http://www.benitec.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 326640479.737221, "evFmt": "$327M", "ticker": "BNTC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Benitec%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer", "Infectious Disease", "Liver Disease", "Neurodegeneration / NMD", "Ophthalmology"]}, {"company": "Beta Bionics Inc.", "city": "Boston", "state": "", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Pilot", "hasOrphan": false, "pipeline": [{"name": "iLet", "phase": "Pilot", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-05-06", "recentDeals": [{"headline": "Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics", "date": "2024-05-06", "value": ""}], "totalRaised": 217000000.0, "totalRaisedFmt": "$217M", "latestFinDate": "2024-11-13", "latestFinType": "Series E rounds", "nRounds": 3, "recentFinancing": [{"type": "Series E rounds", "amount": "$60M", "date": "2024-11-13", "investors": "Wellington Management, Eventide Asset Management LLC, Rtw Investments L.P., Sands Capital Ventures, Soleus Capital, Omeg..."}, {"type": "Series D rounds", "amount": "$100M", "date": "2023-08-30", "investors": "Sands Capital, Omega Funds, Marshall Wace, Soleus Capital, Eventide Asset Management LLC, Farallon Capital Management, P..."}, {"type": "Series C rounds", "amount": "$57M", "date": "2022-02-17", "investors": "Soleus Capital, Perceptive Advisors, Farallon Capital Management, Rtw Investments L.P., Eventide Asset Management LLC, P..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Beta%20Bionics", "hasDealsFin": true, "diseaseGroups": ["Diabetes"]}, {"company": "Bexion Pharmaceuticals Inc.", "city": "Covington", "state": "KY", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "BXQ-350", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.bexionpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bexion%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Bexson Biomedical Inc.", "city": "Santa Barbara", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ketamine (BB106)", "phase": "Phase II", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.bexsonbiomedical.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bexson%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Beyondspring Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "plinabulin (BPI-2358", "phase": "Registration", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "BPI-002", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "BPI-003", "phase": "Preclinical", "indication": "Pancreatic cancer"}, {"name": "BPI-004", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Lan Huang, PhD", "employees": 40, "founded": 2013, "website": "http://www.beyondspringpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 81047104.051731, "evFmt": "$81M", "ticker": "BYSI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Beyondspring", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Bicara Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BCA101", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "BCA202", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "BCA300", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Claire Mazumdar, PhD, MBA", "employees": 55, "founded": 2020, "website": "https://www.bicara.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 459372026.46, "evFmt": "$459M", "ticker": "BCAX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bicara%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Bighat Biosciences Inc.", "city": "San Carlos", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation"], "modalityGroups": ["ADC", "Other", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BigHat-GI Cancers Next-gen ADC-unknown", "phase": "Preclinical", "indication": "Gastrointestinal cancer"}, {"name": "BigHat-Inflammatory Disease-unknown", "phase": "Research", "indication": "Inflammation (unspecified)"}, {"name": "BigHat-Solid Cancers Next-gen ADC-unknown2", "phase": "Research", "indication": "Solid tumors"}, {"name": "BigHat-Solid Cancers Next-gen T cell engager-unknown", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.bighatbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-12-05", "recentDeals": [{"headline": "AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies", "date": "2023-12-05", "value": ""}, {"headline": "BigHat Biosciences Completes First Stage of Research Collaboration with Amgen", "date": "2022-01-11", "value": ""}], "totalRaised": 75000000.0, "totalRaisedFmt": "$75M", "latestFinDate": "2022-07-20", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$75M", "date": "2022-07-20", "investors": "Section 32, Amgen Ventures, Bristol Myers Squibb Co., Quadrille Capital, Gaingels, Grids Capital, Undisclosed Investors,..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bighat%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["GI Cancers", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Bilayer Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Gastrointestinal", "Hepatic"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BL-010", "phase": "Preclinical", "indication": "Constipation"}, {"name": "BL-020", "phase": "Preclinical", "indication": "Constipation"}, {"name": "BL-030", "phase": "Preclinical", "indication": "Colitis"}, {"name": "BL-040", "phase": "Preclinical", "indication": "Crohn's disease"}, {"name": "BL-050", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://bilayer-therapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bilayer%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Obesity / Metabolic", "Other", "Supportive / Other"]}, {"company": "Bimini Health Technologies", "city": "Solana Beach", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology"], "modalityGroups": ["Cell Therapy", "Other"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "KeraStem (IDE 16488)", "phase": "Phase III", "indication": "Androgenetic alopecia"}, {"name": "Puregraft", "phase": "Phase I/II", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://biminihealthtech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bimini%20Health%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Musculoskeletal"]}, {"company": "Bio-path Holdings Inc.", "city": "Bellaire", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "RNA Therapeutics"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Liposomal Grb2 antisense", "phase": "Phase II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Liposomal Bcl-2 (BP1002", "phase": "Phase I", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "liposomal Grb2 (BP1001-A)", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "Liposomal Stat3 (BP1003)", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Vikram Grover, CFA", "employees": 10, "founded": 2007, "website": "http://www.biopathholdings.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1695160.0, "evFmt": "$2M", "ticker": "BPTH", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bio-path%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers"]}, {"company": "Bio4t2 LLC", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "B4T2-001", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "B4T2-002", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "B4T2-003", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "B4T2-004", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "B4T2-100", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "B4T2-M13", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://bio4t2.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bio4t2", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Bioaegis Therapeutics Inc.", "city": "North Brunswick", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Inflammation", "Neurology", "Pulmonary", "Renal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "recombinant human plasma gelsolin", "phase": "Phase II", "indication": "Bronchitis"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.bioaegistherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bioaegis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Bioage Labs Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BGE-102 (BGE-100)", "phase": "Phase I", "indication": "Obesity"}], "ceo": "Kristen Fortney, PhD", "employees": 64, "founded": 2015, "website": "https://bioagelabs.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -138073285.77, "evFmt": "", "ticker": "BIOA", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-06-03", "recentDeals": [{"headline": "BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates", "date": "2025-06-03", "value": ""}], "totalRaised": 170000000.0, "totalRaisedFmt": "$170M", "latestFinDate": "2024-02-13", "latestFinType": "Series D rounds", "nRounds": 1, "recentFinancing": [{"type": "Series D rounds", "amount": "$170M", "date": "2024-02-13", "investors": "Sofinnova Investments Inc., Longitude Capital, Ra Capital Management L.P., Cormorant Asset Management, Rtw Investments L..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bioage%20Labs", "hasDealsFin": true, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Bioatla Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Other", "Protein / Biologic"], "nProducts": 10, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "BA3011", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "BA3021", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "BA3182", "phase": "Phase I", "indication": "Adenocarcinoma"}, {"name": "CAB-CTLA4 (BA3071)", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "BA3361", "phase": "IND", "indication": "Solid tumors"}, {"name": "CAB-EGFR", "phase": "IND", "indication": "Breast cancer"}, {"name": "BA3142", "phase": "Preclinical", "indication": "Head and neck cancer"}, {"name": "BA3151", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Jay M. Short, PhD", "employees": 76, "founded": 2007, "website": "http://www.bioatla.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -19493427.2032, "evFmt": "", "ticker": "BCAB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bioatla", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Head & Neck Cancer", "Solid Tumors (General)"]}, {"company": "Bioaxone Biosciences Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NRL-1049 (BA-1049)", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://bioaxonebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bioaxone%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Biocardia Inc.", "city": "Sunnyvale", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Pulmonary"], "modalityGroups": ["Cell Therapy", "Digital / Device"], "nProducts": 5, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Morph AcessPro", "phase": "Approved", "indication": "Cardiovascular (unspecified)"}, {"name": "Morph Universal Deflectable Guide Catheter", "phase": "Approved", "indication": "Cardiovascular (unspecified)"}, {"name": "CardiAMP", "phase": "Phase III", "indication": "Coronary artery disease (CAD)"}, {"name": "CardiALLO", "phase": "Phase II", "indication": "Cardiomyopathy"}, {"name": "CardiALLO NK1R+ MSC Therapy", "phase": "Preclinical", "indication": "Heart failure"}], "ceo": "Peter Alan Altman, PhD", "employees": 20, "founded": 1999, "website": "http://www.biocardia.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 4561545.04, "evFmt": "$5M", "ticker": "BCDA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biocardia", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Biocorrx Inc.", "city": "Anaheim", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BICX104", "phase": "Phase I", "indication": "Substance use disorders"}, {"name": "Naltrexone (BICX101)", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "Naltrexone (BICX102)", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "Lourdes Felix, MBA", "employees": 0, "founded": 2009, "website": "https://www.biocorrx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 10784984.74, "evFmt": "$11M", "ticker": "BICX", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biocorrx", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Biocryst Pharmaceuticals Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Hematology", "Infectious", "Inflammation", "Musculoskeletal", "Renal"], "modalityGroups": ["Antibody", "Other", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Orladeyo", "phase": "Marketed", "indication": "Angioedema"}, {"name": "Rapivab", "phase": "Marketed", "indication": "Influenza virus"}, {"name": "Mundesine (BCX-1777", "phase": "Approved", "indication": "T cell lymphoma"}, {"name": "navenibart (STAR-0215", "phase": "Phase III", "indication": "Angioedema"}, {"name": "R3421", "phase": "Phase II", "indication": "Hyperuricemia/gout"}, {"name": "BCX10013", "phase": "Phase I", "indication": "Hematology (unspecified)"}, {"name": "galidesivir (BCX4430)", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "BCX9499", "phase": "Preclinical", "indication": "Musculoskeletal (unspecified)"}], "ceo": "Charles K. Gayer, MBA", "employees": 580, "founded": 1986, "website": "http://www.biocryst.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2074711920.0, "evFmt": "$2.1B", "ticker": "BCRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biocryst%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Hematology (non-cancer)", "Infectious Disease", "Musculoskeletal", "Obesity / Metabolic", "Other Inflammation"]}, {"company": "Biocurity Pharmaceuticals Inc.", "city": "Jupiter", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "cerium oxide nanoparticles", "phase": "Preclinical", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.biocurity.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biocurity%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer"]}, {"company": "Bioeclipse Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CRX-100", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.bioeclipse.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bioeclipse%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Biogen Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Gastrointestinal", "Hematology", "Neurology"], "modalityGroups": ["Antibody", "Peptide", "Protein / Biologic", "Small Molecule"], "nProducts": 16, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "avonex pen", "phase": "Marketed", "indication": "Multiple sclerosis (MS)"}, {"name": "Avonex", "phase": "Marketed", "indication": "Multiple sclerosis (MS)"}, {"name": "Fumaderm", "phase": "Marketed", "indication": "Psoriasis"}, {"name": "MabThera", "phase": "Marketed", "indication": "ANCA vasculitis"}, {"name": "Ocrevus", "phase": "Marketed", "indication": "Multiple sclerosis (MS)"}, {"name": "Plegridy", "phase": "Marketed", "indication": "Multiple sclerosis (MS)"}, {"name": "Prialt", "phase": "Marketed", "indication": "Pain"}, {"name": "Skyclarys", "phase": "Marketed", "indication": "Friedreich ataxia"}], "ceo": "Christopher A. Viehbacher, CPA", "employees": 7500, "founded": 1978, "website": "http://www.biogen.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 28730029000.0, "evFmt": "$28.7B", "ticker": "BIIB", "exchange": "NASDAQ", "nDeals": 5, "totalDealValue": 1111000000.0, "totalDealFmt": "$1.1B", "latestDealDate": "2025-10-24", "recentDeals": [{"headline": "Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio", "date": "2025-10-24", "value": "$1.1B"}, {"headline": "Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies", "date": "2025-05-27", "value": ""}, {"headline": "Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease", "date": "2024-03-26", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biogen", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology", "MS / Neuroimmune", "Neurodegeneration / NMD", "Pain / Migraine"]}, {"company": "Biograph 55 Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "B55-001", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.biograph55.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biograph%2055", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Biogx Inc.", "city": "Birmingham", "state": "AL", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Flu A", "phase": "Marketed", "indication": "Infectious, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.biogx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biogx", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Bioharmony Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BH01", "phase": "Preclinical", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.bioharmonytherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bioharmony%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Biohaven Ltd.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Neurology", "Renal"], "modalityGroups": ["ADC", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "Dazluma", "phase": "Registration", "indication": "Ataxia"}, {"name": "opakalim (BHV-7000", "phase": "Phase II/III", "indication": "Bipolar disorder"}, {"name": "BHV-1300", "phase": "Phase I", "indication": "Graves disease"}, {"name": "BHV-1400", "phase": "Phase I", "indication": "IgA nephropathy"}, {"name": "BHV-1600", "phase": "Phase I", "indication": "Cardiomyopathy"}, {"name": "BHV-1310", "phase": "IND", "indication": "Myasthenia gravis"}, {"name": "BHV-1500", "phase": "Preclinical", "indication": "Hodgkin disease"}], "ceo": "Vladimir Coric, MD", "employees": 256, "founded": 2022, "website": "http://biohavenpharma.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2957920486.95, "evFmt": "$3.0B", "ticker": "BHVN", "exchange": "NYSE", "nDeals": 1, "totalDealValue": 970000000.0, "totalDealFmt": "$970M", "latestDealDate": "2023-03-22", "recentDeals": [{"headline": "Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders", "date": "2023-03-22", "value": "$970M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biohaven", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Hematologic Cancers", "Kidney Disease", "MS / Neuroimmune", "Neurodegeneration / NMD", "Other Inflammation", "Psychiatry / Behavioral"]}, {"company": "Biolexis Therapeutics Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BLX-0871", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "BLX-4000", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "BLX-7006", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://biolexistx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 10000000.0, "totalRaisedFmt": "$10M", "latestFinDate": "2023-11-29", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$10M", "date": "2023-11-29", "investors": "Clarke Capital Partners"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biolexis%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Diabetes"]}, {"company": "Biologicsmd Inc.", "city": "Fayetteville", "state": "AR", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PTH-CBD (BMD-1141)", "phase": "Preclinical", "indication": "Osteoporosis"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://biologicsmd.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biologicsmd", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Biom Pharmaceuticals Corp.", "city": "Sarasota", "state": "FL", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BiE123", "phase": "Phase I", "indication": "Clostridium"}, {"name": "BiE127", "phase": "Phase I", "indication": "Infectious (unspecified)"}, {"name": "BiN110", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.biompharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biom%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Infectious Disease"]}, {"company": "Biomarck Pharmaceuticals Ltd.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Pulmonary"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "BIO-11006 Inhalation Solution", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.biomarck.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biomarck%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Biomarin Pharmaceutical Inc.", "city": "San Rafael", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Hematology", "Musculoskeletal", "Neurology", "Other", "Renal"], "modalityGroups": ["Gene Therapy", "Peptide", "Protein / Biologic", "RNA Therapeutics", "Small Molecule"], "nProducts": 14, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Aldurazyme", "phase": "Marketed", "indication": "Mucopolysaccharidosis"}, {"name": "Aryplase", "phase": "Marketed", "indication": "Mucopolysaccharidosis"}, {"name": "Brineura", "phase": "Marketed", "indication": "Neuronal ceroid lipofuscinosis"}, {"name": "Firdapse", "phase": "Marketed", "indication": "Autoimmune (unspecified)"}, {"name": "Kuvan (6R-BH4", "phase": "Marketed", "indication": "Phenylketonuria"}, {"name": "Palynziq (pegvaliase", "phase": "Marketed", "indication": "Phenylketonuria"}, {"name": "Vimizim", "phase": "Marketed", "indication": "Mucopolysaccharidosis"}, {"name": "Voxzogo", "phase": "Marketed", "indication": "Musculoskeletal (unspecified)"}], "ceo": "Alexander Hardy", "employees": 3040, "founded": 1997, "website": "https://www.biomarin.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 12441376840.0, "evFmt": "$12.4B", "ticker": "BMRN", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-09-26", "recentDeals": [{"headline": "CAMP4 Enters Strategic Research Collaboration to Advance Novel Regulatory RNA-Targeting Medicines for Rare Genetic Conditions", "date": "2024-09-26", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biomarin%20Pharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Musculoskeletal", "Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Biomea Fusion Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BMF-219 (AO-001)", "phase": "Phase I/II", "indication": "Diabetes"}, {"name": "BMF-500", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "Michael J. M. Hitchcock, PhD", "employees": 106, "founded": 2017, "website": "https://biomeafusion.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 90582003.48, "evFmt": "$91M", "ticker": "BMEA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biomea%20Fusion", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Hematologic Cancers"]}, {"company": "Biomed Valley Discoveries Inc.", "city": "Kansas City", "state": "MO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ulixertinib (BVD-523)", "phase": "Phase II", "indication": "Melanoma"}, {"name": "BVD-CNV", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.biomed-valley.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biomed%20Valley%20Discoveries", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Biomimetix Pharmaceutical Inc.", "city": "Greenwood Village", "state": "CO", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "BMX-001", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "BMX-010", "phase": "Phase II", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://biomimetixpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biomimetix%20Pharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Dermatology"]}, {"company": "Bionaut Labs Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": true, "pipeline": [{"name": "BNL-101", "phase": "IND", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.bionautlabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bionaut%20Labs", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Bionecure Therapeutics Inc.", "city": "Germantown", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BIO-106", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "BIO-201", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.bionecure.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bionecure%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Bionevia LLC", "city": "Belmont", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "diepalrestat choline (BNV-222)", "phase": "Phase II", "indication": "Neuropathy"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.new-bionevia.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bionevia", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Bionic Sight Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BS01", "phase": "Phase I/II", "indication": "Retinitis"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.bionicsightllc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bionic%20Sight", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Bionumerik Pharmaceuticals Inc.", "city": "San Antonio", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Karenitecin (BNP1350)", "phase": "Phase III", "indication": "Ovarian cancer"}, {"name": "Tavocept (BNP7787)", "phase": "Phase III", "indication": "Adenocarcinoma"}], "ceo": "", "employees": 0, "founded": 1992, "website": "http://www.bionumerik.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bionumerik%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Bioq Pharma Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Digital / Device", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Propofol infusion", "phase": "Marketed", "indication": "Pain"}, {"name": "Ropivacaine infusion", "phase": "Marketed", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.bioqpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bioq%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Biorestorative Therapies Inc.", "city": "Melville", "state": "NY", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Musculoskeletal", "Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "BrtxDISC (BRTX-100)", "phase": "Phase II", "indication": "Musculoskeletal (unspecified)"}, {"name": "ThermoStem", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "Lance Alstodt", "employees": 11, "founded": 1997, "website": "http://www.biorestorative.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 383813.76, "evFmt": "$384K", "ticker": "BRTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biorestorative%20Therapies", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Obesity / Metabolic"]}, {"company": "Biosplice Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Musculoskeletal", "Neurology", "Pulmonary"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "lorecivivint (SM04690)", "phase": "Registration", "indication": "Osteoarthritis"}, {"name": "LNG01 (SM0646)", "phase": "Phase I", "indication": "Pulmonary fibrosis"}, {"name": "SM04554", "phase": "Phase II/III", "indication": "Androgenetic alopecia"}, {"name": "SM04755", "phase": "Phase I", "indication": "Psoriasis"}, {"name": "SM07883", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "SM08502", "phase": "Phase I", "indication": "Pancreatic cancer"}, {"name": "SM09419", "phase": "Phase I", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2007, "website": "https://www.biosplice.com/default.aspx", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biosplice%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Dermatology", "GI Cancers", "Hematologic Cancers", "Musculoskeletal", "Respiratory / Allergy"]}, {"company": "Biostax Corp. (Attune Biotech)", "city": "Orlando", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Musculoskeletal"], "modalityGroups": ["Cell Therapy", "Peptide", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IRT-101 (MENK)", "phase": "Phase II", "indication": "Cancer (unspecified)"}, {"name": "IRT-102", "phase": "Phase II", "indication": "Cancer (unspecified)"}, {"name": "Lodonal", "phase": "Phase II", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 1993, "website": "https://attunebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biostax%20Corp.%20(Attune%20Biotech)", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune", "Solid Tumors (General)"]}, {"company": "Biostem Technologies Inc.", "city": "Pompano Beach", "state": "FL", "country": "United States", "diseaseCats": ["Dermatology", "Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Avenova Allograft", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}, {"name": "Clarix", "phase": "Marketed", "indication": "Wounds"}, {"name": "Neox", "phase": "Marketed", "indication": "Wounds"}], "ceo": "Jason Matuszewski", "employees": 0, "founded": 2014, "website": "https://www.biostemtechnologies.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 281867629.56, "evFmt": "$282M", "ticker": "BSEM", "exchange": "OTCQB", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-09-11", "recentDeals": [{"headline": "NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allograft", "date": "2023-09-11", "value": ""}], "totalRaised": 220002.0, "totalRaisedFmt": "$220K", "latestFinDate": "2023-03-09", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$220K", "date": "2023-03-09", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biostem%20Technologies", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Ophthalmology"]}, {"company": "Biothera Pharmaceuticals Inc.", "city": "Eagan", "state": "MN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AS1402", "phase": "Phase II", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.biothera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biothera%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Biotheryx Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BTX-1188", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Biotheryx-PDE4-unknown", "phase": "Preclinical", "indication": "Inflammatory disease"}, {"name": "Biotheryx-SOS1-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "BTX-9341", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.biotheryx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biotheryx", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Biovest International Inc.", "city": "Minneapolis", "state": "MN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "BiovaxID", "phase": "Registration", "indication": "B cell lymphoma"}], "ceo": "", "employees": 0, "founded": 1981, "website": "http://hollow-fiber.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biovest%20International", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Biovista Inc.", "city": "Charlottesville", "state": "VA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Neurology", "Ophthalmic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 9, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BVA-101", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "BVA-201", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "BVA-202", "phase": "Preclinical", "indication": "Friedreich ataxia"}, {"name": "BVA-203", "phase": "Preclinical", "indication": "Friedreich ataxia"}, {"name": "BVA-501", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "BVA-601", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "BVA-701", "phase": "Preclinical", "indication": "Thyroid cancer"}, {"name": "BVA-901A", "phase": "Preclinical", "indication": "Glycosphingolipid storage disorders"}], "ceo": "", "employees": 0, "founded": 1996, "website": "http://www.biovista.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Biovista", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Epilepsy / Seizures", "Head & Neck Cancer", "MS / Neuroimmune", "Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Bioxcel Therapeutics Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Igalmi", "phase": "Marketed", "indication": "Bipolar disorder"}, {"name": "talabostat (BXCL701)", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "BXCL502", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "Vimal D. Mehta, PhD", "employees": 37, "founded": 2017, "website": "http://www.bioxceltherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 88258384.0, "evFmt": "$88M", "ticker": "BTAI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bioxcel%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "GU / Gynecologic Cancers", "Psychiatry / Behavioral"]}, {"company": "Bioxytran Inc.", "city": "Newton", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious", "Neurology"], "modalityGroups": ["Nanoparticle / Delivery", "Other", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BXT-10", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "BXT-25", "phase": "Preclinical", "indication": "Stroke"}, {"name": "BXT-252", "phase": "Preclinical", "indication": "Wounds"}], "ceo": "David Platt, PhD", "employees": 3, "founded": 2008, "website": "https://www.bioxytraninc.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 13592104.3209, "evFmt": "$14M", "ticker": "BIXT", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bioxytran", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease", "Other Neurology"]}, {"company": "Bitterroot Bio Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BRB-002", "phase": "Preclinical", "indication": "Atherosclerosis"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.bitterrootbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 145000000.0, "totalRaisedFmt": "$145M", "latestFinDate": "2023-06-07", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$145M", "date": "2023-06-07", "investors": "Arch Venture Partners, Deerfield Management, Gv, Koch Disruptive Technologies, Alexandria Venture Investments LLC, Undis..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bitterroot%20Bio", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular"]}, {"company": "Black Diamond Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "silevertinib (BDTX-1535", "phase": "Phase I/II", "indication": "Brain cancer"}, {"name": "BDTX-4933", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "BDTX-4876", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Mark A. Velleca, MD, PhD", "employees": 24, "founded": 2017, "website": "https://www.blackdiamondtherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 41371713.94, "evFmt": "$41M", "ticker": "BDTX", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-12-12", "recentDeals": [{"headline": "Black Diamond Therapeutics announces spinout of Launchpad Therapeutics, Inc., an antibody-focused precision oncology company", "date": "2022-12-12", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Black%20Diamond%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Solid Tumors (General)"]}, {"company": "Blacksmith Medicines Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "FG-LPXC", "phase": "Preclinical", "indication": "Gram-negative bacterial infection"}, {"name": "LpxC inhibitor", "phase": "Preclinical", "indication": "Gram-negative bacterial infection"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://blacksmithmedicines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Blacksmith%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Blade Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Hepatic", "Neurology", "Pulmonary"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "cudetaxestat (BLD-0409", "phase": "Phase I", "indication": "Liver fibrosis"}, {"name": "BLD-2184", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.blademed.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Blade%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Other Neurology"]}, {"company": "Bloom Science Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BL-001", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://bloomscience.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bloom%20Science", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Blossomhill Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BH-30643", "phase": "Phase I/II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "BH-30236", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "http://bhtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Blossomhill%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Lung Cancer"]}, {"company": "Blue Ash Therapeutics LLC", "city": "Blue Ash", "state": "OH", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "azimilide", "phase": "Phase III", "indication": "Arrhythmia"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.blueashtx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Blue%20Ash%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Blue Lake Biotechnology Inc.", "city": "Athens", "state": "GA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Gene Therapy", "Vaccine"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BLB201 (CPI-RSV-F vaccine)", "phase": "Phase I", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "CVXGA1", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "BLB300", "phase": "Preclinical", "indication": "Norovirus"}, {"name": "BLB400", "phase": "Preclinical", "indication": "Lyme disease"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.bluelakebiotechnology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Blue%20Lake%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Blue Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BLUE-181", "phase": "Preclinical", "indication": "Irritable bowel syndrome"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.bluetherapeutics.com/index.shtml", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Blue%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Bluebird Bio Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hematology", "Neurology"], "modalityGroups": ["Cell Therapy", "Gene Therapy"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Lyfgenia", "phase": "Marketed", "indication": "Sickle cell disease"}, {"name": "Zynteglo", "phase": "Marketed", "indication": "Thalassemia"}, {"name": "Skysona", "phase": "Approved", "indication": "Leukodystrophy"}, {"name": "BCL11a shRNA(miR)", "phase": "Phase I", "indication": "Sickle cell disease"}, {"name": "bluebird-gene therapy-unknown", "phase": "Preclinical", "indication": "Mucopolysaccharidosis"}], "ceo": "", "employees": 0, "founded": 1992, "website": "http://www.bluebirdbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-04-02", "recentDeals": [{"headline": "Xcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell disease", "date": "2025-04-02", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bluebird%20Bio", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Bluegrass Pharmaceuticals Inc.", "city": "Lexington", "state": "KY", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BG-101", "phase": "Preclinical", "indication": "Ischemia/reperfusion injury"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://www.bluegrass-pharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bluegrass%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Bluesphere Bio Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TCX-101", "phase": "Preclinical", "indication": "Acute lymphoblastic leukemia (ALL)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://bluespherebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bluesphere%20Bio", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Bluewillow Biologics", "city": "Ann Arbor", "state": "MI", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Protein / Biologic", "Vaccine"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BW-1010", "phase": "Phase I", "indication": "Anthrax"}, {"name": "NB-1008", "phase": "Phase I", "indication": "Influenza virus"}, {"name": "NE80-gD2", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}, {"name": "RSV vaccine", "phase": "Preclinical", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "W805EC", "phase": "Preclinical", "indication": "Influenza virus"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.bluewillow.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bluewillow%20Biologics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Bodor Laboratories Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Ecclock gel 5%", "phase": "Marketed", "indication": "Excessive sweating"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://bodorlaboratories.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bodor%20Laboratories", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Bolder Biotechnology Inc.", "city": "Boulder", "state": "CO", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Hematology", "Infectious", "Neurology", "Other"], "modalityGroups": ["Protein / Biologic"], "nProducts": 8, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BBT-015", "phase": "Phase I", "indication": "Neutropenia"}, {"name": "BBT-007", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "BBT-012", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "BBT-021", "phase": "Preclinical", "indication": "Anemia"}, {"name": "BBT-031", "phase": "Preclinical", "indication": "Growth failure"}, {"name": "BBT-046", "phase": "Preclinical", "indication": "Fungal infection"}, {"name": "BBT-059", "phase": "Preclinical", "indication": "Bleeding"}, {"name": "long-acting beta interferon (BBT-032)", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.bolderbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bolder%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Infectious Disease", "MS / Neuroimmune", "Other", "Solid Tumors (General)"]}, {"company": "Bolt Biotherapeutics Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Antibody"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BDC-3042", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "BDC-4182", "phase": "Phase I/II", "indication": "Gastric cancer"}], "ceo": "William P. Quinn, MBA", "employees": 52, "founded": 2015, "website": "http://boltbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -2465778.5219, "evFmt": "", "ticker": "BOLT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bolt%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers"]}, {"company": "Bond Biosciences Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BBI-001", "phase": "Phase I", "indication": "Iron overload"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://bond.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bond%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Boston Immune Technologies & Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BITR2101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.bostonimmunetech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Boston%20Immune%20Technologies%20%26%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Bostongene Corp.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "BostonGene Tumor Portrait", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.bostongene.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 150000000.0, "totalRaisedFmt": "$150M", "latestFinDate": "2022-04-06", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$150M", "date": "2022-04-06", "investors": "Nec Capital Solutions Ltd., Impact Investment Capital, Japan Industrial Partners"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bostongene", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Botanisol LLC", "city": "Scottsdale", "state": "AZ", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TAI-LCx", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.botanisol.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Botanisol", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Boundless Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BBI-355", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "Zachary D. Hornby, MBA", "employees": 64, "founded": 2018, "website": "http://www.boundlessbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -55228400.0, "evFmt": "", "ticker": "BOLD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Boundless%20Bio", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Bpgbio Inc.", "city": "Framingham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "BPGbio-pancreatic cancer-unknown", "phase": "Phase II", "indication": "Pancreatic cancer"}, {"name": "Coenzyme Q10", "phase": "Phase II", "indication": "Pancreatic cancer"}, {"name": "Topical BPM 31510", "phase": "Phase II", "indication": "Skin cancer"}, {"name": "Topical 31543 (BPM 31543)", "phase": "Phase I", "indication": "Other alopecia"}, {"name": "BPM 28740", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "BPM 42522", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "https://bpgbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bpgbio", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "GI Cancers", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Braasch Biotech LLC", "city": "Garretson", "state": "SD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Somatostatin vaccine", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.braaschbiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Braasch%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Brainstorm Cell Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology", "Pulmonary"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "NurOwn", "phase": "Phase III", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "Chaim Lebovits", "employees": 27, "founded": 2004, "website": "http://www.brainstorm-cell.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 12232481.46, "evFmt": "$12M", "ticker": "BCLI", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Brainstorm%20Cell%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Brenig Therapeutics Inc.", "city": "Dover", "state": "DE", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BT-267", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://biogenerationventures.com/en/portfolio/brenig", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 65000000.0, "totalRaisedFmt": "$65M", "latestFinDate": "2024-07-23", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$65M", "date": "2024-07-23", "investors": "New Enterprise Associates, Orbimed Advisors LLC, Torrey Pines Investment, Biogeneration Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Brenig%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Parkinson's"]}, {"company": "Briacell Therapeutics Corp.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Cell Therapy", "Diagnostics", "Vaccine"], "nProducts": 6, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Bria-IMT", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "Bria-OTS", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "BriaDx", "phase": "Preclinical", "indication": "Cancer, Diagnostic"}, {"name": "Bria-Lung", "phase": "Preclinical", "indication": "Lung cancer"}, {"name": "Bria-Mel", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "Bria-Pros", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "William V. Williams, MD", "employees": 17, "founded": 2004, "website": "https://briacell.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -15322083.703157, "evFmt": "", "ticker": "BCTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Briacell%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Lung Cancer", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Brickbio Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["ADC", "Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BRKB-28", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "BRKB-101", "phase": "Research", "indication": "Breast cancer"}, {"name": "BRKB-201", "phase": "Research", "indication": "Autoimmune (unspecified)"}, {"name": "BRKB-44", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.brickbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2024-03-18", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2024-03-18", "investors": "Samsung Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Brickbio", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Breast Cancer", "Solid Tumors (General)"]}, {"company": "Bridge Medicines LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Bridge Medicines-FXIIa-unknown", "phase": "Preclinical", "indication": "Angioedema"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://bridgemedicines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bridge%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Bridge Therapeutics Inc.", "city": "Birmingham", "state": "AL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "Bunalz (BT-219)", "phase": "IND", "indication": "Substance use disorders"}, {"name": "BT-205", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.bridgetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bridge%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Bridgebio Pharma Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Endocrine/Metabolic", "Inflammation", "Musculoskeletal", "Neurology", "Ophthalmic", "Other", "Otologic"], "modalityGroups": ["Gene Therapy", "Other", "Small Molecule", "Undisclosed"], "nProducts": 17, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Attruby", "phase": "Marketed", "indication": "Amyloidosis"}, {"name": "ribitol (BBP-418)", "phase": "Phase III", "indication": "Muscular dystrophy"}, {"name": "BBP-551", "phase": "Phase II/III", "indication": "Blindness"}, {"name": "encaleret (CLTX-305)", "phase": "Phase II", "indication": "Metabolic (unspecified)"}, {"name": "BBP-631", "phase": "Phase I/II", "indication": "Adrenal insufficiency"}, {"name": "BBP-681", "phase": "Phase I/II", "indication": "Inflammation (unspecified)"}, {"name": "BBP-812", "phase": "Phase I/II", "indication": "Genetic disorders"}, {"name": "BBO-10203", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "Neil Kumar, PhD", "employees": 730, "founded": 2015, "website": "http://bridgebio.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 6644805955.12, "evFmt": "$6.6B", "ticker": "BBIO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bridgebio%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Obesity / Metabolic", "Ophthalmology", "Other Inflammation", "Other Specialties", "Rare / Genetic", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Bridgene Biosciences Inc. (\u6865\u6d4e\u751f\u7269)", "city": "San Jose", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BGI-9004", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "BGS1933", "phase": "Research", "indication": "Gastric cancer"}, {"name": "BGS1949", "phase": "Research", "indication": "Autoimmune (unspecified)"}, {"name": "BGS1989", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "BGS2597", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://bridgenebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 66500000.0, "totalRaisedFmt": "$66M", "latestFinDate": "2025-10-16", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$28M", "date": "2025-10-16", "investors": "Bayland Capital, Shenzhen Gtja Investment Group, Proxima Ventures Ltd., Lapam Capital (\u9f99\u78d0\u6295\u8d44), Grains Valley Venture Capi..."}, {"type": "Series B rounds", "amount": "$38M", "date": "2022-07-27", "investors": "Lapam Capital (\u9f99\u78d0\u6295\u8d44), Junson Capital Co. Ltd., Dyee Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bridgene%20Biosciences%20Inc.%20(\u6865\u6d4e\u751f\u7269)", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "GI Cancers", "Solid Tumors (General)"]}, {"company": "Bright Biologics LLC", "city": "Sunnyvale", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BB-203", "phase": "Preclinical", "indication": "Liver cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://brightbiologicsllc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bright%20Biologics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Brightinsight Inc.", "city": "San Jose", "state": "", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Market (device)", "hasOrphan": false, "pipeline": [{"name": "BrightInsight Disease Management Solution", "phase": "Market (device)", "indication": "Adjunct"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 13000000.0, "totalRaisedFmt": "$13M", "latestFinDate": "2026-01-20", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$13M", "date": "2026-01-20", "investors": "Eclipse Ventures, General Catalyst, Insight Partners, Mayo Clinic, New Leaf Venture Partners"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Brightinsight", "hasDealsFin": true, "diseaseGroups": ["Other"]}, {"company": "Briori Biotech Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Rel\u00ffva", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.brioribiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Briori%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Bristol Myers Squibb Co.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dermatology", "Diagnostic", "Endocrine/Metabolic", "Gastrointestinal", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Pulmonary", "Renal", "Transplant"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Cell Therapy", "Combination", "Diagnostics", "Other", "Peptide", "Protein / Biologic", "Small Molecule", "Undisclosed", "Vaccine"], "nProducts": 207, "mostAdvanced": "Phase IV", "hasOrphan": true, "pipeline": [{"name": "bempikibart (ADX-914", "phase": "Phase II", "indication": "Alopecia areata"}, {"name": "danicamtiv (BMS-986434", "phase": "Phase II", "indication": "Cardiomyopathy"}, {"name": "Revlimid", "phase": "Phase IV", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Abecma", "phase": "Marketed", "indication": "Multiple myeloma (MM)"}, {"name": "Abraxane", "phase": "Marketed", "indication": "Breast cancer"}, {"name": "Avalide", "phase": "Marketed", "indication": "Hypertension"}, {"name": "Azactam", "phase": "Marketed", "indication": "Bacterial infection"}, {"name": "Baraclude", "phase": "Marketed", "indication": "Hepatitis B virus (HBV)"}], "ceo": "Christopher S. Boerner, PhD, MBA", "employees": 0, "founded": 1887, "website": "https://www.bms.com/", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 144421660000.0, "evFmt": "$144.4B", "ticker": "BMY", "exchange": "NYSE", "nDeals": 11, "totalDealValue": 3982750000.0, "totalDealFmt": "$4.0B", "latestDealDate": "2025-09-25", "recentDeals": [{"headline": "Kardigan in-licensed exclusive worldwide development and commercialization rights to danicamtiv from Bristol Myers Squibb", "date": "2025-09-25", "value": ""}, {"headline": "Nabla Bio Partners with Bristol Myers Squib for Generative Protein Design", "date": "2024-05-14", "value": ""}, {"headline": "Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb", "date": "2023-12-14", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bristol%20Myers%20Squibb", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "Cardiovascular", "Dermatology", "Hematologic Cancers", "Infectious Disease", "Liver Disease"]}, {"company": "Bryn Pharma LLC", "city": "Raleigh", "state": "NC", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Pivotal", "hasOrphan": false, "pipeline": [{"name": "epinephrine (BRYN-NDS1C)", "phase": "Pivotal", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.brynpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bryn%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Bugworks Research Inc.", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BWC0977", "phase": "Phase I", "indication": "Infectious (unspecified)"}, {"name": "Gyrox", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://bugworksresearch.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 20000000.0, "totalDealFmt": "$20M", "latestDealDate": "2023-07-27", "recentDeals": [{"headline": "GARDP and Bugworks join forces to accelerate development of a novel antibiotic to treat serious bacterial infections", "date": "2023-07-27", "value": "$20M"}], "totalRaised": 24779976.0, "totalRaisedFmt": "$25M", "latestFinDate": "2024-02-22", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$7M", "date": "2024-02-22", "investors": "Undisclosed Investors"}, {"type": "Series B rounds", "amount": "$18M", "date": "2022-02-09", "investors": "Lightrock, University of Tokyo Edge Capital Partners Co. Ltd., Lord Jim O'neill, Kiran Mazumdar-shaw, Im Holdings B.V., ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Bugworks%20Research", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Burzynski Research Institute Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Antineoplastons (ANP) therapy", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "Stanislaw R. Burzynski, MD, PhD", "employees": 0, "founded": 1983, "website": "http://www.burzynskiresearch.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7610017.9076, "evFmt": "$8M", "ticker": "BZYR", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Burzynski%20Research%20Institute", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "C2n Diagnostics LLC", "city": "St. Louis", "state": "", "country": "United States", "diseaseCats": ["Diagnostic", "Neurology"], "modalityGroups": ["Antibody", "Diagnostics"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "PrecivityAD2", "phase": "Marketed", "indication": "Neurology, Diagnostic"}, {"name": "Precivity-ApoE", "phase": "Marketed", "indication": "Neurology, Diagnostic"}, {"name": "PrecivityAD test", "phase": "Market (diagnostic)", "indication": "Neurology, Diagnostic"}, {"name": "ABBV-8E12", "phase": "Phase II", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 3, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-04-26", "recentDeals": [{"headline": "C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity Blood Testing for Alzheimer\u2019s Disease and Brain Research Market", "date": "2024-04-26", "value": ""}, {"headline": "C2N Diagnostics partners with Grupo Fleury to bring pioneering blood tests to Brazil for advancing brain health", "date": "2022-09-21", "value": ""}, {"headline": "C2N Diagnostics and Healius Ltd announce partnership to bring PrecivityAD and related brain health biomarkers to patients in Australia", "date": "2022-08-30", "value": ""}], "totalRaised": 34999618.0, "totalRaisedFmt": "$35M", "latestFinDate": "2025-03-13", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$10M", "date": "2025-03-13", "investors": "Samsung Electronics Co. Ltd."}, {"type": "Uncategorized venture rounds", "amount": "$25M", "date": "2024-03-01", "investors": "Eisai Co. Ltd., Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=C2n%20Diagnostics", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Other Neurology"]}, {"company": "C4 Therapeutics Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "cemsidomide (CFT7455)", "phase": "Phase I/II", "indication": "Hematologic malignancies"}, {"name": "CFT1946", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "CFT8919", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "Andrew J. Hirsch, MBA", "employees": 110, "founded": 2015, "website": "http://www.c4thera.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 70594774.8, "evFmt": "$71M", "ticker": "CCCC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=C4%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Cabaletta Bio Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "CABA-201", "phase": "Phase I/II", "indication": "Autoimmune (unspecified)"}, {"name": "DSG3-CAART", "phase": "Phase I", "indication": "Pemphigus"}, {"name": "MuSK-CAART", "phase": "Preclinical", "indication": "Myasthenia gravis"}], "ceo": "Steven Nichtberger, MD", "employees": 161, "founded": 2017, "website": "https://www.cabalettabio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -34840475.86, "evFmt": "", "ticker": "CABA", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 162000000.0, "totalDealFmt": "$162M", "latestDealDate": "2022-10-11", "recentDeals": [{"headline": "IASO Biotherapeutics and Cabaletta Bio announce exclusive worldwide license agreement for clinically validated CD19 binder", "date": "2022-10-11", "value": "$162M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cabaletta%20Bio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "MS / Neuroimmune", "Other"]}, {"company": "Cadenza Bio Inc.", "city": "Oklahoma City", "state": "OK", "country": "United States", "diseaseCats": ["Autoimmune", "Genitourinary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Cadenza Bio-endometriosis-unknown", "phase": "Preclinical", "indication": "Endometriosis"}, {"name": "Cadenza Bio-multiple sclerosis-unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.cadenza.bio", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-01-01", "recentDeals": [{"headline": "Cadenza Bio Exclusive License to Technology Developed Through an Academic Research Collaboration Between the University of Illinois Urbana-Champaign (UIUC) and the University of California, Riverside", "date": "2022-01-01", "value": ""}], "totalRaised": 4880000.0, "totalRaisedFmt": "$5M", "latestFinDate": "2025-08-28", "latestFinType": "Venture (Debt)", "nRounds": 2, "recentFinancing": [{"type": "Venture (Debt)", "amount": "$2M", "date": "2025-08-28", "investors": "Undisclosed Investors"}, {"type": "Seed financings", "amount": "$2M", "date": "2023-12-14", "investors": "Plains Ventures, Oklahoma Life Sciences Fund, Cortado Ventures, Boyd Street Ventures LLC, Illinois Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cadenza%20Bio", "hasDealsFin": true, "diseaseGroups": ["MS / Neuroimmune", "Women's Health"]}, {"company": "Cadrenal Therapeutics Inc.", "city": "Florida", "state": "FL", "country": "United States", "diseaseCats": ["Cardiovascular", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "tecarfarin (ATI-5923)", "phase": "Phase II/III", "indication": "Blood clots"}, {"name": "frunexian (EP-7041)", "phase": "Phase I", "indication": "Thrombosis"}, {"name": "EP-7327", "phase": "Preclinical", "indication": "Thrombosis"}], "ceo": "Quang X. Pham", "employees": 4, "founded": 2022, "website": "https://www.cadrenal.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7653337.5, "evFmt": "$8M", "ticker": "CVKD", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-12-11", "recentDeals": [{"headline": "Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)", "date": "2025-12-11", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cadrenal%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Cage Pharmaceuticals Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CP-102 (PS-102)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "https://www.cagephar.ma/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cage%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Cahaba Pharmaceuticals", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Dermatology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "TCN-P (PTX-200", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "1UO", "phase": "Phase I/II", "indication": "Hand-foot syndrome"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.cahabapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cahaba%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Other"]}, {"company": "Calcimedica Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Gastrointestinal", "Infectious", "Ophthalmic"], "modalityGroups": ["Gene Therapy", "Other", "Small Molecule", "Undisclosed"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Auxora (CM4620-IE)", "phase": "Phase III", "indication": "Pneumonia"}, {"name": "Altissimo (GB-102)", "phase": "Phase II", "indication": "Diabetic macular edema (DME)"}, {"name": "CM6325", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}, {"name": "GB-103", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}, {"name": "GB-401", "phase": "Preclinical", "indication": "Glaucoma"}, {"name": "GB-501", "phase": "Preclinical", "indication": "Mucopolysaccharidosis"}, {"name": "GB-601", "phase": "Preclinical", "indication": "Retinitis"}, {"name": "GB-701", "phase": "Preclinical", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "Rachel Anne Leheny, PhD", "employees": 14, "founded": 2006, "website": "http://www.calcimedica.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 21141539.1, "evFmt": "$21M", "ticker": "CALC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Calcimedica", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Diabetes", "Infectious Disease", "Ophthalmology", "Rare / Genetic"]}, {"company": "Calico Life Sciences LLC", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "fosigotifator (ABBV-CLS-7262)", "phase": "Phase II", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "ABBV-CLS-484", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "ABBV-CLS-579", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.calicolabs.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-10-12", "recentDeals": [{"headline": "Terray Therapeutics and Calico Enter into a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Age-Related Diseases", "date": "2022-10-12", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Calico%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Solid Tumors (General)"]}, {"company": "Calidi Biotherapeutics Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NeuroNova (CLD-101", "phase": "Phase I", "indication": "Brain cancer"}, {"name": "Supernova 1 (CLD-201", "phase": "IND", "indication": "Breast cancer"}, {"name": "Supernova 2 (CLD-202", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Eric E. Poma, PhD, MBA", "employees": 28, "founded": 2014, "website": "https://calidibio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 6984750.0, "evFmt": "$7M", "ticker": "CLDI", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Calidi%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Breast Cancer", "Solid Tumors (General)"]}, {"company": "Calissa Therapeutics LLC", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "CX-001", "phase": "Approved", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Calissa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Calmare Therapeutics Inc.", "city": "Fairfield", "state": "CT", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "MC-5A (calmare pain therapy treatment)", "phase": "Marketed", "indication": "Pain"}], "ceo": "Conrad F. Mir", "employees": 7, "founded": 1968, "website": "http://www.calmarett.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 11423700.0, "evFmt": "$11M", "ticker": "CTTC", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Calmare%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Cambium Oncology LLC", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VIP-ANT008", "phase": "Preclinical", "indication": "Leukemia"}, {"name": "VIP-ANT308", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://cambiumoncology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cambium%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Cambrian Biopharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IST-01", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}, {"name": "IST-02", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.cambrianbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cambrian%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Camino Pharma LLC", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SBP-9330 (SBP-0069330)", "phase": "Phase I", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.caminopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Camino%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Camp4 Therapeutics Corp.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Neurology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "CMP-001 (CMP-CPS-001)", "phase": "Phase I", "indication": "Urea cycle disorder (UCD)"}, {"name": "Camp4 - Dementia - unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Camp4 - Dravet - unknown", "phase": "Preclinical", "indication": "Dravet syndrome"}, {"name": "Camp4 - Urea cycle - unknown2", "phase": "Preclinical", "indication": "Urea cycle disorder (UCD)"}, {"name": "CMP-SYNGAP-01", "phase": "Preclinical", "indication": "SYNGAP1-related disorders"}, {"name": "Camp4 - Primary Biliary Cholangitis - unknown", "phase": "Research", "indication": "Primary biliary cholangitis"}], "ceo": "Josh Mandel-Brehm, MBA", "employees": 55, "founded": 2016, "website": "http://www.camp4tx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 49851573.38, "evFmt": "$50M", "ticker": "CAMP", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-09-26", "recentDeals": [{"headline": "CAMP4 Enters Strategic Research Collaboration to Advance Novel Regulatory RNA-Targeting Medicines for Rare Genetic Conditions", "date": "2024-09-26", "value": ""}, {"headline": "Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology", "date": "2023-07-10", "value": ""}], "totalRaised": 100494015.0, "totalRaisedFmt": "$100M", "latestFinDate": "2022-06-03", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$100M", "date": "2022-06-03", "investors": "Enavate Sciences, National Managed Care Organization, Gaingels, Undisclosed Investors, 5am Ventures, Polaris Partners, N..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Camp4%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Epilepsy / Seizures", "GI Cancers", "Other", "Other Neurology", "Rare / Genetic"]}, {"company": "Cancer Advances Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Polyclonal Antibody Stimulator (PAS", "phase": "Phase II", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2009, "website": "https://www.canceradvances.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cancer%20Advances", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Cancer Targeted Technology LLC", "city": "Woodinville", "state": "WA", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "CTT1057", "phase": "Phase II/III", "indication": "Cancer, Diagnostic"}, {"name": "CTT1043", "phase": "Phase I", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.cancertargetedtechnology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cancer%20Targeted%20Technology", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Cancure LLC (Canzx Biotherapeutics)", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CuraB-10", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "CuraB-15", "phase": "Preclinical", "indication": "Lung cancer"}, {"name": "CuraB-20", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "CuraB-25", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.cancurellc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cancure%20LLC%20(Canzx%20Biotherapeutics)", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Candel Therapeutics Inc.", "city": "Needham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "aglatimagene besadenovec", "phase": "Phase III", "indication": "Prostate cancer"}, {"name": "rQNestin34.5 (CAN-3110)", "phase": "Phase I", "indication": "Brain cancer"}, {"name": "Alpha-201-macro1", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Paul-Peter Tak, MD, PhD", "employees": 38, "founded": 1999, "website": "https://www.candeltx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 185756659.68, "evFmt": "$186M", "ticker": "CADL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Candel%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Breast Cancer", "GU / Gynecologic Cancers"]}, {"company": "Cannabis Science Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CS-S/BCC-1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "CS-TATI-1", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 1996, "website": "http://www.cannabisscience.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cannabis%20Science", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)"]}, {"company": "Cantabio Pharmaceuticals Inc.", "city": "Sunnyvale", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CB101", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "CB102", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "CB201", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "CB301", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "CB401", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.cantabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cantabio%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Parkinson's"]}, {"company": "Cantex Pharmaceuticals Inc.", "city": "Weston", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Pulmonary"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "Dociparstat sodium (DSTAT)", "phase": "Phase II/III", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Dicopp (cx-02)", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.cantex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cantex%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Hematologic Cancers"]}, {"company": "Cao Pharmaceuticals Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CZ-48", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://caopharmaceuticals.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cao%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Capgenesis Therapeutics LLC", "city": "Bethesda", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CGS-125", "phase": "Phase I", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.capgenesis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Capgenesis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Capricor Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Infectious", "Musculoskeletal"], "modalityGroups": ["Cell Therapy", "Peptide", "RNA Therapeutics", "Vaccine"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "deramiocel (CAP-1002)", "phase": "Phase III", "indication": "Cardiomyopathy"}, {"name": "Cenderitide (cd-np)", "phase": "Phase II", "indication": "Heart failure"}, {"name": "CU-NP", "phase": "Preclinical", "indication": "Heart failure"}, {"name": "Exosome-SARS-CoV-2 Display vaccine", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Exosome-SARS-CoV-2 mRNA vaccine", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Linda Marb\u00e1n, PhD", "employees": 160, "founded": 2005, "website": "http://www.capricor.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 339328562.4, "evFmt": "$339M", "ticker": "CAPR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Capricor%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Infectious Disease"]}, {"company": "Capsida Biotherapeutics Inc.", "city": "Thousand Oaks", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "CAP-002", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "CAP-003", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://capsida.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Capsida%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Parkinson's"]}, {"company": "Cardax Inc.", "city": "Honolulu", "state": "HI", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CDX-101", "phase": "Preclinical", "indication": "Hypertriglyceridemia"}, {"name": "CDX-301", "phase": "Preclinical", "indication": "Stargardt disease"}], "ceo": "David G. Watumull", "employees": 0, "founded": 2003, "website": "http://cardaxpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "CDXI", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cardax", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Ophthalmology"]}, {"company": "Cardeas Pharma Corp.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Amikacin Fosfomycin Inhalation System (Amikacin/fosfomycin inhalation solution)", "phase": "Phase II", "indication": "Pneumonia"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://cardeaspharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cardeas%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Cardurion Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CRD-740", "phase": "Phase II", "indication": "Heart failure"}, {"name": "CRD-750", "phase": "Phase II", "indication": "Heart failure"}, {"name": "CRD-4730", "phase": "Phase I", "indication": "Tachycardia"}, {"name": "Cardurion Pharmaceuticals-IV program-unknown", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://cardurion.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cardurion%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Caribou Biosciences Inc.", "city": "Berkeley", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "CB-010", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "CB-011", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "CB-012", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "Rachel E. Haurwitz, PhD", "employees": 147, "founded": 2011, "website": "http://cariboubio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -39426499.25, "evFmt": "", "ticker": "CRBU", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Caribou%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Caris Life Sciences Inc. (Caris Mpi)", "city": "Irving", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Carisome Prostate cMV 1.0", "phase": "Marketed", "indication": "Cancer, Diagnostic"}, {"name": "Target Now", "phase": "Marketed", "indication": "Cancer, Diagnostic"}, {"name": "Caris Assure", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "MI Cancer Seek", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "MI Tumor Seek Hybrid", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 168000000.0, "totalRaisedFmt": "$168M", "latestFinDate": "2025-04-07", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$168M", "date": "2025-04-07", "investors": "Braidwell L.P., Perceptive Advisors, Woodline Partners L.P., Ghisallo, New Investors, Millennium Management LLC, First L..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Caris%20Life%20Sciences%20Inc.%20(Caris%20Mpi)", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Carisma Therapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Cell Therapy", "Other", "Protein / Biologic", "Undisclosed"], "nProducts": 9, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "isunakinra (EBI-005)", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "CAR-monoctye (CT-0525)", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "CT-0508 (CARMA-0508)", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "CT-1119", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "VB6-845d", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "VB7-756", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Chimeric Antigen Receptor Monocyte (CAR-M)", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "CT-0729", "phase": "Research", "indication": "Solid tumors"}], "ceo": "Craig R. Jalbert", "employees": 46, "founded": 2016, "website": "http://www.carismatx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1933860.748, "evFmt": "$2M", "ticker": "CARM", "exchange": "Pink", "nDeals": 1, "totalDealValue": 80000000.0, "totalDealFmt": "$80M", "latestDealDate": "2022-01-10", "recentDeals": [{"headline": "Moderna partners with Carisma to develop and commercialize chimeric antigen receptor monocytes (CAR-M) to treat cancer", "date": "2022-01-10", "value": "$80M"}], "totalRaised": 30000000.0, "totalRaisedFmt": "$30M", "latestFinDate": "2023-03-06", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$30M", "date": "2023-03-06", "investors": "Healthcap, Abbvie Inc., Wellington Partners, Symbiosis, Penn Medicine, Tpg Biotech, Mrl Ventures Fund, Agent Capital, So..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Carisma%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Carmel Biosciences Inc.", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Prexxartan (Brand)", "phase": "Approved", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.carmelbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Carmel%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Carogen Corp.", "city": "Hamden", "state": "CT", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AVIDIO COVID-19 vaccine", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.carogencorp.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Carogen", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Carolus Therapeutics Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Inflammation", "Pulmonary"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MKEY2 (CT-2009)", "phase": "Preclinical", "indication": "Atherosclerosis"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.carolustherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Carolus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Carrick Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "samuraciclib (CT7001)", "phase": "Phase II", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.carricktherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Carrick%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Cartesian Therapeutics Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Infectious", "Musculoskeletal", "Other", "Pulmonary", "Renal"], "modalityGroups": ["Cell Therapy", "Gene Therapy", "Protein / Biologic", "Undisclosed"], "nProducts": 15, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "NASP", "phase": "Registration", "indication": "Hyperuricemia/gout"}, {"name": "Descartes-11", "phase": "Phase II", "indication": "Multiple myeloma (MM)"}, {"name": "Descartes-08", "phase": "Phase I/II", "indication": "Myasthenia gravis"}, {"name": "Descartes-30", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "SEL-302 (MMA-101)", "phase": "Phase I", "indication": "Metabolic (unspecified)"}, {"name": "SEL-399", "phase": "Phase I", "indication": "Genetic disorders"}, {"name": "Descartes-15", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "Descartes-25", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}], "ceo": "Carsten Brunn, PhD", "employees": 66, "founded": 2016, "website": "https://www.cartesiantherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 110801882.02, "evFmt": "$111M", "ticker": "RNAC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cartesian%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers", "Infectious Disease", "MS / Neuroimmune", "Obesity / Metabolic", "Rare / Genetic", "Respiratory / Allergy"]}, {"company": "Carthronix Inc.", "city": "Lancaster", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CX-011", "phase": "Preclinical", "indication": "Osteoarthritis"}, {"name": "CX-159X", "phase": "Preclinical", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.carthronix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Carthronix", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Casi Pharmaceuticals Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "CID-103", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "ENMD-2076", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "2ME2", "phase": "IND", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "David A. Cory, MBA", "employees": 233, "founded": 1991, "website": "http://www.casipharmaceuticals.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 49462983.91, "evFmt": "$49M", "ticker": "CASI", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 13000000.0, "totalDealFmt": "$13M", "latestDealDate": "2022-05-24", "recentDeals": [{"headline": "CASI Pharmaceuticals enters into sublicense agreement with Tianshi Pharmaceuticals for anti-CD38 monoclonal antibody  CID-103 in autoimmune field", "date": "2022-05-24", "value": "$13M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Casi%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Breast Cancer", "Hematologic Cancers"]}, {"company": "Casma Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Hepatic", "Inflammation", "Musculoskeletal", "Neurology"], "modalityGroups": ["Other"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Casma Therapeutics-inflammatory disorders-unknown", "phase": "Preclinical", "indication": "Inflammatory disease"}, {"name": "Casma Therapeutics-liver disease-unknown", "phase": "Preclinical", "indication": "Liver disease"}, {"name": "Casma Therapeutics-muscle disorders-unknown", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "Casma Therapeutics-neurodegeneration-unknown", "phase": "Preclinical", "indication": "Nerve damage"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.casmatx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Casma%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Liver Disease", "Neurodegeneration / NMD", "Other"]}, {"company": "Cassava Sciences Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "simufilam (PTI-125)", "phase": "Phase III", "indication": "Alzheimer's disease"}], "ceo": "Richard Jon Barry", "employees": 30, "founded": 1998, "website": "https://www.cassavasciences.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -18588560.0, "evFmt": "", "ticker": "SAVA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cassava%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Castle Creek Biosciences Inc.", "city": "Exton", "state": "PA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Endocrine/Metabolic"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "GM-HDF-COL7 (FCX-013)", "phase": "Phase I/II", "indication": "Scleroderma"}, {"name": "D-Fi", "phase": "Phase III", "indication": "Epidermolysis bullosa"}, {"name": "LV-FAH", "phase": "Preclinical", "indication": "Tyrosinemia type 1"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://castlecreekbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Castle%20Creek%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology", "Other"]}, {"company": "Castlevax Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "NDV-HXP-S", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.castlevax.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Castlevax", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Catalent Inc.", "city": "Somerset", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Genitourinary"], "modalityGroups": ["ADC", "Other", "Small Molecule"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Crinone", "phase": "Marketed", "indication": "Amenorrhea"}, {"name": "Striant SR", "phase": "Marketed", "indication": "Hypogonadism"}, {"name": "DARE-HRT1 (JNP-0201)", "phase": "Phase I/II", "indication": "Menopause"}, {"name": "DARE-FRT1 (JNP-0301)", "phase": "Preclinical", "indication": "Infertility"}, {"name": "CD22-4AP", "phase": "Phase I/II", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "CAT-01-106", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "CAT-03-106", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Catalent-Hematological Tumors-Unknown", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "https://www.catalent.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2026-01-12", "recentDeals": [{"headline": "SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs", "date": "2026-01-12", "value": ""}, {"headline": "Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation", "date": "2023-09-26", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Catalent", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers", "Other", "Other Specialties", "Women's Health"]}, {"company": "Catamaran Bio Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CAT\u2011179", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "CAT-248", "phase": "Preclinical", "indication": "Renal cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://catamaranbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Catamaran%20Bio", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers"]}, {"company": "Catena Pharmaceuticals Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VPC51299", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.catenapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Catena%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Cavogene Lifesciences", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation", "Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SynCav1 (ET-101)", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "SynCav2", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "SynCav3", "phase": "Preclinical", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://cavogene.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cavogene%20Lifesciences", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Supportive / Other"]}, {"company": "Cayuga Biotech Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CAY001", "phase": "Preclinical", "indication": "Bleeding"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.cayugabiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cayuga%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Cdg Therapeutics Inc.", "city": "River Forest", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "P28", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.cdgti.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cdg%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Cel-sci Corp.", "city": "Vienna", "state": "VA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Genitourinary", "Infectious"], "modalityGroups": ["Peptide", "Protein / Biologic", "Vaccine"], "nProducts": 6, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "Multikine", "phase": "Registration", "indication": "Head and neck cancer"}, {"name": "H1N1 peptide-activated dendritic cells (leaps-h1n1-dc)", "phase": "Phase I", "indication": "Infectious (unspecified)"}, {"name": "CEL-2000", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}, {"name": "CEL-4000", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}, {"name": "CEL-SCI-breast cancer-unknown", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "LEAPS COV-19 peptides", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Geert R. Kersten, MBA", "employees": 0, "founded": 1983, "website": "http://www.cel-sci.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 35743233.6, "evFmt": "$36M", "ticker": "CVM", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cel-sci", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Breast Cancer", "Head & Neck Cancer", "Infectious Disease"]}, {"company": "Celcuity Inc.", "city": "Minneapolis", "state": "MN", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CELsignia", "phase": "Phase II", "indication": "Cancer, Diagnostic"}, {"name": "CELx HSF Test", "phase": "Phase II", "indication": "Cancer, Diagnostic"}], "ceo": "Brian F. Sullivan", "employees": 87, "founded": 2012, "website": "http://celcuity.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 379242146.37, "evFmt": "$379M", "ticker": "CELC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Celcuity", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Celea Therapeutics", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "deupirfenidone (LYT-100)", "phase": "Phase II", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2025, "website": "https://www.celeatx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Celea%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Cell Bioengines Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "CBE-101", "phase": "IND", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "CBE-201", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "CBE-301", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}, {"name": "CBE-401", "phase": "Preclinical", "indication": "Thrombocytopenia"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://cellbioengines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-09-07", "recentDeals": [{"headline": "Cell BioEngines Licenses Patent for Allogeneic Hematopoietic Cell Transplantation in Oncology", "date": "2023-09-07", "value": ""}, {"headline": "Cell BioEngines enters into an exclusive worldwide agreement to develop and commercialize potent immune cell states to cure cancer", "date": "2023-01-25", "value": ""}], "totalRaised": 2000000.0, "totalRaisedFmt": "$2M", "latestFinDate": "2024-07-20", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$2M", "date": "2024-07-20", "investors": "Sosv Investments LLC, Partnership Fund for New York City, New York State\u2019s Empire State Development Fund"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cell%20Bioengines", "hasDealsFin": true, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Hematology (non-cancer)"]}, {"company": "Cell Point LLC (Cell Theranostics)", "city": "Centennial", "state": "CO", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Diagnostics", "Other"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Tc-99m-Oncardia", "phase": "Phase III", "indication": "Radiologic imaging"}, {"name": "Technetium-99m-EC-G (99m-Tc-EC-G)", "phase": "Phase III", "indication": "Cancer, Diagnostic"}, {"name": "187Re-EC-G", "phase": "Preclinical", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "Ga-68-Oncardia", "phase": "Preclinical", "indication": "Radiologic imaging"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.cellpointweb.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cell%20Point%20LLC%20(Cell%20Theranostics)", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Cell Source Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Hematology", "Transplant"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Veto Cells", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "Megadose Drug Combination", "phase": "Phase I", "indication": "Hematopoietic transplant"}], "ceo": "Itamar Shimrat, MBA", "employees": 0, "founded": 2012, "website": "http://www.cell-source.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 24650045.95, "evFmt": "$25M", "ticker": "CLCS", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cell%20Source", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)", "Transplant"]}, {"company": "Cellarity Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Diagnostic", "Hematology", "Hepatic"], "modalityGroups": ["Diagnostics", "Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Cellarity-hematology-unknown", "phase": "Preclinical", "indication": "Sickle cell disease"}, {"name": "Cellarity-immunology-unknown", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "Cellarity-MASH-unknown", "phase": "Research", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "CELLARITY MAPS\u2122", "phase": "Not applicable", "indication": "Drug screen"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://cellarity.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 121000000.0, "totalRaisedFmt": "$121M", "latestFinDate": "2022-10-04", "latestFinType": "Series C rounds", "nRounds": 1, "recentFinancing": [{"type": "Series C rounds", "amount": "$121M", "date": "2022-10-04", "investors": "Flagship Pioneering Inc., Existing Investors, Kyowa Kirin Co. Ltd., Hanwha Impact Partners, Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cellarity", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematology (non-cancer)", "Obesity / Metabolic", "Supportive / Other"]}, {"company": "Celldex Therapeutics Inc.", "city": "Needham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Infectious", "Inflammation"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Vaccine"], "nProducts": 12, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "CDX-585", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "Rotarix (SB444563", "phase": "Marketed", "indication": "Rotavirus"}, {"name": "barzolvolimab (CDX-0159)", "phase": "Phase III", "indication": "Urticaria"}, {"name": "CDX-3379", "phase": "Phase II", "indication": "Head and neck cancer"}, {"name": "varlilumab (CDX-1127)", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "CDX-1140", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "CDX-527", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "CDX-622", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "Anthony S. Marucci, MBA", "employees": 186, "founded": 1983, "website": "http://www.celldextherapeutics.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 911893650.0, "evFmt": "$912M", "ticker": "CLDX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Celldex%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Head & Neck Cancer", "Other", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Cellectar Biosciences Inc.", "city": "Florham Park", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Radiopharmaceutical", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "I-124-CLR1404 (LIGHT)", "phase": "Phase II", "indication": "Cancer, Diagnostic"}, {"name": "iopofosine (CLR 131", "phase": "Phase II", "indication": "B cell lymphoma"}, {"name": "CLR 12120", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "CLR 180099", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "CLR 1900", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "CLR 2000", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "CLR 2100", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "CLR 2200", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "James V. Caruso", "employees": 11, "founded": 1996, "website": "http://cellectar.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -9785816.069, "evFmt": "", "ticker": "CLRB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cellectar%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Cellerant Therapeutics Inc.", "city": "Newark", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Infectious", "Other", "Transplant"], "modalityGroups": ["ADC", "Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "romyelocel-L (Myeloid Progenitor (MP) Cells", "phase": "Phase III", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "CLT030", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "CSC012", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.cellerant.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cellerant%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Cellevolve Bio Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "CE-VST01-JC", "phase": "IND", "indication": "Encephalopathy"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.cellevolve.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cellevolve%20Bio", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Cellics Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Inflammation"], "modalityGroups": ["Cell Therapy", "Undisclosed"], "nProducts": 7, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "CTI-005", "phase": "IND", "indication": "Bacterial infection"}, {"name": "ALN-001", "phase": "Preclinical", "indication": "Sepsis"}, {"name": "CTI-036", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "CTI-116", "phase": "Preclinical", "indication": "Cytokine release syndrome (CRS)"}, {"name": "CTI-118", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "CTI-156", "phase": "Preclinical", "indication": "Arthritis"}, {"name": "CTI-168", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.cellics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cellics%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Infectious Disease", "Other", "Supportive / Other"]}, {"company": "Cello Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CE001", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "CE002", "phase": "Preclinical", "indication": "Gastric cancer"}, {"name": "CE003", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "CE004", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "CE005", "phase": "Preclinical", "indication": "Leukemia"}, {"name": "CE120", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://cellotherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cello%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "GU / Gynecologic Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Cellphire Therapeutics Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Cellphire-surgical bleeding-unknown", "phase": "Phase II", "indication": "Hemophilia"}, {"name": "Thrombosomes", "phase": "Phase II", "indication": "Bleeding"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.cellphire.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cellphire%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Cellxlife", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CellxLife-sarcoma-unknown", "phase": "Phase I/II", "indication": "Sarcoma"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.cellxlife.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cellxlife", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Celprogen Inc.", "city": "Torrance", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CEP1430", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.celprogen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Celprogen", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Celularity Inc.", "city": "Florham Park", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Infectious", "Inflammation", "Musculoskeletal", "Ophthalmic"], "modalityGroups": ["Cell Therapy", "Gene Therapy", "Other", "Undisclosed"], "nProducts": 12, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Biovance", "phase": "Marketed", "indication": "Wounds"}, {"name": "Biovance 3L Ocular", "phase": "Marketed", "indication": "Tissue damage"}, {"name": "Rebound matrix", "phase": "Marketed", "indication": "Wounds"}, {"name": "CYNK-001", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "CYNK-101", "phase": "Phase I", "indication": "Gastric cancer"}, {"name": "APPL-001", "phase": "IND", "indication": "Crohn's disease"}, {"name": "CyCART-19", "phase": "IND", "indication": "B cell lymphoma"}, {"name": "AMDAC", "phase": "Preclinical", "indication": "Choroidal neovascularization (CNV)"}], "ceo": "Robert Joseph Hariri Gordon, MD, PhD", "employees": 123, "founded": 2016, "website": "http://www.celularity.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 113630277.44, "evFmt": "$114M", "ticker": "CELU", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Celularity", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "GI Cancers", "Hematologic Cancers", "IBD / GI Inflammatory", "Ophthalmology", "Supportive / Other"]}, {"company": "Cemines Inc.", "city": "Golden", "state": "CO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "CellCorrect KvA-40 LAb Kit (cellcorrect lab)", "phase": "Marketed", "indication": "Lung cancer"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.cemines.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cemines", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Cenna Biosciences Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Cenna Biosciences (C3)", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "P8", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.cennabiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cenna%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Centessa Pharmaceuticals plc", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ORX750", "phase": "Phase II", "indication": "Hypersomnia"}, {"name": "ANB101", "phase": "Phase I", "indication": "Inflammatory disease"}, {"name": "ORX142", "phase": "IND", "indication": "Neurology (unspecified)"}, {"name": "ORX489", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "Mario Alberto Accardi, PhD", "employees": 77, "founded": 2021, "website": "https://www.centessa.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1552479270.75, "evFmt": "$1.6B", "ticker": "CNTA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Centessa%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Other", "Other Neurology"]}, {"company": "Centrexion Therapeutics Corp.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "mazisotine (LY3556050", "phase": "Phase II", "indication": "Pain"}, {"name": "CNTX 6016", "phase": "Phase I", "indication": "Pain"}, {"name": "CNTX-4975", "phase": "Phase III", "indication": "Pain"}, {"name": "CNTX-2022", "phase": "Phase I", "indication": "Pain"}, {"name": "CNTX-6970", "phase": "Phase I", "indication": "Inflammation (unspecified)"}, {"name": "CNTX-6016", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.centrexion.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Centrexion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation", "Pain / Migraine"]}, {"company": "Centrose LLC", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EDC1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "EDC8", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "EDC9", "phase": "Preclinical", "indication": "Non-Hodgkin lymphoma (NHL)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.centrosepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Centrose", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Century Therapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 6, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "GDT-002 (TEG002)", "phase": "Phase I/II", "indication": "Multiple myeloma (MM)"}, {"name": "CNTY-101", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "CNTY-102", "phase": "Preclinical", "indication": "B cell lymphoma"}, {"name": "CNTY-103", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "CNTY-104", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "GDT201 (TEG201)", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "Brent Pfeiffenberger, PharmD", "employees": 150, "founded": 2019, "website": "https://www.centurytx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -56026552.42, "evFmt": "", "ticker": "IPSC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Century%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GI Cancers", "Hematologic Cancers"]}, {"company": "Ceptur Therapeutics Inc.", "city": "Hillsborough", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Ceptur Therapeutics-HTT-unknown", "phase": "Preclinical", "indication": "Huntington disease (HD)"}, {"name": "Ceptur Therapeutics-MYC-unknown", "phase": "Preclinical", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "Ceptur Therapeutics-Pan-KRAS-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ceptur%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Neurodegeneration / NMD", "Solid Tumors (General)"]}, {"company": "Cerebral Therapeutics Inc.", "city": "Aurora", "state": "CO", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Intracerebroventricular valproate (CT-010)", "phase": "Phase I/II", "indication": "Epilepsy"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://www.cerebraltherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cerebral%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures"]}, {"company": "Cerenova LLC", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CN-105", "phase": "Phase I", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cerenova", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Cerevance Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CVN424", "phase": "Phase II", "indication": "Parkinson's disease"}, {"name": "CVN766", "phase": "Phase I", "indication": "Anxiety"}, {"name": "CN101248", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "Target-20 (CVN398)", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "Target-06 (CVN293)", "phase": "Research", "indication": "Alzheimer's disease"}, {"name": "Target-18", "phase": "Research", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.cerevance.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 1125000000.0, "totalDealFmt": "$1.1B", "latestDealDate": "2022-08-09", "recentDeals": [{"headline": "Cerevance Establishes Strategic Research Collaboration with Merck (MSD) for the Discovery of Novel Targets in Alzheimer\u2019s Disease", "date": "2022-08-09", "value": "$1.1B"}], "totalRaised": 98000000.0, "totalRaisedFmt": "$98M", "latestFinDate": "2024-04-25", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$47M", "date": "2024-04-25", "investors": "Agent Capital, Bioluminescence Ventures, Double Point Ventures, Mqb Partners, Liferock Ventures, Gates Frontier Fund, Gv..."}, {"type": "Series B rounds", "amount": "$51M", "date": "2023-02-13", "investors": "Gates Frontier Fund, Dementia Discovery Fund, Foresite Capital, Gv, Lightstone Ventures, Takeda Ventures, Upmc Enterpris..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cerevance", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Parkinson's", "Psychiatry / Behavioral"]}, {"company": "Cerevast Therapeutics Inc.", "city": "Redmond", "state": "WA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Clotbust ER", "phase": "Marketed", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.cerevast.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cerevast%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Ceria Therapeutics Inc.", "city": "Aurora", "state": "CO", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Pulmonary"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CTX-001", "phase": "Preclinical", "indication": "Dermal ulcers"}, {"name": "CTX-002", "phase": "Preclinical", "indication": "Acute lung injury"}, {"name": "CTX-003", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "CTX-004", "phase": "Preclinical", "indication": "Dermal ulcers"}, {"name": "CTX-005", "phase": "Preclinical", "indication": "Dermal ulcers"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://ceriatherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ceria%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "IBD / GI Inflammatory", "Respiratory / Allergy"]}, {"company": "Cero Therapeutics Holdings Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Cero-CER T cell-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Cero-CER/CAR T cell-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Christopher B. Ehrlich, MBA", "employees": 0, "founded": 2016, "website": "https://www.cero.bio/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 15920183.0, "evFmt": "$16M", "ticker": "CERO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cero%20Therapeutics%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Cerrx Inc.", "city": "Lubbock", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "fenretinide (4-hpr)", "phase": "Phase II", "indication": "Cutaneous T cell lymphoma (CTCL)"}, {"name": "safingol", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "PPMP", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.cerrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cerrx", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Cervomed Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Neurology", "Ophthalmic", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Trans sodium crocetinate (TSC)", "phase": "Phase III", "indication": "Brain cancer"}, {"name": "Palomid 529", "phase": "Phase I", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "John J. Alam, MD", "employees": 15, "founded": 2010, "website": "https://www.cervomed.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -20030836.3, "evFmt": "", "ticker": "CRVO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cervomed", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Ophthalmology"]}, {"company": "Cg Oncology Inc.", "city": "Santa Ana", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Oncolytic / Microbiome"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "cretostimogene grenadenorepvec (CG0070)", "phase": "Phase III", "indication": "Bladder cancer"}, {"name": "CG0161", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Arthur Kuan", "employees": 113, "founded": 2010, "website": "https://www.cgoncology.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1442359176.44, "evFmt": "$1.4B", "ticker": "CGON", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cg%20Oncology", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Cga Therapeuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "catestatin (CST)", "phase": "Preclinical", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.cgatherapeuticals.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cga%20Therapeuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Chaperone Technologies Inc.", "city": "East Stroudsburg", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CHP-401", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "CHP-486", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "CHP-490", "phase": "Preclinical", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.chaperonetechnologies.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Chaperone%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Character Biosciences Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Peptide", "Protein / Biologic", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CTX114", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "CTX203", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "Character Biosciences-AMD-unknown", "phase": "Research", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "Character Biosciences-POAG-unknown", "phase": "Research", "indication": "Glaucoma"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://characterbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-01-10", "recentDeals": [{"headline": "Character Biosciences Announces Collaboration with Bausch + Lomb to Transform Ophthalmology with Precision Medicine", "date": "2025-01-10", "value": ""}], "totalRaised": 128000000.0, "totalRaisedFmt": "$128M", "latestFinDate": "2025-09-17", "latestFinType": "Series B rounds", "nRounds": 3, "recentFinancing": [{"type": "Series B rounds", "amount": "$17M", "date": "2025-09-17", "investors": "Sanofi-genzyme Bioventures"}, {"type": "Series B rounds", "amount": "$93M", "date": "2025-03-25", "investors": "Amoon Fund, Luma Group, Bausch + Lomb Corp., Jefferson Life Sciences, Innovation Endeavors, Catalio Capital Management, ..."}, {"type": "Series A rounds", "amount": "$18M", "date": "2022-05-17", "investors": "Innovation Endeavors, Section 32, Catalio Capital Management, Lifeforce Capital, Casdin Capital LLC, Clover Health, Indu..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Character%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Ophthalmology"]}, {"company": "Charles River Laboratories International Inc.", "city": "Wilmington, MA", "state": "", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Centivax-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Charles%20River%20Laboratories%20International", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Charleston Laboratories Inc.", "city": "Jupiter", "state": "FL", "country": "United States", "diseaseCats": ["Gastrointestinal", "Neurology", "Pulmonary"], "modalityGroups": ["Combination", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Hydexor (CL-108)", "phase": "Registration", "indication": "Pain"}, {"name": "CL-H1T", "phase": "Phase II", "indication": "Emesis"}, {"name": "CL-AT-313", "phase": "Preclinical", "indication": "Cough"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.charlestonlabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Charleston%20Laboratories", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Respiratory / Allergy", "Supportive / Other"]}, {"company": "Charlestonpharma LLC", "city": "Charleston", "state": "SC", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CP-101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "CP101.2C8", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.charlestonpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Charlestonpharma", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)"]}, {"company": "Chase Therapeutics Corp.", "city": "Washington", "state": "DC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Pramipexole ER (ALTO-208", "phase": "Phase II", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.chasetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Chase%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Chelexa Biosciences Inc.", "city": "Auburndale", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Biolexa", "phase": "Phase I/II", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2011, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Chelexa%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Chimeron Bio", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CB-106", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://chimeron.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Chimeron%20Bio", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Chromis Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CHR101", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://chromistherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Chromis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Chrysalis Biotherapeutics Inc.", "city": "Galveston", "state": "TX", "country": "United States", "diseaseCats": ["Infectious", "Musculoskeletal", "Other"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Chrysalin", "phase": "Phase II", "indication": "Bone repair"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.chrysbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Chrysalis%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Churchill Pharmaceuticals LLC", "city": "King Of Prussia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Yonsa", "phase": "Approved", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.churchillpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Churchill%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Ciclomed LLC", "city": "Kansas City", "state": "MO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CPX-POM", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.ciclomed.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ciclomed", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Cidara Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Musculoskeletal"], "modalityGroups": ["Other", "Peptide", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "CD388", "phase": "Phase III", "indication": "Influenza virus"}, {"name": "Oratonin", "phase": "Phase II", "indication": "Osteopetrosis"}, {"name": "CBO421 (CBO-212", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Cidara Therapeutics-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Cidara Therapeutics-Oncology DCF-unknown2", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Cidara Therapeutics-Oncology DCF-unknown3", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "oral cefepime (SP 1001)", "phase": "Preclinical", "indication": "Urinary tract infection (UTI)"}, {"name": "SP 2078", "phase": "Preclinical", "indication": "Gram-positive bacterial infection"}], "ceo": "Jeffrey L. Stein, PhD", "employees": 38, "founded": 2012, "website": "https://www.cidara.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": -21922918.72, "evFmt": "", "ticker": "CDTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cidara%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other", "Solid Tumors (General)"]}, {"company": "Cingulate Inc.", "city": "Kansas City", "state": "KS", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "dexmethylphenidate (CTx-1301)", "phase": "Registration", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "buspirone (CTx-21030)", "phase": "Preclinical", "indication": "Anxiety"}, {"name": "dextroamphetamine (CTX-1302)", "phase": "Preclinical", "indication": "Attention deficit hyperactivity disorder (ADHD)"}], "ceo": "Shane J. Schaffer, PharmD", "employees": 13, "founded": 2012, "website": "http://cingulatetherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 405007.21, "evFmt": "$405K", "ticker": "CING", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cingulate", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Cinrx Pharma LLC", "city": "Cincinnati", "state": "OH", "country": "United States", "diseaseCats": ["Cancer", "Gastrointestinal", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CIN-102", "phase": "Phase II", "indication": "Gastroparesis"}, {"name": "CIN-103", "phase": "Phase II", "indication": "Irritable bowel syndrome"}, {"name": "CIN-108", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "CinRx Pharma-neurodegenerative disease-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.cinrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cinrx%20Pharma", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Other Neurology", "Other Specialties", "Solid Tumors (General)"]}, {"company": "Circle Pharma Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Macrocycle"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CID-078", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Circle Pharma-cyclin A-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.circlepharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-10-09", "recentDeals": [{"headline": "Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment Using Circle Pharma's Macrocycle Platform", "date": "2024-10-09", "value": ""}], "totalRaised": 90000000.0, "totalRaisedFmt": "$90M", "latestFinDate": "2024-09-03", "latestFinType": "Series D rounds", "nRounds": 1, "recentFinancing": [{"type": "Series D rounds", "amount": "$90M", "date": "2024-09-03", "investors": "The Column Group, Nextech Invest Ltd., Euclidean Capital, Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Circle%20Pharma", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Cirius Therapeutics Inc.", "city": "Kalamazoo", "state": "MI", "country": "United States", "diseaseCats": ["Hepatic", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "MSDC-0602", "phase": "Phase II", "indication": "Liver disease"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://ciriustx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cirius%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Citius Pharmaceuticals Inc.", "city": "Cranford", "state": "NJ", "country": "United States", "diseaseCats": ["Genitourinary", "Infectious", "Inflammation"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Mino-Lok (CITI-001)", "phase": "Phase III", "indication": "Infectious (unspecified)"}, {"name": "halobetasol-lidocaine formulation", "phase": "Phase II", "indication": "Genitourinary (unspecified)"}, {"name": "HC-LD Cream", "phase": "Phase II", "indication": "Genitourinary (unspecified)"}, {"name": "Mino-Wrap (CITI-101)", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "Leonard L. Mazur, MBA", "employees": 23, "founded": 2007, "website": "http://www.citiuspharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 21259284.0, "evFmt": "$21M", "ticker": "CTXR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Citius%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other", "Other Inflammation"]}, {"company": "Civatech Oncology Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Digital / Device", "Other"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "CivaSheet", "phase": "Marketed", "indication": "Cancer (unspecified)"}, {"name": "Civastring", "phase": "Marketed", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.civatechoncology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Civatech%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Civi Biopharma Inc.", "city": "Chevy Chase", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Endocrine/Metabolic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "CIVI 030 (Intravenous iloprost)", "phase": "Phase III", "indication": "Scleroderma"}, {"name": "Intravenous iloprost", "phase": "Phase III", "indication": "Scleroderma"}, {"name": "CIVI 007", "phase": "Phase II", "indication": "Atherosclerosis"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.civibio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Civi%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Cardiovascular"]}, {"company": "Clairigene LLC", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CLRI-002", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://clairigene.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Clairigene", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Clarametyx Biosciences Inc.", "city": "Columbus", "state": "OH", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CMTX-101", "phase": "Phase I/II", "indication": "Infectious (unspecified)"}, {"name": "CMTX-301", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://clarametyx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Clarametyx%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Claris Biotherapeutics Inc.", "city": "Jersey City", "state": "NJ", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CSB-001", "phase": "Phase I/II", "indication": "Corneal wound"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://clarisbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Claris%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Claritas Pharmaceuticals Inc.", "city": "Beverly", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KAL-1816", "phase": "Preclinical", "indication": "Pain"}], "ceo": "Robert Edward Farrell", "employees": 0, "founded": 2014, "website": "https://claritaspharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "CLAS", "exchange": "TSX-V", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Claritas%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Clear Creek Bio Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Brequinar", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.clearcreekbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Clear%20Creek%20Bio", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Clearb Therapeutics Inc.", "city": "Concord", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CLB-3000", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://clearbtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Clearb%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Clearside Biomedical Inc.", "city": "Alpharetta", "state": "GA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Xipere", "phase": "Marketed", "indication": "Macular edema"}, {"name": "CLS-AX", "phase": "Phase II", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "Clearside-Inherited Retinal Disease-unknown", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "George M. Lasezkay, PharmD", "employees": 32, "founded": 2012, "website": "http://www.clearsidebio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 102563180.600003, "evFmt": "$103M", "ticker": "CLSDQ", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Clearside%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Cleave Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Cleave-VCP/p97-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "CB-5339", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://cleavetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-07-20", "recentDeals": [{"headline": "CLEAVE THERAPEUTICS ANNOUNCES ACQUISITION OF PRE-CLINICAL ASSET BY EIKON THERAPEUTICS", "date": "2023-07-20", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cleave%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Other Neurology"]}, {"company": "Clene Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Infectious", "Neurology", "Ophthalmic"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "CNM-Au8", "phase": "Phase III", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "CNM-AgZn17 (CNM-ZnAg)", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Robert Dee Etherington, MBA", "employees": 76, "founded": 2013, "website": "http://www.clene.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 45614446.677617, "evFmt": "$46M", "ticker": "CLNN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Clene", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Neurodegeneration / NMD"]}, {"company": "Click Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Hepatic", "Neurology"], "modalityGroups": ["Digital / Device"], "nProducts": 13, "mostAdvanced": "Market (device)", "hasOrphan": false, "pipeline": [{"name": "AspyreRx (BT-001)", "phase": "Market (device)", "indication": "Diabetes"}, {"name": "Clickotine (CT-101)", "phase": "Market (device)", "indication": "Substance use disorders"}, {"name": "BI 3972080", "phase": "Phase III", "indication": "Schizophrenia"}, {"name": "CT-152", "phase": "Pivotal", "indication": "Depression"}, {"name": "Clickadian (CT-141)", "phase": "Phase II", "indication": "Insomnia"}, {"name": "Clickheart (CT-111)", "phase": "Phase II", "indication": "Acute coronary syndrome"}, {"name": "CT-132", "phase": "Phase II", "indication": "Migraine"}, {"name": "CT-131", "phase": "Phase I", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.clicktherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 460000000.0, "totalDealFmt": "$460M", "latestDealDate": "2022-12-19", "recentDeals": [{"headline": "Boehringer Ingelheim and Click Therapeutics expand their existing collaboration to develop prescription digital therapeutics for Schizophrenia", "date": "2022-12-19", "value": "$460M"}], "totalRaised": 23269935.0, "totalRaisedFmt": "$23M", "latestFinDate": "2025-03-19", "latestFinType": "Series C rounds", "nRounds": 4, "recentFinancing": [{"type": "Series C rounds", "amount": "", "date": "2025-03-19", "investors": "Dassault Systemes"}, {"type": "Venture (Debt)", "amount": "$8M", "date": "2024-08-30", "investors": "Undisclosed Investors"}, {"type": "Venture (Debt)", "amount": "", "date": "2023-11-06", "investors": "The Hongkong and Shanghai Banking Corp. Ltd. (Hsbc)"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Click%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Diabetes", "Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Climb Bio Inc.", "city": "Wellesley", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Hematology", "Neurology", "Renal"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "budoprutug (TNT119)", "phase": "Phase I", "indication": "Lupus"}, {"name": "Eliem Therapeutics-generalized anxiety disorder-unknown", "phase": "Preclinical", "indication": "Anxiety"}, {"name": "Eliem Therapeutics-Kv7.2/3-unknown", "phase": "Preclinical", "indication": "Depression"}], "ceo": "Aoife M. Brennan, MD", "employees": 18, "founded": 2019, "website": "https://climbbio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -63693058.2, "evFmt": "", "ticker": "CLYM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Climb%20Bio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Psychiatry / Behavioral"]}, {"company": "Cloud Pharmaceuticals Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NB15", "phase": "Preclinical", "indication": "Myeloproliferative disorder"}, {"name": "TA-H8", "phase": "Preclinical", "indication": "T cell lymphoma"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.cloudpharmaceuticals.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cloud%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Cloudbreak Pharma Inc. (\u62e8\u5eb7\u89c6\u4e91)", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "CBT-001", "phase": "Phase III", "indication": "Pterygia"}, {"name": "CBT-004", "phase": "Phase II", "indication": "Ophthalmic (unspecified)"}, {"name": "CBT-006", "phase": "Phase II", "indication": "Dry eye"}, {"name": "CBT-009", "phase": "Phase I/II", "indication": "Myopia"}, {"name": "CBT-007", "phase": "Preclinical", "indication": "Glaucoma"}, {"name": "CBT-011", "phase": "Preclinical", "indication": "Diabetic macular edema (DME)"}, {"name": "CBT-145", "phase": "Preclinical", "indication": "Presbyopia"}, {"name": "CBT-199", "phase": "Preclinical", "indication": "Presbyopia"}], "ceo": "Jin Song Ni, PhD", "employees": 51, "founded": 2015, "website": "https://cloudbreakpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "2592", "exchange": "HKEX", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cloudbreak%20Pharma%20Inc.%20(\u62e8\u5eb7\u89c6\u4e91)", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Ophthalmology", "Other"]}, {"company": "Clywedog Therapeutics Inc.", "city": "Dover", "state": "DE", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "balomenib (CLY101)", "phase": "Phase II", "indication": "Diabetes"}, {"name": "CLY201", "phase": "Phase II", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://www.clywedogther.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Clywedog%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Cmp Pharma Inc.", "city": "Farmville", "state": "NC", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Norliqva", "phase": "Marketed", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 1975, "website": "http://cmppharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cmp%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Cmtx Biotech Inc.", "city": "Stony Brook", "state": "NY", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "COL-3 (incyclinide)", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://cmtxbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cmtx%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Cnd Life Sciences Inc.", "city": "Phoenix", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Syn-One Test", "phase": "Market (diagnostic)", "indication": "Neurology, Diagnostic"}, {"name": "CND Life Sciences-TDP-43-unknown", "phase": "Development (diagnostic)", "indication": "Neurology, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-03-22", "recentDeals": [{"headline": "CND Life Sciences enters into licensing and collaboration agreement to advance diagnostic technology for neurodegenerative diseases", "date": "2023-03-22", "value": ""}], "totalRaised": 25007000.0, "totalRaisedFmt": "$25M", "latestFinDate": "2025-05-01", "latestFinType": "Series A rounds", "nRounds": 4, "recentFinancing": [{"type": "Series A rounds", "amount": "$14M", "date": "2025-05-01", "investors": "Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, Honorhealth Research Institute, Triana Biomedi..."}, {"type": "Uncategorized venture rounds", "amount": "$2M", "date": "2024-03-20", "investors": "Undisclosed Investors"}, {"type": "Seed financings", "amount": "$4M", "date": "2023-04-06", "investors": "Existing Investors, New Investors, Top Corner Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cnd%20Life%20Sciences", "hasDealsFin": true, "diseaseGroups": ["Other Neurology"]}, {"company": "Cns Pharmaceuticals Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "berubicin (RTA 744)", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "WP1874 (WP1244)", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "Rami Levin, MBA", "employees": 5, "founded": 2017, "website": "https://cnspharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -3834215.18, "evFmt": "", "ticker": "CNSP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cns%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Coagulant Therapeutics Corp.", "city": "Berkeley", "state": "CA", "country": "United States", "diseaseCats": ["Hematology", "Inflammation"], "modalityGroups": ["Protein / Biologic"], "nProducts": 3, "mostAdvanced": "IND", "hasOrphan": true, "pipeline": [{"name": "CT-001", "phase": "IND", "indication": "Bleeding"}, {"name": "CT-003", "phase": "Preclinical", "indication": "Shock/trauma"}, {"name": "CT-004", "phase": "Preclinical", "indication": "Hemophilia"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://www.coagulanttherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Coagulant%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Supportive / Other"]}, {"company": "Coastar Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy", "Oncolytic / Microbiome", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CTX-101", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "CTX-106", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "Coastar Therapeutics-DNA-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "CTX-102", "phase": "Research", "indication": "Lung cancer"}, {"name": "CTX-103", "phase": "Research", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://coastartherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2022-11-10", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2022-11-10", "investors": "Panacea Venture, Proxima Ventures (\u6bd4\u90bb\u661f\u521b\u6295)"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Coastar%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "GI Cancers", "GU / Gynecologic Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Cocrystal Pharma Inc.", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CC-31244", "phase": "Phase II", "indication": "Hepatitis C virus (HCV)"}, {"name": "CC-42344", "phase": "Phase I", "indication": "Influenza virus"}, {"name": "CDI-45205", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Cocrystal-Influenza-unknown", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "Cocrystal-Norovirus-unknown", "phase": "Preclinical", "indication": "Norovirus"}], "ceo": "Sam Lee, PhD; James Joseph Martin, MBA, CPA", "employees": 11, "founded": 2007, "website": "http://cocrystalpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 12422480.0, "evFmt": "$12M", "ticker": "COCP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cocrystal%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Codagenix Inc.", "city": "Farmingdale", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Oncolytic / Microbiome", "Vaccine"], "nProducts": 10, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CDX-RSV", "phase": "Phase I", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "CodaVax-COVID", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "CodaVax-H1N1", "phase": "Phase I", "indication": "Influenza virus"}, {"name": "COVI-VAC (CDX-005", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "CDX-DENV", "phase": "Preclinical", "indication": "Dengue fever"}, {"name": "CDX-H7N9", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "CDX-ONC-F", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "CDX-ONC-Z", "phase": "Preclinical", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.codagenix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Codagenix", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Infectious Disease", "Respiratory / Allergy", "Skin Cancer / Melanoma"]}, {"company": "Cogent Biosciences Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CGT4859", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "CGT4255", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "CGT6297", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "CGT6737", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Andrew R. Robbins, MBA", "employees": 205, "founded": 2014, "website": "https://www.cogentbio.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 651071565.8, "evFmt": "$651M", "ticker": "COGT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cogent%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Cognition Therapeutics Inc.", "city": "Purchase", "state": "NY", "country": "United States", "diseaseCats": ["Neurology", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CT1812 (elayta)", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "CT2074", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "CT2168", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "Lisa R. Ricciardi, MBA", "employees": 28, "founded": 2007, "website": "http://www.cogrx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 3388752.7924, "evFmt": "$3M", "ticker": "CGTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cognition%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Ophthalmology", "Other Neurology"]}, {"company": "Cognosci Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "COG112", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.cognosci.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cognosci", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Coherus Oncology Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Hematology", "Ophthalmic"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Udenyca", "phase": "Marketed", "indication": "Neutropenia"}, {"name": "biosimilar ranibizumab (CHS-3351)", "phase": "Registration", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "biosimilar etanercept (BAX 2200", "phase": "Phase III", "indication": "Psoriasis"}, {"name": "casdozokitug (CHS-388", "phase": "Phase II", "indication": "Liver cancer"}, {"name": "SRF114", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "NZV930 (SRF373)", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "SRF617", "phase": "Phase I", "indication": "Pancreatic cancer"}], "ceo": "Denny M. Lanfear, MBA", "employees": 228, "founded": 2010, "website": "http://www.coherus.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 331126037.56, "evFmt": "$331M", "ticker": "CHRS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Coherus%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "GI Cancers", "Hematology (non-cancer)", "Ophthalmology", "Solid Tumors (General)"]}, {"company": "Colby Pharmaceutical Co.", "city": "San Jose", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "APC-100", "phase": "Phase I/II", "indication": "Prostate cancer"}, {"name": "APC-200", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "APC-300", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "OT-551", "phase": "Phase II", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.colbypharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Colby%20Pharmaceutical", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Ophthalmology"]}, {"company": "Collaborative Medicinal Development LLC", "city": "Sausalito", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CuATSM", "phase": "Phase I/II", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://colmeddev.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Collaborative%20Medicinal%20Development", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Collegium Pharmaceutical Inc.", "city": "Stoughton", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Combination", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Belbuca", "phase": "Marketed", "indication": "Pain"}, {"name": "Bunavail (bema buprenorphine/naloxone)", "phase": "Marketed", "indication": "Substance use disorders"}, {"name": "Jornay PM (Benjorna", "phase": "Marketed", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "Xtampza ER", "phase": "Marketed", "indication": "Pain"}, {"name": "HLD100", "phase": "Phase II", "indication": "Attention deficit hyperactivity disorder (ADHD)"}], "ceo": "Vikram Karnani, MBA", "employees": 357, "founded": 2003, "website": "http://www.collegiumpharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1950300757.0, "evFmt": "$2.0B", "ticker": "COLL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Collegium%20Pharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Columbia Northwest Pharmaceuticals LLC", "city": "Bellevue", "state": "WA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Carvedilol", "phase": "Phase II", "indication": "Post-traumatic stress disorder"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.columbianwp.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Columbia%20Northwest%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Comanche Biopharma Corp.", "city": "Concord", "state": "MA", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CBP-4888", "phase": "Phase I", "indication": "Preeclampsia"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://comanchebiopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Comanche%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Women's Health"]}, {"company": "Combined Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Combined Therapeutics-liver cancer-unknown", "phase": "Preclinical", "indication": "Liver cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.combinedtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Combined%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Comera Life Sciences Holdings Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Inflammation", "Other"], "modalityGroups": ["Antibody"], "nProducts": 7, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CLS-001", "phase": "Preclinical", "indication": "Crohn's disease"}, {"name": "CLS-002", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Comera Life Sciences-mAb A-unknown", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "Comera Life Sciences-mAb B-unknown", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}, {"name": "Comera Life Sciences-mAb C-unknown", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "Comera Life Sciences-mAb D-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Comera Life Sciences-mAb E-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://comeralifesciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Comera%20Life%20Sciences%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "IBD / GI Inflammatory", "Other Inflammation", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Compass Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 7, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CTX-471", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "TRIA001", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "TRIA002", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "CTX-10726", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "CTX-2026", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "CTX-5861", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "CTX-8371", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Thomas J. Schuetz, MD, PhD", "employees": 35, "founded": 2014, "website": "http://www.compasstherapeutics.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 79118800.0, "evFmt": "$79M", "ticker": "CMPX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Compass%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Compellis Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CP404", "phase": "Phase I", "indication": "Obesity"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.compellis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Compellis%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Concarlo Therapeutics Inc.", "city": "Brooklyn", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Concarlo-cancer-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.concarlo.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Concarlo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Concentra Biosciences LLC", "city": "", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Other", "Small Molecule", "Undisclosed"], "nProducts": 16, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "denikitug (GS-1811", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "IGM-8444", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "entospletinib", "phase": "Phase III", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Imvotamab (IGM-2323)", "phase": "Phase II", "indication": "B cell lymphoma"}, {"name": "pimivalimab (JTX-4014)", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "vopratelimab (JTX-2011)", "phase": "Phase II", "indication": "Bladder cancer"}, {"name": "KB-0742", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "lanraplenib (GS-9876)", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.concentrabiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Concentra%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Concentric Analgesics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "vocacapsaicin (CA-008)", "phase": "Phase II", "indication": "Pain"}, {"name": "CA-01X", "phase": "Preclinical", "indication": "Pain"}, {"name": "CA-051", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.concentricanalgesics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Concentric%20Analgesics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Consegna Pharma Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Naloxone (CP216)", "phase": "Phase I", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.consegnapharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Consegna%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Constant Therapeutics LLC", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Infectious", "Musculoskeletal"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "linear angiotensin-(1-7) (TXA127)", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.constanttherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Constant%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Consynance Therapeutics Inc.", "city": "Rensselaer", "state": "NY", "country": "United States", "diseaseCats": ["Gastrointestinal", "Other"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "HBS-102 (CSTI-100)", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "CSTI-500 (AMR-001181", "phase": "Phase I", "indication": "Genetic disorders"}, {"name": "CSTI-300", "phase": "Preclinical", "indication": "Irritable bowel syndrome"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.consynance.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Consynance%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Rare / Genetic"]}, {"company": "Context Therapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CT-95 (LNK101)", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "Martin A. Lehr, MA", "employees": 12, "founded": 2015, "website": "http://www.contexttherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -32873495.95, "evFmt": "", "ticker": "CNTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Context%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Contineum Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology", "Otologic"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PIPE-307 (JNJ-5120)", "phase": "Phase II", "indication": "Multiple sclerosis (MS)"}, {"name": "PIPE-505", "phase": "Phase I/II", "indication": "Hearing loss"}, {"name": "PIPE-858", "phase": "Phase I/II", "indication": "Multiple sclerosis (MS)"}, {"name": "PIPE-791 (PIPE-LPA)", "phase": "IND", "indication": "Neuroinflammation"}], "ceo": "Carmine N. Stengone, MBA", "employees": 41, "founded": 2018, "website": "https://www.contineum-tx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 180268142.85, "evFmt": "$180M", "ticker": "CTNM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Contineum%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune", "Other Neurology", "Other Specialties"]}, {"company": "Contrafect Corp.", "city": "Yonkers", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Staphylococcus lysin", "phase": "Phase III", "indication": "Bacteremia"}, {"name": "CF-296", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "CF-370", "phase": "Preclinical", "indication": "Pseudomonas"}, {"name": "Gram-Negative Lysin", "phase": "Preclinical", "indication": "Pseudomonas"}], "ceo": "Michael Messinger, CPA", "employees": 0, "founded": 2008, "website": "http://www.contrafect.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "CFRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Contrafect", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Convelo Therapeutics Inc.", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CVL-1001", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "CVL-2001", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.convelotx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Convelo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Convergent Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "rosopatamab-225Ac (CONV01-alpha", "phase": "Phase I/II", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://convergentrx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Convergent%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Cook Group Inc.", "city": "Bloomington", "state": "IN", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology"], "modalityGroups": ["Digital / Device", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Oasis", "phase": "Marketed", "indication": "Wounds"}, {"name": "Zilver PTX Drug-Eluting Stent (Zilver PTX)", "phase": "Marketed", "indication": "Peripheral vascular disease (PVD)"}, {"name": "Drug-eluting GTX stent", "phase": "Pilot", "indication": "Coronary artery disease (CAD)"}], "ceo": "", "employees": 0, "founded": 1963, "website": "http://www.cook-inc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cook%20Group", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Dermatology"]}, {"company": "Coordination Pharmaceuticals Inc.", "city": "Elk Grove Village", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RiMO-301", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "RiMO-401", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.coordinationpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Coordination%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Copernicus Therapeutics Inc.", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Ophthalmic", "Pulmonary"], "modalityGroups": ["Gene Therapy", "Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CFx", "phase": "Phase I/II", "indication": "Cystic fibrosis (CF)"}, {"name": "DNA nanoparticles", "phase": "Preclinical", "indication": "Retinitis"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.cgsys.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Copernicus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology", "Rare / Genetic"]}, {"company": "Corbus Pharmaceuticals Holdings Inc.", "city": "Norwood", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CRB-601", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "CRB-913", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "Yuval Cohen, PhD", "employees": 28, "founded": 2009, "website": "http://www.CorbusPharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -17306126.6, "evFmt": "", "ticker": "CRBP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Corbus%20Pharmaceuticals%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Solid Tumors (General)"]}, {"company": "Corcept Therapeutics Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Hepatic", "Neurology", "Ophthalmic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Korlym", "phase": "Marketed", "indication": "Cushing disease"}, {"name": "relacorilant (CORT125134)", "phase": "Registration", "indication": "Ovarian cancer"}, {"name": "CORT108297", "phase": "Phase II", "indication": "Post-traumatic stress disorder"}, {"name": "Exicorilant", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "miricorilant", "phase": "Phase II", "indication": "Weight gain"}, {"name": "CORT118335", "phase": "Phase I", "indication": "Metabolic (unspecified)"}, {"name": "Dazucorilant (CORT113176)", "phase": "Phase I", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "CORT125281", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "Joseph K. Belanoff, MD", "employees": 500, "founded": 1998, "website": "http://www.corcept.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 5341859200.0, "evFmt": "$5.3B", "ticker": "CORT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Corcept%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Neurodegeneration / NMD", "Obesity / Metabolic", "Other", "Other Specialties", "Psychiatry / Behavioral"]}, {"company": "Corium LLC", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Musculoskeletal", "Neurology"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Adlarity", "phase": "Approved", "indication": "Alzheimer's disease"}, {"name": "Transdermal MicroCor PTH", "phase": "Phase II", "indication": "Osteoporosis"}, {"name": "Corplex Memantine Transdermal System", "phase": "Phase I", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 1996, "website": "https://corium.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Corium", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Musculoskeletal"]}, {"company": "Cormedix Inc.", "city": "Berkeley Heights", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Hematology", "Infectious"], "modalityGroups": ["Digital / Device", "Peptide", "Small Molecule"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Baxdela IV", "phase": "Marketed", "indication": "Pneumonia"}, {"name": "Baxdela oral", "phase": "Marketed", "indication": "Skin and skin structure infection (SSSI)"}, {"name": "Defencath", "phase": "Marketed", "indication": "Bacterial infection"}, {"name": "Minocin", "phase": "Marketed", "indication": "Infectious (unspecified)"}, {"name": "Orbactiv", "phase": "Marketed", "indication": "Skin and skin structure infection (SSSI)"}, {"name": "Vaborem", "phase": "Marketed", "indication": "Urinary tract infection (UTI)"}, {"name": "Taksta", "phase": "Phase III", "indication": "Skin and skin structure infection (SSSI)"}, {"name": "Radezolid", "phase": "Phase II", "indication": "Acne"}], "ceo": "Joseph Todisco, MBA", "employees": 65, "founded": 2006, "website": "http://www.cormedix.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 425689337.2, "evFmt": "$426M", "ticker": "CRMD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cormedix", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease"]}, {"company": "Corneagen Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Vyznova", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://corneagen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Corneagen", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Cornerstone Pharmaceuticals Inc.", "city": "Cranbury", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "devimistat (CPI-613", "phase": "Phase III", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 1999, "website": "https://cornerstonepharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cornerstone%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Corstasis Therapeutics Inc.", "city": "Henderson", "state": "NV", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Enbumyst", "phase": "Approved", "indication": "Renal (unspecified)"}, {"name": "bumetanide subcutaneous infusion (RSQ-789)", "phase": "Phase III", "indication": "Renal (unspecified)"}, {"name": "bumetanide subcutaneous injection (RSQ-786)", "phase": "Phase III", "indication": "Renal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://corstasis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Corstasis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Cortice Biosciences Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TPI 287", "phase": "Phase II", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.corticebiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cortice%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Corventum Inc.", "city": "Boulder", "state": "CO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CVT-130", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://corventum.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Corventum", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Corvus Pharmaceuticals Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "soquelitinib (CPI-818)", "phase": "Phase III", "indication": "T cell lymphoma"}, {"name": "mupadolimab (CPI-006)", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "CPI-182", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Richard A. Miller, MD", "employees": 31, "founded": 2014, "website": "http://www.corvuspharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 275428632.75, "evFmt": "$275M", "ticker": "CRVS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Corvus%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Corxel Pharmaceuticals (Shanghai) Co. Ltd. ( \u7b95\u661f\u836f\u4e1a)", "city": "Berkeley Heights", "state": "NJ", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "JX09 (PB6440", "phase": "Phase I", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.corxelbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 287000000.0, "totalRaisedFmt": "$287M", "latestFinDate": "2026-01-22", "latestFinType": "Series D rounds", "nRounds": 1, "recentFinancing": [{"type": "Series D rounds", "amount": "$287M", "date": "2026-01-22", "investors": "Sr One Capital Management, Tcgx, Ra Capital Management L.P., Hbm Healthcare Investments AG, Symbiosis, Adage Capital Man..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Corxel%20Pharmaceuticals%20(Shanghai)%20Co.%20Ltd.%20(%20\u7b95\u661f\u836f\u4e1a)", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular"]}, {"company": "Cosciens Biopharma Inc.", "city": "Summerville", "state": "SC", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dermatology", "Diagnostic", "Endocrine/Metabolic", "Infectious", "Neurology"], "modalityGroups": ["Cell Therapy", "Macrocycle", "Other", "Peptide", "Protein / Biologic", "Small Molecule", "Undisclosed", "Vaccine"], "nProducts": 14, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Cetrotide", "phase": "Marketed", "indication": "Infertility"}, {"name": "Ghryvelin", "phase": "Marketed", "indication": "Endocrine, Diagnostic"}, {"name": "perifosine (KRX-0401)", "phase": "Phase III", "indication": "Colorectal cancer"}, {"name": "ozarelix (D-63153", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "Avenanthramide", "phase": "Phase I", "indication": "Cardiovascular (unspecified)"}, {"name": "AeternaZentaris-Coronavirus (COVID-19) and Chlamydia vaccine-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "AEZS-120", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "AEZS-129", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Peter Harry Puccetti, CFA", "employees": 40, "founded": 1991, "website": "https://www.cosciensbio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -7155000.500626, "evFmt": "", "ticker": "CSCI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cosciens%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "GI Cancers", "GU / Gynecologic Cancers", "Infectious Disease", "Other Specialties", "Solid Tumors (General)", "Women's Health"]}, {"company": "Cosette Pharmaceuticals Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Genitourinary", "Renal"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Vyleesi", "phase": "Marketed", "indication": "Sexual dysfunction"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://cosettepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-06-08", "recentDeals": [{"headline": "Cosette Pharmaceuticals Acquires Intrarosa from Endoceutics Inc.", "date": "2023-06-08", "value": ""}, {"headline": "Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio", "date": "2022-01-18", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2024-07-17", "latestFinType": "Venture (Debt)", "nRounds": 2, "recentFinancing": [{"type": "Venture (Debt)", "amount": "", "date": "2024-07-17", "investors": "Hayfin Capital Management LLP"}, {"type": "Venture (Debt)", "amount": "", "date": "2024-07-17", "investors": "Ubs Investment Bank, Capital One Financial Corp., Santander Corporate & Commercial"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cosette%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Other Specialties"]}, {"company": "Cothera Bioscience Inc.", "city": "San Mateo", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CTB-02", "phase": "Phase I/II", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.cotherabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cothera%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Cour Pharmaceuticals Development Co. Inc.", "city": "Elmhurst", "state": "IL", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic"], "modalityGroups": ["Nanoparticle / Delivery", "Other", "Peptide"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "CNP-101", "phase": "Phase II", "indication": "Celiac disease"}, {"name": "CNP-104", "phase": "Phase II", "indication": "Primary biliary cholangitis"}, {"name": "CNP-106", "phase": "Phase I/II", "indication": "Myasthenia gravis"}, {"name": "CNP-103", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "CNP-Aquaporin 4", "phase": "Preclinical", "indication": "Neuromyelitis optica spectrum disorder"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.courpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 940000000.0, "totalDealFmt": "$940M", "latestDealDate": "2024-12-03", "recentDeals": [{"headline": "COUR Pharmaceuticals Enters Collaboration and Licensing Agreement with Genentech to Develop and Commercialize Tolerogenic Therapy for the Treatment of an Autoimmune Disease", "date": "2024-12-03", "value": "$940M"}], "totalRaised": 135000000.0, "totalRaisedFmt": "$135M", "latestFinDate": "2024-01-30", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$105M", "date": "2024-01-30", "investors": "Lumira Ventures, Alpha Wave Ventures, Roche Venture Fund, Pfizer Breakthrough Growth Initiative, Bristol Myers Squibb Co..."}, {"type": "Uncategorized venture rounds", "amount": "$30M", "date": "2022-09-07", "investors": "Alpha Wave Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cour%20Pharmaceuticals%20Development%20Co.", "hasDealsFin": true, "diseaseGroups": ["Diabetes", "GI Cancers", "IBD / GI Inflammatory", "MS / Neuroimmune"]}, {"company": "Courage Therapeutics Inc.", "city": "Newton", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Peptide"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Courage Therapeutics-MC3R agonist-unknown", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "Courage Therapeutics-MC4R agonist-unknown", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.couragetx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Courage%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Covicept Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PSJ-539", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Covicept%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Coya Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Inflammation", "Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "COYA 201", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "COYA 302", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "Arun Swaminathan, PhD", "employees": 8, "founded": 2020, "website": "https://www.coyatherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 48979243.87, "evFmt": "$49M", "ticker": "COYA", "exchange": "NASDAQ", "nDeals": 6, "totalDealValue": 733250000.0, "totalDealFmt": "$733M", "latestDealDate": "2023-12-06", "recentDeals": [{"headline": "Coya Therapeutics Inc. and Dr. Reddy\u2019s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)", "date": "2023-12-06", "value": "$733M"}, {"headline": "Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)", "date": "2023-09-22", "value": ""}, {"headline": "Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)", "date": "2023-06-20", "value": ""}], "totalRaised": 10300000.0, "totalRaisedFmt": "$10M", "latestFinDate": "2022-06-07", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$10M", "date": "2022-06-07", "investors": "Institutional Investors, Accredited Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Coya%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Other Inflammation"]}, {"company": "Create Medicines Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "MT-302", "phase": "Phase I/II", "indication": "Epithelial cancer"}, {"name": "MT-303", "phase": "Phase I", "indication": "Liver cancer"}, {"name": "CRT-401", "phase": "Preclinical", "indication": "Epithelial cancer"}, {"name": "CRT-402", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "MT-304", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://createmedicines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 73000000.0, "totalRaisedFmt": "$73M", "latestFinDate": "2023-05-18", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$73M", "date": "2023-05-18", "investors": "Hatteras Venture Partners, Arch Venture Partners, Moore Strategic Ventures, Newpath Partners, 8Vc, Alexandria Venture In..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Create%20Medicines", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Hematologic Cancers", "Other"]}, {"company": "Creative Bio-peptides Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RAP-103", "phase": "Preclinical", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://creativebiopeptides.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Creative%20Bio-peptides", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Creative Biolabs Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody", "Other", "Peptide"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Creative Biolabs-COVID 19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Creative Biolabs-COVID 19-unknown2", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Creative Biolabs-COVID 19-unknown3", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "https://www.creative-biolabs.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Creative%20Biolabs", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Creative Medical Technology Holdings Inc.", "city": "Phoenix", "state": "AZ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Genitourinary", "Musculoskeletal", "Neurology"], "modalityGroups": ["Cell Therapy", "Undisclosed"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "CaverStem", "phase": "Marketed", "indication": "Erectile dysfunction (ED)"}, {"name": "FemCelz", "phase": "Marketed", "indication": "Sexual dysfunction"}, {"name": "CELZ-201", "phase": "Phase I/II", "indication": "Diabetes"}, {"name": "StemSpine", "phase": "Pilot", "indication": "Musculoskeletal (unspecified)"}, {"name": "AmnioStem", "phase": "Preclinical", "indication": "Stroke"}, {"name": "CELZ-001", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "CELZ-101", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "IMMCELZ", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "Timothy Warbington", "employees": 4, "founded": 1998, "website": "http://www.creativemedicaltechnology.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -2520631.8, "evFmt": "", "ticker": "CELZ", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Creative%20Medical%20Technology%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Diabetes", "Musculoskeletal", "Other Neurology", "Other Specialties"]}, {"company": "Crescent Biopharma Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Hematology", "Inflammation"], "modalityGroups": ["ADC", "Bispecific Antibody", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "iv rivipansel (GMI-1070", "phase": "Phase III", "indication": "Sickle cell disease"}, {"name": "uproleselan (APL-106", "phase": "Phase III", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "GMI-1359", "phase": "Phase I", "indication": "Bone cancer"}, {"name": "CR-001", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "CR-002", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Glycomimetics-Cancer-Unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "GMI-1687 (APL-108)", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}, {"name": "GMI-1757", "phase": "Preclinical", "indication": "Hematologic malignancies"}], "ceo": "Joshua T. Brumm", "employees": 26, "founded": 2024, "website": "https://crescentbiopharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 5401501.001, "evFmt": "$5M", "ticker": "CBIO", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 50000000.0, "totalDealFmt": "$50M", "latestDealDate": "2025-12-04", "recentDeals": [{"headline": "Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics Including SKB105", "date": "2025-12-04", "value": ""}, {"headline": "Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics Including CR-001", "date": "2025-12-04", "value": "$50M"}], "totalRaised": 200000000.0, "totalRaisedFmt": "$200M", "latestFinDate": "2025-06-15", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$200M", "date": "2025-06-15", "investors": "Fairmount Funds Management, Venrock Healthcare Capital Partners, Bvf Partners L.P., Undisclosed Investor, Paradigm Bioca..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Crescent%20Biopharma", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Hematology (non-cancer)", "Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Cresilon Inc.", "city": "Brooklyn", "state": "NY", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Vetigel", "phase": "Registration", "indication": "Bleeding"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.cresilon.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cresilon", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Crestone Inc.", "city": "Boulder", "state": "CO", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CRS3123", "phase": "Phase II", "indication": "Clostridium"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.crestonepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Crestone", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Crinetics Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Ophthalmic", "Renal"], "modalityGroups": ["Radiopharmaceutical", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Palsonify", "phase": "Marketed", "indication": "Acromegaly"}, {"name": "atumelnant (CRN04894)", "phase": "Phase II", "indication": "Adrenal insufficiency"}, {"name": "Crinetics Pharmaceuticals-radionetics-unknown", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "Crinetics Pharmaceuticals-PTH antagonist-unknown", "phase": "Preclinical", "indication": "Hypercalcemia"}, {"name": "Crinetics Pharmaceuticals-SST3 agonist-unknown", "phase": "Preclinical", "indication": "Polycystic kidney disease (PKD)"}, {"name": "Crinetics Pharmaceuticals-SST5 agonist-unknown", "phase": "Preclinical", "indication": "Hypoglycemia"}, {"name": "Crinetics Pharmaceuticals-TSH antagonist-unknown", "phase": "Preclinical", "indication": "Graves disease"}, {"name": "CRN09682", "phase": "Preclinical", "indication": "Neuroendocrine tumors"}], "ceo": "Scott R. Struthers, PhD", "employees": 437, "founded": 2008, "website": "https://crinetics.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2827587790.0, "evFmt": "$2.8B", "ticker": "CRNX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Crinetics%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Kidney Disease", "Other", "Other Inflammation", "Other Solid Tumors", "Other Specialties", "Solid Tumors (General)"]}, {"company": "Crititech Inc.", "city": "Lawrence", "state": "KS", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Nanotax", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.crititech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Crititech", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Crossbow Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CBX-250 (T-Bolt", "phase": "Preclinical", "indication": "Leukemia"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.crossbowtx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 110250000.0, "totalRaisedFmt": "$110M", "latestFinDate": "2025-09-17", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$30M", "date": "2025-09-17", "investors": "Undisclosed Investors"}, {"type": "Series A rounds", "amount": "$80M", "date": "2023-07-11", "investors": "Mpm Bioimpact, Pfizer Ventures, Polaris Partners, Bvf Partners L.P., Eli Lilly and Co., Mirae Asset Venture Investment, ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Crossbow%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Crown Laboratories Inc.", "city": "Johnson City", "state": "TN", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Inflammation", "Musculoskeletal", "Neurology", "Other"], "modalityGroups": ["Nanoparticle / Delivery", "Protein / Biologic", "Small Molecule", "Undisclosed"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Dermasorb HC", "phase": "Marketed", "indication": "Dermatosis"}, {"name": "Luxamend", "phase": "Marketed", "indication": "Wounds"}, {"name": "Targadox", "phase": "Marketed", "indication": "Acne"}, {"name": "Daxxify", "phase": "Approved", "indication": "Scars/wrinkles"}, {"name": "Ala-Quin", "phase": "Marketed", "indication": "Dermatology (unspecified)"}, {"name": "Dermasorb AF", "phase": "Marketed", "indication": "Dermatology (unspecified)"}, {"name": "Dermasorb TA", "phase": "Marketed", "indication": "Dermatitis"}, {"name": "botulinum toxin type a", "phase": "Phase II", "indication": "Excessive sweating"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.crownlaboratories.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Crown%20Laboratories", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Other"]}, {"company": "Cue Biopharma Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Inflammation"], "modalityGroups": ["Cell Therapy", "Other", "Protein / Biologic"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CUE-101", "phase": "Phase II", "indication": "Head and neck cancer"}, {"name": "CUE-102", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "CUE-301", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "CUE-401", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "CUE-501", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "Cue-Cancer-Unknown 1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Usman Azam, MD", "employees": 41, "founded": 2014, "website": "https://www.cuebiopharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 47814899.32, "evFmt": "$48M", "ticker": "CUE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cue%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Head & Neck Cancer", "Solid Tumors (General)"]}, {"company": "Cugene Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CUG-252", "phase": "Phase I", "indication": "Lupus"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.cugene.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cugene", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Cullgen Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CG001419", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "CG009301", "phase": "IND", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "Cullgen-epigenetic factor-unknown", "phase": "Preclinical", "indication": "Bladder cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.cullgen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 40000000.0, "totalRaisedFmt": "$40M", "latestFinDate": "2023-05-08", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$5M", "date": "2023-05-08", "investors": "Gni Group Ltd."}, {"type": "Series C rounds", "amount": "$35M", "date": "2023-05-08", "investors": "Astrazeneca-cicc Capital, Sincere Capital (\u4fe1\u71b9\u8d44\u672c), Voyagers Capital, Wuxi Capital, Gni Group Ltd."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cullgen", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Cullinan Mica Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CLN-619", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cullinan%20Mica", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Cullinan Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Other"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CLN-978", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "CLN-617", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Cullinan-FLT3xCD3-unknown", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Jade-senescence and cancer-related protein-unknown", "phase": "Preclinical", "indication": "Human papillomavirus (HPV)"}, {"name": "NextGem-HSAxCD19xCD3-unknown", "phase": "Preclinical", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "Opal-4-IBB/CD137-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Nadim Ahmed", "employees": 111, "founded": 2016, "website": "http://www.cullinanoncology.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 258104780.0, "evFmt": "$258M", "ticker": "CGEM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cullinan%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Cumberland Pharmaceuticals Inc.", "city": "Nashville", "state": "TN", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Gastrointestinal", "Infectious", "Neurology", "Other", "Pulmonary"], "modalityGroups": ["Macrocycle", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Acetadote", "phase": "Marketed", "indication": "Poisoning"}, {"name": "Caldolor", "phase": "Marketed", "indication": "Pain"}, {"name": "Kristalose", "phase": "Marketed", "indication": "Constipation"}, {"name": "Vibativ", "phase": "Marketed", "indication": "Pneumonia"}, {"name": "Boxaban", "phase": "Phase II", "indication": "Pulmonary (unspecified)"}, {"name": "Hepatoren", "phase": "Phase II", "indication": "Cardiomyopathy"}, {"name": "Vasculan", "phase": "Phase II", "indication": "Scleroderma"}], "ceo": "A. J. Kazimi, MBA", "employees": 91, "founded": 1999, "website": "http://www.cumberlandpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 35623560.64, "evFmt": "$36M", "ticker": "CPIX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cumberland%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Cardiovascular", "Infectious Disease", "Pain / Migraine", "Respiratory / Allergy", "Supportive / Other"]}, {"company": "Curanex Pharmaceuticals Inc.", "city": "Jericho", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Endocrine/Metabolic", "Hepatic", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Phyto-N", "phase": "Preclinical", "indication": "Ulcerative colitis"}], "ceo": "Jun Liu", "employees": 0, "founded": 2018, "website": "https://www.curanexpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "CURX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curanex%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Curative Biotechnology Inc.", "city": "Boca Raton", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Ophthalmic"], "modalityGroups": ["ADC", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CURB906", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "Metformin eye drops", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "I. Richard Garr", "employees": 0, "founded": 2007, "website": "https://curativebiotech.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 14595571.488, "evFmt": "$15M", "ticker": "CUBT", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curative%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Ophthalmology"]}, {"company": "Curefaktor Pharmaceuticals LLC", "city": "Buffalo", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "CFAK-C4", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.curefaktorinfo.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curefaktor%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Curegenix Corp.", "city": "Burlingame", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Musculoskeletal"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CGX1321", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "CGX1321c", "phase": "Preclinical", "indication": "Tissue damage"}, {"name": "CGX1321ia", "phase": "Preclinical", "indication": "Osteoarthritis"}, {"name": "CGX7002", "phase": "Preclinical", "indication": "Tissue damage"}, {"name": "Curegenix-WNT platform-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "https://curegenix.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curegenix", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Musculoskeletal", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Curelab Oncology Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Elenagen", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2000, "website": "https://www.curelaboncology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curelab%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Curemark LLC", "city": "Rye", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "CM-AT", "phase": "Registration", "indication": "Autism"}, {"name": "CM-4612", "phase": "Phase II", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "CM-182", "phase": "Phase I", "indication": "Schizophrenia"}, {"name": "CM-PK", "phase": "Phase I", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.curemark.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curemark", "hasDealsFin": false, "diseaseGroups": ["Parkinson's", "Psychiatry / Behavioral"]}, {"company": "Cureveda LLC", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VEDA-1209", "phase": "Preclinical", "indication": "Ulcerative colitis"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.cureveda.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cureveda", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Curevo Inc. (Curevo Vaccine)", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Amezosvatein (CRV-101)", "phase": "Phase II", "indication": "Varicella zoster virus (VZV)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://curevovaccine.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curevo%20Inc.%20(Curevo%20Vaccine)", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Curis Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "fimepinostat (CUDC-907)", "phase": "Phase II", "indication": "B cell lymphoma"}], "ceo": "James E. Dentzer, MBA", "employees": 34, "founded": 2000, "website": "http://www.curis.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 36428229.04, "evFmt": "$36M", "ticker": "CRIS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curis", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Currax Holdings LLC", "city": "Brentwood", "state": "TN", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Contrave", "phase": "Marketed", "indication": "Obesity"}, {"name": "Treximet", "phase": "Marketed", "indication": "Migraine"}, {"name": "Onzetra Xsail", "phase": "Marketed", "indication": "Migraine"}, {"name": "Silenor", "phase": "Marketed", "indication": "Insomnia"}, {"name": "Vituz", "phase": "Marketed", "indication": "Cough"}, {"name": "Zohydro ER with BeadTek", "phase": "Marketed", "indication": "Pain"}, {"name": "naltrexone hcl/buproprion hcl extended-release (CX-101)", "phase": "Phase II", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.curraxpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Currax%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Pain / Migraine", "Psychiatry / Behavioral", "Respiratory / Allergy"]}, {"company": "Curtana Pharmaceuticals Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "CSNK2 inhibitor", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "CT-179", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.curtanapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curtana%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Curyx Bio Inc.", "city": "Paramus", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Antibody", "Peptide", "Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "CB-301", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "CB-401", "phase": "Preclinical", "indication": "Adrenal insufficiency"}, {"name": "FHL-101 (CB-101)", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "FHL-401 (CB-201)", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.curyxbio.com/index.html", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curyx%20Bio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "MS / Neuroimmune", "Obesity / Metabolic", "Other Specialties"]}, {"company": "Curza", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CZ-02", "phase": "Preclinical", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.curza.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Curza", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Cybrexa Therapeutics Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "alphalex-exatecan (CBX-12)", "phase": "Phase II", "indication": "Colorectal cancer"}, {"name": "CBX-11 (alphalex-rucaparib)", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://cybrexa.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cybrexa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Cyclacel Pharmaceuticals Inc.", "city": "Berkeley Heights", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Infectious", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Roscovitine", "phase": "Phase II", "indication": "Rheumatoid arthritis (RA)"}, {"name": "Fadraciclib (CYC065)", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "CYC140", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "Sing Ee Wong, DBA", "employees": 0, "founded": 1996, "website": "https://cyclacel.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -1123377.496, "evFmt": "", "ticker": "CYCC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cyclacel%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Breast Cancer", "Hematologic Cancers"]}, {"company": "Cyclerion Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Praliciguat", "phase": "Phase II", "indication": "Heart failure"}], "ceo": "Regina Graul, PhD", "employees": 1, "founded": 2019, "website": "https://cyclerion.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 4875960.0, "evFmt": "$5M", "ticker": "CYCN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cyclerion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Cynvec LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CYN 101", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.cynvec.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cynvec", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Cyrano Therapeutics Inc.", "city": "Delray Beach", "state": "FL", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CYR-064", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://cyranotherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-03-18", "recentDeals": [{"headline": "Cyrano Therapeutics and Resyca Announce Exclusive License Agreement for Soft Mist Nasal Spray Technology for the Treatment of Chemosensory Dysfunction", "date": "2025-03-18", "value": ""}], "totalRaised": 9000000.0, "totalRaisedFmt": "$9M", "latestFinDate": "2024-01-16", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$9M", "date": "2024-01-16", "investors": "Deepwork Capital, Lumira Ventures, Remiges Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cyrano%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Cyta Therapeutics Inc.", "city": "Lowell", "state": "MA", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CYTX-100", "phase": "Preclinical", "indication": "Liver disease"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://cytatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cyta%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Cytimmune Sciences Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Aurimune (CYT-6091)", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "Auritol (CYT-21001)", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "CYT-21625", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 1988, "website": "http://www.cytimmune.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cytimmune%20Sciences", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Cytoagents Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GP1681", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.cytoagents.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cytoagents", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Cytodyn Inc.", "city": "Vancouver", "state": "WA", "country": "United States", "diseaseCats": ["Cancer", "Hepatic", "Infectious", "Transplant"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "leronlimab (PRO 140)", "phase": "Approved", "indication": "Breast cancer"}], "ceo": "Jacob P. Lalezari, MD", "employees": 13, "founded": 1986, "website": "http://www.cytodyn.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 440517324.0, "evFmt": "$441M", "ticker": "CYDY", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cytodyn", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Cytogel Pharma LLC", "city": "Darien", "state": "CT", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CYT-1010", "phase": "Phase I", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.cytogelpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cytogel%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Cytoimmune Therapeutics Inc.", "city": "Monrovia", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CYTO NK-102", "phase": "Phase I", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "CYTO NK-201", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "CYTO NK-203", "phase": "Preclinical", "indication": "Biliary cancer"}, {"name": "CYTO NK-301", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://www.cytoimmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cytoimmune%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Lung Cancer"]}, {"company": "Cytokinetics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Musculoskeletal", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 9, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "aficamten (CK-274", "phase": "Registration", "indication": "Cardiomyopathy"}, {"name": "Omecamtiv mecarbil (AMG 423", "phase": "Registration", "indication": "Heart failure"}, {"name": "reldesemtiv (CK-107", "phase": "Phase III", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "oral Omecamtiv mecarbil", "phase": "Phase II", "indication": "Heart failure"}, {"name": "ulacamten (CK-4021586", "phase": "Phase II", "indication": "Heart failure"}, {"name": "CK-136", "phase": "Phase I", "indication": "Heart failure"}, {"name": "CK-271", "phase": "Preclinical", "indication": "Cardiomyopathy"}, {"name": "CK-3672889", "phase": "Preclinical", "indication": "Musculoskeletal (unspecified)"}], "ceo": "Robert I. Blum, MBA", "employees": 498, "founded": 1998, "website": "http://www.cytokinetics.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4979780160.0, "evFmt": "$5.0B", "ticker": "CYTK", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-12-20", "recentDeals": [{"headline": "Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China", "date": "2024-12-20", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cytokinetics", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Musculoskeletal", "Neurodegeneration / NMD"]}, {"company": "Cytomx Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Antibody", "Other", "Protein / Biologic"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "BMS-986288", "phase": "Phase II", "indication": "Colorectal cancer"}, {"name": "CX-072", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "praluzatamab ravtansine", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "BMS-986249", "phase": "Phase I/II", "indication": "Melanoma"}, {"name": "CX-2051", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "CX-801", "phase": "IND", "indication": "Solid tumors"}, {"name": "CX-2043", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Sean A. McCarthy, PhD, MBA", "employees": 121, "founded": 2008, "website": "http://www.cytomx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -3950530.52, "evFmt": "", "ticker": "CTMX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cytomx%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Cytonus Therapeutics Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CA-IL-12", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Cargocytes", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://cytonus.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cytonus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Solid Tumors (General)"]}, {"company": "Cytovia Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Cell Therapy"], "nProducts": 8, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "CYT-303", "phase": "IND", "indication": "Liver cancer"}, {"name": "CYT-100", "phase": "Preclinical", "indication": "Liver cancer"}, {"name": "CYT-150", "phase": "Preclinical", "indication": "Liver cancer"}, {"name": "CYT-338", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}, {"name": "CYT-501", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "CYT-503", "phase": "Preclinical", "indication": "Liver cancer"}, {"name": "CYT-538", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}, {"name": "Cytovia-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.cytoviatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cytovia%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GI Cancers", "Hematologic Cancers", "Infectious Disease"]}, {"company": "Cz Biomed Corp.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Panrvlysin", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.czbiomed.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Cz%20Biomed", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "D.e. Shaw Research LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "DES-7114", "phase": "Phase I", "indication": "Inflammatory disease"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.deshawresearch.com/index.html", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=D.e.%20Shaw%20Research", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Dantari Inc.", "city": "Thousand Oaks", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "DAN-222", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "DAN-311", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "DAN-405", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://dantari.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dantari", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers"]}, {"company": "Dante Labs Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious", "Musculoskeletal", "Neurology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Dante Labs-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Dante Labs-muscle rare disease-unknown", "phase": "Preclinical", "indication": "Musculoskeletal (unspecified)"}, {"name": "Dante Labs-neurological rare disease-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.dantelabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dante%20Labs", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Musculoskeletal", "Other Neurology"]}, {"company": "Dare Bioscience Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Genitourinary", "Infectious"], "modalityGroups": ["Digital / Device", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Xaciato", "phase": "Marketed", "indication": "Bacterial vaginosis"}, {"name": "Ovaprene", "phase": "Phase III", "indication": "Contraception"}, {"name": "Sildenafil Cream", "phase": "Phase II", "indication": "Sexual dysfunction"}, {"name": "DARE-VVA1", "phase": "Phase I/II", "indication": "Atrophic vaginitis"}, {"name": "vaginal diclofenac (DARE-PDM1)", "phase": "Phase I", "indication": "Dysmenorrhea"}, {"name": "DARE-LARC1", "phase": "Preclinical", "indication": "Contraception"}], "ceo": "Sabrina Martucci Johnson, MBA", "employees": 23, "founded": 2015, "website": "http://www.darebioscience.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 16866743.08, "evFmt": "$17M", "ticker": "DARE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dare%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other", "Other Specialties", "Women's Health"]}, {"company": "Dauntless Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "octreotide acetate (DP1038)", "phase": "Phase I", "indication": "Neuroendocrine tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.dauntlessph.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dauntless%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Day One Biopharmaceuticals Inc.", "city": "Brisbane", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "Emi-Le", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "XMT-2056", "phase": "Phase I", "indication": "Gastric cancer"}], "ceo": "Jeremy Bender, PhD, MBA", "employees": 181, "founded": 2018, "website": "https://dayonebio.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 652159250.65, "evFmt": "$652M", "ticker": "DAWN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Day%20One%20Biopharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Decimmune Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DeciMab", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.decimmune.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Decimmune%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Decoy Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "seclidemstat (SP-2577)", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Decoy Therapeutics-pan-coronavirus-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "SP-3164 (DRX-164)", "phase": "Preclinical", "indication": "Hematologic malignancies"}], "ceo": "Frederick E. Pierce, II", "employees": 2, "founded": 2020, "website": "https://decoytx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -442195.6, "evFmt": "", "ticker": "SLRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Decoy%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Infectious Disease"]}, {"company": "Deepcure Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DC-9476", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://deepcure.ai", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Deepcure", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Definium Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "lysergide D-tartrate (MM-120)", "phase": "Phase III", "indication": "Anxiety"}, {"name": "18-MC (18-methoxycoronaridine (18-mc))", "phase": "Phase I", "indication": "Leishmaniasis"}, {"name": "MM-402", "phase": "Preclinical", "indication": "Autism"}], "ceo": "Robert Barrow, CFA", "employees": 74, "founded": 2010, "website": "https://definiumtx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 238522026.32, "evFmt": "$239M", "ticker": "DFTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Definium%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other", "Psychiatry / Behavioral"]}, {"company": "Deka Biosciences Inc.", "city": "Washington", "state": "DC", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious"], "modalityGroups": ["Protein / Biologic", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "DK210 (EGFR)", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "DK4 Diakine", "phase": "Preclinical", "indication": "Crohn's disease"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.dekabiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Deka%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Solid Tumors (General)"]}, {"company": "Dekk-tec Inc.", "city": "New Orleans", "state": "LA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "DM-CHOC-PEN", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 1983, "website": "http://www.dekk-tec.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dekk-tec", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Delfi Diagnostics Inc.", "city": "Baltimore", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Development (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Delfi Liver Cancer ScreeningTest", "phase": "Development (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "Delfi Lung Cancer ScreeningTest", "phase": "Development (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-07-27", "recentDeals": [{"headline": "DELFI Diagnostics Licenses GEMINI Technology from Johns Hopkins University: Study Demonstrates High Performance for Early Stage Lung Cancer Detection When Integrated with DELFI Diagnostics's Platform", "date": "2023-07-27", "value": ""}], "totalRaised": 259333315.0, "totalRaisedFmt": "$259M", "latestFinDate": "2025-12-18", "latestFinType": "Venture (Debt)", "nRounds": 2, "recentFinancing": [{"type": "Venture (Debt)", "amount": "$34M", "date": "2025-12-18", "investors": "Undisclosed Investors"}, {"type": "Series B rounds", "amount": "$225M", "date": "2022-07-18", "investors": "Dfj Growth, Eli Lilly and Co., Point72, Brown Advisory, Point Field Partners, Initiate Studios LLC, Open Field Capital, ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Delfi%20Diagnostics", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Deliver Therapeutics Inc.", "city": "Surfside", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Deliver Therapeutics-AR-unknown", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "Deliver Therapeutics-c-Abl-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Deliver Therapeutics-ERa-unknown", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "Deliver Therapeutics-Foxo4-p53-unknown", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}, {"name": "Deliver Therapeutics-IGF-1R-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Deliver Therapeutics-VEGFR-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://delivertherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Deliver%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Dermatology", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Delix Therapeutics Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Delix Therapeutics-psychiatric and neurological-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.delixtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 65000000.0, "totalRaisedFmt": "$65M", "latestFinDate": "2025-09-10", "latestFinType": "Series B rounds", "nRounds": 3, "recentFinancing": [{"type": "Series B rounds", "amount": "$25M", "date": "2025-09-10", "investors": ""}, {"type": "Venture (Debt)", "amount": "$10M", "date": "2022-01-10", "investors": "Comerica Bank"}, {"type": "Venture (Debt)", "amount": "$30M", "date": "2022-01-10", "investors": "Existing Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Delix%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Other Neurology"]}, {"company": "Deltanoid Pharmaceuticals Inc.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "2MD", "phase": "Phase II", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.deltanoid.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Deltanoid%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Demerx Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "noribogaine (DMX-1001", "phase": "Phase II", "indication": "Substance use disorders"}, {"name": "ibogaine (DMX-1002)", "phase": "Phase I", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://demerx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Demerx", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Denali Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Antibody", "Protein / Biologic", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "tividenofusp alfa (DNL310", "phase": "Registration", "indication": "Mucopolysaccharidosis"}, {"name": "DNL343", "phase": "Phase II/III", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "eclitasertib (DNL758", "phase": "Phase II", "indication": "Ulcerative colitis"}, {"name": "TAK-594 (DNL593", "phase": "Phase I/II", "indication": "Frontotemporal dementia"}, {"name": "ATV:aSyn", "phase": "Preclinical", "indication": "Cognitive dysfunction"}, {"name": "DNL975", "phase": "Preclinical", "indication": "Crohn's disease"}, {"name": "ETV:IDS", "phase": "Preclinical", "indication": "Mucopolysaccharidosis"}], "ceo": "Ryan J. Watts, PhD", "employees": 422, "founded": 2015, "website": "http://www.denalitherapeutics.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2573966473.36, "evFmt": "$2.6B", "ticker": "DNLI", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-05-30", "recentDeals": [{"headline": "PharmEnable announces multi-target collaboration with Denali Therapeutics in neurodegenerative disease", "date": "2022-05-30", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Denali%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "IBD / GI Inflammatory", "Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Denovo Biopharma LLC", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Other"], "modalityGroups": ["Gene Therapy", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "enzastaurin (DB102", "phase": "Phase III", "indication": "B cell lymphoma"}, {"name": "Vocimagene amiretrorepvec/extended release flucytosine (Toca 511/Toca FC", "phase": "Phase III", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.denovobiopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Denovo%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Hematologic Cancers"]}, {"company": "Depymed Inc.", "city": "Farmingdale", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": true, "pipeline": [{"name": "DepYmed-Rett Syndrome-unknown", "phase": "IND", "indication": "Rett syndrome"}, {"name": "DepYmed-CNS Syndromes-unknown", "phase": "Preclinical", "indication": "Central nervous system (CNS) disorders"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.depymed.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 500000.0, "totalRaisedFmt": "$500K", "latestFinDate": "2024-03-06", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$500K", "date": "2024-03-06", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Depymed", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors", "Rare / Genetic"]}, {"company": "Dermaliq Therapeutics Inc.", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Infectious"], "modalityGroups": ["Undisclosed"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DLQ01", "phase": "Preclinical", "indication": "Androgenetic alopecia"}, {"name": "DLQ02", "phase": "Preclinical", "indication": "Psoriasis"}, {"name": "DLQ03", "phase": "Preclinical", "indication": "Skin and skin structure infection (SSSI)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://dermaliq.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 15000000.0, "totalRaisedFmt": "$15M", "latestFinDate": "2025-05-28", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2025-05-28", "investors": "Debra Research GmbH"}, {"type": "Series A rounds", "amount": "$15M", "date": "2022-01-18", "investors": "3e Bioventures Capital, Beijing Whale Technology Co. Ltd., Novaliq GmbH"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dermaliq%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Dermatology"]}, {"company": "Dermata Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "DMT410", "phase": "Phase I", "indication": "Excessive sweating"}], "ceo": "Gerry Proehl, MBA", "employees": 8, "founded": 2014, "website": "http://www.dermatarx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -1096377.8, "evFmt": "", "ticker": "DRMA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dermata%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Dermbiont Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "DBI-001", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "DBI-002", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "ruboxistaurin (SM-030)", "phase": "Phase II", "indication": "Dermatology (unspecified)"}, {"name": "SM-020", "phase": "Phase II", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.dermbiont.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dermbiont", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Design Therapeutics Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Musculoskeletal", "Neurology", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "DT-216", "phase": "Phase I/II", "indication": "Friedreich ataxia"}, {"name": "Design Therapeutics-DMPK-unknown", "phase": "Preclinical", "indication": "Myotonic dystrophy type 1 (DM1)"}, {"name": "Design Therapeutics-Fuchs endothelial corneal dystrophy-unknown", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "Pratik Shah, PhD, MBA", "employees": 54, "founded": 2017, "website": "http://www.designtx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 105999666.14, "evFmt": "$106M", "ticker": "DSGN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Design%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Ophthalmology"]}, {"company": "Deuterx LLC", "city": "Andover", "state": "MA", "country": "United States", "diseaseCats": ["Hematology", "Neurology"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DRX-184", "phase": "Preclinical", "indication": "Central nervous system (CNS) disorders"}, {"name": "DRX-194", "phase": "Preclinical", "indication": "Sickle cell disease"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://deuterx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Deuterx", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Hematology (non-cancer)"]}, {"company": "Devacell Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Gene Therapy", "Oncolytic / Microbiome"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DEVA-COVID19", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "DEVA-OV1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "DEVA-OV2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "DEVA-OV3", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "DEVA-OV4", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://devacell.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Devacell", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)"]}, {"company": "Deverra Therapeutics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Infectious"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "DVX201", "phase": "Phase I", "indication": "Hematologic malignancies"}, {"name": "DV401", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "Dilanubicel (NLA101)", "phase": "Phase II", "indication": "Stem cell transplant"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.deverratx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Deverra%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Transplant"]}, {"company": "Dewpoint Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Infectious", "Musculoskeletal", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DPTX3186", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "TDP-43", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "dewpoint-cardiopulmonary-unknown", "phase": "Research", "indication": "Cardiomyopathy"}, {"name": "dewpoint-neuromuscular-unknown", "phase": "Research", "indication": "Myotonic dystrophy type 1 (DM1)"}, {"name": "dewpoint-oncology-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "dewpoint-virology-unknown", "phase": "Research", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://dewpointx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 745000000.0, "totalDealFmt": "$745M", "latestDealDate": "2023-11-07", "recentDeals": [{"headline": "Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline", "date": "2023-11-07", "value": ""}, {"headline": "Dewpoint Therapeutics partners with Novo Nordisk to explore the field of biomolecular condensates to treat insulin resistance and diabetes progression", "date": "2023-03-22", "value": "$745M"}], "totalRaised": 209124298.0, "totalRaisedFmt": "$209M", "latestFinDate": "2025-09-10", "latestFinType": "Series D rounds", "nRounds": 2, "recentFinancing": [{"type": "Series D rounds", "amount": "$59M", "date": "2025-09-10", "investors": "Existing Investors"}, {"type": "Series C rounds", "amount": "$150M", "date": "2022-02-03", "investors": "Softbank Vision Fund, General Catalyst, Mubadala Capital Ventures, 3e Bioventures, Mirae Asset Capital, Ns Investment, L..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dewpoint%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Infectious Disease", "Neurodegeneration / NMD", "Solid Tumors (General)"]}, {"company": "Dfb Pharmaceuticals LLC", "city": "Fort Worth", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Dermatology"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NanoPac ointment (SOR007)", "phase": "Phase II", "indication": "Skin cancer"}], "ceo": "", "employees": 0, "founded": 1990, "website": "http://www.dfb.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dfb%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Dfh Pharma Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DFH-055", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "DFH-10", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 2011, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dfh%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Diakonos Oncology Corp.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "dubodencel (DOC1021)", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.diakonosoncology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Diakonos%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Diakron Pharmaceutical Inc.", "city": "Morris Hills", "state": "NJ", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DP-3005", "phase": "Preclinical", "indication": "Angina"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.diakron.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Diakron%20Pharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Dialectic Therapeutics Inc.", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DT2216", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.dtsciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dialectic%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Diamedica Therapeutics Inc.", "city": "Minneapolis", "state": "MN", "country": "United States", "diseaseCats": ["Genitourinary", "Neurology", "Renal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "rinvecalinase alfa (DM199)", "phase": "Phase II/III", "indication": "Stroke"}], "ceo": "Rick John Pauls, MBA", "employees": 28, "founded": 2000, "website": "http://www.diamedica.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 175590417.83, "evFmt": "$176M", "ticker": "DMAC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Diamedica%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Diamune Therapeutics Inc.", "city": "Beverly", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AKS-107", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "AKS-440", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://diamune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Diamune%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Dianomi Therapeutics Inc.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Dianomi-osteoarthritis-IL1R", "phase": "Preclinical", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://dianomitx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dianomi%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Dianthus Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "DNTH103", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "DNTH200", "phase": "Research", "indication": "Autoimmune (unspecified)"}, {"name": "DNTH300", "phase": "Research", "indication": "Autoimmune (unspecified)"}], "ceo": "Marino Garcia, MBA", "employees": 78, "founded": 2019, "website": "https://dianthustx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 452491908.2, "evFmt": "$452M", "ticker": "DNTH", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 1000000000.0, "totalDealFmt": "$1.0B", "latestDealDate": "2025-10-16", "recentDeals": [{"headline": "Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases", "date": "2025-10-16", "value": "$1.0B"}], "totalRaised": 171987748.72, "totalRaisedFmt": "$172M", "latestFinDate": "2023-09-10", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$72M", "date": "2023-09-10", "investors": "Fidelity Management & Research Co., Catalio Capital Management, 5am Ventures, Avidity Partners, Wedbush, Fairmount Funds..."}, {"type": "Series A rounds", "amount": "$100M", "date": "2022-04-19", "investors": "5am Ventures, Avidity Partners, Fidelity Management and Research Company, Wedbush & Co. LLC, Fairmount Funds Management,..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dianthus%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Diapin Therapeutics Inc.", "city": "Northville", "state": "MI", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Endocrine/Metabolic", "Hepatic", "Neurology"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "DT-678 (ClopNPT)", "phase": "Phase I", "indication": "Myocardial infarction (MI)"}, {"name": "DT-109 (Diapin)", "phase": "Preclinical", "indication": "Primary biliary cholangitis"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://www.diapin.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Diapin%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "GI Cancers"]}, {"company": "Diasome Pharmaceuticals Inc.", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Injected HDV plus basal analogs", "phase": "Phase II", "indication": "Diabetes"}, {"name": "Injected HDV plus human insulin", "phase": "Phase II", "indication": "Diabetes"}, {"name": "Injected HDV plus intermediate acting insulin", "phase": "Phase II", "indication": "Diabetes"}, {"name": "Injected HDV plus rapid acting analogs", "phase": "Phase II", "indication": "Diabetes"}, {"name": "Oral HDV Biotin", "phase": "Phase II", "indication": "Obesity"}, {"name": "Oral HDV Insulin", "phase": "Phase II", "indication": "Diabetes"}, {"name": "Oral HDV plus an undisclosed candidate", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://diasomepharmaceuticals.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Diasome%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Obesity / Metabolic"]}, {"company": "Diavacs Inc.", "city": "Edgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DiaVacs dendritic cell therapy", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.diavacs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Diavacs", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Differentiated Therapeutics Inc. (Dx/tx)", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Differentiated Therapeutics-cancer-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Differentiated Therapeutics-cancer-unknown2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.dxtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Differentiated%20Therapeutics%20Inc.%20(Dx/tx)", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Digestive Care Inc.", "city": "Bethlehem", "state": "PA", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Pertzye", "phase": "Marketed", "indication": "Pancreatic insufficiency"}], "ceo": "", "employees": 0, "founded": 1990, "website": "http://www.digestivecare.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Digestive%20Care", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Digestome Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DGX-001", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://digestometx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Digestome%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "Dignify Therapeutics Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DTI-100", "phase": "Preclinical", "indication": "Incontinence"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.dignifytherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dignify%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Dimension Inx Corp. (Dimension Bio)", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Dimension Inx-liver failure-unknown", "phase": "Preclinical", "indication": "Liver disease"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.dimensioninx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dimension%20Inx%20Corp.%20(Dimension%20Bio)", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Direct Biologics LLC", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Infectious", "Pulmonary"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "AmnioWrap", "phase": "Marketed", "indication": "Wounds"}, {"name": "ExoFlo", "phase": "Phase II", "indication": "Respiratory distress syndrome (RDS)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://directbiologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Direct%20Biologics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Respiratory / Allergy"]}, {"company": "Discgenics Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "rebonuputemcel (IDCT)", "phase": "Phase I/II", "indication": "Cartilage repair"}, {"name": "a-IDCT", "phase": "Preclinical", "indication": "Cartilage repair"}, {"name": "c-IDCT", "phase": "Preclinical", "indication": "Cartilage repair"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.discgenics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Discgenics", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Dispatch Biotherapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DISP-10", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.dispatchbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dispatch%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Diverse Biotech Inc.", "city": "Doylestown", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "DBT-12733", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://diversebiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Diverse%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Dmk Pharmaceuticals Corp.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Genitourinary", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Symjepi (epinephrine pre-filled single dose syringe)", "phase": "Marketed", "indication": "Allergy"}, {"name": "Zimhi (APC-6000)", "phase": "Marketed", "indication": "Substance use disorders"}, {"name": "DPI-125", "phase": "Phase I", "indication": "Pain"}, {"name": "DPI-221", "phase": "Phase I", "indication": "Benign prostatic hyperplasia (BPH)"}], "ceo": "Ebrahim Versi, MD, PhD", "employees": 0, "founded": 2006, "website": "https://www.dmkpharmaceuticals.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "DMK", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dmk%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Specialties", "Pain / Migraine", "Psychiatry / Behavioral", "Respiratory / Allergy"]}, {"company": "Dna Nanobots LLC", "city": "Powell", "state": "OH", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic", "Musculoskeletal"], "modalityGroups": ["Diagnostics", "Gene Therapy", "Vaccine"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NB-HORSE-001", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "NB-VAC-001", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "Dna Nanobots-Duchenne Muscular Dystrophy-unknown", "phase": "Research", "indication": "Muscular dystrophy"}, {"name": "NB-UGEN-001", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "NB-SSH-001", "phase": "Development (diagnostic)", "indication": "Infectious, Diagnostic"}, {"name": "NB-SSH-002", "phase": "Development (diagnostic)", "indication": "Infectious, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://dnananobots.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-06-05", "recentDeals": [{"headline": "DNA Nanobots Gains Exclusive License to UC Berkeley Gene Editing Technology Platform for Non-Viral Gene Delivery Solution using DNA Nanoparticles and CRISPR-Cas", "date": "2024-06-05", "value": ""}], "totalRaised": 3500000.0, "totalRaisedFmt": "$4M", "latestFinDate": "2025-12-17", "latestFinType": "Seed financings", "nRounds": 2, "recentFinancing": [{"type": "Seed financings", "amount": "$4M", "date": "2025-12-17", "investors": "Undisclosed Investor"}, {"type": "Seed financings", "amount": "", "date": "2024-01-24", "investors": "Angel Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dna%20Nanobots", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Infectious Disease", "Neurodegeneration / NMD", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Dnarx Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Infectious", "Inflammation"], "modalityGroups": ["Antibody", "Gene Therapy", "Vaccine"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HEDGES FVIII", "phase": "Preclinical", "indication": "Hemophilia"}, {"name": "HEDGES G-CSF", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "HEDGES H1N1 flu vaccine", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "HEDGES mepolizumab", "phase": "Preclinical", "indication": "Asthma"}, {"name": "HEDGES Rituximab", "phase": "Preclinical", "indication": "Hematology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://dnarx.net", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dnarx", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Infectious Disease", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Dnatrix Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Gene Therapy", "Oncolytic / Microbiome"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "DNX-2401", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "DNX-2440", "phase": "Phase I", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.dnatrix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dnatrix", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Dogwood Therapeutics Inc.", "city": "Alpharetta", "state": "GA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Infectious", "Musculoskeletal", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Halneuron", "phase": "Phase II", "indication": "Pain"}, {"name": "IMC-1", "phase": "Phase II", "indication": "Fibromyalgia syndrome"}, {"name": "IMC-2", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Gregory Duncan, MBA", "employees": 12, "founded": 1987, "website": "https://dwtx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 77702263.12, "evFmt": "$78M", "ticker": "DWTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dogwood%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Musculoskeletal", "Pain / Migraine"]}, {"company": "Dominari Holdings Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AIkido-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "DHA-dFdC", "phase": "Preclinical", "indication": "Pancreatic cancer"}, {"name": "KPC34", "phase": "Preclinical", "indication": "Acute lymphoblastic leukemia (ALL)"}], "ceo": "Anthony C. Hayes", "employees": 29, "founded": 1967, "website": "https://aikidopharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -726063.9932, "evFmt": "", "ticker": "DOMH", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dominari%20Holdings", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Infectious Disease"]}, {"company": "Dormatarg Inc.", "city": "Oklahoma City", "state": "OK", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DT-310", "phase": "Preclinical", "indication": "Bladder cancer"}, {"name": "DT-320", "phase": "Preclinical", "indication": "Bladder cancer"}, {"name": "DT-330", "phase": "Preclinical", "indication": "Bladder cancer"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.dormatarg.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dormatarg", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Dracen Pharmaceuticals Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DRP-367", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://dracenpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dracen%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Dragonfly Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Bispecific Antibody", "Protein / Biologic"], "nProducts": 12, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ABBV-303", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "DF2001", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "DF8001", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "DF2200", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "DF2500", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "DF4001", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "DF5008", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "DF8101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.dragonflytx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dragonfly%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Other Neurology", "Solid Tumors (General)"]}, {"company": "Dren Bio Inc.", "city": "San Carlos", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "DR-0201", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "DR-01", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "DR-02", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.drenbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 4, "totalDealValue": 7725000000.0, "totalDealFmt": "$7.7B", "latestDealDate": "2025-12-15", "recentDeals": [{"headline": "Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy", "date": "2025-12-15", "value": "$1.8B"}, {"headline": "Sanofi to acquire DR-0201, Dren Bio\u2019s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline", "date": "2025-03-20", "value": "$1.9B"}, {"headline": "Dren Bio Announces Strategic Collaboration with Novartis to Develop Novel Targeted Myeloid Engagers for Cancer", "date": "2024-07-24", "value": "$3.0B"}], "totalRaised": 65000000.0, "totalRaisedFmt": "$65M", "latestFinDate": "2022-06-14", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$65M", "date": "2022-06-14", "investors": "Aisling Capital, Hbm Healthcare Investments AG, Pfizer Inc., Arrowmark Partners, Revelation Partners, Sr One, 8Vc, Taiho..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dren%20Bio", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Dual Therapeutics LLC", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DT-1154", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.dualtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dual%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Dualitas Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DTX-101", "phase": "Preclinical", "indication": "Celiac disease"}, {"name": "DTX-102", "phase": "Preclinical", "indication": "Arthritis"}, {"name": "DTX-103", "phase": "Preclinical", "indication": "Asthma"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.dualitastx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dualitas%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Other", "Respiratory / Allergy"]}, {"company": "Duet Therapeutics Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Genitourinary"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Duet-01", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "DUET-02", "phase": "IND", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://duettx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Duet%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer", "Hematologic Cancers"]}, {"company": "Duo Oncology Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "DUO-207", "phase": "Preclinical", "indication": "Biliary cancer"}, {"name": "DUO-209", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "DUO-307", "phase": "Preclinical", "indication": "Lung cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.duooncology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Duo%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Lung Cancer"]}, {"company": "Dynamic Cell Therapies Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Dynamic Cell Therapies-acute myeloid leukemia (AML)-unknown", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.dynamiccelltherapies.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dynamic%20Cell%20Therapies", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Dynamicure Biotechnology LLC", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "DCBY02", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "DCSZ11", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.dynamicure.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dynamicure%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Dynamis Therapeutics Inc.", "city": "Elkins Park", "state": "PA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DYN-15", "phase": "Preclinical", "indication": "Diabetic retinopathy"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.dynamis-therapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dynamis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Dynavax Technologies Corp.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Heplisav-B", "phase": "Marketed", "indication": "Hepatitis B virus (HBV)"}, {"name": "CpG 1018", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Z-1018", "phase": "Phase I/II", "indication": "Varicella zoster virus (VZV)"}, {"name": "DV281", "phase": "Phase I", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "Ryan Spencer", "employees": 405, "founded": 1996, "website": "http://www.dynavax.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1243385880.0, "evFmt": "$1.2B", "ticker": "DVAX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dynavax%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Lung Cancer"]}, {"company": "Dyne Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Other", "RNA Therapeutics"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "DYNE-101", "phase": "Phase I/II", "indication": "Myotonic dystrophy type 1 (DM1)"}, {"name": "z-rostudirsen (DYNE-251)", "phase": "Phase I/II", "indication": "Muscular dystrophy"}, {"name": "Dyne Therapeutics-exon 45 dystrophin (DMD)-unknown", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "Dyne Therapeutics-exon 53 dystrophin (DMD)-unknown", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "DYNE-301", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "John G. Cox, MBA", "employees": 191, "founded": 2018, "website": "http://www.dyne-tx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1599742391.4, "evFmt": "$1.6B", "ticker": "DYN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dyne%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Dynport Vaccine Co. LLC", "city": "Frederick", "state": "MD", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Protein / Biologic", "Vaccine"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Vaccinia Immune Globulin", "phase": "Marketed", "indication": "Viral infection"}, {"name": "Plague vaccine (rF1V)", "phase": "Phase II", "indication": "Yersinia"}, {"name": "RBV A/B", "phase": "Phase II", "indication": "Clostridium"}, {"name": "Tularemia vaccine", "phase": "Phase I/II", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.csc.com/dvc", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dynport%20Vaccine%20Co.", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Dyve Biosciences Inc.", "city": "Thousand Oaks", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Endocrine/Metabolic"], "modalityGroups": ["Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "DYV700", "phase": "Phase II", "indication": "Hyperuricemia/gout"}, {"name": "DYV600", "phase": "Phase I", "indication": "Dermatology (unspecified)"}, {"name": "DYV024", "phase": "Preclinical", "indication": "Psoriasis"}, {"name": "DYV800", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.dyvebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Dyve%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Obesity / Metabolic", "Solid Tumors (General)"]}, {"company": "E-star Biotech LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MANP", "phase": "Phase I", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.e-star.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=E-star%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Eagle Pharmaceuticals Inc.", "city": "Woodcliff Lake", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Gastrointestinal", "Infectious", "Neurology", "Other"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Barhemsys", "phase": "Marketed", "indication": "Emesis"}, {"name": "Belrapzo (bendamustine hydrochloride)", "phase": "Marketed", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "bendamustine rtd (EP-3101)", "phase": "Marketed", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "Bendeka", "phase": "Marketed", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "Pemfexy (pemetrexed RTD", "phase": "Marketed", "indication": "Mesothelioma"}, {"name": "Ready to use argatroban", "phase": "Marketed", "indication": "Thrombosis"}, {"name": "Ryanodex (dantrolene sodium)", "phase": "Marketed", "indication": "Hyperthermia"}, {"name": "RTU bivalirudin (EP-6101", "phase": "Registration", "indication": "Percutaneous coronary intervention (PCI)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.eagleus.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "EGRX", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eagle%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Hematologic Cancers", "Lung Cancer", "Other", "Supportive / Other"]}, {"company": "Eboo Pharmaceuticals Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DPI-289", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "DPI-290", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.eboopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eboo%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "Ecm Therapeutics Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EsophaGel", "phase": "Preclinical", "indication": "Barrett esophagus"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://ecmtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ecm%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Edgewise Therapeutics Inc.", "city": "Boulder", "state": "CO", "country": "United States", "diseaseCats": ["Cardiovascular", "Musculoskeletal", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "sevasemten (EDG-5506)", "phase": "Phase III", "indication": "Muscular dystrophy"}, {"name": "EDG-7500", "phase": "Phase II", "indication": "Cardiomyopathy"}, {"name": "EDG-002", "phase": "Preclinical", "indication": "Cardiomyopathy"}, {"name": "EDG-003", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "EDG-6289", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "Kevin Koch, PhD", "employees": 110, "founded": 2017, "website": "http://www.edgewisetx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2002037514.2, "evFmt": "$2.0B", "ticker": "EWTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Edgewise%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Neurodegeneration / NMD", "Other Neurology"]}, {"company": "Edgewood Oncology Inc.", "city": "Brookline", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "BTX-A51", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.edgewoodoncology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-01-01", "recentDeals": [{"headline": "Edgewood Oncology acquired the rights to BTX-A51 from Yissum", "date": "2023-01-01", "value": ""}], "totalRaised": 20000000.0, "totalRaisedFmt": "$20M", "latestFinDate": "2024-03-25", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$20M", "date": "2024-03-25", "investors": "Alta Partners"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Edgewood%20Oncology", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Edimer Pharmaceuticals Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "DMX-101", "phase": "Phase II", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.edimerpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Edimer%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Edison Oncology Holding Corp.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "EO1001", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "EO3001", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "Orotecan (irinotecan)", "phase": "Phase I", "indication": "Sarcoma"}, {"name": "EO2000", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.edisononcology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Edison%20Oncology%20Holding", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Editas Medicine Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Ophthalmic", "Other"], "modalityGroups": ["Cell Therapy", "Gene Therapy"], "nProducts": 6, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "EDIT-101 (AGN-151587)", "phase": "Phase I/II", "indication": "Blindness"}, {"name": "EDIT-301", "phase": "Phase I/II", "indication": "Sickle cell disease"}, {"name": "EDIT-102", "phase": "Preclinical", "indication": "Usher syndrome"}, {"name": "EDIT-201", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "EDIT-202", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Editas-alpha beta T cells-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Gilmore O\u2019Neill, MD", "employees": 246, "founded": 2013, "website": "http://www.editasmedicine.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -130311460.6, "evFmt": "", "ticker": "EDIT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Editas%20Medicine", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Ophthalmology", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Effector Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "EFT508", "phase": "Phase II", "indication": "B cell lymphoma"}, {"name": "zotatifin (EFT226)", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "elF4E", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Craig R. Jalbert", "employees": 0, "founded": 2012, "website": "http://effector.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "EFTR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Effector%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Egenesis Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Transplant"], "modalityGroups": ["Undisclosed"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HuCo Heart", "phase": "Preclinical", "indication": "Heart transplant"}, {"name": "HuCo Islet cells", "phase": "Preclinical", "indication": "Islet cell transplant"}, {"name": "HuCo Kidney (EGEN-2784)", "phase": "Preclinical", "indication": "Renal transplant"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.egenesisbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 191000000.0, "totalRaisedFmt": "$191M", "latestFinDate": "2024-09-04", "latestFinType": "Series D rounds", "nRounds": 1, "recentFinancing": [{"type": "Series D rounds", "amount": "$191M", "date": "2024-09-04", "investors": "Lux Capital, Arch Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Egenesis", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Kidney Disease", "Transplant"]}, {"company": "Egret Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "EGT-101", "phase": "IND", "indication": "Ischemia/reperfusion injury"}, {"name": "EGT-102", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://egrettherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Egret%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Supportive / Other"]}, {"company": "Eikon Therapeutics Inc.", "city": "Millbrae", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EIK1004", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "EIK1005", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Eikon-AR antagonist-unknown", "phase": "Research", "indication": "Prostate cancer"}, {"name": "Eikon-AR-v7 antagonist-unknown", "phase": "Research", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://eikontx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "EIKN", "exchange": "NASDAQ", "nDeals": 3, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-07-20", "recentDeals": [{"headline": "CLEAVE THERAPEUTICS ANNOUNCES ACQUISITION OF PRE-CLINICAL ASSET BY EIKON THERAPEUTICS", "date": "2023-07-20", "value": ""}, {"headline": "Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors", "date": "2023-06-01", "value": ""}, {"headline": "Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists", "date": "2023-06-01", "value": ""}], "totalRaised": 974500000.0, "totalRaisedFmt": "$974M", "latestFinDate": "2025-02-26", "latestFinType": "Series D rounds", "nRounds": 3, "recentFinancing": [{"type": "Series D rounds", "amount": "$351M", "date": "2025-02-26", "investors": "Existing Investors, New Investors, Lux Capital, Alexandria Venture Investments LLC, Ame Cloud Ventures, The Column Group..."}, {"type": "Series C rounds", "amount": "$106M", "date": "2023-06-01", "investors": "Existing Investors, New Investors"}, {"type": "Series B rounds", "amount": "$518M", "date": "2022-01-06", "investors": "T. Rowe Price Investment Management Inc., Cpp Investment Board (Cppib), Ecor1 Capital, Uc Investments, Abu Dhabi Investm..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eikon%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Eikonizo Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EKZ-102", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.eikonizo.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eikonizo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Eikonoklastes Therapeutics Inc.", "city": "Cincinnati", "state": "OH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Eikonoklastes-TNBC-unknown", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://eikonoklastes.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-01-19", "recentDeals": [{"headline": "Eikonoklastes Bolsters Pipeline, Announces a License for Novel Gene Therapy to Address Neurodegenerative Diseases", "date": "2022-01-19", "value": ""}], "totalRaised": 13555109.0, "totalRaisedFmt": "$14M", "latestFinDate": "2025-07-14", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$14M", "date": "2025-07-14", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eikonoklastes%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer"]}, {"company": "Eilean Therapeutics LLC", "city": "Dover", "state": "DE", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "lonitoclax", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Bala Therapeutics-menin inhibitor-unknown", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "balamenib (ZE63-0302)", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Lomonitinib (ZE46-0134)", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.eileanther.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 2900000.0, "totalDealFmt": "$3M", "latestDealDate": "2024-10-01", "recentDeals": [{"headline": "Eilean Therapeutics Grants Lomond Therapeutics Exclusive Global Rights to Lonitoclax and a Menin Inhibitor for AML and CLL", "date": "2024-10-01", "value": "$3M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eilean%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Eirion Therapeutics Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Other"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ET-01 (ANT-1401)", "phase": "Phase II", "indication": "Scars/wrinkles"}, {"name": "A1-09", "phase": "Phase I/II", "indication": "Scars/wrinkles"}, {"name": "ET-02", "phase": "Preclinical", "indication": "Androgenetic alopecia"}, {"name": "ET-03", "phase": "Preclinical", "indication": "Androgenetic alopecia"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.eirionthera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eirion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Elastrin Therapeutics Inc.", "city": "Simpsonville", "state": "SC", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Elastrin Therapeutics-cardiovascular-unknown", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.elastrin-therapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elastrin%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Electra Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ELA026", "phase": "Phase I", "indication": "Hemophagocytic lymphohistiocytosis"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://electra-therapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Electra%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Eledon Pharmaceuticals Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology", "Renal", "Transplant"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "tegoprubart (AT-1501)", "phase": "Phase II", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "AT-2001", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "David-Alexandre C. Gros, MD, MBA", "employees": 31, "founded": 2004, "website": "https://eledon.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 60776402.44, "evFmt": "$61M", "ticker": "ELDN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eledon%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Neurodegeneration / NMD"]}, {"company": "Eleison Pharmaceuticals LLC", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Inhaled Lipid-complexed Cisplatin (ILC) (Inhaled Lipid Cisplatin (ILC))", "phase": "Phase II", "indication": "Bone cancer"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.eleison-pharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eleison%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Eleos Inc.", "city": "Omaha", "state": "NE", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Aezea", "phase": "Phase I", "indication": "Myelodysplastic syndrome (MDS)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.eleosinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eleos", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Elevian Inc.", "city": "Allston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ELV-001", "phase": "Preclinical", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.elevian.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elevian", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Eli Lilly and Co.", "city": "Indianapolis", "state": "IN", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dermatology", "Diagnostic", "Endocrine/Metabolic", "Gastrointestinal", "Genitourinary", "Hepatic", "Infectious", "Musculoskeletal", "Neurology", "Other", "Otologic"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Cell Therapy", "Combination", "Diagnostics", "Gene Therapy", "Macrocycle", "Peptide", "Protein / Biologic", "RNA Therapeutics", "Small Molecule"], "nProducts": 131, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "177Lu-PNT2002", "phase": "Phase III", "indication": "Prostate cancer"}, {"name": "EliLilly-alpha-synuclein-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "IRAK4/TrkA", "phase": "Preclinical", "indication": "Dermatitis"}, {"name": "MRGPRX2", "phase": "Preclinical", "indication": "Itch"}, {"name": "Abasaglar", "phase": "Marketed", "indication": "Diabetes"}, {"name": "Adcirca", "phase": "Marketed", "indication": "Hypertension"}, {"name": "Alimta", "phase": "Marketed", "indication": "Mesothelioma"}, {"name": "Amyvid", "phase": "Marketed", "indication": "Neurology, Diagnostic"}], "ceo": "David A. Ricks, MBA", "employees": 0, "founded": 1876, "website": "https://www.lilly.com/", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "LLY", "exchange": "NYSE", "nDeals": 28, "totalDealValue": 17978000000.0, "totalDealFmt": "$18.0B", "latestDealDate": "2026-01-28", "recentDeals": [{"headline": "Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss", "date": "2026-01-28", "value": "$1.1B"}, {"headline": "InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro\u2019s Proximity-Guided Platform", "date": "2026-01-07", "value": "$950M"}, {"headline": "Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment", "date": "2026-01-06", "value": "$1.3B"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eli%20Lilly%20and", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Dermatology", "Diabetes", "GU / Gynecologic Cancers", "Lung Cancer", "Other Neurology"]}, {"company": "Elicio Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Genitourinary", "Infectious", "Pulmonary", "Renal", "Transplant"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule", "Undisclosed", "Vaccine"], "nProducts": 9, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "BB3 (ANG-3777", "phase": "Phase III", "indication": "Renal transplant"}, {"name": "ELI-002", "phase": "Phase I/II", "indication": "Pancreatic cancer"}, {"name": "ANG-3070", "phase": "Phase I", "indication": "Pulmonary fibrosis"}, {"name": "AMP-CAR T Activator", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "AMP-CpG (ELI-004)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ANG-3586", "phase": "Preclinical", "indication": "Renal (unspecified)"}, {"name": "ELI-001", "phase": "Preclinical", "indication": "Head and neck cancer"}, {"name": "ELI-005", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Robert T. Connelly", "employees": 32, "founded": 2011, "website": "https://elicio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 69479279.6, "evFmt": "$69M", "ticker": "ELTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elicio%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Head & Neck Cancer", "Hematologic Cancers", "Infectious Disease", "Kidney Disease", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Elion Oncology Inc.", "city": "Bethesda", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Eniluracil (PCS6422", "phase": "Phase II", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elion%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Elion Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SF001", "phase": "Phase I", "indication": "Fungal infection"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://eliontx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Elios Therapeutics LLC", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TLPLDC (tumor lysate", "phase": "Phase II", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.eliostherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elios%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Elite Pharmaceuticals Inc.", "city": "Northvale", "state": "NJ", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Combination", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Elite Pharmaceuticals (hydromorphone)", "phase": "Marketed", "indication": "Pain"}, {"name": "Lodrane 24", "phase": "Marketed", "indication": "Allergy"}, {"name": "methadone", "phase": "Approved", "indication": "Pain"}, {"name": "SequestOx", "phase": "Registration", "indication": "Pain"}, {"name": "ELI-202", "phase": "Pivotal", "indication": "Pain"}, {"name": "oxycodone/naltrexone (ELI-201)", "phase": "Pivotal", "indication": "Pain"}], "ceo": "Nasrat A. Hakim", "employees": 68, "founded": 1990, "website": "http://www.elitepharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 464305813.08, "evFmt": "$464M", "ticker": "ELTP", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elite%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Respiratory / Allergy"]}, {"company": "Elixir Medical Corp.", "city": "Sunnyvale", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Digital / Device"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System", "phase": "Marketed", "indication": "Cardiovascular (unspecified)"}, {"name": "DESyne BD Novolimus Eluting Coronary Stent System", "phase": "Marketed", "indication": "Coronary artery disease (CAD)"}, {"name": "DESyne Drug Eluting Coronary Stent System", "phase": "Marketed", "indication": "Coronary artery disease (CAD)"}, {"name": "desolve myolimus eluting bioresorbable coronary scaffold system", "phase": "Pilot", "indication": "Coronary artery disease (CAD)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.elixirmedical.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elixir%20Medical", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Elixirgen Therapeutics Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Infectious", "Musculoskeletal", "Other"], "modalityGroups": ["Cell Therapy", "RNA Therapeutics", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "EXG34217", "phase": "Phase I/II", "indication": "Musculoskeletal (unspecified)"}, {"name": "EXG-5003", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Elixirgen Therapeutics-Down Syndrome-Unknown", "phase": "Research", "indication": "Genetic disorders"}, {"name": "Elixirgen Therapeutics-Edwards Syndrome-Unknown", "phase": "Research", "indication": "Genetic disorders"}, {"name": "Elixirgen Therapeutics-Patau Syndrome-Unknown", "phase": "Research", "indication": "Genetic disorders"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://elixirgentherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-03-07", "recentDeals": [{"headline": "Elixirgen Therapeutics partners with Taisho Pharmaceutical on therapeutics for aging-associated diseases", "date": "2022-03-07", "value": ""}], "totalRaised": 6999988.0, "totalRaisedFmt": "$7M", "latestFinDate": "2023-11-09", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$7M", "date": "2023-11-09", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elixirgen%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease", "Musculoskeletal", "Rare / Genetic"]}, {"company": "Ellodi Pharmaceuticals", "city": "Lawrenceville", "state": "NJ", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "APT-1011", "phase": "Phase III", "indication": "Eosinophilic esophagitis"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.ellodipharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ellodi%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Elorac Inc.", "city": "Vernon Hills", "state": "IL", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "naloxone (E-1415)", "phase": "Phase III", "indication": "Itch"}, {"name": "E-10215", "phase": "Phase I", "indication": "Acne"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.eloracpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elorac", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Eloxx Pharmaceuticals Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Endocrine/Metabolic", "Gastrointestinal", "Musculoskeletal", "Neurology", "Ophthalmic", "Other", "Pulmonary", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ELX-02", "phase": "Phase II", "indication": "Alport syndrome"}, {"name": "ZKN-013", "phase": "Phase I", "indication": "Epidermolysis bullosa"}], "ceo": "Sumit Aggarwal, MBA", "employees": 0, "founded": 2013, "website": "http://www.eloxxpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "ELOX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eloxx%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Kidney Disease"]}, {"company": "Elpis Biopharmaceuticals Corp.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "EPC-001", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "EPIM-001", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.elpisbiopharmaceuticals.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elpis%20Biopharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Elucida Oncology Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ELU001", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "ELU002", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.elucidaoncology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elucida%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Solid Tumors (General)"]}, {"company": "Elusys Holdings Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Anthim", "phase": "Marketed", "indication": "Anthrax"}], "ceo": "", "employees": 0, "founded": 2023, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Elusys%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Emalex Biosciences Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Ecopipam", "phase": "Phase II", "indication": "Speech disorder"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://emalexbiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Emalex%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Ember Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Opgenra (BMP-7", "phase": "Phase II", "indication": "Osteoarthritis"}, {"name": "Vavelta (ICX-RHY)", "phase": "Marketed", "indication": "Scars/wrinkles"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.embertx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ember%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Musculoskeletal"]}, {"company": "Embera Neurotherapeutics Inc.", "city": "Sudbury", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Combination"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "metyrapone/oxazepam (EMB-001)", "phase": "Phase II", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.emberaneuro.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Embera%20Neurotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Emergent Biosolutions Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Infectious", "Neurology", "Other"], "modalityGroups": ["Antibody", "Digital / Device", "Other", "Protein / Biologic", "Vaccine"], "nProducts": 19, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "ACAM2000", "phase": "Marketed", "indication": "Smallpox"}, {"name": "Anthrasil", "phase": "Marketed", "indication": "Anthrax"}, {"name": "BioThrax (Anthrax Vaccine Adsorbed (AVA))", "phase": "Marketed", "indication": "Anthrax"}, {"name": "Botulism antitoxin heptavalent (BAT)", "phase": "Marketed", "indication": "Clostridium"}, {"name": "raxibacumab (abthrax)", "phase": "Marketed", "indication": "Anthrax"}, {"name": "Vaccinia Immune Globulin Intravenous (VIGIV) (vaccinia hyperimmune globulin (vig)", "phase": "Marketed", "indication": "Viral infection"}, {"name": "Cyfendus", "phase": "Approved", "indication": "Anthrax"}, {"name": "Trobigard", "phase": "Registration", "indication": "Poisoning"}], "ceo": "Joseph C. Papa, MBA", "employees": 900, "founded": 2006, "website": "http://www.emergentbiosolutions.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1077180000.0, "evFmt": "$1.1B", "ticker": "EBS", "exchange": "NYSE", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-03-12", "recentDeals": [{"headline": "Emergent Biosolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates", "date": "2025-03-12", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Emergent%20Biosolutions", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Supportive / Other"]}, {"company": "Emiliem Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EM 101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.emiliem.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Emiliem", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Emmaus Life Sciences Inc.", "city": "Torrance", "state": "CA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Endari", "phase": "Marketed", "indication": "Short bowel syndrome"}], "ceo": "Willis C. Lee", "employees": 35, "founded": 2000, "website": "http://www.emmausmedical.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 32273495.7065, "evFmt": "$32M", "ticker": "EMMA", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Emmaus%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Emmune Inc.", "city": "Palm Beach", "state": "FL", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody", "Gene Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AAV-eCD4-Ig", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "eCD4-Ig", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://emmune.bio", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Emmune", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Empirico Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "EMP-012", "phase": "Phase I", "indication": "Chronic obstructive pulmonary disease (COPD)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.empiri.co/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 745000000.0, "totalDealFmt": "$745M", "latestDealDate": "2025-10-28", "recentDeals": [{"headline": "GSK and Empirico Enter License Agreement for Clinical-Stage, First-in-Class Oligonucleotide Candidate to Treat Respiratory Diseases", "date": "2025-10-28", "value": "$745M"}], "totalRaised": 45222197.0, "totalRaisedFmt": "$45M", "latestFinDate": "2023-03-09", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$45M", "date": "2023-03-09", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Empirico", "hasDealsFin": true, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Empyrean Neuroscience Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PsiD+", "phase": "Preclinical", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://empyrean.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Empyrean%20Neuroscience", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Emris Pharma Ltd.", "city": "Nazareth", "state": "IL", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SDT-011", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://ngt-healthcare2.com/emris-pharma/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Emris%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Enalare Therapeutics Inc.", "city": "Naples", "state": "FL", "country": "United States", "diseaseCats": ["Cardiovascular", "Infectious", "Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ENA-001", "phase": "Phase II", "indication": "Depression"}, {"name": "ENA-001 IM", "phase": "Preclinical", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://enalare.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 12500000.0, "totalRaisedFmt": "$12M", "latestFinDate": "2022-08-09", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$12M", "date": "2022-08-09", "investors": "Eagle Pharmaceuticals Inc."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enalare%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Enanta Pharmaceuticals Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Hepatic", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Maviret", "phase": "Marketed", "indication": "Hepatitis C virus (HCV)"}, {"name": "EDP-305", "phase": "Phase II", "indication": "Primary biliary cholangitis"}, {"name": "zelicapavir (EDP-938)", "phase": "Phase II", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "EDP-235", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "EDP-297", "phase": "Phase I", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "EDP-514", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "EDP-323", "phase": "Preclinical", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "Enanta Pharmaceuticals-hMPV-unknown", "phase": "Preclinical", "indication": "Viral infection"}], "ceo": "Jay R. Luly, PhD", "employees": 120, "founded": 1998, "website": "http://www.enanta.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 267583920.0, "evFmt": "$268M", "ticker": "ENTA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enanta%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Infectious Disease", "Liver Disease", "Obesity / Metabolic", "Respiratory / Allergy"]}, {"company": "Enb Therapeutics", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ENB-001", "phase": "Preclinical", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://enbpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enb%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Encoded Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "ETX101", "phase": "Phase I/II", "indication": "Dravet syndrome"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://encoded.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Encoded%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures"]}, {"company": "Encore Dermatology Inc.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "BenzEFoam", "phase": "Marketed", "indication": "Acne"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://encorederm.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Encore%20Dermatology", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Endacea Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Renal"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "L-97-1", "phase": "Preclinical", "indication": "Sepsis"}, {"name": "Mutant plasmid cDNA", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 1996, "website": "http://www.endacea.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Endacea", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)", "Supportive / Other"]}, {"company": "Endeavor Biomedicines Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "taladegib (ENV-101)", "phase": "Phase II", "indication": "Cancer (unspecified)"}, {"name": "ENV-201", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.endeavorbiomedicines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 430000000.0, "totalDealFmt": "$430M", "latestDealDate": "2023-10-19", "recentDeals": [{"headline": "Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)", "date": "2023-10-19", "value": "$430M"}], "totalRaised": 233500000.0, "totalRaisedFmt": "$234M", "latestFinDate": "2024-04-24", "latestFinType": "Series C rounds", "nRounds": 2, "recentFinancing": [{"type": "Series C rounds", "amount": "$132M", "date": "2024-04-24", "investors": "Matrix Capital Management, Fidelity Management & Research Co., Invus, Symbiosis, Velosity Capital, Woodline Partners L.P..."}, {"type": "Series B rounds", "amount": "$101M", "date": "2022-02-07", "investors": "Ally Bridge Group, Avidity Partners, Perceptive Advisors, Piper Heartland Healthcare Capital, Revelation Partners, Tekla..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Endeavor%20Biomedicines", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Endece LLC", "city": "Mequon", "state": "WI", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NDC-1308", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.endece.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Endece", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Endevica Bio Inc.", "city": "Northbrook", "state": "IL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TCMCB07", "phase": "Preclinical", "indication": "Cachexia"}], "ceo": "", "employees": 0, "founded": 2009, "website": "https://endevicabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 10000000.0, "totalRaisedFmt": "$10M", "latestFinDate": "2023-01-19", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$10M", "date": "2023-01-19", "investors": "Existing Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Endevica%20Bio", "hasDealsFin": true, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Endologic LLC", "city": "Clifton", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Gastrointestinal", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "renzapride (ATL-1251)", "phase": "Phase II", "indication": "Gastroparesis"}], "ceo": "", "employees": 0, "founded": 1992, "website": "https://www.endologicusa.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Endologic", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Endotarget Inc.", "city": "New Orleans", "state": "LA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ENT-1402", "phase": "Preclinical", "indication": "Lymphoma"}, {"name": "ENT-1454", "phase": "Preclinical", "indication": "B cell lymphoma"}, {"name": "ENT-601", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://endotarget.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Endotarget", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers"]}, {"company": "Enfuego Therapeutics Inc.", "city": "Chapel Hill", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DEFTX-001", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enfuego%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Engrail Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ENX-102", "phase": "Phase II", "indication": "Anxiety"}, {"name": "ENX-101", "phase": "Phase I", "indication": "Epilepsy"}, {"name": "elesclomol (ENX-103)", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "ENX-104", "phase": "Preclinical", "indication": "Depression"}, {"name": "ENX-105", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "ENX-106", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://engrail.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Engrail%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other Neurology", "Psychiatry / Behavioral", "Rare / Genetic"]}, {"company": "Enliven Therapeutics Inc.", "city": "Boulder", "state": "CO", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Hematology", "Renal"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "IMR-261 (CXA-10)", "phase": "Phase II", "indication": "Hypertension"}, {"name": "ELVN-001", "phase": "Phase I", "indication": "Chronic myelogenous leukemia (CML)"}, {"name": "ELVN-002", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "Richard A. Fair, MBA", "employees": 62, "founded": 2019, "website": "https://www.enliventherapeutics.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 745637970.0, "evFmt": "$746M", "ticker": "ELVN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enliven%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Hematologic Cancers", "Lung Cancer"]}, {"company": "Ennaid Therapeutics LLC", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ENU200", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://ennaidtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ennaid%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Enosi Life Sciences Corp.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EN1001", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "EN2001", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://enosi-life.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enosi%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Ensem Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ETX-636", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "BG-68501 (ETX-197)", "phase": "Phase I", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "http://www.ensemtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 1330000000.0, "totalDealFmt": "$1.3B", "latestDealDate": "2023-11-21", "recentDeals": [{"headline": "BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor", "date": "2023-11-21", "value": "$1.3B"}], "totalRaised": 67000000.0, "totalRaisedFmt": "$67M", "latestFinDate": "2023-10-22", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "", "date": "2023-10-22", "investors": "Legend Star, Boquan Equity, Megarobo, Undisclosed Investors"}, {"type": "Series A rounds", "amount": "$67M", "date": "2022-04-06", "investors": "Ggv Capital, Pavilion Capital, Cenova Capital, Mitsui Global Investment, Cbc Group"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ensem%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer"]}, {"company": "Ensemble Therapeutics Corp.", "city": "Salem", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Macrocycle"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IL-17A inhibitor Ensemblin (E-036041)", "phase": "Preclinical", "indication": "Arthritis"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://ensembletx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ensemble%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Ensysce Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "hydromorphone (PF329)", "phase": "Phase I", "indication": "Pain"}, {"name": "oxycodone (PF614)", "phase": "Phase I", "indication": "Pain"}], "ceo": "D. Lynn Kirkpatrick, PhD", "employees": 9, "founded": 2008, "website": "http://www.ensysce.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 2135896.04, "evFmt": "$2M", "ticker": "ENSC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ensysce%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Enterin Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "kenterin", "phase": "Phase II", "indication": "Constipation"}, {"name": "ENT-03", "phase": "Phase I", "indication": "Diabetes"}, {"name": "ENT-05", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://enterininc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enterin", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Other Neurology", "Supportive / Other"]}, {"company": "Entero Therapeutics Inc.", "city": "Boca Raton", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Gastrointestinal"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "adrulipase alfa (FW-EPI)", "phase": "Phase II", "indication": "Pancreatic insufficiency"}, {"name": "latiglutenase (IMGX-003", "phase": "Phase II", "indication": "Celiac disease"}, {"name": "niclosamide (FW-1022", "phase": "Phase II", "indication": "Ulcerative colitis"}], "ceo": "Jason D. Sawyer", "employees": 2, "founded": 2014, "website": "https://www.enterothera.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 63794686.948, "evFmt": "$64M", "ticker": "ENTO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Entero%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "IBD / GI Inflammatory"]}, {"company": "Entrada Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ENTR-701", "phase": "Phase I/II", "indication": "Myotonic dystrophy type 1 (DM1)"}], "ceo": "Dipal Doshi, MBA", "employees": 183, "founded": 2016, "website": "https://www.entradatx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 313573792.01, "evFmt": "$314M", "ticker": "TRDA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Entrada%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Entrega Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ENT-100", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.entregabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Entrega", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Enveda Therapeutics Inc. (Enveda Biosciences)", "city": "Boulder", "state": "CO", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ENV-294", "phase": "Phase I", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.envedabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enveda%20Therapeutics%20Inc.%20(Enveda%20Biosciences)", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Enveric Biosciences Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EB-002 (EB-373)", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "EVM201", "phase": "Research", "indication": "Neurology (unspecified)"}, {"name": "EV102", "phase": "Preclinical", "indication": "Dermatitis"}, {"name": "EVM-101", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "Joseph Tucker, PhD", "employees": 5, "founded": 2017, "website": "https://www.enveric.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 462550.879413, "evFmt": "$463K", "ticker": "ENVB", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-11-12", "recentDeals": [{"headline": "Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002", "date": "2024-11-12", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enveric%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Other Neurology"]}, {"company": "Envisia Therapeutics Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ENV515", "phase": "Phase II", "indication": "Glaucoma"}, {"name": "ENV1105", "phase": "Preclinical", "indication": "Diabetic macular edema (DME)"}, {"name": "ENV1305", "phase": "Preclinical", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.envisiatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Envisia%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Ophthalmology"]}, {"company": "Enzon Pharmaceuticals Inc.", "city": "Cranford", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Cylatron", "phase": "Marketed", "indication": "Melanoma"}], "ceo": "Richard L. Feinstein, CPA", "employees": 0, "founded": 1981, "website": "https://enzon.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7208961.5, "evFmt": "$7M", "ticker": "ENZN", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enzon%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Enzyme by Design Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EbD-1117", "phase": "Preclinical", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "EBD-200", "phase": "Preclinical", "indication": "Acute lymphoblastic leukemia (ALL)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.enzymebydesign.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Enzyme%20by%20Design", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Eom Pharmaceuticals Inc.", "city": "Montvale", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Infectious", "Ophthalmic"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "EOM147 (OHR-102)", "phase": "Phase II", "indication": "Diabetic retinopathy"}, {"name": "EOM613 (OHR/AVR118", "phase": "Phase II", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.eompharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eom%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Diabetes"]}, {"company": "Epibiologics Inc.", "city": "San Mateo", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EPI-326", "phase": "Preclinical", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.epibiologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epibiologics", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer"]}, {"company": "Epibone Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "EB-CMF", "phase": "Phase I/II", "indication": "Bone repair"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://epibone.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epibone", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Epic Sciences Inc.", "city": "San Diego", "state": "", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "AR-V7 test", "phase": "Marketed", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 67000000.0, "totalRaisedFmt": "$67M", "latestFinDate": "2023-04-14", "latestFinType": "Rounds beyond series E", "nRounds": 2, "recentFinancing": [{"type": "Rounds beyond series E", "amount": "$24M", "date": "2023-04-14", "investors": "Deerfield Management, Arsenal Capital Partners, Blue Ox Healthcare Partners, Domain Ventures, Labcorp Venture Fund"}, {"type": "Rounds beyond series E", "amount": "$43M", "date": "2022-06-01", "investors": "Arsenal Capital Partners, Blue Ox Healthcare Partners, Deerfield Management, Laboratory Corp. of America Holdings"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epic%20Sciences", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Epicentrx Inc.", "city": "Mountain View", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Other"], "modalityGroups": ["Oncolytic / Microbiome", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "nibrozetone (RRx-001)", "phase": "Phase III", "indication": "Small cell lung cancer"}, {"name": "AdAPT-001", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.epicentrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epicentrx", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer", "Solid Tumors (General)"]}, {"company": "Epicrispr Biotechnologies Inc. (Epic Bio)", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Musculoskeletal", "Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "EPI-111", "phase": "Preclinical", "indication": "Retinitis"}, {"name": "EPI-141", "phase": "Preclinical", "indication": "Retinitis"}, {"name": "EPI-221", "phase": "Preclinical", "indication": "Hypercholesterolemia"}, {"name": "EPI-241", "phase": "Preclinical", "indication": "Alpha-antitrypsin (AAT) deficiency"}, {"name": "EPI-321", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://epic-bio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 123000000.0, "totalRaisedFmt": "$123M", "latestFinDate": "2025-03-26", "latestFinType": "Series B rounds", "nRounds": 3, "recentFinancing": [{"type": "Series B rounds", "amount": "$68M", "date": "2025-03-26", "investors": "Ally Bridge Group, Solve Fshd Holdings Ltd., New Investors, Existing Investors"}, {"type": "Uncategorized venture rounds", "amount": "", "date": "2023-04-18", "investors": "Solve Fshd Holdings Ltd."}, {"type": "Series A rounds", "amount": "$55M", "date": "2022-07-12", "investors": "Horizons Ventures, Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epicrispr%20Biotechnologies%20Inc.%20(Epic%20Bio)", "hasDealsFin": true, "diseaseGroups": ["Neurodegeneration / NMD", "Obesity / Metabolic", "Ophthalmology", "Rare / Genetic"]}, {"company": "Epicure Therapeutics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EPIC001", "phase": "Preclinical", "indication": "Epilepsy"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://epicuregtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epicure%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures"]}, {"company": "Epidestiny Inc.", "city": "Solon", "state": "OH", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NDec (EPI01", "phase": "Phase II", "indication": "Sickle cell disease"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.epidestiny.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epidestiny", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Epigen Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Hepatic", "Inflammation", "Neurology", "Ophthalmic", "Pulmonary", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EPGN696", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "Epigen Biosciences-PAM II-unknown", "phase": "Preclinical", "indication": "Shock/trauma"}, {"name": "Epigen Biosciences-SIGMA1R-unknown", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.epigenbiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epigen%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Obesity / Metabolic", "Supportive / Other"]}, {"company": "Epigenetix Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "EP31670", "phase": "IND", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.epigenetix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epigenetix", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Epiodyne Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EPD-2520", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://epiodyne.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epiodyne", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Epion Therapeutics Inc.", "city": "Encinitas", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "EpiSmart", "phase": "Phase II", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.epiontx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Epiphany Biosciences Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EPB-415", "phase": "Preclinical", "indication": "Hepatitis C virus (HCV)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.epiphanybio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epiphany%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Epirium Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "EPM-01 (EB 002", "phase": "Phase I", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2008, "website": "https://epirium.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epirium%20Bio", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Epithany Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome", "Vaccine"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "EP-201", "phase": "Phase II", "indication": "Ovarian cancer"}, {"name": "EP-101", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "EP-301", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "EP-202", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "EP-302", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "EP-401", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.epithany.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epithany", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "GU / Gynecologic Cancers"]}, {"company": "Epivario Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MTB-9655", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://epivario.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epivario", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Epivax Inc.", "city": "Providence", "state": "RI", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Infectious"], "modalityGroups": ["Other", "Peptide", "Vaccine"], "nProducts": 8, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "EpiVax-H7N9 Influenza-Unknown", "phase": "Phase I", "indication": "Influenza virus"}, {"name": "EpiVax-H. pylori-unknown", "phase": "Preclinical", "indication": "Gram-negative bacterial infection"}, {"name": "EpiVax-H1N1 Influenza-Unknown", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "EpiVax-Influenza-Unknown", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "EpiVax-Smallpox-Unknown", "phase": "Preclinical", "indication": "Smallpox"}, {"name": "EpiVax-Type 1 Diabetes-Unknown", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "EPV-CoV19", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "TuliVax", "phase": "Preclinical", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.epivax.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epivax", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Infectious Disease"]}, {"company": "Epivax Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EO-PCV-001", "phase": "Preclinical", "indication": "Bladder cancer"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.epivaxonco.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Epivax%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Equillium Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Inflammation"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "BNZ-1", "phase": "Phase II", "indication": "Cutaneous T cell lymphoma (CTCL)"}, {"name": "BNZ-2", "phase": "Preclinical", "indication": "Celiac disease"}, {"name": "EQ302", "phase": "Preclinical", "indication": "Celiac disease"}, {"name": "EQ504", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "Bruce D. Steel, CFA, MBA", "employees": 35, "founded": 2017, "website": "http://equilliumbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 4263586.9962, "evFmt": "$4M", "ticker": "EQ", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Equillium", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "IBD / GI Inflammatory"]}, {"company": "Erasca Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ERAS-007", "phase": "Phase I/II", "indication": "Colorectal cancer"}, {"name": "ERAS-601", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "ERAS-3490", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "Jonathan E. Lim, MD", "employees": 103, "founded": 2018, "website": "http://www.erasca.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 340462969.16, "evFmt": "$340M", "ticker": "ERAS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Erasca", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Erimos Pharmaceutical LLC", "city": "", "state": "", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Terameprocol (intravaginal terameprocol)", "phase": "Phase I/II", "indication": "Cervical cancer"}, {"name": "Oral terameprocol (EM-1421)", "phase": "Phase I", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.erimos.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Erimos%20Pharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GU / Gynecologic Cancers"]}, {"company": "Ernexa Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ERNA-101", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "ERNA-102", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "Sanjeev Luther, MBA", "employees": 6, "founded": 2018, "website": "https://www.ernexatx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 2968218.0, "evFmt": "$3M", "ticker": "ERNA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ernexa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "GU / Gynecologic Cancers"]}, {"company": "Esanex Inc.", "city": "Indianapolis", "state": "IN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SNX-5422", "phase": "Phase II", "indication": "Neuroendocrine tumors"}], "ceo": "", "employees": 0, "founded": 2011, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Esanex", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Escend Pharmaceuticals Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "ES-3000", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "ES-4000", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.escendpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Escend%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers"]}, {"company": "Esperion Therapeutics Inc.", "city": "Ann Arbor", "state": "MI", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Nexletol", "phase": "Marketed", "indication": "Dyslipidemia"}, {"name": "Nexlizet", "phase": "Marketed", "indication": "Dyslipidemia"}, {"name": "Bempedoic Acid/AMG 145", "phase": "Phase II", "indication": "Dyslipidemia"}, {"name": "4WF", "phase": "Preclinical", "indication": "Acute coronary syndrome"}], "ceo": "Sheldon L. Koenig, MBA", "employees": 304, "founded": 2008, "website": "http://www.esperion.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 858251083.2, "evFmt": "$858M", "ticker": "ESPR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Esperion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Obesity / Metabolic"]}, {"company": "Estrella Immunopharma Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "EB103", "phase": "Phase I/II", "indication": "Non-Hodgkin lymphoma (NHL)"}], "ceo": "Cheng Liu, PhD", "employees": 0, "founded": 2022, "website": "https://www.estrellabio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 42901909.6, "evFmt": "$43M", "ticker": "ESLA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Estrella%20Immunopharma", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Ethismos Research Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "amitifadine (EB-1010", "phase": "Phase II/III", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.ethismos.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ethismos%20Research", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Etirarx LLC", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ERX-208", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "ERX-315", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "ERX-342", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "ERX-41", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "TX-542", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.etirarx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Etirarx", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Breast Cancer", "GU / Gynecologic Cancers"]}, {"company": "Eton Pharmaceuticals Inc.", "city": "Deer Park", "state": "IL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Other"], "modalityGroups": ["Other", "Peptide", "Protein / Biologic", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Increlex", "phase": "Marketed", "indication": "Growth hormone deficiency"}, {"name": "Eprontia", "phase": "Approved", "indication": "Migraine"}, {"name": "Zonisamide oral suspension (ET-104)", "phase": "Approved", "indication": "Seizures"}, {"name": "dehydrated alcohol injection (DS-100)", "phase": "Registration", "indication": "Poisoning"}, {"name": "ET-600", "phase": "Registration", "indication": "Endocrine (unspecified)"}, {"name": "levothyroxine oral liquid (ET-103)", "phase": "Registration", "indication": "Endocrine (unspecified)"}], "ceo": "Sean E. Brynjelsen, MBA", "employees": 31, "founded": 2017, "website": "http://etonpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 359979400.0, "evFmt": "$360M", "ticker": "ETON", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eton%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other Specialties", "Pain / Migraine", "Supportive / Other"]}, {"company": "Eumentis Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "EM-113", "phase": "Phase II", "indication": "Autism"}, {"name": "EuMentis Therapeutics-NMDA antagonist-undisclosed", "phase": "Research", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.eumentistx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-03-24", "recentDeals": [{"headline": "Mochida Pharmaceuticals grants EuMentis Therapeutics licensing rights for EM-221, a PDE10A Inhibitor for treatment of tourette syndrome", "date": "2022-03-24", "value": ""}], "totalRaised": 20000000.0, "totalRaisedFmt": "$20M", "latestFinDate": "2023-02-15", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$20M", "date": "2023-02-15", "investors": "Undisclosed Investor"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eumentis%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Psychiatry / Behavioral", "Supportive / Other"]}, {"company": "Eupalinos Inc.", "city": "Nashville", "state": "TN", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GelCad", "phase": "Preclinical", "indication": "Peripheral vascular disease (PVD)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://eupalinosinc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eupalinos", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Evecxia Therapeutics Inc.", "city": "Raleigh", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "EVX-101", "phase": "Phase I", "indication": "Depression"}, {"name": "EVX-301", "phase": "Phase I", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://evecxia.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Evecxia%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Evertree Bio", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Evertree Bio-myelination disorder-unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://www.evertreebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Evertree%20Bio", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Evofem Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Infectious", "Other"], "modalityGroups": ["Combination", "Other", "Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Phexxi", "phase": "Marketed", "indication": "Contraception"}, {"name": "Solosec", "phase": "Marketed", "indication": "Bacterial vaginosis"}, {"name": "Ethinyl estradiol ring", "phase": "Phase III", "indication": "Contraception"}, {"name": "EVO100", "phase": "Phase III", "indication": "Sexually transmitted disease (STD)"}, {"name": "LIPO-202", "phase": "Phase III", "indication": "Body Fat"}, {"name": "LIPO-102", "phase": "Phase II", "indication": "Graves disease"}], "ceo": "Saundra L. Pelletier", "employees": 32, "founded": 2015, "website": "http://www.evofem.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 50752436.5885, "evFmt": "$51M", "ticker": "EVFM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Evofem%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other", "Other Inflammation", "Women's Health"]}, {"company": "Evolus Inc.", "city": "Newport Beach", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Jeuveau", "phase": "Marketed", "indication": "Scars/wrinkles"}], "ceo": "David Moatazedi, MBA", "employees": 332, "founded": 2014, "website": "http://www.evolus.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 727693057.12, "evFmt": "$728M", "ticker": "EOLS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Evolus", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Evolveimmune Therapeutics Inc.", "city": "Branford", "state": "CT", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody", "Cell Therapy", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EVOLVE-104", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "EVOLVE-101", "phase": "Research", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "EVOLVE-105", "phase": "Research", "indication": "B cell lymphoma"}, {"name": "EVOLVE-106", "phase": "Research", "indication": "Solid tumors"}, {"name": "EvolveImmune Therapeutics-T Cell Exhaustion-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.evolveimmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 37000000.0, "totalRaisedFmt": "$37M", "latestFinDate": "2023-12-13", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$37M", "date": "2023-12-13", "investors": "Pfizer Ventures, Solasta Ventures, Takeda Ventures, Bristol Myers Squibb Co."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Evolveimmune%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Evommune Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "EVO756", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "Evommune-PKC theta inhibitor-unknown", "phase": "Preclinical", "indication": "Inflammatory disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.evommune.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "EVMN", "exchange": "NYSE", "nDeals": 2, "totalDealValue": 62000000.0, "totalDealFmt": "$62M", "latestDealDate": "2024-06-24", "recentDeals": [{"headline": "Evommune Secures Exclusive Rights to Develop and Commercialize a Phase 2-ready IL-18 targeted fusion protein from AprilBio", "date": "2024-06-24", "value": ""}, {"headline": "Evommune Announces Strategic Collaboration with Maruho to Develop and Commercialize MRGPRX2 antagonist EVO756 in Japan", "date": "2023-09-27", "value": "$62M"}], "totalRaised": 172500000.0, "totalRaisedFmt": "$172M", "latestFinDate": "2024-10-31", "latestFinType": "Series C rounds", "nRounds": 3, "recentFinancing": [{"type": "Series C rounds", "amount": "$115M", "date": "2024-10-31", "investors": "Ra Capital Management L.P., Sectoral Asset Management Inc., B Capital Group, Marshall Wace, Avego Bioscience Capital, Lo..."}, {"type": "Series B rounds", "amount": "$8M", "date": "2023-06-28", "investors": "Verition Fund Management"}, {"type": "Series B rounds", "amount": "$50M", "date": "2023-04-26", "investors": "Arix Bioscience plc, Eqt Life Sciences, Symbiosis, Amplitude Ventures, Pivotal Bioventure Partners, Andera Partners"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Evommune", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology"]}, {"company": "Evoq Therapeutics Inc.", "city": "Ann Arbor", "state": "MI", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NanoDisc Vaccine", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.evoqtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Evoq%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Evrys Bio LLC", "city": "Doylestown", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EV-100", "phase": "Preclinical", "indication": "Cytomegalovirus (CMV)"}, {"name": "EV-200", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "EV-300", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://evrysbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Evrys%20Bio", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Exacis Biotherapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ExaCAR-NK", "phase": "Preclinical", "indication": "Leukemia"}, {"name": "ExaCAR-T", "phase": "Preclinical", "indication": "Leukemia"}, {"name": "ExaNK", "phase": "Preclinical", "indication": "Leukemia"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.exacis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exacis%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Exact Sciences Corp.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Diagnostics", "Other"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Cologuard (Stool DNA colorectal cancer screening assay)", "phase": "Marketed", "indication": "Cancer, Diagnostic"}, {"name": "Oncotype DX breast cancer assay", "phase": "Marketed", "indication": "Breast cancer"}, {"name": "HCC blood test", "phase": "Phase II", "indication": "Cancer, Diagnostic"}], "ceo": "Kevin T. Conroy", "employees": 7000, "founded": 1995, "website": "http://www.exactsciences.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 12087761430.0, "evFmt": "$12.1B", "ticker": "EXAS", "exchange": "NASDAQ", "nDeals": 4, "totalDealValue": 930000000.0, "totalDealFmt": "$930M", "latestDealDate": "2025-08-06", "recentDeals": [{"headline": "Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests", "date": "2025-08-06", "value": "$885M"}, {"headline": "Exact Sciences entered into an exclusive agreement with TwinStrand Biosciences for TwinStrand Duplex Sequencing error-correction technology", "date": "2024-07-01", "value": "$45M"}, {"headline": "Watchmaker Genomics Announces Co-Exclusive License to Disruptive DNA Methylation Technology and Strategic Supply Agreements with Exact Sciences", "date": "2023-08-30", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exact%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Solid Tumors (General)"]}, {"company": "Exavir Therapeutics Inc.", "city": "Omaha", "state": "NE", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Gene Therapy", "Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Exavir-HIV reverse transcriptase-unknown1", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "exavir-opioid use disorder-unknown", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "XVIR-110 (NM2CAB)", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "XVIR-210 (NM1TFV)", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "XVIR-TAT", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://exavirtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-05-22", "recentDeals": [{"headline": "Exavir Therapeutics Announces Entry Into a Litigation Settlement and License Agreement For Ultra-Long-Acting HIV Compounds With ViiV Healthcare", "date": "2024-05-22", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2022-05-23", "latestFinType": "Seed financings", "nRounds": 1, "recentFinancing": [{"type": "Seed financings", "amount": "", "date": "2022-05-23", "investors": "Alleycorp, Gilead Sciences Inc."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exavir%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Psychiatry / Behavioral"]}, {"company": "Excelimmune Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Staphgard (hrpa against mrsa)", "phase": "Preclinical", "indication": "Staphylococcus"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.excelimmune.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Excelimmune", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Excell Biotech LLC", "city": "Clearwater", "state": "FL", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EXD-12", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.excellbio.io/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Excell%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Excision Biotherapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Gene Therapy", "Protein / Biologic", "RNA Therapeutics"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "EBT-101", "phase": "Phase I/II", "indication": "HIV/AIDS"}, {"name": "EBT-103", "phase": "Preclinical", "indication": "Viral infection"}, {"name": "EBT-104", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}, {"name": "EBT-107", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.excision.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Excision%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Excitant Therapeutics LLC", "city": "Oklahoma City", "state": "OK", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EXT-4U", "phase": "Preclinical", "indication": "Diabetic retinopathy"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.excithera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Excitant%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Exegenesis Bio Inc.", "city": "Lansdale", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hematology", "Neurology", "Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "EXG001-307", "phase": "Phase I", "indication": "Spinal muscular atrophy (SMA)"}, {"name": "EXG102-031", "phase": "Phase I", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "Exegenesis Bio-Hemophilia A-unknown", "phase": "Preclinical", "indication": "Hemophilia"}, {"name": "Exegenesis Bio-Phenylketonuria-unknown", "phase": "Preclinical", "indication": "Phenylketonuria"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.exegenesisbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exegenesis%20Bio", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Neurodegeneration / NMD", "Ophthalmology", "Rare / Genetic"]}, {"company": "Exegi Pharma LLC", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "EXE-346", "phase": "Phase I", "indication": "Gastrointestinal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.exegipharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exegi%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Exela Holdings Inc.", "city": "Lenoir", "state": "NC", "country": "United States", "diseaseCats": ["Cardiovascular", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Akovaz ephedrine sulphate", "phase": "Marketed", "indication": "Hypotension"}, {"name": "Bloxiverz", "phase": "Marketed", "indication": "Anesthesia"}, {"name": "Vazculep", "phase": "Marketed", "indication": "Hypotension"}], "ceo": "", "employees": 0, "founded": 2005, "website": "https://www.exelapharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exela%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Supportive / Other"]}, {"company": "Exelixis Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Hematology", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Cotellic", "phase": "Marketed", "indication": "Melanoma"}, {"name": "Cabometyx", "phase": "Marketed", "indication": "Renal cancer"}, {"name": "Minnebro", "phase": "Marketed", "indication": "Hypertension"}, {"name": "zanzalintinib (XL092)", "phase": "Phase III", "indication": "Colorectal cancer"}, {"name": "SAR245409", "phase": "Phase II", "indication": "Lymphoma"}, {"name": "SAR245408", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "XL499", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Michael M. Morrissey, PhD", "employees": 1147, "founded": 1994, "website": "http://www.exelixis.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 9164162040.0, "evFmt": "$9.2B", "ticker": "EXEL", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-09-12", "recentDeals": [{"headline": "Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor", "date": "2023-09-12", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exelixis", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "GI Cancers", "GU / Gynecologic Cancers", "Hematologic Cancers", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Exicure Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Dermatology", "Infectious", "Neurology"], "modalityGroups": ["Other", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "cavrotolimod (AST-008)", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "Exicure-dermatology-unknown", "phase": "Preclinical", "indication": "Other alopecia"}, {"name": "Exicure-SCN9A-unknown", "phase": "Preclinical", "indication": "Pain"}], "ceo": "Andy Yoo", "employees": 7, "founded": 2011, "website": "", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 21358610.26, "evFmt": "$21M", "ticker": "XCUR", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-02-05", "recentDeals": [{"headline": "Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis", "date": "2024-02-05", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exicure", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Liver Disease", "Pain / Migraine"]}, {"company": "Exodos Life Science Partners", "city": "Chapel Hill", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ELS-M110", "phase": "Phase II", "indication": "Migraine"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.exodosls.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exodos%20Life%20Science%20Partners", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Expression Therapeutics Inc.", "city": "Tucker", "state": "GA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Cell Therapy"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ET3", "phase": "Phase I", "indication": "Hemophilia"}, {"name": "ET206", "phase": "Preclinical", "indication": "Neuroblastoma"}, {"name": "ET257", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "ET356", "phase": "Preclinical", "indication": "Leukemia"}, {"name": "ET406", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.expressiontherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Expression%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Hematologic Cancers", "Hematology (non-cancer)", "Solid Tumors (General)"]}, {"company": "Extended Delivery Pharmaceuticals LLC", "city": "Darien", "state": "CT", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Supramolecular insulin assembly II (SIA-II) insulin", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.extendeddelivery.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Extended%20Delivery%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Exuma Biotech Corp.", "city": "West Palm Beach", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CCT3-AXL-0038 (CCT301-38)", "phase": "Phase I", "indication": "Sarcoma"}, {"name": "CCT3-HER2-0406", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "GCAR", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "rPOC SC 19/220752/0754", "phase": "Preclinical", "indication": "B cell lymphoma"}, {"name": "rPOC SC-0900", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://exumabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exuma%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Exxel Pharma Inc.", "city": "Aurora", "state": "CO", "country": "United States", "diseaseCats": ["Genitourinary", "Neurology", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "EX597", "phase": "Preclinical", "indication": "Anxiety"}, {"name": "EX937", "phase": "Preclinical", "indication": "Incontinence"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://exxelpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Exxel%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Other Specialties", "Psychiatry / Behavioral"]}, {"company": "Eydisbio Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "EYD-001 (HS-276)", "phase": "Preclinical", "indication": "Scleroderma"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://eydisbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eydisbio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Eyecyte Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Peripheral", "phase": "Preclinical", "indication": "Diabetic retinopathy"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.eyecyte.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eyecyte", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Eyepoint Pharmaceuticals Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Ophthalmic"], "modalityGroups": ["Digital / Device", "Other", "Small Molecule"], "nProducts": 11, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Dexycu (IBI-10090", "phase": "Marketed", "indication": "Cataract"}, {"name": "Iluvien", "phase": "Marketed", "indication": "Diabetic macular edema (DME)"}, {"name": "Retisert", "phase": "Marketed", "indication": "Uveitis"}, {"name": "Yutiq", "phase": "Marketed", "indication": "Uveitis"}, {"name": "Duravyu", "phase": "Phase II", "indication": "Diabetic macular edema (DME)"}, {"name": "IBI-20089", "phase": "Phase II", "indication": "Choroidal neovascularization (CNV)"}, {"name": "Yutiq 50 (OT-401)", "phase": "Phase II", "indication": "Uveitis"}, {"name": "Bioerodible latanprost implant (durasert)", "phase": "Phase I/II", "indication": "Ocular hypertension"}], "ceo": "Jay S. Duker, MD", "employees": 165, "founded": 2000, "website": "http://www.eyepointpharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 71612100.0, "evFmt": "$72M", "ticker": "EYPT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Eyepoint%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "Ophthalmology"]}, {"company": "Ezra Innovations LLC", "city": "Little Rock", "state": "AR", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "EZR-104", "phase": "Registration", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.ezrapharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ezra%20Innovations", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Fabre-kramer Pharmaceuticals Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Genitourinary", "Neurology"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Exxua", "phase": "Approved", "indication": "Depression"}, {"name": "FKB01MD", "phase": "Phase II", "indication": "Depression"}, {"name": "FKF02SC", "phase": "Phase II", "indication": "Schizophrenia"}, {"name": "FKW00GA", "phase": "Phase II", "indication": "Anxiety"}, {"name": "FKK01PD", "phase": "Preclinical", "indication": "Erectile dysfunction (ED)"}], "ceo": "", "employees": 0, "founded": 1992, "website": "http://www.fabrekramer.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fabre-kramer%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Specialties", "Psychiatry / Behavioral"]}, {"company": "Factor Bioscience Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TPST-2003 (ERI-2003)", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "TPST-2206 (ERI-2206)", "phase": "Preclinical", "indication": "Renal cancer"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.factorbio.com/index.html", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Factor%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers"]}, {"company": "Faeth Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "FTH01", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "FTH02", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "FTH04", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "FTH05", "phase": "Preclinical", "indication": "Lung cancer"}, {"name": "FTH06", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.faeththerapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Faeth%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Lung Cancer"]}, {"company": "Faknostics Biologics LLC", "city": "Phoenix", "state": "AZ", "country": "United States", "diseaseCats": ["Cancer", "Hepatic"], "modalityGroups": ["Peptide"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Faknostics-liver fibrosis-unknown", "phase": "Preclinical", "indication": "Liver fibrosis"}, {"name": "Faknostics-NRAS melanoma-unknown", "phase": "Preclinical", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.faknostics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Faknostics%20Biologics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Skin Cancer / Melanoma"]}, {"company": "Faraday Pharmaceuticals Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cardiovascular", "Musculoskeletal"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "FDY-5301", "phase": "Phase III", "indication": "Myocardial infarction (MI)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://faradaypharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Faraday%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Fasgen Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Infectious"], "modalityGroups": ["Other"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "FAS 115", "phase": "Preclinical", "indication": "Obesity"}, {"name": "FAS 20013", "phase": "Preclinical", "indication": "Tuberculosis"}, {"name": "FAS 267", "phase": "Preclinical", "indication": "Obesity"}, {"name": "FAS 89B", "phase": "Preclinical", "indication": "Obesity"}, {"name": "FAS31", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.fasgen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fasgen", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Infectious Disease", "Obesity / Metabolic"]}, {"company": "Fate Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "FT522", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "FT819", "phase": "Phase I", "indication": "Lupus"}, {"name": "FT825", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "Fate Therapeutics-solid tumors-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "FT836", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Bahram Valamehr, PhD, MBA", "employees": 181, "founded": 2007, "website": "http://www.fatetherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -6219457.95, "evFmt": "", "ticker": "FATE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fate%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Felicitex Therapeutics Inc.", "city": "Natick", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "FX-1610", "phase": "Preclinical", "indication": "Leukemia"}, {"name": "FX-7742", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "FX-8474", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "FX-9847", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.felicitex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Felicitex%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Hematologic Cancers", "Lung Cancer"]}, {"company": "Femmepharma Inc.", "city": "Wayne", "state": "PA", "country": "United States", "diseaseCats": ["Genitourinary", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "danazol (FP1198)", "phase": "Phase II", "indication": "Pain"}, {"name": "FP 1097", "phase": "Phase II", "indication": "Incontinence"}, {"name": "FP1199", "phase": "Phase II", "indication": "Endometriosis"}], "ceo": "", "employees": 0, "founded": 1996, "website": "https://fpghc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Femmepharma", "hasDealsFin": false, "diseaseGroups": ["Other Specialties", "Pain / Migraine", "Women's Health"]}, {"company": "Femta Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Femta Pharmaceuticals (FM101)", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.femtapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Femta%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Fennec Pharmaceuticals Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Otologic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Pedmark", "phase": "Marketed", "indication": "Hearing loss"}], "ceo": "Jeffrey S Hackman", "employees": 32, "founded": 1996, "website": "http://fennecpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 158535312.891114, "evFmt": "$159M", "ticker": "FENC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fennec%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Ferndale Pharma Group Inc.", "city": "Ferndale", "state": "MI", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Eletone (eletone cream)", "phase": "Marketed", "indication": "Dermatosis"}, {"name": "Locoid", "phase": "Marketed", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 1897, "website": "http://www.ferndalepharmagroup.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ferndale%20Pharma%20Group", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Other"]}, {"company": "Ferrumax Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "FMX-8", "phase": "Phase II", "indication": "Anemia"}], "ceo": "", "employees": 0, "founded": 2008, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ferrumax%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Fervent Pharmaceuticals LLC", "city": "Greenville", "state": "NC", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "FP-101", "phase": "Phase II", "indication": "Menopause"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://ferventpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fervent%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Women's Health"]}, {"company": "Fibrex Medical Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Pulmonary", "Transplant"], "modalityGroups": ["Other", "Peptide"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "FX06MRI", "phase": "Phase II", "indication": "Ischemia/reperfusion injury"}, {"name": "FX201", "phase": "Preclinical", "indication": "Acute lung injury"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.fibrexmedical.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fibrex%20Medical", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy", "Supportive / Other"]}, {"company": "Fibrogen Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Hematology", "Ophthalmic"], "modalityGroups": ["Digital / Device", "Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Evrenzo", "phase": "Marketed", "indication": "Anemia"}, {"name": "FG-2216", "phase": "Phase II", "indication": "Anemia"}, {"name": "FG-5200", "phase": "Pilot", "indication": "Corneal transplant"}, {"name": "Recombinant Human Collagen Based Biosynthetic Cornea (EB-301)", "phase": "Preclinical", "indication": "Blindness"}], "ceo": "Thane Wettig, MBA", "employees": 225, "founded": 1994, "website": "http://www.fibrogen.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 134666298.0, "evFmt": "$135M", "ticker": "FGEN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fibrogen", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Ophthalmology"]}, {"company": "Fibrogenesis", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Infectious", "Musculoskeletal"], "modalityGroups": ["Cell Therapy", "Other", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CybroCell", "phase": "Phase I/II", "indication": "Cartilage repair"}, {"name": "FibroMune", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "PneumoBlast", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "https://www.fibro-genesis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fibrogenesis", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Musculoskeletal"]}, {"company": "Filtricine Inc.", "city": "Santa Clara", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Tality", "phase": "Phase I", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://filtricine.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Filtricine", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Fimbrion Therapeutics Inc.", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GSK3882347", "phase": "Phase I", "indication": "Urinary tract infection (UTI)"}, {"name": "FIM-4269", "phase": "Preclinical", "indication": "Urinary tract infection (UTI)"}, {"name": "FIM-5240", "phase": "Preclinical", "indication": "Urinary tract infection (UTI)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.fimbrion.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fimbrion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Finch Therapeutics Group Inc.", "city": "Somerville", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CP101", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "FIN-524", "phase": "Preclinical", "indication": "Ulcerative colitis"}, {"name": "FIN-525", "phase": "Preclinical", "indication": "Crohn's disease"}], "ceo": "Matthew P. Blischak", "employees": 1, "founded": 2014, "website": "http://finchtherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 35674121.9, "evFmt": "$36M", "ticker": "FNCH", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Finch%20Therapeutics%20Group", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Liver Disease"]}, {"company": "Fiplate Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Fibrinoplate", "phase": "Phase III", "indication": "Bleeding"}, {"name": "Fibrinoplate-S", "phase": "Preclinical", "indication": "Bleeding"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://fiplate.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fiplate", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Flag Therapeutics Inc.", "city": "Raleigh", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "FLAG-003", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.flagtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Flag%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Flare Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "FX-909", "phase": "Phase I", "indication": "Bladder cancer"}, {"name": "Flare Therapeutics-program 2-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Flare Therapeutics-program 3-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.flaretx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-11-12", "recentDeals": [{"headline": "Flare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in Oncology", "date": "2024-11-12", "value": ""}], "totalRaised": 123000000.0, "totalRaisedFmt": "$123M", "latestFinDate": "2023-03-22", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$123M", "date": "2023-03-22", "investors": "Gordonmd Global Investments L.P., Pfizer Venture Investments, Boxer Capital, Casdin Capital LLC, Eventide Asset Manageme..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Flare%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Flatley Discovery Lab LLC", "city": "Charlestown", "state": "MA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "FDL169", "phase": "Phase II", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.flatleydiscoverylab.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Flatley%20Discovery%20Lab", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Flex Biomedical Inc.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Flex polymer", "phase": "Preclinical", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.flexbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Flex%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Flightpath Biosciences Inc.", "city": "Detroit", "state": "MI", "country": "United States", "diseaseCats": ["Cancer", "Dental", "Diagnostic", "Infectious"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "hygromycin A (FP-100)", "phase": "Phase I", "indication": "Lyme disease"}, {"name": "formibactin A (FP530)", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "FP-101", "phase": "Preclinical", "indication": "Lyme disease"}, {"name": "lolamicin (FP380)", "phase": "Preclinical", "indication": "Urinary tract infection (UTI)"}, {"name": "Microbiome Signature", "phase": "Preclinical", "indication": "Infectious, Diagnostic"}, {"name": "Microbiome Consortia", "phase": "Research", "indication": "Lyme disease"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://flightpath.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-11-13", "recentDeals": [{"headline": "Flightpath Biosciences Licenses New Drug from Northeastern University to Advance Precision Antibiotics", "date": "2025-11-13", "value": ""}, {"headline": "Flightpath Biosciences Licenses Microbiome-Sparing Antibiotic Developed at the University of Illinois Urbana-Champaign", "date": "2025-07-09", "value": ""}], "totalRaised": 1100000.0, "totalRaisedFmt": "$1M", "latestFinDate": "2023-02-13", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$1M", "date": "2023-02-13", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Flightpath%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["GI Cancers", "Infectious Disease"]}, {"company": "Florida Biotechnologies Inc.", "city": "Sarasota", "state": "FL", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "scAAV2-P1ND4v2", "phase": "Phase I", "indication": "Optic neuropathy"}], "ceo": "", "employees": 0, "founded": 2022, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Florida%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Flow Pharma Inc.", "city": "East Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Peptide", "Vaccine"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "FLOVID-20", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "FlowVax BreastCA", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "FlowVax Ebola", "phase": "Preclinical", "indication": "Ebola"}, {"name": "FlowVax HPV", "phase": "Preclinical", "indication": "Cervical cancer"}, {"name": "FlowVax Marburg", "phase": "Preclinical", "indication": "Marburg"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.flowpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Flow%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Infectious Disease", "Other"]}, {"company": "Flugen Inc.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "M2SR", "phase": "Phase I", "indication": "Influenza virus"}, {"name": "CoroFlu", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.flugen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Flugen", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Focal Medical Inc.", "city": "Cary", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "ACT-IOP-003", "phase": "IND", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://focalmedical.co/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Focal%20Medical", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Foghorn Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "FHD-286", "phase": "Phase I", "indication": "Myelodysplastic syndrome (MDS)"}, {"name": "FHD-909", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "Foghorn-ARID1A mutated cancers-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Foghorn-BRG1 mutated cancers-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Adrian Gottschalk, MBA", "employees": 112, "founded": 2016, "website": "https://foghorntx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 52509319.04, "evFmt": "$53M", "ticker": "FHTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Foghorn%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "For-robin Inc.", "city": "Buffalo", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "JAA-F11", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://for-robin.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=For-robin", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Forkhead Biotherapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Foxin", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.forkheadbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Forkhead%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Forte Biosciences Inc.", "city": "Sherman Oaks", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Transplant"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "FB-102", "phase": "Preclinical", "indication": "Alopecia areata"}], "ceo": "Paul A. Wagner, PhD, CFA", "employees": 14, "founded": 2017, "website": "http://www.fortebiorx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7854952.74, "evFmt": "$8M", "ticker": "FBRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Forte%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Fortis Therapeutics Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "FOR46", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://fortistx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fortis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Fortress Biotech Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Infectious", "Inflammation", "Other"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule", "Undisclosed"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Ceracade", "phase": "Marketed", "indication": "Dermatitis"}, {"name": "Exelderm", "phase": "Marketed", "indication": "Fungal infection"}, {"name": "Ximino", "phase": "Marketed", "indication": "Acne"}, {"name": "Zycubo (CUTX-101", "phase": "Approved", "indication": "Genetic disorders"}, {"name": "CEVA101", "phase": "Phase II", "indication": "Shock/trauma"}, {"name": "CNDO-109", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "CEVA102", "phase": "Preclinical", "indication": "Shock/trauma"}, {"name": "Fortress-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Lindsay Allan Rosenwald, MD", "employees": 101, "founded": 2006, "website": "http://www.fortressbiotech.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 36407276.35, "evFmt": "$36M", "ticker": "FBIO", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-07-15", "recentDeals": [{"headline": "Urica enters into an asset purchase agreement, royalty agreement, and related agreements with Crystalys Therapeutics, Inc.", "date": "2024-07-15", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fortress%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Hematologic Cancers", "Infectious Disease", "Rare / Genetic", "Supportive / Other"]}, {"company": "Foundation Consumer Healthcare LLC", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Plan B One-Step", "phase": "Marketed", "indication": "Contraception"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://foundationch.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Foundation%20Consumer%20Healthcare", "hasDealsFin": false, "diseaseGroups": ["Women's Health"]}, {"company": "Fractyl Health Inc.", "city": "Burlington", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RJVA-001 (GLP-1 PGTx)", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "RJVA-002", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "Harith Rajagopalan, MD, PhD", "employees": 107, "founded": 2010, "website": "https://www.fractyl.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 95472229.06, "evFmt": "$95M", "ticker": "GUTS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fractyl%20Health", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Obesity / Metabolic"]}, {"company": "Freedom Biosciences Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "FREE001", "phase": "Phase II", "indication": "Post-traumatic stress disorder"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.freedombio.co/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Freedom%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Freenome Inc.", "city": "South San Francisco", "state": "", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Adx SSc Multilisa", "phase": "Marketed", "indication": "Autoimmune, Diagnostic"}, {"name": "Multilisa BICD2 ELISA", "phase": "Marketed", "indication": "Autoimmune, Diagnostic"}, {"name": "Multilisa CENP-B ELISA", "phase": "Marketed", "indication": "Autoimmune, Diagnostic"}, {"name": "Multilisa Scl-70 ELISA", "phase": "Marketed", "indication": "Autoimmune, Diagnostic"}, {"name": "EarlyCDT-Lung (Nodify CDT)", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "Multilisa RA", "phase": "Pilot", "indication": "Autoimmune, Diagnostic"}, {"name": "Multilisa SLE", "phase": "Pilot", "indication": "Autoimmune, Diagnostic"}, {"name": "Freenome-CRC-multiomics blood test", "phase": "Development (diagnostic)", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 885000000.0, "totalDealFmt": "$885M", "latestDealDate": "2025-08-06", "recentDeals": [{"headline": "Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests", "date": "2025-08-06", "value": "$885M"}], "totalRaised": 544000000.0, "totalRaisedFmt": "$544M", "latestFinDate": "2024-02-15", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$254M", "date": "2024-02-15", "investors": "Roche, Andreessen Horowitz (A16z), American Cancer Society Inc., Ark Investment Management LLC, Arrowmark Partners, Arti..."}, {"type": "Uncategorized venture rounds", "amount": "$290M", "date": "2022-01-11", "investors": "Roche"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Freenome", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "GI Cancers", "Solid Tumors (General)"]}, {"company": "Frontera Therapeutics Inc.", "city": "Bedford", "state": "MA", "country": "United States", "diseaseCats": ["Hematology", "Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "FT-001", "phase": "Phase I", "indication": "Blindness"}, {"name": "FT-002", "phase": "Phase I", "indication": "Retinitis"}, {"name": "FT-003", "phase": "Phase I", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "FT-004", "phase": "Preclinical", "indication": "Hematology (unspecified)"}, {"name": "FT-005", "phase": "Preclinical", "indication": "Hematology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.fronteratherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Frontera%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Ophthalmology"]}, {"company": "Frontier Medicines Corp.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "FMC-376", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://frontiermeds.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Frontier%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Fulcrum Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "pociredir (FTX-6058)", "phase": "Phase I", "indication": "Sickle cell disease"}], "ceo": "Alexander C. Sapir, MBA", "employees": 45, "founded": 2016, "website": "http://www.fulcrumtx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 58932800.0, "evFmt": "$59M", "ticker": "FULC", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-07-10", "recentDeals": [{"headline": "Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology", "date": "2023-07-10", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fulcrum%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Functional Neuromodulation Ltd.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "DBS-f", "phase": "Phase I", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.fxneuromod.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Functional%20Neuromodulation", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Fzata Inc.", "city": "Halethorpe", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "FZ002", "phase": "Preclinical", "indication": "Clostridium"}, {"name": "FZ003", "phase": "Preclinical", "indication": "Clostridium"}, {"name": "FZ006", "phase": "Preclinical", "indication": "Ulcerative colitis"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://fzata.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Fzata", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Infectious Disease"]}, {"company": "G2b Pharma Inc.", "city": "Corte Madera", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "G2B011", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.g2bpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=G2b%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Gaba Therapeutics", "city": "Newport Beach", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "deuterated etifoxine (GRX-917)", "phase": "Phase I", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.gabarx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gaba%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Gain Therapeutics Inc.", "city": "Bethesda", "state": "MD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Other"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GT-02287", "phase": "Phase I", "indication": "Parkinson's disease"}, {"name": "GT Gain Therapeutics-alpha L iduronidase-unknown", "phase": "Preclinical", "indication": "Mucopolysaccharidosis"}, {"name": "GT Gain Therapeutics-beta galactosidase-unknown", "phase": "Preclinical", "indication": "GM1 gangliosidosis"}], "ceo": "Gene C. Mack, MBA", "employees": 25, "founded": 2017, "website": "https://www.gaintherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 39691008.4, "evFmt": "$40M", "ticker": "GANX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gain%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other", "Parkinson's", "Rare / Genetic"]}, {"company": "Galaxy Biotech LLC", "city": "Sunnyvale", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HLX56", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.galaxybiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Galaxy%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Galectin Therapeutics Inc.", "city": "Norcross", "state": "GA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Hepatic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "belapectin", "phase": "Phase II/III", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "Joel Lewis, CPA", "employees": 15, "founded": 2000, "website": "http://www.galectintherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 173726610.0, "evFmt": "$174M", "ticker": "GALT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Galectin%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Galera Therapeutics Inc.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Other"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "avasopasem manganese (GC4419", "phase": "Registration", "indication": "Mucositis"}, {"name": "rucosopasem manganese (GC4711)", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Nova Pharmaceuticals-pan-nitric oxide synthase (NOS) inhibitor-unknown", "phase": "Phase I/II", "indication": "Breast cancer"}], "ceo": "John Mel Sorensen, MD", "employees": 3, "founded": 2009, "website": "http://www.galeratx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 145262231.1086, "evFmt": "$145M", "ticker": "GRTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Galera%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Lung Cancer", "Supportive / Other"]}, {"company": "Galileo Biosystems Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GB 499", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Galileo%20Biosystems", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Galimedix Therapeutics Inc.", "city": "Kensington", "state": "MD", "country": "United States", "diseaseCats": ["Neurology", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GAL-101 (EG30", "phase": "Phase I", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "GAL-201 (MRZ-14042)", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.galimedix.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Galimedix%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Ophthalmology"]}, {"company": "Galleon Pharmaceuticals Inc.", "city": "Horsham", "state": "PA", "country": "United States", "diseaseCats": ["Neurology", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GAL-021", "phase": "Phase I", "indication": "Respiratory distress syndrome (RDS)"}, {"name": "GAL-160", "phase": "Preclinical", "indication": "Sleep apnea"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.galleonpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Galleon%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral", "Respiratory / Allergy"]}, {"company": "Gameto Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "Fertilo", "phase": "IND", "indication": "Infertility"}, {"name": "Ameno", "phase": "Preclinical", "indication": "Menopause"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://gametogen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gameto", "hasDealsFin": false, "diseaseGroups": ["Women's Health"]}, {"company": "Gamida Cell Ltd.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Omisirge", "phase": "Marketed", "indication": "Hematologic malignancies"}, {"name": "GDA-201", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}], "ceo": "", "employees": 0, "founded": 1998, "website": "https://www.gamida-cell.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gamida%20Cell", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Garnet Biotherapeutics Inc.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "GBT009", "phase": "Phase II", "indication": "Wounds"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.garnetbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Garnet%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Gb Sciences Inc.", "city": "Las Vegas", "state": "NV", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GBS101", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "GBS102", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "GBS103", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "Andrea Small-Howard, PhD, MBA", "employees": 0, "founded": 2001, "website": "http://gbsciences.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "GBLX", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gb%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "Ge Healthcare Technologies Inc.", "city": "Chicago, IL", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Optison", "phase": "Market (diagnostic)", "indication": "Ultrasound imaging"}, {"name": "EMI-137", "phase": "Phase I/II", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-02-27", "recentDeals": [{"headline": "SonoThera receives exclusive licensing of GE HealthCare\u2019s Optison and Sonazoid Microbubble products for use with its ultrasound-guided gene therapy platform", "date": "2023-02-27", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ge%20Healthcare%20Technologies", "hasDealsFin": true, "diseaseGroups": ["Other", "Solid Tumors (General)"]}, {"company": "Gelesis Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Gastrointestinal", "Hepatic"], "modalityGroups": ["Digital / Device", "Nanoparticle / Delivery", "Other"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Gelesis200", "phase": "Phase I", "indication": "Obesity"}, {"name": "GS300", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "GS400", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "GS500", "phase": "Preclinical", "indication": "Constipation"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.gelesis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gelesis", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Obesity / Metabolic", "Supportive / Other"]}, {"company": "Gen1e Lifesciences Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary"], "modalityGroups": ["Other", "Peptide"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MUC1-ED Non-antibiotic Peptide", "phase": "Preclinical", "indication": "Pseudomonas"}, {"name": "P38 Kinase Inhibitor", "phase": "Preclinical", "indication": "Acute lung injury"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.gen1elifesci.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gen1e%20Lifesciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Genascence Corp.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GNSC-001", "phase": "Phase I", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://genascence.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genascence", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Gene Biotherapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Cardionovo", "phase": "Phase III", "indication": "Angina"}], "ceo": "Christopher J. Reinhard, MBA", "employees": 0, "founded": 2003, "website": "http://www.cardiumthx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1097870.0, "evFmt": "$1M", "ticker": "CRXM", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gene%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Genecure LLC", "city": "Norcross", "state": "GA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Hivax (therapeutic HIV-1 vaccine)", "phase": "Phase I", "indication": "HIV/AIDS"}, {"name": "Therapeutic HCV vaccine", "phase": "Phase I", "indication": "Hepatitis C virus (HCV)"}, {"name": "Prophylactic HCV vaccine", "phase": "Preclinical", "indication": "Hepatitis C virus (HCV)"}, {"name": "Prophylactic HIV-1 vaccine", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "Therapeutic HBV vaccine", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.genecure.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genecure", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Geneius Biotechnology Inc.", "city": "Natick", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Gastrointestinal", "Infectious"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Geneius Biotechnology - EBV + Lymphoma - unknown", "phase": "Preclinical", "indication": "Lymphoma"}, {"name": "Geneius Biotechnology - lung cancer - unknown", "phase": "Preclinical", "indication": "Lung cancer"}, {"name": "Geneius Biotechnology - NPC", "phase": "Preclinical", "indication": "Glycosphingolipid storage disorders"}, {"name": "Geneius Biotechnology - solid tumors - unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.geneiusbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Geneius%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Lung Cancer", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Genelux Corp.", "city": "Westlake Village", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Olvi-Vec (GL-ONC1", "phase": "Phase III", "indication": "Ovarian cancer"}], "ceo": "Thomas D. Zindrick", "employees": 24, "founded": 2001, "website": "http://www.genelux.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 45196715.72, "evFmt": "$45M", "ticker": "GNLX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genelux", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Geneos Therapeutics Inc.", "city": "Plymouth Meeting", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "GNOS-PV02", "phase": "Phase I/II", "indication": "Liver cancer"}, {"name": "GNOS-PV01 (GT-EPIC neoantigen-targeting personalized vaccine)", "phase": "Phase I", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://www.geneostx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Geneos%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GI Cancers"]}, {"company": "Generate Biomedicines Inc.", "city": "Somerville", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Pulmonary"], "modalityGroups": ["Antibody", "Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GB-0895", "phase": "Phase I", "indication": "Asthma"}, {"name": "GB-4362", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "GB-5267", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://generatebiomedicines.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 1065000000.0, "totalDealFmt": "$1.1B", "latestDealDate": "2024-09-24", "recentDeals": [{"headline": "Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI", "date": "2024-09-24", "value": "$1.1B"}, {"headline": "Generate:Biomedicines and MD Anderson Enter Co-Development and Commercialization Agreement to Accelerate Novel Protein Therapeutics for Oncology Using Generative AI", "date": "2023-04-27", "value": ""}], "totalRaised": 273000000.0, "totalRaisedFmt": "$273M", "latestFinDate": "2024-12-18", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2024-12-18", "investors": "Samsung Venture Investment Corp."}, {"type": "Series C rounds", "amount": "$273M", "date": "2023-09-14", "investors": "Amgen Inc., Nventures, Mirae Asset Capital, Pictet Alternative Advisors, Flagship Pioneering Inc., Abu Dhabi Investment ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Generate%20Biomedicines", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Generation Bio Co.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Hematology", "Infectious"], "modalityGroups": ["Gene Therapy", "RNA Therapeutics"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Generation Bio-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Generation Bio-Hemophilia A-unknown", "phase": "Preclinical", "indication": "Hemophilia"}], "ceo": "Yalonda Howze", "employees": 115, "founded": 2016, "website": "http://generationbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -21041296.06, "evFmt": "", "ticker": "GBIO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Generation%20Bio", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Infectious Disease"]}, {"company": "Generex Biotechnology Corp.", "city": "Miramar", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Endocrine/Metabolic", "Infectious"], "modalityGroups": ["Nanoparticle / Delivery", "Other", "Protein / Biologic", "Vaccine"], "nProducts": 9, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Excellagen", "phase": "Marketed", "indication": "Wounds"}, {"name": "Oral Recosulin (generex oral-lyn", "phase": "Marketed", "indication": "Diabetes"}, {"name": "Ii-Key/HER2/neu cancer vaccine (AE37)", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "AE-AI vaccine (ii-key/h5 influenza vaccine)", "phase": "Phase I", "indication": "Influenza virus"}, {"name": "AE-H vaccine", "phase": "Phase I", "indication": "HIV/AIDS"}, {"name": "AE-M vaccine", "phase": "Phase I", "indication": "Melanoma"}, {"name": "AE-O vaccine", "phase": "Phase I", "indication": "Ovarian cancer"}, {"name": "ExtraCellular Matrix Hydrogel (ECMH)", "phase": "Preclinical", "indication": "Ulcerative colitis"}], "ceo": "Joseph Moscato", "employees": 0, "founded": 1997, "website": "http://www.generex.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "GNBT", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Generex%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Dermatology", "Diabetes", "GU / Gynecologic Cancers", "IBD / GI Inflammatory", "Infectious Disease", "Skin Cancer / Melanoma"]}, {"company": "Genervon Biopharmaceuticals LLC", "city": "Pasadena", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Musculoskeletal", "Neurology"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "GM6 (GM602", "phase": "Phase II", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.genervon.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genervon%20Biopharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Genetic Immunity LLC", "city": "Mclean", "state": "VA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "DermaVir Patch (lc002)", "phase": "Phase III", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.geneticimmunity.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genetic%20Immunity", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Genetic Intelligence Inc. (Genetic Leap)", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Genetic Intelligence-amyotrophic lateral sclerosis-unknown", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.genetic-leap.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genetic%20Intelligence%20Inc.%20(Genetic%20Leap)", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Geneventiv Therapeutics Inc.", "city": "Raleigh", "state": "NC", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GENV-002", "phase": "Preclinical", "indication": "Pompe disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.geneventiv.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Geneventiv%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Genialis Inc.", "city": "Boston", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Development (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Predictive biomarker for WEE1-targeted therapy", "phase": "Development (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 13000000.0, "totalRaisedFmt": "$13M", "latestFinDate": "2023-03-29", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$13M", "date": "2023-03-29", "investors": "Taiwania Capital, Debiopharm Innovation Fund, First Star Ventures, Redalpine, Pikas, P5 Health Ventures, Angel Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genialis", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Genisphere LLC", "city": "Hatfield", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "3DNA-Dox-FA", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.genisphere.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genisphere", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Genomas Inc.", "city": "Hartford", "state": "CT", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SINM PhyzioType System", "phase": "Preclinical", "indication": "Drug screen"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.genomas.net", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genomas", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Genosco", "city": "Billerica", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "denfivontinib (SKI-G-801)", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "G-749", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "G-969", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "GNS 1653", "phase": "Preclinical", "indication": "Lymphoma"}, {"name": "SKI-O-282", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.genosco.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genosco", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers", "Parkinson's"]}, {"company": "Genosera Inc.", "city": "Columbus", "state": "OH", "country": "United States", "diseaseCats": ["Musculoskeletal", "Other"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GA-001", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "GA-002", "phase": "Preclinical", "indication": "Muscular atrophy"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.genosera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genosera", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Genprex Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Reqorsa", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "GPX-002", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "GPX-003", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "Ryan M. Confer", "employees": 15, "founded": 2009, "website": "http://www.genprex.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1809844.4904, "evFmt": "$2M", "ticker": "GNPX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genprex", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Lung Cancer"]}, {"company": "Gensco Pharma LLC", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Nanoparticle / Delivery", "Other"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Astero", "phase": "Marketed", "indication": "Pain"}, {"name": "ColciGel", "phase": "Marketed", "indication": "Hyperuricemia/gout"}, {"name": "LiDORx", "phase": "Marketed", "indication": "Pain"}, {"name": "SpeedGel Rx", "phase": "Marketed", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2009, "website": "https://genscopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gensco%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Pain / Migraine"]}, {"company": "Gentibio Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GNTI-122", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.gentibio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gentibio", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Genus Oncology LLC", "city": "Vernon Hills", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "GO-203-2c", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.genusoncology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genus%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Genvivo Inc.", "city": "San Marino", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GEN2", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2000, "website": "https://genvivoinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Genvivo", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Georgiamune Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "GIM-122", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "GIM-531", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "GIM-407", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "GIM-0915", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "GIM-616 (GIM-0616)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "GIM-710 (GIM-0710)", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "GIM-0228", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "GIM-1213s", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.georgiamune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 75000000.0, "totalRaisedFmt": "$75M", "latestFinDate": "2023-08-09", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$75M", "date": "2023-08-09", "investors": "General Catalyst, Parker Institute for Cancer Immunotherapy, Mubadala Capital Ventures, Alexandria Venture Investments L..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Georgiamune", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Geovax Labs Inc.", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 8, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "HIV/AIDS vaccine (GOVX-B11", "phase": "Phase I/II", "indication": "HIV/AIDS"}, {"name": "GEO-EM01", "phase": "Preclinical", "indication": "Ebola"}, {"name": "GEO-LM01", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "GEO-ZM02", "phase": "Preclinical", "indication": "Zika virus"}, {"name": "GOVX-E301", "phase": "Preclinical", "indication": "Ebola"}, {"name": "GOVX-E302", "phase": "Preclinical", "indication": "Ebola"}, {"name": "GOVX-E303", "phase": "Preclinical", "indication": "Ebola"}, {"name": "Zaire MVA-VLP", "phase": "Preclinical", "indication": "Ebola"}], "ceo": "David A. Dodd", "employees": 17, "founded": 2001, "website": "http://www.geovax.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7305042.86, "evFmt": "$7M", "ticker": "GOVX", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Geovax%20Labs", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Geron Corp.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Rytelo", "phase": "Marketed", "indication": "Myelodysplastic syndrome (MDS)"}], "ceo": "Harout Semerjian, MBA", "employees": 229, "founded": 1990, "website": "https://www.geron.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2125040694.38, "evFmt": "$2.1B", "ticker": "GERN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Geron", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Gibson Oncology LLC", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "LMP400", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "Gibson Oncology-c-Myc-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Gibson Oncology-TOP1-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://gibsononcology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gibson%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Solid Tumors (General)"]}, {"company": "Gid Bio Inc.", "city": "Louisville", "state": "CO", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Genitourinary", "Infectious", "Neurology", "Pulmonary"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "GID SVF-2", "phase": "Phase III", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://gidbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gid%20Bio", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Gilead Sciences Inc.", "city": "Foster City", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Diagnostic", "Endocrine/Metabolic", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Pulmonary", "Renal"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Cell Therapy", "Combination", "Diagnostics", "Macrocycle", "Other", "Peptide", "Small Molecule", "Undisclosed"], "nProducts": 100, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "lefitolimod (GS-1703", "phase": "Phase III", "indication": "Colorectal cancer"}, {"name": "andecaliximab (GS-5745)", "phase": "Phase I/II", "indication": "Musculoskeletal (unspecified)"}, {"name": "AmBisome", "phase": "Marketed", "indication": "Fungal infection"}, {"name": "Atripla", "phase": "Marketed", "indication": "HIV/AIDS"}, {"name": "Biktarvy", "phase": "Marketed", "indication": "HIV/AIDS"}, {"name": "Cayston", "phase": "Marketed", "indication": "Bacterial respiratory infection"}, {"name": "Complera", "phase": "Marketed", "indication": "HIV/AIDS"}, {"name": "DaunoXome", "phase": "Marketed", "indication": "Cancer (unspecified)"}], "ceo": "Daniel P. O'Day, MBA", "employees": 17600, "founded": 1987, "website": "http://www.gilead.com", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 131594350000.0, "evFmt": "$131.6B", "ticker": "GILD", "exchange": "NASDAQ", "nDeals": 5, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-09-29", "recentDeals": [{"headline": "Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences", "date": "2025-09-29", "value": ""}, {"headline": "Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies using Genesis\u2019 Field-leading AI Platform", "date": "2024-09-10", "value": ""}, {"headline": "ashibio Licensed andecaliximab from Gilead Sciences", "date": "2024-06-20", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gilead%20Sciences", "hasDealsFin": true, "diseaseGroups": ["GI Cancers", "Infectious Disease", "Musculoskeletal", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Gilgamesh Pharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "blixeprodil (GM-1020)", "phase": "Phase II", "indication": "Depression"}, {"name": "GM-3009", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2025, "website": "https://www.gilgameshpharmaceutical.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gilgamesh%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Glg Pharma LLC", "city": "Jupiter", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "GLG-801", "phase": "Phase II", "indication": "Leukemia"}, {"name": "GLG-101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "GLG-202", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "GLG-302", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "GLG-401", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.glgpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Glg%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Gliknik Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Inflammation"], "modalityGroups": ["Peptide", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Biropepimut-S (GL-0817)", "phase": "Phase II", "indication": "Head and neck cancer"}, {"name": "GL-0719", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.gliknik.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gliknik", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer", "Other Inflammation"]}, {"company": "Globavir Biosciences Inc.", "city": "Los Altos", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic", "Infectious"], "modalityGroups": ["Combination", "Diagnostics", "Other", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "BC001", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "BC087", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "PanGlob Dengue (panglob)", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "DenGlob", "phase": "Pivotal", "indication": "Infectious, Diagnostic"}, {"name": "GBV006", "phase": "Preclinical", "indication": "Dengue fever"}, {"name": "GBV1012", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.globavir.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Globavir%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)"]}, {"company": "Globeimmune Inc.", "city": "Louisville", "state": "CO", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "GI-4000", "phase": "Phase II", "indication": "Colorectal cancer"}, {"name": "GI-6207", "phase": "Phase II", "indication": "Thyroid cancer"}, {"name": "GI-6301", "phase": "Phase II", "indication": "Bone cancer"}, {"name": "GS-4774", "phase": "Phase II", "indication": "Hepatitis B virus (HBV)"}, {"name": "GI-18000", "phase": "Preclinical", "indication": "Hepatitis D virus (HDV)"}, {"name": "GI-19000", "phase": "Preclinical", "indication": "Tuberculosis"}, {"name": "GI-2010", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "Timothy C. Rodell, Jr., MD", "employees": 0, "founded": 1995, "website": "http://www.globeimmune.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "GBIM", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Globeimmune", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Head & Neck Cancer", "Infectious Disease", "Liver Disease", "Other Solid Tumors"]}, {"company": "Glsynthesis Inc.", "city": "Worcester", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ibezapolstat (ACX-362E)", "phase": "Phase II", "indication": "Clostridium"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.glsynthesis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Glsynthesis", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Glubio Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GLB-001", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "GLB-002", "phase": "Preclinical", "indication": "B cell lymphoma"}, {"name": "GluBio Therapeutics-liquid and solid tumors-unknown", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "GluBio Therapeutics-sickle cell disease-unknown", "phase": "Preclinical", "indication": "Sickle cell disease"}, {"name": "GluBio Therapeutics-solid tumors-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "GluBio Therapeutics-solid tumors-unknown2", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.glubiotx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Glubio%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Hematology (non-cancer)", "Solid Tumors (General)"]}, {"company": "Glycadia Pharmaceuticals Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cardiovascular", "Neurology", "Ophthalmic", "Renal"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "GLY-230", "phase": "Phase II", "indication": "Diabetic nephropathy"}, {"name": "A717", "phase": "Preclinical", "indication": "Diabetic neuropathy"}, {"name": "ES12", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "GLY-220", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}], "ceo": "", "employees": 0, "founded": 1988, "website": "http://www.glycadia.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Glycadia%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "Pain / Migraine"]}, {"company": "Glycomantra Inc.", "city": "Aldie", "state": "VA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Hepatic", "Pulmonary"], "modalityGroups": ["Cell Therapy", "Protein / Biologic", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GM100", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "GM200", "phase": "Preclinical", "indication": "Renal cancer"}, {"name": "GM300", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.glycomantra.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Glycomantra", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "GU / Gynecologic Cancers"]}, {"company": "Glycomine Inc.", "city": "San Carlos", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "GLM101", "phase": "Phase II", "indication": "Congenital disorders of glycosylation"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://glycomine.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Glycomine", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Glyscend Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GLY-200", "phase": "Phase I", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.glyscend.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Glyscend", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Go Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GO-2", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "GO-6", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.gotherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Go%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Gossamer Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Infectious", "Inflammation"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "GB001", "phase": "Phase II", "indication": "Sinusitis"}, {"name": "GB1275 (ADH-503)", "phase": "Phase I/II", "indication": "Pancreatic cancer"}], "ceo": "Faheem Hasnain", "employees": 145, "founded": 2015, "website": "http://gossamerbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 113009863.2736, "evFmt": "$113M", "ticker": "GOSS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gossamer%20Bio", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Respiratory / Allergy"]}, {"company": "Grace Science LLC", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Gene Therapy", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Grace Science-NFE2L1-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Grace Science-NGLY1 deficiency-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Grace Science-NGLY1 inhibitor-unknown", "phase": "Preclinical", "indication": "Mantle cell lymphoma (MCL)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.gracescience.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Grace%20Science", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Other Neurology"]}, {"company": "Grace Therapeutics Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "GTX-104", "phase": "Registration", "indication": "Stroke"}], "ceo": "Prashant Kohli, MBA", "employees": 0, "founded": 2008, "website": "https://www.gracetx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 5425975.6, "evFmt": "$5M", "ticker": "GRCE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Grace%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Gradalis Inc.", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Other", "RNA Therapeutics", "Vaccine"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Vigil vaccine (fang vaccine)", "phase": "Phase III", "indication": "Ovarian cancer"}, {"name": "GNE Lipoplex", "phase": "Phase I", "indication": "Muscular atrophy"}, {"name": "Pbi-shSTMN1LP", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "Pbi-shRNA K-ras LP", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.gradalisinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gradalis", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Neurodegeneration / NMD", "Solid Tumors (General)"]}, {"company": "Granata Bio Corp.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic", "Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Pivotal", "hasOrphan": false, "pipeline": [{"name": "clomiphene citrate", "phase": "Pivotal", "indication": "Infertility"}, {"name": "GB-hMG", "phase": "Preclinical", "indication": "Infertility"}, {"name": "OVI-586", "phase": "Preclinical", "indication": "Infertility"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.granata.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 29000000.0, "totalRaisedFmt": "$29M", "latestFinDate": "2025-05-13", "latestFinType": "Uncategorized venture rounds", "nRounds": 3, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2025-05-13", "investors": "Gedeon Richter plc"}, {"type": "Series A rounds", "amount": "$15M", "date": "2025-01-15", "investors": "Gedeon Richter plc, Coopersurgical, Amboy Street Ventures, Undisclosed Investors"}, {"type": "Series A rounds", "amount": "$14M", "date": "2024-01-16", "investors": "Gv, The Cooper Companies Inc., Gedeon Richter plc, Alumni Ventures Group, Amboy Street Ventures, Vibe Biotechnology Inc...."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Granata%20Bio", "hasDealsFin": true, "diseaseGroups": ["Women's Health"]}, {"company": "Grander Acquisition LLC (Polarityte)", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "SkinTE (361 HCT/P)", "phase": "Phase III", "indication": "Wounds"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.polarityte.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Grander%20Acquisition%20LLC%20(Polarityte)", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Grannus Therapeutics Inc.", "city": "Indianapolis", "state": "IN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Grannus Therapeutics-Hsp90-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.grannustherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Grannus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Greenlight Biosciences Holdings PBC", "city": "Medford", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GreenLight Biosciences-COVID 19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "https://www.greenlightbiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Greenlight%20Biosciences%20Holdings%20PBC", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Greenwich Lifesciences Inc.", "city": "Stafford", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "GP2 + GM-CSF (GLSI-100)", "phase": "Phase III", "indication": "Breast cancer"}], "ceo": "Snehal S. Patel, MBA", "employees": 8, "founded": 2006, "website": "https://greenwichlifesciences.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 142061799.55, "evFmt": "$142M", "ticker": "GLSI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Greenwich%20Lifesciences", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Greffex Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Greffex-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.greffex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Greffex", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Gri Bio Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Hepatic", "Neurology", "Pulmonary"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Tazarotene (GRI-0621)", "phase": "Phase II", "indication": "Liver disease"}, {"name": "abuse-deterrent formulation of immediate-release (IR) dextroamphetamine", "phase": "Phase I", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "GRI-0124", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "GRI-0803", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "W. Marc Hertz, PhD", "employees": 4, "founded": 2009, "website": "https://gribio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -7479655.888448, "evFmt": "", "ticker": "GRI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gri%20Bio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Liver Disease", "Psychiatry / Behavioral"]}, {"company": "Grid Therapeutics LLC", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "GT103", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.gridtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Grid%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Gro Biosciences Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ProGly-Uricase", "phase": "Preclinical", "indication": "Hyperuricemia/gout"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://grobio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gro%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Grove Biopharma Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Grove Biopharma-AR/AR-V7-unknown", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "Grove Biopharma-KEAP1/NRF2-unknown", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}, {"name": "Grove Biopharma-MYC-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Grove Biopharma-SHOC2/MRAS/PP1C-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Grove Biopharma-TAU-unknown", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "Grove Biopharma-WDR5/MYC-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "http://grovebiopharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Grove%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Cardiovascular", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Gt Biopharma Inc.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Neurology"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "GTB-3550", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "GTP-004", "phase": "Phase I", "indication": "Myasthenia gravis"}, {"name": "GTB-4550", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "GTB-5550", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "GTB-C3550", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "GTP-011", "phase": "Preclinical", "indication": "Motion sickness"}, {"name": "OXS-2175", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "OXS-4235", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}], "ceo": "Michael Breen", "employees": 1, "founded": 1965, "website": "http://gtbiopharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1743993.75, "evFmt": "$2M", "ticker": "GTBP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gt%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers", "MS / Neuroimmune", "Other", "Solid Tumors (General)"]}, {"company": "Gv20 Therapeutics LLC (Xunbaihui Biotechnology)", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GV20-0251", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.gv20tx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gv20%20Therapeutics%20LLC%20(Xunbaihui%20Biotechnology)", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Gyre Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Hepatic", "Neurology", "Pulmonary"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Etuary", "phase": "Marketed", "indication": "Pulmonary fibrosis"}, {"name": "hydronidone (F351)", "phase": "Phase III", "indication": "Liver fibrosis"}, {"name": "F573 (ep1013", "phase": "Phase II", "indication": "Liver failure"}, {"name": "F230", "phase": "IND", "indication": "Hypertension"}, {"name": "F528", "phase": "Preclinical", "indication": "Chronic obstructive pulmonary disease (COPD)"}], "ceo": "Ping Zhang, MBA", "employees": 5, "founded": 1997, "website": "https://www.gyretx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1247761664.6, "evFmt": "$1.2B", "ticker": "GYRE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Gyre%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Liver Disease", "Respiratory / Allergy"]}, {"company": "Halia Therapeutics Inc.", "city": "Lehi", "state": "UT", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Gastrointestinal", "Musculoskeletal", "Neurology", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "HT-6184", "phase": "Phase II", "indication": "Myelodysplastic syndrome (MDS)"}, {"name": "HT-4253", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "HT-4403", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "HT-6258", "phase": "Preclinical", "indication": "Gastrointestinal (unspecified)"}, {"name": "HT-6283", "phase": "Preclinical", "indication": "Neuroinflammation"}, {"name": "HT-6153", "phase": "Research", "indication": "Musculoskeletal (unspecified)"}, {"name": "HT-6515", "phase": "Research", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://haliatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 42560171.0, "totalRaisedFmt": "$43M", "latestFinDate": "2025-07-01", "latestFinType": "Uncategorized venture rounds", "nRounds": 3, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$337K", "date": "2025-07-01", "investors": "Undisclosed Investors"}, {"type": "Series C rounds", "amount": "$30M", "date": "2024-01-31", "investors": "Todd Pedersen, Existing Investors"}, {"type": "Uncategorized venture rounds", "amount": "$12M", "date": "2022-12-30", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Halia%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Dermatology", "Hematologic Cancers", "Musculoskeletal", "Other", "Other Neurology", "Parkinson's"]}, {"company": "Hallux Inc.", "city": "Laguna Hills", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "HTS-519", "phase": "Phase II", "indication": "Onychomycosis"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://halluxinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hallux", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Halo Biosciences Inc.", "city": "Stanford", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "H01", "phase": "Phase II", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://halobiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Halo%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Halo-bio Rnai Therapeutics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HALOVIRIN nCov", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.halo-bio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Halo-bio%20Rnai%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Halozyme Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Genitourinary", "Neurology", "Other"], "modalityGroups": ["Digital / Device", "Other", "Protein / Biologic", "Small Molecule"], "nProducts": 12, "mostAdvanced": "Phase IV", "hasOrphan": false, "pipeline": [{"name": "Hylenex (rHuPH20", "phase": "Phase IV", "indication": "Diabetes"}, {"name": "Cumulase", "phase": "Marketed", "indication": "Infertility"}, {"name": "Elestrin", "phase": "Marketed", "indication": "Menopause"}, {"name": "Gelnique", "phase": "Marketed", "indication": "Incontinence"}, {"name": "Medi-jector vision", "phase": "Marketed", "indication": "Diabetes"}, {"name": "Xyosted", "phase": "Marketed", "indication": "Hypogonadism"}, {"name": "LibiGel", "phase": "Phase III", "indication": "Sexual dysfunction"}, {"name": "NES/E2 transdermal gel", "phase": "Phase II", "indication": "Contraception"}], "ceo": "Helen I. Torley, MD", "employees": 350, "founded": 1998, "website": "http://www.halozyme.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 7128190440.0, "evFmt": "$7.1B", "ticker": "HALO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Halozyme%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Other Specialties", "Women's Health"]}, {"company": "Halsa Pharmaceuticals Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Zinc-alpha-2-glycoprotein (zag)", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.halsapharma.net", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Halsa%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Hapten Pharmaceuticals LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Samcyprone (RXI-SCP)", "phase": "Phase II", "indication": "Alopecia areata"}], "ceo": "", "employees": 0, "founded": 2012, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hapten%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Harmony Biosciences Holdings Inc.", "city": "Plymouth Meeting", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "clemizole hydrochloride (EPX-100)", "phase": "Phase III", "indication": "Dravet syndrome"}, {"name": "Zygel (ZYN002)", "phase": "Phase III", "indication": "Fragile X syndrome"}, {"name": "lorcaserin (EPX-200)", "phase": "Preclinical", "indication": "Epilepsy"}], "ceo": "Jeffrey M. Dayno, MD", "employees": 268, "founded": 2017, "website": "https://www.harmonybiosciences.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1757269775.15, "evFmt": "$1.8B", "ticker": "HRMY", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Harmony%20Biosciences%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other"]}, {"company": "Harrow Inc.", "city": "Nashville", "state": "TN", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Iheezo (chloroprocaine hydrochloride)", "phase": "Marketed", "indication": "Anesthesia"}, {"name": "MELT-300 (MELT-100)", "phase": "Phase III", "indication": "Pain"}, {"name": "midazolam (MELT-210)", "phase": "Phase I", "indication": "Anesthesia"}, {"name": "ketamine (MELT-400)", "phase": "Preclinical", "indication": "Pain"}], "ceo": "Mark L. Baum", "employees": 382, "founded": 2018, "website": "https://www.harrow.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1377307454.7, "evFmt": "$1.4B", "ticker": "HROW", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Harrow", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Supportive / Other"]}, {"company": "Harvard Apparatus Regenerative Technology Inc.", "city": "Holliston", "state": "MA", "country": "United States", "diseaseCats": ["Transplant"], "modalityGroups": ["Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Cellspan Bronchial Implants", "phase": "Preclinical", "indication": "Tissue replacement"}, {"name": "Cellspan Esophageal Implants", "phase": "Preclinical", "indication": "Tissue replacement"}, {"name": "Cellspan Tracheal Implants", "phase": "Preclinical", "indication": "Tissue replacement"}, {"name": "HART-Trachea", "phase": "Preclinical", "indication": "Tissue replacement"}], "ceo": "Jun Li He, CFA, MBA", "employees": 8, "founded": 2013, "website": "http://www.biostage.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 39766916.24, "evFmt": "$40M", "ticker": "HRGN", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Harvard%20Apparatus%20Regenerative%20Technology", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Hawaii Biotech Inc.", "city": "Honolulu", "state": "HI", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Dengue fever vaccine (HBV-001 D1)", "phase": "Phase I", "indication": "Dengue fever"}, {"name": "HBV-002", "phase": "Phase I", "indication": "West Nile virus"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.hibiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hawaii%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Hbm Alpha Therapeutics Inc.", "city": "Delaware", "state": "OH", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HAT002", "phase": "Preclinical", "indication": "Polycystic ovary syndrome (PCOS)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://www.hbmalphatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 395000000.0, "totalDealFmt": "$395M", "latestDealDate": "2025-02-26", "recentDeals": [{"headline": "HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies", "date": "2025-02-26", "value": "$395M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2023-01-26", "latestFinType": "Seed financings", "nRounds": 1, "recentFinancing": [{"type": "Seed financings", "amount": "", "date": "2023-01-26", "investors": "Harbour Biomed"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hbm%20Alpha%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Other"]}, {"company": "Hcw Biologics Inc.", "city": "Miramar Beach", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "HCW9201", "phase": "Phase II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "HCW9218", "phase": "Phase I", "indication": "Pancreatic cancer"}, {"name": "HCW9206", "phase": "IND", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "HCW11-006", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Hing C. Wong, PhD", "employees": 36, "founded": 2018, "website": "https://hcwbiologics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 26323542.3298, "evFmt": "$26M", "ticker": "HCWB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hcw%20Biologics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Hdt Bio Corp.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Diagnostic", "Infectious"], "modalityGroups": ["Diagnostics", "RNA Therapeutics"], "nProducts": 2, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Gemcovac (HDT-301", "phase": "Approved", "indication": "Coronavirus disease (COVID-19)"}, {"name": "HDT-leprosy-unknown", "phase": "Phase I", "indication": "Infectious, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.hdt.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hdt%20Bio", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Helix Biomedix Inc.", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious"], "modalityGroups": ["Peptide"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HB1275", "phase": "Preclinical", "indication": "Fungal infection"}, {"name": "HB1345", "phase": "Preclinical", "indication": "Acne"}, {"name": "HB4208", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}], "ceo": "Robin L. Carmichael", "employees": 8, "founded": 1988, "website": "http://www.helixbiomedix.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 10741100.0, "evFmt": "$11M", "ticker": "HXBM", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Helix%20Biomedix", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease"]}, {"company": "Helix Nanotechnologies Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "HN-0001", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://helixnano.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Helix%20Nanotechnologies", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Helocyte Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Gene Therapy", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PepVax", "phase": "Phase II", "indication": "Cytomegalovirus (CMV)"}, {"name": "Triplex", "phase": "Phase II", "indication": "Cytomegalovirus (CMV)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.helocyte.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Helocyte", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Hemacure Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Hemacure-anti-aging-unknown", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}, {"name": "Hemacure-Parkinsons's disease-unknown", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://hemacure.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hemacure", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Parkinson's"]}, {"company": "Hemera Biosciences Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AAVCAGsCD59 (HMR59", "phase": "Phase II", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://hemerabiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hemera%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Hemoglobin Oxygen Therapeutics LLC", "city": "Souderton", "state": "PA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Hemopure", "phase": "Approved", "indication": "Anemia"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.hbo2therapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hemoglobin%20Oxygen%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Hemoshear Therapeutics Inc.", "city": "Charlottesville", "state": "VA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HST301", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.hemoshear.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hemoshear%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Hennepin Life Sciences LLC", "city": "Plymouth", "state": "MN", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ABV3", "phase": "Phase II", "indication": "Bacterial vaginosis"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.hennepinlifesciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hennepin%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Hepion Pharmaceuticals Inc.", "city": "Edison", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "rencofilstat (CRV431)", "phase": "Phase II", "indication": "Liver cancer"}], "ceo": "Kaouthar Lbiati, MD", "employees": 0, "founded": 2013, "website": "https://hepionpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7077343.47, "evFmt": "$7M", "ticker": "HEPA", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hepion%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Hera Biotech Inc.", "city": "San Antonio", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "HeraFem", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "MetriDx", "phase": "Development (diagnostic)", "indication": "Genitourinary, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 2000000.0, "totalRaisedFmt": "$2M", "latestFinDate": "2024-08-01", "latestFinType": "Seed financings", "nRounds": 3, "recentFinancing": [{"type": "Seed financings", "amount": "$100K", "date": "2024-08-01", "investors": "Cedars-sinai Medical Center"}, {"type": "Seed financings", "amount": "", "date": "2023-06-20", "investors": "Monday Capital"}, {"type": "Seed financings", "amount": "$2M", "date": "2022-08-24", "investors": "Individual Investors, Coyote Ventures, Stella Angels, Althea Group Ventures, Kendra Scott Women's Entrepreneurial Leader..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hera%20Biotech", "hasDealsFin": true, "diseaseGroups": ["Other", "Solid Tumors (General)"]}, {"company": "Heron Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Infectious", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Aponvie", "phase": "Marketed", "indication": "Emesis"}, {"name": "Cinvanti", "phase": "Marketed", "indication": "Emesis"}, {"name": "Sustol (Brand)", "phase": "Marketed", "indication": "Emesis"}, {"name": "Zynrelef", "phase": "Approved", "indication": "Pain"}, {"name": "HTX-034", "phase": "Phase I/II", "indication": "Pain"}, {"name": "buprenorphine (HTX-003)", "phase": "Preclinical", "indication": "Pain"}], "ceo": "Craig A. Collard", "employees": 122, "founded": 1983, "website": "http://www.herontx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 351726970.0, "evFmt": "$352M", "ticker": "HRTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Heron%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Supportive / Other"]}, {"company": "Herophilus Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Herophilus-Rett Syndrome-Unknown 1", "phase": "Preclinical", "indication": "Rett syndrome"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://herophilus.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Herophilus", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Hexim Pharmaceuticals Inc.", "city": "Secaucus", "state": "NJ", "country": "United States", "diseaseCats": ["Dermatology", "Other"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Xclair", "phase": "Marketed", "indication": "Dermatitis"}, {"name": "Numoisyn (sst)", "phase": "Marketed", "indication": "Xerostomia"}, {"name": "Salinum", "phase": "Marketed", "indication": "Xerostomia"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://www.sst.care/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hexim%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Other"]}, {"company": "Hibercell Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Imprime PGG", "phase": "Phase II", "indication": "Head and neck cancer"}, {"name": "Odetiglucan", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "HC-5404 (HC-5404-FU)", "phase": "Phase I", "indication": "Gastric cancer"}, {"name": "HC-7366", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.hibercell.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hibercell", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Head & Neck Cancer", "Hematologic Cancers"]}, {"company": "Hifibio Inc. (Hifibio Therapeutics)", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "HFB101110", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "HFB200902", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "HFB200301", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "HFB200603", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "HFB301001", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://hifibio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hifibio%20Inc.%20(Hifibio%20Therapeutics)", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Highpassbio", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "HA-1 T TCR T cell immunotherapy", "phase": "Phase I", "indication": "Leukemia"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://highpassbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Highpassbio", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Hinge Bio Inc.", "city": "Burlingame", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Covicept", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "HB2198", "phase": "Preclinical", "indication": "Lupus"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.hingebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-09-30", "recentDeals": [{"headline": "Hinge Bio Announces License and Collaboration with Kyorin Pharmaceutical Co., Ltd. for the Development and Commercialization of HB2198 in Japan for Autoimmune Diseases", "date": "2025-09-30", "value": ""}], "totalRaised": 30000000.0, "totalRaisedFmt": "$30M", "latestFinDate": "2025-01-15", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$30M", "date": "2025-01-15", "investors": "Point72, Ridgeback Capital, Invivium Capital, Lightswitch Capital, Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hinge%20Bio", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Infectious Disease"]}, {"company": "Ho'ola Therapeutics Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "zilovertamab (cirmtuzumab", "phase": "Phase II", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "ONCT-808", "phase": "Preclinical", "indication": "Non-Hodgkin lymphoma (NHL)"}], "ceo": "", "employees": 0, "founded": 2025, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ho'ola%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Hookipa Pharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Gene Therapy", "Undisclosed", "Vaccine"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "eseba-vec (HB-200)", "phase": "Phase II", "indication": "Cancer (unspecified)"}, {"name": "HB-201", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "HB-202", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "GS-2829", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "HB-300", "phase": "IND", "indication": "Prostate cancer"}, {"name": "HB-700", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "Hookipa Pharma-HIV therapies-unknown", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "Malte Peters, MD", "employees": 87, "founded": 2011, "website": "https://www.hookipapharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -13704024.06, "evFmt": "", "ticker": "HOOK", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hookipa%20Pharma", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "GU / Gynecologic Cancers", "Infectious Disease", "Liver Disease", "Solid Tumors (General)"]}, {"company": "Hope Biosciences Inc.", "city": "Sugarland", "state": "TX", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Inflammation", "Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "HB-adMSC (autologous)", "phase": "Phase II/III", "indication": "Rheumatoid arthritis (RA)"}, {"name": "HB-adMSC (allogenic)", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.hope.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hope%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Infectious Disease"]}, {"company": "Hopo Therapeutics Inc.", "city": "Berkeley", "state": "CA", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "HOPO-101", "phase": "Phase I", "indication": "Poisoning"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.hopotx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hopo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Hoth Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Infectious", "Inflammation", "Neurology", "Pulmonary"], "modalityGroups": ["Gene Therapy", "Other", "Peptide", "Small Molecule", "Undisclosed"], "nProducts": 9, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "HT-001", "phase": "Phase II", "indication": "Dermatology (unspecified)"}, {"name": "Exon Skipping", "phase": "Preclinical", "indication": "Allergy"}, {"name": "HT-002", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "HT-004", "phase": "Preclinical", "indication": "Allergy"}, {"name": "HT-006", "phase": "Preclinical", "indication": "Pneumonia"}, {"name": "HT-ALZ", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "HT-KIT", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "HT-TBI", "phase": "Preclinical", "indication": "Shock/trauma"}], "ceo": "Robbie Knie", "employees": 6, "founded": 2017, "website": "http://www.hoththerapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -2238590.0559, "evFmt": "", "ticker": "HOTH", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hoth%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Dermatology", "Hematologic Cancers", "Infectious Disease", "Respiratory / Allergy", "Supportive / Other"]}, {"company": "Hotspot Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "HST-1011", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.hotspotthera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hotspot%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Hs Pharmaceuticals LLC", "city": "Greenville", "state": "SC", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HS-X", "phase": "Preclinical", "indication": "Burns"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.hspharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hs%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Hubble Therapeutics LLC", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "HUB-101", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hubble%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Humacyte Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Inflammation", "Renal"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Humacyl", "phase": "Registration", "indication": "Shock/trauma"}, {"name": "BioVascular Pancreas (BVP)", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "Laura E. Niklason, MD, PhD", "employees": 220, "founded": 2004, "website": "http://www.humacyte.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 633729439.85, "evFmt": "$634M", "ticker": "HUMA", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-07-09", "recentDeals": [{"headline": "Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs", "date": "2024-07-09", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Humacyte", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Supportive / Other"]}, {"company": "Humanetics Corp.", "city": "Minneapolis", "state": "MN", "country": "United States", "diseaseCats": ["Cancer", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BIO 300", "phase": "Phase I/II", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 1988, "website": "http://www.humaneticscorp.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Humanetics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Huya Bioscience International LLC", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "sulcardine (HBI-3000)", "phase": "Phase II", "indication": "Arrhythmia"}, {"name": "HBI-3802", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.huyabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Huya%20Bioscience%20International", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Hybrid Medical LLC", "city": "Edina", "state": "MN", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "H100", "phase": "Phase I", "indication": "Peyronie disease"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://www.hybridmedical.org/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hybrid%20Medical", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Hydra Biosciences Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "HX-100", "phase": "Phase I", "indication": "Asthma"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.hydrabiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Hydra%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "I2o Therapeutics Inc.", "city": "Allston", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["Digital / Device", "Peptide"], "nProducts": 6, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "exanatide implant (ITCA 650)", "phase": "Registration", "indication": "Diabetes"}, {"name": "i2o-105s", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "i2o-107", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "i2o-110", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "i2o-120", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "i2o-130", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.i2obio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-08-28", "recentDeals": [{"headline": "i2o has entered into a new 4-year sponsored research and licensing agreement with the Mitragotri Lab at Harvard University", "date": "2023-08-28", "value": ""}], "totalRaised": 79539921.0, "totalRaisedFmt": "$80M", "latestFinDate": "2023-08-28", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$46M", "date": "2023-08-28", "investors": "Undisclosed Investors"}, {"type": "Uncategorized venture rounds", "amount": "$34M", "date": "2022-10-11", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=I2o%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Diabetes"]}, {"company": "Iacta Pharmaceuticals Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious", "Inflammation", "Neurology", "Ophthalmic"], "modalityGroups": ["Other", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "antihistamine-IC265 combination (IC270", "phase": "Phase II", "indication": "Allergic conjunctivitis"}, {"name": "IC265", "phase": "Phase II", "indication": "Conjunctivitis"}, {"name": "IC 702", "phase": "Phase I", "indication": "Conjunctivitis"}, {"name": "IC 805", "phase": "Preclinical", "indication": "Pain"}, {"name": "IC800", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.iactapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iacta%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology", "Pain / Migraine"]}, {"company": "Iambic Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IAM1363 (ENT-H1", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "IAM-C1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Iambic Therapeutics-effector protein-unknown", "phase": "Research", "indication": "Solid tumors"}, {"name": "Iambic Therapeutics-protein-complex target-unknown", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.iambic.ai/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-09-26", "recentDeals": [{"headline": "Lundbeck and Iambic Therapeutics announce strategic partnership to leverage AI for drug discovery", "date": "2024-09-26", "value": ""}], "totalRaised": 200000000.0, "totalRaisedFmt": "$200M", "latestFinDate": "2025-11-10", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$100M", "date": "2025-11-10", "investors": "Abingworth LLP, Alexandria Venture Investments LLC, Alumni Ventures, Ark Investment Management LLC, Ascenta Capital, Cat..."}, {"type": "Series B rounds", "amount": "$100M", "date": "2023-10-03", "investors": "Ascenta Capital, Abingworth LLP, Nvidia Corp., Illumina Ventures, Gradiant Corp., Shanda Group, Bill Rastetter, Nexus Ve..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iambic%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "Solid Tumors (General)"]}, {"company": "Ibio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Infectious", "Pulmonary"], "modalityGroups": ["Antibody", "Other", "Peptide", "Vaccine"], "nProducts": 8, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "biosimilar rituximab (iBio rituximab)", "phase": "Preclinical", "indication": "Lymphoma"}, {"name": "IBIO-100 (IBIO-CFB03)", "phase": "Preclinical", "indication": "Scleroderma"}, {"name": "IBIO-101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "IBIO-200", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "IBIO-201", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "IBIO-600", "phase": "Preclinical", "indication": "Obesity"}, {"name": "IBIO-610", "phase": "Preclinical", "indication": "Obesity"}, {"name": "Plant-produced human alpha-galactosidase A", "phase": "Preclinical", "indication": "Fabry disease"}], "ceo": "Martin B. Brenner, PhD, DVM", "employees": 20, "founded": 2008, "website": "http://ibioinc.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 2937786.9, "evFmt": "$3M", "ticker": "IBIO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ibio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers", "Infectious Disease", "Obesity / Metabolic", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Icell Gene Therapeutics LLC", "city": "Stony Brook", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "CD4CAR", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "ICG138", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}, {"name": "ICGN1", "phase": "Preclinical", "indication": "B cell lymphoma"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.icellgene.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Icell%20Gene%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Ichnos Sciences Inc. (Ichnos Glenmark Innovation)", "city": "Paramus", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "telazorlimab (ISB 830", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "ALM27134 (ISB 880)", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "ISB 2001", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "STAR-0310", "phase": "Preclinical", "indication": "Dermatitis"}, {"name": "ISB 1342 (GBR 1342)", "phase": "Phase I/II", "indication": "Multiple myeloma (MM)"}, {"name": "ISB 1442", "phase": "Preclinical", "indication": "Acute lymphoblastic leukemia (ALL)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://iginnovate.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ichnos%20Sciences%20Inc.%20(Ichnos%20Glenmark%20Innovation)", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology", "Hematologic Cancers"]}, {"company": "Iconic Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Ophthalmic"], "modalityGroups": ["ADC", "Antibody", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ICON-2", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "ICON-1", "phase": "Phase II", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "ICON-4", "phase": "Preclinical", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.iconictherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iconic%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology", "Solid Tumors (General)"]}, {"company": "Iconovir Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ICVB-1042 (IOV-1042)", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://iconovir.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iconovir%20Bio", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Icura Vision", "city": "Westlake Village", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ICR-14967", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.icuravision.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Icura%20Vision", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Idbiologics Inc.", "city": "Nashville", "state": "TN", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IDB003", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.idbiologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Idbiologics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Ideaya Biosciences Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "GSK4362676", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "IDE161", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "IDE-275", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "AHR antagonist (IDE697)", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "IDE892", "phase": "IND", "indication": "Solid tumors"}, {"name": "IDE574", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "IDE705", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Yujiro S. Hata, MBA", "employees": 131, "founded": 2015, "website": "http://www.ideayabio.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1441978373.3, "evFmt": "$1.4B", "ticker": "IDYA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ideaya%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Iecure Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "GTP-506", "phase": "Preclinical", "indication": "Urea cycle disorder (UCD)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://iecure.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iecure", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Igan Biosciences Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Igan-IgA protease-unknown", "phase": "Preclinical", "indication": "IgA nephropathy"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.iganbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Igan%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Igc Pharma Inc. (Igc)", "city": "Bethesda", "state": "MD", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IGC-AD1", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "Naphthalene monoimide (TGR 63)", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "Ram Mukunda", "employees": 70, "founded": 2005, "website": "https://igcpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 21643394.875, "evFmt": "$22M", "ticker": "IGC", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Igc%20Pharma%20Inc.%20(Igc)", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Igenica Inc.", "city": "Burlingame", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Antibody"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IGN523", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "CRC-02", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "IGN786", "phase": "Preclinical", "indication": "Chronic lymphocytic leukemia (CLL)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.igenica.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Igenica", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers"]}, {"company": "Igf Oncology LLC", "city": "Birchwood", "state": "MN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "IGF-methotrexate (IGF-MTX)", "phase": "Phase I/II", "indication": "Myelodysplastic syndrome (MDS)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.igfoncology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Igf%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Iggenix Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IGNX001", "phase": "Phase I", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://iggenix.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iggenix", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Igxbio Inc.", "city": "Lenexa", "state": "KS", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GenePro", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://igxbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Igxbio", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Ihp Therapeutics Inc.", "city": "San Carlos", "state": "CA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IHP-102", "phase": "Preclinical", "indication": "Sickle cell disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.ihptherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ihp%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Ikaika Therapeutics Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IKN-001", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://ikaikatherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ikaika%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Ikano Therapeutics Inc.", "city": "Saddle Brook", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Nayzilam", "phase": "Marketed", "indication": "Seizures"}, {"name": "Ikano Therapeutics (hydromorphone)", "phase": "Phase II", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.ikanotherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ikano%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Pain / Migraine"]}, {"company": "Ikonisys Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "oncoFISH ALK", "phase": "Marketed", "indication": "Cancer, Diagnostic"}, {"name": "oncofish bladder", "phase": "Marketed", "indication": "Cardiovascular, Diagnostic"}, {"name": "oncofish her2", "phase": "Marketed", "indication": "Cancer, Diagnostic"}, {"name": "oncoFISH PTEN", "phase": "Marketed", "indication": "Cardiovascular, Diagnostic"}], "ceo": "Mario P. Crovetto", "employees": 15, "founded": 1999, "website": "http://www.ikonisys.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 21686716.955774, "evFmt": "$22M", "ticker": "ALIKO", "exchange": "Euronext Paris", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ikonisys", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Solid Tumors (General)"]}, {"company": "Iliad Biotechnologies LLC", "city": "Weston", "state": "FL", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "BPZE1", "phase": "Phase II", "indication": "Pertussis"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.iliadbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iliad%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Iliad Neurosciences Inc.", "city": "Plymouth Meeting", "state": "PA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "FRAT (folate receptor antibody test)", "phase": "Marketed", "indication": "Neurology, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://iliadneuro.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iliad%20Neurosciences", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Imagenebio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Protein / Biologic", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "IK-175 (KYN-175)", "phase": "Phase I", "indication": "Bladder cancer"}, {"name": "IK-930", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "PY159", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "PY314", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "IK-412 (KYN-412)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "IK-595", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "PY265", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Kristin Yarema, PhD", "employees": 10, "founded": 2019, "website": "https://inmagenebio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -37721704.323121, "evFmt": "", "ticker": "IMA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imagenebio", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Imaginab Inc.", "city": "Inglewood", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Antibody", "Diagnostics", "Radiopharmaceutical"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CD8 ImmunoPET (Zirconium Zr 89 crefmirlimab berdoxam", "phase": "Phase II", "indication": "Cancer, Diagnostic"}, {"name": "IAB2M", "phase": "Phase II", "indication": "Cancer, Diagnostic"}, {"name": "IR800-IAB2MA", "phase": "Phase I", "indication": "Cancer, Diagnostic"}, {"name": "89Zr-Df-IAB41M2C", "phase": "Preclinical", "indication": "Autoimmune, Diagnostic"}, {"name": "IAB2MA", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.imaginab.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imaginab", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Imagine Pharma Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Endocrine/Metabolic", "Hematology"], "modalityGroups": ["Cell Therapy", "Peptide", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Activated islet progenitor cells (AIPCs)", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "erythropoietin (EPO", "phase": "Preclinical", "indication": "Anemia"}, {"name": "IMG-1", "phase": "Preclinical", "indication": "Wounds"}, {"name": "Octreotide (PT-2)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "PT-3", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://imaginepharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 10000000.0, "totalRaisedFmt": "$10M", "latestFinDate": "2023-10-31", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$10M", "date": "2023-10-31", "investors": "Ip Investors LLC"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imagine%20Pharma", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Diabetes", "Hematology (non-cancer)", "Solid Tumors (General)"]}, {"company": "Imbria Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ninerafaxstat (IMB-101", "phase": "Phase II", "indication": "Cardiomyopathy"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.imbria.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imbria%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Imetabolic Biopharma Corp.", "city": "Tempe", "state": "AZ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic", "Renal"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "iMBP-001", "phase": "Preclinical", "indication": "Hypertriglyceridemia"}, {"name": "iMBP-EX-03", "phase": "Preclinical", "indication": "Diabetic nephropathy"}, {"name": "iMBP-He-03", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "iMBP-XR-02", "phase": "Preclinical", "indication": "Diabetic nephropathy"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://imbiopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imetabolic%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Obesity / Metabolic"]}, {"company": "Immediate Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IMT-358", "phase": "Phase II", "indication": "Acute coronary syndrome"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://immtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immediate%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Immix Biopharma Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Cell Therapy", "Nanoparticle / Delivery", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "IMX-110", "phase": "Phase I/II", "indication": "Sarcoma"}, {"name": "NXC-201 (HBI0101)", "phase": "Phase I/II", "indication": "Multiple myeloma (MM)"}, {"name": "Imx-111", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Ilya Rachman, MD, PhD", "employees": 21, "founded": 2012, "website": "http://www.immixbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 45621217.4, "evFmt": "$46M", "ticker": "IMMX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immix%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Immune Response Biopharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Ravax", "phase": "Phase III", "indication": "Rheumatoid arthritis (RA)"}, {"name": "NeuroVax (IR208)", "phase": "Phase II", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.immuneresponsebiopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immune%20Response%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "MS / Neuroimmune"]}, {"company": "Immune-onc Therapeutics Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Cell Therapy"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "IO-108", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "IO-202", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Immune-Onc Therapeutics-LILRB4-unknown", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "IO-106", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "IO-312", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.immune-onc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immune-onc%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Immuneering Corp.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "atebimetinib (IMM-1-104)", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "IMM-6-415", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Benjamin J. Zeskind, PhD, MBA", "employees": 66, "founded": 2008, "website": "https://immuneering.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 33977580.0, "evFmt": "$34M", "ticker": "IMRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immuneering", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Immunesensor Therapeutics Inc.", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "GB492", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.immunesensor.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunesensor%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Immunext Inc.", "city": "Lebanon", "state": "NH", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Renal"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "frexalimab (INX-021", "phase": "Phase III", "indication": "Multiple sclerosis (MS)"}, {"name": "Anti-VISTA", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.immunext.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunext", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune", "Solid Tumors (General)"]}, {"company": "Immungene Inc.", "city": "Camarillo", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IGN002 (Anti\u2013CD20-IFN\u03b1)", "phase": "Phase I", "indication": "Lymphoma"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.immungene.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immungene", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Immunic Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "vidofludimus calcium (IMU-838)", "phase": "Phase III", "indication": "Multiple sclerosis (MS)"}, {"name": "IMU-935", "phase": "Phase I", "indication": "Psoriasis"}], "ceo": "Daniel Vitt, PhD", "employees": 91, "founded": 2016, "website": "https://imux.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 65510766.0, "evFmt": "$66M", "ticker": "IMUX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunic", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "MS / Neuroimmune"]}, {"company": "Immunis Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IMM01-STEM (IMMUNA)", "phase": "Phase II", "indication": "Muscular atrophy"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://immunisbiomedical.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-05-22", "recentDeals": [{"headline": "Immunis licensed development and commercial rights to TRK-820 from Japanese drug company Toray to reverse sarcopenia", "date": "2024-05-22", "value": ""}], "totalRaised": 35000000.0, "totalRaisedFmt": "$35M", "latestFinDate": "2025-01-11", "latestFinType": "Series A rounds", "nRounds": 3, "recentFinancing": [{"type": "Series A rounds", "amount": "$25M", "date": "2025-01-11", "investors": "Remiges Ventures, Continuum Health Ventures, Bold Capital Partners, Lifespan Vision Ventures, Jls Fund, Undisclosed Inve..."}, {"type": "Series A rounds", "amount": "$10M", "date": "2022-08-03", "investors": "Remiges Ventures, Undisclosed Investors, Continuum Health Ventures"}, {"type": "Seed financings", "amount": "", "date": "2022-01-01", "investors": "Healthspan Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunis", "hasDealsFin": true, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Immunitas Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "IMT-009", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://www.immunitastx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunitas%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Immunitor Inc.", "city": "Vancouver", "state": "BC", "country": "United States", "diseaseCats": ["Cancer", "Hepatic", "Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Hepcortespenlisimut-L (V5)", "phase": "Phase II", "indication": "Liver cancer"}, {"name": "V3-P", "phase": "Phase I/II", "indication": "Pancreatic cancer"}, {"name": "V3-X", "phase": "Phase I/II", "indication": "Biliary cancer"}, {"name": "V-SARS", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.immunitor.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunitor", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Infectious Disease"]}, {"company": "Immunitybio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Cell Therapy", "Gene Therapy"], "nProducts": 11, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Ad5[E1-", "phase": "Phase II", "indication": "Cancer (unspecified)"}, {"name": "ANK (NK-92", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "PD-L1 t-haNK", "phase": "Phase II", "indication": "Pancreatic cancer"}, {"name": "Ad5-Covid-S/N (Ad5 2nd Generation Adenovirus)", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "BM-Allo-MSC", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "CD19.taNK", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "ceNK", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "HaNK cell therapy", "phase": "IND", "indication": "Breast cancer"}], "ceo": "Richard Adcock, MBA", "employees": 680, "founded": 2014, "website": "https://immunitybio.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2434112080.0, "evFmt": "$2.4B", "ticker": "IBRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunitybio", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Hematologic Cancers", "Infectious Disease", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Immunochem Therapeutics LLC", "city": "Auburndale", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "MW01-6-189WH", "phase": "Phase II", "indication": "Stroke"}, {"name": "MW01-2-151SRM", "phase": "Phase I", "indication": "Cognitive dysfunction"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.ict-rx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunochem%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Other Neurology"]}, {"company": "Immunogenesis Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IMGS-001", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "IMGS-501", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ImmunoGenesis-PD-L1/PD-L2 + 4-1BB-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "ImmunoGenesis-PD-L1/PD-L2 + CTLA-4-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.immunogenesis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 4500000.0, "totalRaisedFmt": "$4M", "latestFinDate": "2023-06-27", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$4M", "date": "2023-06-27", "investors": "Cancer Focus Fund"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunogenesis", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Immunome Inc.", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Antibody", "Radiopharmaceutical"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "APN-497444", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "IM-1021 (ZPC-21)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "IM-4320 (IMM-ONC-01", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Immunome-FAP RLT-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Clay B. Siegall, PhD", "employees": 118, "founded": 2006, "website": "https://www.immunome.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 410279863.42, "evFmt": "$410M", "ticker": "IMNM", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-07-25", "recentDeals": [{"headline": "Nectin Therapeutics Licenses Novel Antibodies to Immunome", "date": "2024-07-25", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunome", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Immunomet Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "IM156", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "IM188", "phase": "Preclinical", "indication": "Lung cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://immunomet.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunomet%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer", "Solid Tumors (General)"]}, {"company": "Immunomic Therapeutics Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Cell Therapy", "Vaccine"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ITI-1000", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "ITI-1001", "phase": "Phase I", "indication": "Brain cancer"}, {"name": "ITI-3000", "phase": "Phase I", "indication": "Skin cancer"}, {"name": "ITI-2000", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "ITI-ID Candidate", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.immunomix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunomic%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Infectious Disease", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Immunomolecular Therapeutics Inc.", "city": "Broomfield", "state": "CO", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "IMT-002", "phase": "Phase I", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://imtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunomolecular%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Immunophotonics Inc.", "city": "Columbia", "state": "MO", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IP-001", "phase": "Phase II", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.immunophotonics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunophotonics", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Immunotech Laboratories Inc.", "city": "Pasadena", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Immune therapeutic vaccine-1 (ITV-1)", "phase": "Phase I", "indication": "HIV/AIDS"}, {"name": "ITV-2", "phase": "Phase I", "indication": "Hepatitis C virus (HCV)"}], "ceo": "Harry H. Zhabilov, Jr.", "employees": 1, "founded": 2000, "website": "http://www.immunotechlab.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 3179550.0, "evFmt": "$3M", "ticker": "IMMB", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunotech%20Laboratories", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Immunotope Inc.", "city": "Doylestown", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IMT-1012", "phase": "Phase I", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.immunotope.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunotope", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Immunova Therapeutics LLC", "city": "Monrovia", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy", "Vaccine"], "nProducts": 3, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "Immunova Therapeutics-CAR-T-unknown", "phase": "IND", "indication": "B cell lymphoma"}, {"name": "Immunova Therapeutics-TCR-T-unknown", "phase": "IND", "indication": "Breast cancer"}, {"name": "Immunova Therapeutics-Vaccine-unknown", "phase": "IND", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.immunovatherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunova%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Immunowake Inc.", "city": "Birmingham", "state": "AL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Immunowake-PD-L1/VEGF trap-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.immunowake.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immunowake", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Immusoft Corp.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": true, "pipeline": [{"name": "ISP-001", "phase": "IND", "indication": "Mucopolysaccharidosis"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.immusoft.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immusoft", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Immuven Inc.", "city": "Champaign", "state": "IL", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IMV0123", "phase": "Preclinical", "indication": "Staphylococcus"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.immuven.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immuven", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Immvention Therapeutix Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hematology", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IMM\u2013002 Systemic (IMM\u2013002)", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "IMM\u2013004 Systemic (IMM\u2013004)", "phase": "Preclinical", "indication": "Sickle cell disease"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://immventionthera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Immvention%20Therapeutix", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Obesity / Metabolic"]}, {"company": "Impact Biomedical Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LB-1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "LB-2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Frank D. Heuszel, CPA", "employees": 2, "founded": 2018, "website": "https://www.impactbiomedinc.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 26597734.75, "evFmt": "$27M", "ticker": "IBO", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Impact%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Imstem Biotechnology Inc.", "city": "Farmington", "state": "CT", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Infectious", "Musculoskeletal", "Pulmonary", "Transplant"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IMS001", "phase": "Phase I", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.imstem.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imstem%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Imunon Inc.", "city": "Lawrenceville", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Gene Therapy", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ThermoDox", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "GEN-1 (EGEN-001)", "phase": "Phase I/II", "indication": "Colorectal cancer"}, {"name": "Celsion-SARS-CoV-2 S-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Stacy R. Lindborg, PhD", "employees": 25, "founded": 1982, "website": "https://imunon.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 6199277.05, "evFmt": "$6M", "ticker": "IMNN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imunon", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Imvaq Therapeutics Corp.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "MQ710", "phase": "IND", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.imvaq.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imvaq%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Imvax Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IGV-001", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "IHV-001", "phase": "Preclinical", "indication": "Liver cancer"}, {"name": "IOV-001", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "IPV-001", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.imvax.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imvax", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GI Cancers", "GU / Gynecologic Cancers"]}, {"company": "Imviva US Holdings LLC (\u5317\u6052\u751f\u7269)", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CTD402", "phase": "Phase I/II", "indication": "T cell lymphoma"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.imvivabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Imviva%20US%20Holdings%20LLC%20(\u5317\u6052\u751f\u7269)", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "In8bio Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "DeltEx Allo DRI (INB-400)", "phase": "Phase I/II", "indication": "Brain cancer"}, {"name": "INB-100", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "INB-200", "phase": "Phase I", "indication": "Brain cancer"}], "ceo": "William T. Ho, MBA", "employees": 18, "founded": 2016, "website": "https://in8bio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7682296.116, "evFmt": "$8M", "ticker": "INAB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=In8bio", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Hematologic Cancers"]}, {"company": "Incarda Therapeutics Inc.", "city": "Newark", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "InRhythm", "phase": "Phase II", "indication": "Fibrillation"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://incardatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Incarda%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Incendia Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PRTH-101", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.incendiatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Incendia%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Inceptor Bio LLC", "city": "Morrisville", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "Phase 0", "hasOrphan": false, "pipeline": [{"name": "IB-T101", "phase": "Phase 0", "indication": "Renal cancer"}, {"name": "Inceptor Bio-CAR-M-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Inceptor Bio-CAR-T-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Inceptor Bio-CAR-NK-unknown", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.inceptor.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-06-30", "recentDeals": [{"headline": "Inceptor Bio announces strategic collaboration with University of Minnesota to develop novel iPSC platform for the advancement of next-generation allogeneic cell therapies", "date": "2022-06-30", "value": ""}], "totalRaised": 21000000.0, "totalRaisedFmt": "$21M", "latestFinDate": "2025-02-25", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$21M", "date": "2025-02-25", "investors": "Kineticos Life Sciences, Undisclosed Investors"}, {"type": "Series A rounds", "amount": "", "date": "2022-05-19", "investors": "Kineticos Life Sciences"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inceptor%20Bio", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Incyclix Bio LLC", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "INX-315", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://incyclixbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Incyclix%20Bio", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Incyte Corp.", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Diagnostic", "Hematology", "Hepatic", "Infectious", "Musculoskeletal", "Pulmonary", "Transplant"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Other", "Small Molecule"], "nProducts": 24, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Jakafi", "phase": "Marketed", "indication": "Myeloproliferative disorder"}, {"name": "Olumiant", "phase": "Marketed", "indication": "Alopecia areata"}, {"name": "Opzelura", "phase": "Marketed", "indication": "Vitiligo"}, {"name": "Pemazyre", "phase": "Marketed", "indication": "Biliary cancer"}, {"name": "Tabrecta (capmatinib", "phase": "Marketed", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "parsaclisib (INCB050465", "phase": "Registration", "indication": "Mantle cell lymphoma (MCL)"}, {"name": "epacadostat (INCB24360", "phase": "Phase III", "indication": "Melanoma"}, {"name": "Povorcitinib (INCB54707)", "phase": "Phase III", "indication": "Vitiligo"}], "ceo": "William J. Meury", "employees": 0, "founded": 1991, "website": "http://www.incyte.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 16277250000.0, "evFmt": "$16.3B", "ticker": "INCY", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Incyte", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "GI Cancers", "Hematologic Cancers", "Lung Cancer", "Skin Cancer / Melanoma"]}, {"company": "Incytu Inc.", "city": "Lincoln", "state": "RI", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Cellarium vaccine", "phase": "Preclinical", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.incytu.org", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Incytu", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Indalo Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IDL-2965", "phase": "Phase I", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "CWHM-12", "phase": "Preclinical", "indication": "Liver fibrosis"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.indalotherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Indalo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Obesity / Metabolic"]}, {"company": "Indapta Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "IDP-023", "phase": "Phase I/II", "indication": "Lymphoma"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://indapta.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Indapta%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Indaptus Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Decoy20", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "Decoy10", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "INDP012", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "INDP014", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "David Elliot Lazar; Jeffrey A. Meckler", "employees": 7, "founded": 2013, "website": "https://indaptusrx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 2175855.251171, "evFmt": "$2M", "ticker": "INDP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Indaptus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)"]}, {"company": "Indivior plc", "city": "Richmond", "state": "VA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Combination", "Digital / Device", "Small Molecule", "Vaccine"], "nProducts": 13, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Narcan", "phase": "Marketed", "indication": "Substance use disorders"}, {"name": "Opvee", "phase": "Marketed", "indication": "Substance use disorders"}, {"name": "Sublocade", "phase": "Marketed", "indication": "Substance use disorders"}, {"name": "Suboxone sublingual film", "phase": "Marketed", "indication": "Substance use disorders"}, {"name": "Suboxone", "phase": "Marketed", "indication": "Substance use disorders"}, {"name": "Perseris", "phase": "Approved", "indication": "Schizophrenia"}, {"name": "Naloxone nasal spray", "phase": "Registration", "indication": "Neurology (unspecified)"}, {"name": "Naloxone intranasal", "phase": "Phase III", "indication": "Substance use disorders"}], "ceo": "Joseph J. Ciaffoni, MBA", "employees": 1051, "founded": 2014, "website": "http://indivior.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1708189982.12539, "evFmt": "$1.7B", "ticker": "INDV", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Indivior", "hasDealsFin": false, "diseaseGroups": ["Other Neurology", "Psychiatry / Behavioral"]}, {"company": "Indupro Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IDP-003", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.induprotx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 950000000.0, "totalDealFmt": "$950M", "latestDealDate": "2026-01-07", "recentDeals": [{"headline": "InduPro Therapeutics Announces Strategic Collaboration with Lilly to Develop First-in-Class Bispecific/Multispecific Oncology Therapeutics Using InduPro\u2019s Proximity-Guided Platform", "date": "2026-01-07", "value": "$950M"}], "totalRaised": 85000000.0, "totalRaisedFmt": "$85M", "latestFinDate": "2026-01-07", "latestFinType": "Uncategorized venture rounds", "nRounds": 3, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2026-01-07", "investors": "Eli Lilly and Co."}, {"type": "Uncategorized venture rounds", "amount": "", "date": "2025-12-10", "investors": "Sanofi"}, {"type": "Series A rounds", "amount": "$85M", "date": "2024-06-13", "investors": "The Column Group, Vida Ventures, Mrl Ventures Fund, Emerson Collective, Euclidean Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Indupro", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Infinant Health Inc.", "city": "Davis", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Gastrointestinal"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Evivo (EVC001)", "phase": "Marketed", "indication": "Gastrointestinal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.evolvebiosystems.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Infinant%20Health", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Inflabloc Pharmaceuticals Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IP-1001", "phase": "Phase II", "indication": "Crohn's disease"}], "ceo": "", "employees": 0, "founded": 1991, "website": "http://www.inflabloc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inflabloc%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Inflamacore LLC", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IC 100", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.inflamacore.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inflamacore", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Inflammx Therapeutics Inc.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Peptide", "RNA Therapeutics", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Nexagon", "phase": "Phase II", "indication": "Corneal wound"}, {"name": "Xiflam (HCB1019)", "phase": "Phase II", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "Xentry-Gap19 (Peptagon)", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://inflammx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inflammx%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Ophthalmology"]}, {"company": "Inhalon Biopharma Inc.", "city": "Carrboro", "state": "NC", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IN-006", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "IN-002", "phase": "Preclinical", "indication": "Respiratory syncytial virus (RSV)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.inhalon.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inhalon%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Inhibikase Therapeutics Inc.", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "IkT-001Pro", "phase": "Phase I", "indication": "Chronic myelogenous leukemia (CML)"}, {"name": "IkT-01427", "phase": "Preclinical", "indication": "Viral infection"}, {"name": "IkT-148x", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "Mark T. Iwicki, MBA", "employees": 16, "founded": 2008, "website": "https://www.inhibikase.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -20368296.0, "evFmt": "", "ticker": "IKT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inhibikase%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Infectious Disease", "Other Neurology"]}, {"company": "Inhibrx Biosciences Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ozekibart (INBRX-109", "phase": "Phase II", "indication": "Sarcoma"}, {"name": "INBRX-106 (ES102)", "phase": "Phase I", "indication": "Esophageal cancer"}], "ceo": "Mark Paul Lappe", "employees": 161, "founded": 2024, "website": "https://inhibrx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 78380921.6, "evFmt": "$78M", "ticker": "INBX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inhibrx%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Other Solid Tumors"]}, {"company": "Inimmune Corp.", "city": "Missoula", "state": "MT", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "INI-2004", "phase": "Phase I", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://inimmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inimmune", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Inmune Bio Inc.", "city": "Boca Raton", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Gastrointestinal", "Hepatic", "Musculoskeletal", "Neurology"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "XPro1595", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "INKmune", "phase": "Phase I", "indication": "Myelodysplastic syndrome (MDS)"}, {"name": "LIVNate", "phase": "Phase I", "indication": "Gastrointestinal (unspecified)"}, {"name": "INmune Bio-DN-TNF-unknown", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "David J. Moss, MBA", "employees": 22, "founded": 2015, "website": "https://www.inmunebio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 72601899.68, "evFmt": "$73M", "ticker": "INMB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inmune%20Bio", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Hematologic Cancers", "Neurodegeneration / NMD", "Other"]}, {"company": "Innova Therapeutics Inc.", "city": "Isle Of Palms", "state": "SC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "IVT-8086", "phase": "Preclinical", "indication": "Bone cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.innovatherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Innova%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Innovac Therapeutics Usa Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "INV001", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.innovactx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Innovac%20Therapeutics%20Usa", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Innovation Pharmaceuticals Inc.", "city": "Beverly", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Infectious", "Other"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "brilacidin", "phase": "Phase II", "indication": "Ulcerative colitis"}, {"name": "Brilacidin-OM", "phase": "Phase II", "indication": "Mucositis"}, {"name": "iv brilacidin (pmx-30063)", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Kevetrin", "phase": "Phase II", "indication": "Ovarian cancer"}, {"name": "Prurisol", "phase": "Phase II", "indication": "Psoriasis"}, {"name": "CTIX-1502", "phase": "Preclinical", "indication": "Candida"}], "ceo": "Leo Ehrlich, CPA", "employees": 0, "founded": 2007, "website": "http://www.ipharminc.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "IPIX", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Innovation%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "GU / Gynecologic Cancers", "IBD / GI Inflammatory", "Infectious Disease", "Supportive / Other"]}, {"company": "Innovations in Sight LLC", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Vitreosolve", "phase": "Phase III", "indication": "Diabetic retinopathy"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.innovations-insight.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Innovations%20in%20Sight", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Innovimmune Biotherapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Inflammation", "Ophthalmic", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "INV-17", "phase": "Preclinical", "indication": "Ankylosing spondylitis"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.innovimmune.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Innovimmune%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Innoviva Inc.", "city": "Burlingame", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Hepatic", "Infectious", "Musculoskeletal", "Pulmonary"], "modalityGroups": ["Other", "Peptide", "Small Molecule", "Undisclosed"], "nProducts": 15, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Giapreza", "phase": "Marketed", "indication": "Hypotension"}, {"name": "Xacduro", "phase": "Marketed", "indication": "Bacterial infection"}, {"name": "Xerava", "phase": "Marketed", "indication": "Intra-abdominal infection"}, {"name": "zoliflodacin (ETX0914", "phase": "Registration", "indication": "Sexually transmitted disease (STD)"}, {"name": "durlobactam (ETX2514)", "phase": "Phase II", "indication": "Bacterial infection"}, {"name": "LJPC-0118", "phase": "Phase II", "indication": "Malaria"}, {"name": "ETX0282", "phase": "Phase I", "indication": "Gram-negative bacterial infection"}, {"name": "TP-271", "phase": "Phase I", "indication": "Bacterial respiratory infection"}], "ceo": "Pavel Raifeld, CFA, MBA", "employees": 127, "founded": 1996, "website": "http://www.inva.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1325743450.0, "evFmt": "$1.3B", "ticker": "INVA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Innoviva", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Infectious Disease", "Other", "Respiratory / Allergy"]}, {"company": "Inomagen Therapeutics Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NOX2 shRNA", "phase": "Preclinical", "indication": "Fibrillation"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://inomagen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inomagen%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Inovio Pharmaceuticals Inc.", "city": "Plymouth Meeting", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Gastrointestinal", "Genitourinary", "Infectious"], "modalityGroups": ["Antibody", "Cell Therapy", "Digital / Device", "Vaccine"], "nProducts": 17, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "INO-4800", "phase": "Phase III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Biojector 2000 (B-2000)", "phase": "Marketed", "indication": "Influenza virus"}, {"name": "Cool.click", "phase": "Marketed", "indication": "Growth failure"}, {"name": "SeroJet", "phase": "Marketed", "indication": "Cachexia"}, {"name": "INO-3107", "phase": "Registration", "indication": "Human papillomavirus (HPV)"}, {"name": "VGX-3100", "phase": "Phase III", "indication": "Cervical cancer"}, {"name": "INO-5151", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "INO-5401", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "Jacqueline E. Shea, PhD", "employees": 134, "founded": 1983, "website": "http://www.inovio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -32543962.71, "evFmt": "", "ticker": "INO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inovio%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors", "GU / Gynecologic Cancers", "Infectious Disease", "Obesity / Metabolic", "Other"]}, {"company": "Insero Health Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Huperzine A (INS001)", "phase": "Phase I", "indication": "Epilepsy"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.inserohealth.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Insero%20Health", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures"]}, {"company": "Insilico Medicine Inc. (\u82f1\u77fd\u667a\u80fd)", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Endocrine/Metabolic", "Hematology", "Infectious", "Inflammation", "Neurology", "Pulmonary", "Renal"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 40, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "INS018_055", "phase": "Phase II", "indication": "Pulmonary fibrosis"}, {"name": "rentosertib (ISM001-055)", "phase": "Phase II", "indication": "Pulmonary fibrosis"}, {"name": "ISM3312", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "ISM3412", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "ISM5411", "phase": "Phase I", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "ISM6331", "phase": "Phase I", "indication": "Mesothelioma"}, {"name": "ISM8207", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "MEN2312 (ISM5043)", "phase": "Phase I", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.insilicomedicine.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "3696", "exchange": "HKEX", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 318000000.0, "totalRaisedFmt": "$318M", "latestFinDate": "2025-06-15", "latestFinType": "Series E rounds", "nRounds": 6, "recentFinancing": [{"type": "Series E rounds", "amount": "$13M", "date": "2025-06-15", "investors": "Value Partners, Pudong Venture Capital (\u6d66\u4e1c\u521b\u6295\u96c6\u56e2), Shanghai Pudong Development Bank, Wuxi Capital, Yixing State-owned Inve..."}, {"type": "Series E rounds", "amount": "$110M", "date": "2025-03-13", "investors": "Value Partners, Pudong Venture Capital (\u6d66\u4e1c\u521b\u6295\u96c6\u56e2), Shanghai Pudong Development Bank, Wuxi Capital, Yixing State-owned Inve..."}, {"type": "Venture (Debt)", "amount": "$100M", "date": "2024-12-05", "investors": "Hsbc Hong Kong"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Insilico%20Medicine%20Inc.%20(\u82f1\u77fd\u667a\u80fd)", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "IBD / GI Inflammatory", "Infectious Disease", "Lung Cancer", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Insitu Biologics Inc.", "city": "Woodbury", "state": "MN", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AnestaGel\u2122(INSB200)", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://insitubiologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-12-22", "recentDeals": [{"headline": "InSitu Biologics announces license agreement with Mayo Clinic for co-development of anti-cancer therapeutics", "date": "2022-12-22", "value": ""}], "totalRaised": 3950000.0, "totalRaisedFmt": "$4M", "latestFinDate": "2025-11-13", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$4M", "date": "2025-11-13", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Insitu%20Biologics", "hasDealsFin": true, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Insmed Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Cardiovascular", "Infectious", "Ophthalmic", "Pulmonary"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Arikayce", "phase": "Marketed", "indication": "Mycobacterium"}, {"name": "Premiplex", "phase": "Phase II", "indication": "Retinopathy of prematurity"}, {"name": "Treprostinil Palmitil (INS1009)", "phase": "Phase I", "indication": "Hypertension"}, {"name": "RV94", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "Will Lewis, MBA", "employees": 1271, "founded": 1988, "website": "http://www.insmed.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 11205823720.0, "evFmt": "$11.2B", "ticker": "INSM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Insmed", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Infectious Disease", "Other"]}, {"company": "Inspirna Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ompenaclid (RGX-202", "phase": "Phase II", "indication": "Colorectal cancer"}, {"name": "RGX-104", "phase": "Phase I/II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "RGX-019", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://inspirna.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-01-04", "recentDeals": [{"headline": "Merck KGaA, Darmstadt, Germany, Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna", "date": "2024-01-04", "value": ""}], "totalRaised": 50000000.0, "totalRaisedFmt": "$50M", "latestFinDate": "2022-07-11", "latestFinType": "Series D rounds", "nRounds": 1, "recentFinancing": [{"type": "Series D rounds", "amount": "$50M", "date": "2022-07-11", "investors": "Sands Capital Ventures, Vivo Capital, Dreavent 6, Novo Holdings A/S, Sofinnova Partners, Sixty Degree Capital, The New Y..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inspirna", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Lung Cancer"]}, {"company": "Instil Bio Inc.", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ITIL-306", "phase": "Phase I", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "Bronson Crouch", "employees": 14, "founded": 2018, "website": "https://instilbio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 96019534.42, "evFmt": "$96M", "ticker": "TIL", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 2120000000.0, "totalDealFmt": "$2.1B", "latestDealDate": "2024-08-01", "recentDeals": [{"headline": "Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody", "date": "2024-08-01", "value": "$2.1B"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Instil%20Bio", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Integerbio Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IB-001", "phase": "Preclinical", "indication": "Hepatitis"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://integer.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Integerbio", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Integrated Biotherapeutics LLC", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "LBT-SA7 (IBT-V02)", "phase": "Phase I", "indication": "Staphylococcus"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.integratedbiotherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Integrated%20Biotherapeutics", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Intellia Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Hematology", "Hepatic", "Inflammation"], "modalityGroups": ["Gene Therapy"], "nProducts": 7, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "lonvo-z", "phase": "Phase III", "indication": "Angioedema"}, {"name": "nex-z", "phase": "Phase III", "indication": "Amyloidosis"}, {"name": "OTQ923", "phase": "Phase I", "indication": "Sickle cell disease"}, {"name": "Intellia Therapeutics-hemophilia B-unknown", "phase": "Preclinical", "indication": "Hemophilia"}, {"name": "NTLA-2003", "phase": "Preclinical", "indication": "Liver disease"}, {"name": "NTLA-3001", "phase": "Preclinical", "indication": "Alpha-antitrypsin (AAT) deficiency"}, {"name": "NTLA-6001", "phase": "Preclinical", "indication": "Lymphoma"}], "ceo": "John M. Leonard, MD", "employees": 403, "founded": 2014, "website": "http://intelliatx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 761262340.0, "evFmt": "$761M", "ticker": "NTLA", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 184000000.0, "totalDealFmt": "$184M", "latestDealDate": "2022-02-15", "recentDeals": [{"headline": "Intellia and ONK Therapeutics Announce Collaboration to Advance\u00a0Allogeneic CRISPR-Edited NK Cell Therapies for the\u00a0Treatment of Patients with Cancer", "date": "2022-02-15", "value": "$184M"}, {"headline": "Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases", "date": "2022-01-05", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Intellia%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Hematology (non-cancer)", "Liver Disease", "Other Inflammation", "Rare / Genetic", "Supportive / Other"]}, {"company": "Intensity Therapeutics Inc.", "city": "Shelton", "state": "CT", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "INT230-6", "phase": "Phase II", "indication": "Breast cancer"}], "ceo": "Lewis H. Bender, MBA", "employees": 16, "founded": 2012, "website": "http://www.intensitytherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 22024272.48, "evFmt": "$22M", "ticker": "INTS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Intensity%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Interactome Biotherapeutics Inc.", "city": "Kalamazoo", "state": "MI", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Interactome Biotherapeutics (IB001)", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://interactomebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Interactome%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "International Stem Cell Corp.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Hepatic", "Inflammation", "Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "HpNSCs", "phase": "Phase I/II", "indication": "Parkinson's disease"}, {"name": "ChondroStem", "phase": "Preclinical", "indication": "Osteoarthritis"}, {"name": "HpSC-derived hepatocytes (cytohep)", "phase": "Preclinical", "indication": "Cirrhosis"}], "ceo": "Andrey Semechkin, PhD", "employees": 32, "founded": 2005, "website": "http://www.internationalstemcell.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7565756.8257, "evFmt": "$8M", "ticker": "ISCO", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=International%20Stem%20Cell", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Other", "Parkinson's"]}, {"company": "Intervexion Therapeutics LLC", "city": "Little Rock", "state": "AR", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IXT-m200 (Ch-mAb7F9)", "phase": "Phase II", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.intervexion.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Intervexion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Intezyne Inc.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "IT-139", "phase": "Phase I/II", "indication": "Gastric cancer"}, {"name": "IT-141", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "IT-147", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.intezyne.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Intezyne", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Solid Tumors (General)"]}, {"company": "Intima Bioscience Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Intima Bioscience-CISH-unknown", "phase": "Phase I/II", "indication": "Gastrointestinal cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.intimabioscience.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Intima%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Intrabio Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Aqneursa", "phase": "Approved", "indication": "Glycosphingolipid storage disorders"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://intrabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Intrabio", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Intrepida Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Intrepida Bio (IB001)", "phase": "Preclinical", "indication": "Pancreatic cancer"}, {"name": "Intrepida Bio-cancer-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://intrepidabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Intrepida%20Bio", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Intrinsic Medicine Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Gastrointestinal", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "OM002 (2\u2019-fucosyllactose)", "phase": "Phase I", "indication": "Irritable bowel syndrome"}, {"name": "OM001 (3\u2019sialyllactose)", "phase": "Preclinical", "indication": "Arthritis"}, {"name": "OM003 (6\u2019-sialyllactose)", "phase": "Preclinical", "indication": "Autism"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.intrinsicmedicine.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Intrinsic%20Medicine", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Other", "Psychiatry / Behavioral"]}, {"company": "Intrommune Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "INT301", "phase": "Phase I", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.intrommune.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Intrommune%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Invamet Therapeutics Inc.", "city": "Henrico", "state": "VA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PDZ1i", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Invamet%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Invasc Therapeutics Inc.", "city": "Tucker", "state": "GA", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "INV-144", "phase": "Phase II", "indication": "Diabetic nephropathy"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.invasc.net", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Invasc%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Invea Therapeutics Inc.", "city": "Guilford", "state": "CT", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "INVA8003", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://inveatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Invea%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Invectys Inc.", "city": "Huston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Cell Therapy", "Vaccine"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "INVAC1", "phase": "Phase II", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "UCPvax", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "IVS-3001", "phase": "IND", "indication": "Renal cancer"}, {"name": "INMAB-1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.invectys.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Invectys", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Invent Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "INV-300", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "INV-400", "phase": "Phase I", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.inventpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Invent%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Psychiatry / Behavioral"]}, {"company": "Inventprise LLC", "city": "Redmond", "state": "WA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 5, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "IVT-25", "phase": "IND", "indication": "Pneumococcus"}, {"name": "IVT-Pneumo Conj. Vacc. Adult", "phase": "IND", "indication": "Pneumococcus"}, {"name": "IVT-Group B Strep-06", "phase": "Preclinical", "indication": "Streptococcus"}, {"name": "IVT-Haemophilus influenzae type A", "phase": "Preclinical", "indication": "Haemophilus"}, {"name": "IVT-Shigella", "phase": "Preclinical", "indication": "Diarrhea (infectious)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://inventprise.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Inventprise", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Invero Pharma LLC", "city": "Montville", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Xenex", "phase": "Phase III", "indication": "Cognitive dysfunction"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://inveropharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Invero%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Invirsa Inc.", "city": "Columbus", "state": "OH", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "INV-102", "phase": "Preclinical", "indication": "Conjunctivitis"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://invirsa.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Invirsa", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Invivis Pharmaceuticals Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "onapristone", "phase": "Phase I/II", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.invivis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Invivis%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Invivyd Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Pemgarda", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Adintrevimab (ADG20)", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "ADG10", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "NVD200", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "William E. Duke, Jr., MBA", "employees": 99, "founded": 2020, "website": "https://www.invivyd.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -15513247.1537, "evFmt": "", "ticker": "IVVD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Invivyd", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Io Therapeutics Inc.", "city": "Santa Ana", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Hematology", "Inflammation", "Neurology"], "modalityGroups": ["Gene Therapy", "Other"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IRX4204", "phase": "Phase I", "indication": "Multiple sclerosis (MS)"}, {"name": "IRX4310", "phase": "Phase I", "indication": "Neutropenia"}, {"name": "IRX4647", "phase": "Preclinical", "indication": "Lung cancer"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.io-therapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Io%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Lung Cancer", "MS / Neuroimmune"]}, {"company": "Iolyx Therapeutics Inc.", "city": "Burlingame", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ILYX-002", "phase": "Phase II", "indication": "Dry eye"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://iolyx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 280000000.0, "totalDealFmt": "$280M", "latestDealDate": "2025-12-03", "recentDeals": [{"headline": "Iolyx Therapeutics Enters Strategic Agreement with Laboratoires Th\u00e9a to Develop and Commercialize ILYX-002 intended for the Treatment of Autoimmune Associated Dry Eye Disease", "date": "2025-12-03", "value": "$280M"}], "totalRaised": 15000000.0, "totalRaisedFmt": "$15M", "latestFinDate": "2025-12-03", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$15M", "date": "2025-12-03", "investors": "Frazier Life Sciences, Gc&h Investments"}, {"type": "Series A rounds", "amount": "", "date": "2023-04-20", "investors": "Alumni Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iolyx%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Ophthalmology"]}, {"company": "Ioncologi Inc.", "city": "Gainesville", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy", "Nanoparticle / Delivery"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "iOi7", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "IONC201", "phase": "Preclinical", "indication": "Bladder cancer"}, {"name": "TAR002", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://ioncologi.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ioncologi", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Ionis Pharmaceuticals Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Endocrine/Metabolic", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Ophthalmic", "Other", "Pulmonary", "Renal"], "modalityGroups": ["Other", "RNA Therapeutics", "Small Molecule"], "nProducts": 51, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "IONIS-GCGRRx", "phase": "Phase II", "indication": "Diabetes"}, {"name": "tonlamarsen (ION904)", "phase": "Phase II", "indication": "Hypertension"}, {"name": "ION674", "phase": "Preclinical", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "Dawnzera", "phase": "Marketed", "indication": "Angioedema"}, {"name": "Kynamro", "phase": "Marketed", "indication": "Hypercholesterolemia"}, {"name": "Qalsody", "phase": "Marketed", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "Spinraza", "phase": "Marketed", "indication": "Spinal muscular atrophy (SMA)"}, {"name": "Tegsedi", "phase": "Marketed", "indication": "Amyloidosis"}], "ceo": "Brett P. Monia, PhD", "employees": 1069, "founded": 1989, "website": "http://www.ionispharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4882871440.0, "evFmt": "$4.9B", "ticker": "IONS", "exchange": "NASDAQ", "nDeals": 3, "totalDealValue": 80000000.0, "totalDealFmt": "$80M", "latestDealDate": "2025-09-25", "recentDeals": [{"headline": "Kardigan in-licensed exclusive worldwide development and commercialization rights to tonlamarsen from Ionis", "date": "2025-09-25", "value": ""}, {"headline": "Scipher Medicine Signs Multi-Target Partnership with Ionis", "date": "2023-07-17", "value": ""}, {"headline": "Ionis partners with Metagenomi to add gene editing to its broad technology platform", "date": "2022-11-14", "value": "$80M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ionis%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Diabetes", "Hematologic Cancers", "Neurodegeneration / NMD", "Obesity / Metabolic", "Other Inflammation", "Supportive / Other"]}, {"company": "Iovance Biotherapeutics Inc.", "city": "San Carlos", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy", "Other"], "nProducts": 3, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Amtagvi", "phase": "Approved", "indication": "Melanoma"}, {"name": "LN-145", "phase": "Phase III", "indication": "Cervical cancer"}, {"name": "IOV-2001", "phase": "Phase I", "indication": "Chronic lymphocytic leukemia (CLL)"}], "ceo": "Frederick G. Vogt, PhD", "employees": 838, "founded": 2007, "website": "http://www.iovance.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1879572800.0, "evFmt": "$1.9B", "ticker": "IOVA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iovance%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Skin Cancer / Melanoma"]}, {"company": "Iqure Pharma Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "iQ-007", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "iQ-008", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.iqurepharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iqure%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Pain / Migraine"]}, {"company": "Ironwood Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Genitourinary", "Neurology"], "modalityGroups": ["Antibody", "Other", "Peptide", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Constella", "phase": "Marketed", "indication": "Constipation"}, {"name": "IW-3300", "phase": "Phase II", "indication": "Cystitis"}, {"name": "P-PantSAc (TM-1803)", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "VB-1197", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "Thomas A. McCourt", "employees": 253, "founded": 1998, "website": "http://www.ironwoodpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1220094120.0, "evFmt": "$1.2B", "ticker": "IRWD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ironwood%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Other", "Other Neurology", "Supportive / Other"]}, {"company": "Ischemix Inc.", "city": "Maynard", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CMX-2043", "phase": "Phase II", "indication": "Ischemia/reperfusion injury"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.ischemix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ischemix", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Islet Sciences Inc.", "city": "Raleigh", "state": "NC", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ISLT-2669", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.isletsciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Islet%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Ism Therapeutics", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "INO-4995", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.ismtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ism%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Isoprene Pharmaceuticals Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HT-003", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Isoprene%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Isosterix Inc.", "city": "San Carlos", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Isosterix-KAT6A Inhibitor-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.isosterix.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Isosterix", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Istari Oncology Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Lerapolturev (pvsripo)", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "D2C7-IT", "phase": "Phase I", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.istarioncology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Istari%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Iterion Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Tegavivint (APL-121", "phase": "Phase II", "indication": "Sarcoma"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://iteriontherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iterion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Itherx Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ITX 5061", "phase": "Phase I", "indication": "Hepatitis C virus (HCV)"}], "ceo": "", "employees": 0, "founded": 1994, "website": "http://www.itherx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Itherx%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Itolerance Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Cell Therapy", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "iTOL-101", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "iTOL-102", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://itolerance.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Itolerance", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Iveena Delivery Systems Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Digital / Device", "Other", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "IVMED-80", "phase": "Phase II", "indication": "Ophthalmic (unspecified)"}, {"name": "dexamethasone (IVMED-20)", "phase": "Phase I/II", "indication": "Macular edema"}, {"name": "IVMED-85", "phase": "Preclinical", "indication": "Myopia"}, {"name": "IVMED-95", "phase": "Preclinical", "indication": "Myopia"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://iveenamed.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 10000000.0, "totalDealFmt": "$10M", "latestDealDate": "2022-08-24", "recentDeals": [{"headline": "Glaukos licenses Iveena\u2019s investigational keratoconus therapy", "date": "2022-08-24", "value": "$10M"}], "totalRaised": 3000000.0, "totalRaisedFmt": "$3M", "latestFinDate": "2025-02-05", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$3M", "date": "2025-02-05", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iveena%20Delivery%20Systems", "hasDealsFin": true, "diseaseGroups": ["Ophthalmology"]}, {"company": "Iview Therapeutics Inc.", "city": "Cranbury", "state": "NJ", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "povidone-iodine (IVIEW-1201)", "phase": "Phase II", "indication": "Conjunctivitis"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.iviewtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Iview%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Ivrea Pharmaceuticals Inc.", "city": "Quincy", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IVR 101", "phase": "Phase II", "indication": "Onychomycosis"}, {"name": "IVR 102", "phase": "Phase II", "indication": "Onychomycosis"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.ivreapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ivrea%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Izun Pharmaceuticals Corp.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Dental", "Other"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "PerioPatch", "phase": "Marketed", "indication": "Dental (unspecified)"}, {"name": "IZN-6N4", "phase": "Phase II", "indication": "Mucositis"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://izunpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Izun%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other", "Supportive / Other"]}, {"company": "Jacobus Pharmaceutical Co. Inc.", "city": "Plainsboro", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Ruzurgi", "phase": "Approved", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jacobus%20Pharmaceutical%20Co.", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Jade Biosciences Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Renal"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "JADE-001", "phase": "Phase I", "indication": "IgA nephropathy"}, {"name": "JADE-002", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "JADE-003", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "Tom Frohlich, MBA", "employees": 30, "founded": 2024, "website": "https://jadebiosciences.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -2463185.9, "evFmt": "", "ticker": "JBIO", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 22000000.0, "totalDealFmt": "$22M", "latestDealDate": "2025-10-03", "recentDeals": [{"headline": "Paragon Therapeutics grants Jade Biosciences an exclusive license to develop and commercialize BAFF-R programs", "date": "2025-10-03", "value": "$22M"}], "totalRaised": 414200000.0, "totalRaisedFmt": "$414M", "latestFinDate": "2025-04-27", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$334M", "date": "2025-04-27", "investors": "Fairmount Funds Management, Venrock Healthcare Capital Partners, Undisclosed Investor, Deep Track Capital, Braidwell L.P..."}, {"type": "Uncategorized venture rounds", "amount": "$80M", "date": "2024-08-01", "investors": "Fairmount Funds, Venrock Healthcare Capital Partners, Deep Track Capital, Driehaus Capital Management, Franklin Templeto..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jade%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Kidney Disease"]}, {"company": "Jaguar Gene Therapy LLC", "city": "Lake Forest", "state": "IL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Other"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "JAG201", "phase": "Phase I/II", "indication": "Genetic disorders"}, {"name": "JAG101", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "JAG301", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://jaguargenetherapy.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jaguar%20Gene%20Therapy", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Rare / Genetic"]}, {"company": "Jaguar Health Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Mytesi", "phase": "Marketed", "indication": "Diarrhea (non-infectious)"}], "ceo": "Lisa A. Conte, MBA", "employees": 49, "founded": 2001, "website": "http://jaguar.health", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 37654983.5, "evFmt": "$38M", "ticker": "JAGX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jaguar%20Health", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Jal Therapeutics LLC", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DB2ClPP", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.jaltherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jal%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Janone Inc.", "city": "Las Vegas", "state": "NV", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Jan123 (Naltrexone )", "phase": "Preclinical", "indication": "Pain"}], "ceo": "Antonios Isaac", "employees": 10, "founded": 2019, "website": "https://janone.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 81148793.85, "evFmt": "$81M", "ticker": "JAN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Janone", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Janus Biotherapeutics Inc.", "city": "Wellesley", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "JB6121", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Janus%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Janux Therapeutics Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "EGFR-TRACTr (JANX008)", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "PSMA-TRACTr (JANX007)", "phase": "Phase I", "indication": "Prostate cancer"}, {"name": "Costim bispecific", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "HER2-TRACTr", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "TROP2-TRACTr", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "David Campbell, PhD", "employees": 81, "founded": 2017, "website": "https://www.januxrx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1875706239.2, "evFmt": "$1.9B", "ticker": "JANX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Janux%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Jcyte Inc.", "city": "Newport Beach", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "JCell (hrpcs", "phase": "Phase II", "indication": "Retinitis"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://jcyte.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jcyte", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Jenrin Discovery Inc.", "city": "West Chester", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic", "Pulmonary", "Renal"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CRB-4001", "phase": "Preclinical", "indication": "Liver fibrosis"}, {"name": "JD-2114", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "JD-5006", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "JD-5037", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.jenrindiscovery.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jenrin%20Discovery", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Liver Disease"]}, {"company": "Jerome Stevens Pharmaceuticals Inc.", "city": "Bohemia", "state": "NY", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Thyquidity", "phase": "Marketed", "indication": "Thyroid disease"}], "ceo": "", "employees": 0, "founded": 1976, "website": "https://www.jeromestevens.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jerome%20Stevens%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Jn-international Medical Corp.", "city": "Omaha", "state": "NE", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NmVac4", "phase": "Phase II", "indication": "Meningococcus"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.jn-vaccines.org", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jn-international%20Medical", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Johnson & Johnson", "city": "New Brunswick", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dermatology", "Diagnostic", "Endocrine/Metabolic", "Gastrointestinal", "Genitourinary", "Hematology", "Infectious", "Inflammation", "Neurology", "Ophthalmic", "Pulmonary", "Renal", "Transplant"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Cell Therapy", "Combination", "Diagnostics", "Digital / Device", "Gene Therapy", "Oncolytic / Microbiome", "Other", "Peptide", "Protein / Biologic", "Radiopharmaceutical", "Small Molecule", "Undisclosed", "Vaccine"], "nProducts": 178, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Valchlor", "phase": "Marketed", "indication": "Cutaneous T cell lymphoma (CTCL)"}, {"name": "CR9114", "phase": "Phase II", "indication": "Influenza virus"}, {"name": "Caelyx", "phase": "Marketed", "indication": "Kaposi sarcoma"}, {"name": "Caplyta", "phase": "Marketed", "indication": "Bipolar disorder"}, {"name": "Caripul", "phase": "Marketed", "indication": "Hypertension"}, {"name": "CellSearch Circulating Tumor Cell Kit (CellSearch circulating tumor cells count (CTC) system", "phase": "Marketed", "indication": "Cancer, Diagnostic"}, {"name": "Concerta", "phase": "Marketed", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "Dermabond (2-octyl cyanoacrylate)", "phase": "Marketed", "indication": "Wounds"}], "ceo": "Joaquin Duato, MBA", "employees": 0, "founded": 1887, "website": "https://www.jnj.com/", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "JNJ", "exchange": "NYSE", "nDeals": 5, "totalDealValue": 1793000000.0, "totalDealFmt": "$1.8B", "latestDealDate": "2026-01-09", "recentDeals": [{"headline": "Prazer Therapeutics Enters into Strategic Collaboration and License Agreement with Johnson & Johnson to Develop Novel Targeted Protein Degraders for Neurodegenerative Diseases Using SPiDEM Technology", "date": "2026-01-09", "value": ""}, {"headline": "Elektrofi and Janssen Biotech Enter Worldwide Collaboration and License Agreement\u00a0to Exclusively Develop up to Five Programs Utilizing Elektrofi\u2019s Formulation Technology", "date": "2024-01-03", "value": "$793M"}, {"headline": "Remix Therapeutics enters collaboration with Janssen to advance small molecule therapeutics using REMaster drug discovery platform to modulate RNA processing", "date": "2022-02-17", "value": "$1.0B"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Johnson%20%26%20Johnson", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Dermatology", "Hematologic Cancers", "Infectious Disease", "Other Solid Tumors", "Psychiatry / Behavioral", "Solid Tumors (General)"]}, {"company": "Journey Colab Corp.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Mescaline HCI (JOUR-5700)", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2020, "website": "http://www.journeycolab.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Journey%20Colab", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Journey Medical Corp.", "city": "Scottsdale", "state": "AZ", "country": "United States", "diseaseCats": ["Dermatology", "Other"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Amzeeq", "phase": "Marketed", "indication": "Acne"}, {"name": "Qbrexza", "phase": "Marketed", "indication": "Excessive sweating"}, {"name": "Zilxi (minocycline topical foam 1.5%", "phase": "Marketed", "indication": "Rosacea"}, {"name": "FCD105", "phase": "Phase II", "indication": "Acne"}], "ceo": "Claude Maraoui", "employees": 41, "founded": 2014, "website": "http://www.journeymedicalcorp.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 85286774.0, "evFmt": "$85M", "ticker": "DERM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Journey%20Medical", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Journey Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Journey Therapeutics-non-Hodgkin\u2019s lymphoma-unknown", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "nab-paclitaxel/bevacizumab (AB160)", "phase": "Phase I", "indication": "Endometrial cancer"}], "ceo": "", "employees": 0, "founded": 2024, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Journey%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers"]}, {"company": "Jsr Corp.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "APL-509", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "bozitinib", "phase": "Approved", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jsr", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors", "Skin Cancer / Melanoma"]}, {"company": "Jubilant Therapeutics Inc.", "city": "Bedminster", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "TG-1601", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "JBI-802", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "JBI-778", "phase": "IND", "indication": "Brain cancer"}, {"name": "JBI-1044", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "JBI-1527 (Jubilant-PD-L1-unknown)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "JBI-2174", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Jubilant-undisclosed target-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.jubilanttx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jubilant%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Brain / CNS Tumors", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Junevity Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic", "Musculoskeletal", "Neurology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "JUN 02", "phase": "Preclinical", "indication": "Obesity"}, {"name": "JUN 03", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "JUN 04", "phase": "Preclinical", "indication": "Muscular atrophy"}, {"name": "JUN 05", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "JUN_01", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "JUN 06", "phase": "Research", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.junevity.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-01-01", "recentDeals": [{"headline": "Junevity RESET Platform is Based on Exclusively Licensed Research by Co-founder Dr. Janine Sengstack at the University of California at San Francisco", "date": "2023-01-01", "value": ""}], "totalRaised": 20000000.0, "totalRaisedFmt": "$20M", "latestFinDate": "2025-12-03", "latestFinType": "Seed financings", "nRounds": 2, "recentFinancing": [{"type": "Seed financings", "amount": "$10M", "date": "2025-12-03", "investors": "Goldcrest Capital, Godfrey Capital"}, {"type": "Seed financings", "amount": "$10M", "date": "2025-02-13", "investors": "Goldcrest Capital, Godfrey Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Junevity", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Diabetes", "Neurodegeneration / NMD", "Obesity / Metabolic", "Parkinson's"]}, {"company": "Jupiter Neurosciences Inc.", "city": "Jupiter", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "JNS101 (JOT101)", "phase": "Phase II", "indication": "Friedreich ataxia"}, {"name": "JNS108 (JOT108)", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "JNS102", "phase": "Phase I", "indication": "Mucopolysaccharidosis"}, {"name": "JNS107 (JOT107)", "phase": "Phase I", "indication": "Mitochondrial disease"}, {"name": "JNS109", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "JNS110", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "Christer Ros\u00e9n", "employees": 4, "founded": 2015, "website": "https://jupiterneurosciences.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 350659553.0, "evFmt": "$351M", "ticker": "JUNS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Jupiter%20Neurosciences", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD", "Other Neurology", "Rare / Genetic"]}, {"company": "Juvaris Biotherapeutics Inc.", "city": "Burlingame", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Cationic liposome DNA complexes (JVRS-100", "phase": "Phase II", "indication": "Influenza virus"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.juvaris.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Juvaris%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Juvena Therapeutics Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Hepatic", "Musculoskeletal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "JUV-161", "phase": "Phase I", "indication": "Myotonic dystrophy type 1 (DM1)"}, {"name": "Juvena-Duchenne muscular dystrophy-unknown", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "Juvena-hepatic diseases-unknown", "phase": "Research", "indication": "Hepatic (unspecified)"}, {"name": "Juvena-metabolic-related diseases-unknown", "phase": "Research", "indication": "Metabolic (unspecified)"}, {"name": "Juvena-osteoarthritis-unknown", "phase": "Research", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.juvenatherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-06-11", "recentDeals": [{"headline": "Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health", "date": "2025-06-11", "value": ""}], "totalRaised": 104993884.0, "totalRaisedFmt": "$105M", "latestFinDate": "2026-01-12", "latestFinType": "Series B rounds", "nRounds": 3, "recentFinancing": [{"type": "Series B rounds", "amount": "$34M", "date": "2026-01-12", "investors": "Bison Venture Partners, Eli Lilly and Co., Jefferson Life Sciences, Mubadala Capital Ventures, Manta Ray Ventures"}, {"type": "Uncategorized venture rounds", "amount": "$30M", "date": "2025-06-27", "investors": "Undisclosed Investors"}, {"type": "Series A rounds", "amount": "$41M", "date": "2022-11-08", "investors": "Mubadala Capital Ventures, Horizons Ventures, Bison Venture Partners, Manta Ray Ventures, Irongrey, Alumni Ventures Grou..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Juvena%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Liver Disease", "Musculoskeletal", "Neurodegeneration / NMD", "Obesity / Metabolic"]}, {"company": "Juventas Therapeutics Inc.", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Musculoskeletal"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "JVS-100", "phase": "Phase II", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.juventasinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Juventas%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Kaida Biopharma Inc.", "city": "Fort Lauderdale", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KAD101", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://kaida-biopharma.com/home/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kaida%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Kaigene Inc.", "city": "North Bethesda", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KG002", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "KG006", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.kaigene.us/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kaigene", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Kairos Pharma Ltd.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic", "Endocrine/Metabolic"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ENV-105", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "ENV 205", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "KROS-101", "phase": "Preclinical", "indication": "Cancer, Diagnostic"}], "ceo": "John S. Yu, MD", "employees": 4, "founded": 2013, "website": "https://kairospharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 19607627.44, "evFmt": "$20M", "ticker": "KAPA", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kairos%20Pharma", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Kala Bio Inc.", "city": "Arlington", "state": "MA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Cell Therapy", "Nanoparticle / Delivery", "Other", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Eysuvis", "phase": "Marketed", "indication": "Dry eye"}, {"name": "Inveltys", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}, {"name": "KPI-012 (CMB-012)", "phase": "Phase I", "indication": "Ophthalmic (unspecified)"}, {"name": "Kala-SEGRM-unknown", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}, {"name": "KPI-287", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}, {"name": "Sorafenib-MPP", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "Avi Minkowitz", "employees": 38, "founded": 2009, "website": "http://www.kalarx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7415566.18, "evFmt": "$7M", "ticker": "KALA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kala%20Bio", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Kalaris Therapeutics Inc.", "city": "Berkeley Heights", "state": "NJ", "country": "United States", "diseaseCats": ["Infectious", "Ophthalmic"], "modalityGroups": ["Cell Therapy", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "Prelym", "phase": "Phase I/II", "indication": "BK virus (BKV)"}, {"name": "TH103", "phase": "Phase I", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "Viralym-C", "phase": "Phase I", "indication": "Cytomegalovirus (CMV)"}, {"name": "ALVR107", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "ALVR108", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "Andrew Oxtoby, MBA", "employees": 6, "founded": 2019, "website": "https://kalaristx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -69907092.368554, "evFmt": "", "ticker": "KLRS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kalaris%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Ophthalmology", "Other"]}, {"company": "Kalidex Pharmaceuticals Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "KPI-10", "phase": "Phase I", "indication": "Infectious (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.kalidex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kalidex%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Kalivir Immunotherapeutics Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VET1-INT", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "VET3-T12", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "VET-AST2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://kalivir.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-05-23", "recentDeals": [{"headline": "KaliVir Immunotherapeutics enters into global exclusive licensing agreement with Roche for novel oncolytic viruses", "date": "2022-05-23", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2022-03-16", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "", "date": "2022-03-16", "investors": "Premier Partners LLC, Company K Partners Ltd., Quad Investment Management"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kalivir%20Immunotherapeutics", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Kallyope Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 8, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "K-196", "phase": "Phase I", "indication": "Gastrointestinal (GI) dysfunction"}, {"name": "K-757", "phase": "Phase I", "indication": "Metabolic (unspecified)"}, {"name": "K-833", "phase": "Phase I", "indication": "Metabolic (unspecified)"}, {"name": "Kallyope-gastrointestinal-unknown2", "phase": "Research", "indication": "Gastrointestinal (GI) dysfunction"}, {"name": "Kallyope-gastrointestinal-unknowon", "phase": "Research", "indication": "Gastrointestinal (GI) dysfunction"}, {"name": "Kallyope-migraine-unknown", "phase": "Research", "indication": "Migraine"}, {"name": "Kallyope-neuroinflammation-unknown", "phase": "Research", "indication": "Neuroinflammation"}, {"name": "Kallyope-Parkinson's disease-unknown", "phase": "Research", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.kallyope.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 236000000.0, "totalRaisedFmt": "$236M", "latestFinDate": "2022-02-15", "latestFinType": "Series D rounds", "nRounds": 1, "recentFinancing": [{"type": "Series D rounds", "amount": "$236M", "date": "2022-02-15", "investors": "Mubadala Investment Co., The Column Group, New Investors, Existing Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kallyope", "hasDealsFin": true, "diseaseGroups": ["Obesity / Metabolic", "Other", "Other Neurology", "Pain / Migraine", "Parkinson's"]}, {"company": "Kalocyte Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Erythromer", "phase": "Preclinical", "indication": "Blood substitute"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://kalocyte.com/wordpress/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kalocyte", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Kalos Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KTH 222", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.kalostherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kalos%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Kanvas Biosciences Inc.", "city": "Monmouth Junction", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "KAN-002 (FB-001)", "phase": "Phase I", "indication": "Hyperoxaluria"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.kanvasbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kanvas%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Karius Inc.", "city": "Redwood City", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Karius Test", "phase": "Market (diagnostic)", "indication": "Infectious, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 100000000.0, "totalRaisedFmt": "$100M", "latestFinDate": "2024-05-02", "latestFinType": "Series C rounds", "nRounds": 2, "recentFinancing": [{"type": "Series C rounds", "amount": "$100M", "date": "2024-05-02", "investors": "Khosla Ventures, 5am Ventures, Gilde Healthcare Partners B.V., Seventure Partners, Softbank Vision Fund, General Catalys..."}, {"type": "Series B rounds", "amount": "", "date": "2022-03-07", "investors": "Hbm Bioventures AG"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Karius", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Kartos Therapeutics Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "KRT-232", "phase": "Phase II", "indication": "Skin cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.kartosthera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kartos%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Karyopharm Therapeutics Inc.", "city": "Newton", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Hematology", "Infectious", "Inflammation", "Transplant"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Xpovio", "phase": "Marketed", "indication": "B cell lymphoma"}, {"name": "eltanexor (ATG-016", "phase": "Phase I/II", "indication": "Colorectal cancer"}, {"name": "verdinexor (ATG-527", "phase": "Phase I", "indication": "Lupus"}, {"name": "BIIB100 (KPT-350)", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "Richard A. Paulson, MBA", "employees": 279, "founded": 2008, "website": "http://www.karyopharm.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 168197946.9, "evFmt": "$168M", "ticker": "KPTI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Karyopharm%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "GI Cancers", "Hematologic Cancers", "Other Inflammation"]}, {"company": "Kashiv Biosciences LLC", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Hematology", "Infectious", "Ophthalmic"], "modalityGroups": ["Antibody", "Protein / Biologic", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Fylnetra", "phase": "Marketed", "indication": "Neutropenia"}, {"name": "Releuko (biosimilar filgrastim)", "phase": "Approved", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "biosimilar omalizumab (ADL018", "phase": "Phase III", "indication": "Urticaria"}, {"name": "biosimilar pegfilgrastim (TPI-120)", "phase": "Phase I", "indication": "Infectious (unspecified)"}, {"name": "K127 (pyridostigmin)", "phase": "Phase I", "indication": "Myasthenia gravis"}, {"name": "biosimilar adalimumab", "phase": "Preclinical", "indication": "Ankylosing spondylitis"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.kashivbiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 3, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-09-11", "recentDeals": [{"headline": "Kashiv BioSciences and Cristalia Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America", "date": "2025-09-11", "value": ""}, {"headline": "Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR (Omalizumab)", "date": "2024-07-01", "value": ""}, {"headline": "Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair (omalizumab)", "date": "2023-10-03", "value": ""}], "totalRaised": 222323850.13, "totalRaisedFmt": "$222M", "latestFinDate": "2025-12-22", "latestFinType": "Venture (Debt)", "nRounds": 2, "recentFinancing": [{"type": "Venture (Debt)", "amount": "$72M", "date": "2025-12-22", "investors": "Union Bank of India"}, {"type": "Venture (Debt)", "amount": "$150M", "date": "2025-04-07", "investors": "Goldentree Asset Management"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kashiv%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers", "Hematology (non-cancer)", "Infectious Disease", "MS / Neuroimmune", "Other Inflammation"]}, {"company": "Kato Pharmaceuticals Inc.", "city": "Laguna Hills", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Resolvine", "phase": "Phase I", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://www.katopharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kato%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Keiferx LLC", "city": "Mclean", "state": "VA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Nilotinib BE (KFRX01)", "phase": "Phase III", "indication": "Alzheimer's disease"}, {"name": "Bosutinib (KFRX02)", "phase": "Phase II", "indication": "Neurology (unspecified)"}, {"name": "KFRX03", "phase": "Preclinical", "indication": "Lyme disease"}, {"name": "KFRX04", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}, {"name": "KFRX05", "phase": "Preclinical", "indication": "Allergy"}, {"name": "KFRX06", "phase": "Preclinical", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.keiferx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Keiferx", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Dermatology", "Infectious Disease", "Other Neurology", "Respiratory / Allergy"]}, {"company": "Kemia Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "KC706", "phase": "Phase II", "indication": "Pemphigus"}], "ceo": "", "employees": 0, "founded": 2002, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kemia", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Kernal Biologics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy", "RNA Therapeutics"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KR-335", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "KR-336", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "KR-402", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "KR-505", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.kernalbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kernal%20Biologics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Breast Cancer", "GI Cancers", "Solid Tumors (General)"]}, {"company": "Keros Therapeutics Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Hematology", "Musculoskeletal", "Pulmonary"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "elritercept (KER-050", "phase": "Phase II", "indication": "Myelodysplastic syndrome (MDS)"}, {"name": "KER-012", "phase": "Phase I", "indication": "Musculoskeletal (unspecified)"}, {"name": "KER-047", "phase": "Phase I", "indication": "Anemia"}, {"name": "Keros-ActRIIB variant-unknown", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "Jasbir S. Seehra, PhD", "employees": 169, "founded": 2015, "website": "http://www.kerostx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 51568031.16, "evFmt": "$52M", "ticker": "KROS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Keros%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Hematology (non-cancer)", "Musculoskeletal", "Obesity / Metabolic"]}, {"company": "Kestrel Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MCI-062", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kestrel%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Kevirx Inc.", "city": "Charlottesville", "state": "VA", "country": "United States", "diseaseCats": ["Cancer", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KVX-053", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.kevirx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kevirx", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Keystone Bio Inc.", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody", "Vaccine"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "KB-001", "phase": "Phase I", "indication": "Bacterial infection"}, {"name": "KBhu-007", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "KBvx-001", "phase": "Preclinical", "indication": "Viral infection"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://keystonebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Keystone%20Bio", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Keystone Nano Inc.", "city": "State College", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "Ceramide NanoLiposome", "phase": "Phase I", "indication": "Liver cancer"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.keystonenano.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Keystone%20Nano", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Kezar Life Sciences Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "zetomipzomib (KZR-616)", "phase": "Phase II", "indication": "Lupus"}, {"name": "KZR-261", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "Christopher J. Kirk, PhD", "employees": 55, "founded": 2015, "website": "http://kezarlifesciences.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -67074553.6, "evFmt": "", "ticker": "KZR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kezar%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Kibow Biotech Inc.", "city": "Newtown Square", "state": "PA", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "US-APR2020", "phase": "Phase II", "indication": "Renal (unspecified)"}], "ceo": "", "employees": 0, "founded": 1997, "website": "https://kibowbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kibow%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Kinagen Inc.", "city": "Rancho Santa Fe", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RAF Blockade", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.kinagen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kinagen", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Kinea Bio Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KNA-155", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.kineabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-09-23", "recentDeals": [{"headline": "Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101", "date": "2025-09-23", "value": ""}], "totalRaised": 500000.0, "totalRaisedFmt": "$500K", "latestFinDate": "2024-02-13", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$500K", "date": "2024-02-13", "investors": "Parent Project Muscular Dystrophy"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kinea%20Bio", "hasDealsFin": true, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Kiora Pharmaceuticals Inc.", "city": "Encinitas", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Neurology", "Ophthalmic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "EGP-437", "phase": "Phase III", "indication": "Uveitis"}, {"name": "Ocular Bandage Gel (OBG) (JDE-001", "phase": "Phase III", "indication": "Corneal wound"}, {"name": "EyeGate Pharmaceuticals (PP-001)", "phase": "Phase II", "indication": "Ophthalmic (unspecified)"}, {"name": "KIO-301", "phase": "Phase I/II", "indication": "Retinitis"}, {"name": "MoxiGel", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "Brian Matthew Strem, PhD", "employees": 12, "founded": 1998, "website": "https://kiorapharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -13122160.5, "evFmt": "", "ticker": "KPRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kiora%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease", "Ophthalmology"]}, {"company": "Kira Pharmaceuticals LLC", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Hematology", "Renal"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "KP104", "phase": "Phase II", "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)"}, {"name": "KP301", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "KP501", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.kirapharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kira%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematology (non-cancer)"]}, {"company": "Kiyatec Inc.", "city": "Pendleton", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Pivotal", "hasOrphan": false, "pipeline": [{"name": "EV3D", "phase": "Pivotal", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 18000000.0, "totalRaisedFmt": "$18M", "latestFinDate": "2023-05-18", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2023-05-18", "investors": "Brain Tumor Investment Fund LLC, Sontag Innovation Fund LLC"}, {"type": "Series C rounds", "amount": "$18M", "date": "2022-12-12", "investors": "Bruker Corp., Venturesouth, Seae Ventures, Laboratory Corp. of America Holdings"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kiyatec", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Klotho Neurosciences Inc.", "city": "Omaha", "state": "NE", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KLTO-101", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "KLTO-202 (ANEW-202)", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "Joseph Sinkule, PharmD", "employees": 3, "founded": 2019, "website": "https://klothoneuro.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 9542958.805, "evFmt": "$10M", "ticker": "KLTO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Klotho%20Neurosciences", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD"]}, {"company": "Knopp Biosciences LLC", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "dexpramipexole (KNS-760704)", "phase": "Phase III", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.knoppbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Knopp%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Kodiak Sciences Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "KSI-101 (KSI-501P)", "phase": "Phase III", "indication": "Macular edema"}, {"name": "KSI-501", "phase": "Phase I", "indication": "Macular edema"}, {"name": "KSI-601", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "Victor Perlroth, MD, MBA", "employees": 109, "founded": 2009, "website": "http://www.kodiak.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 525473322.6, "evFmt": "$525M", "ticker": "KOD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kodiak%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Kolon Tissuegene Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Musculoskeletal"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Invossa", "phase": "Marketed", "indication": "Osteoarthritis"}, {"name": "TG-B", "phase": "Preclinical", "indication": "Bone repair"}, {"name": "TG-D", "phase": "Preclinical", "indication": "Cartilage repair"}], "ceo": "Seung-Ho Jeon, PhD, MBA; Moon-Jong Noh, PhD", "employees": 56, "founded": 1999, "website": "http://www.tissuegene.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1222789869.86834, "evFmt": "$1.2B", "ticker": "950160", "exchange": "KOSDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kolon%20Tissuegene", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Korro Bio Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "KRRO-110", "phase": "Phase I/II", "indication": "Alpha-antitrypsin (AAT) deficiency"}, {"name": "KRRO-121", "phase": "Preclinical", "indication": "Urea cycle disorder (UCD)"}], "ceo": "Ram Aiyar, PhD, MBA", "employees": 104, "founded": 2014, "website": "https://www.korrobio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 258275757.27, "evFmt": "$258M", "ticker": "KRRO", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 530000000.0, "totalDealFmt": "$530M", "latestDealDate": "2024-09-13", "recentDeals": [{"headline": "Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates", "date": "2024-09-13", "value": "$530M"}], "totalRaised": 233249988.9, "totalRaisedFmt": "$233M", "latestFinDate": "2023-11-02", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$117M", "date": "2023-11-02", "investors": "Surveyor Capital, Cormorant Asset Management, Eventide Asset Management LLC, Atlas Venture, New Enterprise Associates, I..."}, {"type": "Series B rounds", "amount": "$116M", "date": "2022-01-05", "investors": "Eventide Asset Management LLC, Fidelity Management and Research Company, Invus, Point72, Verition Fund Management, Monas..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Korro%20Bio", "hasDealsFin": true, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Koutif Therapeutics LLC", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "KT-1002", "phase": "Phase I", "indication": "Crohn's disease"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://koutiftherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Koutif%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Kp Biosciences Inc.", "city": "Orem", "state": "UT", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "F4-4", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://kpbiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kp%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Krenitsky Pharmaceuticals Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TriRima (KP157", "phase": "Phase II", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 1995, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Krenitsky%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Kriya Therapeutics Inc.", "city": "Morrisville", "state": "NC", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic", "Neurology", "Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 9, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "KRIYA-825", "phase": "Phase I/II", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "KRIYA-497", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "KRIYA-586", "phase": "Preclinical", "indication": "Thyroid eye disease"}, {"name": "KRIYA-748", "phase": "Preclinical", "indication": "Neuralgia"}, {"name": "KRIYA-839", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "KRIYA-296", "phase": "Research", "indication": "Ophthalmic (unspecified)"}, {"name": "KRIYA-382", "phase": "Research", "indication": "Epilepsy"}, {"name": "KRIYA-454", "phase": "Research", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://kriyatherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-09-27", "recentDeals": [{"headline": "Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy", "date": "2023-09-27", "value": ""}, {"headline": "Kriya licenses next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases", "date": "2022-01-26", "value": ""}], "totalRaised": 740000000.0, "totalRaisedFmt": "$740M", "latestFinDate": "2025-09-10", "latestFinType": "Series D rounds", "nRounds": 3, "recentFinancing": [{"type": "Series D rounds", "amount": "$320M", "date": "2025-09-10", "investors": "Patient Square Capital, Pi International Holdings LLC (Premji Invest), Peter Thiel, Narya Capital, Jdrf T1d Fund LLC, Un..."}, {"type": "Series C rounds", "amount": "$150M", "date": "2023-07-26", "investors": "Patient Square Capital"}, {"type": "Series C rounds", "amount": "$270M", "date": "2022-05-16", "investors": "Patient Square Capital, Bluebird Ventures, Cam Capital, Dexcel Pharma Technologies Ltd., Foresite Capital Management LLC..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kriya%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Diabetes", "Epilepsy / Seizures", "Obesity / Metabolic", "Ophthalmology", "Other Neurology", "Pain / Migraine"]}, {"company": "Krystal Biotech Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Dermatology", "Pulmonary"], "modalityGroups": ["Gene Therapy"], "nProducts": 6, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "VYJUVEK", "phase": "Approved", "indication": "Epidermolysis bullosa"}, {"name": "KB105", "phase": "Phase I/II", "indication": "Ichthyosis"}, {"name": "KB301", "phase": "Phase I/II", "indication": "Acne"}, {"name": "KB407", "phase": "Phase I", "indication": "Cystic fibrosis (CF)"}, {"name": "KB104", "phase": "Preclinical", "indication": "Netherton syndrome"}, {"name": "KB107", "phase": "Preclinical", "indication": "Epidermolysis bullosa"}], "ceo": "Krish S. Krishnan, MBA", "employees": 275, "founded": 2016, "website": "http://www.krystalbio.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4068812400.0, "evFmt": "$4.1B", "ticker": "KRYS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Krystal%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Rare / Genetic"]}, {"company": "Ksq Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "KSQ-4279", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "KSQ-004EX", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "IO-10", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "KSQ-001", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "KSQ-4271 (TO-4)", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://ksqtx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ksq%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Solid Tumors (General)"]}, {"company": "Kumquat Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "KQB168", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "KQB548", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.kumquatbiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kumquat%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Kura Oncology Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Komzifti", "phase": "Approved", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "KO-947", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "Troy E. Wilson, PhD", "employees": 192, "founded": 2014, "website": "http://www.kuraoncology.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 39661310.0, "evFmt": "$40M", "ticker": "KURA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kura%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Kurome Therapeutics", "city": "Cincinnati", "state": "OH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Kurome-cancer-unknown", "phase": "Preclinical", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://kurometherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kurome%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Kymera Therapeutics Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Inflammation", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "KT-474", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "KT-621", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "IRAKIMiD", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "KT-485 (SAR447971)", "phase": "Preclinical", "indication": "Inflammatory disease"}, {"name": "KT-579", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "KTX-201", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Kymera-STAT3-unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "Nello Mainolfi, PhD", "employees": 188, "founded": 2016, "website": "http://www.kymeratx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2618036757.93, "evFmt": "$2.6B", "ticker": "KYMR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kymera%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology", "Hematologic Cancers", "IBD / GI Inflammatory", "MS / Neuroimmune"]}, {"company": "Kyverna Therapeutics Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "miv-cel (KYV-101)", "phase": "Phase II/III", "indication": "Myasthenia gravis"}, {"name": "KYV-201", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "Warner Biddle", "employees": 112, "founded": 2018, "website": "http://kyvernatx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -134365704.46, "evFmt": "", "ticker": "KYTX", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-01-05", "recentDeals": [{"headline": "Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases", "date": "2022-01-05", "value": ""}, {"headline": "Kyverna Therapeutics announces exclusive worldwide licenses with National Institutes of Health for autologous and allogeneic anti-CD19 CAR T cellular therapies to treat autoimmune diseases", "date": "2022-01-03", "value": ""}], "totalRaised": 145000000.0, "totalRaisedFmt": "$145M", "latestFinDate": "2023-08-03", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$60M", "date": "2023-08-03", "investors": "Bain Capital Life Sciences, Gordonmd Global Investments L.P., Gilead Sciences Inc., Westlake Biopartners, Vida Ventures,..."}, {"type": "Series B rounds", "amount": "$85M", "date": "2022-01-26", "investors": "Northpond Ventures LLC, Westlake Biopartners, Vida Ventures, Gilead Sciences Inc., Rtw Investments L.P., Cam Capital, In..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Kyverna%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "MS / Neuroimmune"]}, {"company": "Lacerta Therapeutics Inc.", "city": "Alachua", "state": "FL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Lacerta Therapeutics-central nervous system (CNS-1) disorders-unknown", "phase": "Preclinical", "indication": "Central nervous system (CNS) disorders"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.lacertatherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lacerta%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Ladrx Corp.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Musculoskeletal"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Miplyffa", "phase": "Approved", "indication": "Glycosphingolipid storage disorders"}, {"name": "aldoxorubicin (doxo-emch", "phase": "Phase III", "indication": "Sarcoma"}, {"name": "AE-Ester-Sulf07", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "AE-Keto-Sulf07", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "LADR-10", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "LADR-9", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Stephen Snowdy, PhD, MBA", "employees": 2, "founded": 1985, "website": "https://www.ladrxcorp.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 72012.56, "evFmt": "$72K", "ticker": "LADX", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ladrx", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Lung Cancer", "Other Solid Tumors", "Rare / Genetic", "Skin Cancer / Melanoma"]}, {"company": "Lakewood-amedex Biotherapeutics Inc.", "city": "University Park", "state": "FL", "country": "United States", "diseaseCats": ["Dermatology", "Infectious", "Other", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Bisphosphocin Nu-3 (Nu-3)", "phase": "Phase I/II", "indication": "Dermal ulcers"}, {"name": "Nu-8", "phase": "Preclinical", "indication": "Urinary tract infection (UTI)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.lakewoodamedex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lakewood-amedex%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease"]}, {"company": "Lannett Co. Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Morphine sulfate", "phase": "Marketed", "indication": "Pain"}, {"name": "C-Topical", "phase": "Registration", "indication": "Anesthesia"}, {"name": "Lannett (biosimilar insulin glargine)", "phase": "Phase III", "indication": "Diabetes"}, {"name": "Lannett (biosimilar insulin aspart)", "phase": "Phase I/II", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 1942, "website": "http://www.lannett.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lannett%20Co.", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Pain / Migraine", "Supportive / Other"]}, {"company": "Lantern Pharma Inc.", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "LP-100 (Irofulven-1)", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "LP-300", "phase": "Phase II", "indication": "Lung cancer"}, {"name": "LP-184", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "LP-284", "phase": "Preclinical", "indication": "Mantle cell lymphoma (MCL)"}], "ceo": "Panna L. Sharma", "employees": 24, "founded": 2013, "website": "http://www.lanternpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 10562391.61, "evFmt": "$11M", "ticker": "LTRN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lantern%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GU / Gynecologic Cancers", "Hematologic Cancers", "Lung Cancer"]}, {"company": "Lantheus Holdings Inc.", "city": "North Billerica", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Diagnostic", "Gastrointestinal"], "modalityGroups": ["ADC", "Antibody", "Diagnostics", "Digital / Device", "Radiopharmaceutical", "Small Molecule"], "nProducts": 16, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Azedra (iobenguane i 131", "phase": "Marketed", "indication": "Neuroendocrine tumors"}, {"name": "CarThera-Glioblastoma-unknown", "phase": "Marketed", "indication": "Brain cancer"}, {"name": "Definity (Perflutren Lipid Microsphere)", "phase": "Marketed", "indication": "Cardiovascular, Diagnostic"}, {"name": "Oral Relistor", "phase": "Marketed", "indication": "Constipation"}, {"name": "Relistor", "phase": "Marketed", "indication": "Constipation"}, {"name": "flurpiridaz", "phase": "Phase III", "indication": "Cardiovascular, Diagnostic"}, {"name": "Insightec-Glioblastoma-unknown", "phase": "Phase III", "indication": "Brain cancer"}, {"name": "LMI 1195", "phase": "Phase III", "indication": "Neuroendocrine tumors"}], "ceo": "Mary Anne Heino, MBA", "employees": 808, "founded": 1956, "website": "http://www.lantheus.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 6118389460.0, "evFmt": "$6.1B", "ticker": "LNTH", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-12-12", "recentDeals": [{"headline": "Lantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy Platform", "date": "2022-12-12", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lantheus%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Cardiovascular", "Other Solid Tumors", "Supportive / Other"]}, {"company": "Larimar Therapeutics Inc.", "city": "Bala Cynwyd", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "nomlabofusp (CTI-1601)", "phase": "Phase II", "indication": "Friedreich ataxia"}], "ceo": "Carole S. Ben-Maimon, MD", "employees": 65, "founded": 2013, "website": "https://larimartx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 58724045.08, "evFmt": "$59M", "ticker": "LRMR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Larimar%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Larkspur Biosciences Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LRK-4189", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://larkspur.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Larkspur%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Lassen Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Pulmonary"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "LASN01", "phase": "Phase I", "indication": "Pulmonary fibrosis"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://lassentherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lassen%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Lassogen Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LAS-103", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://www.lassogen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lassogen", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Layerbio Inc.", "city": "Arlington", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Musculoskeletal", "Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LB-100", "phase": "Preclinical", "indication": "Glaucoma"}, {"name": "LB-110", "phase": "Preclinical", "indication": "Glaucoma"}, {"name": "LB-200", "phase": "Preclinical", "indication": "Wounds"}, {"name": "LB-210", "phase": "Preclinical", "indication": "Wounds"}, {"name": "LB-300", "phase": "Preclinical", "indication": "Musculoskeletal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.layerbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Layerbio", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Musculoskeletal", "Ophthalmology"]}, {"company": "Lb Pharmaceuticals Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "N-methyl amisulpride (LB-102)", "phase": "Phase I", "indication": "Schizophrenia"}, {"name": "LB-103", "phase": "Preclinical", "indication": "Schizophrenia"}, {"name": "LB-104", "phase": "Preclinical", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://lbpharma.us", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "LBRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lb%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Leal Therapeutics Inc.", "city": "Worcester", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["RNA Therapeutics", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LTX-001", "phase": "Preclinical", "indication": "Schizophrenia"}, {"name": "LTX-002", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://lealtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Leal%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Psychiatry / Behavioral"]}, {"company": "Leap Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation"], "modalityGroups": ["Antibody", "Other"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "FL-101", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "sirexatamab (DKN-01)", "phase": "Phase II", "indication": "Cervical cancer"}, {"name": "TRX518", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "FL-201", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "Doug E. Onsi", "employees": 52, "founded": 2011, "website": "https://www.leaptx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 60975196.375, "evFmt": "$61M", "ticker": "LPTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Leap%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Lung Cancer", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Legend Biotech Corp.", "city": "Somerset", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Carvykti", "phase": "Marketed", "indication": "Multiple myeloma (MM)"}, {"name": "LB1901", "phase": "Phase I", "indication": "Cutaneous T cell lymphoma (CTCL)"}, {"name": "LB1904", "phase": "Phase I", "indication": "Gastric cancer"}, {"name": "LB1908", "phase": "Phase I", "indication": "Esophageal cancer"}, {"name": "LB2101", "phase": "Phase I", "indication": "Liver cancer"}, {"name": "LCAR-AIO", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "LCAR-BCDR", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "LB2102", "phase": "IND", "indication": "Small cell lung cancer"}], "ceo": "Ying Huang, PhD", "employees": 2609, "founded": 2014, "website": "http://www.legendbiotech.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 5177825990.0225, "evFmt": "$5.2B", "ticker": "LEGN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Legend%20Biotech", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Lung Cancer"]}, {"company": "Leios Therapeutics Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "polidocanol (10XB101)", "phase": "Phase II", "indication": "Body Fat"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://leiostherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Leios%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Lenz Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Vizz", "phase": "Approved", "indication": "Presbyopia"}, {"name": "aceclidine/ brimonidine (LNZ101)", "phase": "Phase III", "indication": "Presbyopia"}], "ceo": "Evert B. Schimmelpennink", "employees": 42, "founded": 2013, "website": "https://lenz-tx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 406620567.06, "evFmt": "$407M", "ticker": "LENZ", "exchange": "NASDAQ", "nDeals": 3, "totalDealValue": 315000000.0, "totalDealFmt": "$315M", "latestDealDate": "2025-07-07", "recentDeals": [{"headline": "Lenz Therapeutics and Laboratoires Th\u00e9a Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada", "date": "2025-07-07", "value": "$70M"}, {"headline": "Lenz Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia", "date": "2025-05-09", "value": "$125M"}, {"headline": "LENZ Therapeutics and JIXING announce an exclusive Greater China license agreement and RTW to invest in LENZ Therapeutics", "date": "2022-04-13", "value": "$120M"}], "totalRaised": 83500000.0, "totalRaisedFmt": "$84M", "latestFinDate": "2023-03-07", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$84M", "date": "2023-03-07", "investors": "Sectoral Asset Management Inc., Alpha Wave Ventures, Point 72, Ra Capital Management L.P., Versant Ventures, Rtw Investm..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lenz%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Ophthalmology"]}, {"company": "Leonabio Inc.", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "fosgonimeton (ATH-1017", "phase": "Phase II/III", "indication": "Alzheimer's disease"}, {"name": "ATH-1020", "phase": "Phase I", "indication": "Neurology (unspecified)"}, {"name": "ATH-1105", "phase": "Phase I", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "Athira Pharma-early compounds-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "Mark J. Litton, PhD, MBA", "employees": 26, "founded": 2011, "website": "https://leonabio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -27481270.6375, "evFmt": "", "ticker": "LONA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Leonabio", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD", "Other Neurology"]}, {"company": "Letsgetchecked Inc.", "city": "New York", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 5, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "MyBRCA", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "myGenome", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "myHealthScore", "phase": "Market (diagnostic)", "indication": "Genetic disorders, Diagnostic"}, {"name": "myNewborn", "phase": "Market (diagnostic)", "indication": "Genetic disorders, Diagnostic"}, {"name": "Pregnancy Loss test", "phase": "Market (diagnostic)", "indication": "Genetic disorders, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-05-08", "recentDeals": [{"headline": "Genetiks and Veritas announce a collaboration to complete the Turkish laboratory's preventive and perinatal portfolio", "date": "2023-05-08", "value": ""}], "totalRaised": 295000000.0, "totalRaisedFmt": "$295M", "latestFinDate": "2025-01-08", "latestFinType": "Rounds beyond series E", "nRounds": 3, "recentFinancing": [{"type": "Rounds beyond series E", "amount": "$165M", "date": "2025-01-08", "investors": "Optum Ventures"}, {"type": "Venture (Debt)", "amount": "$110M", "date": "2023-01-01", "investors": "K2 Healthventures"}, {"type": "Series D rounds", "amount": "$20M", "date": "2022-09-08", "investors": "Transformation Capital Partners L.P. (Ltp), Casdin Capital LLC, Rory Mcilroy, Morgan Health, Illumina Ventures, Common F..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Letsgetchecked", "hasDealsFin": true, "diseaseGroups": ["Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Leuvas Therapeutics Inc.", "city": "Mountain View", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LV02", "phase": "Preclinical", "indication": "Epilepsy"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.leuvas.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Leuvas%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures"]}, {"company": "Levolta Pharmaceuticals Inc.", "city": "Bethlehem", "state": "PA", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "VOLT01", "phase": "Phase III", "indication": "Osteoarthritis"}, {"name": "VOLT02", "phase": "Phase II", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.levoltapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Levolta%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Supportive / Other"]}, {"company": "Lexeo Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular", "Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "AAVrh.10hFXN", "phase": "Phase I/II", "indication": "Cardiomyopathy"}, {"name": "LX1001", "phase": "Phase I/II", "indication": "Alzheimer's disease"}, {"name": "LX1004", "phase": "Phase I/II", "indication": "Neuronal ceroid lipofuscinosis"}, {"name": "LX2020", "phase": "Phase I/II", "indication": "Cardiomyopathy"}], "ceo": "R. Nolan Townsend, MBA", "employees": 72, "founded": 2017, "website": "https://www.lexeotx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 97567690.78, "evFmt": "$98M", "ticker": "LXEO", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-04-22", "recentDeals": [{"headline": "Lexeo Therapeutics Announces License Agreement with Cornell University to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy", "date": "2024-04-22", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2023-08-28", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2023-08-28", "investors": "Sarepta Therapeutics Inc."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lexeo%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Cardiovascular", "Neurodegeneration / NMD"]}, {"company": "Lexicon Pharmaceuticals Inc.", "city": "The Woodlands", "state": "TX", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Inpefa", "phase": "Approved", "indication": "Heart failure"}, {"name": "LX1033", "phase": "Phase II", "indication": "Irritable bowel syndrome"}, {"name": "LX2761", "phase": "Phase I", "indication": "Diabetes"}, {"name": "LX9851", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "Michael Exton, PhD", "employees": 103, "founded": 1995, "website": "http://www.lexpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 104458893.5, "evFmt": "$104M", "ticker": "LXRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lexicon%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "IBD / GI Inflammatory", "Obesity / Metabolic"]}, {"company": "Lib Therapeutics Inc.", "city": "Cincinnati", "state": "OH", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Lerochol", "phase": "Approved", "indication": "Hypercholesterolemia"}, {"name": "LIB002", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.libtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 325000000.0, "totalDealFmt": "$325M", "latestDealDate": "2023-09-12", "recentDeals": [{"headline": "LIB Therapeutics and Hasten Biopharmaceutical Co. Announce $325 Million Strategic Collaboration to Develop and Commercialize Lerodalcibep in Greater China", "date": "2023-09-12", "value": "$325M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lib%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Obesity / Metabolic"]}, {"company": "Libella Gene Therapeutics LLC", "city": "Manhattan", "state": "KS", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AAV-hTERT", "phase": "Phase I", "indication": "Ischemia/reperfusion injury"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.libellagenetherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Libella%20Gene%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Life Biosciences Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Ophthalmic"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CMA-100", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "CMA-200", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}, {"name": "ER-100", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}, {"name": "ER-200", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}, {"name": "MU-100", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "MU-200", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://lifebiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 82000000.0, "totalRaisedFmt": "$82M", "latestFinDate": "2022-01-05", "latestFinType": "Series C rounds", "nRounds": 1, "recentFinancing": [{"type": "Series C rounds", "amount": "$82M", "date": "2022-01-05", "investors": "Alpha Wave Ventures, Individual Investors, Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Life%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Obesity / Metabolic", "Ophthalmology"]}, {"company": "Life Science Pharmaceuticals Inc.", "city": "Darien", "state": "CT", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ABT-806", "phase": "Phase II", "indication": "Cancer (unspecified)"}, {"name": "KW2871", "phase": "Phase II", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.investinlife.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Life%20Science%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Lifemax Laboratories Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Hepatic", "Neurology", "Pulmonary"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "LM-011", "phase": "Phase II", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "LM-007", "phase": "Preclinical", "indication": "Schizophrenia"}, {"name": "LM-022", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.lifemaxlabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lifemax%20Laboratories", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Psychiatry / Behavioral", "Respiratory / Allergy"]}, {"company": "Lifesplice Pharma LLC", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LSP-GR1", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://lifesplicepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lifesplice%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Lifesprout Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Pivotal", "hasOrphan": false, "pipeline": [{"name": "Lumina", "phase": "Pivotal", "indication": "Scars/wrinkles"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.lifesproutbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lifesprout", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Lifordi Immunotherapeutics Inc.", "city": "Burlington", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["ADC"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LFD-200", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.lifordi.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lifordi%20Immunotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Ligand Pharmaceuticals Inc.", "city": "Jupiter", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Diagnostic", "Endocrine/Metabolic", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Other", "Pulmonary", "Transplant"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Combination", "Diagnostics", "Other", "Protein / Biologic", "Small Molecule", "Undisclosed"], "nProducts": 34, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Bonsity", "phase": "Marketed", "indication": "Osteoporosis"}, {"name": "Ohtuvayre", "phase": "Marketed", "indication": "Chronic obstructive pulmonary disease (COPD)"}, {"name": "ensifentrine (DPI ensifentrine", "phase": "Phase II", "indication": "Asthma"}, {"name": "ensifentrine (pMDI ensifentrine", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Captisol-enabled Vfend", "phase": "Marketed", "indication": "Candida"}, {"name": "Conbriza", "phase": "Marketed", "indication": "Osteoporosis"}, {"name": "Duavee", "phase": "Marketed", "indication": "Menopause"}, {"name": "Evomela", "phase": "Marketed", "indication": "Multiple myeloma (MM)"}], "ceo": "Todd Christopher Davis, MBA", "employees": 68, "founded": 1987, "website": "http://www.ligand.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1710713500.0, "evFmt": "$1.7B", "ticker": "LGND", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ligand%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Infectious Disease", "Musculoskeletal", "Respiratory / Allergy", "Women's Health"]}, {"company": "Ligandal Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Ligandal-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.ligandal.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ligandal", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Light Sciences Oncology Inc.", "city": "Bellevue", "state": "WA", "country": "United States", "diseaseCats": ["Cancer", "Genitourinary"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Aptocine talaporfin sodium (litx)", "phase": "Phase III", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.lsoncology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Light%20Sciences%20Oncology", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Limbix", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LX003", "phase": "Preclinical", "indication": "Anxiety"}, {"name": "LX005", "phase": "Preclinical", "indication": "Pain"}, {"name": "LX006", "phase": "Preclinical", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.limbix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Limbix", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Liminatus Pharma Inc.", "city": "La Palma", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "GCC-Targeted CAR-T", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "IBA101", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Chris Kim", "employees": 3, "founded": 2018, "website": "http://liminatuspharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 85007546.2, "evFmt": "$85M", "ticker": "LIMN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Liminatus%20Pharma", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Lineage Cell Therapeutics Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology", "Ophthalmic", "Otologic"], "modalityGroups": ["Cell Therapy", "Vaccine"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "OpRegen (RG6501)", "phase": "Phase II", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "OPC1", "phase": "Phase I/II", "indication": "Spinal cord injury (SCI)"}, {"name": "VAC2 (AST-VAC2)", "phase": "Phase I", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "ANP1", "phase": "Preclinical", "indication": "Hearing loss"}, {"name": "PNC1", "phase": "Preclinical", "indication": "Blindness"}], "ceo": "Brian M. Culley, MBA", "employees": 77, "founded": 1990, "website": "https://lineagecell.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 53936982.5, "evFmt": "$54M", "ticker": "LCTX", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lineage%20Cell%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer", "Ophthalmology", "Other Neurology", "Other Specialties"]}, {"company": "Link Cell Therapies Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LNK001", "phase": "Preclinical", "indication": "Renal cancer"}, {"name": "Link Cell Therapies-colorectal cancer-unknown", "phase": "Research", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://linkcelltx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 72000000.0, "totalRaisedFmt": "$72M", "latestFinDate": "2025-12-15", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$60M", "date": "2025-12-15", "investors": "Johnson & Johnson Innovation \u2013 Jjdc Inc., Samsara Biocapital L.P., Sheatree Capital, Wing Venture Capital, Bristol Myers..."}, {"type": "Seed financings", "amount": "$12M", "date": "2022-05-01", "investors": "Samsara Biocapital L.P., Sheatree Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Link%20Cell%20Therapies", "hasDealsFin": true, "diseaseGroups": ["GI Cancers", "GU / Gynecologic Cancers"]}, {"company": "Linnaeus Therapeutics Inc.", "city": "Haddonfield", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "LNS8801", "phase": "Phase I/II", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.linnaeustx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Linnaeus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Lipac Oncology LLC", "city": "Pomona", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "LiPax", "phase": "Phase II", "indication": "Bladder cancer"}, {"name": "TSD-001 (TBC-1002)", "phase": "Preclinical", "indication": "Bladder cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.lipaconcology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lipac%20Oncology", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Lipella Pharmaceuticals Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Diagnostic", "Genitourinary", "Inflammation", "Transplant"], "modalityGroups": ["Diagnostics", "Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ICE-MRI", "phase": "Phase II", "indication": "Genitourinary, Diagnostic"}, {"name": "LP-10", "phase": "Phase II", "indication": "Cystitis"}, {"name": "LP-310", "phase": "Phase II", "indication": "Inflammation (unspecified)"}, {"name": "LP-20", "phase": "Preclinical", "indication": "Radiologic imaging"}], "ceo": "Jonathan Kaufman, PhD, MBA", "employees": 7, "founded": 2005, "website": "http://www.lipella.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1059739.25, "evFmt": "$1M", "ticker": "LIPO", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lipella%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other", "Other Inflammation", "Supportive / Other"]}, {"company": "Lipidio Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Endocrine/Metabolic", "Hepatic", "Other"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "GDD3898", "phase": "Phase II", "indication": "Acne"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://lipidiopharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lipidio%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Lipocine Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Genitourinary", "Hepatic", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Tlando", "phase": "Marketed", "indication": "Hypogonadism"}, {"name": "LPCN 1107", "phase": "Phase II", "indication": "Genitourinary (unspecified)"}, {"name": "LPCN 1111", "phase": "Phase II", "indication": "Hypogonadism"}, {"name": "LPCN 1144", "phase": "Phase II", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "oral brexanolone (LPCN 1154)", "phase": "Phase II", "indication": "Depression"}, {"name": "LPCN 1148", "phase": "Phase I", "indication": "Cirrhosis"}], "ceo": "Mahesh V. Patel, PhD", "employees": 16, "founded": 1997, "website": "http://www.lipocine.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 4828996.52, "evFmt": "$5M", "ticker": "LPCN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lipocine", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Other", "Other Specialties", "Psychiatry / Behavioral"]}, {"company": "Liquidia Corp.", "city": "Morrisville", "state": "NC", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Yutrepia", "phase": "Approved", "indication": "Hypertension"}], "ceo": "Roger A. Jeffs, PhD", "employees": 157, "founded": 2004, "website": "http://www.liquidia.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 871511235.28, "evFmt": "$872M", "ticker": "LQDA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Liquidia", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Lirum Therapeutics Inc.", "city": "New York City", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Ophthalmic"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "LX-101", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.lirumtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lirum%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Lisata Therapeutics Inc.", "city": "Basking Ridge", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Genitourinary", "Renal"], "modalityGroups": ["Cell Therapy", "Peptide", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Ologo (LSTA14", "phase": "Phase III", "indication": "Angina"}, {"name": "certepetide (LSTA1", "phase": "Phase II", "indication": "Pancreatic cancer"}, {"name": "Honedra (LSTA12", "phase": "Phase II", "indication": "Ischemia/reperfusion injury"}, {"name": "Xowna", "phase": "Phase II", "indication": "Cardiovascular (unspecified)"}, {"name": "LSTA201 (CLBS201)", "phase": "Phase I", "indication": "Diabetic nephropathy"}, {"name": "Lisata Therapeutics-TPN development candidate-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "David J. Mazzo, PhD", "employees": 26, "founded": 2006, "website": "https://www.lisata.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -6541580.0, "evFmt": "", "ticker": "LSTA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lisata%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "GI Cancers", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Lite Strategy Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "pracinostat (sb939)", "phase": "Phase III", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "ME-401", "phase": "Phase III", "indication": "Lymphoma"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lite%20Strategy", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Lixte Biotechnology Holdings Inc.", "city": "Boca Raton", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "LB-100 (Lixte)", "phase": "Phase II", "indication": "Myelodysplastic syndrome (MDS)"}, {"name": "LB-201 HDACi", "phase": "Preclinical", "indication": "Neurofibromatosis"}, {"name": "LB-205", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Geordan G. Pursglove", "employees": 2, "founded": 2005, "website": "http://www.lixte.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7026431.913, "evFmt": "$7M", "ticker": "LIXT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lixte%20Biotechnology%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Locus Biosciences Inc.", "city": "Morrisville", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious"], "modalityGroups": ["Other"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "LBP-EC01", "phase": "Phase I", "indication": "Urinary tract infection (UTI)"}, {"name": "Locus Biosciences-bacterial infection-unknown", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "Locus Biosciences-CDI-unknown", "phase": "Preclinical", "indication": "Clostridium"}, {"name": "Locus Biosciences-Respiratory Infection-unknown", "phase": "Preclinical", "indication": "Respiratory infection"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.locus-bio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Locus%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Logical Therapeutics Inc.", "city": "Foxboro", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Gastrointestinal", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "LT-NS001", "phase": "Phase II/III", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.logicaltherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Logical%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Loki Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AWAKE-LM-PV", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "AWAKE-LM-TT", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "Loki Therapeutics-cancer-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.lokitx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Loki%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Lonestar Heart Inc.", "city": "Laguna Hills", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Algisyl-LVR", "phase": "Marketed", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.lonestarheartinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lonestar%20Heart", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Longeveron Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Musculoskeletal", "Neurology", "Pulmonary"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Lomecel-B", "phase": "Phase II", "indication": "Congestive heart failure (CHF)"}], "ceo": "Than Powell, MBA", "employees": 26, "founded": 2014, "website": "http://www.longeveron.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -1503686.28, "evFmt": "", "ticker": "LGVN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Longeveron", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Longevity Biomedical Inc.", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Musculoskeletal", "Neurology", "Ophthalmic"], "modalityGroups": ["Digital / Device", "Other"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "LBI-201", "phase": "Phase III", "indication": "Stroke"}, {"name": "LBI-002", "phase": "Phase II", "indication": "Corneal transplant"}, {"name": "LBI-101", "phase": "Phase II", "indication": "Tissue damage"}, {"name": "LBI-001", "phase": "Phase I", "indication": "Retinal vein occlusion"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://longevitybiomedical.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Longevity%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology", "Other Neurology", "Supportive / Other"]}, {"company": "Lpoxy Therapeutics Inc.", "city": "Platte City", "state": "MO", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Sidiprev", "phase": "Preclinical", "indication": "Clostridium"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.lpoxy.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lpoxy%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Ltz Therapeutics Inc. (\u6cfd\u5b89\u751f\u7269\u533b\u836f)", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Bispecific Antibody", "Cell Therapy"], "nProducts": 5, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "LTZ-301", "phase": "IND", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "LTZ-121", "phase": "Research", "indication": "Solid tumors"}, {"name": "LTZ-122", "phase": "Research", "indication": "Solid tumors"}, {"name": "LTZ-231", "phase": "Research", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "LTZ-232", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2022, "website": "http://www.ltztherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 89500000.0, "totalRaisedFmt": "$90M", "latestFinDate": "2025-04-23", "latestFinType": "Series A rounds", "nRounds": 4, "recentFinancing": [{"type": "Series A rounds", "amount": "$40M", "date": "2025-04-23", "investors": "Boyu Capital Consultancy Co. Ltd., 5y Capital (\u4e94\u6e90\u8d44\u672c), Bluerun Ventures (Lanchi Ventures), Unicorn Capital Partners Ltd.,..."}, {"type": "Series A rounds", "amount": "$20M", "date": "2024-07-30", "investors": "Lapam Capital (\u9f99\u78d0\u6295\u8d44), Gl Ventures LLC, K2 Venture Partners, Shunwei Capital"}, {"type": "Uncategorized venture rounds", "amount": "$12M", "date": "2023-05-31", "investors": "Qiming Venture Partners (\u542f\u660e\u521b\u6295), Shunwei Capital, Lihehongxin Venture Capital Partnership, K2 Venture Partners"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ltz%20Therapeutics%20Inc.%20(\u6cfd\u5b89\u751f\u7269\u533b\u836f)", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Lubris LLC (Lubris Biopharma)", "city": "Framingham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Musculoskeletal", "Ophthalmic", "Other"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Recombinant human lubricin (rhLub)", "phase": "Phase II", "indication": "Dry eye"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.lubris.net", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lubris%20LLC%20(Lubris%20Biopharma)", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Luca Biologics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Genitourinary", "Infectious"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LUCA Biologics-preterm birth-unknown", "phase": "Preclinical", "indication": "Genitourinary (unspecified)"}, {"name": "LUCA-bacterial vaginosis-unknown", "phase": "Preclinical", "indication": "Bacterial vaginosis"}, {"name": "LUCA-UTI-unknown", "phase": "Preclinical", "indication": "Urinary tract infection (UTI)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.luca.bio", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Luca%20Biologics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Lucina Biotherapeutics Inc.", "city": "Santa Cruz", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LUC-101", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "LUC-201", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://lucina.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lucina%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Lumen Bioscience Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Gastrointestinal", "Infectious"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "Lumen Bioscience-metabolic disease- unknown", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "LMN-201", "phase": "Phase II/III", "indication": "Clostridium"}, {"name": "LMN-101", "phase": "Phase II", "indication": "Diarrhea (infectious)"}, {"name": "LMN-301", "phase": "IND", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Lumen Bioscience-inflammatory bowel disease-unknown", "phase": "Preclinical", "indication": "Crohn's disease"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.lumen.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lumen%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Infectious Disease", "Obesity / Metabolic"]}, {"company": "Lumen Therapeutics LLC", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "LT-1951", "phase": "Phase II", "indication": "Coronary artery bypass graft (CABG) surgery"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.lumentherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lumen%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Luminary Therapeutics Inc.", "city": "Minneapolis", "state": "MN", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "LMY-920", "phase": "Phase I", "indication": "Lymphoma"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.luminarytx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Luminary%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Lumos Pharma Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Ervebo (rVSV-EBOV", "phase": "Marketed", "indication": "Ebola"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://lumos-pharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lumos%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Lunai Bioworks Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RENB-DC-11 (ENOB-DC-11)", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "RENB-DC-12-XX", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "RENB-DC20", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "RENB-HV-12 (ENOB-HV-12)", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "David Weinstein", "employees": 29, "founded": 2001, "website": "https://www.lunaibioworks.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 57650985.2663, "evFmt": "$58M", "ticker": "LNAI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lunai%20Bioworks", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Breast Cancer", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Luxa Biotechnology LLC (Luxabio)", "city": "Fort Lee", "state": "NJ", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "RPESC-RPE-4W", "phase": "Phase I/II", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Luxa%20Biotechnology%20LLC%20(Luxabio)", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Lycera Corp.", "city": "Ann Arbor", "state": "MI", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "LYC-30937-Enteric Coated (LYC-30937-EC", "phase": "Phase II", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "RORgamma agonist (LYC-55716)", "phase": "Phase I/II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "LYC-56056", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.lycera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lycera", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "IBD / GI Inflammatory", "Lung Cancer"]}, {"company": "Lyell Immunopharma Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "IMPT-314", "phase": "Phase I/II", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "LYL119", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Lynn Seely, MD", "employees": 300, "founded": 2018, "website": "https://www.lyell.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -144211800.0, "evFmt": "", "ticker": "LYEL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lyell%20Immunopharma", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Lygenesis Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Hepatic", "Transplant"], "modalityGroups": ["Other"], "nProducts": 4, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "LyGenesis-liver transplant", "phase": "IND", "indication": "Liver disease"}, {"name": "LyGenesis-kidney transplant", "phase": "Preclinical", "indication": "Organ transplant"}, {"name": "LyGenesis-pancreas transplant", "phase": "Preclinical", "indication": "Organ transplant"}, {"name": "LyGenesis-thymus transplant", "phase": "Preclinical", "indication": "Organ transplant"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.lygenesis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 19000000.0, "totalRaisedFmt": "$19M", "latestFinDate": "2023-10-24", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$19M", "date": "2023-10-24", "investors": "Prime Movers Lab, Juvenescence Ltd., Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lygenesis", "hasDealsFin": true, "diseaseGroups": ["Liver Disease", "Transplant"]}, {"company": "Lykos Therapeutics PBC", "city": "San Jose", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "midomafetamine (MDMA", "phase": "Registration", "indication": "Post-traumatic stress disorder"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://lykospbc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lykos%20Therapeutics%20PBC", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Lyndra Therapeutics Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Infectious", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "risperidone (LYN-005)", "phase": "Phase III", "indication": "Schizophrenia"}, {"name": "dapagliflozin (LYN-045)", "phase": "Phase I", "indication": "Diabetes"}, {"name": "ivermectin (LYN-163)", "phase": "Phase I", "indication": "Malaria"}, {"name": "memantine hydrochloride XR and donepezil (LYN-157)", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "rosuvastatin (LYN-047)", "phase": "Phase I", "indication": "Dyslipidemia"}, {"name": "aripiprazole (LYN-006)", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "levomethadone (LYN-014)", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "LYN-064", "phase": "Preclinical", "indication": "Contraception"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.lyndra.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-12-21", "recentDeals": [{"headline": "Sun Pharma acquires exclusive license from Lyndra Therapeutics to market three oral weekly clinical candidates using LYNX drug delivery platform in six global markets", "date": "2023-12-21", "value": ""}], "totalRaised": 121300000.0, "totalRaisedFmt": "$121M", "latestFinDate": "2023-12-21", "latestFinType": "Series E rounds", "nRounds": 2, "recentFinancing": [{"type": "Series E rounds", "amount": "$101M", "date": "2023-12-21", "investors": "Sarissa Capital Management, Sun Pharmaceutical Industries Ltd., Polaris Partners"}, {"type": "Series D rounds", "amount": "$20M", "date": "2023-06-01", "investors": "Polaris Partners"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lyndra%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Diabetes", "Infectious Disease", "Obesity / Metabolic", "Other Neurology", "Psychiatry / Behavioral", "Women's Health"]}, {"company": "Lyotropic Therapeutics Inc.", "city": "Richmond", "state": "VA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Ryanodex", "phase": "Marketed", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 1999, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lyotropic%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Lyra Therapeutics Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "mometasone furoate (LYR-210)", "phase": "Phase III", "indication": "Sinusitis"}, {"name": "LYR-220", "phase": "Preclinical", "indication": "Sinusitis"}], "ceo": "Maria Palasis, PhD", "employees": 30, "founded": 2011, "website": "https://lyratherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7242500.4976, "evFmt": "$7M", "ticker": "LYRA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lyra%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Lyric Pharmaceuticals Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Macrocycle"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ulimorelin (LP101", "phase": "Phase II", "indication": "Gastrointestinal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.lyricpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lyric%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Lz Therapeutics Inc.", "city": "Bethlehem", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "LZT-1000", "phase": "Phase II", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.lztherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Lz%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "M6p Therapeutics Inc.", "city": "St Louis", "state": "MO", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Other"], "modalityGroups": ["Gene Therapy", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "M002", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "M011", "phase": "Preclinical", "indication": "Gaucher disease"}, {"name": "M021", "phase": "Preclinical", "indication": "Pompe disease"}, {"name": "M052", "phase": "Preclinical", "indication": "Fabry disease"}, {"name": "M6P Therapeutics (M012)", "phase": "Preclinical", "indication": "Gaucher disease"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://m6ptherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=M6p%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Maas Biolab LLC", "city": "albuquerque", "state": "NM", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Mitogard", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.maasbiolab.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Maas%20Biolab", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Macrogenics Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Margenza", "phase": "Marketed", "indication": "Breast cancer"}, {"name": "Zynyz", "phase": "Marketed", "indication": "Skin cancer"}, {"name": "Tebotelimab (PD-1 x LAG-3 DART molecule", "phase": "Phase II/III", "indication": "Gastric cancer"}, {"name": "enoblituzumab (MGA271", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "PRV-3279 (MGD010", "phase": "Phase II", "indication": "Lupus"}, {"name": "vobramitamab duocarmazine (vobra duo", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "flotetuzumab", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "CD3 x HIV DART molecule (MGD014)", "phase": "Phase I", "indication": "HIV/AIDS"}], "ceo": "Eric Risser, MBA", "employees": 341, "founded": 2000, "website": "http://www.macrogenics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 39312851.25, "evFmt": "$39M", "ticker": "MGNX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Macrogenics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Breast Cancer", "GI Cancers", "GU / Gynecologic Cancers", "Hematologic Cancers", "Infectious Disease", "Skin Cancer / Melanoma"]}, {"company": "Macuclear Inc.", "city": "Plano", "state": "TX", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "MC-1101", "phase": "Phase II/III", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.macuclear.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Macuclear", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Madison Vaccines Inc.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PTVG-HP (MVI-816)", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "PTVG-AR (MVI-118)", "phase": "Phase I", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.madisonvaccines.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Madison%20Vaccines", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Magnifygen Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IT-4", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.magnifygen.com/default.aspx", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Magnifygen", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Magnolia Neurosciences Corp.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Magnolia-CIPN/CICD-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://magnolianeurosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Magnolia%20Neurosciences", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Mahzi Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology", "Other"], "modalityGroups": ["Gene Therapy", "RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Mahzi Therapeutics-CHD2 deficiency-unknown", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "Mahzi Therapeutics-Pitt Hopkins (TCF4 deficiency)-unknown", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "Mahzi Therapeutics-WOREE/SCAR12 (WWOX deficiency)-unknown", "phase": "Preclinical", "indication": "Ataxia"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://mahzi.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mahzi%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Maia Biotechnology Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "6-thio-dG (THIO-101", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "THIO-102", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "THIO-103", "phase": "Phase I", "indication": "Brain cancer"}], "ceo": "Vlad Vitoc, MD, MBA", "employees": 13, "founded": 2018, "website": "https://maiabiotech.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 34349785.66, "evFmt": "$34M", "ticker": "MAIA", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Maia%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GI Cancers", "Lung Cancer"]}, {"company": "Makindus Inc.", "city": "Doylestown", "state": "PA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "MI-100", "phase": "Phase II", "indication": "Stargardt disease"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://makindus.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Makindus", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Makscientific LLC", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Gastrointestinal", "Hepatic", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AM1710", "phase": "Preclinical", "indication": "Neuropathy"}, {"name": "AM4113", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "AM6527", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "AM6545", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "MAK11049", "phase": "Preclinical", "indication": "Crohn's disease"}, {"name": "MAK1400", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "MAK2124", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.makscientific.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Makscientific", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "MS / Neuroimmune", "Obesity / Metabolic", "Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Mana Therapeutics Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MANA-312", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "MANA-412", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.manatherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mana%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Mannkind Corp.", "city": "Westlake Village", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Gastrointestinal", "Infectious", "Inflammation", "Renal"], "modalityGroups": ["Digital / Device", "Other", "Protein / Biologic", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Afrezza (afresa", "phase": "Marketed", "indication": "Diabetes"}, {"name": "Furoscix", "phase": "Marketed", "indication": "Congestive heart failure (CHF)"}, {"name": "Tyvaso DPI", "phase": "Marketed", "indication": "Hypertension"}, {"name": "Furoscix ReadyFlow Autoinjector", "phase": "Registration", "indication": "Heart failure"}, {"name": "inhaled clofazimine (MNKD-101)", "phase": "Phase II/III", "indication": "Mycobacterium"}, {"name": "ScCeftriaxone", "phase": "Pilot", "indication": "Bacterial infection"}, {"name": "epinephrine", "phase": "Preclinical", "indication": "Allergy"}, {"name": "palonosetron", "phase": "Preclinical", "indication": "Emesis"}], "ceo": "Michael E. Castagna, MBA", "employees": 407, "founded": 1991, "website": "http://www.mannkindcorp.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1785080920.0, "evFmt": "$1.8B", "ticker": "MNKD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mannkind", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "Infectious Disease", "Respiratory / Allergy", "Supportive / Other"]}, {"company": "Maplight Therapeutics Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ML-004", "phase": "Phase II", "indication": "Cognitive dysfunction"}, {"name": "ML-007", "phase": "Phase I", "indication": "Neurology (unspecified)"}, {"name": "ML-007C-MA", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "ML-009", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "ML-016", "phase": "Preclinical", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://maplightrx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "MPLT", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-12-16", "recentDeals": [{"headline": "SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies", "date": "2025-12-16", "value": ""}], "totalRaised": 647499997.0, "totalRaisedFmt": "$647M", "latestFinDate": "2025-07-28", "latestFinType": "Series D rounds", "nRounds": 3, "recentFinancing": [{"type": "Series D rounds", "amount": "$372M", "date": "2025-07-28", "investors": "Forbion, Goldman Sachs Asset Management, Sanofi, T. Rowe Price Investment Management Inc., Avego Bioscience Capital, Nov..."}, {"type": "Series C rounds", "amount": "$225M", "date": "2023-10-30", "investors": "Novo Holdings A/S, 5am Ventures, Cowen Healthcare Investments, Undisclosed Investors"}, {"type": "Uncategorized venture rounds", "amount": "$50M", "date": "2023-07-05", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Maplight%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Other Neurology", "Psychiatry / Behavioral"]}, {"company": "Mapp Biopharmaceutical Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "MBP091", "phase": "Phase I", "indication": "Marburg"}, {"name": "MBP134", "phase": "Phase I", "indication": "Ebola"}, {"name": "Zmapp", "phase": "Phase II", "indication": "Ebola"}, {"name": "MB66", "phase": "Phase I", "indication": "Herpes simplex virus (HSV)"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.mappbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mapp%20Biopharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "March Biosciences Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "MB-105", "phase": "Phase II", "indication": "T cell lymphoma"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://march.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=March%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Marea Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "MAR001", "phase": "Phase II", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.mareatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Marea%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Marengo Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Undisclosed"], "nProducts": 8, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "STAR0501", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "STAR0502", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "invikafusp alfa (STAR0602)", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "CO-STAR", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "SKAR001", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "STAR002", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "STAR003", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "TRI-STAR001", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.marengotx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Marengo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Mariposa Health Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "HI-1640V", "phase": "Phase II", "indication": "Chronic obstructive pulmonary disease (COPD)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.mariposahealth.com.au", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mariposa%20Health", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Marius Pharmaceuticals LLC", "city": "Raleigh", "state": "NC", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Kyzatrex", "phase": "Approved", "indication": "Hypogonadism"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.mariuspharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Marius%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Marker Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "zedenoleucel (MT-401)", "phase": "Phase II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "MT-601", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "MT-401-OTS", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "Juan F. Vera, MD", "employees": 5, "founded": 2007, "website": "https://markertherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 8736003.77, "evFmt": "$9M", "ticker": "MRKR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Marker%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Martin Pharmaceuticals Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular", "Hepatic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "Livantra", "phase": "Phase I", "indication": "Liver failure"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.martinpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Martin%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Mati Therapeutics Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Latanoprost punctal plug delivery system (L-PPDS)", "phase": "Phase II", "indication": "Glaucoma"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.matitherapeutics.com/about/corporate-overview", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mati%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Matinas Biopharma Holdings Inc.", "city": "Bedminster", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Infectious"], "modalityGroups": ["Macrocycle", "Nanoparticle / Delivery"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "MAT2203 (CAmB)", "phase": "Phase II", "indication": "Candida"}, {"name": "MAT9001", "phase": "Phase II", "indication": "Hypertriglyceridemia"}, {"name": "MAT2501 (C-Amikacin)", "phase": "Phase I", "indication": "Gram-negative bacterial infection"}], "ceo": "Jerome D. Jabbour", "employees": 7, "founded": 2011, "website": "http://www.matinasbiopharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -1958427.21, "evFmt": "", "ticker": "MTNB", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Matinas%20Biopharma%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Obesity / Metabolic"]}, {"company": "Matrisys Bioscience Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MSB-0221", "phase": "Phase I", "indication": "Dermatitis"}, {"name": "MSB-6005", "phase": "Phase I", "indication": "Netherton syndrome"}, {"name": "MSB-2040", "phase": "Preclinical", "indication": "Netherton syndrome"}, {"name": "MSB-2179", "phase": "Preclinical", "indication": "Netherton syndrome"}, {"name": "MSB-3163", "phase": "Preclinical", "indication": "Acne"}, {"name": "MSB-5710", "phase": "Preclinical", "indication": "Actinic keratosis"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://matrisysbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Matrisys%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Skin Cancer / Melanoma"]}, {"company": "Matrix Biomed Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Dermatology", "Infectious", "Neurology", "Ophthalmic", "Other"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 9, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "MBI-06-01 (MTS-01)", "phase": "Phase III", "indication": "Dermatitis"}, {"name": "Tempol (APC-410)", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Tempol (APC-400)", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "MBI-04-04 (MBM-01)", "phase": "Phase II", "indication": "Mucositis"}, {"name": "MBI-05-01", "phase": "Phase II", "indication": "Cardiovascular (unspecified)"}, {"name": "MBI-08-01", "phase": "Phase II", "indication": "Neuropathy"}, {"name": "MBI-10-01 (MBM-02)", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "MBI-17-01 (MBM-02)", "phase": "Phase II", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://matrixbiomed.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Matrix%20Biomed", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Cardiovascular", "Dermatology", "GU / Gynecologic Cancers", "Infectious Disease", "Pain / Migraine", "Supportive / Other"]}, {"company": "Maxwell Biosciences Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Claromer", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://maxwellbiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Maxwell%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Maze Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Ophthalmic", "Renal"], "modalityGroups": ["Antibody", "Gene Therapy", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "MZE001 (S-606001)", "phase": "Phase I", "indication": "Pompe disease"}, {"name": "MZE782", "phase": "Phase I", "indication": "Phenylketonuria"}, {"name": "MZE829", "phase": "Phase I", "indication": "Renal (unspecified)"}, {"name": "Maze-ATXN2-unknown", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "Maze-ophthalmic-unknown", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "Jason V. Coloma, PhD, MBA", "employees": 125, "founded": 2018, "website": "https://mazetx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "MAZE", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 750000000.0, "totalDealFmt": "$750M", "latestDealDate": "2024-05-10", "recentDeals": [{"headline": "Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease", "date": "2024-05-10", "value": ""}, {"headline": "Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease", "date": "2023-05-01", "value": "$750M"}], "totalRaised": 115000000.0, "totalRaisedFmt": "$115M", "latestFinDate": "2024-12-03", "latestFinType": "Series D rounds", "nRounds": 1, "recentFinancing": [{"type": "Series D rounds", "amount": "$115M", "date": "2024-12-03", "investors": "Frazier Life Sciences, Deep Track Capital, Janus Henderson Investors, Logos Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Maze%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Kidney Disease", "Neurodegeneration / NMD", "Ophthalmology", "Rare / Genetic"]}, {"company": "Mbc Pharma Inc.", "city": "Aurora", "state": "CO", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MBC-11", "phase": "Phase I", "indication": "Bone cancer"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.mbcpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mbc%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Mbrace Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MBRC-101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://mbracetrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mbrace%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Mbx Biosciences Inc.", "city": "Carmel", "state": "IN", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Peptide"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "canvuparatide (MBX 2109)", "phase": "Phase II", "indication": "Endocrine (unspecified)"}, {"name": "Imapextide (MBX 1416)", "phase": "Phase II", "indication": "Hypoglycemia"}, {"name": "MBX 4291", "phase": "Phase I", "indication": "Obesity"}], "ceo": "Peter Kent Hawryluk, MBA", "employees": 43, "founded": 2019, "website": "https://www.mbxbio.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 354022705.75, "evFmt": "$354M", "ticker": "MBX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mbx%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Obesity / Metabolic", "Other Specialties"]}, {"company": "Mebias Discovery Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MEB-1166", "phase": "Preclinical", "indication": "Pain"}, {"name": "MEB-1170", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://mebiasdiscovery.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mebias%20Discovery", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Medabome Inc.", "city": "Fremont", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MAI002", "phase": "Preclinical", "indication": "Gastric cancer"}, {"name": "MAI003", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "MAI008", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "MAI009", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "MAI014", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.medabome.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Medabome", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Hematologic Cancers", "Lung Cancer"]}, {"company": "Medeor Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Hematology", "Transplant"], "modalityGroups": ["Cell Therapy", "Vaccine"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "MDR-101", "phase": "Phase III", "indication": "Renal transplant"}, {"name": "MDR-102", "phase": "Phase II", "indication": "Renal transplant"}, {"name": "MDR-103", "phase": "Phase II", "indication": "Renal transplant"}, {"name": "MDR-104", "phase": "Preclinical", "indication": "Renal transplant"}, {"name": "MDR-201", "phase": "Preclinical", "indication": "Liver transplant"}, {"name": "MDR-301", "phase": "Preclinical", "indication": "Hematopoietic transplant"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.medeortx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Medeor%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease", "Transplant"]}, {"company": "Mediar Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Pulmonary", "Renal"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "MTX-463", "phase": "Phase II", "indication": "Pulmonary fibrosis"}, {"name": "MTX-474", "phase": "Phase II", "indication": "Scleroderma"}, {"name": "MTX-439", "phase": "Preclinical", "indication": "Renal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.mediartx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 786000000.0, "totalDealFmt": "$786M", "latestDealDate": "2025-01-10", "recentDeals": [{"headline": "Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)", "date": "2025-01-10", "value": "$786M"}], "totalRaised": 161000000.0, "totalRaisedFmt": "$161M", "latestFinDate": "2026-01-07", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$76M", "date": "2026-01-07", "investors": "Amplitude Venture Capital, Intermediate Capital Group, Longwood Fund, Asahi Kasei Pharma Corp., Alexandria Real Estate E..."}, {"type": "Series A rounds", "amount": "$85M", "date": "2023-03-15", "investors": "Novartis Venture Fund, Sofinnova Partners, Pfizer Ventures, Mission Biocapital, Gimv, Pureos Bioventures, Bristol Myers ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mediar%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Kidney Disease", "Respiratory / Allergy"]}, {"company": "Medicinova Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Gene Therapy", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "MN-305", "phase": "Phase II/III", "indication": "Anxiety"}, {"name": "SAR444836", "phase": "Phase I/II", "indication": "Phenylketonuria"}], "ceo": "Yuichi Iwaki, MD, PhD", "employees": 13, "founded": 2000, "website": "http://www.medicinova.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 63042607.6, "evFmt": "$63M", "ticker": "MNOV", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Medicinova", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral", "Rare / Genetic"]}, {"company": "Medicus Pharma Ltd.", "city": "Conshohocken", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Genitourinary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SkinJect (Doxorubicin Microneedle Array)", "phase": "Phase II", "indication": "Skin cancer"}, {"name": "teverelix trifluoroacetate (teverelix TFA)", "phase": "Phase II", "indication": "Prostate cancer"}], "ceo": "Raza Bokhari, MD, MBA", "employees": 12, "founded": 2015, "website": "https://medicuspharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 26043198.988698, "evFmt": "$26M", "ticker": "MDCX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Medicus%20Pharma", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Skin Cancer / Melanoma"]}, {"company": "Medikine Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MDK-703", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "https://www.medikine.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Medikine", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Medimetriks Pharmaceuticals Inc.", "city": "Fairfield", "state": "NJ", "country": "United States", "diseaseCats": ["Dermatology", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Centany", "phase": "Marketed", "indication": "Skin and skin structure infection (SSSI)"}, {"name": "Morgidox", "phase": "Marketed", "indication": "Acne"}, {"name": "Rosadan Cream", "phase": "Marketed", "indication": "Rosacea"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.medimetriks.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Medimetriks%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Medinox Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NOX-100", "phase": "Phase II", "indication": "Hypotension"}, {"name": "MX-1094", "phase": "Phase II", "indication": "Arthritis"}], "ceo": "", "employees": 0, "founded": 1995, "website": "http://www.medinox.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Medinox", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Other"]}, {"company": "Mediprint Ophthalmics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation", "Ophthalmic"], "modalityGroups": ["Digital / Device"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "LL-BMT1", "phase": "Phase II", "indication": "Glaucoma"}, {"name": "LL-A1", "phase": "Preclinical", "indication": "Allergy"}, {"name": "LL-C1", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}, {"name": "LL-D1", "phase": "Preclinical", "indication": "Dry eye"}, {"name": "LL-M1", "phase": "Preclinical", "indication": "Myopia"}, {"name": "LL-PC1", "phase": "Preclinical", "indication": "Cataract"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.mediprintlens.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mediprint%20Ophthalmics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology", "Respiratory / Allergy"]}, {"company": "Mediquest Therapeutics Inc.", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "MQX-503", "phase": "Registration", "indication": "Raynaud's disease"}], "ceo": "", "employees": 0, "founded": 1994, "website": "http://www.mqti.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mediquest%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Meiragtx Holdings plc", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Neurology", "Ophthalmic"], "modalityGroups": ["Cell Therapy", "Gene Therapy"], "nProducts": 11, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "AAV-AIPL", "phase": "Phase III", "indication": "Ophthalmic (unspecified)"}, {"name": "AAV-GAD (NLX-P101", "phase": "Phase II", "indication": "Parkinson's disease"}, {"name": "AAV-CNGA3 (A003)", "phase": "Phase I/II", "indication": "Ophthalmic (unspecified)"}, {"name": "AAV-CNGB3 (A002)", "phase": "Phase I/II", "indication": "Ophthalmic (unspecified)"}, {"name": "AAV-RPE65 (A001)", "phase": "Phase I/II", "indication": "Ophthalmic (unspecified)"}, {"name": "AAV5 vector encoding IFN beta (ART-I02)", "phase": "Phase I", "indication": "Rheumatoid arthritis (RA)"}, {"name": "A005", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "A007", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "Alexandria Forbes, PhD", "employees": 381, "founded": 2015, "website": "https://meiragtx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 406356129.77, "evFmt": "$406M", "ticker": "MGTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Meiragtx%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Ophthalmology", "Parkinson's"]}, {"company": "Meissa Vaccines Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MV-012-968", "phase": "Preclinical", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "MV-014-210", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.meissavaccines.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Meissa%20Vaccines", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Meitheal Pharmaceuticals Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "fosfomycin (Contepo", "phase": "Approved", "indication": "Urinary tract infection (UTI)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.meithealpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 4, "totalDealValue": 120000000.0, "totalDealFmt": "$120M", "latestDealDate": "2024-07-18", "recentDeals": [{"headline": "Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO (Fosfomycin for Injection) from Nabriva Therapeutics", "date": "2024-07-18", "value": ""}, {"headline": "Meitheal Pharmaceuticals Strengthens Biologics Portfolio with an Exclusive Commercial Licensing Agreement for Yusimry, a Biosimilar of Humira", "date": "2024-06-27", "value": "$40M"}, {"headline": "Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.", "date": "2023-09-21", "value": ""}], "totalRaised": 35000000.0, "totalRaisedFmt": "$35M", "latestFinDate": "2023-08-22", "latestFinType": "Venture (Debt)", "nRounds": 1, "recentFinancing": [{"type": "Venture (Debt)", "amount": "$35M", "date": "2023-08-22", "investors": "J.P. Morgan"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Meitheal%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Mekanistic Therapeutics Inc.", "city": "Minneapolis", "state": "MN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "MTX-531", "phase": "IND", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.mekanistic.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mekanistic%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer"]}, {"company": "Melior Pharmaceuticals Inc.", "city": "Exton", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic", "Infectious", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "tolimidone (MLR-1023)", "phase": "Phase II", "indication": "Diabetes"}, {"name": "Mesocarb (Armesocarb", "phase": "Phase I", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://meliorpharmaceuticals.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Melior%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Parkinson's"]}, {"company": "Memgen Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Oncolytic / Microbiome", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "MEM-288", "phase": "Phase I/II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Memgen - Vaccine Adjuvant - unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.memgenbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Memgen", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Lung Cancer"]}, {"company": "Menon Biosensors Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "M2 NMR Technology", "phase": "Marketed", "indication": "Infectious, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.menon.us/menon-biosensors", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Menon%20Biosensors", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Mentrik Biotech LLC", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ocaratuzumab (AME-133v", "phase": "Phase II", "indication": "Non-Hodgkin lymphoma (NHL)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.mentrik.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mentrik%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Merakris Therapeutics Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Dermatology", "Ophthalmic"], "modalityGroups": ["Digital / Device", "Other"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Opticyte Amniotic Ocular Matrix", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}, {"name": "Dermacyte Matrix", "phase": "Phase II", "indication": "Dermal ulcers"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.merakris.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Merakris%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Ophthalmology"]}, {"company": "Mercator Medsystems Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Digital / Device"], "nProducts": 2, "mostAdvanced": "Phase IV", "hasOrphan": false, "pipeline": [{"name": "Bullfrog Micro-Infusion dexamethasone", "phase": "Phase IV", "indication": "Peripheral vascular disease (PVD)"}, {"name": "Bullfrog Micro-Infusion Temsirolimus", "phase": "Phase III", "indication": "Ischemia/reperfusion injury"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.mercatormed.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mercator%20Medsystems", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Supportive / Other"]}, {"company": "Mercia Pharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Infectious", "Neurology"], "modalityGroups": ["Protein / Biologic", "Vaccine"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "MER4101", "phase": "Phase I/II", "indication": "Influenza virus"}, {"name": "MER3101", "phase": "IND", "indication": "Diabetes"}, {"name": "MER5101", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://merciapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mercia%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Diabetes", "Infectious Disease"]}, {"company": "Merck & Co. Inc.", "city": "Rahway", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dermatology", "Endocrine/Metabolic", "Gastrointestinal", "Genitourinary", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Ophthalmic", "Other", "Pulmonary", "Renal", "Transplant"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Combination", "Gene Therapy", "Macrocycle", "Oncolytic / Microbiome", "Other", "Protein / Biologic", "Small Molecule", "Undisclosed", "Vaccine"], "nProducts": 159, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Keytruda", "phase": "Marketed", "indication": "Solid tumors"}, {"name": "Stilamin", "phase": "Marketed", "indication": "Gastroenteritis"}, {"name": "Aerinaze", "phase": "Marketed", "indication": "Rhinitis"}, {"name": "Aggrastat", "phase": "Marketed", "indication": "Acute coronary syndrome"}, {"name": "Altocor", "phase": "Marketed", "indication": "Cardiovascular (unspecified)"}, {"name": "Aquipta", "phase": "Marketed", "indication": "Migraine"}, {"name": "Arcoxia", "phase": "Marketed", "indication": "Ankylosing spondylitis"}, {"name": "Belsomra", "phase": "Marketed", "indication": "Insomnia"}], "ceo": "Robert M. Davis, MBA", "employees": 0, "founded": 1891, "website": "https://www.merck.com/", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "MRK", "exchange": "NYSE", "nDeals": 9, "totalDealValue": 20084000000.0, "totalDealFmt": "$20.1B", "latestDealDate": "2024-11-14", "recentDeals": [{"headline": "Merck (MSD) Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from Lanova Medicines", "date": "2024-11-14", "value": "$3.3B"}, {"headline": "Merck & Co. signs $220M macrocyclic peptide deal after hailing next wave of drug discovery", "date": "2024-01-23", "value": ""}, {"headline": "ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics", "date": "2023-12-14", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Merck%20%26%20Co.", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Cardiovascular", "Other", "Pain / Migraine", "Psychiatry / Behavioral", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Mercury Bio Inc.", "city": "Santa Fe", "state": "NM", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SIREN-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.mercurybio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-09-17", "recentDeals": [{"headline": "Frame Bio Licenses Novel Drug Delivery Technology from Mercury Bio to Develop Regenerative Therapies for Bone and Collagen Diseases and Disorders", "date": "2025-09-17", "value": ""}], "totalRaised": 2376107.0, "totalRaisedFmt": "$2M", "latestFinDate": "2025-09-30", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$2M", "date": "2025-09-30", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mercury%20Bio", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Mercury Therapeutics Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Debio 0930", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.mtipharm.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mercury%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Merlin Biotech LLC", "city": "Doylestown", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["RNA Therapeutics", "Undisclosed", "Vaccine"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Merlin Biotech - Hepatitis B - unknown", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "Merlin Biotech - Lyme disease - unknown", "phase": "Preclinical", "indication": "Lyme disease"}, {"name": "Merlin Biotech - Oncology - unknown", "phase": "Preclinical", "indication": "Sarcoma"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.merlinbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Merlin%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Other Solid Tumors"]}, {"company": "Metabiomics Corp.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "LifeKit Prevent", "phase": "Marketed", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.metabiomics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metabiomics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Metabolic Solutions Development Co.", "city": "Kalamazoo", "state": "MI", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MSDC-5514", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.msdrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metabolic%20Solutions%20Development", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Metabolon Inc.", "city": "Morrisville", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 3, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Meta UDx", "phase": "Market (diagnostic)", "indication": "Metabolic, Diagnostic"}, {"name": "Prostarix DRE Urine Test", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "Quantose IR test", "phase": "Market (diagnostic)", "indication": "Endocrine, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 85043517.0, "totalRaisedFmt": "$85M", "latestFinDate": "2024-12-31", "latestFinType": "Uncategorized venture rounds", "nRounds": 4, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$8M", "date": "2024-12-31", "investors": "Undisclosed Investors"}, {"type": "Venture (Debt)", "amount": "$42M", "date": "2024-05-16", "investors": "Trinity Capital Inc."}, {"type": "Uncategorized venture rounds", "amount": "$25M", "date": "2023-01-24", "investors": "New Investors, Existing Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metabolon", "hasDealsFin": true, "diseaseGroups": ["Obesity / Metabolic", "Other Specialties", "Solid Tumors (General)"]}, {"company": "Metagenomi Therapeutics Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Hepatic", "Pulmonary"], "modalityGroups": ["Cell Therapy", "Gene Therapy"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Metagenomi - blood cancer - unknown", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "Metagenomi - hemophilia A - unknown", "phase": "Preclinical", "indication": "Hemophilia"}, {"name": "Metagenomi - hepatic - unknown", "phase": "Preclinical", "indication": "Liver disease"}, {"name": "Metagenomi - solid tumors - unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Metagenomi - cystic fibrosis - unknown", "phase": "Research", "indication": "Cystic fibrosis (CF)"}, {"name": "Metagenomi - solid tumors - unknown2", "phase": "Research", "indication": "Solid tumors"}], "ceo": "Jian Irish, PhD, MBA", "employees": 202, "founded": 2018, "website": "https://metagenomi.co/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -67448323.3, "evFmt": "", "ticker": "MGX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 275000000.0, "totalRaisedFmt": "$275M", "latestFinDate": "2023-01-05", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$100M", "date": "2023-01-05", "investors": "Novo Holdings A/S, Catalio Capital Management, Symbiosis LLC, New Investors, Existing Investors, Leaps by Bayer, Moderna..."}, {"type": "Series B rounds", "amount": "$175M", "date": "2022-01-25", "investors": "Pfm Health Sciences, Farallon Capital Management, Undisclosed Investor, Deep Track Capital, Eventide Asset Management LL..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metagenomi%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Hematology (non-cancer)", "Liver Disease", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Metame Health Inc.", "city": "Chicago", "state": "", "country": "United States", "diseaseCats": ["Gastrointestinal", "Neurology"], "modalityGroups": ["Digital / Device", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Market (device)", "hasOrphan": false, "pipeline": [{"name": "Regulora", "phase": "Market (device)", "indication": "Pain"}, {"name": "DT1", "phase": "Research", "indication": "Gastroesophageal reflux disease (GERD)"}, {"name": "DT2", "phase": "Research", "indication": "Irritable bowel syndrome"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-03-22", "recentDeals": [{"headline": "metaMe Health partners with Indegene to launch Regulora, an FDA-cleared prescription digital therapeutic for adults with Irritable Bowel Syndrome", "date": "2022-03-22", "value": ""}], "totalRaised": 2575500.0, "totalRaisedFmt": "$3M", "latestFinDate": "2024-03-26", "latestFinType": "Venture (Debt)", "nRounds": 3, "recentFinancing": [{"type": "Venture (Debt)", "amount": "$140K", "date": "2024-03-26", "investors": "Undisclosed Investors"}, {"type": "Venture (Debt)", "amount": "$235K", "date": "2023-04-19", "investors": "Undisclosed Investors"}, {"type": "Uncategorized venture rounds", "amount": "$2M", "date": "2022-03-15", "investors": "Hyde Park Angels, Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metame%20Health", "hasDealsFin": true, "diseaseGroups": ["GI Cancers", "IBD / GI Inflammatory", "Pain / Migraine"]}, {"company": "Metastx LLC", "city": "Baskin Ridge", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MetasTx (MTX-101)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://metastx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metastx", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Metavia Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "niclosamide (ANA001", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Hyung-Heon Kim", "employees": 9, "founded": 2017, "website": "https://metaviatx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -134030.161685, "evFmt": "", "ticker": "MTVA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metavia", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Metro International Biotech LLC", "city": "Birmingham", "state": "MI", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MIB-626", "phase": "Phase I", "indication": "Cardiovascular (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metro%20International%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Metronomx Pte. Ltd.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "MNX-100", "phase": "Phase II", "indication": "Neuroblastoma"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.metronomxgroup.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metronomx%20Pte.", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Metvital Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Anhydrous Enol-Oxaloacetate (AEO)", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://metvital.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Metvital", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Microbiotix (USA) Inc.", "city": "Worcester", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Oncolytic / Microbiome", "Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "filociclovir (MBX-400)", "phase": "Phase I", "indication": "Cytomegalovirus (CMV)"}, {"name": "Gon-X", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "Type III Secretion System", "phase": "Preclinical", "indication": "Bacterial respiratory infection"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.microbiotix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Microbiotix%20(USA)", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Microcures Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Neurology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "siFi2", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.microcures.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Microcures", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Mid-atlantic Biotherapeutics Inc.", "city": "Doylestown", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "IMT504", "phase": "Phase I", "indication": "Rabies"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://mabt.us/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mid-atlantic%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Midway Biome Inc.", "city": "Spring House", "state": "PA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Infectious"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MDY-1001", "phase": "Preclinical", "indication": "Irritable bowel syndrome"}, {"name": "PEG 15-20", "phase": "Preclinical", "indication": "Sepsis"}], "ceo": "", "employees": 0, "founded": 2005, "website": "https://midwaybiome.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Midway%20Biome", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Supportive / Other"]}, {"company": "Mindimmune Therapeutics Inc.", "city": "Providence", "state": "RI", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Antibody", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MITI-101", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "MITI-102", "phase": "Preclinical", "indication": "Cognitive dysfunction"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://mindimmune.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mindimmune%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Mindlab LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MLB-001", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://mindlabpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mindlab", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Minerva Biotechnologies Corp.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MN-384", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.minervabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Minerva%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Minerva Neurosciences Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MIN-301 (NRG-101)", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "R\u00e9my Henri Luthringer, PhD", "employees": 8, "founded": 2007, "website": "http://www.minervaneurosciences.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 55363863.8808, "evFmt": "$55M", "ticker": "NERV", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Minerva%20Neurosciences", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "Minivax Inc.", "city": "New Orleans", "state": "LA", "country": "United States", "diseaseCats": ["Diagnostic", "Infectious"], "modalityGroups": ["Diagnostics", "Other", "Vaccine"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PCP-Antibody", "phase": "Preclinical", "indication": "Pneumonia"}, {"name": "PCP-Diagnostic", "phase": "Preclinical", "indication": "Infectious, Diagnostic"}, {"name": "PCP-Vaccine", "phase": "Preclinical", "indication": "Pneumonia"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.minivaxcorp.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Minivax", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Mink Therapeutics Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MiNK-215", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "MiNK-413", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Jennifer S. Buell, PhD", "employees": 23, "founded": 2017, "website": "https://minktherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 26643880.894, "evFmt": "$27M", "ticker": "INKT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mink%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Minneamrita Therapeutics LLC", "city": "Moline", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Minnelide", "phase": "Phase II", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Minneamrita%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Miodx", "city": "San Jose", "state": "CA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Pivotal", "hasOrphan": false, "pipeline": [{"name": "VerifyDx Prostate Cancer Test", "phase": "Pivotal", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.miodx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Miodx", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Miomics Bio Therapeutics LLC", "city": "New York City", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PH100", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.miomics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Miomics%20Bio%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Mira Pharmaceuticals Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Ketamir-2", "phase": "Preclinical", "indication": "Depression"}, {"name": "MIRA1a", "phase": "Preclinical", "indication": "Anxiety"}], "ceo": "Erez Aminov", "employees": 5, "founded": 2020, "website": "https://mirapharmaceuticals.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 14773398.86, "evFmt": "$15M", "ticker": "MIRA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mira%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Miragene Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "IMG-008", "phase": "IND", "indication": "Psoriasis"}, {"name": "IMG-018", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2025, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Miragene", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Other Inflammation"]}, {"company": "Mirecule Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MC-DX4", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "MC-30", "phase": "Preclinical", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://mirecule.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mirecule", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer", "Neurodegeneration / NMD"]}, {"company": "Mirum Pharmaceuticals Inc.", "city": "Foster City", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Hepatic", "Infectious", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Chenodal", "phase": "Marketed", "indication": "Gastrointestinal (unspecified)"}, {"name": "Cholbam", "phase": "Marketed", "indication": "Pancreatic insufficiency"}, {"name": "BJT-188", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "BJT-628", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "Christopher Peetz, MBA", "employees": 322, "founded": 2018, "website": "http://www.mirumpharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2002507261.9, "evFmt": "$2.0B", "ticker": "MIRM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mirum%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Liver Disease", "Obesity / Metabolic", "Other"]}, {"company": "Mithridion Inc.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MI-08-016", "phase": "Preclinical", "indication": "Cognitive dysfunction"}, {"name": "MI-08-035", "phase": "Preclinical", "indication": "Cognitive dysfunction"}, {"name": "MI-10-022", "phase": "Preclinical", "indication": "Schizophrenia"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.mithridion.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mithridion", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Psychiatry / Behavioral"]}, {"company": "Mito Biopharm LLC", "city": "Piscataway", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MT-2", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "MT-238", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "MT-514", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://mitobiopharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mito%20Biopharm", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Obesity / Metabolic", "Solid Tumors (General)"]}, {"company": "Mitochon Pharmaceuticals Inc.", "city": "Radnor", "state": "PA", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "MP101", "phase": "Phase II", "indication": "Multiple sclerosis (MS)"}, {"name": "MP201", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.mitochonpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mitochon%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune", "Other Neurology"]}, {"company": "Mitotherapeutix LLC", "city": "Farmington", "state": "CT", "country": "United States", "diseaseCats": ["Hepatic", "Renal"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MT-001", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "MT-002", "phase": "Preclinical", "indication": "Hepatic (unspecified)"}, {"name": "MT-003", "phase": "Preclinical", "indication": "Polycystic kidney disease (PKD)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://mitotherapeutix.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mitotherapeutix", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease", "Liver Disease", "Obesity / Metabolic"]}, {"company": "Moat Biotechnology Corp.", "city": "Oklahoma City", "state": "OK", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Moat Biotechnology-COVID-19-unknown", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-09-20", "recentDeals": [{"headline": "MoatBio holds an exclusive patent license from Mayo Clinic for the novel second generation single-cycle adenovirus vaccine platform", "date": "2022-09-20", "value": ""}], "totalRaised": 6500000.0, "totalRaisedFmt": "$6M", "latestFinDate": "2023-06-13", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$6M", "date": "2023-06-13", "investors": "Cortado Ventures, Boyd Street Ventures LLC"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Moat%20Biotechnology", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Mobius Therapeutics LLC", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Mitosol", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.mobiustherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mobius%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Model Medicines Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Gastrointestinal", "Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 13, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MDL-001 (T 001)", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "MDL-010 (T 010)", "phase": "Preclinical", "indication": "Gastrointestinal (GI) dysfunction"}, {"name": "MDL-020 (T 010)", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "MDL-030 (T 010)", "phase": "Preclinical", "indication": "Obesity"}, {"name": "Model Medicines - T 002 - unknown", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "Model Medicines - T 003 - unknown", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "Model Medicines - T 004 - unknown", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "Model Medicines - T 005 - unknown", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.modelmedicines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Model%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Obesity / Metabolic", "Other", "Other Neurology"]}, {"company": "Moderna Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Endocrine/Metabolic", "Infectious", "Pulmonary"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 45, "mostAdvanced": "Phase IV", "hasOrphan": true, "pipeline": [{"name": "Moderna COVID-19 Vaccine (mRNA-1273.351)", "phase": "Phase IV", "indication": "Infectious (unspecified)"}, {"name": "Moderna COVID-19 Vaccine (mRNA-1273.214)", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Moderna COVID-19 Vaccine (mRNA-1273.222)", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Spikevax (spikevax elasomeran", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}, {"name": "mNEXSPIKE", "phase": "Approved", "indication": "Coronavirus disease (COVID-19)"}, {"name": "mResvia (mRNA-1345)", "phase": "Approved", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "intismeran autogene (mRNA-4157", "phase": "Phase III", "indication": "Melanoma"}, {"name": "Moderna COVID-19 Vaccine (mRNA-1273.529)", "phase": "Phase III", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "St\u00e9phane Bancel, MBA", "employees": 5800, "founded": 2010, "website": "http://www.modernatx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 9687720000.0, "evFmt": "$9.7B", "ticker": "MRNA", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 80000000.0, "totalDealFmt": "$80M", "latestDealDate": "2023-02-22", "recentDeals": [{"headline": "Moderna and Life Edit Therapeutics enter strategic collaboration to accelerate the development of novel in vivo gene editing therapies", "date": "2023-02-22", "value": ""}, {"headline": "Moderna partners with Carisma to develop and commercialize chimeric antigen receptor monocytes (CAR-M) to treat cancer", "date": "2022-01-10", "value": "$80M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Moderna", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy", "Skin Cancer / Melanoma"]}, {"company": "Modulation Therapeutics Inc.", "city": "Morgantown", "state": "WV", "country": "United States", "diseaseCats": ["Cancer", "Hepatic"], "modalityGroups": ["Peptide", "Radiopharmaceutical", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "MTI-201", "phase": "Phase I", "indication": "Melanoma"}, {"name": "MTI-101", "phase": "Preclinical", "indication": "Lung cancer"}, {"name": "MTI-301 (SSI-4)", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://www.modulationtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Modulation%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Lung Cancer", "Skin Cancer / Melanoma"]}, {"company": "Moerae Matrix Inc.", "city": "Morristown", "state": "NJ", "country": "United States", "diseaseCats": ["Inflammation", "Pulmonary"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MMI-0100", "phase": "Phase I", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.moeraematrix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Moerae%20Matrix", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Molecular Targeting Technologies Inc.", "city": "West Chester", "state": "PA", "country": "United States", "diseaseCats": ["Diagnostic", "Infectious"], "modalityGroups": ["Antibody", "Diagnostics"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Amiscan", "phase": "Phase II", "indication": "Cardiovascular, Diagnostic"}, {"name": "Anti-Rabies mAb", "phase": "Phase II", "indication": "Rabies"}, {"name": "BTSCAN", "phase": "Phase II", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 1995, "website": "http://www.mtarget.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Molecular%20Targeting%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Molecules for Health Inc.", "city": "Richmond", "state": "VA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Didox", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 1983, "website": "http://www.moleculesforhealth.net", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Molecules%20for%20Health", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Moleculin Biotech Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Annamycin", "phase": "Phase II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "WP1066", "phase": "Phase I", "indication": "Brain cancer"}, {"name": "WP1122", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "WP1220", "phase": "Phase I", "indication": "T cell lymphoma"}, {"name": "WP1096", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "WP1097", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "WP1234", "phase": "Preclinical", "indication": "Pancreatic cancer"}, {"name": "WP1732", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Walter V. Klemp, CPA", "employees": 17, "founded": 2015, "website": "http://www.moleculin.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 2053094.9, "evFmt": "$2M", "ticker": "MBRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Moleculin%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GI Cancers", "Hematologic Cancers", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Moma Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MOMA-989", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://momatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 2066000000.0, "totalDealFmt": "$2.1B", "latestDealDate": "2025-01-08", "recentDeals": [{"headline": "MOMA Therapeutics Announces Exclusive License Agreement for Selective PARP1 Inhibitor", "date": "2025-01-08", "value": ""}, {"headline": "MOMA Therapeutics Announces Five-Year Discovery Collaboration with Roche Focused on Critical Cancer Dependencies", "date": "2024-01-04", "value": "$2.1B"}], "totalRaised": 150000000.0, "totalRaisedFmt": "$150M", "latestFinDate": "2022-05-10", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$150M", "date": "2022-05-10", "investors": "Goldman Sachs Asset Management, Section 32, Pavilion Capital, Invus, Lifesci Venture Partners, Third Rock Ventures, Next..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Moma%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Mongoose Bio Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MGB-001", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.mongoosebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mongoose%20Bio", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Monopar Therapeutics Inc.", "city": "Wilmette", "state": "IL", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Antibody", "Other"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Camsirubicin (MNPR-201", "phase": "Phase II", "indication": "Sarcoma"}, {"name": "MNPR-101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "MNPR-101RIT (HuATN-658)", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "MNPR-202", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Chandler Drew Robinson, MD, MBA", "employees": 16, "founded": 2014, "website": "https://www.monopartx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 23172242.0, "evFmt": "$23M", "ticker": "MNPR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Monopar%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Monopteros Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MPT-0118", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://monopterostx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Monopteros%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Montara Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MT1110", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://montaratx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Montara%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Monte Rosa Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "MRT-2359", "phase": "Phase I/II", "indication": "B cell lymphoma"}, {"name": "MRT-6160", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "MRT-8102", "phase": "Preclinical", "indication": "Inflammatory disease"}], "ceo": "Markus Warmuth, MD", "employees": 134, "founded": 2018, "website": "https://www.monterosatx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 183501580.44, "evFmt": "$184M", "ticker": "GLUE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Monte%20Rosa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers"]}, {"company": "Mopac Biologics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MB1", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mopac%20Biologics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Morphiex Biotherapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MBT-001", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "MBT-002", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://morphiex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Morphiex%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Mount Tam Biotechnologies Inc.", "city": "Novato", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TAM-03", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Richard Marshak, PhD, MBA", "employees": 0, "founded": 2014, "website": "http://www.MountTamBiotech.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "MNTM", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mount%20Tam%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Mozart Therapeutics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MTX-101", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.mozart-tx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mozart%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Mucodel LLC", "city": "Greensboro", "state": "NC", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Exonal (MDL-001)", "phase": "Phase I", "indication": "Substance use disorders"}, {"name": "MDL-003", "phase": "Phase I", "indication": "Seizures"}], "ceo": "", "employees": 0, "founded": 2014, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mucodel", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Psychiatry / Behavioral"]}, {"company": "Mucommune LLC", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MM006", "phase": "Preclinical", "indication": "Contraception"}, {"name": "MM008", "phase": "Preclinical", "indication": "Contraception"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.mucommune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mucommune", "hasDealsFin": false, "diseaseGroups": ["Women's Health"]}, {"company": "Multitude Therapeutics USA LLC", "city": "Redwood", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 9, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ADCE-T02", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "DAY301 (MTX-13)", "phase": "IND", "indication": "Cancer (unspecified)"}, {"name": "AMT-116", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "AMT-151", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "AMT-253", "phase": "Phase I", "indication": "Melanoma"}, {"name": "AMT-707", "phase": "Phase I", "indication": "Biliary cancer"}, {"name": "AMT-562", "phase": "IND", "indication": "Solid tumors"}, {"name": "AMT-676", "phase": "Preclinical", "indication": "Gastrointestinal cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.multitudetherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 1000000000.0, "totalDealFmt": "$1.0B", "latestDealDate": "2024-08-20", "recentDeals": [{"headline": "Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement for ADCE-T02", "date": "2024-08-20", "value": "$1.0B"}, {"headline": "OnCusp Therapeutics and Multitude Therapeutics enter into an Ex-China licensing agreement for a potentially highly differentiated CDH6-targeting antibody drug conjugate", "date": "2022-06-08", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Multitude%20Therapeutics%20USA", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Multivir Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Gene Therapy", "Oncolytic / Microbiome", "Other"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Adenoviral IL24 (Ad-IL24)", "phase": "Phase I", "indication": "Melanoma"}, {"name": "Advexin (Ad-p53", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "Ad-VirRx 007", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "HSV-Rb-p450", "phase": "Phase I", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.multivir.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Multivir", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Mustang Bio Inc.", "city": "Worcester", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Cell Therapy", "Gene Therapy", "Oncolytic / Microbiome"], "nProducts": 10, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "LVXSCID gene therapy", "phase": "Phase I/II", "indication": "Hematology (unspecified)"}, {"name": "MB-102", "phase": "Phase I/II", "indication": "Hematologic malignancies"}, {"name": "MB-106", "phase": "Phase I/II", "indication": "B cell lymphoma"}, {"name": "MB-107", "phase": "Phase I/II", "indication": "Immunodeficiency"}, {"name": "MB-110", "phase": "Phase I/II", "indication": "Immunodeficiency"}, {"name": "MB-207", "phase": "Phase I/II", "indication": "Immunodeficiency"}, {"name": "MB-101", "phase": "Phase I", "indication": "Brain cancer"}, {"name": "MB-103", "phase": "Phase I", "indication": "Brain cancer"}], "ceo": "Manuel Litchman, MD", "employees": 6, "founded": 2015, "website": "http://www.mustangbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -565190.4, "evFmt": "", "ticker": "MBIO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mustang%20Bio", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Hematologic Cancers", "Hematology (non-cancer)", "Other Inflammation"]}, {"company": "Mycovia Pharmaceuticals Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Vivjoa", "phase": "Marketed", "indication": "Candida"}, {"name": "VT-1598", "phase": "Phase I", "indication": "Fungal infection"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.mycovia.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mycovia%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Mycrodose Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Dental", "Other"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MDT-001", "phase": "Preclinical", "indication": "Dental (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://mycrodosethera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mycrodose%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Myelorx LLC", "city": "Vallejo", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MRx102", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "MRx109", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.myelorx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Myelorx", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers"]}, {"company": "Myogene Bio LLC", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MYODYS45-55", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.myogenebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Myogene%20Bio", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Myogenica Inc.", "city": "Saint Paul", "state": "MN", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "MyoPAXon", "phase": "IND", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.myogenica.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-07-17", "recentDeals": [{"headline": "The University of Minnesota grants Myogenica an exclusive license for MyoPAXon", "date": "2024-07-17", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2023-01-01", "latestFinType": "Seed financings", "nRounds": 1, "recentFinancing": [{"type": "Seed financings", "amount": "", "date": "2023-01-01", "investors": "Seedfolio"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Myogenica", "hasDealsFin": true, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Myosin Therapeutics Inc.", "city": "Jupiter", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "MT-125", "phase": "IND", "indication": "Brain cancer"}, {"name": "MT-110", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.myosintherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Myosin%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Psychiatry / Behavioral"]}, {"company": "Myrobalan Therapeutics Inc.", "city": "Medford", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Myro Therapeutics-CSF1R-unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "Myro Therapeutics-GPR17-unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "Myro Therapeutics-TYK2-unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://myrotx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Myrobalan%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Myrtelle Inc.", "city": "Wakefield", "state": "MA", "country": "United States", "diseaseCats": ["Neurology", "Other", "Otologic"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "rAAV-Olig001-ASPA (MYR-101)", "phase": "Phase I/II", "indication": "Genetic disorders"}, {"name": "Myr-103", "phase": "Preclinical", "indication": "Leukodystrophy"}, {"name": "Myr-201", "phase": "Preclinical", "indication": "Hearing loss"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.myrtellegtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Myrtelle", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Other Specialties", "Rare / Genetic"]}, {"company": "Mythic Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MYTX-011", "phase": "Phase I", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://mythictx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Mythic%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "N&n Pharmaceuticals Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "N-MCT (n-methanocarbathymidine)", "phase": "Phase I", "indication": "Varicella zoster virus (VZV)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=N%26n%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "N-gene Research Laboratories Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BGP-15", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.ngene.us", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=N-gene%20Research%20Laboratories", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Nacuity Pharmaceuticals Inc.", "city": "Fort Worth", "state": "TX", "country": "United States", "diseaseCats": ["Neurology", "Ophthalmic", "Other", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "N-acetylcysteine-amide (NPI-001)", "phase": "Phase I/II", "indication": "Usher syndrome"}, {"name": "NPI-002", "phase": "Phase I/II", "indication": "Cataract"}, {"name": "NPI-003", "phase": "Phase I", "indication": "Nephropathy"}, {"name": "NPI-005", "phase": "Phase I", "indication": "Neurology (unspecified)"}, {"name": "NPI-004", "phase": "IND", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.nacuity.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-09-13", "recentDeals": [{"headline": "Nacuity Pharmaceuticals grants Arctic Therapeutics exclusive rights to develop and commercialize NPI-001 to treat hereditary cystatin C amyloid angiopathy in Iceland", "date": "2022-09-13", "value": ""}], "totalRaised": 16500000.0, "totalRaisedFmt": "$16M", "latestFinDate": "2022-06-15", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$16M", "date": "2022-06-15", "investors": "Foundation Fighting Blindness, Retinal Degeneration Fund, Existing Investors, Maxim Group"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nacuity%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Ophthalmology", "Other", "Other Neurology", "Rare / Genetic"]}, {"company": "Nammi Therapeutics Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "NTI-55", "phase": "Preclinical", "indication": "Bladder cancer"}, {"name": "QXL138AM", "phase": "Preclinical", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.nammirx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nammi%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Head & Neck Cancer"]}, {"company": "Nano Cures Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Nano Cures-COVID-19 vaccine-unknown", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.nanocures.com/index.php", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nano%20Cures", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Nanocan Therapeutics Corp.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Nanocan Therapeutics-breast cancer-unknown", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "Nanocan Therapeutics-cervical cancer-unknown", "phase": "Preclinical", "indication": "Cervical cancer"}, {"name": "Nanocan Therapeutics-liver cancer-unknown", "phase": "Preclinical", "indication": "Liver cancer"}, {"name": "Nanocan Therapeutics-lung cancer-unknown", "phase": "Preclinical", "indication": "Lung cancer"}, {"name": "Nanocan Therapeutics-pancreatic cancer-unknown", "phase": "Preclinical", "indication": "Pancreatic cancer"}, {"name": "Nanocan Therapeutics-prostate cancer-unknown", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.nanocan.life/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanocan%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "GU / Gynecologic Cancers", "Lung Cancer"]}, {"company": "Nanocor Therapeutics Inc.", "city": "Chapel Hill", "state": "NC", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Carfostin", "phase": "Preclinical", "indication": "Congestive heart failure (CHF)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.nanocorthx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanocor%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Nanode Therapeutics Inc.", "city": " Barrington", "state": "RI", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Musculoskeletal"], "modalityGroups": ["Other", "RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ND1001", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ND1002", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "ND1003", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://nanodetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanode%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Neurodegeneration / NMD", "Solid Tumors (General)"]}, {"company": "Nanology LLC", "city": "Fort Worth", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery", "Other"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NanoPac", "phase": "Phase II", "indication": "Ovarian cancer"}, {"name": "NanoDoce", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "NanoPac for nebulized inhalation", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://nanology.us", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanology", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Nanoscope Therapeutics Inc.", "city": "Bedford", "state": "TX", "country": "United States", "diseaseCats": ["Ophthalmic", "Other"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "MCO-010", "phase": "Phase II/III", "indication": "Retinitis"}, {"name": "MCO-020", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.nanostherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanoscope%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Nanosmart Pharmaceuticals Inc.", "city": "Laguna Hills", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Conjugated liposomal doxorubicin", "phase": "Preclinical", "indication": "Sarcoma"}, {"name": "Dactinomycin lipid nanoparticle", "phase": "Preclinical", "indication": "Sarcoma"}], "ceo": "", "employees": 0, "founded": 2006, "website": "https://www.nanosmartpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanosmart%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Nanospectra Biosciences Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Pivotal", "hasOrphan": false, "pipeline": [{"name": "Aurolase Therapy", "phase": "Pivotal", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.nanospectra.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanospectra%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Nanotics LLC", "city": "Mill Valley", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NN/sTNF-R1", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "NN/sTNF-R2", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.nanotics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2023-10-30", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2023-10-30", "investors": "Lifespan Vision Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanotics", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Nanotope Inc.", "city": "Skokie", "state": "IL", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Nanofiber gel", "phase": "Preclinical", "indication": "Cartilage repair"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.nanotope.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanotope", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Nanotx Therapeutics Inc.", "city": "San Antonio", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "BMEDA-Chelated Rhenium NanoLiposome", "phase": "Phase I/II", "indication": "Brain cancer"}, {"name": "Co-Encapsulated Doxorubicin & BMEDA-Chelated Rhenium NanoLiposome", "phase": "Preclinical", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.nano-tx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanotx%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Head & Neck Cancer"]}, {"company": "Nanoviricides Inc.", "city": "West Haven", "state": "CT", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 8, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Anti-Ebola virus nanoviricides", "phase": "Preclinical", "indication": "Ebola"}, {"name": "DengueCide (anti-dengue nanoviricides", "phase": "Preclinical", "indication": "Dengue fever"}, {"name": "HerpeCide Eye drops", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}, {"name": "HIVCide (hivcide-i)", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "Injectable FluCide (iv flucide", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "NV-HHV-101", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}, {"name": "Oral FluCide", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "RabiCide 1", "phase": "Preclinical", "indication": "Rabies"}], "ceo": "Anil R. Diwan, PhD", "employees": 7, "founded": 2005, "website": "http://www.nanoviricides.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 19604612.2, "evFmt": "$20M", "ticker": "NNVC", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nanoviricides", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Napajen Pharma Inc.", "city": "Burlingame", "state": "CA", "country": "United States", "diseaseCats": ["Transplant"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NJA-730", "phase": "Phase I", "indication": "Graft-versus-host disease (GvHD)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.napajen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Napajen%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Nascent Biotech Inc.", "city": "Vero Beach", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Antibody", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "pritumumab", "phase": "Phase I", "indication": "Brain cancer"}, {"name": "Nascent Biotech-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Sean Carrick", "employees": 0, "founded": 2008, "website": "http://www.nascentbiotech.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "NBIO", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nascent%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Infectious Disease"]}, {"company": "National Institute on Aging", "city": "Bethesda, MD", "state": "", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AEV103 (3", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=National%20Institute%20on%20Aging", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "National Resilience Inc.", "city": "San Diego", "state": "", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Infectious", "Neurology"], "modalityGroups": ["Antibody", "Combination", "Nanoparticle / Delivery", "Other", "Small Molecule", "Vaccine"], "nProducts": 9, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Celvapan (H1N1 pandemic influenza vaccine)", "phase": "Marketed", "indication": "Influenza virus"}, {"name": "Preflucel (influenza vaccine)", "phase": "Marketed", "indication": "Influenza virus"}, {"name": "Vepacel (pandemic influenza vaccine", "phase": "Marketed", "indication": "Influenza virus"}, {"name": "NanoDOX (1% doxycycline monohydrate hydrogel)", "phase": "Phase II", "indication": "Wounds"}, {"name": "Triapine (NTO-1151)", "phase": "Phase II", "indication": "Cervical cancer"}, {"name": "H9N2 influenza A vaccine", "phase": "Phase I/II", "indication": "Influenza virus"}, {"name": "NanoBUP (buprenorphine/naloxone)", "phase": "Phase I", "indication": "Substance use disorders"}, {"name": "XOMA 3AB", "phase": "Phase I", "indication": "Infectious (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-02-05", "recentDeals": [{"headline": "National Resilience and Taiwan Bio-Manufacturing Corporation Announce Groundbreaking Partnership in Biomanufacturing Innovation", "date": "2024-02-05", "value": ""}], "totalRaised": 660000000.0, "totalRaisedFmt": "$660M", "latestFinDate": "2025-06-09", "latestFinType": "Venture (Debt)", "nRounds": 3, "recentFinancing": [{"type": "Venture (Debt)", "amount": "$250M", "date": "2025-06-09", "investors": "Existing Investors"}, {"type": "Venture (Debt)", "amount": "$410M", "date": "2023-03-24", "investors": "U.S. Department of Defense, U.S. International Development Finance Corp"}, {"type": "Series D rounds", "amount": "", "date": "2022-06-06", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=National%20Resilience", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "GU / Gynecologic Cancers", "Infectious Disease", "Psychiatry / Behavioral"]}, {"company": "Nautilus Neurosciences Inc.", "city": "Bedminster", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Cambia", "phase": "Marketed", "indication": "Migraine"}, {"name": "PRO-571", "phase": "Phase I", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.nautilusneurosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nautilus%20Neurosciences", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Navega Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NT-Z001", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.navegatx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Navega%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Navidea Biopharmaceuticals Inc.", "city": "Dublin", "state": "OH", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic", "Infectious", "Inflammation"], "modalityGroups": ["Diagnostics", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Lymphoaim", "phase": "Marketed", "indication": "Cancer, Diagnostic"}, {"name": "Navidea Biopharmaceuticals-Anti-inflammatory Therapeutic-unknown", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}, {"name": "Navidea Biopharmaceuticals-Kaposi's Sarcoma-unknown", "phase": "Preclinical", "indication": "Kaposi sarcoma"}, {"name": "Navidea Biopharmaceuticals-Leishmaniasis Therapeutic-unknown", "phase": "Preclinical", "indication": "Leishmaniasis"}, {"name": "Navidea Biopharmaceuticals-Oncology Therapeutic-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 1983, "website": "http://www.navidea.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Navidea%20Biopharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Other", "Other Inflammation", "Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Navire Pharma Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "BBP-398", "phase": "Phase I/II", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://navirepharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Navire%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Navitor Pharmaceuticals Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SPN-820 (NV-5138)", "phase": "Phase I", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.navitorpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Navitor%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Navrogen Inc.", "city": "Cheyney", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NAV-001", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "NAV-003", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "NAV-004", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "NAV-005", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "NAV-006", "phase": "Preclinical", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "NAV-201", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://navrogen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Navrogen", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Naya Therapeutics Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NY-500", "phase": "Preclinical", "indication": "Liver cancer"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.nayatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Naya%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Nayaderm LLC", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ND-101", "phase": "Preclinical", "indication": "Scars/wrinkles"}], "ceo": "", "employees": 0, "founded": 2012, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nayaderm", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Nb Therapeutics Inc.", "city": "Bristol", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "GNO (nitric oxide)", "phase": "Phase II", "indication": "Tinea pedis"}, {"name": "NBT-320", "phase": "Phase II", "indication": "Onychomycosis"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.nitricbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nb%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Other"]}, {"company": "Nchroma Bio Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CRMA-1001", "phase": "Preclinical", "indication": "Hepatitis"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.nchromabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nchroma%20Bio", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Ncontrol Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Neurology", "Pulmonary"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NCTX-01", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "NCTX-02", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.ncontroltx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ncontrol%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Other Neurology"]}, {"company": "Neela Therapeutics Inc.", "city": "Lowell", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CLN-301", "phase": "Phase I/II", "indication": "Neuronal ceroid lipofuscinosis"}, {"name": "EPH-101", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "XGR-101", "phase": "Preclinical", "indication": "Rett syndrome"}], "ceo": "", "employees": 0, "founded": 2025, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neela%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Nektar Therapeutics", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Gastrointestinal", "Neurology"], "modalityGroups": ["Antibody", "Other", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Movantik", "phase": "Marketed", "indication": "Constipation"}, {"name": "Onzeald", "phase": "Registration", "indication": "Breast cancer"}, {"name": "NKTR-255", "phase": "Phase II/III", "indication": "B cell lymphoma"}, {"name": "NKTR-262", "phase": "Phase I/II", "indication": "Bladder cancer"}, {"name": "Rezpeg", "phase": "Phase I", "indication": "Psoriasis"}, {"name": "NKTR-119", "phase": "Preclinical", "indication": "Pain"}, {"name": "NKTR-288", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Howard W. Robin", "employees": 61, "founded": 1990, "website": "http://www.nektar.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 130378730.0, "evFmt": "$130M", "ticker": "NKTR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nektar%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Dermatology", "GU / Gynecologic Cancers", "Hematologic Cancers", "Pain / Migraine", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Nellone Therapeutics Inc.", "city": "Knoxville", "state": "TN", "country": "United States", "diseaseCats": ["Cardiovascular", "Musculoskeletal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Nell1 protein", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.nell-one.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nellone%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Nemucore Medical Innovations Inc.", "city": "Worcester", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NMI-500", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "NMI-300", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "NMI-8000", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.nemucore.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nemucore%20Medical%20Innovations", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers"]}, {"company": "Neoimmunetech Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Infectious"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "efineptakin alfa", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "NIT-02", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Luke Oh, PhD", "employees": 52, "founded": 2014, "website": "http://www.neoimmunetech.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 48962273.28247, "evFmt": "$49M", "ticker": "950220", "exchange": "KOSDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neoimmunetech", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Solid Tumors (General)"]}, {"company": "Neok Bio Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NEOK001 (ABL206)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "NEOK002 (ABL209)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2025, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neok%20Bio", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Neonc Technologies Holdings Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "NEO100", "phase": "Phase I/II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2008, "website": "https://neonc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neonc%20Technologies%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Nephraegis Therapeutics Inc.", "city": "Lake Forest", "state": "IL", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NPH-022", "phase": "Preclinical", "indication": "Renal (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.nephraegis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nephraegis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Nephrodi Therapeutics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NDI-5001", "phase": "Preclinical", "indication": "Renal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://nephrodi.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 2000000.0, "totalRaisedFmt": "$2M", "latestFinDate": "2024-06-11", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$2M", "date": "2024-06-11", "investors": "Sound Bioventures Management AB"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nephrodi%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Kidney Disease"]}, {"company": "Nephrogenex Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Pyridorin", "phase": "Phase III", "indication": "Diabetic nephropathy"}, {"name": "Pyridorin Intravenous", "phase": "Preclinical", "indication": "Renal damage"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.nephrogenex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nephrogenex", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Kidney Disease"]}, {"company": "Nephrx Corp.", "city": "Kalamazoo", "state": "MI", "country": "United States", "diseaseCats": ["Other", "Transplant"], "modalityGroups": ["Peptide"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "NX001", "phase": "Phase I", "indication": "Renal transplant rejection"}, {"name": "NX002", "phase": "Preclinical", "indication": "Mucositis"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.nephrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nephrx", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease", "Supportive / Other"]}, {"company": "Nerx Biosciences Inc.", "city": "Indianapolis", "state": "IN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NERx-505", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "NERx329", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.nerxbiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nerx%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer", "Solid Tumors (General)"]}, {"company": "Nested Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Nest-1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Nest-2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Nest-3", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Nest-4", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.nestedtx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 125000000.0, "totalRaisedFmt": "$125M", "latestFinDate": "2022-10-06", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$90M", "date": "2022-10-06", "investors": "Goldman Sachs Asset Management, Foresite Capital Management LLC, Avidity Partners, Cowen Healthcare Investments, Section..."}, {"type": "Seed financings", "amount": "$35M", "date": "2022-01-01", "investors": "Versant Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nested%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Neumedicines Inc.", "city": "Pasadena", "state": "CA", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NMIL 12-1", "phase": "Phase I", "indication": "Poisoning"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.neumedicines.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neumedicines", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Neumentum Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Ketorolac PMB (NTM-001)", "phase": "Phase III", "indication": "Pain"}, {"name": "Ketorolac PCA (NTM-002)", "phase": "Phase III", "indication": "Pain"}, {"name": "APAP Analogue (NTM-004)", "phase": "Preclinical", "indication": "Pain"}, {"name": "APAP Analogue (NTM-005)", "phase": "Preclinical", "indication": "Pain"}, {"name": "Ketorolac Intrathecal (NTM-003)", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.neumentum.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neumentum", "hasDealsFin": true, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Neumora Therapeutics Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Navacaprant (NMRA-140", "phase": "Phase III", "indication": "Depression"}, {"name": "NMRA-266", "phase": "Phase I", "indication": "Schizophrenia"}, {"name": "NMRA-511 (BTRX-323511)", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "NMRA-M4R", "phase": "Preclinical", "indication": "Schizophrenia"}, {"name": "NMRA-NMDA", "phase": "Preclinical", "indication": "Schizophrenia"}, {"name": "NMRA-GRIN2A", "phase": "Research", "indication": "Neurology (unspecified)"}, {"name": "NMRA-GRIN2B", "phase": "Research", "indication": "Neurology (unspecified)"}, {"name": "NMRA-NLRP3", "phase": "Research", "indication": "Parkinson's disease"}], "ceo": "Paul L. Berns", "employees": 110, "founded": 2019, "website": "http://www.neumoratx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1382458200.0, "evFmt": "$1.4B", "ticker": "NMRA", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 435400000.0, "totalDealFmt": "$435M", "latestDealDate": "2022-02-17", "recentDeals": [{"headline": "Neumora expands precision neuroscience pipeline with novel M4 receptor modulator program through exclusive license agreement with Vanderbilt University", "date": "2022-02-17", "value": "$435M"}], "totalRaised": 112000000.0, "totalRaisedFmt": "$112M", "latestFinDate": "2022-10-11", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$112M", "date": "2022-10-11", "investors": "Abu Dhabi Growth Fund, Altitude Life Science Ventures, Amgen Inc., Arch Venture Partners, Exor N.V., F-prime Inc. (F-pri..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neumora%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Other Neurology", "Parkinson's", "Psychiatry / Behavioral"]}, {"company": "Neuphoria Therapeutics Inc.", "city": "Burlington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "BNC210", "phase": "Phase III", "indication": "Anxiety"}, {"name": "MK-1167", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "MK-4334", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "BNC101", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Spyridon Papapetropoulos, MD, PhD", "employees": 8, "founded": 1999, "website": "https://www.neuphoriatx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -2616865.117919, "evFmt": "", "ticker": "NEUP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuphoria%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Breast Cancer", "Psychiatry / Behavioral"]}, {"company": "Neuraegis Inc.", "city": "Southborough", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NeurAegis-traumatic brain injury-unknown", "phase": "Preclinical", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.neuraegis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuraegis", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Neuraltus Pharmaceuticals Inc.", "city": "San Bruno", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NP001", "phase": "Phase I", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.neuraltus.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuraltus%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Neuraly Inc.", "city": "Germantown", "state": "MD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Peptide", "Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NLY01", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "NLY02", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "NLY12", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.neuralymed.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuraly", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Diabetes"]}, {"company": "Neurelis Inc.", "city": "Encinitas", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Spydia", "phase": "Marketed", "indication": "Seizures"}, {"name": "NRL-2017", "phase": "Preclinical", "indication": "Stroke"}, {"name": "NRL-4", "phase": "Preclinical", "indication": "Bipolar disorder"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.neurelis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-01-26", "recentDeals": [{"headline": "Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of Valtoco", "date": "2022-01-26", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurelis", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other Neurology", "Psychiatry / Behavioral"]}, {"company": "Neurmedix Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "NE3107 (HE3286)", "phase": "Phase III", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.neurmedixinc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurmedix", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Neuro Pharmalogics Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NP-101", "phase": "Preclinical", "indication": "Migraine"}], "ceo": "", "employees": 0, "founded": 2012, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuro%20Pharmalogics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Neurocrine Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Genitourinary", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Alkindi", "phase": "Marketed", "indication": "Adrenal insufficiency"}, {"name": "Dysval", "phase": "Marketed", "indication": "Hyperkinetic movement disorder"}, {"name": "Oriahnn", "phase": "Marketed", "indication": "Endometriosis"}, {"name": "crinecerfont capsule (NBI-74788)", "phase": "Registration", "indication": "Adrenal insufficiency"}, {"name": "crinecerfont oral solution (NBI-74788)", "phase": "Registration", "indication": "Adrenal insufficiency"}, {"name": "Efmody", "phase": "Registration", "indication": "Adrenal insufficiency"}, {"name": "DITEST (Native oral testosterone)", "phase": "Phase I/II", "indication": "Hypogonadism"}, {"name": "NBI-1065890", "phase": "Phase I", "indication": "Neurology (unspecified)"}], "ceo": "Kyle W. Gano, PhD, MBA", "employees": 1800, "founded": 1992, "website": "http://www.neurocrine.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 13574650000.0, "evFmt": "$13.6B", "ticker": "NBIX", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 881500000.0, "totalDealFmt": "$882M", "latestDealDate": "2025-11-03", "recentDeals": [{"headline": "Transthera Grants Neurocrine Exclusive Rights in Ex-Greater China Region to Develop, Manufacture, and Commercialize NLRP3 Inhibitors from Transthera\u2019s NLRP3 Portfolio", "date": "2025-11-03", "value": "$882M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurocrine%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Other", "Other Neurology", "Other Specialties", "Women's Health"]}, {"company": "Neurofx Inc.", "city": "Fishers", "state": "IN", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NFx-101", "phase": "Preclinical", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://neurofx.co", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurofx", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Neurogastrx Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NG101", "phase": "Preclinical", "indication": "Gastroparesis"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.neurogastrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurogastrx", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Neurogene Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Neurology"], "modalityGroups": ["Cell Therapy", "Gene Therapy", "Protein / Biologic"], "nProducts": 8, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "NGN-401", "phase": "Phase I/II", "indication": "Rett syndrome"}, {"name": "NL-201", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "NGN-101", "phase": "IND", "indication": "Neuronal ceroid lipofuscinosis"}, {"name": "NEO-TRA1", "phase": "Preclinical", "indication": "Lupus"}, {"name": "Neurogene-AGA-unknown", "phase": "Preclinical", "indication": "Neuropathy"}, {"name": "Neurogene-CLN7-unknown", "phase": "Preclinical", "indication": "Neuronal ceroid lipofuscinosis"}, {"name": "Neurogene-FIG4-unknown", "phase": "Preclinical", "indication": "Charcot-Marie-Tooth disease"}, {"name": "Neurogene-Krabbe-unknown", "phase": "Preclinical", "indication": "Leukodystrophy"}], "ceo": "Rachel L. McMinn, PhD", "employees": 107, "founded": 2018, "website": "https://www.neurogene.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 101606494.52, "evFmt": "$102M", "ticker": "NGNE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurogene", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Neurodegeneration / NMD", "Other", "Pain / Migraine", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Neurogenetic Pharmaceuticals Inc.", "city": "Del Mar", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NGP 555", "phase": "Phase I", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.neurogeneticpharmaceuticals.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurogenetic%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Neurohealing Pharmaceuticals Inc.", "city": "Newton", "state": "MA", "country": "United States", "diseaseCats": ["Genitourinary", "Inflammation", "Other"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NH001", "phase": "Phase II", "indication": "Shock/trauma"}, {"name": "tropicamide (NH004)", "phase": "Phase II", "indication": "Drooling"}, {"name": "NH02D", "phase": "Preclinical", "indication": "Premature ejaculation"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.neurohealing.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurohealing%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other", "Supportive / Other"]}, {"company": "Neurolixis Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NLX-204", "phase": "Preclinical", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.neurolixis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurolixis", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Neurolucent Inc.", "city": "North Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NeuroLucent-Alzheimer\u2019s disease-unknown", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.neurolucent.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurolucent", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Neuron23 Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NEU-411", "phase": "Phase II", "indication": "Parkinson's disease"}, {"name": "NEU-723", "phase": "Phase I", "indication": "Parkinson's disease"}, {"name": "Neuron23-TYK2-unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "Neuron23-amyotrophic lateral sclerosis-unknown", "phase": "Research", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://neuron23.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 196500000.0, "totalRaisedFmt": "$196M", "latestFinDate": "2025-06-24", "latestFinType": "Series D rounds", "nRounds": 2, "recentFinancing": [{"type": "Series D rounds", "amount": "$96M", "date": "2025-06-24", "investors": "Undisclosed Investor, Westlake Biopartners, Softbank Vision Fund 2, Redmile Group, Blue Owl Capital Inc., Kleiner Perkin..."}, {"type": "Series C rounds", "amount": "$100M", "date": "2022-03-30", "investors": "Softbank Vision Fund, Westlake Biopartners, Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventu..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuron23", "hasDealsFin": true, "diseaseGroups": ["MS / Neuroimmune", "Neurodegeneration / NMD", "Parkinson's"]}, {"company": "Neurona Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "NRTX-1001", "phase": "Phase I/II", "indication": "Epilepsy"}, {"name": "Neurona Therapeutics-myelinating glial cells-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Neurona Therapeutics-myelinating glial cells-unknown2", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.neuronatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurona%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other Neurology"]}, {"company": "Neuronasal Inc.", "city": "Wexford", "state": "PA", "country": "United States", "diseaseCats": ["Infectious", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Intranasal NAC (NN-101; N-acetylcysteine)", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://neuronasal.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuronasal", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Neuronascent Inc.", "city": "Clarksville", "state": "MD", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NNI-362", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "NNI-351", "phase": "Preclinical", "indication": "Cognitive dysfunction"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.neuronascent.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuronascent", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Neuronos Ltd.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BA102", "phase": "Preclinical", "indication": "Autism"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.neuro-nos.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuronos", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Neurop Inc.", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Neurology", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "NP10679", "phase": "Phase I", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.neuropinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurop", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Neuropathix Inc.", "city": "Bayville", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KLS-13019", "phase": "Preclinical", "indication": "Nerve damage"}], "ceo": "Dean Petkanas", "employees": 0, "founded": 2010, "website": "http://www.kannalife.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "NPTX", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neuropathix", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Neurosigma Inc.", "city": "Los Angeles", "state": "", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Digital / Device"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "External Trigeminal Nerve Stimulation (eTNS) (monarch", "phase": "Marketed", "indication": "Depression"}, {"name": "STNS", "phase": "Phase II", "indication": "Epilepsy"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-01-26", "recentDeals": [{"headline": "Ignis Therapeutics Licenses NeuroSigma eTNS Technology\u00a0for ADHD in a Significant China Licensing Transaction", "date": "2022-01-26", "value": ""}], "totalRaised": 1000000.0, "totalRaisedFmt": "$1M", "latestFinDate": "2025-12-15", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$1M", "date": "2025-12-15", "investors": "Checkmate Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurosigma", "hasDealsFin": true, "diseaseGroups": ["Epilepsy / Seizures", "Psychiatry / Behavioral"]}, {"company": "Neurotech Pharmaceuticals Inc.", "city": "Cumberland", "state": "RI", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Encelto", "phase": "Approved", "indication": "Ophthalmic (unspecified)"}, {"name": "NT-503 ECT", "phase": "Phase II", "indication": "Choroidal neovascularization (CNV)"}], "ceo": "", "employees": 0, "founded": 1995, "website": "http://www.neurotechusa.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurotech%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Neurotez Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other", "Peptide"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Memtin", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "NT1", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "NT2", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.neurotez.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurotez", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Neurotherapia Inc.", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NTRX-07", "phase": "Phase I", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.neurotherapia.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neurotherapia", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Neutrolis Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Inflammation", "Ophthalmic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "L301", "phase": "Phase I", "indication": "Inflammation (unspecified)"}, {"name": "L304", "phase": "Preclinical", "indication": "Dry eye"}, {"name": "L305", "phase": "Preclinical", "indication": "Thrombosis"}, {"name": "Neutrolis (L302)", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "Neutrolis (L303)", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "Neutrolis-L200 Series-unknown", "phase": "Research", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.neutrolis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 964955.0, "totalRaisedFmt": "$965K", "latestFinDate": "2025-02-28", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$965K", "date": "2025-02-28", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Neutrolis", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Cardiovascular", "Ophthalmology", "Other Inflammation"]}, {"company": "Nevakar Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "atropine (NVK-002", "phase": "Registration", "indication": "Myopia"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.nevakar.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nevakar", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "New Alliance Biosciences", "city": "Roswell", "state": "GA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Fluosol", "phase": "Marketed", "indication": "Blood substitute"}, {"name": "PHER-02", "phase": "Pivotal", "indication": "Blood substitute"}], "ceo": "", "employees": 0, "founded": 1990, "website": "", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "SGUI", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=New%20Alliance%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "New Amsterdam Sciences", "city": "Scottsdale", "state": "AZ", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NAS911B", "phase": "Preclinical", "indication": "Influenza virus"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.newamsterdamsciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=New%20Amsterdam%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Newg Lab Pharma Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 11, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "KAT-001", "phase": "Preclinical", "indication": "Liver cancer"}, {"name": "KAT-002", "phase": "Preclinical", "indication": "Bladder cancer"}, {"name": "KAT-003", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "KAT-004", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "KAT-005", "phase": "Preclinical", "indication": "Pancreatic cancer"}, {"name": "KAT-006", "phase": "Preclinical", "indication": "Leukemia"}, {"name": "KAT-007", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "KAT-008", "phase": "Preclinical", "indication": "Lung cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://newglabpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Newg%20Lab%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "GU / Gynecologic Cancers", "Hematologic Cancers", "Lung Cancer", "Skin Cancer / Melanoma"]}, {"company": "Nexien Biopharma Inc.", "city": "Denver", "state": "CO", "country": "United States", "diseaseCats": ["Musculoskeletal", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Nexien BioPharma-DM1/2-unknown", "phase": "Preclinical", "indication": "Myotonic dystrophy type 1 (DM1)"}, {"name": "NX01R1", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "NX01R2", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "NX01R3", "phase": "Preclinical", "indication": "Epilepsy"}], "ceo": "Richard Greenberg", "employees": 0, "founded": 2017, "website": "http://www.nexienbiopharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "NXEN", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nexien%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Neurodegeneration / NMD"]}, {"company": "Nextcure Inc.", "city": "Beltsville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal", "Neurology", "Pulmonary"], "modalityGroups": ["ADC", "Antibody", "Protein / Biologic"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NC410", "phase": "Phase II", "indication": "Pancreatic cancer"}, {"name": "NC762", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "NC525", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "LNCB74", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "NC181", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "NC605", "phase": "Preclinical", "indication": "Osteogenesis imperfecta"}, {"name": "NextCure-VSTM-1-unknown", "phase": "Preclinical", "indication": "Chronic obstructive pulmonary disease (COPD)"}], "ceo": "Michael S. Richman", "employees": 43, "founded": 2015, "website": "http://nextcure.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -41111263.331, "evFmt": "", "ticker": "NXTC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nextcure", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Breast Cancer", "GI Cancers", "Hematologic Cancers", "Other", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Nextphase Therapeutics", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NP-015", "phase": "Preclinical", "indication": "Psoriasis"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.nextphasetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nextphase%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Nextpoint Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NPX267", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "NPX887", "phase": "IND", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://nextpointtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nextpoint%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Nflection Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NFX-179 Gel", "phase": "Phase I", "indication": "Neurofibromatosis"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.nflectionrx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nflection%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Nggt Inc. (Next Generation Gene Therapeutics)", "city": "Walnut Creek", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "NGGT-001", "phase": "Phase I/II", "indication": "Ophthalmic (unspecified)"}, {"name": "NGGT-002", "phase": "Phase I/II", "indication": "Phenylketonuria"}, {"name": "NGGT-006", "phase": "Phase I", "indication": "Hypercholesterolemia"}, {"name": "NGGT-007", "phase": "Preclinical", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://nggtbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nggt%20Inc.%20(Next%20Generation%20Gene%20Therapeutics)", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Ophthalmology", "Rare / Genetic"]}, {"company": "Ngm Biopharmaceuticals Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Gastrointestinal", "Hepatic", "Ophthalmic"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Protein / Biologic"], "nProducts": 8, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "MK-3655 (NGM313)", "phase": "Phase II", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "Aldafermin (NGM282)", "phase": "Phase II", "indication": "Primary biliary cholangitis"}, {"name": "CATALINA (NGM621)", "phase": "Phase II", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "NGM120", "phase": "Phase II", "indication": "Pancreatic cancer"}, {"name": "NGM707", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "NGM831", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "NGM438", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "NGM936", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "https://www.ngmbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ngm%20Biopharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Obesity / Metabolic", "Ophthalmology", "Solid Tumors (General)"]}, {"company": "Nido Biosciences Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NIDO-361", "phase": "Phase I", "indication": "Spinal muscular atrophy (SMA)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.nidobio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nido%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Nielsen Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Candin (Candida albicans Skin Test Antigen for Cellular Immunity)", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://nielsenbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nielsen%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Nika Pharmaceuticals Inc.", "city": "Henderson", "state": "NV", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Thymus Nuclear Glycoprotein (TNG)", "phase": "Phase III", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 1999, "website": "https://www.nikapharmaceuticals.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "NIKA", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nika%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Nikang Therapeutics Inc.", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NKT2152", "phase": "Phase II", "indication": "Renal cancer"}, {"name": "NKT3447", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "NKT3964", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.nikangtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nikang%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Nimbus Therapeutics LLC", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "NDI-101150", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "NTX-801", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Nimbus Therapeutics-metabolic-unknown", "phase": "Research", "indication": "Obesity"}, {"name": "Nimbus-AMPK-unknown", "phase": "Research", "indication": "Metabolic (unspecified)"}, {"name": "Nimbus-CTPS1-unknown", "phase": "Research", "indication": "Autoimmune (unspecified)"}, {"name": "Nimbus-WRN-unknown", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://nimbustx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 1796000000.0, "totalDealFmt": "$1.8B", "latestDealDate": "2026-01-06", "recentDeals": [{"headline": "Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment", "date": "2026-01-06", "value": "$1.3B"}, {"headline": "Nimbus Therapeutics announces research collaboration and license agreement with Lilly for small molecule activators of AMPK", "date": "2022-10-11", "value": "$496M"}], "totalRaised": 335000000.0, "totalRaisedFmt": "$335M", "latestFinDate": "2023-09-06", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$210M", "date": "2023-09-06", "investors": "Google Ventures, Sr One, Atlas Venture, Undisclosed Investor, Bain Capital Life Sciences, Bvf Partners L.P., Gates Front..."}, {"type": "Uncategorized venture rounds", "amount": "$125M", "date": "2022-09-12", "investors": "Bain Capital Life Sciences, Sv Health Investors, Access Biotechnology, Atlas Venture, Bvf Partners L.P., Bill Gates, Lig..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nimbus%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Obesity / Metabolic", "Solid Tumors (General)"]}, {"company": "Nimmune Biopharma Inc.", "city": "Blacksburg", "state": "VA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NIM-1324", "phase": "Phase I", "indication": "Lupus"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://nimmunebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nimmune%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Nirogy Therapeutics Inc.", "city": "Framingham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NGY-B", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://nirogytx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nirogy%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Nitrase Therapeutics Inc.", "city": "Brisbane", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NDC-0524", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://nitrasetx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nitrase%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "Nkarta Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "NKX019", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "NKX101", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Nkarta-CD70-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Paul J. Hastings", "employees": 157, "founded": 2015, "website": "http://www.nkartatx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -18096345.73, "evFmt": "", "ticker": "NKTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nkarta", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Nkgen Biotech Inc.", "city": "Santa Ana", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "troculeucel (SNK01)", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "SNK02", "phase": "IND", "indication": "Solid tumors"}], "ceo": "Paul Y. Song, MD, PhD", "employees": 26, "founded": 2017, "website": "https://nkgenbiotech.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 71806649.2512, "evFmt": "$72M", "ticker": "NKGN", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nkgen%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer", "Solid Tumors (General)"]}, {"company": "Nkt Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "NKTT120", "phase": "Phase I", "indication": "Sickle cell disease"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.nktrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nkt%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Nobias Therapeutics Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "fasoracetam", "phase": "Phase II", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.nobiastx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nobias%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Nocion Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "taplucainium (NTX-1175)", "phase": "Phase II", "indication": "Cough"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.nociontx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nocion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Nod Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "nodlin", "phase": "Phase I", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.nodpharm.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nod%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Nodthera Ltd.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NT-0796", "phase": "Phase II", "indication": "Obesity"}, {"name": "NT-0249", "phase": "Phase I", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://nodthera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nodthera", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Other Inflammation"]}, {"company": "Nora Therapeutics Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NT100", "phase": "Phase II", "indication": "Infertility"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.noratherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nora%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Women's Health"]}, {"company": "Normoxys Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "OXY111A", "phase": "Phase I/II", "indication": "Biliary cancer"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.normoxys.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Normoxys", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Normunity Inc.", "city": "West Haven", "state": "CT", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NRM-823", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://normunity.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 140000000.0, "totalRaisedFmt": "$140M", "latestFinDate": "2025-01-13", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$75M", "date": "2025-01-13", "investors": "Samsara Biocapital L.P., Enavate Sciences, Regeneron Ventures, Pfizer Venture Investments, Yk Bioventures, Canaan Partne..."}, {"type": "Series A rounds", "amount": "$65M", "date": "2022-10-25", "investors": "Canaan, Sanofi Ventures, Taiho Ventures, Oup (Osage University Partners)"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Normunity", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Northwest Biotherapeutics Inc.", "city": "Bethesda", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 3, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "DCVax-Brain (DCVax-L)", "phase": "Registration", "indication": "Brain cancer"}, {"name": "DCVax-Prostate", "phase": "Phase III", "indication": "Prostate cancer"}, {"name": "DCVax-Direct", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "Linda F. Powers", "employees": 25, "founded": 1996, "website": "http://www.nwbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 422076615.75, "evFmt": "$422M", "ticker": "NWBO", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Northwest%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Nostrum Pharmaceuticals LLC", "city": "New Brunswick", "state": "NJ", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SMRX11", "phase": "Preclinical", "indication": "Thrombosis"}], "ceo": "", "employees": 0, "founded": 1995, "website": "http://www.nostrumpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nostrum%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Nour Heart Inc.", "city": "Hartford", "state": "CT", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Nourexal", "phase": "Preclinical", "indication": "Ischemia/reperfusion injury"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.nourheart.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nour%20Heart", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Nova Anchora LLC", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "NvA-011", "phase": "Preclinical", "indication": "Epidermolysis bullosa"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://vikingglobal.com/portfolio/nova-anchora/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nova%20Anchora", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Novabay Pharmaceuticals Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious", "Ophthalmic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Avenova (i-lid cleanser)", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}, {"name": "CelleRx", "phase": "Marketed", "indication": "Dermatology (unspecified)"}, {"name": "NeutroPhase (NVC-101)", "phase": "Marketed", "indication": "Wounds"}, {"name": "auriclosene (CD07223", "phase": "Phase II", "indication": "Infectious (unspecified)"}], "ceo": "Michael Kazley", "employees": 14, "founded": 2000, "website": "http://www.novabaypharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 3288996.0, "evFmt": "$3M", "ticker": "NBY", "exchange": "NYSE-A", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-09-11", "recentDeals": [{"headline": "NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allograft", "date": "2023-09-11", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Novabay%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease", "Ophthalmology"]}, {"company": "Novabridge Biosciences", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Inflammation", "Neurology"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Protein / Biologic"], "nProducts": 11, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "ragistomig (TJ-L14B", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "plonmarlimab (TJM2", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "lemzoparlimab (TJC4", "phase": "Phase II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "uliledlimab (TJD5", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "givastomig (ABL111", "phase": "Phase I", "indication": "Esophageal cancer"}, {"name": "Protollin", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "TJ-C4GM (Fortified BsAbs)", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "TJ-L1C4", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Xi-Yong Fu, PhD, MBA", "employees": 32, "founded": 2015, "website": "https://www.novabridge.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -100507222.439696, "evFmt": "", "ticker": "NBP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Novabridge%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "GI Cancers", "Hematologic Cancers", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Novaccess Global Inc.", "city": "Washington", "state": "OH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "StemVax Glioblast", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "Dwain Morris-Irvin, PhD", "employees": 0, "founded": 2020, "website": "https://novaccessglobal.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "XSNX", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Novaccess%20Global", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Novadigm Therapeutics Inc.", "city": "Grand Forks", "state": "ND", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "NDV-3A", "phase": "Phase II", "indication": "Candida"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.novadigmtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Novadigm%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Novarock Biotherapeutics Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Inflammation"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Undisclosed"], "nProducts": 9, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "NBL-015", "phase": "Phase I", "indication": "Gastric cancer"}, {"name": "NBL-012", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "NBL-020", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "NovaRock Biotherapeutics-cancer-unknown2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "NovaRock Biotherapeutics-CLDN18.2/CD137-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "NovaRock Biotherapeutics-CLDN6/CD137-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "NovaRock Biotherapeutics-PD-L1/CD137-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "NovaRock-IL-8-unknown", "phase": "Preclinical", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.novarockbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Novarock%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "GI Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Novavax Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Infectious", "Other"], "modalityGroups": ["Other", "Small Molecule", "Vaccine"], "nProducts": 14, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Covovax", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Estrasorb", "phase": "Marketed", "indication": "Menopause"}, {"name": "Matrix M adjuvant (matrix-m)", "phase": "Marketed", "indication": "Adjuvant"}, {"name": "Novavax COVID-19 vaccine (NVX-CoV2705)", "phase": "Approved", "indication": "Coronavirus disease (COVID-19)"}, {"name": "NanoFlu", "phase": "Phase III", "indication": "Influenza virus"}, {"name": "ResVax", "phase": "Phase III", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "Quadrivalent seasonal influenza VLP vaccine", "phase": "Phase II", "indication": "Influenza virus"}, {"name": "Trivalent seasonal influenza vaccine", "phase": "Phase II", "indication": "Influenza virus"}], "ceo": "John C.s Jacobs, MBA", "employees": 952, "founded": 1987, "website": "http://www.novavax.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 553334600.0, "evFmt": "$553M", "ticker": "NVAX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Novavax", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy", "Supportive / Other", "Women's Health"]}, {"company": "Noveome Biotherapeutics Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Dental", "Inflammation"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ST266", "phase": "Phase II", "indication": "Periodontitis"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://noveome.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Noveome%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Novoteris LLC", "city": "Garden Grove", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Thiolanox (inhaled nitric oxide)", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.novoteris.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Novoteris", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Npharmakon LLC", "city": "Piscataway", "state": "NJ", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NPH29", "phase": "Phase I", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.npharmakon.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Npharmakon", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Nrx Pharmaceuticals Inc.", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "IV ketamine (HTX-100", "phase": "Phase III", "indication": "Bipolar disorder"}, {"name": "Cyclurad (NRX-101)", "phase": "Phase II/III", "indication": "Depression"}], "ceo": "Jonathan C. Javitt, MD", "employees": 0, "founded": 2015, "website": "https://www.nrxpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 28551814.2, "evFmt": "$29M", "ticker": "NRXP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nrx%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Nterica Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NTR-101", "phase": "Preclinical", "indication": "Hepatitis"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://nterica.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nterica%20Bio", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Nuago Therapeutics Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NU001", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://nuagotherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nuago%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Nubiyota LLC", "city": "Teaneck", "state": "NJ", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TAK-039", "phase": "Phase I", "indication": "Renal (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.nubiyota.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nubiyota", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Nucleobio Inc.", "city": "Manhattan", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Prostreat", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.nucleobio.net", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nucleobio", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Nura Bio Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NB-4746", "phase": "Phase I", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://nurabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nura%20Bio", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Nuravax Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Vaccine"], "nProducts": 4, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "AV-1959D", "phase": "IND", "indication": "Alzheimer's disease"}, {"name": "AV-1959R + AV-1980R", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "AV-1959R", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "AV-1980R", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.nuravax.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nuravax", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Nurix Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Inflammation", "Transplant"], "modalityGroups": ["Cell Therapy", "Small Molecule", "Undisclosed"], "nProducts": 7, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "bexobrutideg (NX-5948)", "phase": "Phase I", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "DeTIL-0255", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "GS-6791", "phase": "Phase I", "indication": "Inflammation (unspecified)"}, {"name": "NX-1607", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "zelebrudomide (NX-2127)", "phase": "Phase I", "indication": "Hematologic malignancies"}, {"name": "Nurix-CTM3 kinase-unknown", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "NX-3911", "phase": "Preclinical", "indication": "Dermatitis"}], "ceo": "Arthur T. Sands, MD, PhD", "employees": 317, "founded": 2012, "website": "http://www.nurix-inc.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 995059915.76, "evFmt": "$995M", "ticker": "NRIX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nurix%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology", "Hematologic Cancers", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Nurron Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ATH-399A", "phase": "Phase I", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://nurronpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nurron%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "Nusirt Biopharma Inc.", "city": "Nashville", "state": "TN", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "leucine/metformin/sildenafil", "phase": "Phase II", "indication": "Liver disease"}, {"name": "NS-0200", "phase": "Phase II", "indication": "Liver disease"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.nusirt.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nusirt%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Nutcracker Therapeutics Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NTX-0250", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "NTX-0565", "phase": "Preclinical", "indication": "T cell lymphoma"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.nutcrackerx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nutcracker%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Nutra Pharma Corp.", "city": "Coral Springs", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "RPI-78M", "phase": "Phase III", "indication": "Leukodystrophy"}, {"name": "Pepteron (RPI-MN)", "phase": "Phase II", "indication": "Herpes simplex virus (HSV)"}, {"name": "RPI-78", "phase": "Phase I", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "Rik J. Deitsch", "employees": 0, "founded": 2000, "website": "http://www.nutrapharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "NPHC", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nutra%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Infectious Disease", "Neurodegeneration / NMD"]}, {"company": "Nuvalent Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "zidesamtinib (NVL-520", "phase": "Registration", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "neladalkib (NVL-655", "phase": "Phase III", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "NVL-330", "phase": "Phase I", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "James R. Porter, PhD", "employees": 142, "founded": 2017, "website": "https://www.nuvalent.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4080179411.96, "evFmt": "$4.1B", "ticker": "NUVL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nuvalent", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Nuvation Bio Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NUV-868", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "DDC1", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "DDC2", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "DDC3", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "DDC4", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "NUV-1182", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "NUV-569", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "David T. Hung, MD", "employees": 220, "founded": 2018, "website": "https://www.nuvationbio.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 221156520.0, "evFmt": "$221M", "ticker": "NUVB", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nuvation%20Bio", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Nuvectis Pharma Inc.", "city": "Fort Lee", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "NXP800", "phase": "Phase I", "indication": "Ovarian cancer"}, {"name": "NXP900", "phase": "IND", "indication": "Cancer (unspecified)"}], "ceo": "Ronald E. Bentsur, MBA", "employees": 13, "founded": 2020, "website": "https://nuvectis.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 74049244.29, "evFmt": "$74M", "ticker": "NVCT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nuvectis%20Pharma", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Nuvig Therapeutics Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NVG-2089", "phase": "Phase I", "indication": "Bullous pemphigoid"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.nuvigtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nuvig%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Nuvox Therapeutics Inc.", "city": "Tucson", "state": "AZ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "dodecofluoropentane (NVX-108)", "phase": "Phase I/II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.nuvoxpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Nuvox%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Obsidian Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Obsidian Therapeutics-CD40L-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "OBX-115", "phase": "Phase I/II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Obsidian Therapeutics-additional solid tumors-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Obsidian Therapeutics-non-small cell lung cancer-unknown", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.obsidiantx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Obsidian%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer", "Solid Tumors (General)"]}, {"company": "Ocean Biomedical Inc.", "city": "Providence", "state": "RI", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Infectious", "Pulmonary"], "modalityGroups": ["Antibody", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Anti-PfGARP", "phase": "Preclinical", "indication": "Malaria"}, {"name": "Ocean Biomedical-pulmonary fibrosis-unknown", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}, {"name": "OCX-253", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "M. Michelle Berrey, MD", "employees": 7, "founded": 2019, "website": "https://www.oceanbiomedical.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 31284902.961, "evFmt": "$31M", "ticker": "OCEA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ocean%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Infectious Disease", "Respiratory / Allergy"]}, {"company": "Ocelot Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "OCE-205", "phase": "Phase II", "indication": "Hepatic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "http://www.ocelotbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ocelot%20Bio", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Octagon Therapeutics Inc.", "city": "Providence", "state": "RI", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "OW177", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.octagontherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Octagon%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Octant Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Octant-autosomal dominant retinitis pigmentosa-unknown", "phase": "Preclinical", "indication": "Retinitis"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.octant.bio", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Octant", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Ocugen Inc.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Infectious", "Musculoskeletal", "Ophthalmic"], "modalityGroups": ["Gene Therapy", "Other", "Protein / Biologic", "Vaccine"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "AAV-NR2E3 (OCU400", "phase": "Phase III", "indication": "Retinitis"}, {"name": "NeoCart", "phase": "Phase III", "indication": "Cartilage repair"}, {"name": "OCU410ST", "phase": "Phase II/III", "indication": "Stargardt disease"}, {"name": "AAV-hRORA", "phase": "Phase I/II", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "OCU500", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "OCU200", "phase": "Preclinical", "indication": "Diabetic macular edema (DME)"}], "ceo": "Shankar Musunuri, PhD, MBA", "employees": 95, "founded": 2013, "website": "http://ocugen.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 192140072.405, "evFmt": "$192M", "ticker": "OCGN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ocugen", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Infectious Disease", "Musculoskeletal", "Ophthalmology"]}, {"company": "Ocular Therapeutix Inc.", "city": "Bedford", "state": "MA", "country": "United States", "diseaseCats": ["Infectious", "Inflammation", "Neurology", "Ophthalmic"], "modalityGroups": ["Nanoparticle / Delivery", "Small Molecule"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Dextenza", "phase": "Marketed", "indication": "Inflammation (unspecified)"}, {"name": "ReSure Sealant", "phase": "Marketed", "indication": "Corneal wound"}, {"name": "Sustained-release travoprost (OTX-TP)", "phase": "Phase III", "indication": "Glaucoma"}, {"name": "OTX-CSI", "phase": "Phase II", "indication": "Dry eye"}, {"name": "OTX-DED", "phase": "Phase II", "indication": "Dry eye"}, {"name": "Travoprost intracameral injection (OTX-TIC", "phase": "Phase II", "indication": "Glaucoma"}, {"name": "Travoprost-loaded punctum plug (OTX-TP2)", "phase": "Phase II", "indication": "Glaucoma"}, {"name": "Travoprost-loaded punctum plug (OTX-TP1)", "phase": "Phase I/II", "indication": "Glaucoma"}], "ceo": "Pravin U. Dugel, MD", "employees": 325, "founded": 2006, "website": "http://www.ocutx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1613019603.62, "evFmt": "$1.6B", "ticker": "OCUL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ocular%20Therapeutix", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Ophthalmology", "Other Inflammation"]}, {"company": "Oculogenex Inc.", "city": "La Habra", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Oculogenex-AMD-unknown", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "Oculogenex-geographic atrophy-unknown", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "Oculogenex-glaucoma-unknown", "phase": "Preclinical", "indication": "Glaucoma"}, {"name": "Oculogenex-retinitis pigmentosa-unknown", "phase": "Preclinical", "indication": "Retinitis"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://oculogenex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oculogenex", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Ocuterra Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "OTT166 (SF0166 Topical Ophthalmic Solution", "phase": "Phase II", "indication": "Diabetic retinopathy"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://www.ocuterratx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ocuterra%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Odyssey Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Endocrine/Metabolic", "Inflammation"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "OD-07656", "phase": "Phase II", "indication": "Crohn's disease"}, {"name": "OD-00910", "phase": "Preclinical", "indication": "Lupus"}, {"name": "Odyssey Therapeutics-IRAK4 scaffolding inhibitor-unknown", "phase": "Preclinical", "indication": "Osteoarthritis"}, {"name": "Odyssey Therapeutics-MDA5-unknown", "phase": "Research", "indication": "Sjogren syndrome"}, {"name": "Odyssey Therapeutics-NLRP1-unknown", "phase": "Research", "indication": "Scleroderma"}, {"name": "Odyssey Therapeutics-TSLP/IL-33-unknown", "phase": "Research", "indication": "Asthma"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://odysseytx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 482000000.0, "totalRaisedFmt": "$482M", "latestFinDate": "2025-09-10", "latestFinType": "Series D rounds", "nRounds": 3, "recentFinancing": [{"type": "Series D rounds", "amount": "$213M", "date": "2025-09-10", "investors": "Existing Investors, Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Venture Partners, Tpg Capital,..."}, {"type": "Series C rounds", "amount": "$101M", "date": "2023-12-05", "investors": "Ascenta Capital, Orbimed Advisors LLC, Sr One, General Catalyst, Foresite Capital, Woodline Partners L.P., Hbm Healthcar..."}, {"type": "Series B rounds", "amount": "$168M", "date": "2022-10-13", "investors": "General Catalyst, Fidelity Management and Research Company, T. Rowe Price Associates Inc., Greatpoint Ventures, Catalio ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Odyssey%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "IBD / GI Inflammatory", "Musculoskeletal", "Respiratory / Allergy"]}, {"company": "Okogen Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ophthalmic ranpirnase (OKG-0301)", "phase": "Phase II", "indication": "Conjunctivitis"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.okogen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Okogen", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Olaris Inc.", "city": "Framingham", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Development (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Cerebro", "phase": "Development (diagnostic)", "indication": "Drug screen"}, {"name": "myOLARIS-KTdx", "phase": "Development (diagnostic)", "indication": "Genitourinary, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2025-05-19", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "", "date": "2025-05-19", "investors": "Bruker Corp."}, {"type": "Series B rounds", "amount": "", "date": "2025-04-08", "investors": "Laboratory Corp. of America Holdings"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Olaris", "hasDealsFin": true, "diseaseGroups": ["Other", "Supportive / Other"]}, {"company": "Olatec Therapeutics LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Endocrine/Metabolic", "Infectious", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "dapansutrile (OLT1177)", "phase": "Phase II/III", "indication": "Hyperuricemia/gout"}], "ceo": "", "employees": 0, "founded": 2003, "website": "https://www.olatec.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Olatec%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Olema Pharmaceuticals Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "palazestrant (OP-1250)", "phase": "Phase III", "indication": "Breast cancer"}], "ceo": "Sean P. Bohen, MD, PhD", "employees": 96, "founded": 2007, "website": "https://olema.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": -90182266.74, "evFmt": "", "ticker": "OLMA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Olema%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Oligomerix Inc.", "city": "White Plains", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "OLX-07010", "phase": "Phase I", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.oligomerix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oligomerix", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Omega Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Hepatic", "Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "OTX-2002", "phase": "Phase I/II", "indication": "Liver cancer"}, {"name": "Omega Therapeutics-CXCL 1/8-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Omega Therapeutics-HNF4A-unknown", "phase": "Preclinical", "indication": "Hepatic (unspecified)"}, {"name": "Omega Therapeutics-SFRP1-unknown", "phase": "Preclinical", "indication": "Androgenetic alopecia"}, {"name": "OTX-2101", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "Kaan Certel, PhD", "employees": 0, "founded": 2016, "website": "https://www.omegatherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "OMGA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Omega%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "GI Cancers", "Infectious Disease", "Liver Disease", "Lung Cancer"]}, {"company": "Omeros Corp.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Hematology", "Inflammation", "Neurology", "Ophthalmic", "Pulmonary", "Renal"], "modalityGroups": ["Antibody", "Other", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Omridia", "phase": "Marketed", "indication": "Cataract"}, {"name": "narsoplimab (OMS721)", "phase": "Registration", "indication": "Thrombocytopenia"}, {"name": "OMS405", "phase": "Phase II", "indication": "Substance use disorders"}, {"name": "zaltenibart (OMS906)", "phase": "Phase II", "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)"}, {"name": "OMS1029", "phase": "Phase I", "indication": "Inflammation (unspecified)"}, {"name": "Omeros-GPR161-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Omeros-GPR174-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Gregory A. Demopulos, MD", "employees": 202, "founded": 1994, "website": "http://www.omeros.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 907873798.28, "evFmt": "$908M", "ticker": "OMER", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Omeros", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Ophthalmology", "Other Inflammation", "Psychiatry / Behavioral", "Solid Tumors (General)"]}, {"company": "Omnitura Therapeutics Inc.", "city": "Henderson", "state": "NV", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Aneustat (OMN54)", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.omnitura.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Omnitura%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "On Target Laboratories Inc.", "city": "West Lafayette", "state": "IN", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "pafolacianine sodium (OTL38)", "phase": "Registration", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://ontargetlabs.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=On%20Target%20Laboratories", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Onchilles Pharma Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "N17350", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "N17465", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://onchillespharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Onchilles%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Solid Tumors (General)"]}, {"company": "Oncoc4 Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Inflammation"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Cell Therapy"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "gotistobart (BNT316", "phase": "Phase III", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "AI-061", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "AI-071", "phase": "Phase I", "indication": "Inflammation (unspecified)"}, {"name": "ONC-841", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "AI-081", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "ONC-782", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "ONC-783", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "ONC-784", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://oncoc4.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncoc4", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Lung Cancer", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Oncocube Therapeutics LLC", "city": "Lexington", "state": "SC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AO-252", "phase": "Phase I", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "http://www.oncocube.net/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncocube%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Oncoheroes Biosciences Inc.", "city": "Brookline", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "Volasertib (BI 6727)", "phase": "Phase I", "indication": "Sarcoma"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://oncoheroes.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncoheroes%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Oncolix Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Prolanta", "phase": "Phase I", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.oncolixbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncolix", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Oncomyx Therapeutics Inc.", "city": "Phoenix", "state": "AZ", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "OM1 (OM101)", "phase": "Preclinical", "indication": "Gastric cancer"}, {"name": "OM4", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.oncomyx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncomyx%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers"]}, {"company": "Onconetix Inc.", "city": "Cincinnati", "state": "OH", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Blue Water Vaccines-chlamydia-unknown", "phase": "Preclinical", "indication": "Sexually transmitted disease (STD)"}, {"name": "BWV-101", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "BWV-201", "phase": "Preclinical", "indication": "Otitis media"}], "ceo": "Karina M. Fedasz, MBA, CPA", "employees": 7, "founded": 2018, "website": "https://www.onconetix.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 15721621.32, "evFmt": "$16M", "ticker": "ONCO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Onconetix", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Oncopep Inc.", "city": "North Andover", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "PVX-410", "phase": "Phase I", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.oncopep.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncopep", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Oncoresponse Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "anti-LILRB2 (OR502)", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "OR2805", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "OR641", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://oncoresponse.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 64000000.0, "totalRaisedFmt": "$64M", "latestFinDate": "2023-05-18", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$14M", "date": "2023-05-18", "investors": "Rivervest Venture Partners, Arch Venture Partners, Canaan, 3b Future Health Fund S.A., Bering Capital, Takeda Ventures, ..."}, {"type": "Venture (Debt)", "amount": "$50M", "date": "2022-02-15", "investors": "Oxford Finance LLC"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncoresponse", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Oncosenx Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "OSX-001", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "OSX-002", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.oncosenx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncosenx", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Oncosynergy Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "OS2966", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "OS342", "phase": "Preclinical", "indication": "Neurofibromatosis"}, {"name": "OS47720", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.oncosynergy.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncosynergy", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Rare / Genetic"]}, {"company": "Oncotartis Inc.", "city": "Buffalo", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "OT-82", "phase": "Phase I/II", "indication": "Lymphoma"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.oncotartis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncotartis", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Oncotelic Therapeutics Inc.", "city": "Agoura Hills", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "ArtiShield", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Zybrestat", "phase": "Phase III", "indication": "Ovarian cancer"}, {"name": "OXi-4503 (OXi4503", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "KGP94", "phase": "Preclinical", "indication": "Head and neck cancer"}], "ceo": "Vuong Trieu, PhD", "employees": 40, "founded": 2015, "website": "http://oncotelic.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 27065319.555, "evFmt": "$27M", "ticker": "OTLC", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncotelic%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Head & Neck Cancer", "Hematologic Cancers", "Infectious Disease"]}, {"company": "Oncotide Pharmaceuticals Inc.", "city": "Research Triangle Park", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "OP449", "phase": "Preclinical", "indication": "Chronic lymphocytic leukemia (CLL)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.oncotide.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncotide%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Oncovir Inc.", "city": "Washington", "state": "DC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Poly-ICLC (hiltonol)", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.oncovir.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncovir", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Oncusp Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "CUSP06 (AMT-707)", "phase": "IND", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.oncusptx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-06-08", "recentDeals": [{"headline": "OnCusp Therapeutics and Multitude Therapeutics enter into an Ex-China licensing agreement for a potentially highly differentiated CDH6-targeting antibody drug conjugate", "date": "2022-06-08", "value": ""}], "totalRaised": 100000000.0, "totalRaisedFmt": "$100M", "latestFinDate": "2024-01-04", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$100M", "date": "2024-01-04", "investors": "Novo Holdings, Orbimed Advisors LLC, F-prime Inc. (F-prime Capital Partners), Sofinnova Investments Inc., Catalio Capita..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncusp%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Oncxerna Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Antibody", "Diagnostics"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "bavituximab (3G4", "phase": "Phase III", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Xerna TME Panel", "phase": "Development (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://oncxerna.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-01-09", "recentDeals": [{"headline": "Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy Response for More Patients", "date": "2022-01-09", "value": ""}], "totalRaised": 30000000.0, "totalRaisedFmt": "$30M", "latestFinDate": "2022-03-03", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$30M", "date": "2022-03-03", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oncxerna%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Lung Cancer", "Solid Tumors (General)"]}, {"company": "Onkure Therapeutics Inc.", "city": "Boulder", "state": "CO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic", "Undisclosed"], "nProducts": 8, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "OKI-179", "phase": "Phase I", "indication": "Melanoma"}, {"name": "OKI-1546", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "ONK-001", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "ONK-002", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "ONK-003", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "ONK-004", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "ONK-005", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "ONK-006", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "Nicholas A. Saccomano, PhD", "employees": 46, "founded": 2011, "website": "http://onkuretherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 5109206.2, "evFmt": "$5M", "ticker": "OKUR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 54000000.0, "totalRaisedFmt": "$54M", "latestFinDate": "2023-05-23", "latestFinType": "Series C rounds", "nRounds": 1, "recentFinancing": [{"type": "Series C rounds", "amount": "$54M", "date": "2023-05-23", "investors": "Surveyor Capital, Deep Track Capital, Acorn Bioventures L.P., Cormorant Asset Management, Perceptive Advisors, Samsara B..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Onkure%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Onl Therapeutics Inc.", "city": "Ann Arbor", "state": "MI", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ONL1204", "phase": "Phase II", "indication": "Retinal detachment"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.onltherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Onl%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Ophidion Inc.", "city": "Pasadena", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Peptide", "RNA Therapeutics"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Ophidion-Cognition-unknown", "phase": "Preclinical", "indication": "Cognitive dysfunction"}, {"name": "Ophidion-glioblastoma (target-ASO)-unknown", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "Ophidion-glioblastoma (target-peptide)-unknown", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "Ophidion-Huntington-unknown", "phase": "Preclinical", "indication": "Huntington disease (HD)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://ophidion.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ophidion", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Brain / CNS Tumors", "Neurodegeneration / NMD"]}, {"company": "Ophirex Inc.", "city": "Corte Madera", "state": "CA", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "varespladib", "phase": "Phase II", "indication": "Poisoning"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.ophirex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ophirex", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Opko Health Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Infectious", "Neurology"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule", "Vaccine"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "AntagoNAT (OPK88001", "phase": "Preclinical", "indication": "Dravet syndrome"}, {"name": "Lagova", "phase": "Marketed", "indication": "Growth hormone deficiency"}, {"name": "Rayaldee", "phase": "Marketed", "indication": "Thyroid disease"}, {"name": "Varubi (Brand)", "phase": "Marketed", "indication": "Emesis"}, {"name": "Varubi IV", "phase": "Marketed", "indication": "Emesis"}, {"name": "MDX-2201", "phase": "Preclinical", "indication": "Epstein-Barr virus (EBV)"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Opko%20Health", "hasDealsFin": true, "diseaseGroups": ["Epilepsy / Seizures", "Other", "Other Specialties", "Supportive / Other"]}, {"company": "Opsidio LLC", "city": "Bryn Mawr", "state": "PA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "OpSCF", "phase": "Phase II", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.opsidio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Opsidio", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Opsis Therapeutics LLC", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "OpCT-001", "phase": "Phase I/II", "indication": "Ophthalmic (unspecified)"}, {"name": "Opsis Therapeutics-early / intermediate dry AMD-unknown", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "Opsis Therapeutics-late dry AMD / GA-unknown", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://opsistherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Opsis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Optherion Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RhCFH", "phase": "Preclinical", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.optherion.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Optherion", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Opus Bio Inc.", "city": "Greenwich", "state": "CT", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Infectious"], "modalityGroups": ["Cell Therapy", "Vaccine"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "LG631-CD34", "phase": "Phase I", "indication": "Hematology (unspecified)"}, {"name": "LG611", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "LG889", "phase": "Preclinical", "indication": "Hemophilia"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.opusbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Opus%20Bio", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Infectious Disease"]}, {"company": "Opus Genetics Inc.", "city": "Farmington Hills", "state": "MI", "country": "United States", "diseaseCats": ["Cancer", "Ophthalmic"], "modalityGroups": ["Gene Therapy", "RNA Therapeutics", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Ryzumvi", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}, {"name": "nano-liposomal Archexin (HC0201", "phase": "Phase II", "indication": "Liver cancer"}, {"name": "RX-3117", "phase": "Phase II", "indication": "Bladder cancer"}, {"name": "OPGx-LCA5 (OPGx-001)", "phase": "Phase I/II", "indication": "Blindness"}, {"name": "OPGx-CNGB1", "phase": "Preclinical", "indication": "Retinitis"}, {"name": "OPGx-MERTK", "phase": "Preclinical", "indication": "Retinitis"}, {"name": "OPGx-NMNAT1 (OPGx-003)", "phase": "Preclinical", "indication": "Blindness"}, {"name": "OPGx-RDH12 (OPGx-002)", "phase": "Preclinical", "indication": "Blindness"}], "ceo": "George Magrath, III, MD", "employees": 18, "founded": 2018, "website": "https://opusgtx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 20311475.94, "evFmt": "$20M", "ticker": "IRD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Opus%20Genetics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "GU / Gynecologic Cancers", "Ophthalmology"]}, {"company": "Oqory Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "OQY-3258 (ESG401)", "phase": "Phase III", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2012, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oqory", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Oragenics Inc.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Infectious", "Neurology"], "modalityGroups": ["Peptide", "Small Molecule", "Vaccine"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ONP-002", "phase": "Phase I", "indication": "Neurology (unspecified)"}, {"name": "OG716", "phase": "Preclinical", "indication": "Clostridium"}, {"name": "ONP-001", "phase": "Preclinical", "indication": "Glycosphingolipid storage disorders"}, {"name": "Terra CoV-2 (NT-CoV2-1)", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Janet Huffman", "employees": 3, "founded": 1996, "website": "http://www.oragenics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1909168.2262, "evFmt": "$2M", "ticker": "OGEN", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oragenics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other Neurology", "Rare / Genetic"]}, {"company": "Orano Med LLC", "city": "Plano", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Peptide"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "AlphaMedix", "phase": "Phase II", "indication": "Neuroendocrine tumors"}, {"name": "212Pb TAT", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "212Pb PRIT", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "212Pb-DOTAM-GRPR1", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "212Pb PRRT", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2009, "website": "https://www.oranomed.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 352260000.0, "totalDealFmt": "$352M", "latestDealDate": "2024-09-12", "recentDeals": [{"headline": "Sanofi, RadioMedix, and Orano Med announce exclusive licensing agreement on AlphaMedix (212Pb-DOTAMTATE), next-generation radioligand medicine for rare cancers", "date": "2024-09-12", "value": "$352M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orano%20Med", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Orbus Therapeutics Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "eflornithine (alpha-diflurormethylornithine)", "phase": "Phase III", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.orbustherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orbus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Orca Biosystems Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Orca-T (TRGFT-201)", "phase": "Registration", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "OGFT-001", "phase": "Phase I", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://orcabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orca%20Biosystems", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Organon & Co.", "city": "Jersey City", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Dermatology", "Endocrine/Metabolic", "Genitourinary", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Pulmonary"], "modalityGroups": ["Digital / Device", "Other", "Peptide", "Protein / Biologic", "Small Molecule"], "nProducts": 28, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Aerius", "phase": "Marketed", "indication": "Urticaria"}, {"name": "Antagon", "phase": "Marketed", "indication": "Infertility"}, {"name": "Asmanex HFA", "phase": "Marketed", "indication": "Asthma"}, {"name": "Asmanex Twisthaler", "phase": "Marketed", "indication": "Allergy"}, {"name": "Bonalon", "phase": "Marketed", "indication": "Osteoporosis"}, {"name": "Celestone Soluspan", "phase": "Marketed", "indication": "Inflammation (unspecified)"}, {"name": "Clarinex-D 12 Hour (Clarinex-D", "phase": "Marketed", "indication": "Rhinitis"}, {"name": "Cozaar", "phase": "Marketed", "indication": "Heart failure"}], "ceo": "Joseph T. Morrissey, Jr., MBA", "employees": 10000, "founded": 2020, "website": "http://www.organon.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 12227547840.0, "evFmt": "$12.2B", "ticker": "OGN", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Organon%20%26", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Musculoskeletal", "Other Inflammation", "Respiratory / Allergy", "Women's Health"]}, {"company": "Orgenesis Inc.", "city": "Germantown", "state": "MD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Infectious"], "modalityGroups": ["Cell Therapy", "Other", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Kyslecel", "phase": "Marketed", "indication": "Pancreatitis"}, {"name": "ranpirnase (AutoVac", "phase": "Phase I/II", "indication": "Human papillomavirus (HPV)"}, {"name": "Autologous Insulin Producing (AIP) cells", "phase": "Preclinical", "indication": "Hypoglycemia"}, {"name": "KT-CP-203", "phase": "Preclinical", "indication": "Pancreatitis"}, {"name": "KT-PC-301", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Vered Caplan", "employees": 0, "founded": 2008, "website": "http://www.orgenesis.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "ORGS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orgenesis", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Infectious Disease", "Supportive / Other"]}, {"company": "Oric Pharmaceuticals Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ORIC-101", "phase": "Phase I", "indication": "Prostate cancer"}, {"name": "ORIC-533", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "ORIC Pharmaceuticals-PLK4 inhibitor program-unknown", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "ORIC Pharmaceuticals-PLK4-unknown", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Jacob M. Chacko, MD, MBA", "employees": 115, "founded": 2014, "website": "http://oricpharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 316101475.8, "evFmt": "$316M", "ticker": "ORIC", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oric%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Hematologic Cancers"]}, {"company": "Oricula Therapeutics LLC", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Otologic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ORC-13661", "phase": "Phase I", "indication": "Hearing loss"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.oricularx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oricula%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Orionis Biosciences Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic", "Undisclosed"], "nProducts": 25, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Orionis Biosciences-CD8 T cell-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Orionis Biosciences-checkpoint target-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Orionis Biosciences-checkpoint target-unknown2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Orionis Biosciences-myeloid DC-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Orionis Biosciences-CD8 T cell-unknown2", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Orionis Biosciences-CD8 T cell-unknown3", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Orionis Biosciences-CD8 T cell-unknown4", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Orionis Biosciences-checkpoint target-unknown3", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://orionisbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 4152000000.0, "totalDealFmt": "$4.2B", "latestDealDate": "2025-05-21", "recentDeals": [{"headline": "Orionis Biosciences Announces Strategic Partnership with Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer", "date": "2025-05-21", "value": "$2.1B"}, {"headline": "Orionis Biosciences Announces Collaboration with Genentech to Discover and Develop Molecular Glue Class Medicines", "date": "2023-09-20", "value": "$2.0B"}], "totalRaised": 55000000.0, "totalRaisedFmt": "$55M", "latestFinDate": "2022-10-19", "latestFinType": "Series C rounds", "nRounds": 1, "recentFinancing": [{"type": "Series C rounds", "amount": "$55M", "date": "2022-10-19", "investors": "Cormorant Asset Management, Novartis AG, Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orionis%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Orlance Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Infectious", "Inflammation"], "modalityGroups": ["Vaccine"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Orlance-food allergies-unknown", "phase": "Preclinical", "indication": "Allergy"}, {"name": "Orlance-HBV in immunocompromised-unknown", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "Orlance-seasonal SARS-CoV-2 DNA Vaccine-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Orlance-Universal Influenza (UFlu) DNA Vaccine-unknown", "phase": "Preclinical", "indication": "Influenza virus"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.orlance.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orlance", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Respiratory / Allergy"]}, {"company": "Orna Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Musculoskeletal", "Other"], "modalityGroups": ["Cell Therapy", "RNA Therapeutics"], "nProducts": 7, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ORN-252", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "ORN-101", "phase": "Research", "indication": "B cell lymphoma"}, {"name": "Orna Therapeutics-COVID-19-unknown", "phase": "Research", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Orna Therapeutics-Duchenne muscular dystrophy-unknown", "phase": "Research", "indication": "Muscular dystrophy"}, {"name": "Orna Therapeutics-genetic disease-unknown", "phase": "Research", "indication": "Genetic disorders"}, {"name": "Orna Therapeutics-infectious disease-unknown", "phase": "Research", "indication": "Infectious (unspecified)"}, {"name": "Orna Therapeutics-isCAR-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.ornatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 3, "totalDealValue": 3750000000.0, "totalDealFmt": "$3.8B", "latestDealDate": "2025-01-07", "recentDeals": [{"headline": "Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)", "date": "2025-01-07", "value": ""}, {"headline": "Simnova and Orna Therapeutics collaborate to advance Orna's next generation circular RNA technology in China", "date": "2023-01-05", "value": ""}, {"headline": "Merck partners with Orna Therapeutics to develop and commercialize vaccines and therapeutics using Orna's oRNA-LNP technology", "date": "2022-08-16", "value": "$3.8B"}], "totalRaised": 221000000.0, "totalRaisedFmt": "$221M", "latestFinDate": "2022-08-16", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$221M", "date": "2022-08-16", "investors": "Merck & Co. Inc., Mpm Capital L.P., Bioimpact Co. Ltd."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orna%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers", "Infectious Disease", "Neurodegeneration / NMD", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Orphagen Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "OR-812", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.orphagen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orphagen%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Orphai Therapeutics Inc.", "city": "Guilford", "state": "CT", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "apilimod dimesylate (LAM-002", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "LAM-001", "phase": "Phase I", "indication": "Pulmonary (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.orphai-therapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orphai%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Orphomed Inc.", "city": "Mill Valley", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Gastrointestinal", "Neurology", "Pulmonary"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ORP-101", "phase": "Phase II", "indication": "Irritable bowel syndrome"}, {"name": "ORP-105", "phase": "Preclinical", "indication": "Pain"}, {"name": "ORP-110", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.orphomed.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orphomed", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Pain / Migraine", "Rare / Genetic"]}, {"company": "Orpro Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Theradux (ORP-100S)", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.orprotherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orpro%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Orsobio Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TLC-2716", "phase": "Phase II", "indication": "Hypertriglyceridemia"}, {"name": "TLC-6740", "phase": "Phase I", "indication": "Metabolic (unspecified)"}, {"name": "TLC-065", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "TLC-097", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "TLC-1180", "phase": "Preclinical", "indication": "Obesity"}, {"name": "TLC-1235", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://orsobio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-11-02", "recentDeals": [{"headline": "OrsoBio acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi &amp; Co., Ltd. for the treatment of Type 2 Diabetes", "date": "2022-11-02", "value": ""}, {"headline": "OrsoBio announces exclusive license to intellectual property relating to mitochondrial protonophores for the treatment of severe metabolic disorders", "date": "2022-11-02", "value": ""}], "totalRaised": 151629383.0, "totalRaisedFmt": "$152M", "latestFinDate": "2024-09-06", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$67M", "date": "2024-09-06", "investors": "Ascenta Capital, Woodline Partners L.P., Samsara Biocapital L.P., Longitude Capital, Enavate Sciences, Nuevabio, Eli Lil..."}, {"type": "Series A rounds", "amount": "$85M", "date": "2023-11-07", "investors": "Longitude Capital, Enavate Sciences, Samsara Biocapital L.P., Nuevabio, Eli Lilly and Co."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orsobio", "hasDealsFin": true, "diseaseGroups": ["Diabetes", "Obesity / Metabolic"]}, {"company": "Orthogon Therapeutics LLC", "city": "Canton", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Orthogon-polyomavirus-unknown", "phase": "Preclinical", "indication": "Viral infection"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.orthogontherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orthogon%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Orthotrophix Inc.", "city": "Oakland", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TPX-100", "phase": "Phase II", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.orthotrophix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Orthotrophix", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Oruka Therapeutics Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Infectious"], "modalityGroups": ["Antibody", "Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Gencaro", "phase": "Phase III", "indication": "Fibrillation"}, {"name": "rNAPc2 (AB201)", "phase": "Phase II", "indication": "Coronary artery disease (CAD)"}, {"name": "ORKA-001", "phase": "Preclinical", "indication": "Psoriasis"}, {"name": "ORKA-002", "phase": "Preclinical", "indication": "Psoriasis"}], "ceo": "Lawrence O. Klein, PhD", "employees": 28, "founded": 2024, "website": "https://www.orukatx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": -46203270.82, "evFmt": "", "ticker": "ORKA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oruka%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Dermatology"]}, {"company": "Os Therapies Inc.", "city": "Cambridge", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "axalimogene filolisbac", "phase": "Phase III", "indication": "Cervical cancer"}, {"name": "ADXS-HER2", "phase": "Phase II", "indication": "Bone cancer"}, {"name": "HOT Lung (ADXS-503", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Listeria monocytogenes/PSA (Lm-LLO-PSA) vaccine", "phase": "Phase I/II", "indication": "Prostate cancer"}], "ceo": "Paul A. Romness", "employees": 5, "founded": 2018, "website": "https://www.ostherapies.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 89839679.24, "evFmt": "$90M", "ticker": "OSTX", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Os%20Therapies", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Lung Cancer", "Other Solid Tumors"]}, {"company": "Osel Inc.", "city": "Mountain View", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Infectious", "Transplant"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Lactin-V", "phase": "Phase II", "indication": "Infertility"}, {"name": "Cbm588", "phase": "Phase I", "indication": "Renal cancer"}, {"name": "Mucocept HIV", "phase": "Phase I", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.oselinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Osel", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Infectious Disease", "Women's Health"]}, {"company": "Osmol Therapeutics Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "OSM-0205", "phase": "IND", "indication": "Neuropathy"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://osmoltherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Osmol%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Ossianix Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VNAR antibodies", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.ossianix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ossianix", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Otodyne Inc.", "city": "Morristown", "state": "NJ", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Aquadyne:", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "Otodyne", "phase": "Preclinical", "indication": "Otitis media"}, {"name": "Otodyne-AI", "phase": "Preclinical", "indication": "Otitis media"}], "ceo": "", "employees": 0, "founded": 2010, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Otodyne", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Otologic Pharmaceutics Inc.", "city": "Oklahoma City", "state": "OK", "country": "United States", "diseaseCats": ["Otologic"], "modalityGroups": ["RNA Therapeutics", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NHPN-1010", "phase": "Phase I", "indication": "Hearing loss"}, {"name": "OPI-001", "phase": "Preclinical", "indication": "Hearing loss"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://otologicpharmaceutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Otologic%20Pharmaceutics", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Outlook Therapeutics Inc.", "city": "Iselin", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Musculoskeletal", "Ophthalmic"], "modalityGroups": ["Antibody"], "nProducts": 5, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Lytenava", "phase": "Registration", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "biosimilar adalimumab (ONS-3010)", "phase": "Phase I", "indication": "Crohn's disease"}, {"name": "ONS-1045", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "biosimilar denosumab (ONS-4010)", "phase": "Preclinical", "indication": "Osteoporosis"}, {"name": "biosimilar trastuzumab (ONS-1050)", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Robert Charles Jahr, MBA", "employees": 17, "founded": 2010, "website": "https://outlooktherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 58995500.2, "evFmt": "$59M", "ticker": "OTLK", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Outlook%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "IBD / GI Inflammatory", "Musculoskeletal", "Ophthalmology", "Solid Tumors (General)"]}, {"company": "Outpace Bio Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Outpace Bio/Lyell-cancer-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "OPB-101", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "OPB-201", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "OPB-301", "phase": "Preclinical", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.outpacebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Outpace%20Bio", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Outpost Medicine LLC", "city": "Indianapolis", "state": "IN", "country": "United States", "diseaseCats": ["Gastrointestinal", "Genitourinary"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "OP-687", "phase": "Preclinical", "indication": "Irritable bowel syndrome"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.outpostmedicine.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Outpost%20Medicine", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Ovid Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "OV329", "phase": "Phase I", "indication": "Seizures"}], "ceo": "Margaret Alexander", "employees": 23, "founded": 2014, "website": "https://ovidrx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 27884392.5214, "evFmt": "$28M", "ticker": "OVID", "exchange": "NASDAQ", "nDeals": 3, "totalDealValue": 15000000.0, "totalDealFmt": "$15M", "latestDealDate": "2023-05-01", "recentDeals": [{"headline": "Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors", "date": "2023-05-01", "value": "$10M"}, {"headline": "Gensaic enters into collaboration to develop phage-derived gene therapies for central nervous system", "date": "2022-08-24", "value": "$5M"}, {"headline": "Healx and Ovid Therapeutics to Enter Strategic Partnership", "date": "2022-02-08", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ovid%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures"]}, {"company": "Owp Pharmaceuticals Inc.", "city": "Lisle", "state": "IL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Subvenite", "phase": "Approved", "indication": "Bipolar disorder"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://owppharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Owp%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Oxeia Biopharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "OXE103", "phase": "Phase II", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.oxeiabiopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oxeia%20Biopharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Oxidien Pharmaceuticals LLC", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "OX-1", "phase": "Phase I", "indication": "Hyperoxaluria"}, {"name": "AA-1", "phase": "Preclinical", "indication": "Hyperoxaluria"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://oxidien.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oxidien%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Oyagen Inc.", "city": "Rochester", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "sangivamycin (TNX-3500", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.oyageninc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Oyagen", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Pacdna LLC", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular"], "modalityGroups": ["Other", "RNA Therapeutics"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PAC007", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "PAC101", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "PAC201", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}, {"name": "PAC301", "phase": "Preclinical", "indication": "Psoriasis"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://pacdnatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pacdna", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Dermatology", "GU / Gynecologic Cancers", "Lung Cancer"]}, {"company": "Pacific Genetech Ltd.", "city": "Louisburg", "state": "KS", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Hercules Adjuvant", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "Pacific GeneTech-Enteric Vaccine-Unknown", "phase": "Preclinical", "indication": "Escherichia"}, {"name": "Pacific GeneTech-Malaria-Unknown", "phase": "Preclinical", "indication": "Malaria"}, {"name": "Pacific GeneTech-ToxoPlasma/Cryptosporidium-Unknown", "phase": "Preclinical", "indication": "Cryptosporidium"}], "ceo": "", "employees": 0, "founded": 2009, "website": "https://www.pacificgenetech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pacific%20Genetech", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Pacira Biosciences Inc.", "city": "Parsippany", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Hematology", "Neurology"], "modalityGroups": ["Gene Therapy", "Small Molecule"], "nProducts": 11, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "DepoDur", "phase": "Marketed", "indication": "Pain"}, {"name": "Exparel", "phase": "Marketed", "indication": "Pain"}, {"name": "Zilretta", "phase": "Marketed", "indication": "Pain"}, {"name": "enekinragene inzadenovec (PCRX-201", "phase": "Phase II", "indication": "Osteoarthritis"}, {"name": "FX005", "phase": "Phase II", "indication": "Osteoarthritis"}, {"name": "FX201 (humantakinogene hadenovec)", "phase": "Phase I", "indication": "Osteoarthritis"}, {"name": "DepoMeloxicam", "phase": "Preclinical", "indication": "Pain"}, {"name": "DepoTranexamic acid", "phase": "Preclinical", "indication": "Bleeding"}], "ceo": "Frank D. Lee, MBA", "employees": 790, "founded": 2007, "website": "http://www.pacira.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1025493800.0, "evFmt": "$1.0B", "ticker": "PCRX", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 230000000.0, "totalDealFmt": "$230M", "latestDealDate": "2025-11-04", "recentDeals": [{"headline": "AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform", "date": "2025-11-04", "value": "$230M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pacira%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Musculoskeletal", "Pain / Migraine"]}, {"company": "Paganini Biopharma Inc.", "city": "Encino", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PG-101", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2009, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Paganini%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Paka Pulmonary Pharmaceuticals Inc.", "city": "Acton", "state": "MA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PDP1", "phase": "Preclinical", "indication": "Emphysema"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.pakapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Paka%20Pulmonary%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Palatin Technologies Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Ophthalmic"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "PL9643", "phase": "Phase III", "indication": "Dry eye"}, {"name": "PL8177", "phase": "Phase II", "indication": "Ulcerative colitis"}, {"name": "PL7737", "phase": "Preclinical", "indication": "Obesity"}, {"name": "PL9588", "phase": "Preclinical", "indication": "Glaucoma"}, {"name": "PL9654", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "Carl Spana, PhD", "employees": 29, "founded": 1986, "website": "http://www.palatin.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1368026.0, "evFmt": "$1M", "ticker": "PTN", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Palatin%20Technologies", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Obesity / Metabolic", "Ophthalmology"]}, {"company": "Palisade Bio Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Infectious", "Inflammation", "Musculoskeletal", "Neurology"], "modalityGroups": ["Cell Therapy", "Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "LB1148", "phase": "Phase III", "indication": "Gastrointestinal (GI) dysfunction"}, {"name": "Human neural stem cells (hNSCs) (NSI-566", "phase": "Phase II", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "InflammaGen Shok-Pak", "phase": "Phase II", "indication": "Shock/trauma"}, {"name": "NSI-189", "phase": "Phase II", "indication": "Depression"}, {"name": "HK532-IGF-1", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "J. D. Finley", "employees": 8, "founded": 2005, "website": "https://www.palisadebio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -7312822.85, "evFmt": "", "ticker": "PALI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Palisade%20Bio", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD", "Other", "Psychiatry / Behavioral", "Supportive / Other"]}, {"company": "Palleon Pharmaceuticals Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Inflammation", "Neurology"], "modalityGroups": ["Antibody", "Protein / Biologic", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "bi-sialidase (E-602", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "Sialidase-Her2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Palleon Pharmaceutical-PDL1-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Sialidase-Fc", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Siglec-9 mAb", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://palleonpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Palleon%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Palvella Therapeutics Inc.", "city": "Wayne", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology"], "modalityGroups": ["Macrocycle", "Other"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Qtorin", "phase": "Phase III", "indication": "Dermatology (unspecified)"}, {"name": "BOS-342 (PRS-342)", "phase": "Phase I/II", "indication": "Liver cancer"}, {"name": "PRS-343", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "PRS-332", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "PRS-344 (S095012)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "PRS-352", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Wesley H. Kaupinen, MBA", "employees": 14, "founded": 2015, "website": "https://palvellatx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -44948792.0, "evFmt": "", "ticker": "PVLA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Palvella%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "GI Cancers", "Solid Tumors (General)"]}, {"company": "Pamlico Biopharma Inc.", "city": "Oklahoma City", "state": "OK", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PneumomAb", "phase": "Preclinical", "indication": "Streptococcus"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://pamlicobio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pamlico%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Pan Genome Systems", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Pan Genome Systems-COVID 19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://pangenosys.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pan%20Genome%20Systems", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Panavance Therapeutics Inc.", "city": "Berwyn", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "misetionamide (GP-2250)", "phase": "Phase I", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://panavance.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Panavance%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Panbela Therapeutics Inc.", "city": "Gainesville", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "eflornithine (difluoromethylornithine", "phase": "Phase III", "indication": "Colorectal cancer"}, {"name": "Flynpovi", "phase": "Phase III", "indication": "Colorectal cancer"}, {"name": "ivospemin (SBP-101)", "phase": "Phase III", "indication": "Pancreatic cancer"}], "ceo": "Jennifer K. Simpson, PhD", "employees": 0, "founded": 2011, "website": "http://www.panbela.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "PBLA", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Panbela%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Panmira Pharmaceuticals LLC", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AM211", "phase": "Phase I", "indication": "Asthma"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.panmira.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Panmira%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Panoptica Inc.", "city": "Mount Arlington", "state": "NJ", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "PAN-90806", "phase": "Phase I/II", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.panopticapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Panoptica", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Panther Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PTM-101", "phase": "Phase I", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.panthertx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Panther%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Papillon Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology", "Renal"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "AVR-RD-04", "phase": "Phase I/II", "indication": "Nephropathy"}, {"name": "PPL-001 (Friedreich's ataxia stem cell therapy)", "phase": "Preclinical", "indication": "Friedreich ataxia"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.papillon-tx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Papillon%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Other"]}, {"company": "Paq Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PT0253", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.paqtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Paq%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Parabilis Medicines Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 6, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "FOG-001", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "Fog Pharmaceuticals-cyclin E1-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Fog Pharmaceuticals-ERG-unknown", "phase": "Research", "indication": "Prostate cancer"}, {"name": "Fog Pharmaceuticals-NRAS (ON)-unknown", "phase": "Research", "indication": "Solid tumors"}, {"name": "Fog Pharmaceuticals-PanKRAS (ON)-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Fog Pharmaceuticals-pan-TEAD-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://parabilismed.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 305000000.0, "totalRaisedFmt": "$305M", "latestFinDate": "2026-01-08", "latestFinType": "Rounds beyond series E", "nRounds": 1, "recentFinancing": [{"type": "Rounds beyond series E", "amount": "$305M", "date": "2026-01-08", "investors": "Ra Capital Management L.P., Fidelity Management & Research Co., Janus Henderson Investors, Frazier Life Sciences, Soleus..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Parabilis%20Medicines", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Parabon Nanolabs Inc.", "city": "Reston", "state": "VA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "P24RDN", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.parabon-nanolabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Parabon%20Nanolabs", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Paracrine Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Dermatology"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Paracrine-diabetic foot ulcers-unknown", "phase": "Preclinical", "indication": "Dermal ulcers"}, {"name": "Paracrine-heart failure-unknown", "phase": "Preclinical", "indication": "Heart failure"}, {"name": "Paracrine-pressure ulcers-unknown", "phase": "Preclinical", "indication": "Dermal ulcers"}, {"name": "Paracrine-scleroderma hand dysfunction-unknown", "phase": "Preclinical", "indication": "Scleroderma"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://paracrine.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Paracrine", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Cardiovascular", "Dermatology"]}, {"company": "Paradigm Therapeutics Inc.", "city": "Mt Pleasant", "state": "SC", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Zorblisa", "phase": "Phase III", "indication": "Epidermolysis bullosa"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.paradigmtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Paradigm%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Paragon Bioteck Inc.", "city": "Portland", "state": "OR", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Phenylephrine Hydrochloride Ophthalmic Solution (phenylephrine hydrochloride)", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://paragonbioteck.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Paragon%20Bioteck", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Paragon Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Inflammation"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "zumilokibart (PR004", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "PR001 (APG808)", "phase": "Phase I", "indication": "Asthma"}, {"name": "PR007 (APG990)", "phase": "Research", "indication": "Inflammation (unspecified)"}, {"name": "PR012 (APR222)", "phase": "Research", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.paragontherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 22000000.0, "totalDealFmt": "$22M", "latestDealDate": "2025-10-03", "recentDeals": [{"headline": "Paragon Therapeutics grants Jade Biosciences an exclusive license to develop and commercialize BAFF-R programs", "date": "2025-10-03", "value": "$22M"}, {"headline": "Paragon Therapeutics launches first spinout, Apogee Therapeutics, to advance novel therapies for inflammatory and immunological conditions", "date": "2022-12-07", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Paragon%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Other Inflammation", "Respiratory / Allergy"]}, {"company": "Paratek Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious", "Inflammation", "Neurology", "Pulmonary"], "modalityGroups": ["Digital / Device", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Nuzyra", "phase": "Marketed", "indication": "Pneumonia"}, {"name": "Seysara", "phase": "Marketed", "indication": "Acne"}, {"name": "Intermezzo", "phase": "Marketed", "indication": "Insomnia"}, {"name": "Xhance", "phase": "Marketed", "indication": "Inflammation (unspecified)"}, {"name": "Intranasal oxytocin (OPN-300)", "phase": "Phase II", "indication": "Autism"}, {"name": "OPN-019", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 1996, "website": "https://www.paratekpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Paratek%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease", "Other Inflammation", "Psychiatry / Behavioral"]}, {"company": "Parion Sciences Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Ophthalmic", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "GS-5737", "phase": "Phase II", "indication": "Cystic fibrosis (CF)"}, {"name": "p-321 ophthalmic solution (SHP659)", "phase": "Phase II", "indication": "Dry eye"}, {"name": "P-1055", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 1999, "website": "http://www.parion.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Parion%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology", "Rare / Genetic"]}, {"company": "Parow Entheobiosciences LLC", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "MESH-P601", "phase": "IND", "indication": "Obsessive compulsive disorder (OCD)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.parowentheobio.science/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Parow%20Entheobiosciences", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Particella Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DNAlite-gastrointestinal-unknown", "phase": "Preclinical", "indication": "Gastrointestinal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://particella.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Particella", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Parvus Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Infectious", "Transplant"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 6, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "PVT401", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "PVT201", "phase": "Phase I/II", "indication": "Primary biliary cholangitis"}, {"name": "Parvus Therapeutics-Rheumatoid Arthritis-unknown", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}, {"name": "PVT101", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "PVT301", "phase": "Preclinical", "indication": "Celiac disease"}, {"name": "PVT501", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://parvustx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Parvus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Diabetes", "GI Cancers", "IBD / GI Inflammatory", "MS / Neuroimmune"]}, {"company": "Pasithea Therapeutics Corp.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Macrocycle"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CIP-137401", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Tiago Reis Marques, MD, PhD", "employees": 4, "founded": 2020, "website": "https://www.pasithea.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -3470070.7, "evFmt": "", "ticker": "KTTA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pasithea%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Passage Bio Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Neurology", "Other"], "modalityGroups": ["Gene Therapy"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "PBFT02", "phase": "Phase I/II", "indication": "Frontotemporal dementia"}, {"name": "PBGM01", "phase": "Phase I/II", "indication": "GM1 gangliosidosis"}, {"name": "PBKR03", "phase": "Phase I/II", "indication": "Leukodystrophy"}, {"name": "PBML04", "phase": "IND", "indication": "Leukodystrophy"}], "ceo": "William Chou, MD, MBA", "employees": 60, "founded": 2018, "website": "http://www.passagebio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -17024304.0844, "evFmt": "", "ticker": "PASG", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 134000000.0, "totalDealFmt": "$134M", "latestDealDate": "2024-08-01", "recentDeals": [{"headline": "Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration", "date": "2024-08-01", "value": "$134M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Passage%20Bio", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD", "Other"]}, {"company": "Patagonia Pharmaceuticals LLC", "city": "Woodcliff Lake", "state": "NJ", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "topical isotretinoin (TMB-001", "phase": "Phase III", "indication": "Ichthyosis"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.patagoniarx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Patagonia%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Pathfinder Cell Therapy Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Musculoskeletal", "Renal"], "modalityGroups": ["Digital / Device", "Other"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Repel-CV", "phase": "Marketed", "indication": "Adhesions"}, {"name": "SinusShield", "phase": "Marketed", "indication": "Adhesions"}, {"name": "Pathfinder Cells", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}], "ceo": "", "employees": 0, "founded": 1990, "website": "http://www.pathfindercelltherapy.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pathfinder%20Cell%20Therapy", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Supportive / Other"]}, {"company": "Pathos Ai Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Rain Therapeutics-RAD52-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://pathos.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 3, "totalDealValue": 200000000.0, "totalDealFmt": "$200M", "latestDealDate": "2025-04-23", "recentDeals": [{"headline": "Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology", "date": "2025-04-23", "value": "$200M"}, {"headline": "Pathos announced today the world-wide license of PRT811 from Prelude Therapeutics", "date": "2024-08-15", "value": ""}, {"headline": "Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor", "date": "2023-05-23", "value": ""}], "totalRaised": 427000000.0, "totalRaisedFmt": "$427M", "latestFinDate": "2025-05-15", "latestFinType": "Series D rounds", "nRounds": 2, "recentFinancing": [{"type": "Series D rounds", "amount": "$365M", "date": "2025-05-15", "investors": "Undisclosed Investors"}, {"type": "Series C rounds", "amount": "$62M", "date": "2024-10-24", "investors": "New Enterprise Associates, Revolution Growth, Lightbank, Builders Vc"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pathos%20Ai", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Paxmedica Inc.", "city": "Tarrytown", "state": "NY", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "suramin (PAX-101)", "phase": "Phase III", "indication": "Trypanosome"}, {"name": "PAX-102", "phase": "Preclinical", "indication": "Autism"}], "ceo": "Howard J. Weisman", "employees": 0, "founded": 2018, "website": "https://www.paxmedica.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "PXMD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Paxmedica", "hasDealsFin": false, "diseaseGroups": ["Other", "Psychiatry / Behavioral"]}, {"company": "Pds Biotechnology Corp.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Protein / Biologic", "Vaccine"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "PDS0101", "phase": "Phase III", "indication": "Head and neck cancer"}, {"name": "PDS0102", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "PDS0103", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "PDS0104", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "PDS0201", "phase": "Preclinical", "indication": "Tuberculosis"}, {"name": "PDS0202", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "PDS0203", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "PDS0204 (Versamune-CoV-2FC)", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Frank K. Bedu-Addo, PhD", "employees": 24, "founded": 2006, "website": "http://www.pdsbiotech.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 39556048.41, "evFmt": "$40M", "ticker": "PDSB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pds%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Head & Neck Cancer", "Infectious Disease", "Skin Cancer / Melanoma"]}, {"company": "Peel Therapeutics Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Musculoskeletal"], "modalityGroups": ["Nanoparticle / Delivery", "Peptide"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "anti-inflammatory peptides", "phase": "Preclinical", "indication": "Tissue damage"}, {"name": "Neonatal NET-inhibitory factor (nNIF)", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "small molecule NPs", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.peeltx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Peel%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Pelage Pharmaceuticals Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PP405", "phase": "Phase II", "indication": "Androgenetic alopecia"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://pelagepharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pelage%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Pellepharm Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "BBP-009", "phase": "Phase III", "indication": "Basal cell carcinoma (BCC)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.pellepharm.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pellepharm", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Pelthos Therapeutics Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Xeglyze", "phase": "Approved", "indication": "Lice"}, {"name": "ASP1807", "phase": "Phase I", "indication": "Pain"}, {"name": "CT2000", "phase": "Preclinical", "indication": "Pain"}, {"name": "CT3000", "phase": "Preclinical", "indication": "Pain"}], "ceo": "Scott M. Plesha", "employees": 4, "founded": 2024, "website": "https://pelthos.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 5245864.193, "evFmt": "$5M", "ticker": "PTHS", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pelthos%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other", "Pain / Migraine"]}, {"company": "Penrose Therapeutx", "city": "Plymouth", "state": "MI", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Penrose-cancer-unknown", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://penrosetherapeutx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Penrose%20Therapeutx", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Pepgen Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "PGN-EDODM1", "phase": "Phase II", "indication": "Myotonic dystrophy type 1 (DM1)"}], "ceo": "James Gregg McArthur, PhD", "employees": 81, "founded": 2018, "website": "https://pepgen.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 18169846.67, "evFmt": "$18M", "ticker": "PEPG", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pepgen", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Pepromene Bio Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PMB-CT01", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://pepromenebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pepromene%20Bio", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Peptilogics Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "PLG0206", "phase": "Phase I", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.peptilogics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 78000000.0, "totalRaisedFmt": "$78M", "latestFinDate": "2025-10-16", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$78M", "date": "2025-10-16", "investors": "Presight Capital, Thiel Bio, Founders Fund, Amr Action Fund, Narya Capital, Beyond Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Peptilogics", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Peptivir Inc.", "city": "Aurora", "state": "CO", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PVI-1000", "phase": "Preclinical", "indication": "Influenza virus"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.peptivir.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Peptivir", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Pepvax Inc.", "city": "Bethesda", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PVX-009", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "PVX-201", "phase": "Preclinical", "indication": "Liver cancer"}, {"name": "PVX-301", "phase": "Preclinical", "indication": "Liver cancer"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.pepvax.co", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pepvax", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers"]}, {"company": "Perceive Biotherapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Perceive Biotherapeutics-Dry AMD-unknown", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}, {"name": "Perceive Biotherapeutics-glaucoma-unknown", "phase": "Preclinical", "indication": "Glaucoma"}, {"name": "Perceive Biotherapeutics-Retinitis Pigmentosa-unknown", "phase": "Preclinical", "indication": "Retinitis"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://perceivebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Perceive%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Perceive Pharma Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PBI-671", "phase": "Preclinical", "indication": "Glaucoma"}], "ceo": "", "employees": 0, "founded": 2023, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Perceive%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Perceiver Pharmaceuticals LLC", "city": "", "state": "", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Seneca Valley Virus (NTX-010", "phase": "Phase II", "indication": "Small cell lung cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Perceiver%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Perfuse Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PER-001", "phase": "Phase II", "indication": "Diabetic retinopathy"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://perfusetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Perfuse%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Periphagen Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PGN-503", "phase": "Preclinical", "indication": "Neuropathy"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://periphagen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Periphagen", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Perle Bioscience Inc.", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "PBS1104", "phase": "Phase III", "indication": "Diabetes"}, {"name": "PRL001", "phase": "Phase III", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.perlebioscience.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Perle%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Peroxitech Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary", "Renal"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PIP-2", "phase": "Preclinical", "indication": "Sepsis"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.peroxitech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Peroxitech", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Persephone Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Diagnostic", "Infectious"], "modalityGroups": ["Diagnostics", "Oncolytic / Microbiome"], "nProducts": 2, "mostAdvanced": "Development (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Persephone-COVID-19-unknown", "phase": "Research", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Persephone-COVID-19 diagnostic", "phase": "Development (diagnostic)", "indication": "Infectious, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://persephonebiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 15000000.0, "totalRaisedFmt": "$15M", "latestFinDate": "2025-04-03", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2025-04-03", "investors": "Ocampo Capital"}, {"type": "Seed financings", "amount": "$15M", "date": "2022-07-19", "investors": "First Bight Ventures, Propel Bio Partners, Y Combinator, Fifty Years, Susa Ventures, Brightedge Fund, Pioneer Fund, Zhen..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Persephone%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Perseus Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Perseus Therapeutics-anti-TSLP mAb-unknown", "phase": "Preclinical", "indication": "Alopecia areata"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.perseustherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Perseus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Persimmune Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PACTN", "phase": "Phase I", "indication": "Myelodysplastic syndrome (MDS)"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://persimmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Persimmune", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Personalis Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "NeXT Personal", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-11-28", "recentDeals": [{"headline": "Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing", "date": "2023-11-28", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Personalis", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Personalized Stem Cells Inc.", "city": "Poway", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Pulmonary"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Adipose derived mesenchymal stem cells (MSCs)", "phase": "Phase II", "indication": "Respiratory distress syndrome (RDS)"}, {"name": "Personalized-knee osteoarthritis-unknown", "phase": "Phase I/II", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://personalizedstemcells.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Personalized%20Stem%20Cells", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Respiratory / Allergy"]}, {"company": "Perspective Therapeutics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide", "Radiopharmaceutical"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Cesium Blu", "phase": "Marketed", "indication": "Brain cancer"}, {"name": "PSV359", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "VMT01", "phase": "Phase I/II", "indication": "Melanoma"}, {"name": "VMT-alpha-NET", "phase": "Phase I/II", "indication": "Neuroendocrine tumors"}], "ceo": "Johan M. Spoor, MBA", "employees": 140, "founded": 2008, "website": "https://perspectivetherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -17338250.0, "evFmt": "", "ticker": "CATX", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Perspective%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Other Solid Tumors", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Pfizer Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dermatology", "Diagnostic", "Endocrine/Metabolic", "Gastrointestinal", "Genitourinary", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Ophthalmic", "Pulmonary", "Renal", "Transplant"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Combination", "Diagnostics", "Digital / Device", "Macrocycle", "Other", "Peptide", "Protein / Biologic", "RNA Therapeutics", "Small Molecule", "Undisclosed", "Vaccine"], "nProducts": 317, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Daypro", "phase": "Marketed", "indication": "Osteoarthritis"}, {"name": "Mektovi", "phase": "Registration", "indication": "Melanoma"}, {"name": "Zyvox", "phase": "Phase IV", "indication": "Staphylococcus"}, {"name": "Abrysvo", "phase": "Marketed", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "Accupril", "phase": "Marketed", "indication": "Congestive heart failure (CHF)"}, {"name": "Accuretic", "phase": "Marketed", "indication": "Hypertension"}, {"name": "Adcetris", "phase": "Marketed", "indication": "Hodgkin disease"}, {"name": "Adenoscan", "phase": "Marketed", "indication": "Cardiovascular, Diagnostic"}], "ceo": "Albert Bourla, PhD, DVM", "employees": 0, "founded": 1849, "website": "http://www.pfizer.com", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "PFE", "exchange": "NYSE", "nDeals": 2, "totalDealValue": 1025000000.0, "totalDealFmt": "$1.0B", "latestDealDate": "2024-06-12", "recentDeals": [{"headline": "Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer", "date": "2024-06-12", "value": ""}, {"headline": "Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer", "date": "2022-01-11", "value": "$1.0B"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pfizer", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Hematologic Cancers", "Infectious Disease", "Musculoskeletal", "Respiratory / Allergy", "Skin Cancer / Melanoma"]}, {"company": "Phagenova Bio Inc.", "city": "Summit", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PNB-001", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.phagenovabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Phagenova%20Bio", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Phanes Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 8, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "peluntamig (PT217)", "phase": "Phase II", "indication": "Neuroendocrine tumors"}, {"name": "mavrostobart (PT199)", "phase": "Phase I/II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "spevatamig (PT886)", "phase": "Phase I/II", "indication": "Adenocarcinoma"}, {"name": "Phanes Therapeutics-others-unknown", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "PT586", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "PT796", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "PT950", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "PT973", "phase": "Preclinical", "indication": "Liver cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://phanesthera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2024-01-01", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2024-01-01", "investors": "Kaitai Capital (\u51ef\u6cf0\u8d44\u672c)"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Phanes%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors", "GI Cancers", "GU / Gynecologic Cancers", "Lung Cancer", "Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Pharmacyte Biotech Inc.", "city": "Las Vegas", "state": "NV", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Cell-in-a-Box", "phase": "Phase II", "indication": "Pancreatic cancer"}, {"name": "Melligen cells", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "Joshua Nathaniel Silverman", "employees": 2, "founded": 1996, "website": "http://www.pharmacytebiotech.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -6449779.96, "evFmt": "", "ticker": "PMCB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pharmacyte%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "GI Cancers"]}, {"company": "Pharmatrophix Inc.", "city": "Raleigh", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "LM11A-31-BHS", "phase": "Phase I/II", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.pharmatrophix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pharmatrophix", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Pharmazz Inc.", "city": "Willowbrook", "state": "IL", "country": "United States", "diseaseCats": ["Cardiovascular", "Diagnostic", "Inflammation", "Neurology", "Renal"], "modalityGroups": ["Other", "Peptide", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Lyfaquin", "phase": "Marketed", "indication": "Shock/trauma"}, {"name": "Tyvalzi", "phase": "Marketed", "indication": "Stroke"}, {"name": "PMZ-2123", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.pharmazz.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-03-22", "recentDeals": [{"headline": "Dr. Reddy's and Pharmazz, Inc. enter into licensing agreement to market first-in-class Centhaquine (Lyfaquin) for hypovolemic shock in India", "date": "2024-03-22", "value": ""}, {"headline": "Pharmazz Inc. and Sun Pharma enter into licensing agreement for introducing Tyvalzi (Sovateltide) in India", "date": "2023-09-14", "value": ""}], "totalRaised": 7500000.0, "totalRaisedFmt": "$8M", "latestFinDate": "2024-08-15", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$8M", "date": "2024-08-15", "investors": "Sun Pharmaceutical Industries Ltd."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pharmazz", "hasDealsFin": true, "diseaseGroups": ["Other Neurology", "Supportive / Other"]}, {"company": "Pharmos Corp.", "city": "Iselin", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Neurology"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Coaxil", "phase": "Marketed", "indication": "Depression"}, {"name": "Dextofisopam (R-tofisopam)", "phase": "Phase II", "indication": "Irritable bowel syndrome"}, {"name": "S-tofisopam", "phase": "Phase II", "indication": "Hyperuricemia/gout"}], "ceo": "Zhilong Liao", "employees": 0, "founded": 1992, "website": "http://www.pharmoscorp.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "PARS", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pharmos", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Obesity / Metabolic", "Psychiatry / Behavioral"]}, {"company": "Pharus Inc. (Pharus Diagnostics)", "city": "Los Angeles", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Development (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "OncoSweep", "phase": "Development (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "Pharus-single-cancer liquid biopsy test-unknown", "phase": "Development (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 11000000.0, "totalRaisedFmt": "$11M", "latestFinDate": "2022-07-25", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$11M", "date": "2022-07-25", "investors": "Ck Life Sciences International Inc., Ck Hutchison Holdings Ltd."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pharus%20Inc.%20(Pharus%20Diagnostics)", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Phathom Pharmaceuticals Inc.", "city": "Florham Park", "state": "NJ", "country": "United States", "diseaseCats": ["Gastrointestinal", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "voquezna (vonoprazan tablets", "phase": "Marketed", "indication": "Helicobacter"}], "ceo": "Steven L. Basta, MBA", "employees": 427, "founded": 2018, "website": "https://www.phathompharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 770675825.2, "evFmt": "$771M", "ticker": "PHAT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Phathom%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Pheast Therapeutics Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PHST001", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.pheast.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pheast%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Phio Pharmaceuticals Corp.", "city": "Marlborough", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 6, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "PH-762 (RXI-762)", "phase": "IND", "indication": "Head and neck cancer"}, {"name": "PH-790", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "PH-804 (RXI-804)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "PH-894", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Phio Pharmaceuticals-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Phio Pharmaceuticals-PD-1/CTLA-4 dual-targeting INTASYL-unknown", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "Robert J. Bitterman, Sr., MBA", "employees": 5, "founded": 2006, "website": "https://phiopharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -3964561.2, "evFmt": "", "ticker": "PHIO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Phio%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Head & Neck Cancer", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Phoenix Biotechnology Inc.", "city": "San Antonio", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PBI-05204", "phase": "Phase II", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.phoenixbiotechnology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Phoenix%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Phoenix Pharmalabs Inc.", "city": "Providence", "state": "UT", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PPL-103", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.phoenixpharmalabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Phoenix%20Pharmalabs", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Phoenix Tissue Repair Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "PTR-01 (BBP-589)", "phase": "Phase II", "indication": "Epidermolysis bullosa"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://phoenixtissuerepair.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Phoenix%20Tissue%20Repair", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Photonpharma Inc.", "city": "Fort Collins", "state": "CO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "Innocell", "phase": "IND", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://photonpharmaceuticals.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Photonpharma", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Phusis Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PHT-427", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.phusistherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Phusis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Phylex Biosciences Inc.", "city": "Del Mar", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Phylex BioSciences-COVID 19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "http://www.phylexbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Phylex%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Pillar Biosciences Inc.", "city": "Natick", "state": "MA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 15, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "oncoReveal BRCA1 & BRCA2 plus CNV Panel", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "oncoReveal Core LBx", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "oncoReveal Dx Colon Cancer Assay", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "oncoReveal Essential LBx", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "oncoReveal Essential MPN Panel", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "oncoReveal Fusion LBx", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "oncoReveal Lung and Colon Cancer Panel", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "oncoReveal MSI Panel", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.pillar-biosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-07-25", "recentDeals": [{"headline": "Illumina and Pillar Biosciences Partner to Improve Access to Personalized Cancer Treatment Options", "date": "2023-07-25", "value": ""}, {"headline": "Pillar Biosciences and KeyGene Enter into Licensing Agreement", "date": "2023-04-13", "value": ""}], "totalRaised": 34500000.0, "totalRaisedFmt": "$34M", "latestFinDate": "2025-05-27", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$34M", "date": "2025-05-27", "investors": "Illumina Inc., Soleus Capital, Existing Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pillar%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Pin Pharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PIN-2", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.pinpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pin%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Pinpoint Therapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "DQ661", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.pinpointtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pinpoint%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Pinteon Therapeutics", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PNT001", "phase": "Phase I", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.pinteon.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pinteon%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Pipr Therapeutics Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ARZC-001", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "ARZB-001", "phase": "Research", "indication": "Parkinson's disease"}, {"name": "ARZC-003", "phase": "Research", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "ARZC-005", "phase": "Research", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://piprtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 1499995.0, "totalRaisedFmt": "$1M", "latestFinDate": "2025-10-31", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$1M", "date": "2025-10-31", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pipr%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["IBD / GI Inflammatory", "Parkinson's"]}, {"company": "Pisgah Labs Inc.", "city": "Pisgah Forest", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Hydrocodone salt", "phase": "Phase I", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 1979, "website": "http://www.pisgahlabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pisgah%20Labs", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Pixarbio Corp.", "city": "Medford", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Pivotal", "hasOrphan": false, "pipeline": [{"name": "NeuroRelease", "phase": "Pivotal", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://pixarbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pixarbio", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Placon Therapeutics", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BTP-114", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Placon%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Plakous Therapeutics Inc.", "city": "Winston Salem", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Gastrointestinal"], "modalityGroups": ["Cell Therapy", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Exam", "phase": "Preclinical", "indication": "Wounds"}, {"name": "Protego-PD", "phase": "Preclinical", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://plakoustherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Plakous%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Musculoskeletal"]}, {"company": "Planet Biotechnology Inc.", "city": "Hayward", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ACE2-Fc", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "CaroRx SIgA", "phase": "Phase II", "indication": "Streptococcus"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.planetbiotechnology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Planet%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Plantacor Inc.", "city": "College Station", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CDIM-9", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.plantacor.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Plantacor", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Pleopharma Inc.", "city": "Phoenixville", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PP-01", "phase": "Phase II", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.pleopharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pleopharma", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Plexcera Therapeutics LLC", "city": "Vero Beach", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Recombinant human acid ceramidase (rhAC)", "phase": "Preclinical", "indication": "Lipodystrophy"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.plexcera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Plexcera%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Plexium Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PLX-4545", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "PLX-61639", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Plexium-CDK2-unknown", "phase": "Research", "indication": "Breast cancer"}, {"name": "Plexium-CRAF-unknown", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.plexium.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 500000000.0, "totalDealFmt": "$500M", "latestDealDate": "2022-04-28", "recentDeals": [{"headline": "Abbvie and Plexium enter into multi-target strategic collaboration to develop and commercialize targeted protein degradation therapies for neurological conditions", "date": "2022-04-28", "value": ""}, {"headline": "Amgen and Plexium announce multi-year, drug discovery collaboration to identify novel targeted protein degradation therapies", "date": "2022-02-03", "value": "$500M"}], "totalRaised": 162115703.0, "totalRaisedFmt": "$162M", "latestFinDate": "2025-07-14", "latestFinType": "Series C rounds", "nRounds": 2, "recentFinancing": [{"type": "Series C rounds", "amount": "$60M", "date": "2025-07-14", "investors": "Undisclosed Investors"}, {"type": "Series B rounds", "amount": "$102M", "date": "2022-02-23", "investors": "Bvf Partners L.P., Tcg Crossover, Softbank Vision Fund 2, Ra Capital Management L.P., Surveyor Capital, Pappas Capital L..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Plexium", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Pliant Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Hepatic", "Musculoskeletal", "Pulmonary"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "bexotegrast (PLN-74809)", "phase": "Phase II", "indication": "Primary sclerosing cholangitis"}, {"name": "PLN-1474", "phase": "Phase I", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "PLN-101095", "phase": "IND", "indication": "Solid tumors"}, {"name": "Integrin alpha(V)beta(6) inhibitor", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}, {"name": "PLN-101325", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "Bernard Coulie, MD, PhD", "employees": 171, "founded": 2016, "website": "http://www.pliantrx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 501761875.63, "evFmt": "$502M", "ticker": "PLRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pliant%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Neurodegeneration / NMD", "Obesity / Metabolic", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Plus Therapeutics Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Rhenium (186Re) obisbemeda", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "DocePlus", "phase": "Phase I", "indication": "Small cell lung cancer"}], "ceo": "Marc H. Hedrick, MD, MBA", "employees": 21, "founded": 1996, "website": "http://www.plustherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 8616890.1, "evFmt": "$9M", "ticker": "PSTV", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Plus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Lung Cancer"]}, {"company": "Pmv Pharmaceuticals Inc.", "city": "Cranbury", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "PC14586", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "David H. Mack, PhD", "employees": 47, "founded": 2013, "website": "http://www.pmvpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -90380001.43, "evFmt": "", "ticker": "PMVP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pmv%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Pnp Therapeutics Inc.", "city": "Birmingham", "state": "AL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "Gedeptin (AD/PNP-FaraAMP)", "phase": "Phase I", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.pnptherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pnp%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer"]}, {"company": "Polaryx Therapeutics Inc.", "city": "Paramus", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "PLX-200", "phase": "Phase III", "indication": "Neuronal ceroid lipofuscinosis"}, {"name": "PLX-100", "phase": "Preclinical", "indication": "Glycosphingolipid storage disorders"}, {"name": "PLX-300", "phase": "Preclinical", "indication": "Glycosphingolipid storage disorders"}], "ceo": "Alex Yang", "employees": 0, "founded": 2014, "website": "https://www.polaryx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "PLYX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Polaryx%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Polycore Therapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PCT-3012", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.polycoretherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Polycore%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "Ponce Therapeutics Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Dermatology", "Endocrine/Metabolic", "Ophthalmic"], "modalityGroups": ["Gene Therapy", "Peptide", "Undisclosed"], "nProducts": 7, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Ponce Therapeutics-p16 and/or UPAR-unknown", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "PTC-1102", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "PTC-2101", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "PTC-2105", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "PTC-3101", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}, {"name": "PTC-3102", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}, {"name": "PTC-3103", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://poncetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ponce%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Obesity / Metabolic"]}, {"company": "Pop Therapeutics PBC", "city": "Huntsville", "state": "AL", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Undisclosed"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CFD-110", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "PBD-407", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.poptherapeutics.org/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pop%20Therapeutics%20PBC", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Infectious Disease"]}, {"company": "Postera Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "COVID Moonshot", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://postera.ai/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 24000000.0, "totalRaisedFmt": "$24M", "latestFinDate": "2022-01-11", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$24M", "date": "2022-01-11", "investors": "Clermont Group, Breyer Capital, Lifeforce Capital, I2bf Global Ventures, Metaplanet Holdings LLC, Hof Capital, Ace & Co...."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Postera", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Potentia Pharmaceuticals Inc.", "city": "Louisville", "state": "KY", "country": "United States", "diseaseCats": ["Ophthalmic", "Pulmonary"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Compstatin (APL-1", "phase": "Phase I", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.potentiapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Potentia%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Praetego Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PTG-630", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.praetego.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Praetego", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Pragma Pharmaceuticals LLC", "city": "Locust Valley", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Keflex", "phase": "Marketed", "indication": "Skin and skin structure infection (SSSI)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pragma%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Praxis Bioresearch LLC", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PRX-P4-003", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.praxisbioresearch.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Praxis%20Bioresearch", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Praxis Precision Medicines Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["RNA Therapeutics", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Ulixacaltamide (PRAX-944", "phase": "Phase III", "indication": "Essential tremor"}, {"name": "PRAX-562", "phase": "Phase II", "indication": "Epilepsy"}, {"name": "PRAX-628", "phase": "Phase II", "indication": "Epilepsy"}, {"name": "elsunersen (PRAX-222)", "phase": "Phase I/II", "indication": "Epilepsy"}, {"name": "PRAX-020", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "PRAX-090", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "PRAX-100", "phase": "Preclinical", "indication": "Epilepsy"}], "ceo": "Marcio Souza, MBA", "employees": 116, "founded": 2015, "website": "https://praxismedicines.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 986908866.24, "evFmt": "$987M", "ticker": "PRAX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Praxis%20Precision%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other"]}, {"company": "Precigen Inc.", "city": "Germantown", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Endocrine/Metabolic", "Infectious", "Inflammation"], "modalityGroups": ["Cell Therapy", "Gene Therapy", "Other", "Protein / Biologic"], "nProducts": 18, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Papzimeos", "phase": "Approved", "indication": "Human papillomavirus (HPV)"}, {"name": "ActoBiotic for Type I diabetes (AG019)", "phase": "Phase II", "indication": "Diabetes"}, {"name": "Endometrial Regenerative Cells (ERCs) (ERC-124)", "phase": "Phase II", "indication": "Heart failure"}, {"name": "PRGN-2009", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "AG014", "phase": "Phase I", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "INXN-4001", "phase": "Phase I", "indication": "Heart failure"}, {"name": "PRGN-3005", "phase": "Phase I", "indication": "Ovarian cancer"}, {"name": "PRGN-3006", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "Helen Sabzevari, PhD", "employees": 143, "founded": 1998, "website": "https://precigen.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 235664717.12, "evFmt": "$236M", "ticker": "PGEN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Precigen", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "GU / Gynecologic Cancers", "Hematologic Cancers", "IBD / GI Inflammatory", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Precisio Biotix Therapeutics Inc.", "city": "Dover", "state": "DE", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NJ-01-SS", "phase": "Preclinical", "indication": "Burns"}, {"name": "NJ-03-BM", "phase": "Preclinical", "indication": "Dermal ulcers"}, {"name": "NJ-06-FC", "phase": "Preclinical", "indication": "Acne"}, {"name": "WH-01-SZ", "phase": "Preclinical", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.precisiobiotix.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Precisio%20Biotix%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Supportive / Other"]}, {"company": "Precision Biologics Inc.", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Ensituximab (NEO-102", "phase": "Phase III", "indication": "Colorectal cancer"}, {"name": "NEO-201", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.precision-biologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Precision%20Biologics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Precision Biosciences Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Hematology", "Hepatic", "Infectious", "Musculoskeletal"], "modalityGroups": ["Cell Therapy", "Gene Therapy", "Protein / Biologic"], "nProducts": 14, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "azercabtagene zapreleucel (azer-cel", "phase": "Phase I/II", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "PBCAR269A", "phase": "Phase I/II", "indication": "Multiple myeloma (MM)"}, {"name": "PBCAR19B", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "PBGENE-DMD", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "PBGENE-HAO1", "phase": "Preclinical", "indication": "Hyperoxaluria"}, {"name": "PBGENE-HbE", "phase": "Preclinical", "indication": "Sickle cell disease"}, {"name": "PBGENE-HBV", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "PBGENE-Hepatitis B", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}], "ceo": "Michael Amoroso, EMBA", "employees": 108, "founded": 2005, "website": "http://www.precisionbiosciences.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -30039299.09, "evFmt": "", "ticker": "DTIL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Precision%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Hematology (non-cancer)", "Kidney Disease", "Liver Disease", "Neurodegeneration / NMD"]}, {"company": "Prelude Corp.", "city": "Laguna Hills", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "DCISionRT", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 20000000.0, "totalRaisedFmt": "$20M", "latestFinDate": "2022-03-22", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$20M", "date": "2022-03-22", "investors": "Evidity Health Capital, Existing Investors, New Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prelude", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Prelude Therapeutics Inc.", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "P-500 (PRT811)", "phase": "Phase I", "indication": "Brain cancer"}, {"name": "PRT3789 (PRT-SCA2)", "phase": "Phase II", "indication": "Cancer (unspecified)"}, {"name": "PRT1419", "phase": "Phase I", "indication": "Hematologic malignancies"}, {"name": "PRT2527", "phase": "Phase I", "indication": "Hematologic malignancies"}, {"name": "PRT3645", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "JAK2V617F", "phase": "Preclinical", "indication": "Myeloproliferative disorder"}, {"name": "PRD2527", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Krishna Vaddi, PhD", "employees": 131, "founded": 2016, "website": "http://www.preludetx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -18936554.0, "evFmt": "", "ticker": "PRLD", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-08-15", "recentDeals": [{"headline": "Pathos announced today the world-wide license of PRT811 from Prelude Therapeutics", "date": "2024-08-15", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prelude%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Prenosis Inc.", "city": "Champaign", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Sepsis ImmunoScore", "phase": "Market (diagnostic)", "indication": "Infectious, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-04-10", "recentDeals": [{"headline": "Prenosis Announces Commercial Distribution Collaboration with Roche for Sepsis ImmunoScore", "date": "2024-04-10", "value": ""}], "totalRaised": 20000000.0, "totalRaisedFmt": "$20M", "latestFinDate": "2026-01-29", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$20M", "date": "2026-01-29", "investors": "Pace Healthcare Capital, Uc Investments, Labcorp Venture Fund, Global Health Investment Corporation"}, {"type": "Uncategorized venture rounds", "amount": "", "date": "2022-03-09", "investors": "Pace Healthcare Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prenosis", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Prescient Medicine Holdings Inc.", "city": "Hummelstown", "state": "PA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "INFINITI CYP2C19 Assay", "phase": "Marketed", "indication": "Genetic disorders, Diagnostic"}, {"name": "INFINITI Factor II Assay", "phase": "Marketed", "indication": "Hematology, Diagnostic"}, {"name": "INFINITI Factor II-V Leiden Panel Assay", "phase": "Marketed", "indication": "Hematology, Diagnostic"}, {"name": "INFINITI Factor V Leiden Assay", "phase": "Marketed", "indication": "Hematology, Diagnostic"}, {"name": "INFINITI Warfarin Assay", "phase": "Marketed", "indication": "Cardiovascular, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.prescientmedicine.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prescient%20Medicine%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Hematology (non-cancer)", "Rare / Genetic"]}, {"company": "Presidio Pharmaceuticals Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Asclevir", "phase": "Marketed", "indication": "Hepatitis C virus (HCV)"}, {"name": "PPI-383", "phase": "Phase I", "indication": "Hepatitis C virus (HCV)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.presidiopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Presidio%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Pretzel Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PX578", "phase": "Phase I", "indication": "Mitochondrial disease"}, {"name": "Pretzel Therapeutics-POLRMT-unknown", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "Pretzel Therapeutics-SAMHD1-unknown", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.pretzeltx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pretzel%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Rare / Genetic"]}, {"company": "Prevacus Inc.", "city": "Tallahassee", "state": "FL", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Prevasol (PRV-001)", "phase": "Preclinical", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://prevacus.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prevacus", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Prime Medicine Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "PM359", "phase": "Phase I/II", "indication": "Chronic granulomatous disease (CGD)"}], "ceo": "Allan Jacob Reine, MD", "employees": 214, "founded": 2019, "website": "https://primemedicine.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 196665112.52, "evFmt": "$197M", "ticker": "PRME", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prime%20Medicine", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Primevax Immuno-oncology Inc.", "city": "Orange", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PV-001", "phase": "Phase I", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.primevax.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Primevax%20Immuno-oncology", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma"]}, {"company": "Primmune Therapeutics Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PRTX007", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.primmunerx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Primmune%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Privo Technologies Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Gastrointestinal"], "modalityGroups": ["Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PRV111", "phase": "Phase II", "indication": "Cancer (unspecified)"}, {"name": "PRV211", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "PRV411", "phase": "Preclinical", "indication": "Gastrointestinal (GI) dysfunction"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.privotechnologies.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Privo%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Other", "Solid Tumors (General)"]}, {"company": "Prizm LLC", "city": "Chandler", "state": "AZ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "diiodothyropropionic acid (SRW101", "phase": "Preclinical", "indication": "Allan-Herndon-Dudley syndrome"}], "ceo": "", "employees": 0, "founded": 2020, "website": "http://www.prizmtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prizm", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Proacta Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PR509", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.proacta.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Proacta", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Procertus Biopharm Inc.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Dermatology", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "DermX", "phase": "Phase I/II", "indication": "Dermatitis"}, {"name": "OralX", "phase": "Phase I/II", "indication": "Mucositis"}, {"name": "ProDermaCel", "phase": "Phase I/II", "indication": "Other alopecia"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.procertus.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Procertus%20Biopharm", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Supportive / Other"]}, {"company": "Proclara Biosciences Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "NPT088", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "NPT189", "phase": "Phase I", "indication": "Amyloidosis"}, {"name": "NPT289", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.proclarabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Proclara%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Supportive / Other"]}, {"company": "Projenx Inc.", "city": "Nissequogue", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "prosetin (PRO-101)", "phase": "Phase I", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://projenx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Projenx", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Prokidney Corp.", "city": "Winston-Salem", "state": "NC", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Renal"], "modalityGroups": ["Cell Therapy", "Other"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "REACT (Renal Autologous Cell Therapy)/DKD", "phase": "Phase III", "indication": "Renal damage"}, {"name": "Neo-Kidney Augment (NKA)", "phase": "Phase II", "indication": "Diabetes"}, {"name": "REACT (Renal Autologous Cell Therapy)/ CAKUT", "phase": "Phase II", "indication": "Metabolic (unspecified)"}, {"name": "REACT (Renal Autologous Cell Therapy)/ Gen", "phase": "Preclinical", "indication": "Renal (unspecified)"}], "ceo": "Bruce Culleton, MD, MBA", "employees": 204, "founded": 2015, "website": "http://www.prokidney.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1207013366.17, "evFmt": "$1.2B", "ticker": "PROK", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prokidney", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Kidney Disease", "Obesity / Metabolic"]}, {"company": "Prolifagen LLC", "city": "Villanova", "state": "PA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Mir302", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://prolifagen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prolifagen", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Prolong Pharmaceuticals LLC", "city": "South Plainfield", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Hematology"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "EPEG", "phase": "Phase I", "indication": "Anemia"}, {"name": "ANF-Rho", "phase": "Phase II", "indication": "Neutropenia"}, {"name": "PP-007 (Sanguinate)", "phase": "Phase II", "indication": "Sickle cell disease"}, {"name": "PP-403", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.prolongpharmaceuticals.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prolong%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Solid Tumors (General)"]}, {"company": "Prolynx Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "PLX038 (PL0264", "phase": "Phase I/II", "indication": "Lung cancer"}], "ceo": "", "employees": 0, "founded": 2009, "website": "https://prolynxinc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Prolynx", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Promentis Pharmaceuticals Inc.", "city": "Milwaukee", "state": "WI", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SXC-2023", "phase": "Phase I", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.promentispharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Promentis%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Promontory Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "PT-112", "phase": "Phase II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://promontorytx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Promontory%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Proneurogen Inc.", "city": "Tucson", "state": "AZ", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation", "Neurology", "Renal"], "modalityGroups": ["Peptide"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PNA1", "phase": "Phase II", "indication": "Cognitive dysfunction"}, {"name": "PNA5", "phase": "Preclinical", "indication": "Shock/trauma"}, {"name": "PNA6", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.proneurogen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Proneurogen", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "MS / Neuroimmune", "Supportive / Other"]}, {"company": "Protagenic Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Genitourinary", "Inflammation", "Neurology"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PT00114", "phase": "Phase I", "indication": "Anxiety"}, {"name": "PHYX-001", "phase": "Preclinical", "indication": "Epilepsy"}, {"name": "PHYX-002", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "PHYX-003", "phase": "Preclinical", "indication": "Obesity"}, {"name": "PHYX-004", "phase": "Preclinical", "indication": "Cystitis"}, {"name": "PHYX-005", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "Barrett Evans", "employees": 3, "founded": 2024, "website": "https://protagenic.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 562507.97, "evFmt": "$563K", "ticker": "PTIX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Protagenic%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Epilepsy / Seizures", "Obesity / Metabolic", "Other", "Other Inflammation", "Psychiatry / Behavioral"]}, {"company": "Protagonist Therapeutics Inc.", "city": "Newark", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Hematology"], "modalityGroups": ["Peptide"], "nProducts": 4, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "icotrokinra (PN-235", "phase": "Registration", "indication": "Psoriasis"}, {"name": "rusfertide (PTG-300", "phase": "Phase III", "indication": "Myeloproliferative disorder"}, {"name": "PN-943", "phase": "Phase II", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "PTG-200 (JNJ-67864238", "phase": "Phase II", "indication": "Crohn's disease"}], "ceo": "Dinesh V. Patel, PhD", "employees": 126, "founded": 2007, "website": "http://www.protagonist-inc.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2103953069.2, "evFmt": "$2.1B", "ticker": "PTGX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Protagonist%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Hematologic Cancers", "IBD / GI Inflammatory"]}, {"company": "Protara Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Inflammation"], "modalityGroups": ["Cell Therapy", "Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "IV choline chloride", "phase": "Phase II", "indication": "Metabolic (unspecified)"}, {"name": "TARA-002", "phase": "Phase II", "indication": "Inflammation (unspecified)"}], "ceo": "Jesse Shefferman, MBA", "employees": 33, "founded": 2017, "website": "http://www.protaratx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -57078767.84, "evFmt": "", "ticker": "TARA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Protara%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Other Inflammation"]}, {"company": "Proteotech Inc.", "city": "Kirkland", "state": "WA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Synuclere (PD-61-W3)", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "Systebryl (PTI-110)", "phase": "Preclinical", "indication": "Amyloidosis"}], "ceo": "", "employees": 0, "founded": 1996, "website": "http://www.proteotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Proteotech", "hasDealsFin": false, "diseaseGroups": ["Parkinson's", "Supportive / Other"]}, {"company": "Proteothera Inc.", "city": "Newton", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MB-IL1RA (PRT-1000)", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.proteothera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Proteothera", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Protokinetix Inc.", "city": "Marietta", "state": "OH", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Inflammation", "Transplant"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "AAGP (PKX-001)", "phase": "Phase I", "indication": "Diabetes"}], "ceo": "Michael Richard Guzzetta, MBA, CPA", "employees": 0, "founded": 2002, "website": "http://www.protokinetix.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 3590276.3, "evFmt": "$4M", "ticker": "PKTX", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Protokinetix", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Provasculon Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PRV-0023", "phase": "Preclinical", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.provasculon.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Provasculon", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Provectus Biopharmaceuticals Inc.", "city": "Knoxville", "state": "TN", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Provecta (PV-10)", "phase": "Phase III", "indication": "Melanoma"}, {"name": "Rose bengal (RB-PDAT)", "phase": "Phase III", "indication": "Ophthalmic (unspecified)"}, {"name": "PH-10", "phase": "Phase II", "indication": "Psoriasis"}], "ceo": "Edward V. Pershing, CPA", "employees": 6, "founded": 2002, "website": "http://www.pvct.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 53118394.0859, "evFmt": "$53M", "ticker": "PVCT", "exchange": "OTCQB", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-03-27", "recentDeals": [{"headline": "Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium", "date": "2024-03-27", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Provectus%20Biopharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Ophthalmology", "Skin Cancer / Melanoma"]}, {"company": "Psilera Inc.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PSIL-006", "phase": "Preclinical", "indication": "Frontotemporal dementia"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://www.psilera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Psilera", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Psycheceutical Inc.", "city": "Fort Lauderdale", "state": "FL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NeuroDirect", "phase": "Preclinical", "indication": "Post-traumatic stress disorder"}], "ceo": "Neilank K. Jha, MD, MBA", "employees": 0, "founded": 2020, "website": "https://psycheceutical.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "BWVI", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Psycheceutical", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Ptc Therapeutics Inc.", "city": "South Plainfield", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Gastrointestinal", "Infectious", "Musculoskeletal", "Neurology", "Ophthalmic", "Pulmonary"], "modalityGroups": ["Gene Therapy", "Other", "Small Molecule"], "nProducts": 11, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Emflaza", "phase": "Marketed", "indication": "Muscular dystrophy"}, {"name": "Evrysdi", "phase": "Marketed", "indication": "Spinal muscular atrophy (SMA)"}, {"name": "Kebilidi", "phase": "Marketed", "indication": "Central nervous system (CNS) disorders"}, {"name": "Translarna", "phase": "Marketed", "indication": "Muscular dystrophy"}, {"name": "Alpha-tocotrienol quinone", "phase": "Registration", "indication": "Friedreich ataxia"}, {"name": "Sephience", "phase": "Registration", "indication": "Phenylketonuria"}, {"name": "PTC299", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "votoplam (HTT227", "phase": "Phase II", "indication": "Huntington disease (HD)"}], "ceo": "Matthew B. Klein, MD", "employees": 939, "founded": 1998, "website": "http://www.ptcbio.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2718385782.7, "evFmt": "$2.7B", "ticker": "PTCT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ptc%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Infectious Disease", "Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Pulmatrix Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Pulmazole (PUR1900", "phase": "Phase II", "indication": "Fungal infection"}, {"name": "PUR1800", "phase": "Phase I", "indication": "Lung cancer"}, {"name": "PUR3100", "phase": "Preclinical", "indication": "Migraine"}], "ceo": "Peter B. Ludlum, MBA", "employees": 2, "founded": 2003, "website": "http://www.pulmatrix.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 15971949.3, "evFmt": "$16M", "ticker": "PULM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pulmatrix", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Lung Cancer", "Pain / Migraine"]}, {"company": "Pulmotect Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PUL-042", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.pulmotect.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pulmotect", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Purdue Pharma L.P.", "city": "Stamford", "state": "CT", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 10, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "BTDS", "phase": "Marketed", "indication": "Pain"}, {"name": "OxyContin", "phase": "Marketed", "indication": "Pain"}, {"name": "OxyNEO (Brand)", "phase": "Marketed", "indication": "Pain"}, {"name": "Dilaudid", "phase": "Marketed", "indication": "Pain"}, {"name": "Foquest", "phase": "Marketed", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "Hydrocodone bitartrate ER", "phase": "Marketed", "indication": "Pain"}, {"name": "MS Contin", "phase": "Marketed", "indication": "Pain"}, {"name": "Palladone", "phase": "Marketed", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 1952, "website": "http://www.purduepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Purdue%20Pharma%20L.P.", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Puretech Health plc", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Genitourinary"], "modalityGroups": ["Antibody", "Other", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "LYT-200", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "ALV-306", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "LYT-210", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "LYT-500 (ALV-304)", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "LYT-503/IMB-150 (ALV-107)", "phase": "Preclinical", "indication": "Cystitis"}], "ceo": "Robert William Henry Lyne", "employees": 0, "founded": 2001, "website": "http://www.puretechhealth.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 128732536.313168, "evFmt": "$129M", "ticker": "PRTC", "exchange": "LSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Puretech%20Health", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "IBD / GI Inflammatory", "Other", "Solid Tumors (General)"]}, {"company": "Purpose Bio Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PB-001", "phase": "Preclinical", "indication": "Hyperlipidemia"}, {"name": "PB-002", "phase": "Preclinical", "indication": "Liver disease"}, {"name": "PB-003", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.purposebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Purpose%20Bio", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Obesity / Metabolic", "Other"]}, {"company": "Pxradia Inc.", "city": "Savannah", "state": "GA", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "2A2", "phase": "Preclinical", "indication": "Gastrointestinal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.pxradia.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pxradia", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Pylum Biosciences Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Avidocin proteins", "phase": "Preclinical", "indication": "Clostridium"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.pylumbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pylum%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Pyxis Oncology Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Inflammation", "Ophthalmic"], "modalityGroups": ["Antibody", "Cell Therapy", "Undisclosed"], "nProducts": 10, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "sevacizumab", "phase": "Phase III", "indication": "Ovarian cancer"}, {"name": "APX001", "phase": "Phase II", "indication": "Rheumatoid arthritis (RA)"}, {"name": "sotigalimab (APX005M)", "phase": "Phase II", "indication": "Esophageal cancer"}, {"name": "APX002", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}, {"name": "APX201", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "APX601", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "APX701", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "APX800", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Thomas Civik, MBA", "employees": 44, "founded": 2019, "website": "https://www.pyxisoncology.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -17027606.6, "evFmt": "", "ticker": "PYXS", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 232500000.0, "totalDealFmt": "$232M", "latestDealDate": "2022-03-29", "recentDeals": [{"headline": "Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology", "date": "2022-03-29", "value": "$232M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Pyxis%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "GI Cancers", "GU / Gynecologic Cancers", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Q Biomed Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Metastron", "phase": "Marketed", "indication": "Pain"}, {"name": "Q Biomed-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "QBM-001", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Uttroside B", "phase": "Preclinical", "indication": "Liver cancer"}], "ceo": "Denis D. Corin", "employees": 0, "founded": 2013, "website": "http://qbiomed.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "QBIO", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Q%20Biomed", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Infectious Disease", "Other Neurology", "Pain / Migraine"]}, {"company": "Q Therapeutics Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": true, "pipeline": [{"name": "Q-Cells", "phase": "IND", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.qthera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Q%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Q32 Bio Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Renal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ADX-097", "phase": "Phase II", "indication": "Lupus"}], "ceo": "Jodie P. Morrison", "employees": 42, "founded": 2018, "website": "https://www.q32bio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -25841525.76, "evFmt": "", "ticker": "QTTB", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 604000000.0, "totalDealFmt": "$604M", "latestDealDate": "2025-12-01", "recentDeals": [{"headline": "Q32 Bio Sells Complement Inhibitor ADX-097", "date": "2025-12-01", "value": "$604M"}, {"headline": "Q32 Bio and Horizon Therapeutics announce collaboration in autoimmune diseases", "date": "2022-08-15", "value": ""}], "totalRaised": 42000000.0, "totalRaisedFmt": "$42M", "latestFinDate": "2024-03-24", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$42M", "date": "2024-03-24", "investors": "Orbimed Advisors LLC, Atlas Venture, Abingworth Management Ltd., Bristol Myers Squibb Co., Acorn Bioventures L.P., Osage..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Q32%20Bio", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Qilu Puget Sound Biotherapeutics Corp. (Sound Biologics)", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PSB205", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.soundbiologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Qilu%20Puget%20Sound%20Biotherapeutics%20Corp.%20(Sound%20Biologics)", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Qinotto Inc.", "city": "Hillsborough", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "C381", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.qinotto.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Qinotto", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Qlaris Bio Inc.", "city": "Wellesley", "state": "MA", "country": "United States", "diseaseCats": ["Neurology", "Ophthalmic"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "QLS-101", "phase": "Phase II", "indication": "Glaucoma"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://qlaris.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Qlaris%20Bio", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Qnovia Inc.", "city": "Richmond", "state": "", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Inflammation", "Neurology", "Pulmonary"], "modalityGroups": ["Digital / Device", "Peptide"], "nProducts": 7, "mostAdvanced": "Market (device)", "hasOrphan": false, "pipeline": [{"name": "RespiRx", "phase": "Market (device)", "indication": "Cancer (unspecified)"}, {"name": "QN-01", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "QN-02", "phase": "Preclinical", "indication": "Asthma"}, {"name": "QN-03", "phase": "Preclinical", "indication": "Pain"}, {"name": "QN-04", "phase": "Preclinical", "indication": "Anxiety"}, {"name": "QN-05", "phase": "Preclinical", "indication": "Pneumonia"}, {"name": "QN-06", "phase": "Preclinical", "indication": "Anthrax"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 17000000.0, "totalRaisedFmt": "$17M", "latestFinDate": "2022-09-28", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$17M", "date": "2022-09-28", "investors": "Blue Ledge Capital, Dg Ventures, Evolution Vc Partners, Gaingels, Tl Capital, Vice Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Qnovia", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease", "Pain / Migraine", "Psychiatry / Behavioral", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Qol Medical LLC", "city": "Vero Beach", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Gimoti", "phase": "Marketed", "indication": "Gastroparesis"}, {"name": "Nascobal", "phase": "Marketed", "indication": "Vitamin B-12 deficiency"}, {"name": "Sucraid", "phase": "Marketed", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.qolmed.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Qol%20Medical", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Other", "Other Specialties"]}, {"company": "Quadriga Biosciences Inc.", "city": "Los Altos", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "QBS72S", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.quadrigabiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Quadriga%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Quanta Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "QTX3034", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "QTX3046", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "QTX3544", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Quanta Therapeutics-RAF1-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.quantatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Quanta%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Quatrx Pharmaceuticals Co.", "city": "Ann Arbor", "state": "MI", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Osphena", "phase": "Marketed", "indication": "Menopause"}, {"name": "Asord", "phase": "Phase II", "indication": "Psoriasis"}, {"name": "Sobetirome (qrx-431)", "phase": "Phase I", "indication": "Dyslipidemia"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.quatrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Quatrx%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Obesity / Metabolic", "Women's Health"]}, {"company": "Que Oncology Inc.", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Q-122", "phase": "Phase II", "indication": "Menopause"}, {"name": "Q-102", "phase": "Preclinical", "indication": "Prostate cancer"}, {"name": "Q-201", "phase": "Preclinical", "indication": "Neuropathy"}, {"name": "Q-202", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "Q-203", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}, {"name": "Q-204", "phase": "Preclinical", "indication": "Melanoma"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://queoncology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Que%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Hematologic Cancers", "Pain / Migraine", "Skin Cancer / Melanoma", "Women's Health"]}, {"company": "Quince Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Dental", "Endocrine/Metabolic", "Infectious", "Musculoskeletal", "Neurology"], "modalityGroups": ["Other", "Peptide", "Protein / Biologic", "Small Molecule"], "nProducts": 10, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "EryDex", "phase": "Phase III", "indication": "Ataxia"}, {"name": "atuzaginstat (COR388)", "phase": "Phase II/III", "indication": "Alzheimer's disease"}, {"name": "COR588", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "COR803", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "COR852", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "Ery-CoCe", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "Ery-GAMT", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "Ery-PAL", "phase": "Preclinical", "indication": "Phenylketonuria"}], "ceo": "Dirk Thye, MD", "employees": 36, "founded": 2012, "website": "https://quincetx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 54927443.03, "evFmt": "$55M", "ticker": "QNCX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Quince%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Infectious Disease", "Neurodegeneration / NMD", "Obesity / Metabolic", "Psychiatry / Behavioral", "Rare / Genetic"]}, {"company": "Quintessence Biosciences Inc.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "QBI-139", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.quintbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Quintessence%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Quoin Pharmaceuticals Ltd.", "city": "Ashburn", "state": "VA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Transplant"], "modalityGroups": ["Cell Therapy", "Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "QRX-003", "phase": "Phase II/III", "indication": "Netherton syndrome"}, {"name": "ApoGraft", "phase": "Phase I", "indication": "Graft-versus-host disease (GvHD)"}, {"name": "QRX-004", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}, {"name": "QRX-006", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}, {"name": "QRX-007", "phase": "Preclinical", "indication": "Netherton syndrome"}, {"name": "QRX-008", "phase": "Preclinical", "indication": "Scleroderma"}], "ceo": "Michael Myers, PhD", "employees": 5, "founded": 2018, "website": "http://quoinpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -11005922.31662, "evFmt": "", "ticker": "QNRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Quoin%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology"]}, {"company": "Quralis Corp.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["RNA Therapeutics", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "QRL-101 (QRA-244)", "phase": "Phase I", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "QRL-201", "phase": "Phase I", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "QRL-204", "phase": "Phase I", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "ARL-TBA-Fragile-X", "phase": "Preclinical", "indication": "Fragile X syndrome"}, {"name": "ARL-TBA-PSP", "phase": "Preclinical", "indication": "Progressive supranuclear palsy (PSP)"}, {"name": "QRL-203", "phase": "Preclinical", "indication": "Frontotemporal dementia"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://quralis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-05-15", "recentDeals": [{"headline": "QurAlis Announces Exclusive License with UMass Chan Medical School on Novel Mechanism for Fragile X Syndrome (FXS) to Enable Development of First Potential Disease-Modifying Therapy", "date": "2025-05-15", "value": ""}], "totalRaised": 88000000.0, "totalRaisedFmt": "$88M", "latestFinDate": "2023-03-09", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$88M", "date": "2023-03-09", "investors": "Eqt Life Sciences, Lsp Dementia Fund, Sanofi Ventures, Droia Oncology Ventures, Als Investment Fund, Ls Polaris Innovati..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Quralis", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD", "Other"]}, {"company": "Qx Therapeutics Inc.", "city": "Branford", "state": "CT", "country": "United States", "diseaseCats": ["Pulmonary", "Transplant"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "QXT-101", "phase": "Phase II", "indication": "Acute lung injury"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.qxtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Qx%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Radiomedix Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic", "Renal"], "modalityGroups": ["Diagnostics", "Peptide", "Protein / Biologic", "Radiopharmaceutical", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "203Pb-AR-RMX", "phase": "Phase II", "indication": "Neuroendocrine tumors"}, {"name": "AminoMedix", "phase": "Phase I/II", "indication": "Renal damage"}, {"name": "RMX-PSMA", "phase": "Phase I", "indication": "Cancer, Diagnostic"}, {"name": "GlucoMedix", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "RMX-GPC3", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "RMX-VH-GBM", "phase": "Preclinical", "indication": "Radiologic imaging"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.radiomedix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 40000000.0, "totalRaisedFmt": "$40M", "latestFinDate": "2022-10-07", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$40M", "date": "2022-10-07", "investors": "Portland Investment Counsel"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Radiomedix", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "Kidney Disease", "Other Solid Tumors", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Radionetics Oncology Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Development (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Ga-R8760", "phase": "Development (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://radionetics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 52500000.0, "totalRaisedFmt": "$52M", "latestFinDate": "2023-08-01", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$52M", "date": "2023-08-01", "investors": "Frazier Life Sciences, 5am Ventures, Dcvc Bio, Crinetics Pharmaceuticals Inc., Gordonmd Global Investments L.P."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Radionetics%20Oncology", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Radiopharm Ventures LLC", "city": "", "state": "", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Radiopharm Ventures-B7-H3(CD276)-unknown", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2022, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Radiopharm%20Ventures", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Rafael Holdings Inc.", "city": "Newark", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Gastrointestinal", "Neurology"], "modalityGroups": ["Macrocycle", "Peptide", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Trappsol Cyclo (HP-beta-CD", "phase": "Phase III", "indication": "Glycosphingolipid storage disorders"}, {"name": "AMT-101", "phase": "Phase II", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "AMT-126", "phase": "Phase I", "indication": "Gastrointestinal (unspecified)"}, {"name": "AMT-gastrointestinal-unknown", "phase": "Preclinical", "indication": "Gastrointestinal (unspecified)"}, {"name": "AMT-metabolism-unknown", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "Howard S. Jonas", "employees": 23, "founded": 2017, "website": "https://rafaelholdings.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1626553.49, "evFmt": "$2M", "ticker": "RFL", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rafael%20Holdings", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Obesity / Metabolic", "Other", "Rare / Genetic"]}, {"company": "Rakuten Medical Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Antibody", "Other"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "ASP-1929 (RM-1929)", "phase": "Marketed", "indication": "Head and neck cancer"}, {"name": "RM-1995", "phase": "IND", "indication": "Head and neck cancer"}, {"name": "Antibody B-IR700", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Antibody C-IR700", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://rakuten-med.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-08-10", "recentDeals": [{"headline": "Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox Platform Cancer Treatment in the Middle East and North Africa", "date": "2023-08-10", "value": ""}], "totalRaised": 189000000.0, "totalRaisedFmt": "$189M", "latestFinDate": "2026-01-07", "latestFinType": "Rounds beyond series E", "nRounds": 2, "recentFinancing": [{"type": "Rounds beyond series E", "amount": "$70M", "date": "2026-01-07", "investors": "Taiax Life Science Fund L.P., Daiwa Securities Group, Mitsui Sumitomo Insurance Venture Capital Co. Ltd., Sumitomo Mitsu..."}, {"type": "Series E rounds", "amount": "$119M", "date": "2024-03-06", "investors": "Hikma Pharmaceuticals plc, Rakuten, Hiroshi Mikitani (Mickey), Sbi Group, Mizuho Bank, Dai-ichi Life Insurance Co. Ltd."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rakuten%20Medical", "hasDealsFin": true, "diseaseGroups": ["Head & Neck Cancer", "Solid Tumors (General)"]}, {"company": "Ralexar Therapeutics Inc.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ALX-101", "phase": "Phase II", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.ralexar.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ralexar%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Rallybio Corp.", "city": "Farmington", "state": "CT", "country": "United States", "diseaseCats": ["Hematology", "Inflammation"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "RLYB212", "phase": "Phase I/II", "indication": "Inflammatory disease"}, {"name": "RLYB211", "phase": "Phase I", "indication": "Fetal and neonatal alloimmune thrombocytopenia (FNAIT)"}], "ceo": "Stephen Uden, MD", "employees": 25, "founded": 2018, "website": "http://www.rallybio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -23553968.96, "evFmt": "", "ticker": "RLYB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rallybio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematology (non-cancer)"]}, {"company": "Rani Therapeutics Holdings Inc.", "city": "San Jose", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Musculoskeletal"], "modalityGroups": ["Digital / Device"], "nProducts": 7, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RT-102", "phase": "Phase I", "indication": "Osteoporosis"}, {"name": "RT-104", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "RT-105", "phase": "Preclinical", "indication": "Psoriatic arthritis"}, {"name": "RT-106", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "RT-109", "phase": "Preclinical", "indication": "Growth hormone deficiency"}, {"name": "RT-110", "phase": "Preclinical", "indication": "Thyroid disease"}, {"name": "RT-111", "phase": "Preclinical", "indication": "Arthritis"}], "ceo": "Talat Imran", "employees": 105, "founded": 2012, "website": "http://www.ranitherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 42083120.0, "evFmt": "$42M", "ticker": "RANI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rani%20Therapeutics%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Diabetes", "Musculoskeletal", "Other", "Other Specialties"]}, {"company": "Rapamycin Holdings Inc. (Emtora Biosciences)", "city": "San Antonio", "state": "TX", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "eRapa", "phase": "Phase II", "indication": "Adenomatous polyps"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://emtorabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rapamycin%20Holdings%20Inc.%20(Emtora%20Biosciences)", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Rapport Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RAP-219", "phase": "Phase I", "indication": "Bipolar disorder"}], "ceo": "Abraham N. Ceesay, MBA", "employees": 69, "founded": 2022, "website": "https://www.rapportrx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 345023783.48, "evFmt": "$345M", "ticker": "RAPP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rapport%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Rapt Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "tivumecirnon (FLX475)", "phase": "Phase II", "indication": "Cancer (unspecified)"}], "ceo": "Brian Russell Wong, MD, PhD", "employees": 68, "founded": 2015, "website": "https://www.rapt.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": -162160394.06, "evFmt": "", "ticker": "RAPT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rapt%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Rascal Therapeutics Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RSC-1255", "phase": "Phase I", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.rascaltherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rascal%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Rasna Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Actinomycin D", "phase": "Phase II", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "Kunwar Shailubhai, PhD, MBA", "employees": 0, "founded": 2013, "website": "http://www.rasna.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "RASP", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rasna%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Ratio Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Diagnostics", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RTX-1363S", "phase": "Phase I", "indication": "Cancer, Diagnostic"}, {"name": "Ratio Therapeutics-CAIX-targeting program-unknown", "phase": "Preclinical", "indication": "Renal cancer"}, {"name": "Ratio Therapeutics-FAPA-targeting program-unknown", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://ratiotx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 745000000.0, "totalDealFmt": "$745M", "latestDealDate": "2024-11-18", "recentDeals": [{"headline": "Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate", "date": "2024-11-18", "value": "$745M"}, {"headline": "Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck", "date": "2023-03-28", "value": ""}], "totalRaised": 90000000.0, "totalRaisedFmt": "$90M", "latestFinDate": "2024-01-17", "latestFinType": "Series B rounds", "nRounds": 3, "recentFinancing": [{"type": "Series B rounds", "amount": "$50M", "date": "2024-01-17", "investors": "Schusterman Family Investments, Duquesne Capital, Pagsgroup, Bristol Myers Squibb Co., Cornell University"}, {"type": "Series A rounds", "amount": "$20M", "date": "2023-02-01", "investors": "Duquesne Capital, Schusterman Family Investments, Existing Investors"}, {"type": "Seed financings", "amount": "$20M", "date": "2022-06-10", "investors": "Bayer AG, Lantheus Holdings Inc."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ratio%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Rational Vaccines Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Profavax HSV-1 (RVx-1001)", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}, {"name": "Rational Vaccines-HSV-1 strain VC2-unknown", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}, {"name": "RVx-201 (Theravax HSV-2)", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}, {"name": "RVx-202", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://rationalvaccines.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rational%20Vaccines", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Ray Therapeutics Inc.", "city": "Berkeley", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RTX-015 (RAY-001)", "phase": "Phase I", "indication": "Blindness"}, {"name": "RTX-021 (RAY-002)", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://raytherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-06-12", "recentDeals": [{"headline": "Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid", "date": "2023-06-12", "value": ""}], "totalRaised": 106000000.0, "totalRaisedFmt": "$106M", "latestFinDate": "2023-05-16", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$100M", "date": "2023-05-16", "investors": "Novo Holdings A/S, Deerfield Management, Norwest Venture Partners, Platanus, Mrl Ventures Fund, 4bio Capital, Wu Capital"}, {"type": "Seed financings", "amount": "$6M", "date": "2022-01-04", "investors": "4bio Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ray%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Ophthalmology"]}, {"company": "Realta Life Sciences Inc.", "city": "Norfolk", "state": "VA", "country": "United States", "diseaseCats": ["Hematology", "Neurology", "Other", "Pulmonary"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "RLS-0071", "phase": "Phase I", "indication": "Encephalopathy"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://realtalifesciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Realta%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Recardio Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Dutogliptin (REC-01", "phase": "Phase II", "indication": "Myocardial infarction (MI)"}, {"name": "REC 02", "phase": "Phase I", "indication": "Congestive heart failure (CHF)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.recardio.eu", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Recardio", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Receptor Life Sciences Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Digital / Device", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "RLS103", "phase": "Phase I/II", "indication": "Anxiety"}, {"name": "RLS102", "phase": "Phase I", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.receptorlife.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Receptor%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Recludix Pharma Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Inflammation", "Pulmonary"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "STAT6 (REX-8756", "phase": "Phase I", "indication": "Dermatitis"}, {"name": "STAT3", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Recludix Pharma-inflammatory disease-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Recludix Pharma-Non-SH2 domain-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Recludix Pharma-SH2 domain-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://recludixpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 1325000000.0, "totalDealFmt": "$1.3B", "latestDealDate": "2023-07-20", "recentDeals": [{"headline": "Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications", "date": "2023-07-20", "value": "$1.3B"}], "totalRaised": 63000000.0, "totalRaisedFmt": "$63M", "latestFinDate": "2026-01-12", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$63M", "date": "2026-01-12", "investors": "Access Biotechnology, Alexandria Venture Investments LLC, New Enterprise Associates, Westlake Biopartners, Eli Lilly and..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Recludix%20Pharma", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Solid Tumors (General)"]}, {"company": "Recode Therapeutics Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Other", "Pulmonary"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 9, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RCT1100", "phase": "Phase I", "indication": "Pulmonary (unspecified)"}, {"name": "ReCode Therapeutics-Cystic Fibrosis-unknown", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}, {"name": "ReCode Therapeutics-Cystic Fibrosis-unknown2", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}, {"name": "ReCode Therapeutics-Primary Ciliary Dyskinesia-unknown2", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}, {"name": "ReCode Therapeutics-Primary Ciliary Dyskinesia-unknown3", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}, {"name": "ReCode Therapeutics-Alpha-1 antitrypsin-unknown", "phase": "Research", "indication": "Alpha-antitrypsin (AAT) deficiency"}, {"name": "ReCode Therapeutics-CNS-unknown", "phase": "Research", "indication": "Central nervous system (CNS) disorders"}, {"name": "ReCode Therapeutics-Surfactant deficiencies-unknown", "phase": "Research", "indication": "Pulmonary (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://recodetx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-01-09", "recentDeals": [{"headline": "ReCode Therapeutics announces strategic collaboration with AskBio to explore single vector gene-editing platform", "date": "2023-01-09", "value": ""}], "totalRaised": 224441931.0, "totalRaisedFmt": "$224M", "latestFinDate": "2025-09-23", "latestFinType": "Venture (Debt)", "nRounds": 5, "recentFinancing": [{"type": "Venture (Debt)", "amount": "$29M", "date": "2025-09-23", "investors": "Undisclosed Investors"}, {"type": "Uncategorized venture rounds", "amount": "$15M", "date": "2024-11-18", "investors": "Cystic Fibrosis Foundation"}, {"type": "Series B rounds", "amount": "$50M", "date": "2023-09-19", "investors": "Bioluminescence Ventures, Solasta Ventures, Orbimed Advisors LLC, Ayurmaya Capital Management, Leaps by Bayer, Vida Vent..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Recode%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Brain / CNS Tumors", "Rare / Genetic", "Respiratory / Allergy"]}, {"company": "Recursion Pharmaceuticals Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Dermatology", "Endocrine/Metabolic", "Hematology", "Infectious", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 18, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "REC-994", "phase": "Phase II", "indication": "Neurology (unspecified)"}, {"name": "REC-1245", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "REC-617 (GTAEXS617)", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "DSP-0038", "phase": "Phase I", "indication": "Psychosis"}, {"name": "DSP-1181", "phase": "Phase I", "indication": "Obsessive compulsive disorder (OCD)"}, {"name": "DSP-2342", "phase": "Phase I", "indication": "Neurology (unspecified)"}, {"name": "REC-2282 (OSU-HDAC42)", "phase": "Phase I", "indication": "Neurofibromatosis"}, {"name": "Rec-3599", "phase": "Phase I", "indication": "GM2 gangliosidosis"}], "ceo": "Najat Khan, PhD", "employees": 0, "founded": 2013, "website": "https://www.recursion.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1364737306.96, "evFmt": "$1.4B", "ticker": "RXRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Recursion%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other", "Other Neurology", "Psychiatry / Behavioral", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Recurv Pharma Inc.", "city": "Newark", "state": "DE", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "RP-001", "phase": "Phase II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2022, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Recurv%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Red Queen Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Peptide"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RQ-01", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "RQ-02", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "RQ-03", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "RQ-04", "phase": "Research", "indication": "Ebola"}, {"name": "RQ-05", "phase": "Research", "indication": "Herpes simplex virus (HSV)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://redqueentx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-12-03", "recentDeals": [{"headline": "Red Queen Therapeutics Announces Expanded Licensing Agreement, Progress in Its Pan-Influenza Program", "date": "2024-12-03", "value": ""}], "totalRaised": 55000000.0, "totalRaisedFmt": "$55M", "latestFinDate": "2024-08-06", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$55M", "date": "2024-08-06", "investors": "Apple Tree Partners"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Red%20Queen%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease"]}, {"company": "Rediscovery Life Sciences LLC", "city": "Raleigh", "state": "NC", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "suramin (RLS003)", "phase": "Phase II", "indication": "Renal damage"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://rediscoveryls.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rediscovery%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Reflexion Medical Inc.", "city": "Hayward", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "RefleXion X1", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-09-20", "recentDeals": [{"headline": "RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver", "date": "2023-09-20", "value": ""}, {"headline": "Telix and RefleXion expand partnership for prostate cancer treatment", "date": "2022-06-10", "value": ""}], "totalRaised": 240000000.0, "totalRaisedFmt": "$240M", "latestFinDate": "2023-11-15", "latestFinType": "Uncategorized venture rounds", "nRounds": 3, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$105M", "date": "2023-11-15", "investors": "Tpg, Ally Bridge Group, Pfizer Ventures, Johnson & Johnson Innovation \u2013 Jjdc Inc., T. Rowe Price Associates Inc., Venroc..."}, {"type": "Venture (Debt)", "amount": "$55M", "date": "2022-07-06", "investors": "Oxford Finance LLC"}, {"type": "Uncategorized venture rounds", "amount": "$80M", "date": "2022-03-10", "investors": "Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, Hillenbrand Capital Partners LLC, The Rise Fund, K..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Reflexion%20Medical", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Regel Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RT101", "phase": "Preclinical", "indication": "Dravet syndrome"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://regeltherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regel%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures"]}, {"company": "Regen Biopharma Inc.", "city": "La Mesa", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Cell Therapy", "Other", "Small Molecule", "Vaccine"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "HemaXellerate", "phase": "Phase I/II", "indication": "Anemia"}, {"name": "DCellVax", "phase": "IND", "indication": "Breast cancer"}, {"name": "DiffronC", "phase": "Preclinical", "indication": "Leukemia"}, {"name": "RG-NI01", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "RG-NI02", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "David Raymond Koos, MD, PhD", "employees": 0, "founded": 2012, "website": "http://regenbiopharmainc.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1446867.595, "evFmt": "$1M", "ticker": "RGBP", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regen%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers", "Hematology (non-cancer)", "Solid Tumors (General)"]}, {"company": "Regenerative Patch Technologies LLC", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CPCB-RPE1", "phase": "Phase I/II", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.regenerativepatch.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regenerative%20Patch%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Regeneron Pharmaceuticals Inc.", "city": "Tarrytown", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Endocrine/Metabolic", "Hematology", "Infectious", "Inflammation", "Musculoskeletal", "Ophthalmic", "Other", "Otologic", "Pulmonary", "Renal"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Cell Therapy", "Gene Therapy", "Protein / Biologic", "Small Molecule"], "nProducts": 48, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Arcalyst", "phase": "Marketed", "indication": "CIAS1-associated periodic syndrome (CAPS)"}, {"name": "Evkeeza", "phase": "Marketed", "indication": "Hypercholesterolemia"}, {"name": "Eylea HD", "phase": "Marketed", "indication": "Diabetic macular edema (DME)"}, {"name": "Eylea", "phase": "Marketed", "indication": "Choroidal neovascularization (CNV)"}, {"name": "Inmazeb", "phase": "Marketed", "indication": "Ebola"}, {"name": "Kevzara", "phase": "Marketed", "indication": "Rheumatoid arthritis (RA)"}, {"name": "Libtayo", "phase": "Marketed", "indication": "Basal cell carcinoma (BCC)"}, {"name": "Ronapreve", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Leonard S. Schleifer, MD, PhD", "employees": 15410, "founded": 1988, "website": "https://www.regeneron.com/", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 78186982000.0, "evFmt": "$78.2B", "ticker": "REGN", "exchange": "NASDAQ", "nDeals": 3, "totalDealValue": 395000000.0, "totalDealFmt": "$395M", "latestDealDate": "2025-12-01", "recentDeals": [{"headline": "Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)", "date": "2025-12-01", "value": "$275M"}, {"headline": "Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases", "date": "2023-03-28", "value": "$120M"}, {"headline": "ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target", "date": "2022-04-06", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regeneron%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Diabetes", "Infectious Disease", "Obesity / Metabolic", "Ophthalmology", "Other", "Skin Cancer / Melanoma"]}, {"company": "Regenerx Biopharmaceuticals Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Infectious", "Neurology", "Ophthalmic"], "modalityGroups": ["Peptide", "Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "GBT-201", "phase": "Phase III", "indication": "Dry eye"}, {"name": "RGN-137", "phase": "Phase II", "indication": "Dermal ulcers"}, {"name": "RGN-352", "phase": "Phase II", "indication": "Myocardial infarction (MI)"}, {"name": "Thymosin Beta-4", "phase": "Phase I", "indication": "Cardiovascular (unspecified)"}], "ceo": "J. J. Finkelstein", "employees": 0, "founded": 1982, "website": "http://www.regenerx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "RGRX", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regenerx%20Biopharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Dermatology", "Ophthalmology"]}, {"company": "Regenocyte Therapeutic", "city": "Bonita Springs", "state": "FL", "country": "United States", "diseaseCats": ["Cardiovascular", "Pulmonary"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Regenocytes", "phase": "Marketed", "indication": "Cardiomyopathy"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.regenocyte.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regenocyte%20Therapeutic", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Regenxbio Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Inflammation", "Musculoskeletal", "Neurology", "Ophthalmic"], "modalityGroups": ["Gene Therapy", "Other"], "nProducts": 9, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "clemidsogene lanparvovec (RGX-121)", "phase": "Registration", "indication": "Mucopolysaccharidosis"}, {"name": "RGX-314", "phase": "Phase III", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "RGX-111", "phase": "Phase I/II", "indication": "Mucopolysaccharidosis"}, {"name": "RGX-202", "phase": "Phase I/II", "indication": "Muscular dystrophy"}, {"name": "RGX-501", "phase": "Phase I/II", "indication": "Hypercholesterolemia"}, {"name": "RegenxBio-Hereditary Angioedema-unknown", "phase": "Preclinical", "indication": "Angioedema"}, {"name": "RGX-181", "phase": "Preclinical", "indication": "Neuronal ceroid lipofuscinosis"}, {"name": "RGX-321", "phase": "Preclinical", "indication": "Retinitis"}], "ceo": "Curran M. Simpson", "employees": 353, "founded": 2009, "website": "http://www.regenxbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 289737570.0, "evFmt": "$290M", "ticker": "RGNX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regenxbio", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Obesity / Metabolic", "Ophthalmology", "Other Inflammation", "Rare / Genetic"]}, {"company": "Reglagene Inc.", "city": "Tucson", "state": "AZ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "RGN6024", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.reglagene.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Reglagene", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Regor Therapeutics Group", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "RGT-075", "phase": "Phase II", "indication": "Obesity"}, {"name": "RGT-274", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.regor.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regor%20Therapeutics%20Group", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Obesity / Metabolic"]}, {"company": "Regranion LLC", "city": "Mount Pleasant", "state": "SC", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "MC2-32", "phase": "Phase II", "indication": "Hidradenitis suppurativa"}], "ceo": "", "employees": 0, "founded": 2017, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regranion", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Regulon Inc.", "city": "Mountain View", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Nanoplatin (lipoplatin)", "phase": "Phase III", "indication": "Head and neck cancer"}, {"name": "Lipoxal", "phase": "Phase II", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.regulon.org", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Regulon", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Head & Neck Cancer"]}, {"company": "Reheva Biosciences Inc.", "city": "Dublin", "state": "OH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RH324", "phase": "Phase I", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.rehevabiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Reheva%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Rein Therapeutics Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Other", "Pulmonary"], "modalityGroups": ["Macrocycle", "Peptide", "Protein / Biologic", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ALRN-6924", "phase": "Phase II", "indication": "Lymphoma"}, {"name": "LTI-01", "phase": "Phase II", "indication": "Pulmonary (unspecified)"}, {"name": "LTI-03", "phase": "Phase I", "indication": "Pulmonary fibrosis"}, {"name": "LTI-05", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}, {"name": "LTI-07", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}], "ceo": "Brian J. Windsor, PhD", "employees": 11, "founded": 2005, "website": "http://www.aileronrx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 73399467.7, "evFmt": "$73M", "ticker": "RNTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rein%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Rare / Genetic", "Respiratory / Allergy"]}, {"company": "Rejuvenate Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Hematology", "Musculoskeletal", "Neurology", "Renal"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RJB-01", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "RJB-02", "phase": "Preclinical", "indication": "Hemophilia"}, {"name": "RJB-03", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.rejuvenatebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rejuvenate%20Bio", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Hematology (non-cancer)"]}, {"company": "Rejuvenation Technologies Inc.", "city": "Mountain View", "state": "CA", "country": "United States", "diseaseCats": ["Hepatic", "Neurology", "Pulmonary"], "modalityGroups": ["Undisclosed"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Rejuvenation Technologies-Idiopathic pulmonary fibrosis-unknown", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}, {"name": "Rejuvenation Technologies-Liver disease-unknown", "phase": "Preclinical", "indication": "Liver disease"}, {"name": "Rejuvenation Technologies-Rejuvenation-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.rejuvenationtech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rejuvenation%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Liver Disease", "Other Neurology", "Respiratory / Allergy"]}, {"company": "Rel-md Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "REM-1086", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.relmd.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rel-md", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Relay Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "lirafugratinib (RLY-4008)", "phase": "Phase I/II", "indication": "Biliary cancer"}, {"name": "migoprotafib (GDC-1971", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "RLY-2608 (RLY-PI3K1047)", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "Relay-ER\u03b1-unknown", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "RLY-5836", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Sanjiv K. Patel, MD, MBA", "employees": 261, "founded": 2016, "website": "http://relaytx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": -144205482.72, "evFmt": "", "ticker": "RLAY", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Relay%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Solid Tumors (General)"]}, {"company": "Relburn-metabolomics Inc.", "city": "Westfield", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RLBN1127", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "RLBN1136", "phase": "Preclinical", "indication": "Hyperuricemia/gout"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.relburn.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Relburn-metabolomics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Relmada Therapeutics Inc.", "city": "Coral Gables", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "sepranolone (UC1010)", "phase": "Phase II", "indication": "Premenstrual syndrome (PMS)"}, {"name": "BuTab", "phase": "Phase I", "indication": "Pain"}], "ceo": "Sergio Traversa, PhD, MBA", "employees": 17, "founded": 2004, "website": "http://www.relmada.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -29224231.48, "evFmt": "", "ticker": "RLMD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Relmada%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other", "Pain / Migraine"]}, {"company": "Remedium Bio Inc.", "city": "Needham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RMD1101", "phase": "Preclinical", "indication": "Osteoarthritis"}, {"name": "RMD1202", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "RMD1501", "phase": "Preclinical", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://remedium-bio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Remedium%20Bio", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Musculoskeletal", "Other Neurology"]}, {"company": "Remedy Pharmaceuticals Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "glibenclamide", "phase": "Phase III", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.remedypharmaceuticals.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Remedy%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Remix Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "REM-422", "phase": "Phase I", "indication": "Adenocarcinoma"}, {"name": "Remix Therapeutics-fusion driver-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Remix Therapeutics-toxic protein aggregate modifier-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Remix Therapeutics-toxic protein modifier-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Remix Therapeutics-J&J collaboration-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.remixtx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 2042000000.0, "totalDealFmt": "$2.0B", "latestDealDate": "2024-01-03", "recentDeals": [{"headline": "Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing", "date": "2024-01-03", "value": "$1.0B"}, {"headline": "Remix Therapeutics enters collaboration with Janssen to advance small molecule therapeutics using REMaster drug discovery platform to modulate RNA processing", "date": "2022-02-17", "value": "$1.0B"}], "totalRaised": 130000000.0, "totalRaisedFmt": "$130M", "latestFinDate": "2024-01-03", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$60M", "date": "2024-01-03", "investors": "The Column Group, Atlas Venture, Foresite Capital, Alexandria Venture Investments LLC, Arch Venture Partners, Casdin Cap..."}, {"type": "Series B rounds", "amount": "$70M", "date": "2022-05-17", "investors": "Surveyor Capital, Foresite Capital Management LLC, Atlas Venture, The Column Group, Arch Venture Partners, Alexandria Ve..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Remix%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Other Neurology", "Solid Tumors (General)"]}, {"company": "Renbio", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RB-100", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.renbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Renbio", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Renetx Bio", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Nogo trap", "phase": "Preclinical", "indication": "Spinal cord injury (SCI)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.renetx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Renetx%20Bio", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Renexxion LLC", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "naronapride (SNV005", "phase": "Phase II", "indication": "Constipation"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.renexxion.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Renexxion", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Renibus Therapeutics Inc.", "city": "Southlake", "state": "TX", "country": "United States", "diseaseCats": ["Cardiovascular", "Renal"], "modalityGroups": ["Nanoparticle / Delivery", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "iron sucrose", "phase": "Phase II", "indication": "Coronary artery bypass graft (CABG) surgery"}, {"name": "iron sucrose (RBT-3)", "phase": "Preclinical", "indication": "Renal failure"}, {"name": "RBT-2", "phase": "Preclinical", "indication": "Renal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.renibus.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Renibus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Kidney Disease", "Other"]}, {"company": "Renova Therapeutics", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Ad5.hAC6 (RT-100)", "phase": "Phase III", "indication": "Heart failure"}, {"name": "RT-200 (Compound #)", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.renovatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Renova%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes"]}, {"company": "Renovacare Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CellMist Solution", "phase": "Preclinical", "indication": "Wounds"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.renovacareinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Renovacare", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Renovion Inc.", "city": "Chapel Hill", "state": "NC", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Arina-1", "phase": "Phase II", "indication": "Bronchiolitis obliterans syndrome"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.renovion.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Renovion", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Renovorx Inc.", "city": "Los Altos", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "RenovoGem", "phase": "Phase III", "indication": "Pancreatic cancer"}], "ceo": "Shaun R. Bagai", "employees": 10, "founded": 2012, "website": "http://renovorx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 21853800.27, "evFmt": "$22M", "ticker": "RNXT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Renovorx", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Repair Biotechnologies Inc.", "city": "Syracuse", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Hematology", "Infectious"], "modalityGroups": ["Other"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Repair-atherosclerosis-unknown", "phase": "Research", "indication": "Atherosclerosis"}, {"name": "Repair-cancer-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Repair-HIV-unknown", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "Repair-t cell-unknown", "phase": "Preclinical", "indication": "Immunodeficiency"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.repairbiotechnologies.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Repair%20Biotechnologies", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Infectious Disease", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Repertoire Immune Medicines Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "PRIME IL-15", "phase": "Phase I", "indication": "Hematologic malignancies"}, {"name": "TRQ-1501", "phase": "Phase I", "indication": "Hematologic malignancies"}, {"name": "PRIME IL-12", "phase": "IND", "indication": "Hematologic malignancies"}, {"name": "PRIME TLR", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "TRQ-1201", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "TRQ-1502", "phase": "Preclinical", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.repertoire.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Repertoire%20Immune%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Replicate Bioscience Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RBI-4000", "phase": "Phase I", "indication": "Rabies"}, {"name": "RBI-1000", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "RBI-2000", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://replicatebioscience.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Replicate%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Replikins Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "H1N1 vaccine", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "H5N1 vaccine", "phase": "Preclinical", "indication": "Influenza virus"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.replikins.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Replikins", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Replimune Group Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "vusolimogene oderparepvec (RP1)", "phase": "Registration", "indication": "Melanoma"}, {"name": "RP2", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "RP3", "phase": "Phase I", "indication": "Colorectal cancer"}], "ceo": "Sushil Patel, PhD", "employees": 479, "founded": 2015, "website": "http://www.replimune.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 377861433.25, "evFmt": "$378M", "ticker": "REPL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Replimune%20Group", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Skin Cancer / Melanoma"]}, {"company": "Reprotect Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "BufferGel", "phase": "Phase II/III", "indication": "Sexually transmitted disease (STD)"}], "ceo": "", "employees": 0, "founded": 1993, "website": "http://www.reprotect.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Reprotect", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Repurposed Therapeutics Inc. (Defender Pharmaceuticals)", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Gastrointestinal", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 7, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "scopolamine HBr (INSCOP", "phase": "Registration", "indication": "Emesis"}, {"name": "DPI-387", "phase": "Phase II", "indication": "Bipolar disorder"}, {"name": "DPI-386SG", "phase": "Phase I", "indication": "Motion sickness"}, {"name": "DPI-521CG", "phase": "Phase I", "indication": "Motion sickness"}, {"name": "DPI-385CVS", "phase": "Preclinical", "indication": "Emesis"}, {"name": "DPI-386SS", "phase": "Preclinical", "indication": "Motion sickness"}, {"name": "DPI-550TBI", "phase": "Preclinical", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://defenderpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 70000000.0, "totalRaisedFmt": "$70M", "latestFinDate": "2023-07-18", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$70M", "date": "2023-07-18", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Repurposed%20Therapeutics%20Inc.%20(Defender%20Pharmaceuticals)", "hasDealsFin": true, "diseaseGroups": ["Other", "Psychiatry / Behavioral", "Supportive / Other"]}, {"company": "Rescue Hearing Inc.", "city": "Gainesville", "state": "FL", "country": "United States", "diseaseCats": ["Otologic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RHI100", "phase": "Preclinical", "indication": "Hearing loss"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://rescuehearing.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rescue%20Hearing", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Resolute Science Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RS-5", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "RS-7", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "RS-8", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://resolutescience.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Resolute%20Science", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Solid Tumors (General)"]}, {"company": "Resolve Therapeutics LLC", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "RSLV-132", "phase": "Phase II", "indication": "Lupus"}, {"name": "RSLV-133", "phase": "Preclinical", "indication": "Lupus"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.resolvebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Resolve%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Resolvyx Pharmaceuticals Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Inflammation", "Ophthalmic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "RX-10045", "phase": "Phase II", "indication": "Dry eye"}, {"name": "RX-10001", "phase": "Phase I", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "NPD1", "phase": "Preclinical", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.resolvyx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Resolvyx%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Ophthalmology"]}, {"company": "Respira Therapeutics Inc.", "city": "albuquerque", "state": "NM", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "vardenafil Inhalation powder (RT234)", "phase": "Preclinical", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.respiratherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Respira%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Respirerx Pharmaceuticals Inc.", "city": "Glen Rock", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "BVF-007", "phase": "Phase II", "indication": "Respiratory distress syndrome (RDS)"}, {"name": "CX1739", "phase": "Phase II", "indication": "Sleep apnea"}, {"name": "oral dronabinol", "phase": "Phase II", "indication": "Sleep apnea"}, {"name": "S47445", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "CX1942", "phase": "Preclinical", "indication": "Respiratory distress syndrome (RDS)"}], "ceo": "", "employees": 0, "founded": 1987, "website": "http://www.respirerx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Respirerx%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Psychiatry / Behavioral", "Respiratory / Allergy"]}, {"company": "Retrotope Inc.", "city": "Los Altos", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "RT001", "phase": "Phase II/III", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.retrotope.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Retrotope", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Revalesio Corp.", "city": "Tacoma", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation", "Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "RNS60", "phase": "Phase II", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.revalesio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Revalesio", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Revelation Biosciences Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Inflammation"], "modalityGroups": ["Digital / Device", "Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "REVTx-99b", "phase": "Phase I", "indication": "Rhinitis"}, {"name": "phosphorylated hexaacyl disaccharide (PHAD)", "phase": "Preclinical", "indication": "Bacterial infection"}, {"name": "REVTx-100", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "REVTx-200", "phase": "Preclinical", "indication": "Viral infection"}], "ceo": "James M. Rolke", "employees": 9, "founded": 2020, "website": "https://www.revbiosciences.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -5233960.240885, "evFmt": "", "ticker": "REVB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Revelation%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Reven Pharmaceuticals Inc.", "city": "Sarasota", "state": "FL", "country": "United States", "diseaseCats": ["Cardiovascular", "Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Rejuveinix (RJX)", "phase": "Phase II", "indication": "Peripheral vascular disease (PVD)"}], "ceo": "", "employees": 0, "founded": 1999, "website": "https://reven.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Reven%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Reveragen Biopharma Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation", "Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Agamree", "phase": "Marketed", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.reveragen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Reveragen%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Revimmune Inc.", "city": "Bethesda", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Infectious"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CYT107", "phase": "Phase II", "indication": "Bladder cancer"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.revimmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Revimmune", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Revision Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "fenretinide (RT-101", "phase": "Phase II", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.revisiontherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Revision%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Reviva Pharmaceuticals Holdings Inc.", "city": "Santa Clara", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Neurology", "Pulmonary"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "brilaroxazine (RP5063)", "phase": "Phase III", "indication": "Schizophrenia"}, {"name": "RP1000", "phase": "Preclinical", "indication": "Obesity"}, {"name": "RP6000", "phase": "Preclinical", "indication": "Depression"}], "ceo": "Laxminarayan Bhat, PhD", "employees": 14, "founded": 2006, "website": "http://www.revivapharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 46978660.44, "evFmt": "$47M", "ticker": "RVPH", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Reviva%20Pharmaceuticals%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Psychiatry / Behavioral"]}, {"company": "Revogenex Inc.", "city": "Duluth", "state": "GA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "IV tramadol", "phase": "Phase III", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://revogenex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Revogenex", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Revolution Medicines Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 7, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "daraxonrasib (RMC-6236)", "phase": "Phase III", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "RMC-4630", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "RMC-5552", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "WDB002", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "zoldonrasib (RMC-9805)", "phase": "Phase I", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "elironrasib (RMC-6291)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "RMC-5845", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Mark A. Goldsmith, MD, PhD", "employees": 534, "founded": 2014, "website": "https://www.revmed.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 5183389773.28, "evFmt": "$5.2B", "ticker": "RVMD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Revolution%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Revopsis Therapeutics Inc.", "city": "Springfield", "state": "IL", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RO-104", "phase": "Preclinical", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://revopsis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Revopsis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Rezolute Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "RZ402", "phase": "Phase II", "indication": "Diabetic macular edema (DME)"}], "ceo": "Nevan Charles Elam", "employees": 71, "founded": 2010, "website": "https://www.rezolutebio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 172713833.4, "evFmt": "$173M", "ticker": "RZLT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rezolute", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Rezq Bio Inc.", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Rezq-type 1 diabetes-unknown", "phase": "Phase I/II", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://rezq.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rezq%20Bio", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Rheumagen Inc.", "city": "Aurora", "state": "CO", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RG0401", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.rheumagen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rheumagen", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Rhodes Pharmaceuticals L.P.", "city": "Coverntry", "state": "RI", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Aptensio XR", "phase": "Marketed", "indication": "Depression"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.rhodespharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rhodes%20Pharmaceuticals%20L.P.", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Ribometrix Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Ribometrix-elF4E-unknown", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.ribometrix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ribometrix", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Riboscience LLC", "city": "Sunnyvale", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RBS2418", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.riboscience.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Riboscience", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Ridgeback Biotherapeutics L.P.", "city": "Coconut Grove", "state": "FL", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Lagevrio", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.ridgebackbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ridgeback%20Biotherapeutics%20L.P.", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Rigel Pharmaceuticals Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Endocrine/Metabolic", "Hematology", "Infectious", "Inflammation", "Pulmonary", "Renal", "Transplant"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Tavalisse", "phase": "Marketed", "indication": "Immune thrombocytopenia (ITP)"}, {"name": "ATI-50002", "phase": "Phase II", "indication": "Alopecia areata"}, {"name": "ATI-501 (ATI-50001", "phase": "Phase II", "indication": "Alopecia areata"}, {"name": "bemcentinib (BGB324", "phase": "Phase II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "R348", "phase": "Phase II", "indication": "Graft-versus-host disease (GvHD)"}, {"name": "R552", "phase": "Phase II", "indication": "Rheumatoid arthritis (RA)"}, {"name": "AZD0449", "phase": "Phase I", "indication": "Asthma"}, {"name": "R835", "phase": "Phase I", "indication": "Arthritis"}], "ceo": "Raul R. Rodriguez, MBA", "employees": 164, "founded": 1996, "website": "http://www.rigel.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 280139340.0, "evFmt": "$280M", "ticker": "RIGL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rigel%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology", "Hematologic Cancers", "Hematology (non-cancer)", "Other", "Respiratory / Allergy"]}, {"company": "Rigimmune Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RIG-101", "phase": "Preclinical", "indication": "Influenza virus"}], "ceo": "", "employees": 0, "founded": 2020, "website": "http://rigimmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rigimmune", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Rila Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RLA-23174", "phase": "Phase I", "indication": "Renal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://rilatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rila%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Rion Inc.", "city": "Rochester", "state": "MN", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Dermatology", "Musculoskeletal", "Pulmonary"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 8, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "RioDerm001", "phase": "Phase II", "indication": "Dermal ulcers"}, {"name": "RioCard001", "phase": "Phase I", "indication": "Myocardial infarction (MI)"}, {"name": "RioDerm002", "phase": "Phase I", "indication": "Wounds"}, {"name": "RioDerm003", "phase": "Phase I", "indication": "Dermatitis"}, {"name": "RioDerm004", "phase": "Phase I", "indication": "Wounds"}, {"name": "RioMSK001", "phase": "Phase I", "indication": "Osteoarthritis"}, {"name": "RioMSK002", "phase": "Preclinical", "indication": "Tissue damage"}, {"name": "RioPulm001", "phase": "Preclinical", "indication": "Acute lung injury"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://riontx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rion", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Dermatology", "Musculoskeletal", "Respiratory / Allergy", "Supportive / Other"]}, {"company": "Riptide Bioscience Inc.", "city": "Vallejo", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RP182", "phase": "Preclinical", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.riptidebio.com/index.php", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Riptide%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Riptide Therapeutics LLC", "city": "Evanstan", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RTTX401", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Riptide%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Rise Therapeutics LLC", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Inflammation"], "modalityGroups": ["Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "R-3750", "phase": "Phase I", "indication": "Ulcerative colitis"}, {"name": "R-2487", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}, {"name": "R-4329", "phase": "Preclinical", "indication": "Gastrointestinal infection"}, {"name": "R-5780", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.risetherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rise%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Other", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Rivertown Therapeutics Inc.", "city": "", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "RT1840", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.rivertowntherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rivertown%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Rivus Pharmaceuticals Inc.", "city": "Charlottesville", "state": "VA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "HU6", "phase": "Phase II", "indication": "Heart failure"}, {"name": "RV-200", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "RV-300", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.rivuspharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rivus%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Obesity / Metabolic"]}, {"company": "Rnaimmune Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RNAimmune-cancer-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "RV1730", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.rnaimmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rnaimmune", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)"]}, {"company": "Rocket Pharmaceuticals Inc.", "city": "Cranbury", "state": "NJ", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Hematology", "Musculoskeletal"], "modalityGroups": ["Gene Therapy"], "nProducts": 7, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "Kresladi", "phase": "Registration", "indication": "Anemia"}, {"name": "RP-L02", "phase": "Phase II", "indication": "Anemia"}, {"name": "RP-A501", "phase": "Phase I", "indication": "Cardiomyopathy"}, {"name": "RP-L301", "phase": "Phase I", "indication": "Metabolic (unspecified)"}, {"name": "RP-L401", "phase": "Phase I", "indication": "Osteopetrosis"}, {"name": "RP-A601", "phase": "IND", "indication": "Cardiomyopathy"}, {"name": "REN-001", "phase": "Preclinical", "indication": "Cardiomyopathy"}], "ceo": "Gaurav D. Shah, MD", "employees": 299, "founded": 2015, "website": "https://rocketpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 844895706.61, "evFmt": "$845M", "ticker": "RCKT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rocket%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Hematology (non-cancer)", "Obesity / Metabolic", "Other"]}, {"company": "Rockwell Medical Inc.", "city": "Wixom", "state": "MI", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hematology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Calcitriol", "phase": "Marketed", "indication": "Thyroid disease"}, {"name": "Triferic", "phase": "Marketed", "indication": "Anemia"}], "ceo": "Mark Strobeck, PhD", "employees": 244, "founded": 1995, "website": "http://www.rockwellmed.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 55292419.56, "evFmt": "$55M", "ticker": "RMTI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rockwell%20Medical", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Other Specialties"]}, {"company": "Rogne Bioscience Inc.", "city": "Portola Valley", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RON2315", "phase": "Preclinical", "indication": "Psoriasis"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.rognebioscience.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rogne%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Roivant Sciences Ltd.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ARU-2801", "phase": "Preclinical", "indication": "Genetic disorders"}], "ceo": "Matthew Gline", "employees": 750, "founded": 2014, "website": "http://www.roivant.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 3029755846.16, "evFmt": "$3.0B", "ticker": "ROIV", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Roivant%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Romark Laboratories L.C.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Gastrointestinal", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Alinia", "phase": "Marketed", "indication": "Diarrhea (infectious)"}, {"name": "nitazoxanide (NT-300)", "phase": "Phase III", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 1993, "website": "http://www.romark.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Romark%20Laboratories%20L.C.", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Romeg Therapeutics LLC", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Gloperba (colchicine)", "phase": "Marketed", "indication": "Hyperuricemia/gout"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://romegrx.com/our-company/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Romeg%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Rondo Therapeutics Inc.", "city": "Hayward", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RNDO-564", "phase": "Preclinical", "indication": "Bladder cancer"}, {"name": "RNDO-Program 2-unknown 1", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "RNDO-Program 2-unknown 2", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "RNDO-Program 3-unknown", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://www.rondotx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-12-04", "recentDeals": [{"headline": "Rondo Therapeutics Announces Collaboration with Lilly to Develop Novel CD28 Bispecific Antibodies for Solid Tumors", "date": "2024-12-04", "value": ""}], "totalRaised": 67000000.0, "totalRaisedFmt": "$67M", "latestFinDate": "2022-03-02", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$67M", "date": "2022-03-02", "investors": "Red Tree Venture Capital, Canaan, Johnson & Johnson Innovation, Novo Holdings A/S, Sv Health Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rondo%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers", "Solid Tumors (General)"]}, {"company": "Rose Biosciences Inc.", "city": "Milwaukee", "state": "WI", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RB014", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.rosebiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rose%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Rosvivo Therapeutics Inc.", "city": "Reno", "state": "NV", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Hepatic", "Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RSVI-301", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "RSVI-302", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "RSVI-303", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "RSVI-305", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "RSVI-306", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "RSVI-307", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://rosvivo.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rosvivo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Infectious Disease"]}, {"company": "Rs Biotherapeutics Inc.", "city": "Cumberland", "state": "MD", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RSBT-001", "phase": "Preclinical", "indication": "Pulmonary (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://rsbiotherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-05-23", "recentDeals": [{"headline": "RS BioTherapeutics enters into license agreement with Synthonics for first investigational compound", "date": "2022-05-23", "value": ""}], "totalRaised": 4035021.0, "totalRaisedFmt": "$4M", "latestFinDate": "2023-07-20", "latestFinType": "Seed financings", "nRounds": 4, "recentFinancing": [{"type": "Seed financings", "amount": "$250K", "date": "2023-07-20", "investors": "Undisclosed Investors"}, {"type": "Seed financings", "amount": "$100K", "date": "2022-11-16", "investors": "Undisclosed Investor"}, {"type": "Seed financings", "amount": "$3M", "date": "2022-09-26", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rs%20Biotherapeutics", "hasDealsFin": true, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Rs Oncology LLC", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "RSO-021", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "RSO-024", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.rsoncology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rs%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Ruagen Bio Inc", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "SP-101", "phase": "Phase I/II", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 2024, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ruagen%20Bio", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Rubedo Life Sciences Inc.", "city": "Sunnyvale", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RLS-1496", "phase": "Preclinical", "indication": "Psoriasis"}, {"name": "Rubedo Life Sciences-pulmonary-unknown", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.rubedolife.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rubedo%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Respiratory / Allergy"]}, {"company": "Rxbio Inc.", "city": "Johnson City", "state": "TN", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Rx100", "phase": "Preclinical", "indication": "Poisoning"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.rxbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rxbio", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Rxmp Therapeutics LLC", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RMP-HPE", "phase": "Preclinical", "indication": "Bleeding"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.rxmptherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rxmp%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Rycarma Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Musculoskeletal", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ARM036", "phase": "Phase II", "indication": "Arrhythmia"}, {"name": "ARM210", "phase": "Phase II", "indication": "Tachycardia"}, {"name": "Rycals", "phase": "Phase II", "indication": "Arrhythmia"}], "ceo": "", "employees": 0, "founded": 2004, "website": "https://rycarma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Rycarma%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Ryne Biotechnology Inc. (Kenai Therapeutics)", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "RNDP-001", "phase": "Phase I/II", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.kenaitx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ryne%20Biotechnology%20Inc.%20(Kenai%20Therapeutics)", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "S1 Biopharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Lorexys (S1P-104)", "phase": "Phase II", "indication": "Sexual dysfunction"}, {"name": "Orexa (S1P-205)", "phase": "IND", "indication": "Sexual dysfunction"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.s1biopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=S1%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Sab Biotherapeutics Inc. (Sab Bio)", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Infectious", "Transplant"], "modalityGroups": ["Antibody"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SAB-176", "phase": "Phase II", "indication": "Influenza virus"}, {"name": "SAB-301", "phase": "Phase I/II", "indication": "Middle East respiratory syndrome coronavirus (MERS-CoV)"}, {"name": "SAB-142", "phase": "Phase I", "indication": "Diabetes"}, {"name": "SAB-195", "phase": "Preclinical", "indication": "Clostridium"}], "ceo": "Samuel J. Reich", "employees": 63, "founded": 2014, "website": "https://www.sab.bio/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 19049771.2756, "evFmt": "$19M", "ticker": "SABS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sab%20Biotherapeutics%20Inc.%20(Sab%20Bio)", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Infectious Disease", "Respiratory / Allergy"]}, {"company": "Safenia Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "C9224", "phase": "Phase I", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2022, "website": "http://www.safeniapharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Safenia%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Sagene Pharmaceuticals Inc.", "city": "Oldsmar", "state": "FL", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "SPI-1972", "phase": "IND", "indication": "Erectile dysfunction (ED)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.sagenepharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sagene%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Saghmos Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "ST-62516", "phase": "Phase III", "indication": "Renal damage"}], "ceo": "", "employees": 0, "founded": 2016, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Saghmos%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Sagimet Biosciences Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "denifanstat (ASC40", "phase": "Phase III", "indication": "Brain cancer"}], "ceo": "David A. Happel, MBA", "employees": 14, "founded": 2007, "website": "https://www.sagimet.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -10093737.5, "evFmt": "", "ticker": "SGMT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sagimet%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Sail Biomedicines Inc.", "city": "Somerville", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Neurology", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Senda Biosciences-chronic kidney disease-unknown", "phase": "Preclinical", "indication": "Renal (unspecified)"}, {"name": "Senda Biosciences-colorectal cancer-unknown", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "Senda Biosciences-immuno-oncology-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Senda Biosciences-multiple sclerosis-unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "Senda Biosciences-obesity-unknown", "phase": "Preclinical", "indication": "Obesity"}, {"name": "Senda Biosciences-Parkinson's disease-unknown", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.sail.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sail%20Biomedicines", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Kidney Disease", "MS / Neuroimmune", "Obesity / Metabolic", "Parkinson's", "Solid Tumors (General)"]}, {"company": "Salient Pharmaceuticals Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Calcium aluminosilicate anti-diarrheal", "phase": "Phase II", "indication": "Diarrhea (non-infectious)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.salientpharmaceuticals.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Salient%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Salubris Biotherapeutics Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "JK08", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}, {"name": "JK06", "phase": "IND", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.salubrisbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Salubris%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Samus Therapeutics Inc.", "city": "Topsfield", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Neurology"], "modalityGroups": ["Diagnostics", "Other"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "PU-AD", "phase": "Phase I", "indication": "Alzheimer's disease"}, {"name": "PU-H71", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "PU-PET", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "PU-PET-AD", "phase": "Phase I", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.samustherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Samus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Breast Cancer", "Other Neurology", "Solid Tumors (General)"]}, {"company": "San Rocco Therapeutics LLC", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Cell Therapy", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Thalagen", "phase": "Phase I", "indication": "Thalassemia"}, {"name": "CG-1521 (JW-1521)", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.errantgene.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=San%20Rocco%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematology (non-cancer)"]}, {"company": "Sana Biotechnology Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Endocrine/Metabolic", "Hematology", "Neurology"], "modalityGroups": ["Cell Therapy", "Other"], "nProducts": 13, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SC291", "phase": "Phase I", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "Astrocyte progenitor cell compound", "phase": "Preclinical", "indication": "Huntington disease (HD)"}, {"name": "Oligodendrocyte progenitor cell compound", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "SC187", "phase": "Preclinical", "indication": "Heart failure"}, {"name": "SC255", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}, {"name": "SC379", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "SC451", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "SG221 (CD4/BCMA)", "phase": "Preclinical", "indication": "Multiple myeloma (MM)"}], "ceo": "Steven D. Harr, MD", "employees": 194, "founded": 2018, "website": "http://sana.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 314220330.0, "evFmt": "$314M", "ticker": "SANA", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-01-10", "recentDeals": [{"headline": "Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics announce non-exclusive license agreement for clinically validated BCMA CAR construct", "date": "2022-01-10", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sana%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "Hematologic Cancers", "MS / Neuroimmune", "Neurodegeneration / NMD"]}, {"company": "Sanaria Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "PfSPZ Challenge", "phase": "Phase II", "indication": "Malaria"}, {"name": "PfSPZ-Cvac", "phase": "Phase II", "indication": "Malaria"}, {"name": "Whole-Parasite Malaria Vaccine (PfSPZ Vaccine)", "phase": "Phase II", "indication": "Malaria"}, {"name": "PfSPZ-GA1", "phase": "Phase I", "indication": "Malaria"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.sanaria.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sanaria", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Sancilio Pharmaceuticals Co. Inc.", "city": "Riviera Beach", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Hematology", "Hepatic"], "modalityGroups": ["Nanoparticle / Delivery", "Other"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Altemia", "phase": "Phase II", "indication": "Sickle cell disease"}, {"name": "SC401", "phase": "Preclinical", "indication": "Hypertriglyceridemia"}, {"name": "SC403", "phase": "Preclinical", "indication": "Short bowel syndrome"}, {"name": "SC410", "phase": "Preclinical", "indication": "Liver disease"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.sancilio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sancilio%20Pharmaceuticals%20Co.", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "IBD / GI Inflammatory", "Liver Disease", "Obesity / Metabolic"]}, {"company": "Sanegene Bio Inc. (\u5723\u56e0\u751f\u7269)", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Endocrine/Metabolic"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SGB-3403", "phase": "Phase I", "indication": "Hypercholesterolemia"}, {"name": "SGB-3908", "phase": "Phase I", "indication": "Hypertension"}, {"name": "SGB-9768", "phase": "IND", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.sanegenebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 210500000.0, "totalRaisedFmt": "$210M", "latestFinDate": "2025-12-08", "latestFinType": "Series B rounds", "nRounds": 3, "recentFinancing": [{"type": "Series B rounds", "amount": "$110M", "date": "2025-12-08", "investors": "Institutional Investor, Undisclosed Investor, Sino Biopharmaceutical Ltd., Legend Capital (\u541b\u8054\u8d44\u672c), Vivo Capital, Invus, S..."}, {"type": "Series C rounds", "amount": "$20M", "date": "2025-08-18", "investors": "Qiming Venture Partners (\u542f\u660e\u521b\u6295)"}, {"type": "Series A rounds", "amount": "$80M", "date": "2023-11-30", "investors": "Tencent Holdings Ltd., Yuanbio Ventures, Northern Light Venture Capital (\u5317\u6781\u5149\u521b\u6295), Xiamen C&d Emerging Industry Equity Inv..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sanegene%20Bio%20Inc.%20(\u5723\u56e0\u751f\u7269)", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Cardiovascular", "Obesity / Metabolic"]}, {"company": "Sangamo Therapeutics Inc.", "city": "Richmond", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Hematology", "Neurology", "Transplant"], "modalityGroups": ["Cell Therapy", "Gene Therapy"], "nProducts": 13, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "BIVV003 (SAR445136)", "phase": "Phase I/II", "indication": "Sickle cell disease"}, {"name": "isaralgagene civaparvovec (ST-920)", "phase": "Phase I/II", "indication": "Fabry disease"}, {"name": "TX200 (HLA-A2 CAR-Treg)", "phase": "Phase I/II", "indication": "Organ transplant rejection"}, {"name": "MOG-CAR Treg", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "Sangamo Therapeutics-ALS/FTD-unknown", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "Sangamo Therapeutics-cancer-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Sangamo Therapeutics-inflammatory bowel disease-unknown", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "Sangamo Therapeutics-neuro-developmental disorders-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "Alexander D. Macrae, PhD", "employees": 183, "founded": 1995, "website": "http://www.sangamo.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 194380980.0, "evFmt": "$194M", "ticker": "SGMO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sangamo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "IBD / GI Inflammatory", "MS / Neuroimmune", "Neurodegeneration / NMD", "Other Neurology", "Rare / Genetic", "Solid Tumors (General)", "Transplant"]}, {"company": "Santa Ana Bio Inc.", "city": "Alameda", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Inflammation"], "modalityGroups": ["ADC", "Antibody", "Bispecific Antibody", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SAB01", "phase": "Preclinical", "indication": "Urticaria"}, {"name": "SAB03", "phase": "Preclinical", "indication": "Ankylosing spondylitis"}, {"name": "SAB05", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "SAB06", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "SAB07", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.santaanabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Santa%20Ana%20Bio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "IBD / GI Inflammatory", "Other Inflammation"]}, {"company": "Saol Therapeutics LLC", "city": "Roswell", "state": "GA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Hematology", "Infectious", "Musculoskeletal", "Neurology"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "HepaGam B (Anti-hepatitis B hyperimmune purified antibody", "phase": "Marketed", "indication": "Hepatitis B virus (HBV)"}, {"name": "Varizig (VZIG)", "phase": "Marketed", "indication": "Varicella zoster virus (VZV)"}, {"name": "WinRho SD", "phase": "Marketed", "indication": "Hemolytic disease"}, {"name": "Sodium dichloroacetate (DCA", "phase": "Registration", "indication": "Metabolic (unspecified)"}, {"name": "SL-1002", "phase": "Phase II", "indication": "Spasticity"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.saolrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Saol%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Musculoskeletal", "Obesity / Metabolic", "Other"]}, {"company": "Sapheon Inc.", "city": "Morrisville", "state": "NC", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Pivotal", "hasOrphan": false, "pipeline": [{"name": "VenaSeal Sapheon Closure System", "phase": "Pivotal", "indication": "Peripheral vascular disease (PVD)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.sapheoninc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sapheon", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Sapience Therapeutics Inc.", "city": "Scarsdale", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ST101", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "ST316", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.sapiencetherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sapience%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Solid Tumors (General)"]}, {"company": "Sapvax LLC", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SapVax-ovarian cancer-unknown", "phase": "Preclinical", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://sapvaxllc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sapvax", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Sarcoma Oncology Center Inc.", "city": "Santa Monica", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "DeltaRex-G", "phase": "Approved", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2005, "website": "https://sarcomaoncology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sarcoma%20Oncology%20Center", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Sarcomatrix Therapeutics Corp.", "city": "Reno", "state": "NV", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "laminin-111 (LAM 111", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "S-969", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "sunitinib", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://sarcomatrix.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sarcomatrix%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Sarcomed USA", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "SM001", "phase": "Phase I", "indication": "Sarcoidosis"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.sarcomedusa.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sarcomed%20USA", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Sarepta Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Musculoskeletal", "Neurology"], "modalityGroups": ["Gene Therapy", "RNA Therapeutics"], "nProducts": 22, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Amondys 45", "phase": "Marketed", "indication": "Muscular dystrophy"}, {"name": "Exondys 51", "phase": "Marketed", "indication": "Muscular dystrophy"}, {"name": "Vyondys 53", "phase": "Marketed", "indication": "Muscular dystrophy"}, {"name": "Elevidys", "phase": "Approved", "indication": "Muscular dystrophy"}, {"name": "vesleteplirsen (SRP-5051)", "phase": "Phase II", "indication": "Muscular dystrophy"}, {"name": "patidistrogene bexoparvovec (SRP-9004", "phase": "Phase I/II", "indication": "Muscular dystrophy"}, {"name": "rAAVrh74.MCK.GALGT2 (GALGT2)", "phase": "Phase I/II", "indication": "Muscular dystrophy"}, {"name": "SRP-6004 (MYO-201)", "phase": "Phase I/II", "indication": "Muscular dystrophy"}], "ceo": "Douglas S. Ingram", "employees": 1372, "founded": 1980, "website": "http://www.sareptatherapeutics.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 13104599250.0, "evFmt": "$13.1B", "ticker": "SRPT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sarepta%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Sarfez Pharmaceuticals Inc.", "city": "Mclean", "state": "VA", "country": "United States", "diseaseCats": ["Cardiovascular", "Gastrointestinal", "Hematology", "Renal"], "modalityGroups": ["Other"], "nProducts": 8, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SP20101", "phase": "Phase II", "indication": "Hypertension"}, {"name": "SP20103", "phase": "Phase II", "indication": "Renal (unspecified)"}, {"name": "SP20104", "phase": "Phase II", "indication": "Renal damage"}, {"name": "SP20102", "phase": "Phase I", "indication": "Myeloproliferative disorder"}, {"name": "SP20201", "phase": "Preclinical", "indication": "Pancreatitis"}, {"name": "SP20202", "phase": "Preclinical", "indication": "Diabetic nephropathy"}, {"name": "SP20301", "phase": "Preclinical", "indication": "Congestive heart failure (CHF)"}, {"name": "SP20302", "phase": "Preclinical", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://sarfez.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sarfez%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "Hematologic Cancers", "Kidney Disease", "Supportive / Other"]}, {"company": "Saronic Biotechnology Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "SBI1997", "phase": "Phase I/II", "indication": "Liver cancer"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.saronicbiotechnology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Saronic%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Saros Therapeutics Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Saros Therapeutics-STING program-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.sarostx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Saros%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Savara Inc.", "city": "Langhorne", "state": "PA", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Pulmonary"], "modalityGroups": ["Macrocycle", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "Molbreevi", "phase": "Registration", "indication": "Autoimmune (unspecified)"}, {"name": "AeroVanc (SAV005)", "phase": "Phase III", "indication": "Staphylococcus"}], "ceo": "Matthew Pauls, MBA", "employees": 59, "founded": 2007, "website": "http://savarapharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 438944243.52, "evFmt": "$439M", "ticker": "SVRA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Savara", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Infectious Disease"]}, {"company": "Schedule 1 Therapeutics Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Schedule 1 Therapeutics-Pain-Unknown", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.s1therapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Schedule%201%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Scholar Rock Holding Corp.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hematology", "Musculoskeletal", "Neurology", "Renal"], "modalityGroups": ["Antibody"], "nProducts": 5, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "apitegromab (SRK-015)", "phase": "Registration", "indication": "Spinal muscular atrophy (SMA)"}, {"name": "Scholar Rock-neuromuscular disorders-unknown", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "SRK-256", "phase": "Preclinical", "indication": "Anemia"}, {"name": "SRK-373", "phase": "Preclinical", "indication": "Renal (unspecified)"}, {"name": "SRK-439", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "David L. Hallal", "employees": 196, "founded": 2012, "website": "https://scholarrock.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 3942850768.44, "evFmt": "$3.9B", "ticker": "SRRK", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scholar%20Rock%20Holding", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Kidney Disease", "Neurodegeneration / NMD", "Obesity / Metabolic", "Other Neurology"]}, {"company": "Schrodinger Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "SGR-1505 (SDGR3)", "phase": "IND", "indication": "B cell lymphoma"}, {"name": "SDGR1", "phase": "Preclinical", "indication": "Esophageal cancer"}, {"name": "SDGR2", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Ramy Farid, PhD", "employees": 891, "founded": 1990, "website": "http://www.schrodinger.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1152183990.55, "evFmt": "$1.2B", "ticker": "SDGR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Schrodinger", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Scibac Inc.", "city": "Burlingame", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Aeruguard (SCB-203)", "phase": "Preclinical", "indication": "Pseudomonas"}, {"name": "DiffiKil", "phase": "Preclinical", "indication": "Clostridium"}, {"name": "Mybacguard (SCB-211)", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.scibac.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scibac", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Rare / Genetic"]}, {"company": "Sciclone Pharmaceuticals Holdings Ltd.", "city": "Foster City", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Other"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Zadaxin", "phase": "Marketed", "indication": "Hepatitis B virus (HBV)"}], "ceo": "", "employees": 0, "founded": 1990, "website": "http://www.sciclone.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sciclone%20Pharmaceuticals%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Scienture Holdings Inc.", "city": "Lutz", "state": "FL", "country": "United States", "diseaseCats": ["Cardiovascular", "Neurology"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Arbli", "phase": "Marketed", "indication": "Hypertension"}, {"name": "multi-dose dihydroergotamine mesylate injection pen (SCN-104)", "phase": "Phase I", "indication": "Migraine"}, {"name": "SCN-106", "phase": "Phase I", "indication": "Thrombosis"}, {"name": "bupivacaine (SCN-107)", "phase": "Preclinical", "indication": "Pain"}], "ceo": "Shankar Hariharan, PhD; Narasimhan Mani, PhD, MBA", "employees": 19, "founded": 2010, "website": "https://scienture.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 23645121.25, "evFmt": "$24M", "ticker": "SCNX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scienture%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Pain / Migraine"]}, {"company": "Scilex Holding Co.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "ZTlido", "phase": "Marketed", "indication": "Pain"}, {"name": "5.4% lidocaine patch (SP-103)", "phase": "Phase II", "indication": "Pain"}, {"name": "SP-104 (ARD-301)", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Henry H. Ji, PhD", "employees": 115, "founded": 2019, "website": "https://www.scilexpharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 97403401.9352, "evFmt": "$97M", "ticker": "SCLX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scilex%20Holding", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Pain / Migraine"]}, {"company": "Scineuro Therapeutics Inc. (Scineuro Pharmaceuticals)", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SNP234", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.scineuro.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 53000000.0, "totalRaisedFmt": "$53M", "latestFinDate": "2025-12-04", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$53M", "date": "2025-12-04", "investors": "Lilly Asia Ventures (\u793c\u6765\u4e9a\u6d32\u57fa\u91d1), Arch Venture Partners, New Investors, Existing Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scineuro%20Therapeutics%20Inc.%20(Scineuro%20Pharmaceuticals)", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Scioto Biosciences Inc.", "city": "Indianapolis", "state": "IN", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Gastrointestinal", "Infectious", "Neurology"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SB-121 (Lactobacillus reuteri)", "phase": "Phase I", "indication": "Autism"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://sciotobiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scioto%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Scipher Medicine Corp.", "city": "Waltham", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "PrismRA", "phase": "Market (diagnostic)", "indication": "Autoimmune, Diagnostic"}, {"name": "PrismUC", "phase": "Development (diagnostic)", "indication": "Autoimmune, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-11-28", "recentDeals": [{"headline": "Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis", "date": "2023-11-28", "value": ""}, {"headline": "Scipher Medicine Signs Multi-Target Partnership with Ionis", "date": "2023-07-17", "value": ""}], "totalRaised": 110000000.0, "totalRaisedFmt": "$110M", "latestFinDate": "2022-02-24", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$110M", "date": "2022-02-24", "investors": "Cowen Healthcare Investments, Neuberger Berman Group, Hitachi Ventures, Laurion Capital Management L.P., Monashee Invest..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scipher%20Medicine", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Scitech Development LLC", "city": "Grosse Pointe Farms", "state": "MI", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "ST-001 nanoFenretinide", "phase": "Phase I", "indication": "Cutaneous T cell lymphoma (CTCL)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "https://www.scitechdevelopment.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scitech%20Development", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Scopus Biopharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "OLIM-01", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Scopus BioPharma (SBP-101)", "phase": "Preclinical", "indication": "Anesthesia"}], "ceo": "Morris C. Laster, MD", "employees": 0, "founded": 2017, "website": "https://scopusbiopharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "SCPS", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scopus%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)", "Supportive / Other"]}, {"company": "Scriptr Global Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CAN204", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://scriptr.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scriptr%20Global", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Scynexis Inc.", "city": "Jersey City", "state": "NJ", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Brexafemme", "phase": "Marketed", "indication": "Candida"}, {"name": "IV SCY-078", "phase": "Phase II", "indication": "Aspergillus"}, {"name": "SCY-635", "phase": "Phase II", "indication": "Hepatitis C virus (HCV)"}], "ceo": "David Angulo Gonzalez, MD", "employees": 28, "founded": 1999, "website": "http://www.scynexis.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 15235818.33, "evFmt": "$15M", "ticker": "SCYX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Scynexis", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Other"]}, {"company": "Sea Pharmaceuticals LLC", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology", "Otologic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SPM-0404", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "SPM-0606", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.seapharmaceuticals.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sea%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Seal Rock Therapeutics Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SRT-015", "phase": "Phase I", "indication": "Non-alcoholic steatohepatitis (NASH)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.sealrocktx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seal%20Rock%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Seaport Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SPT-300 (LYT-300)", "phase": "Phase II", "indication": "Depression"}, {"name": "SPT-320 (LYT-320)", "phase": "Preclinical", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 2024, "website": "https://seaporttx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seaport%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Sebela Pharmaceuticals Inc.", "city": "Roswell", "state": "GA", "country": "United States", "diseaseCats": ["Dermatology", "Gastrointestinal", "Genitourinary"], "modalityGroups": ["Digital / Device", "Other", "Small Molecule", "Undisclosed"], "nProducts": 11, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Suprep (BLI-800", "phase": "Marketed", "indication": "Gastrointestinal (unspecified)"}, {"name": "GoLytely", "phase": "Marketed", "indication": "Gastrointestinal (unspecified)"}, {"name": "NuLytely", "phase": "Marketed", "indication": "Gastrointestinal (unspecified)"}, {"name": "BLI4900", "phase": "Registration", "indication": "Gastrointestinal (GI) dysfunction"}, {"name": "BLI400", "phase": "Phase III", "indication": "Constipation"}, {"name": "BLI5100", "phase": "Phase III", "indication": "Gastrointestinal (GI) dysfunction"}, {"name": "COPPER 175 mm IUD", "phase": "Phase III", "indication": "Sexual dysfunction"}, {"name": "BLI801", "phase": "Phase II/III", "indication": "Constipation"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.sebelapharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sebela%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other", "Other Specialties", "Supportive / Other"]}, {"company": "Second Genome Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Hepatic"], "modalityGroups": ["Protein / Biologic", "Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SGM-1019", "phase": "Phase II", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "SG-2-0776", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "SG-5-00455", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.secondgenome.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Second%20Genome", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Obesity / Metabolic"]}, {"company": "Seed Therapeutics Inc.", "city": "King Of Prussia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RBM39", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Seed Therapeutics-KRAS G12D-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Seed Therapeutics-cancer-unknown", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "Seed Therapeutics-infectious disease-unknown", "phase": "Research", "indication": "Infectious (unspecified)"}, {"name": "Seed Therapeutics-neurodegeneration-unknown", "phase": "Research", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.seedtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 30000000.0, "totalRaisedFmt": "$30M", "latestFinDate": "2025-08-01", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$6M", "date": "2025-08-01", "investors": "Undisclosed Investors"}, {"type": "Series A rounds", "amount": "$24M", "date": "2024-08-06", "investors": "Eisai Co. Ltd., Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seed%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Seelos Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Endocrine/Metabolic", "Genitourinary", "Infectious", "Inflammation", "Musculoskeletal", "Neurology"], "modalityGroups": ["Gene Therapy", "Other", "Small Molecule", "Undisclosed"], "nProducts": 11, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Savene", "phase": "Marketed", "indication": "Tissue damage"}, {"name": "Vitaros", "phase": "Marketed", "indication": "Erectile dysfunction (ED)"}, {"name": "alprostadil (Femprox)", "phase": "Phase III", "indication": "Female sexual arousal disorder (FSAD)"}, {"name": "MycoVa (NM100060", "phase": "Phase III", "indication": "Onychomycosis"}, {"name": "SLS-005 (trehalose)", "phase": "Phase II/III", "indication": "Muscular dystrophy"}, {"name": "RayVa", "phase": "Phase II", "indication": "Raynaud's disease"}, {"name": "SLS-002", "phase": "Phase II", "indication": "Depression"}, {"name": "SLS-004 (CLRI-001)", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.seelostherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seelos%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Neurodegeneration / NMD", "Other", "Other Specialties", "Parkinson's", "Psychiatry / Behavioral", "Supportive / Other"]}, {"company": "Seismic Therapeutic Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "S-1117", "phase": "Preclinical", "indication": "Immunodeficiency"}, {"name": "S-4321", "phase": "Preclinical", "indication": "Immunodeficiency"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://seismictx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-01-04", "recentDeals": [{"headline": "Integral Molecular Enters Into Exclusive Antibody License With Seismic Therapeutic", "date": "2024-01-04", "value": ""}], "totalRaised": 222000000.0, "totalRaisedFmt": "$222M", "latestFinDate": "2023-12-04", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$121M", "date": "2023-12-04", "investors": "Bessemer Venture Partners, Amgen Ventures, Codon Capital, Alexandria Venture Investments LLC, Gaingels, Gc&h Investments..."}, {"type": "Series A rounds", "amount": "$101M", "date": "2022-02-09", "investors": "Lightspeed Venture Partners, Individual Investors, Polaris Partners, Gv, Boxer Capital, Samsara Biocapital L.P., Undiscl..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seismic%20Therapeutic", "hasDealsFin": true, "diseaseGroups": ["Other Inflammation"]}, {"company": "Seldar Pharma Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "ASP7147", "phase": "Phase II", "indication": "Irritable bowel syndrome"}], "ceo": "", "employees": 0, "founded": 2012, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seldar%20Pharma", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Selection Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "si-544 (Cgtx-544)", "phase": "Phase I", "indication": "Psoriasis"}], "ceo": "", "employees": 0, "founded": 2002, "website": "https://selectiontherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Selection", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Sellas Life Sciences Group Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Small Molecule", "Vaccine"], "nProducts": 7, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "galinpepimut-S (WT1 vaccine", "phase": "Phase III", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Anagrelide CR (GALE-401)", "phase": "Phase II", "indication": "Thrombocytopenia"}, {"name": "FBP vaccine (GALE-301)", "phase": "Phase II", "indication": "Endometrial cancer"}, {"name": "NeuVax", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "GALE-302", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "GALE-301/GALE-302", "phase": "Phase I", "indication": "Breast cancer"}, {"name": "galinpepimut-S+", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Angelos M. Stergiou, MD", "employees": 15, "founded": 2012, "website": "http://www.sellaslifesciences.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 50665508.48, "evFmt": "$51M", "ticker": "SLS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sellas%20Life%20Sciences%20Group", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Hematologic Cancers", "Hematology (non-cancer)", "Solid Tumors (General)"]}, {"company": "Selva Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SLV213", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://selvarx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Selva%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Semnur Pharmaceuticals Inc.", "city": "Palo Alto", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Semdexa (SP-102)", "phase": "Phase III", "indication": "Pain"}], "ceo": "Jaisim Shah, MBA", "employees": 2, "founded": 2013, "website": "https://semnurpharma.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 65530391.585, "evFmt": "$66M", "ticker": "SMNR", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Semnur%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Sen-jam Pharmaceutical LLC", "city": "Huntington", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 7, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SJP-002C", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "SJP-001", "phase": "IND", "indication": "Inflammation (unspecified)"}, {"name": "SJP-005", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "SJP-006", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "SJP-007", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "SJP-100", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "SJP-004", "phase": "Research", "indication": "Arthritis"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://sen-jam.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-03-22", "recentDeals": [{"headline": "Sen-Jam Pharmaceutical partners with specialty pharmaceutical manufacturer to provide formulation and chemistry, manufacturing & controls for covid-19 oral therapeutic", "date": "2022-03-22", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2025-01-22", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2025-01-22", "investors": "5 Horizons Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sen-jam%20Pharmaceutical", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease", "Other", "Other Inflammation", "Psychiatry / Behavioral"]}, {"company": "Sengine Precision Medicine Inc.", "city": "Seattle", "state": "", "country": "United States", "diseaseCats": ["Cancer", "Diagnostic"], "modalityGroups": ["Diagnostics", "Other", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "PARIS Test", "phase": "Marketed", "indication": "Cancer, Diagnostic"}, {"name": "MYC-SL1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "MYC-SL2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "RAS-SL1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "RAS-SL2", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 10000000.0, "totalRaisedFmt": "$10M", "latestFinDate": "2022-07-28", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$10M", "date": "2022-07-28", "investors": "Washington Research Foundation, Alethea Capital Management, Vincere Capital Biotech LLC, Bangarang Group, Undisclosed In..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sengine%20Precision%20Medicine", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Sensei Biotherapeutics Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Vaccine"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SNS-301 (PAN-301-1)", "phase": "Phase II", "indication": "Head and neck cancer"}, {"name": "SNS-101", "phase": "IND", "indication": "Solid tumors"}, {"name": "SNS-103", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "SNS-401", "phase": "Preclinical", "indication": "Skin cancer"}, {"name": "SNS-VISTA", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Christopher W. Gerry", "employees": 15, "founded": 1999, "website": "https://www.senseibio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -25180041.6562, "evFmt": "", "ticker": "SNSE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sensei%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Senseion Therapeutics Inc.", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SN-40X", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.senseion.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Senseion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Sensor Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SEN-20128", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sensor%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Sensorium Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SENS-01", "phase": "Preclinical", "indication": "Anxiety"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.sensorium.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sensorium%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Senti Biosciences Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SENTI-202", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "SENTI-301A", "phase": "Phase I", "indication": "Liver cancer"}, {"name": "Senti Biosciences-multiple iPSC cell therapy programs-unknown", "phase": "Preclinical", "indication": "Tissue damage"}], "ceo": "Timothy K. Lu, MD, PhD", "employees": 34, "founded": 2016, "website": "http://www.sentibio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 26601770.46, "evFmt": "$27M", "ticker": "SNTI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Senti%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Hematologic Cancers", "Supportive / Other"]}, {"company": "Sentien Biotechnologies Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation", "Renal"], "modalityGroups": ["Cell Therapy", "Other"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "sbi-101", "phase": "Phase I/II", "indication": "Renal damage"}, {"name": "Sentien-acute inflammation-mediated disease-unknown", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.sentienbiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sentien%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease", "Other Inflammation"]}, {"company": "Sequella Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Diagnostic", "Infectious"], "modalityGroups": ["Diagnostics", "Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "TB Patch", "phase": "Phase III", "indication": "Infectious, Diagnostic"}, {"name": "SQ109", "phase": "Phase II/III", "indication": "Tuberculosis"}, {"name": "SQ641", "phase": "Preclinical", "indication": "Clostridium"}], "ceo": "", "employees": 0, "founded": 1996, "website": "http://www.sequella.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sequella", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Sequoia Vaccines Inc.", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SEQ-400", "phase": "Phase I", "indication": "Urinary tract infection (UTI)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.sequoiavaccines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sequoia%20Vaccines", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Sera Prognostics Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "PreTRM test", "phase": "Marketed", "indication": "Genitourinary, Diagnostic"}], "ceo": "Evguenia Lindgardt, MBA", "employees": 64, "founded": 2008, "website": "http://www.seraprognostics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 224501459.04, "evFmt": "$225M", "ticker": "SERA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sera%20Prognostics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Seraxis Pte. Ltd.", "city": "Germantown", "state": "MD", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SR-01", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.seraxis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seraxis%20Pte.", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Serenity Bioworks Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SER-101 (DC-TAB)", "phase": "Preclinical", "indication": "Lupus"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.serenitybioworks.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Serenity%20Bioworks", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Seres Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Transplant"], "modalityGroups": ["Oncolytic / Microbiome", "Other"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "SER-287", "phase": "Phase II", "indication": "Ulcerative colitis"}, {"name": "SER-155", "phase": "Phase I", "indication": "Graft-versus-host disease (GvHD)"}, {"name": "SER-301", "phase": "Phase I", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "Thomas J. DesRosier; Ann Marella Thorell, CPA", "employees": 103, "founded": 2010, "website": "http://serestherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 189985031.56, "evFmt": "$190M", "ticker": "MCRB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seres%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "IBD / GI Inflammatory"]}, {"company": "Serina Therapeutics Inc.", "city": "Huntsville", "state": "AL", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Cell Therapy", "Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SER-214", "phase": "Phase I", "indication": "Parkinson's disease"}, {"name": "AGEX-BAT1", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "AGEX-iTR1547", "phase": "Preclinical", "indication": "Congestive heart failure (CHF)"}, {"name": "AGEX-VASC1", "phase": "Preclinical", "indication": "Coronary artery disease (CAD)"}, {"name": "POZ-apomorphine (SER-252)", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "Steven A. Ledger", "employees": 13, "founded": 2007, "website": "https://serinatherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 33524590.0, "evFmt": "$34M", "ticker": "SER", "exchange": "NYSE-A", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-05-15", "recentDeals": [{"headline": "Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse for Advanced Parkinson\u2019s Disease", "date": "2024-05-15", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Serina%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Diabetes", "Parkinson's"]}, {"company": "Serometrix LLC", "city": "Pittsford", "state": "NY", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SX-PCK9", "phase": "Preclinical", "indication": "Hypercholesterolemia"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.serometrix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Serometrix", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Serpin Pharma LLC", "city": "Manassas", "state": "VA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SP16", "phase": "Phase I", "indication": "Neuropathy"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.serpinpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Serpin%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Seven and Eight Biopharmaceuticals Inc.", "city": "Edison", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "BDB001", "phase": "Phase II/III", "indication": "Melanoma"}, {"name": "BDB018", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "BDB101", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "BDB102", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-06-01", "recentDeals": [{"headline": "Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists", "date": "2023-06-01", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seven%20and%20Eight%20Biopharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Seyltx Inc.", "city": "New Castle", "state": "DE", "country": "United States", "diseaseCats": ["Cancer", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ifenprodil (NP-120)", "phase": "Phase II", "indication": "Cough"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://seyltx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Seyltx", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Shal Technologies Inc.", "city": "Livermore", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SH7139", "phase": "Preclinical", "indication": "Non-Hodgkin lymphoma (NHL)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.shaltech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Shal%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Shasqi Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "SQ3370", "phase": "Phase I/II", "indication": "Sarcoma"}, {"name": "SQ0170", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.shasqi.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Shasqi", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Shattuck Labs Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SL-172154", "phase": "Phase I", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "SL-115154", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SL-279137", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SL-325", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "SL-6159", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SL-9258", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Taylor H. Schreiber, MD, PhD", "employees": 44, "founded": 2016, "website": "http://www.shattucklabs.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -8163469.1, "evFmt": "", "ticker": "STTK", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Shattuck%20Labs", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "IBD / GI Inflammatory", "Solid Tumors (General)"]}, {"company": "Shifa Biomedical Corp.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "P-21", "phase": "Preclinical", "indication": "Dyslipidemia"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.shifabiomedical.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Shifa%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Shinkei Therapeutics", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MR-201", "phase": "Phase I", "indication": "Emotional lability"}, {"name": "MR-301", "phase": "IND", "indication": "Shock/trauma"}, {"name": "MR-401", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.shinkeitherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Shinkei%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Other", "Supportive / Other"]}, {"company": "Shoreline Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Shoreline iPSC NK cells", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://shorelinebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Shoreline%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Shuttle Pharmaceuticals Holdings Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "IPdR", "phase": "Phase II", "indication": "Sarcoma"}, {"name": "Doranidazole", "phase": "Phase 0", "indication": "Pancreatic cancer"}, {"name": "Shuttle-HDAC6-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Shuttle-histone deacetylase (HDAC)-unknown", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "SP-2-225", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.shuttlepharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "SHPH", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Shuttle%20Pharmaceuticals%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Siege Pharmaceuticals Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SGE-893", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.kairosventures.com/siege-pharmaceuticals/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Siege%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Siga Technologies Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Oral TPOXX", "phase": "Marketed", "indication": "Smallpox"}, {"name": "IV TPOXX", "phase": "Approved", "indication": "Smallpox"}, {"name": "Dengue antiviral", "phase": "Preclinical", "indication": "Dengue fever"}, {"name": "ST-357 (Liquid TPOXX)", "phase": "Preclinical", "indication": "Smallpox"}], "ceo": "Diem Nguyen, PhD, MBA", "employees": 46, "founded": 1995, "website": "http://www.siga.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 278099887.12, "evFmt": "$278M", "ticker": "SIGA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Siga%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Signalrx Pharmaceuticals Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SF1126", "phase": "Phase I", "indication": "Liver cancer"}, {"name": "SF2523", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SF2535", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SF2558HA", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SF2626", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.signalrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Signalrx%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Signpath Pharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Lipocurc", "phase": "Phase I/II", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.signpathpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Signpath%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Signum Dermalogix Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "DMT210", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "SIG1311", "phase": "Preclinical", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.signumdermalogix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Signum%20Dermalogix", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Silk Road Therapies Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "pentoxifylline (tPTX", "phase": "Phase II", "indication": "Behcet disease"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://silkroadthx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Silk%20Road%20Therapies", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Silo Pharma Inc.", "city": "Sarasota", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Musculoskeletal", "Neurology"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ketamine (SP-26 with subcutaneous insertion device)", "phase": "Preclinical", "indication": "Fibromyalgia syndrome"}, {"name": "ketamine (SP-26)", "phase": "Preclinical", "indication": "Fibromyalgia syndrome"}, {"name": "SPC-14", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "SPC-15", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "SPU-16", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "Eric Weisblum", "employees": 3, "founded": 2010, "website": "http://silopharma.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -3804976.79, "evFmt": "", "ticker": "SILO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Silo%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "MS / Neuroimmune", "Musculoskeletal", "Other Neurology"]}, {"company": "Silver Creek Pharmaceuticals Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SFG-1", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.silvercreekpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Silver%20Creek%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Simcha Therapeutics Holding Co. LLC", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "ST-067", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "Simcha Therapeutics Holding-cancer-undisclosed", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.simchatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-08-16", "recentDeals": [{"headline": "Simcha Therapeutics expands research and option agreement with Yale School of Medicine", "date": "2022-08-16", "value": ""}], "totalRaised": 40000000.0, "totalRaisedFmt": "$40M", "latestFinDate": "2022-01-27", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$40M", "date": "2022-01-27", "investors": "Sr One, Bvf Partners L.P., Samsara Biocapital L.P., Rock Springs Capital, Arrowmark Partners, Logos Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Simcha%20Therapeutics%20Holding%20Co.", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Sinopia Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SB-0110", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.sinopiabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sinopia%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Parkinson's"]}, {"company": "Siolta Therapeutics Inc.", "city": "San Carlos", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Endocrine/Metabolic", "Infectious", "Inflammation"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "STMC-103H", "phase": "Phase II", "indication": "Dermatitis"}, {"name": "STMC-123R", "phase": "Preclinical", "indication": "Infectious (unspecified)"}, {"name": "STMC-144M", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.sioltatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 12000000.0, "totalRaisedFmt": "$12M", "latestFinDate": "2024-03-12", "latestFinType": "Series C rounds", "nRounds": 1, "recentFinancing": [{"type": "Series C rounds", "amount": "$12M", "date": "2024-03-12", "investors": "Symbiosis Capital Management, Khosla Ventures, Existing Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Siolta%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Infectious Disease", "Obesity / Metabolic"]}, {"company": "Sionna Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SION-638", "phase": "Phase I", "indication": "Cystic fibrosis (CF)"}, {"name": "SION-109", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}, {"name": "SION-451", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}, {"name": "SION-676", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}, {"name": "SION-719", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}], "ceo": "Michael Cloonan, MBA", "employees": 41, "founded": 2019, "website": "https://www.sionnatx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "SION", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-07-16", "recentDeals": [{"headline": "Sionna Therapeutics Expands Pipeline with Multiple Clinical Stage Cystic Fibrosis Compounds Through a License Agreement with AbbVie", "date": "2024-07-16", "value": ""}], "totalRaised": 293000000.0, "totalRaisedFmt": "$293M", "latestFinDate": "2024-03-06", "latestFinType": "Series C rounds", "nRounds": 2, "recentFinancing": [{"type": "Series C rounds", "amount": "$182M", "date": "2024-03-06", "investors": "Enavate Sciences, Viking Global Investors, Perceptive Advisors, Ra Capital Management L.P., Orbimed Advisors LLC, Tpg, A..."}, {"type": "Series B rounds", "amount": "$111M", "date": "2022-04-19", "investors": "Orbimed Advisors LLC, T. Rowe Price Associates Inc., Q Healthcare Holdings LLC, Ra Capital Advisors, The Rise Fund, Atla..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sionna%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Sirius Therapeutics Inc. (\u9756\u56e0\u836f\u4e1a)", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SRSD101", "phase": "Phase I", "indication": "Dyslipidemia"}, {"name": "SRSD107", "phase": "Phase I", "indication": "Thrombosis"}, {"name": "SRSD216", "phase": "IND", "indication": "Dyslipidemia"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.siriusrna.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 150000000.0, "totalRaisedFmt": "$150M", "latestFinDate": "2025-05-09", "latestFinType": "Series B rounds", "nRounds": 3, "recentFinancing": [{"type": "Series B rounds", "amount": "$50M", "date": "2025-05-09", "investors": "Undisclosed Investor, Biotrack Capital, Orbimed Advisors LLC, Creacion Ventures, Hankang Capital"}, {"type": "Series B rounds", "amount": "$60M", "date": "2023-10-09", "investors": "Hankang Capital, Delos Capital, Orbimed Advisors LLC, Creacion Ventures"}, {"type": "Series A rounds", "amount": "$40M", "date": "2022-07-01", "investors": "Orbimed Advisors LLC, Creacion Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sirius%20Therapeutics%20Inc.%20(\u9756\u56e0\u836f\u4e1a)", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Obesity / Metabolic"]}, {"company": "Sirnaomics Ltd.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dermatology", "Endocrine/Metabolic", "Hepatic", "Infectious", "Other", "Pulmonary"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 11, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Cutasil (SGY-101", "phase": "Phase II", "indication": "Skin cancer"}, {"name": "STP707", "phase": "Phase I", "indication": "Primary sclerosing cholangitis"}, {"name": "STP302", "phase": "IND", "indication": "Colorectal cancer"}, {"name": "STP122G", "phase": "Preclinical", "indication": "Blood clots"}, {"name": "STP133G", "phase": "Preclinical", "indication": "Dyslipidemia"}, {"name": "STP144G", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "STP355", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "STP702", "phase": "Preclinical", "indication": "Influenza virus"}], "ceo": "Hong Hui Pan, PhD, MBA", "employees": 69, "founded": 2007, "website": "http://www.sirnaomics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 40239246.443789, "evFmt": "$40M", "ticker": "2257", "exchange": "HKEX", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sirnaomics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Cardiovascular", "GI Cancers", "Infectious Disease", "Liver Disease", "Obesity / Metabolic", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Sironax Ltd. (\u7ef4\u6cf0\u745e\u9686)", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation", "Musculoskeletal", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "SIR2501", "phase": "Phase I/II", "indication": "Neurology (unspecified)"}, {"name": "SIR2446", "phase": "Phase I", "indication": "Central nervous system (CNS) disorders"}, {"name": "SIR4156", "phase": "Phase I", "indication": "Musculoskeletal (unspecified)"}, {"name": "SIR9900", "phase": "Phase I", "indication": "Central nervous system (CNS) disorders"}, {"name": "SIR8752", "phase": "Preclinical", "indication": "Inflammatory disease"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.sironax.com.cn/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 200000000.0, "totalRaisedFmt": "$200M", "latestFinDate": "2022-08-02", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$200M", "date": "2022-08-02", "investors": "Gaorong Ventures (\u9ad8\u6995\u521b\u6295), Yunfeng Capital, Temasek, Invus, F-prime Inc. (F-prime Capital Partners), Eight Roads Ventures,..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sironax%20Ltd.%20(\u7ef4\u6cf0\u745e\u9686)", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Brain / CNS Tumors", "Musculoskeletal", "Other Neurology"]}, {"company": "Sirpant Immunotherapeutics Inc.", "city": "Hummelstown", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SIRPant-M (SI-101)", "phase": "Preclinical", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://sirpantimmunotx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sirpant%20Immunotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer"]}, {"company": "Siwa Therapeutics Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SIWA 318", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.siwatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Siwa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Skny Pharmaceuticals Inc.", "city": "Delaware", "state": "OH", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SKNY-1", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "", "employees": 0, "founded": 2024, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Skny%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Skye Bioscience Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic", "Ophthalmic"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "nimacimab", "phase": "Phase II", "indication": "Obesity"}, {"name": "THCVHS (SBI-100", "phase": "Phase II", "indication": "Glaucoma"}], "ceo": "Punit S. Dhillon", "employees": 16, "founded": 2011, "website": "https://skyebioscience.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 35296697.77, "evFmt": "$35M", "ticker": "SKYE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Skye%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Ophthalmology"]}, {"company": "Skyhawk Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "SKY-0515", "phase": "Phase II/III", "indication": "Huntington disease (HD)"}, {"name": "Skyhawk Neuro Target 2", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Skyhawk Neuro Target 3", "phase": "Preclinical", "indication": "Neurology (unspecified)"}, {"name": "Skyhawk Oncology Target 1", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.skyhawktx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Skyhawk%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Other Neurology", "Solid Tumors (General)"]}, {"company": "Slate Bio Inc.", "city": "Charlottesville", "state": "VA", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "IL233", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "http://slatebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Slate%20Bio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Slayback Pharma LLC", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Prevduo", "phase": "Marketed", "indication": "Anesthesia"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.slayback-pharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Slayback%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Slbst Pharma Inc.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Slbst Pharma-endometriosis-unknown", "phase": "Phase II", "indication": "Endometriosis"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.slbstpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Slbst%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Women's Health"]}, {"company": "Slil Biomedical Corp.", "city": "Madison", "state": "WI", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "SLI 1047", "phase": "Phase I/II", "indication": "Lymphoma"}], "ceo": "", "employees": 0, "founded": 1996, "website": "http://www.slil.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Slil%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Smc Biotechnology Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SMC-103", "phase": "Preclinical", "indication": "Bone repair"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.smcbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Smc%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Sno Bio Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SNO1 Programs", "phase": "Preclinical", "indication": "Cardiovascular (unspecified)"}, {"name": "SNO2 Programs", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SNO3 Programs", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://sno-bio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sno%20Bio", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Other Neurology", "Solid Tumors (General)"]}, {"company": "Soin Neuroscience Inc.", "city": "Dayton", "state": "OH", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Musculoskeletal", "Neurology", "Renal"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TV1001SR", "phase": "Phase II", "indication": "Cardiovascular (unspecified)"}, {"name": "Soin-myopathy-unknown", "phase": "Phase I", "indication": "Musculoskeletal (unspecified)"}, {"name": "Soin-stroke-unknown", "phase": "Preclinical", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.soinneuroscience.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Soin%20Neuroscience", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Musculoskeletal", "Other Neurology"]}, {"company": "Sola Biosciences LLC", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SOL-257", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.sola-bio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sola%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Soleno Therapeutics Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Vykat XR", "phase": "Approved", "indication": "Obesity"}, {"name": "Nasal CO2", "phase": "Phase II", "indication": "Migraine"}], "ceo": "Anish Bhatnagar, MD", "employees": 92, "founded": 1999, "website": "https://soleno.life/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1567296873.7, "evFmt": "$1.6B", "ticker": "SLNO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Soleno%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Pain / Migraine"]}, {"company": "Solid Biosciences Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Musculoskeletal", "Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "IND", "hasOrphan": true, "pipeline": [{"name": "SGT-003", "phase": "IND", "indication": "Muscular dystrophy"}, {"name": "AVB-202", "phase": "Preclinical", "indication": "Friedreich ataxia"}, {"name": "AVB-401", "phase": "Preclinical", "indication": "Cardiomyopathy"}], "ceo": "Alexander Gery Cumbo", "employees": 100, "founded": 2013, "website": "http://solidbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 38523776.0, "evFmt": "$39M", "ticker": "SLDB", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-09-23", "recentDeals": [{"headline": "Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101", "date": "2025-09-23", "value": ""}, {"headline": "Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD", "date": "2024-03-07", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Solid%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Neurodegeneration / NMD"]}, {"company": "Soligenix Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Gastrointestinal", "Infectious", "Other"], "modalityGroups": ["Other", "Peptide", "Small Molecule", "Vaccine"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "dusquetide (SGX94", "phase": "Phase III", "indication": "Mucositis"}, {"name": "HyBryte", "phase": "Phase III", "indication": "Cutaneous T cell lymphoma (CTCL)"}, {"name": "SGX203", "phase": "Phase II", "indication": "Crohn's disease"}, {"name": "SGX201", "phase": "Phase I/II", "indication": "Gastroenteritis"}, {"name": "OrbeShield (SGX202)", "phase": "Phase I", "indication": "Poisoning"}, {"name": "Ricin Toxin Vaccine", "phase": "Phase I", "indication": "Poisoning"}, {"name": "CiVax", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "SGX943", "phase": "Preclinical", "indication": "Bacterial infection"}], "ceo": "Christopher J. Schaber, PhD", "employees": 16, "founded": 1987, "website": "http://www.soligenix.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -1859965.965, "evFmt": "", "ticker": "SNGX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Soligenix", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "IBD / GI Inflammatory", "Infectious Disease", "Other", "Supportive / Other"]}, {"company": "Sollis Therapeutics Inc.", "city": "Columbus", "state": "OH", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "STX-015 (clonidine micropellet)", "phase": "Phase III", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.sollistx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sollis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Soltego Inc.", "city": "Newport Beach", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Soltego-dermatology-SIK inhibitor", "phase": "Preclinical", "indication": "Vitiligo"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.soltego.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Soltego", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Solu Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "STX-0712", "phase": "Phase I", "indication": "Hematologic malignancies"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://solutherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-08-01", "recentDeals": [{"headline": "Solu Therapeutics in-licenses Cytotoxicity Targeting Chimera platform from GSK", "date": "2023-08-01", "value": ""}], "totalRaised": 72000000.0, "totalRaisedFmt": "$72M", "latestFinDate": "2025-04-09", "latestFinType": "Series A rounds", "nRounds": 2, "recentFinancing": [{"type": "Series A rounds", "amount": "$41M", "date": "2025-04-09", "investors": "Eli Lilly and Co., Biovision Ventures, Pappas Capital LLC, Hengdian Group, The Leukemia & Lymphoma Society, Longwood Fun..."}, {"type": "Seed financings", "amount": "$31M", "date": "2023-08-01", "investors": "Longwood Fund, Sante Ventures, Dcvc Bio, Astellas Venture Management, Alexandria Venture Investments LLC"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Solu%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Solve Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SLV-154", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "SLV-324", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://solvetx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-06-05", "recentDeals": [{"headline": "Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates", "date": "2023-06-05", "value": ""}], "totalRaised": 296388557.0, "totalRaisedFmt": "$296M", "latestFinDate": "2025-11-17", "latestFinType": "Uncategorized venture rounds", "nRounds": 3, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$120M", "date": "2025-11-17", "investors": "Yosemite, Abingworth Management Ltd., Ally Bridge Group, B Capital Group, Balyasny Asset Management L.P., Merck & Co. In..."}, {"type": "Uncategorized venture rounds", "amount": "$50M", "date": "2024-12-13", "investors": "Undisclosed Investors"}, {"type": "Series A rounds", "amount": "$126M", "date": "2022-01-21", "investors": "Matrix Capital Management, Decheng Capital, General Atlantic, Surveyor Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Solve%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Sonalasense Inc.", "city": "Berkeley", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SONALA-001", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://sonalasense.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sonalasense", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Sonde Health Inc.", "city": "Boston", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 2, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "Sonde Mental Fitness", "phase": "Market (diagnostic)", "indication": "Neurology, Diagnostic"}, {"name": "Sonde One", "phase": "Market (diagnostic)", "indication": "Pulmonary, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 19250000.0, "totalRaisedFmt": "$19M", "latestFinDate": "2022-12-08", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$19M", "date": "2022-12-08", "investors": "Partners Investment, Neom, Kt Corp, Puretech Health plc, M Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sonde%20Health", "hasDealsFin": true, "diseaseGroups": ["Other", "Other Neurology"]}, {"company": "Sonnet Biotherapeutics Holdings Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SON-1010", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "SON-1210", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "SON-1410", "phase": "Preclinical", "indication": "Melanoma"}], "ceo": "Raghu Rao, MBA", "employees": 9, "founded": 2011, "website": "https://www.sonnetbio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 5381643.68, "evFmt": "$5M", "ticker": "SONN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sonnet%20Biotherapeutics%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Sonoma Biotherapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Inflammation"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "SBT-11-5301", "phase": "IND", "indication": "Autoimmune (unspecified)"}, {"name": "SBT-77-7101", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.sonomabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 120000000.0, "totalDealFmt": "$120M", "latestDealDate": "2023-03-28", "recentDeals": [{"headline": "Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases", "date": "2023-03-28", "value": "$120M"}], "totalRaised": 30000000.0, "totalRaisedFmt": "$30M", "latestFinDate": "2023-04-01", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$30M", "date": "2023-04-01", "investors": "Regeneron Pharmaceuticals Inc."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sonoma%20Biotherapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Sonoma Pharmaceuticals Inc.", "city": "Woodstock", "state": "GA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Nanoparticle / Delivery", "Other", "Small Molecule"], "nProducts": 12, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Celacyn", "phase": "Marketed", "indication": "Scars/wrinkles"}, {"name": "Dermacyn", "phase": "Marketed", "indication": "Wounds"}, {"name": "Epicyn (microcyn scar management hydrogel)", "phase": "Marketed", "indication": "Scars/wrinkles"}, {"name": "Epicyn HydroGel", "phase": "Marketed", "indication": "Dermatology (unspecified)"}, {"name": "GramaDerm Hydrogel", "phase": "Marketed", "indication": "Acne"}, {"name": "GramaDerm Liquid", "phase": "Marketed", "indication": "Acne"}, {"name": "Lasercyn Hydrogel", "phase": "Marketed", "indication": "Dermatology (unspecified)"}, {"name": "Lasercyn Spray", "phase": "Marketed", "indication": "Dermatology (unspecified)"}], "ceo": "Amy M. Trombly", "employees": 168, "founded": 1999, "website": "http://www.sonomapharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -2351210.0, "evFmt": "", "ticker": "SNOA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sonoma%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Sorbent Therapeutics Inc.", "city": "Sunnyvale", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CLP-1001", "phase": "Phase II", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.sorbent.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sorbent%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Sorriso Pharmaceuticals Inc.", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SOR102", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sorriso%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Sotira Scientific", "city": "Wauwatosa", "state": "WI", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "KepTide Covid", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.sotirascientific.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sotira%20Scientific", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Sound Pharmaceuticals Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Infectious", "Neurology", "Otologic"], "modalityGroups": ["RNA Therapeutics", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "SPI-1005 (ebselen)", "phase": "Phase III", "indication": "Meniere disease"}, {"name": "SPI-3005 (ebselen)", "phase": "Phase II/III", "indication": "Hearing loss"}, {"name": "SPI-5557", "phase": "Preclinical", "indication": "Hearing loss"}], "ceo": "", "employees": 0, "founded": 2001, "website": "https://soundpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sound%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other", "Other Specialties"]}, {"company": "South Rampart Pharma Inc.", "city": "New Orleans", "state": "LA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SRP-3D diethylamide", "phase": "Phase I", "indication": "Pain"}, {"name": "South Rampart-acute pain-unknown", "phase": "Preclinical", "indication": "Pain"}, {"name": "South Rampart-fever-unknown", "phase": "Preclinical", "indication": "Pain"}, {"name": "South Rampart-ocular pain-unknown", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://southrampartpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=South%20Rampart%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Sov Therapeutics Inc.", "city": "Morrisville", "state": "NC", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Testosterone undecanoate", "phase": "Phase II", "indication": "Hypogonadism"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.sovtherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sov%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Sparian Biosciences Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SBS-1000", "phase": "Phase I", "indication": "Pain"}, {"name": "SBS-147", "phase": "Preclinical", "indication": "Pain"}, {"name": "SBS-226", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "SBS-371", "phase": "Preclinical", "indication": "Substance use disorders"}, {"name": "SBS-518", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.sparianbiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sparian%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Sparrow Pharmaceuticals Inc.", "city": "Portland", "state": "OR", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SPI-62", "phase": "Phase II", "indication": "Cushing disease"}, {"name": "SPI-47", "phase": "Phase I", "indication": "Large vessel vasculitis"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.sparrowpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sparrow%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Other Specialties"]}, {"company": "Sparx Biopharmaceutical Corp.", "city": "Mount Prospect", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC", "Bispecific Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SPX-308", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SPX-603", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://sparxbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sparx%20Biopharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Speragen Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ALDH5A1 enzyme replacement therapy", "phase": "Preclinical", "indication": "Genetic disorders"}], "ceo": "", "employees": 0, "founded": 0, "website": "https://www.speragen.com/home.html", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Speragen", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Spero Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "EVER206", "phase": "Phase I", "indication": "Bacterial infection"}], "ceo": "Esther Rajavelu, MBA", "employees": 32, "founded": 2013, "website": "http://www.sperotherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 7067054.51, "evFmt": "$7M", "ticker": "SPRO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Spero%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Spine Biopharma Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Remedisc (SB-01)", "phase": "Phase III", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.spinebiopharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Spine%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Spinethera Inc.", "city": "Plymouth", "state": "MN", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SX600", "phase": "Phase II", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://spinethera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Spinethera", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Spinogenix Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SPG302", "phase": "Preclinical", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.spinogenix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Spinogenix", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Spiral Therapeutics Inc.", "city": "Brisbane", "state": "CA", "country": "United States", "diseaseCats": ["Otologic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "OTO-510", "phase": "Preclinical", "indication": "Hearing loss"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.spiraltx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Spiral%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Spriaso LLC", "city": "Salt Lake City", "state": "UT", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Combination"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Tuxarin ER", "phase": "Marketed", "indication": "Cough"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://spriasollc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Spriaso", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Spruce Biosciences Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Genitourinary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "tildacerfont (SPR001)", "phase": "Phase II", "indication": "Adrenal insufficiency"}], "ceo": "Javier Szwarcberg, MD", "employees": 21, "founded": 2014, "website": "http://www.sprucebiosciences.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -18656721.840037, "evFmt": "", "ticker": "SPRB", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 395000000.0, "totalDealFmt": "$395M", "latestDealDate": "2025-02-26", "recentDeals": [{"headline": "HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies", "date": "2025-02-26", "value": "$395M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Spruce%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Spyre Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Inflammation", "Renal"], "modalityGroups": ["Antibody", "Protein / Biologic", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Loargys", "phase": "Approved", "indication": "Metabolic (unspecified)"}, {"name": "AGLE-177", "phase": "Phase I/II", "indication": "Metabolic (unspecified)"}, {"name": "SPY001", "phase": "Phase I", "indication": "Inflammatory disease"}, {"name": "AGLE-325", "phase": "Preclinical", "indication": "Renal (unspecified)"}], "ceo": "Cameron Turtle, PhD", "employees": 65, "founded": 2023, "website": "https://spyretx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 647535412.64, "evFmt": "$648M", "ticker": "SYRE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Spyre%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Kidney Disease", "Obesity / Metabolic"]}, {"company": "Squarex Pharmaceutical Corp.", "city": "Saint Paul", "state": "MN", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SQX770", "phase": "Phase II", "indication": "Herpes simplex virus (HSV)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://squarex-pharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Squarex%20Pharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Stamford Pharmaceuticals Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ASN-004", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2006, "website": "https://stamfordpharmaceuticals.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stamford%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Star Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "VGA039", "phase": "Phase III", "indication": "Bleeding"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://star-therapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Star%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Starton Holdings Inc.", "city": "Paramus", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer", "Gastrointestinal", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "STAR-OLZ (Olanzapine)", "phase": "Phase II/III", "indication": "Emesis"}, {"name": "STAR-LLD (lenalidomide)", "phase": "Preclinical", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "STAR-RK", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.startontx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Starton%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Other Neurology", "Supportive / Other"]}, {"company": "Stat3 Therapeutics Inc.", "city": "Coral Springs", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "S3T-001", "phase": "Preclinical", "indication": "Head and neck cancer"}], "ceo": "", "employees": 0, "founded": 2017, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stat3%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Head & Neck Cancer"]}, {"company": "Statera Biopharma Inc.", "city": "Fort Collins", "state": "CO", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Hematology", "Infectious", "Other"], "modalityGroups": ["Gene Therapy", "Other", "Peptide", "Protein / Biologic", "Small Molecule"], "nProducts": 11, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Protectan", "phase": "Phase III", "indication": "Poisoning"}, {"name": "STAT-201 (CYTO-201)", "phase": "Phase III", "indication": "Crohn's disease"}, {"name": "CBLB612", "phase": "Phase II", "indication": "Hematology (unspecified)"}, {"name": "STAT-401 (CYTO-401)", "phase": "Phase II", "indication": "Pancreatic cancer"}, {"name": "Intravenous CBL0137", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "Mobilan", "phase": "Phase I", "indication": "Prostate cancer"}, {"name": "Oral CBL0137", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "STAT-203", "phase": "Phase I", "indication": "Multiple sclerosis (MS)"}], "ceo": "Michael Kevin Handley, MBA", "employees": 0, "founded": 2014, "website": "https://www.staterabiopharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "STAB", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Statera%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "GU / Gynecologic Cancers", "Hematology (non-cancer)", "IBD / GI Inflammatory", "MS / Neuroimmune", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Stealth Biotherapeutics Inc.", "city": "Needham", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Musculoskeletal", "Neurology", "Ophthalmic"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Forzinity", "phase": "Approved", "indication": "Metabolic (unspecified)"}, {"name": "SBT-272", "phase": "Phase I", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.stealthbt.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stealth%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Obesity / Metabolic"]}, {"company": "Stelexis Therapeutics LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "STLX1018", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.stelexis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stelexis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Stellanova Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "STE-6", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://stellanovatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stellanova%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Stellate Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "STEL-101", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://www.stellate-tx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stellate%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Stellular Bio Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "STLR-201", "phase": "Preclinical", "indication": "Sjogren syndrome"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.stellularbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stellular%20Bio", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Stemedica Cell Technologies Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Inflammation", "Neurology", "Pulmonary"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "ischemic tolerant mesenchymal stem cell", "phase": "Phase II/III", "indication": "Stroke"}, {"name": "ItNSCs", "phase": "Preclinical", "indication": "Spinal cord injury (SCI)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.stemedica.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stemedica%20Cell%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Stempar Sciences Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SPS-201", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.stempar.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stempar%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Stemsynergy Therapeutics Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SSTC3", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://stemsynergy.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stemsynergy%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Sterotherapeutics LLC", "city": "Spring House", "state": "PA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "fluasterone (ST-002)", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://sterotx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sterotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Stingray Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SR-8541A", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://stingraytx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stingray%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Stingthera Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SNX281", "phase": "Phase I", "indication": "Lymphoma"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stingthera", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Stoke Therapeutics Inc.", "city": "Bedford", "state": "MA", "country": "United States", "diseaseCats": ["Neurology", "Ophthalmic"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "zorevunersen (STK-001)", "phase": "Phase III", "indication": "Dravet syndrome"}, {"name": "STK-002", "phase": "IND", "indication": "Ophthalmic (unspecified)"}, {"name": "Stoke Therapeutics-SYNGAP1-unknown", "phase": "Preclinical", "indication": "SYNGAP1-related disorders"}], "ceo": "Ian Frederick Smith, CPA", "employees": 128, "founded": 2016, "website": "http://www.stoketherapeutics.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 383517979.49, "evFmt": "$384M", "ticker": "STOK", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stoke%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Ophthalmology", "Other"]}, {"company": "Strategic Science and Technologies LLC", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SST-6006", "phase": "Phase II", "indication": "Erectile dysfunction (ED)"}, {"name": "SST-6007", "phase": "Phase II", "indication": "Female sexual arousal disorder (FSAD)"}], "ceo": "", "employees": 0, "founded": 1994, "website": "http://www.strategicscience.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Strategic%20Science%20and%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Other", "Other Specialties"]}, {"company": "Stridebio Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "STRX-230", "phase": "Preclinical", "indication": "Rett syndrome"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.stridebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stridebio", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Structure Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "aleniglipron (GSBR-1290)", "phase": "Phase II", "indication": "Diabetes"}, {"name": "ANPA-0073", "phase": "Phase I", "indication": "Hypertension"}, {"name": "LTSE", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}, {"name": "Next Gen GSBR", "phase": "Research", "indication": "Diabetes"}], "ceo": "Raymond C. Stevens, PhD", "employees": 163, "founded": 2016, "website": "https://structuretx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 547961299.054009, "evFmt": "$548M", "ticker": "GPCR", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 100000000.0, "totalDealFmt": "$100M", "latestDealDate": "2025-12-30", "recentDeals": [{"headline": "Structure Therapeutics grants ROG unit non-exclusive license to GLP-1 program, enters covenant in which ROG will not assert GLP-1 patent", "date": "2025-12-30", "value": "$100M"}], "totalRaised": 33000000.0, "totalRaisedFmt": "$33M", "latestFinDate": "2022-08-01", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$33M", "date": "2022-08-01", "investors": "Deep Track Capital, Piper Heartland Healthcare Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Structure%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Diabetes", "Respiratory / Allergy"]}, {"company": "Stuart Therapeutics Inc.", "city": "Stuart", "state": "FL", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Peptide"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "vezocolmitide (ST-100)", "phase": "Phase III", "indication": "Dry eye"}, {"name": "ST-113", "phase": "Preclinical", "indication": "Glaucoma"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.stuarttherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Stuart%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Sudo Biosciences Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Oral TYK2 (JH2)", "phase": "Preclinical", "indication": "Inflammatory disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.sudobio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sudo%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Sulfagenix Inc.", "city": "Chesterland", "state": "OH", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SG1002", "phase": "Phase I", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.sulfagenixinc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sulfagenix", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Summit Therapeutics Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Ridinilazole (smt19969", "phase": "Phase III", "indication": "Clostridium"}, {"name": "SMT-738 (SMT026738)", "phase": "Preclinical", "indication": "Gram-negative bacterial infection"}], "ceo": "Robert William Duggan; Mahkam Zanganeh, DDS, MBA", "employees": 159, "founded": 2003, "website": "https://www.summittxinc.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 12416924488.5005, "evFmt": "$12.4B", "ticker": "SMMT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Summit%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Suneva Medical Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "ArteColl", "phase": "Marketed", "indication": "Scars/wrinkles"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.sunevamedical.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Suneva%20Medical", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Supercede Therapeutics Inc.", "city": "Belmont", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "STX-001", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://supercedetherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 100000000.0, "totalDealFmt": "$100M", "latestDealDate": "2024-06-25", "recentDeals": [{"headline": "Supercede Therapeutics Obtains Global Rights to Preclinical Small Molecule from Fudan University and East China Normal University", "date": "2024-06-25", "value": "$100M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2024-06-17", "latestFinType": "Seed financings", "nRounds": 1, "recentFinancing": [{"type": "Seed financings", "amount": "", "date": "2024-06-17", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Supercede%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Supernus Pharmaceuticals Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology", "Other"], "modalityGroups": ["Combination", "Digital / Device", "Other", "Protein / Biologic", "Small Molecule", "Undisclosed"], "nProducts": 15, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Gocovri", "phase": "Marketed", "indication": "Parkinson's disease"}, {"name": "Myobloc", "phase": "Marketed", "indication": "Hyperkinetic movement disorder"}, {"name": "Namzaric", "phase": "Marketed", "indication": "Alzheimer's disease"}, {"name": "Oxtellar XR", "phase": "Marketed", "indication": "Seizures"}, {"name": "Trokendi XR", "phase": "Marketed", "indication": "Epilepsy"}, {"name": "Zurzuvae", "phase": "Marketed", "indication": "Depression"}, {"name": "Qelbree", "phase": "Approved", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "apomorphine infusion pump (SPN-830)", "phase": "Registration", "indication": "Parkinson's disease"}], "ceo": "Jack A. Khattar, MBA", "employees": 674, "founded": 2006, "website": "http://www.supernus.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1604119697.92, "evFmt": "$1.6B", "ticker": "SUPN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Supernus%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Epilepsy / Seizures", "Other", "Parkinson's", "Psychiatry / Behavioral"]}, {"company": "Surface Ophthalmics Inc.", "city": "Pleasanton", "state": "CA", "country": "United States", "diseaseCats": ["Neurology", "Ophthalmic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "betasol (SURF-201)", "phase": "Phase II", "indication": "Pain"}, {"name": "mycophenolic acid (SURF-100)", "phase": "Phase II", "indication": "Dry eye"}, {"name": "SURF-200", "phase": "Phase II", "indication": "Dry eye"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://surfaceophthalmics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Surface%20Ophthalmics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology", "Pain / Migraine"]}, {"company": "Surge Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "STM-416", "phase": "Phase I/II", "indication": "Bladder cancer"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://surgetx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Surge%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Surrozen Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Hepatic", "Ophthalmic"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SZN-1326", "phase": "Phase I", "indication": "Ulcerative colitis"}, {"name": "SWAP-4", "phase": "Preclinical", "indication": "Wet age-related macular degeneration (wet AMD)"}, {"name": "SZN-043", "phase": "Preclinical", "indication": "Liver disease"}, {"name": "SZN-413", "phase": "Preclinical", "indication": "Diabetic retinopathy"}, {"name": "SZN-8141", "phase": "Preclinical", "indication": "Macular edema"}, {"name": "SZN-8143", "phase": "Preclinical", "indication": "Macular edema"}], "ceo": "Craig C. Parker, MBA", "employees": 41, "founded": 2016, "website": "https://surrozen.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 15992550.0, "evFmt": "$16M", "ticker": "SRZN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Surrozen", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "IBD / GI Inflammatory", "Liver Disease", "Ophthalmology"]}, {"company": "Susavion Biosciences Inc.", "city": "Tempe", "state": "AZ", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Peptide"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Sv6B", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Sv6D", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SvC2", "phase": "Preclinical", "indication": "Viral infection"}, {"name": "SvH1C", "phase": "Preclinical", "indication": "Viral infection"}, {"name": "SvH1D", "phase": "Preclinical", "indication": "Viral infection"}, {"name": "SvL4", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://susavion.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Susavion%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Solid Tumors (General)"]}, {"company": "Sutro Biopharma Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dental", "Infectious"], "modalityGroups": ["ADC", "Undisclosed", "Vaccine"], "nProducts": 12, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "VAX-24 (SVX-24)", "phase": "Phase II", "indication": "Pneumococcus"}, {"name": "CC-99712 (BCMA ADC)", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "Luvelta", "phase": "Phase I", "indication": "Endometrial cancer"}, {"name": "M1231", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "MK-1484", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "STRO-003", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "STRO-004", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "STRO-006", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Jane Chung", "employees": 338, "founded": 2004, "website": "http://www.sutrobio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 28433724.32, "evFmt": "$28M", "ticker": "STRO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sutro%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Switch Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CASi-002", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "CASi-003", "phase": "Preclinical", "indication": "Central nervous system (CNS) disorders"}, {"name": "CASi-APOE", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://switchthera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Switch%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Brain / CNS Tumors"]}, {"company": "Sydnexis Inc.", "city": "Del Mar", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "atropine sulfate (SYD-101)", "phase": "Registration", "indication": "Myopia"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://sydnexis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Sydnexis", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Symberix Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune", "Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SBX-101", "phase": "Preclinical", "indication": "Gastrointestinal (unspecified)"}, {"name": "SBX-201", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "https://www.symberix.net/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Symberix", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Other"]}, {"company": "Symic Bio Inc.", "city": "Emeryville", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Pulmonary"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "SB061", "phase": "Phase II", "indication": "Osteoarthritis"}, {"name": "SBVC (SB-030", "phase": "Phase II", "indication": "Peripheral vascular disease (PVD)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.symic.bio", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Symic%20Bio", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Musculoskeletal"]}, {"company": "Symphony Evolution Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "tesevatinib (XL647", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.symphonyevolution.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Symphony%20Evolution", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Synactix Pharmaceuticals Inc.", "city": "Tuscon", "state": "AZ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SYN-001", "phase": "Preclinical", "indication": "Myelomonocytic leukemia"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.synactixpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synactix%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Synchronicity Pharma Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SHP-1705", "phase": "Phase I", "indication": "Cushing disease"}, {"name": "Orexin-A", "phase": "Preclinical", "indication": "Excessive sleepiness"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.resettherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synchronicity%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Other Specialties", "Psychiatry / Behavioral"]}, {"company": "Syndax Pharmaceuticals Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Revuforj", "phase": "Approved", "indication": "Leukemia"}], "ceo": "Michael A. Metzger, MBA", "employees": 270, "founded": 2005, "website": "http://www.syndax.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 904778699.3, "evFmt": "$905M", "ticker": "SNDX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Syndax%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Syndevrx Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "evexomostat (SDX-7320)", "phase": "Phase II", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.syndevrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Syndevrx", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Synedgen Inc.", "city": "Claremont", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Gastrointestinal", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MIIST305 (SYGN305)", "phase": "Preclinical", "indication": "Ulcerative colitis"}, {"name": "SYGN303", "phase": "Preclinical", "indication": "Gastrointestinal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "https://www.synedgen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synedgen", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Other"]}, {"company": "Synerk Inc.", "city": "Concord", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Hepatic"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SNK-2726", "phase": "Preclinical", "indication": "Hypertension"}, {"name": "SynerK-cardiovascular-unknown", "phase": "Phase I", "indication": "Cardiovascular (unspecified)"}, {"name": "SynerK-liver-unknown", "phase": "Preclinical", "indication": "Liver disease"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://synerk.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synerk", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Liver Disease"]}, {"company": "Synhale Therapeutics Inc.", "city": "Pittsburgh", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "telaglenastat (CB-839)", "phase": "Phase II", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.synhale.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synhale%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Synlogic Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic"], "modalityGroups": ["Oncolytic / Microbiome", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "SYNB1618", "phase": "Phase II", "indication": "Phenylketonuria"}, {"name": "SYNB1353", "phase": "Phase I", "indication": "Metabolic (unspecified)"}, {"name": "SYNB2081", "phase": "Phase I", "indication": "Hyperuricemia/gout"}, {"name": "SYNB8802", "phase": "Phase I", "indication": "Hyperoxaluria"}, {"name": "SYNB1891 (SYN-STING)", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "Mary Beth Dooley", "employees": 1, "founded": 2014, "website": "http://synlogictx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -1785307.4, "evFmt": "", "ticker": "SYBX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synlogic", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Kidney Disease", "Obesity / Metabolic", "Rare / Genetic"]}, {"company": "Synnovation Therapeutics Inc.", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SNV-001", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "SNV1521", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "SNV4818", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.synnovationtx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synnovation%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Synthekine Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy", "Protein / Biologic"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "STK-009 + SYNCAR-001", "phase": "Phase I", "indication": "Hematologic malignancies"}, {"name": "STK-012", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "STK009 + SYNCAR-002", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Synthekine-IL-12 partial agonist-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Synthekine-IL-10 partial agonist/surrogate cytokine agonist-unknown", "phase": "Research", "indication": "Autoimmune (unspecified)"}, {"name": "Synthekine-IL-22 partial agonist-unknown", "phase": "Research", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.synthekine.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-01-29", "recentDeals": [{"headline": "Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases", "date": "2024-01-29", "value": ""}], "totalRaised": 100000000.0, "totalRaisedFmt": "$100M", "latestFinDate": "2023-01-06", "latestFinType": "Series C rounds", "nRounds": 1, "recentFinancing": [{"type": "Series C rounds", "amount": "$100M", "date": "2023-01-06", "investors": "The Column Group, New Investors, Existing Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synthekine", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Synthex Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "STX100", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "STX200", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "STX300", "phase": "Research", "indication": "Cancer (unspecified)"}, {"name": "STX400", "phase": "Research", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.synthexlabs.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 550000000.0, "totalDealFmt": "$550M", "latestDealDate": "2022-10-04", "recentDeals": [{"headline": "SyntheX and Bristol Myers Squibb enter into a research collaboration to discover and develop targeted protein degradation therapeutics", "date": "2022-10-04", "value": "$550M"}], "totalRaised": 5175000.0, "totalRaisedFmt": "$5M", "latestFinDate": "2023-12-29", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$5M", "date": "2023-12-29", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synthex", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Synthis Therapeutics Inc.", "city": "New York City", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SYN101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "SYN-201", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.synthistx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Synthis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Syntis Bio Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "SYNT-101", "phase": "Phase I", "indication": "Obesity"}, {"name": "SYNT-202", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "SYNT-203", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.syntis.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Syntis%20Bio", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Syntrix Pharmaceuticals", "city": "Auburn", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "aminopterin", "phase": "Phase II", "indication": "Psoriasis"}, {"name": "SX-682", "phase": "Phase I/II", "indication": "Melanoma"}, {"name": "Omnitram", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.syntrixbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Syntrix%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Pain / Migraine", "Skin Cancer / Melanoma"]}, {"company": "Syros Pharmaceuticals Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Other", "Peptide", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "Oral SM-88", "phase": "Phase II/III", "indication": "Pancreatic cancer"}, {"name": "SY-2101 (ORH-2014)", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "SY-5609", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "Nasal SM-88", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "Transdermal SM-88", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "TYME-18", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "TYME-19", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://syros.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Syros%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Breast Cancer", "GI Cancers", "Hematologic Cancers", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Systems Oncology LLC", "city": "Scottsdale", "state": "AZ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TEQ103 (SERA2)", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "ERSO", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.systemsoncology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-11-21", "recentDeals": [{"headline": "Oncoteq expands pipeline with the in-licensing of TEQ103 from Systems Oncology", "date": "2023-11-21", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Systems%20Oncology", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer"]}, {"company": "T-cure Bioscience Inc.", "city": "Sherman Oaks", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "800TCR", "phase": "Phase I", "indication": "Renal cancer"}, {"name": "402TCR", "phase": "Preclinical", "indication": "Bladder cancer"}, {"name": "820TCR", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://t-cure.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=T-cure%20Bioscience", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers"]}, {"company": "Tactiva Therapeutics Inc.", "city": "Buffalo", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CD4/CD8 TCR", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://tactivatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tactiva%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Tacurion Pharma Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ASP7035", "phase": "Phase I", "indication": "Nocturia"}], "ceo": "", "employees": 0, "founded": 2013, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tacurion%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Tae Life Sciences LLC", "city": "Foothill Ranch", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase 0", "hasOrphan": false, "pipeline": [{"name": "BPA", "phase": "Phase 0", "indication": "Brain cancer"}, {"name": "Tae Life Sciences-colon cancer-unknown", "phase": "Preclinical", "indication": "Colorectal cancer"}, {"name": "Tae Life Sciences-head and neck cancer-unknown", "phase": "Preclinical", "indication": "Head and neck cancer"}, {"name": "Tae Life Sciences-lung cancer-unknown", "phase": "Preclinical", "indication": "Lung cancer"}, {"name": "TC220", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "TC221", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.taelifesciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tae%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GI Cancers", "Head & Neck Cancer", "Lung Cancer"]}, {"company": "Taiga Biotechnologies Inc.", "city": "Aurora", "state": "CO", "country": "United States", "diseaseCats": ["Cancer", "Hematology", "Infectious"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "TBX-2400", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "TBX-3400", "phase": "Phase I/II", "indication": "Melanoma"}, {"name": "TBX-1400", "phase": "Phase I", "indication": "Immunodeficiency"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://taigabiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Taiga%20Biotechnologies", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Other Inflammation", "Skin Cancer / Melanoma"]}, {"company": "Tairx US", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TaiRxUS-cancer-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.tairxus.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tairx%20US", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Talee Bio Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TL-101", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}, {"name": "TL-102", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://taleebio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Talee%20Bio", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Tallac Therapeutics Inc.", "city": "Burlingame", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "TAC-001", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.tallactherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tallac%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Talphera Inc.", "city": "San Mateo", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Gastrointestinal", "Infectious", "Neurology", "Pulmonary", "Renal"], "modalityGroups": ["Digital / Device", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Zalviso (Brand)", "phase": "Marketed", "indication": "Pain"}, {"name": "nafamostat (LTX-608)", "phase": "Preclinical", "indication": "Block coagulation"}, {"name": "Niyad", "phase": "Preclinical", "indication": "Dialysis"}], "ceo": "Vincent J. Angotti, MBA", "employees": 13, "founded": 2005, "website": "https://talphera.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 4682699.3999, "evFmt": "$5M", "ticker": "TLPH", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Talphera", "hasDealsFin": false, "diseaseGroups": ["Other", "Pain / Migraine"]}, {"company": "Talus Biosciences Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TAL61", "phase": "Preclinical", "indication": "Bone cancer"}, {"name": "Talus - Pediatric Sarcoma - unknown", "phase": "Research", "indication": "Bone cancer"}, {"name": "Talus - Pediatric Sarcoma - unknown1", "phase": "Research", "indication": "Bone cancer"}, {"name": "Talus - solid tumors - unknown", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.talus.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 18200000.0, "totalRaisedFmt": "$18M", "latestFinDate": "2024-08-20", "latestFinType": "Seed financings", "nRounds": 2, "recentFinancing": [{"type": "Seed financings", "amount": "$11M", "date": "2024-08-20", "investors": "Two Bear Capital, Wrf Capital, Nfx Capital Management LLC, Yc Continuity Fund, Fundersclub, Boxone Ventures"}, {"type": "Seed financings", "amount": "$7M", "date": "2022-01-06", "investors": "Nfx Capital Management LLC"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Talus%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Tango Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "TNG908", "phase": "Phase I/II", "indication": "Brain cancer"}, {"name": "TNG260", "phase": "IND", "indication": "Cancer (unspecified)"}, {"name": "TNG462", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Malte Peters, MD", "employees": 155, "founded": 2017, "website": "http://www.tangotx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 116086598.79, "evFmt": "$116M", "ticker": "TNGX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tango%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Solid Tumors (General)"]}, {"company": "Taran Therapeutics Inc.", "city": "", "state": "DE", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Inflammation", "Transplant"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "lenzilumab (KB003)", "phase": "Phase III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "ifabotuzumab (kb004)", "phase": "Phase II", "indication": "Hematologic malignancies"}, {"name": "HGEN005", "phase": "Preclinical", "indication": "Asthma"}], "ceo": "", "employees": 0, "founded": 2023, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Taran%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Infectious Disease", "Respiratory / Allergy"]}, {"company": "Targa Therapeutics Corp.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Ophthalmic"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BreMel/rGel (scfvmel/rgel)", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "BreMel/TNF-a (scfvmel/tnf-a)", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "Granzyme B/VEGF", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "ScFv23/rGel", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "VEGF/rGel", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.targatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Targa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Targagenix Inc.", "city": "Stony Brook", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SBT-1214", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://www.targagenix.net/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Targagenix", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Targazyme Inc.", "city": "Floresville", "state": "TX", "country": "United States", "diseaseCats": ["Transplant"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "TZ101", "phase": "Phase I/II", "indication": "Graft-versus-host disease (GvHD)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://targazyme.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Targazyme", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Targeted Diagnostics & Therapeutics Inc.", "city": "West Chester", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "GCC Cancer Vaccine (Vaccine Ad5. F35-hGCC-Padre)", "phase": "Phase II", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 1994, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Targeted%20Diagnostics%20%26%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Tarsa Therapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "Tbria", "phase": "Registration", "indication": "Osteoporosis"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.tarsatherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tarsa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Tarsus Pharmaceuticals Inc.", "city": "Irvine", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious", "Ophthalmic"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Xdemvy", "phase": "Marketed", "indication": "Ophthalmic (unspecified)"}, {"name": "TP-05", "phase": "Phase II", "indication": "Lyme disease"}, {"name": "TP-04", "phase": "Preclinical", "indication": "Rosacea"}], "ceo": "Bobak Azamian, MD, PhD", "employees": 323, "founded": 2017, "website": "https://www.tarsusrx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1863240269.06, "evFmt": "$1.9B", "ticker": "TARS", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tarsus%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease", "Ophthalmology"]}, {"company": "Tasca Therapeutics Corp.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "CP-383", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.tascatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tasca%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Tavanta Therapeutics", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Gastrointestinal", "Pulmonary"], "modalityGroups": ["Macrocycle", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "oral abiraterone acetate", "phase": "Phase III", "indication": "Prostate cancer"}, {"name": "TAVT-119 (DRGT-119", "phase": "Phase II", "indication": "Gastrointestinal (unspecified)"}, {"name": "TAVT-18 (formulation of sirolimus)", "phase": "Phase I", "indication": "Cancer (unspecified)"}, {"name": "TAVT-135", "phase": "Preclinical", "indication": "Cystic fibrosis (CF)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "https://www.tavanta.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tavanta%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Other", "Rare / Genetic", "Solid Tumors (General)"]}, {"company": "Taxis Pharmaceuticals Inc.", "city": "North Brunswick", "state": "NJ", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TXA707", "phase": "Preclinical", "indication": "Staphylococcus"}, {"name": "TXA709", "phase": "Preclinical", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.taxispharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Taxis%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Taxolog Inc.", "city": "Fairfield", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Milataxel IV (MAC-321", "phase": "Phase II", "indication": "Colorectal cancer"}, {"name": "Milataxel Oral (MAC-321)", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "Simotaxel IV (MST-997", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "TL-310", "phase": "Phase I", "indication": "Colorectal cancer"}, {"name": "TL-1836", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "TL-1892", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.taxolog.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Taxolog", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Taysha Gene Therapies Inc.", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "TGTX-104", "phase": "Phase I/II", "indication": "Rett syndrome"}], "ceo": "Sean P. Nolan", "employees": 73, "founded": 2019, "website": "https://tayshagtx.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 357197548.33, "evFmt": "$357M", "ticker": "TSHA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Taysha%20Gene%20Therapies", "hasDealsFin": false, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Techfields Inc.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "X0002", "phase": "Phase III", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://tfpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Techfields", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Teclison Ltd.", "city": "Princeton", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "tirapazamine (TEC-001", "phase": "Phase II", "indication": "Colorectal cancer"}, {"name": "TEC-002", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "TEC-003", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.teclison.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Teclison", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Solid Tumors (General)"]}, {"company": "Tectonic Therapeutic Inc.", "city": "Allston", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic"], "modalityGroups": ["Cell Therapy", "Gene Therapy", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "AVR-RD-01", "phase": "Phase II", "indication": "Fabry disease"}, {"name": "AVR-RD-02", "phase": "Phase I/II", "indication": "Gaucher disease"}, {"name": "AVR-RD-05", "phase": "Phase I/II", "indication": "Mucopolysaccharidosis"}, {"name": "TX000045", "phase": "Phase I", "indication": "Hypertension"}, {"name": "AVR-RD-03", "phase": "Preclinical", "indication": "Pompe disease"}], "ceo": "Alise S. Reicin, MD", "employees": 51, "founded": 2020, "website": "https://tectonictx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 254055195.07, "evFmt": "$254M", "ticker": "TECX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tectonic%20Therapeutic", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Rare / Genetic"]}, {"company": "Tellus Therapeutics Inc.", "city": "Hillsborough", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "TT-20", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.tellustherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tellus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Tempest Therapeutics Inc.", "city": "Brisbane", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Gastrointestinal"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TPST-1495", "phase": "Phase II", "indication": "Adenomatous polyps"}, {"name": "amezalpat (TPST-1120)", "phase": "Phase I", "indication": "Biliary cancer"}, {"name": "OvaPrime", "phase": "Phase I", "indication": "Infertility"}, {"name": "OvaTure", "phase": "Preclinical", "indication": "Infertility"}, {"name": "TPST-8844", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Matthew Angel, Ph.D", "employees": 25, "founded": 2011, "website": "https://www.tempesttx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 8381001.1955, "evFmt": "$8M", "ticker": "TPST", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tempest%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Other", "Solid Tumors (General)", "Women's Health"]}, {"company": "Temprian Therapeutics Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HSP70iQ435A", "phase": "Preclinical", "indication": "Vitiligo"}], "ceo": "", "employees": 0, "founded": 2019, "website": "http://tempriantherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Temprian%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Tempus Ai Inc.", "city": "Chicago", "state": "", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 5, "mostAdvanced": "Market (diagnostic)", "hasOrphan": false, "pipeline": [{"name": "clinical diagnostic exome", "phase": "Market (diagnostic)", "indication": "Personal genomics testing"}, {"name": "HRD Test", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "OvaNext", "phase": "Market (diagnostic)", "indication": "Cancer, Diagnostic"}, {"name": "Tempus CDx test", "phase": "Development (diagnostic)", "indication": "Radiologic imaging"}, {"name": "Tempus TO test", "phase": "Development (diagnostic)", "indication": "Cancer, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 200000000.0, "totalDealFmt": "$200M", "latestDealDate": "2025-04-23", "recentDeals": [{"headline": "Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology", "date": "2025-04-23", "value": "$200M"}], "totalRaised": 100000000.0, "totalRaisedFmt": "$100M", "latestFinDate": "2022-10-20", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$100M", "date": "2022-10-20", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tempus%20Ai", "hasDealsFin": true, "diseaseGroups": ["Other", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Tenax Therapeutics Inc.", "city": "Chapel Hill", "state": "NC", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "TNX-201 (oral enteric coated imatinib)", "phase": "IND", "indication": "Hypertension"}], "ceo": "Christopher T. Giordano", "employees": 6, "founded": 1990, "website": "http://www.tenaxthera.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -319146.05, "evFmt": "", "ticker": "TENX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tenax%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Tenaya Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Gene Therapy", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "TN-201", "phase": "Preclinical", "indication": "Cardiomyopathy"}, {"name": "TN-301", "phase": "Preclinical", "indication": "Heart failure"}, {"name": "TN-401", "phase": "Preclinical", "indication": "Cardiomyopathy"}], "ceo": "Faraz Ali, MBA", "employees": 97, "founded": 2016, "website": "http://www.tenayatherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 73458129.24, "evFmt": "$73M", "ticker": "TNYA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tenaya%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Teon Therapeutics Inc.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "TT-702", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "TT-816", "phase": "Phase I/II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "TT-373", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.teontherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Teon%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Terapio Corp.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "RLIP76-LyoPL", "phase": "Preclinical", "indication": "Poisoning"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.terapio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Terapio", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Teres Bio Inc.", "city": "Oakland", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TER-101", "phase": "Phase II", "indication": "Dermatitis"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.teresbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Teres%20Bio", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Terns Pharmaceuticals Inc.", "city": "Foster City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hepatic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "HS-10382", "phase": "Phase I", "indication": "Chronic myelogenous leukemia (CML)"}, {"name": "TERN-501", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}, {"name": "TERN-601", "phase": "Preclinical", "indication": "Non-alcoholic steatohepatitis (NASH)"}], "ceo": "Amy L. Burroughs, MBA", "employees": 59, "founded": 2017, "website": "http://www.ternspharma.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 83654405.96, "evFmt": "$84M", "ticker": "TERN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Terns%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Obesity / Metabolic"]}, {"company": "Terremoto Biosciences Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "TER-2013", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "TER-1754", "phase": "Preclinical", "indication": "Telangiectasia"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://terremotobio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Terremoto%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Other", "Solid Tumors (General)"]}, {"company": "Tersera Therapeutics LLC", "city": "Deerfield", "state": "IL", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Gastrointestinal", "Inflammation"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Xermelo (Brand)", "phase": "Marketed", "indication": "Neuroendocrine tumors"}, {"name": "Quzyttir", "phase": "Marketed", "indication": "Urticaria"}, {"name": "JDP-207", "phase": "Phase I/II", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://tersera.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tersera%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation", "Other Solid Tumors", "Respiratory / Allergy"]}, {"company": "Tesorx Pharma LLC", "city": "Pomona", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TSX-002", "phase": "Phase II", "indication": "Hypogonadism"}, {"name": "THG-1001", "phase": "Preclinical", "indication": "Hypogonadism"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.tesorx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tesorx%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Tessera Therapeutics Inc.", "city": "Somerville", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TSRA-196", "phase": "Preclinical", "indication": "Alpha-antitrypsin (AAT) deficiency"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.tesseratherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 275000000.0, "totalDealFmt": "$275M", "latestDealDate": "2025-12-01", "recentDeals": [{"headline": "Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)", "date": "2025-12-01", "value": "$275M"}], "totalRaised": 300000000.0, "totalRaisedFmt": "$300M", "latestFinDate": "2024-12-18", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2024-12-18", "investors": "Bill & Melinda Gates Foundation"}, {"type": "Series C rounds", "amount": "$300M", "date": "2022-04-19", "investors": "Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Artis Ventures, Cormorant Asset M..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tessera%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Rare / Genetic"]}, {"company": "Tetherex Pharmaceuticals Inc.", "city": "Oklahoma City", "state": "OK", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SelK2", "phase": "Preclinical", "indication": "Venous thromboembolism (VTE)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.tetherex.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tetherex%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Tevogen Bio Holdings Inc.", "city": "Warren", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious"], "modalityGroups": ["Cell Therapy", "Undisclosed"], "nProducts": 12, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TVGN-489", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Tevogen Bio-CD8-Unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "Tevogen Bio-cervical cancer-unknown", "phase": "Preclinical", "indication": "Cervical cancer"}, {"name": "Tevogen Bio-COVID 19-unknown2", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Tevogen Bio-hepatitis B-unknown", "phase": "Preclinical", "indication": "Hepatitis B virus (HBV)"}, {"name": "Tevogen Bio-HIV-unknown", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "Tevogen Bio-Hodgkins lymphoma-unknown", "phase": "Preclinical", "indication": "Hodgkin disease"}, {"name": "Tevogen Bio-long COVID-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Ryan Saadi, MD", "employees": 18, "founded": 2020, "website": "http://www.tevogen.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 161475564.02, "evFmt": "$161M", "ticker": "TVGN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tevogen%20Bio%20Holdings", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Infectious Disease", "Liver Disease", "MS / Neuroimmune"]}, {"company": "Tg Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "TG-1101/TG-1202", "phase": "Phase III", "indication": "Chronic lymphocytic leukemia (CLL)"}], "ceo": "Michael Sean Weiss", "employees": 338, "founded": 2012, "website": "http://www.tgtherapeutics.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4768834135.1, "evFmt": "$4.8B", "ticker": "TGTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tg%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Tgv-laboratories Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Mul-1867", "phase": "Preclinical", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://tgv-labs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tgv-laboratories", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Tharimmune Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "HSB-114", "phase": "Preclinical", "indication": "Sarcoma"}, {"name": "HSB-501", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "HSB-888", "phase": "Preclinical", "indication": "Bone cancer"}, {"name": "salinomycin (HSB-1216)", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "Mark Wendland", "employees": 2, "founded": 2017, "website": "https://tharimmune.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -927892.3, "evFmt": "", "ticker": "THAR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tharimmune", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Hematologic Cancers", "Other Solid Tumors"]}, {"company": "The Chao Center for Industrial Pharmacy & Contract Manufacturing", "city": "West Lafayette", "state": "IN", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Seromycin", "phase": "Marketed", "indication": "Tuberculosis"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.thechaocenter.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=The%20Chao%20Center%20for%20Industrial%20Pharmacy%20%26%20Contract%20Manufacturing", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Thera Neuropharma Inc.", "city": "Berwyn", "state": "PA", "country": "United States", "diseaseCats": ["Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "SYN1", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "SYN2", "phase": "Preclinical", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.theraneuro.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Thera%20Neuropharma", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Supportive / Other"]}, {"company": "Therabiologics Inc.", "city": "Arcadia", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TBX02", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "TBX-01", "phase": "Preclinical", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.therabiologics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Therabiologics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Solid Tumors (General)"]}, {"company": "Therabron Therapeutics Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Infectious", "Inflammation", "Pulmonary"], "modalityGroups": ["Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "CG100", "phase": "Phase II", "indication": "Bronchopulmonary dysplasia (BPD)"}, {"name": "CG201", "phase": "Phase I", "indication": "Sinusitis"}, {"name": "CG367", "phase": "Preclinical", "indication": "Bronchiolitis obliterans syndrome"}, {"name": "CG459", "phase": "Preclinical", "indication": "Asthma"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.therabron.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Therabron%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Other", "Respiratory / Allergy"]}, {"company": "Theraclone Sciences Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Human anti-M2e antibody (TCN-032", "phase": "Phase II", "indication": "Influenza virus"}, {"name": "TCN-202", "phase": "Phase II", "indication": "Cytomegalovirus (CMV)"}, {"name": "PGT121", "phase": "Phase I", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.theraclone-sciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Theraclone%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Theracos Inc.", "city": "Marlborough", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Brenzavvy", "phase": "Marketed", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.theracos.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Theracos", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Theraly Fibrosis Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Gastrointestinal", "Hepatic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "TLY012", "phase": "Preclinical", "indication": "Scleroderma"}, {"name": "TLY014", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2015, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Theraly%20Fibrosis", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Theranostec Inc.", "city": "Sacramento", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AiSN", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "TheraPBC", "phase": "Preclinical", "indication": "Bladder cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.theranostec.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Theranostec", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GU / Gynecologic Cancers"]}, {"company": "Therapeutic Solutions International Inc.", "city": "Oceanside", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Cell Therapy", "Vaccine"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "BRS-001", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "StemVacs", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://therapeuticsolutionsint.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Therapeutic%20Solutions%20International", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Infectious Disease"]}, {"company": "Therapeuticsmd Inc.", "city": "Boca Raton", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Bijuva/ Bijuve", "phase": "Marketed", "indication": "Menopause"}, {"name": "Imvexxy (TX-004HR", "phase": "Marketed", "indication": "Menopause"}, {"name": "Low dose bijuva/bijuve", "phase": "Registration", "indication": "Menopause"}, {"name": "progesterone (TX-002HR", "phase": "Phase III", "indication": "Amenorrhea"}], "ceo": "Marlan D. Walker", "employees": 1, "founded": 2008, "website": "http://www.therapeuticsmd.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 12033520.0, "evFmt": "$12M", "ticker": "TXMD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Therapeuticsmd", "hasDealsFin": false, "diseaseGroups": ["Other", "Women's Health"]}, {"company": "Theravance Biopharma Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Gastrointestinal", "Infectious", "Inflammation", "Neurology", "Pulmonary", "Renal"], "modalityGroups": ["Combination", "Other", "Small Molecule", "Undisclosed"], "nProducts": 14, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Yupelri", "phase": "Marketed", "indication": "Chronic obstructive pulmonary disease (COPD)"}, {"name": "ampreloxetine (TD-9855)", "phase": "Phase III", "indication": "Hypotension"}, {"name": "axelopran (TD-1211)", "phase": "Phase II", "indication": "Constipation"}, {"name": "Felcisetrag (TAK-954", "phase": "Phase II", "indication": "Gastrointestinal motility disorder"}, {"name": "JNJ-8398", "phase": "Phase II", "indication": "Crohn's disease"}, {"name": "TD-1792", "phase": "Phase II", "indication": "Bacterial infection"}, {"name": "TD-6450", "phase": "Phase II", "indication": "Hepatitis C virus (HCV)"}, {"name": "TD-8236", "phase": "Phase II", "indication": "Asthma"}], "ceo": "Rick E. Winningham, MBA", "employees": 97, "founded": 2014, "website": "http://www.theravance.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 421120270.0, "evFmt": "$421M", "ticker": "TBPH", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Theravance%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "IBD / GI Inflammatory", "Infectious Disease", "Liver Disease", "Other", "Respiratory / Allergy", "Supportive / Other"]}, {"company": "Theravasc Inc.", "city": "Cleveland", "state": "OH", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Infectious", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "JAN101", "phase": "Phase II", "indication": "Peripheral vascular disease (PVD)"}, {"name": "TV1001", "phase": "Phase II", "indication": "Peripheral vascular disease (PVD)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.theravasc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Theravasc", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Theravida Inc.", "city": "Chapel Hill", "state": "NC", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Combination", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Tolenix", "phase": "Phase II", "indication": "Incontinence"}, {"name": "THVD-202", "phase": "Preclinical", "indication": "Incontinence"}, {"name": "oxybutynin (THVD-101a)", "phase": "Phase II", "indication": "Incontinence"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.theravida.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Theravida", "hasDealsFin": false, "diseaseGroups": ["Other Specialties"]}, {"company": "Theregen Corp.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Anginera", "phase": "Phase I", "indication": "Coronary artery disease (CAD)"}], "ceo": "", "employees": 0, "founded": 2003, "website": "http://www.theregen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Theregen", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Therini Bio Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology", "Ophthalmic"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "THN391", "phase": "Phase I", "indication": "Diabetic macular edema (DME)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.therinibio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Therini%20Bio", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Theriva Biologics Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Gastrointestinal", "Hematology", "Infectious"], "modalityGroups": ["Antibody", "Oncolytic / Microbiome", "Other", "Protein / Biologic", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "ribaxamase (SYN-004", "phase": "Phase II", "indication": "Stem cell transplant"}, {"name": "SYN-010", "phase": "Phase II", "indication": "Irritable bowel syndrome"}, {"name": "VCN-01", "phase": "Phase II", "indication": "Pancreatic cancer"}, {"name": "SYN-020", "phase": "Phase I", "indication": "Gastrointestinal (unspecified)"}, {"name": "SYN-005", "phase": "Preclinical", "indication": "Pertussis"}, {"name": "SYN-006", "phase": "Preclinical", "indication": "Clostridium"}, {"name": "SYN-007", "phase": "Preclinical", "indication": "Irritable bowel syndrome"}, {"name": "VCN-11", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Steven A. Shallcross, MBA, CPA", "employees": 22, "founded": 2001, "website": "http://www.syntheticbiologics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -7684779.5, "evFmt": "", "ticker": "TOVX", "exchange": "NYSE-A", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Theriva%20Biologics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "IBD / GI Inflammatory", "Infectious Disease", "Other", "Solid Tumors (General)", "Transplant"]}, {"company": "Thetis Pharmaceuticals LLC", "city": "Southport", "state": "CT", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "TP-113", "phase": "Preclinical", "indication": "Diabetes"}, {"name": "TP-252", "phase": "Preclinical", "indication": "Amyloidosis"}, {"name": "TP-317", "phase": "Preclinical", "indication": "Crohn's disease"}, {"name": "TP-4311", "phase": "Preclinical", "indication": "Post-operative ileus"}, {"name": "TP-452", "phase": "Preclinical", "indication": "Hypercholesterolemia"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.thetispharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Thetis%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "IBD / GI Inflammatory", "Obesity / Metabolic", "Other", "Supportive / Other"]}, {"company": "Third Coast Therapeutics Inc.", "city": "Evanston", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "3crx98", "phase": "Preclinical", "indication": "Prostate cancer"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.3crx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Third%20Coast%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Thrombolytic Science International LLC", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TS01", "phase": "Phase I", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.tsillc.net", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Thrombolytic%20Science%20International", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Thunder Biotech Inc.", "city": "Provo", "state": "UT", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MOTO-CAR multiple sclerosis", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.thunderbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Thunder%20Biotech", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune"]}, {"company": "Thymmune Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "THY-100", "phase": "Preclinical", "indication": "Immunodeficiency"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.thymmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Thymmune%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Inflammation"]}, {"company": "Tiba Biotech LLC", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Tiba-Ebola-unknown", "phase": "Preclinical", "indication": "Ebola"}, {"name": "Tiba-H1N1-unknown", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "Tiba-Toxoplasma-unknown", "phase": "Preclinical", "indication": "Toxoplasmosis"}, {"name": "Tiba-Zika-unknown", "phase": "Preclinical", "indication": "Zika virus"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.tiba.bio", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tiba%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Tikkunlev Therapeutics Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TLT-101", "phase": "Preclinical", "indication": "Cardiomyopathy"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.tikkunlev.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tikkunlev%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Tilde Sciences LLC", "city": "Jersey City", "state": "NJ", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Vecamyl", "phase": "Marketed", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.tildesciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tilde%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Tioga Pharmaceuticals Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Dermatology", "Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "asimadoline (ONO-3951)", "phase": "Phase III", "indication": "Irritable bowel syndrome"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.tiogapharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tioga%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Tisento Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Zagociguat (CY6463", "phase": "Phase II", "indication": "Mitochondrial disease"}, {"name": "CY3018", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://www.tisentotx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tisento%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology", "Rare / Genetic"]}, {"company": "Tivorsan Pharmaceuticals Inc.", "city": "Providence", "state": "RI", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "Biglycan (TVN-102)", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.tivorsan.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tivorsan%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Tiximed Inc.", "city": "Birmingham", "state": "AL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "TIX100", "phase": "IND", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://tiximed.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tiximed", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Tizona Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TTX-080", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://tizonatx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tizona%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Tocopherx Inc.", "city": "Burlington", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TOP001", "phase": "Preclinical", "indication": "Infertility"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.tocopherx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tocopherx", "hasDealsFin": false, "diseaseGroups": ["Women's Health"]}, {"company": "Tolera Therapeutics Inc.", "city": "Kalamazoo", "state": "MI", "country": "United States", "diseaseCats": ["Transplant"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "TOL101", "phase": "Preclinical", "indication": "Organ transplant rejection"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.tolera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tolera%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Transplant"]}, {"company": "Tolerion Inc.", "city": "Portola Valley", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TOL-3021", "phase": "Phase II", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.tolerioninc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tolerion", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Tonix Pharmaceuticals Holding Corp.", "city": "Chatham", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Endocrine/Metabolic", "Infectious", "Musculoskeletal", "Neurology", "Other", "Transplant"], "modalityGroups": ["Antibody", "Other", "Peptide", "Protein / Biologic", "Small Molecule", "Vaccine"], "nProducts": 23, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Tosymra", "phase": "Marketed", "indication": "Migraine"}, {"name": "Zembrace SymTouch", "phase": "Marketed", "indication": "Migraine"}, {"name": "Tonmya", "phase": "Registration", "indication": "Fibromyalgia syndrome"}, {"name": "intranasal oxytocin (TNX-1900", "phase": "Phase II", "indication": "Migraine"}, {"name": "tianeptine hemioxalate (TNX-601 ER)", "phase": "Phase II", "indication": "Cognitive dysfunction"}, {"name": "cocaine esterase (TNX-1300", "phase": "Phase I", "indication": "Substance use disorders"}, {"name": "TNX-1500", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "intranasal potentiated oxytocin (TNX-2900)", "phase": "Preclinical", "indication": "Genetic disorders"}], "ceo": "Seth Lederman, MD", "employees": 81, "founded": 2007, "website": "http://www.tonixpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -90414155.600928, "evFmt": "", "ticker": "TNXP", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tonix%20Pharmaceuticals%20Holding", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Autoimmune / Rheumatology", "Musculoskeletal", "Pain / Migraine", "Psychiatry / Behavioral", "Rare / Genetic"]}, {"company": "Tonus Therapeutics Inc.", "city": "Williamsville", "state": "NY", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "AT-300", "phase": "Preclinical", "indication": "Muscular dystrophy"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.tonustherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tonus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Toragen Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TGN-S11", "phase": "Preclinical", "indication": "Human papillomavirus (HPV)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://toragenbiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Toragen", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Torl Biotherapeutics LLC", "city": "Culver City", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["ADC"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TORL-1-23", "phase": "Phase II", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://torlbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Torl%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Totus Medicines Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TOS-358", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.totusmedicines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Totus%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Tr1x Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Transplant"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TRX103", "phase": "Preclinical", "indication": "Graft-versus-host disease (GvHD)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.tr1x.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tr1x", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology"]}, {"company": "Tract Therapeutics Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Autoimmune", "Transplant"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TregCel (T-reg adoptive cell transfer", "phase": "Phase I", "indication": "Renal transplant rejection"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.tracttherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tract%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Tranquis Therapeutics Inc.", "city": "San Mateo", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TQS-168", "phase": "Preclinical", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.tranquis.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tranquis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Transchromix LLC", "city": "Chapel Hill", "state": "NC", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "MS1262", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2015, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Transchromix", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Transcode Therapeutics Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "RNA Therapeutics"], "nProducts": 4, "mostAdvanced": "Phase 0", "hasOrphan": true, "pipeline": [{"name": "TTX-MC138", "phase": "Phase 0", "indication": "Solid tumors"}, {"name": "TTX-RIGA", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "TTX-siLIN28b", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "TTX-siPDL1", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Philippe P. Calais, PhD", "employees": 7, "founded": 2016, "website": "https://www.transcodetherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -4572665.45, "evFmt": "", "ticker": "RNAZ", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Transcode%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Transderm Inc.", "city": "Santa Cruz", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TD101", "phase": "Phase I", "indication": "Dermatology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.transderminc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Transderm", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Transition Bio Inc.", "city": "Cambridge", "state": "", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal", "Neurology"], "modalityGroups": ["Protein / Biologic", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Transition Bio-MYC RNA/YTHDC1-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Transition Bio/Voyager-TDP-43-unknown", "phase": "Research", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "Transition Bio-DMPK RNA/MBNL1-unknown", "phase": "Research", "indication": "Myotonic dystrophy type 1 (DM1)"}, {"name": "Transition Bio-fusion protein-unknown", "phase": "Research", "indication": "Solid tumors"}, {"name": "Transition Bio-transcription factor-unknown", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "", "ownership": "", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 50000000.0, "totalRaisedFmt": "$50M", "latestFinDate": "2022-06-02", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$50M", "date": "2022-06-02", "investors": "Northpond Ventures LLC, Taiho Ventures LLC, Bristol Myers Squibb Co., Magnetic Ventures, Lifeforce Capital, Existing Inv..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Transition%20Bio", "hasDealsFin": true, "diseaseGroups": ["Neurodegeneration / NMD", "Solid Tumors (General)"]}, {"company": "Translational Sciences Inc.", "city": "Memphis", "state": "TN", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CSL301", "phase": "Phase II", "indication": "Blood clots"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://ww.translationalsciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Translational%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Travere Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Other"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "Erythrocyte Encapsulated Thymidine Phosphorylase (EE-TP) (OT-15)", "phase": "Phase II/III", "indication": "Mitochondrial disease"}, {"name": "Pegtibatinase (TVT-058", "phase": "Phase I/II", "indication": "Metabolic (unspecified)"}, {"name": "Erythrocyte Encapsulated Adenosine Deaminase (EE-ADA) (OT-81)", "phase": "Preclinical", "indication": "Metabolic (unspecified)"}, {"name": "Retrophin-Alagille Syndrome-unknown", "phase": "Preclinical", "indication": "Genetic disorders"}, {"name": "Retrophin-NGLY1-unknown", "phase": "Preclinical", "indication": "Genetic disorders"}], "ceo": "Eric M. Dube, PhD", "employees": 385, "founded": 2011, "website": "https://travere.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1405126958.62, "evFmt": "$1.4B", "ticker": "TVTX", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-01-25", "recentDeals": [{"headline": "Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations", "date": "2024-01-25", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Travere%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Rare / Genetic"]}, {"company": "Traverse Biotech Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Traverse Biotech-orally available I/O-unknown", "phase": "Preclinical", "indication": "Bone cancer"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.traversebiotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Traverse%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Other Solid Tumors"]}, {"company": "Traws Pharma Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Infectious", "Other"], "modalityGroups": ["Small Molecule"], "nProducts": 10, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "IV rigosertib sodium (ON 01910.Na", "phase": "Phase III", "indication": "Myelodysplastic syndrome (MDS)"}, {"name": "oral rigosertib sodium (ON 01910.Na", "phase": "Phase II/III", "indication": "Myelodysplastic syndrome (MDS)"}, {"name": "narazaciclib (ON 123300)", "phase": "Phase I/II", "indication": "Endometrial cancer"}, {"name": "briciclib (ON 013105)", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "Oral Ex-RAD", "phase": "Phase I", "indication": "Poisoning"}, {"name": "Subcutaneous Ex-RAD", "phase": "Phase I", "indication": "Poisoning"}, {"name": "travatrelvir (TRX01)", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Viroksavir (TRX100)", "phase": "Phase I", "indication": "Influenza virus"}], "ceo": "Iain David Dukes, PhD", "employees": 7, "founded": 2021, "website": "https://www.trawsfynyddther.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -7550157.2, "evFmt": "", "ticker": "TRAW", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Traws%20Pharma", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Infectious Disease", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Treadwell Therapeutics", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "CFI-400945", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "CFI-402257", "phase": "Phase I/II", "indication": "Breast cancer"}, {"name": "CFI-402411", "phase": "Phase I/II", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://treadwelltx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Treadwell%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "Solid Tumors (General)"]}, {"company": "Trefoil Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TTHX1114", "phase": "Phase II", "indication": "Ophthalmic (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.trefoiltherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trefoil%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Tremrx Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TremRx vaccine", "phase": "Preclinical", "indication": "Infectious (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://www.tremrx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tremrx", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Treovir LLC", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "G207", "phase": "Phase II", "indication": "Brain cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://treovir.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Treovir", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors"]}, {"company": "Trethera Corp.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "TRE-515 (DI-87)", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://trethera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-06-03", "recentDeals": [{"headline": "Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045", "date": "2025-06-03", "value": ""}], "totalRaised": 250000.0, "totalRaisedFmt": "$250K", "latestFinDate": "2025-04-29", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$250K", "date": "2025-04-29", "investors": "Undisclosed Investor"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trethera", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Trevena Inc.", "city": "Chesterbrook", "state": "PA", "country": "United States", "diseaseCats": ["Cardiovascular", "Infectious", "Neurology", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Olinvyk", "phase": "Marketed", "indication": "Pain"}, {"name": "TRV027 (TRV120027)", "phase": "Phase II/III", "indication": "Blood clots"}, {"name": "TRV734", "phase": "Phase II", "indication": "Substance use disorders"}, {"name": "TRV045", "phase": "Phase I", "indication": "Pain"}, {"name": "TRV250", "phase": "Phase I", "indication": "Migraine"}], "ceo": "Carrie L. Bourdow, MBA", "employees": 0, "founded": 2007, "website": "https://www.trevena.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "TRVN", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trevena", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Pain / Migraine", "Psychiatry / Behavioral"]}, {"company": "Treventis Corp.", "city": "Bryn-Mawr", "state": "PA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TRV 101", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.treventis.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Treventis", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Trevi Therapeutics Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Dermatology", "Hepatic", "Neurology", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "Haduvio (nalbuphine ER)", "phase": "Phase II/III", "indication": "Itch"}], "ceo": "Jennifer L. Good, CPA", "employees": 26, "founded": 2011, "website": "http://www.trevitherapeutics.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 313534116.76, "evFmt": "$314M", "ticker": "TRVI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trevi%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Trex Bio Inc. (Trexbio)", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology"], "modalityGroups": ["Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TRB-051", "phase": "Phase I", "indication": "Autoimmune (unspecified)"}, {"name": "TRB-061", "phase": "Phase I", "indication": "Dermatitis"}, {"name": "TRB-071", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "TRB-081", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "TRB-031", "phase": "Research", "indication": "Autoimmune (unspecified)"}, {"name": "TRB-041", "phase": "Research", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://trex.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 160000000.0, "totalRaisedFmt": "$160M", "latestFinDate": "2026-01-27", "latestFinType": "Uncategorized venture rounds", "nRounds": 3, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$50M", "date": "2026-01-27", "investors": "Janus Henderson Investors, Balyasny Asset Management L.P., Affinity Asset Advisors, Alexandria Venture Investments LLC, ..."}, {"type": "Series B rounds", "amount": "$84M", "date": "2024-11-13", "investors": "Delos Capital, Avego Bioscience Capital, Agent Capital, Eli Lilly and Co., Sv Health Investors LLP, Pfizer Venture Inves..."}, {"type": "Series A rounds", "amount": "$26M", "date": "2022-03-08", "investors": "Polaris Venture Partners L.P., Laurion Capital Management L.P., Sv Health Investors LLP, Eli Lilly & Company Foundation,..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trex%20Bio%20Inc.%20(Trexbio)", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology"]}, {"company": "Triact Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "iniparib", "phase": "Phase III", "indication": "Brain cancer"}, {"name": "TT-100", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Triact%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Lung Cancer"]}, {"company": "Triana Biomedicines Inc.", "city": "Lexington", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TRI-611", "phase": "Preclinical", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Triana Biomedicines-breast cancer-unknown", "phase": "Research", "indication": "Breast cancer"}, {"name": "Triana Biomedicines-colorectal cancer-unknown", "phase": "Research", "indication": "Colorectal cancer"}, {"name": "Triana Biomedicines-ongcogene MG-unknown", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://trianabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 230000000.0, "totalRaisedFmt": "$230M", "latestFinDate": "2025-12-03", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$120M", "date": "2025-12-03", "investors": "Ascenta Capital, Bessemer Venture Partners, Yk Bioventures, Regeneron Ventures, Invus, Finchley Healthcare Ventures, Ra ..."}, {"type": "Series A rounds", "amount": "$110M", "date": "2022-04-06", "investors": "Lightspeed Venture Partners, Ra Capital Advisors, Atlas Venture, Pfizer Ventures, Surveyor Capital, Logos Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Triana%20Biomedicines", "hasDealsFin": true, "diseaseGroups": ["Breast Cancer", "GI Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Triarm Therapeutics Ltd.", "city": "San Mateo", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "Phase 0", "hasOrphan": false, "pipeline": [{"name": "FINETUNE", "phase": "Phase 0", "indication": "Hodgkin disease"}, {"name": "FLEXTUNE", "phase": "Phase 0", "indication": "Breast cancer"}, {"name": "FLOWTUNE", "phase": "Phase 0", "indication": "Autoimmune (unspecified)"}, {"name": "Fast-In-Time", "phase": "IND", "indication": "Acute lymphoblastic leukemia (ALL)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.triarm.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Triarm%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Breast Cancer", "Hematologic Cancers"]}, {"company": "Trident Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "HF1020", "phase": "Phase I", "indication": "Asthma"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.tridentpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trident%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Trio Pharmaceuticals Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CD22 TRAILBody", "phase": "Preclinical", "indication": "Lupus"}, {"name": "CD33 TRAILBody", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "FOLR1 TRAILBody", "phase": "Preclinical", "indication": "Endometrial cancer"}, {"name": "TROP2 TIE-ADC", "phase": "Preclinical", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.triopharmaceuticals.com/home", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trio%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Breast Cancer", "GU / Gynecologic Cancers", "Hematologic Cancers"]}, {"company": "Tris Pharma Inc.", "city": "Monmouth Junction", "state": "NJ", "country": "United States", "diseaseCats": ["Cardiovascular", "Infectious", "Inflammation", "Neurology", "Pulmonary"], "modalityGroups": ["Other", "Small Molecule", "Undisclosed"], "nProducts": 17, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Karbinal (Brand)", "phase": "Marketed", "indication": "Allergy"}, {"name": "Tuzistra XR", "phase": "Marketed", "indication": "Cough"}, {"name": "CCP-07", "phase": "Registration", "indication": "Cough"}, {"name": "CCP-08", "phase": "Registration", "indication": "Cough"}, {"name": "Dyanavel XR", "phase": "Marketed", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "Nexiclon XR", "phase": "Marketed", "indication": "Hypertension"}, {"name": "QuilliChew ER", "phase": "Marketed", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "TRN-110", "phase": "Registration", "indication": "Attention deficit hyperactivity disorder (ADHD)"}], "ceo": "", "employees": 0, "founded": 2000, "website": "http://www.trispharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-04-16", "recentDeals": [{"headline": "Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD", "date": "2024-04-16", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tris%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Psychiatry / Behavioral", "Respiratory / Allergy"]}, {"company": "Trisalus Life Sciences Inc.", "city": "Westminster", "state": "CO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "HCV Therapy (SD-101)", "phase": "Phase I/II", "indication": "Biliary cancer"}], "ceo": "Mary T. Szela, MBA", "employees": 110, "founded": 2009, "website": "http://www.trisaluslifesci.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 142016082.53, "evFmt": "$142M", "ticker": "TLSI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trisalus%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Trishula Therapeutics", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TTX-030", "phase": "Phase II", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trishula%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Triumvira Immunologics Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "TAC01-HER2", "phase": "Phase I/II", "indication": "Gastric cancer"}, {"name": "TAC-Claudin 18.2", "phase": "Preclinical", "indication": "Gastric cancer"}, {"name": "TAC-GPC3", "phase": "Preclinical", "indication": "Liver cancer"}, {"name": "TAC-GUCY2C", "phase": "Research", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.triumvira.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 45000000.0, "totalRaisedFmt": "$45M", "latestFinDate": "2022-03-17", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$45M", "date": "2022-03-17", "investors": "B Capital Group, Atem Capital Fund L.P., Myeloma Investment Fund, Leaps by Bayer, Northpond Ventures LLC"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Triumvira%20Immunologics", "hasDealsFin": true, "diseaseGroups": ["GI Cancers"]}, {"company": "Triveni Bio Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Gastrointestinal", "Inflammation"], "modalityGroups": ["Antibody", "Bispecific Antibody"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TRIV-509", "phase": "Preclinical", "indication": "Dermatitis"}, {"name": "TRIV-573", "phase": "Research", "indication": "Inflammation (unspecified)"}, {"name": "Triveni Bio-trypsin 1-unknown", "phase": "Research", "indication": "Pancreatitis"}, {"name": "Triveni Bio-trypsin 2-unknown", "phase": "Research", "indication": "Pancreatitis"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://triveni.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 207000000.0, "totalRaisedFmt": "$207M", "latestFinDate": "2024-10-02", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$115M", "date": "2024-10-02", "investors": "Goldman Sachs, Fidelity Management & Research Co., Deep Track Capital, Atlas Venture, Cormorant Asset Management, Orbime..."}, {"type": "Series A rounds", "amount": "$92M", "date": "2023-10-26", "investors": "Atlas Venture, Cormorant Asset Management, Orbimed Advisors LLC, Viking Global Investors L.P., Invus, Polaris Partners, ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Triveni%20Bio", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Other Inflammation", "Supportive / Other"]}, {"company": "Tron Group Inc.", "city": "Alachua", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Gastrointestinal", "Infectious", "Neurology"], "modalityGroups": ["Macrocycle", "Small Molecule"], "nProducts": 9, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Triapine injection", "phase": "Phase III", "indication": "Cervical cancer"}, {"name": "Ammonium Tetrathiomolybdate (ATTM)", "phase": "Phase II", "indication": "Breast cancer"}, {"name": "NanoBUP Capsule", "phase": "Phase II", "indication": "Pain"}, {"name": "NP-18-2 Capsule", "phase": "Phase II", "indication": "Central nervous system (CNS) disorders"}, {"name": "NP-18-3 Capsule", "phase": "Phase II", "indication": "Central nervous system (CNS) disorders"}, {"name": "PRX-3140 Capsule", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "Ramoplanin Capsule", "phase": "Phase II", "indication": "Diarrhea (infectious)"}, {"name": "Triapine Capsule", "phase": "Phase II", "indication": "Pancreatic cancer"}], "ceo": "James David Talton, PhD", "employees": 0, "founded": 2018, "website": "http://www.nanopharmaceutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 17513388.0, "evFmt": "$18M", "ticker": "TGRP", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tron%20Group", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Brain / CNS Tumors", "Breast Cancer", "GI Cancers", "GU / Gynecologic Cancers", "Infectious Disease", "Pain / Migraine"]}, {"company": "Trove Therapeutics Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Infectious", "Inflammation", "Pulmonary", "Transplant"], "modalityGroups": ["Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CTB201", "phase": "Phase I", "indication": "Sinusitis"}, {"name": "CTB367", "phase": "Preclinical", "indication": "Pneumonia"}, {"name": "CTB405", "phase": "Preclinical", "indication": "Asthma"}, {"name": "TTI1011", "phase": "Preclinical", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://trovetherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Trove%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Respiratory / Allergy"]}, {"company": "Truebinding Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TB006", "phase": "Phase II", "indication": "Stroke"}, {"name": "IMT001", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "TB200 (IMT200)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.truebinding.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Truebinding", "hasDealsFin": false, "diseaseGroups": ["Other Neurology", "Solid Tumors (General)"]}, {"company": "Tscan Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Cell Therapy"], "nProducts": 8, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TSC-100", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "TSC-101", "phase": "Phase I", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "TSC-200", "phase": "Preclinical", "indication": "Cervical cancer"}, {"name": "TSC-201", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "TSC-202", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "TSC-203", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "TSC-204", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "Tscan-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Gavin MacBeath, PhD", "employees": 194, "founded": 2018, "website": "http://www.tscan.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 147721867.68, "evFmt": "$148M", "ticker": "TCRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tscan%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Infectious Disease", "Solid Tumors (General)"]}, {"company": "Ttc Oncology LLC", "city": "Minneapolis", "state": "MN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "TTC-352", "phase": "Phase I", "indication": "Breast cancer"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.ttconcology.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ttc%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer"]}, {"company": "Tuhura Biosciences Inc.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Infectious", "Neurology", "Ophthalmic", "Pulmonary"], "modalityGroups": ["Antibody", "Digital / Device", "Gene Therapy", "Other", "Peptide", "RNA Therapeutics", "Small Molecule"], "nProducts": 16, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "DAG for Injection", "phase": "Marketed", "indication": "Chronic myelogenous leukemia (CML)"}, {"name": "PTI-808", "phase": "Phase II", "indication": "Cystic fibrosis (CF)"}, {"name": "PTI-801", "phase": "Phase I/II", "indication": "Cystic fibrosis (CF)"}, {"name": "TBS-2025 (KVA12123", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "IFx-Hu2.0", "phase": "Phase I", "indication": "Melanoma"}, {"name": "LHF-535", "phase": "Phase I", "indication": "Viral hemorrhagic fever"}, {"name": "REM-001", "phase": "Phase I", "indication": "Basal cell carcinoma (BCC)"}, {"name": "CSP-4", "phase": "Preclinical", "indication": "Pain"}], "ceo": "James A. Bianco, MD", "employees": 19, "founded": 1995, "website": "https://tuhurabio.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 58159793.1, "evFmt": "$58M", "ticker": "HURA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 31301001.0, "totalRaisedFmt": "$31M", "latestFinDate": "2022-10-17", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$22M", "date": "2022-10-17", "investors": "Undisclosed Investors"}, {"type": "Uncategorized venture rounds", "amount": "$9M", "date": "2022-07-11", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tuhura%20Biosciences", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Other", "Pain / Migraine", "Rare / Genetic", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Tune Therapeutics Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Tune-401", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://tunetx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tune%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Tunitas Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Epsi-gam", "phase": "Phase I", "indication": "Allergy"}, {"name": "GFD (cat allergen vaccine)", "phase": "Preclinical", "indication": "Allergy"}, {"name": "Peanut allergy vaccine", "phase": "Preclinical", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.tunitastherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tunitas%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Turn Biotechnologies Inc.", "city": "Menlo Park", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Inflammation", "Musculoskeletal", "Ophthalmic"], "modalityGroups": ["Cell Therapy"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "TRN-001", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}, {"name": "TRN-004", "phase": "Preclinical", "indication": "Dry eye"}, {"name": "TRN-005", "phase": "Preclinical", "indication": "Muscular atrophy"}, {"name": "TRN-003", "phase": "Research", "indication": "Osteoarthritis"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.turn.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 300000000.0, "totalDealFmt": "$300M", "latestDealDate": "2024-05-28", "recentDeals": [{"headline": "HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases", "date": "2024-05-28", "value": "$300M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2022-04-11", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2022-04-11", "investors": "Astellas Venture Management, Daewoong Pharmaceutical Co. Ltd., Hanall Biopharma Co. Ltd., Longevc, Threed Capital, Vital..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Turn%20Biotechnologies", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Musculoskeletal", "Neurodegeneration / NMD", "Ophthalmology"]}, {"company": "Turn Therapeutics Inc.", "city": "Calabasas", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "AtopX Emulsion", "phase": "Marketed", "indication": "Dermatitis"}, {"name": "Hexagen", "phase": "Marketed", "indication": "Wounds"}], "ceo": "Bradley Burnam", "employees": 0, "founded": 2015, "website": "https://turntherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "TTRX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Turn%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Tvardi Therapeutics Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Pulmonary"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "oral Korsuva", "phase": "Phase III", "indication": "Itch"}, {"name": "TTI-101", "phase": "Phase II", "indication": "Pulmonary fibrosis"}, {"name": "TTI-109", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Imran Alibhai, PhD", "employees": 10, "founded": 2017, "website": "https://tvarditherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 34468956.56, "evFmt": "$34M", "ticker": "TVRD", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tvardi%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Respiratory / Allergy", "Solid Tumors (General)"]}, {"company": "Tvax Biomedical Inc.", "city": "Lenexa", "state": "KS", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "TVI-Brain-1", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "TVI-Kidney-1", "phase": "Phase II", "indication": "Renal cancer"}], "ceo": "", "employees": 0, "founded": 2004, "website": "http://www.tvaxbiomedical.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tvax%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "GU / Gynecologic Cancers"]}, {"company": "Twentyeight-seven Therapeutics", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Twentyeight-seven-LIN28-unknown", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.twentyeight-seven.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Twentyeight-seven%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Tyra Biosciences Inc.", "city": "Carlsbad", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "TYRA-300", "phase": "Phase I/II", "indication": "Bladder cancer"}, {"name": "TYRA-200", "phase": "Preclinical", "indication": "Biliary cancer"}], "ceo": "Todd J. Harris, PhD", "employees": 60, "founded": 2018, "website": "https://tyra.bio", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 460107669.4, "evFmt": "$460M", "ticker": "TYRA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tyra%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "GU / Gynecologic Cancers"]}, {"company": "Tyrogenex Inc.", "city": "Rockville", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "vorolanib (CM082", "phase": "Phase III", "indication": "Renal cancer"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.tyrogenex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Tyrogenex", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "U.S. Stem Cell Inc.", "city": "Sunrise", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Pulmonary"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "MyoCell", "phase": "Phase III", "indication": "Heart failure"}, {"name": "AdipoCell", "phase": "Phase I/II", "indication": "Congestive heart failure (CHF)"}, {"name": "MyoCell SDF-1", "phase": "Phase I", "indication": "Heart failure"}], "ceo": "Miguel Tom\u00e1s, MBA", "employees": 0, "founded": 1999, "website": "http://us-stemcell.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 11781200.0, "evFmt": "$12M", "ticker": "USRM", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=U.S.%20Stem%20Cell", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "US Worldmeds LLC", "city": "Louisville", "state": "KY", "country": "United States", "diseaseCats": ["Cancer", "Other"], "modalityGroups": ["Cell Therapy", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "uzatresgene autoleucel (uza-cel", "phase": "Phase I", "indication": "Esophageal cancer"}, {"name": "Revonto", "phase": "Marketed", "indication": "Hyperthermia"}, {"name": "Tecelra", "phase": "Marketed", "indication": "Sarcoma"}, {"name": "letetresgene autoleucel (ADAP NY-ESO TCR", "phase": "Phase II", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2001, "website": "http://www.usworldmeds.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=US%20Worldmeds", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "Other", "Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Ubivac LLC", "city": "Portland", "state": "OR", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 8, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "DPV-001", "phase": "Phase II", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "DPV-007", "phase": "Preclinical", "indication": "Head and neck cancer"}, {"name": "CorVax (UBI-VLP-201)", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "DPV-008", "phase": "Preclinical", "indication": "Thyroid cancer"}, {"name": "DPV-009", "phase": "Preclinical", "indication": "Melanoma"}, {"name": "UPV-101", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "UPV-102", "phase": "Preclinical", "indication": "Ovarian cancer"}, {"name": "UPV-103", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.ubivac.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ubivac", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Head & Neck Cancer", "Hematologic Cancers", "Infectious Disease", "Lung Cancer", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Ufovax LLC", "city": "Wilmington", "state": "DE", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Ufovax-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.ufovax.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ufovax", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Ugp-therapeutics Inc.", "city": "Boonton", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Musculoskeletal"], "modalityGroups": ["Peptide", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Oral PTH (768974)", "phase": "Phase II", "indication": "Osteoporosis"}, {"name": "UGP281", "phase": "Preclinical", "indication": "Obesity"}], "ceo": "", "employees": 0, "founded": 2013, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ugp-therapeutics", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Obesity / Metabolic"]}, {"company": "Ultragenyx Pharmaceutical Inc.", "city": "Novato", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hematology", "Neurology"], "modalityGroups": ["Gene Therapy", "Protein / Biologic", "RNA Therapeutics", "Small Molecule"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Dojolvi (triheptanoin", "phase": "Marketed", "indication": "Mitochondrial disease"}, {"name": "Mepsevii", "phase": "Marketed", "indication": "Mucopolysaccharidosis"}, {"name": "DTX301 (DTX301 AAV OTC)", "phase": "Phase III", "indication": "Urea cycle disorder (UCD)"}, {"name": "DTX401 (DTX401 AAV G6Pase)", "phase": "Phase III", "indication": "Glycosphingolipid storage disorders"}, {"name": "GTX-102", "phase": "Phase I/II", "indication": "Neurology (unspecified)"}, {"name": "Peboctocogene Camaparvovec (BAY2599023", "phase": "Phase I/II", "indication": "Hemophilia"}, {"name": "UX701", "phase": "Phase I/II", "indication": "Wilson disease"}], "ceo": "Emil D. Kakkis, MD, PhD", "employees": 1294, "founded": 2010, "website": "http://www.ultragenyx.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 4109117624.26, "evFmt": "$4.1B", "ticker": "RARE", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-10-16", "recentDeals": [{"headline": "Ultragenyx Spin Out New Company, Amlogenyx", "date": "2023-10-16", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ultragenyx%20Pharmaceutical", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Other", "Other Neurology", "Rare / Genetic"]}, {"company": "Umoja Biopharma Inc.", "city": "Seattle", "state": "WA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Cell Therapy", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "UB-TT170", "phase": "Phase I", "indication": "Bone cancer"}, {"name": "UB-VV111", "phase": "Phase I", "indication": "B cell lymphoma"}, {"name": "UB-VV100", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "UB-VV400", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.umoja-biopharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 1440000000.0, "totalDealFmt": "$1.4B", "latestDealDate": "2024-09-13", "recentDeals": [{"headline": "Nona Biosciences (HBM Holdings subsidiary) Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies", "date": "2024-09-13", "value": ""}, {"headline": "AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies", "date": "2024-01-04", "value": "$1.4B"}], "totalRaised": 100000000.0, "totalRaisedFmt": "$100M", "latestFinDate": "2025-01-14", "latestFinType": "Series C rounds", "nRounds": 1, "recentFinancing": [{"type": "Series C rounds", "amount": "$100M", "date": "2025-01-14", "investors": "Double Point Ventures, Dcvc Bio, Ark Investment Management LLC, Cormorant Asset Management, Mpm Capital, Qiming Venture ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Umoja%20Biopharma", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers", "Other Solid Tumors"]}, {"company": "Unicycive Therapeutics Inc.", "city": "Los Altos", "state": "CA", "country": "United States", "diseaseCats": ["Renal", "Transplant"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "UNI-494", "phase": "Phase I", "indication": "Renal damage"}], "ceo": "Shalabh Gupta, MD", "employees": 22, "founded": 2016, "website": "https://unicycive.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 27830589.4518, "evFmt": "$28M", "ticker": "UNCY", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Unicycive%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "United Biomedical Inc.", "city": "Hauppauge", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Dermatology", "Infectious", "Inflammation", "Neurology"], "modalityGroups": ["Antibody", "Peptide", "Vaccine"], "nProducts": 8, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "UBI therapeutics mAb for AIDS (UB-421)", "phase": "Phase III", "indication": "HIV/AIDS"}, {"name": "UB-311", "phase": "Phase II", "indication": "Alzheimer's disease"}, {"name": "UB-612", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "UB-221", "phase": "Phase I", "indication": "Urticaria"}, {"name": "biosimilar trastuzumab (UB-921)", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "UB-313", "phase": "Preclinical", "indication": "Migraine"}, {"name": "UBI HIV-RC", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "UBITh IgE Immunotherapeutics", "phase": "Preclinical", "indication": "Allergy"}], "ceo": "", "employees": 0, "founded": 1983, "website": "http://www.unitedbiomedical.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=United%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Breast Cancer", "Infectious Disease", "Other Inflammation", "Pain / Migraine", "Respiratory / Allergy"]}, {"company": "United Therapeutics Corp.", "city": "Silver Spring", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Hepatic", "Infectious", "Pulmonary"], "modalityGroups": ["Antibody", "Cell Therapy", "Digital / Device", "Gene Therapy", "Other", "Small Molecule"], "nProducts": 11, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Orenitram", "phase": "Marketed", "indication": "Hypertension"}, {"name": "Remodulin", "phase": "Marketed", "indication": "Hypertension"}, {"name": "Subcutaneous Remodulin", "phase": "Marketed", "indication": "Hypertension"}, {"name": "Tyvaso", "phase": "Marketed", "indication": "Hypertension"}, {"name": "Unituxin", "phase": "Marketed", "indication": "Neuroblastoma"}, {"name": "Trevyent", "phase": "Registration", "indication": "Hypertension"}, {"name": "Sapphire", "phase": "Phase III", "indication": "Pulmonary (unspecified)"}, {"name": "Aurora-GT", "phase": "Phase II", "indication": "Hypertension"}], "ceo": "Martine A. Rothblatt, PhD, MBA", "employees": 1305, "founded": 1996, "website": "http://www.unither.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 14145740000.0, "evFmt": "$14.1B", "ticker": "UTHR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=United%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Cardiovascular", "Respiratory / Allergy"]}, {"company": "Unleash Immuno Oncolytics Inc.", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "UIO-512", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "UIO-623", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://unleash.bio/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Unleash%20Immuno%20Oncolytics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "V2act Therapeutics LLC", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "V2ACT Immunotherapy", "phase": "Phase I/II", "indication": "Pancreatic cancer"}], "ceo": "", "employees": 0, "founded": 2019, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=V2act%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Vaccex Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VX001", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2001, "website": "https://www.vaccex.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vaccex", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Vaccinex Inc.", "city": "Rochester", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Neurology"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "pepinemab (VX15/VX2503", "phase": "Phase II", "indication": "Huntington disease (HD)"}], "ceo": "Maurice Zauderer, PhD", "employees": 27, "founded": 2001, "website": "http://www.vaccinex.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 2639968.06, "evFmt": "$3M", "ticker": "VCNX", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vaccinex", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Vakston Inc.", "city": "Beverly", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "AKS-452 (SARS-CoV-2-RBD-Fc)", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://vakston.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vakston", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Valerion Therapeutics LLC", "city": "Concord", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Musculoskeletal"], "modalityGroups": ["Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "VAL-1221", "phase": "Phase I/II", "indication": "Pompe disease"}, {"name": "VAL-0411", "phase": "Preclinical", "indication": "Myotonic dystrophy type 1 (DM1)"}, {"name": "VAL-0620", "phase": "Preclinical", "indication": "Musculoskeletal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.valerion.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Valerion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Neurodegeneration / NMD", "Rare / Genetic"]}, {"company": "Valitor Inc.", "city": "Berkeley", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Ophthalmic"], "modalityGroups": ["Antibody", "Other", "Undisclosed"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VLTR-116xx", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "VLTR-557", "phase": "Preclinical", "indication": "Diabetic macular edema (DME)"}, {"name": "VLTR-621", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}, {"name": "VLTR-751", "phase": "Preclinical", "indication": "Uveitis"}, {"name": "VLTR-93xx", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.valitorbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Valitor", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Ophthalmology", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Valley Fever Solutions Inc.", "city": "Tucson", "state": "AZ", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Nikkomycin Z", "phase": "Phase I", "indication": "Fungal infection"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.valleyfeversolutions.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Valley%20Fever%20Solutions", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Valo Health Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Other", "Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "OPL-0001", "phase": "Preclinical", "indication": "Brain cancer"}, {"name": "OPL-0015", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "OPL-0021", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "OPL-0024", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "OPL-0101", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.valohealth.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Valo%20Health", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Solid Tumors (General)"]}, {"company": "Vanda Pharmaceuticals Inc.", "city": "Washington", "state": "DC", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Inflammation", "Neurology"], "modalityGroups": ["RNA Therapeutics", "Small Molecule"], "nProducts": 6, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Fanapt", "phase": "Marketed", "indication": "Bipolar disorder"}, {"name": "Hetlioz", "phase": "Marketed", "indication": "Insomnia"}, {"name": "Bysanti", "phase": "Registration", "indication": "Bipolar disorder"}, {"name": "VTR-297", "phase": "Phase I", "indication": "Hematologic malignancies"}, {"name": "VCA-894A", "phase": "IND", "indication": "Charcot-Marie-Tooth disease"}, {"name": "VSJ-110 (CFTRact-K267)", "phase": "IND", "indication": "Allergic conjunctivitis"}], "ceo": "Mihael Hristos Polymeropoulos, MD", "employees": 368, "founded": 2003, "website": "http://www.vandapharmaceuticals.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -83748873.27, "evFmt": "", "ticker": "VNDA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vanda%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Ophthalmology", "Other", "Psychiatry / Behavioral"]}, {"company": "Vaneltix Pharma Inc.", "city": "North Brunswick", "state": "NJ", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Hep-Lido-A (URG101", "phase": "Marketed", "indication": "Cystitis"}], "ceo": "", "employees": 0, "founded": 1997, "website": "https://vaneltix.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vaneltix%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Vanqua Bio Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Inflammation", "Neurology"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "GCase (VQ-101)", "phase": "Phase I", "indication": "Parkinson's disease"}, {"name": "Vanqua Bio-neurology-unknown", "phase": "Preclinical", "indication": "Multiple sclerosis (MS)"}, {"name": "VQ-201", "phase": "Preclinical", "indication": "Inflammation (unspecified)"}, {"name": "Vanqua Bio-neurodegenerative diseases-unknown", "phase": "Research", "indication": "Neurology (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.vanquabio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 1060000000.0, "totalDealFmt": "$1.1B", "latestDealDate": "2025-10-24", "recentDeals": [{"headline": "Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio", "date": "2025-10-24", "value": "$1.1B"}], "totalRaised": 44979987.0, "totalRaisedFmt": "$45M", "latestFinDate": "2024-02-15", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$45M", "date": "2024-02-15", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vanqua%20Bio", "hasDealsFin": true, "diseaseGroups": ["MS / Neuroimmune", "Other Inflammation", "Other Neurology", "Parkinson's"]}, {"company": "Vanquish Oncology Inc.", "city": "Champaign", "state": "IL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Procaspase-activating compound (PAC-1)", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2012, "website": "http://vanquishoncology.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vanquish%20Oncology", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Vapogenix Inc.", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Topical analgesic", "phase": "Phase II", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.vapogenix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vapogenix", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Vascular Dynamics Inc.", "city": "Mountain View", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "MobiusHD", "phase": "Phase I", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.vasculardynamics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vascular%20Dynamics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Vascular Nanotransfer Technologies", "city": "Auburndale", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Paclitaxel DCB", "phase": "Preclinical", "indication": "Peripheral vascular disease (PVD)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.vnanotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vascular%20Nanotransfer%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Vasgene Therapeutics Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "sEphB4-HSA", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 1998, "website": "http://www.vasgene.com", "companyType": "Private Biopharma", "ownership": "Other", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vasgene%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Vast Therapeutics Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ALX1", "phase": "Preclinical", "indication": "Mycobacterium"}, {"name": "BIOC11", "phase": "Preclinical", "indication": "Pseudomonas"}, {"name": "BIOC51", "phase": "Preclinical", "indication": "Pseudomonas"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://vasttherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vast%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Vaxart Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Pulmonary"], "modalityGroups": ["Small Molecule", "Vaccine"], "nProducts": 15, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Vapendavir (BTA798", "phase": "Phase II", "indication": "Enterovirus"}, {"name": "Relenza", "phase": "Marketed", "indication": "Influenza virus"}, {"name": "Relenza intravenous", "phase": "Registration", "indication": "Influenza virus"}, {"name": "bivalent VXA-G1.1-NN and VXA-GII.4-NS", "phase": "Phase II", "indication": "Norovirus"}, {"name": "BTA585", "phase": "Phase II", "indication": "Respiratory syncytial virus (RSV)"}, {"name": "oral H1N1 influenza vaccine (VXA-A1.1)", "phase": "Phase II", "indication": "Influenza virus"}, {"name": "oral norovirus vaccine (VXA-GI.1.NN", "phase": "Phase II", "indication": "Norovirus"}, {"name": "oral norovirus vaccine (VXA-GII.4-NS)", "phase": "Phase II", "indication": "Norovirus"}], "ceo": "Steven Lo", "employees": 115, "founded": 2004, "website": "http://www.vaxart.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 105396259.2751, "evFmt": "$105M", "ticker": "VXRT", "exchange": "OTCQX", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vaxart", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease", "Other", "Respiratory / Allergy"]}, {"company": "Vaxent LLC", "city": "Memphis", "state": "TN", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "StreptAnova (StepNovA)", "phase": "Phase II", "indication": "Streptococcus"}], "ceo": "", "employees": 0, "founded": 2008, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vaxent", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Vaxform LLC", "city": "Lehigh Valley", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "CoV2-OGEN1", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://www.vaxform.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vaxform", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Vaxxinity Inc.", "city": "Cape Canaveral", "state": "FL", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "UB-312", "phase": "Phase I", "indication": "Parkinson's disease"}, {"name": "VXX-401", "phase": "Phase I", "indication": "Hypercholesterolemia"}, {"name": "Vaxxinity-tau-unknown", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://vaxxinity.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vaxxinity", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Obesity / Metabolic", "Parkinson's"]}, {"company": "Vbi Vaccines Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Protein / Biologic", "Vaccine"], "nProducts": 9, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "PreHevbri", "phase": "Marketed", "indication": "Hepatitis B virus (HBV)"}, {"name": "VBI-1901", "phase": "Phase II", "indication": "Brain cancer"}, {"name": "VBI-2601 (BRII-179", "phase": "Phase II", "indication": "Hepatitis B virus (HBV)"}, {"name": "VBI-2902", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "CMV eVLP (VBI-1501", "phase": "Phase I", "indication": "Cytomegalovirus (CMV)"}, {"name": "VBI-2901", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "VBI-2905", "phase": "Phase I", "indication": "Coronavirus disease (COVID-19)"}, {"name": "VBI-2501", "phase": "Preclinical", "indication": "Zika virus"}], "ceo": "", "employees": 0, "founded": 2001, "website": "https://www.vbivaccines.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vbi%20Vaccines", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Infectious Disease", "Liver Disease"]}, {"company": "Vdm Biochemicals Inc.", "city": "Lake Forest", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VDM-001", "phase": "Preclinical", "indication": "Substance use disorders"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.vdmbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vdm%20Biochemicals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Vedanta Biosciences Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "VE202 (VE-202)", "phase": "Phase II", "indication": "Ulcerative colitis"}, {"name": "VE303", "phase": "Phase III", "indication": "Clostridium"}, {"name": "VE707", "phase": "Preclinical", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.vedantabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vedanta%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Infectious Disease"]}, {"company": "Velicept Therapeutics Inc.", "city": "Wayne", "state": "PA", "country": "United States", "diseaseCats": ["Gastrointestinal", "Genitourinary"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "solabegron (GW427353)", "phase": "Phase II", "indication": "Irritable bowel syndrome"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://velicept.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Velicept%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Venatorx Pharmaceuticals Inc.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "cefepime/taniborbactam", "phase": "Registration", "indication": "Urinary tract infection (UTI)"}, {"name": "taniborbactam (VNRX-5133)", "phase": "Phase III", "indication": "Urinary tract infection (UTI)"}, {"name": "Ceftibuten-ledaborbactam etzadroxil", "phase": "Phase I", "indication": "Urinary tract infection (UTI)"}, {"name": "Ledaborbactam etzadroxil", "phase": "Phase I", "indication": "Urinary tract infection (UTI)"}, {"name": "VNRX-9945", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}, {"name": "VNRX-PBP", "phase": "Preclinical", "indication": "Bacterial infection"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.venatorx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 3, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-08-14", "recentDeals": [{"headline": "Basilea Announces In-Licensing of a Novel Clinical Phase 3-Ready Oral Antibiotic with Venatorx Pharmaceuticals", "date": "2025-08-14", "value": ""}, {"headline": "Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries", "date": "2024-01-09", "value": ""}, {"headline": "Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S.", "date": "2023-11-09", "value": ""}], "totalRaised": 46700002.0, "totalRaisedFmt": "$47M", "latestFinDate": "2022-09-02", "latestFinType": "Uncategorized venture rounds", "nRounds": 2, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$13M", "date": "2022-09-02", "investors": "Undisclosed Investors"}, {"type": "Series C rounds", "amount": "$34M", "date": "2022-04-04", "investors": "Amr Action Fund, Abingworth Management Ltd."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Venatorx%20Pharmaceuticals", "hasDealsFin": true, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Venn Therapeutics LLC", "city": "Mason", "state": "OH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Other", "Vaccine"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Tumor-associated antigen", "phase": "Phase II", "indication": "Solid tumors"}, {"name": "Venn Therapeutics (VTX-001)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Venn Therapeutics (VTX-002)", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.venntherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Venn%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Ventoux Biosciences Inc.", "city": "Encinitas", "state": "CA", "country": "United States", "diseaseCats": ["Musculoskeletal"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VEN-201", "phase": "Preclinical", "indication": "Dupuytren disease"}, {"name": "VEN-202", "phase": "Preclinical", "indication": "Dupuytren disease"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://www.ventouxbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ventoux%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal"]}, {"company": "Ventrinova Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VN-100", "phase": "Preclinical", "indication": "Myocardial infarction (MI)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.ventrinovainc.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ventrinova", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Ventrix Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VentriGel", "phase": "Preclinical", "indication": "Congestive heart failure (CHF)"}], "ceo": "", "employees": 0, "founded": 2009, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ventrix", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular"]}, {"company": "Venturis Therapeutics Inc.", "city": "Dallas", "state": "TX", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Genitourinary", "Musculoskeletal", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Vascu-Grow (VT-141", "phase": "Phase II", "indication": "Coronary artery disease (CAD)"}, {"name": "VT-141D", "phase": "Preclinical", "indication": "Musculoskeletal (unspecified)"}, {"name": "VT-141ED", "phase": "Preclinical", "indication": "Erectile dysfunction (ED)"}, {"name": "VT-141P", "phase": "Preclinical", "indication": "Parkinson's disease"}, {"name": "VT-141S", "phase": "Preclinical", "indication": "Stroke"}], "ceo": "", "employees": 0, "founded": 1998, "website": "https://www.venturistherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Venturis%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Musculoskeletal", "Other Neurology", "Other Specialties", "Parkinson's"]}, {"company": "Ventus Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cardiovascular", "Dermatology", "Gastrointestinal", "Hepatic", "Inflammation", "Neurology", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VENT-01", "phase": "Phase I", "indication": "Cardiovascular (unspecified)"}, {"name": "VENT-02", "phase": "Phase I", "indication": "Central nervous system (CNS) disorders"}, {"name": "VENT-03", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "VENT-04", "phase": "Research", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.ventustx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 703000000.0, "totalDealFmt": "$703M", "latestDealDate": "2025-10-21", "recentDeals": [{"headline": "Ventus Therapeutics Enters into a Collaboration and License Agreement with Genentech to Discover and Develop Small-Molecule Medicines Using Ventus\u2019 ReSOLVE Platform", "date": "2025-10-21", "value": ""}, {"headline": "Ventus Therapeutics enters exclusive development and license agreement with Novo Nordisk for NLRP3 inhibitor program", "date": "2022-09-29", "value": "$703M"}], "totalRaised": 140000000.0, "totalRaisedFmt": "$140M", "latestFinDate": "2022-02-09", "latestFinType": "Series C rounds", "nRounds": 1, "recentFinancing": [{"type": "Series C rounds", "amount": "$140M", "date": "2022-02-09", "investors": "Softbank Vision Fund, Ra Capital Management L.P., Qatar Investment Authority, Andreessen Horowitz (A16z), Bvf Partners L..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ventus%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Brain / CNS Tumors", "Cardiovascular"]}, {"company": "Ventyx Biosciences Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Inflammation", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "tamuzimod (VTX002", "phase": "Phase II", "indication": "Ulcerative colitis"}, {"name": "VTX-2735", "phase": "Phase II", "indication": "Inflammation (unspecified)"}, {"name": "VTX3232", "phase": "Phase II", "indication": "Obesity"}, {"name": "VTX-958", "phase": "Preclinical", "indication": "Crohn's disease"}], "ceo": "Raju S. Mohan, PhD", "employees": 82, "founded": 2018, "website": "https://ventyxbio.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": -56560803.32, "evFmt": "", "ticker": "VTYX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Ventyx%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Obesity / Metabolic", "Other Inflammation"]}, {"company": "Veradermics Inc.", "city": "New Haven", "state": "CT", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "VDPHL01", "phase": "Phase II/III", "indication": "Androgenetic alopecia"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.veradermics.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "MANE", "exchange": "NYSE", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Veradermics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Veralox Therapeutics Inc.", "city": "Frederick", "state": "MD", "country": "United States", "diseaseCats": ["Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "VLX-1005", "phase": "Phase II", "indication": "Thrombocytopenia"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://veralox.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-12-11", "recentDeals": [{"headline": "Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)", "date": "2025-12-11", "value": ""}], "totalRaised": 24000000.0, "totalRaisedFmt": "$24M", "latestFinDate": "2023-06-20", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$24M", "date": "2023-06-20", "investors": "Pappas Capital LLC, Nybc Ventures, Hatteras Venture Partners, Sanofi Ventures, Jdrf T1d Fund LLC, Genesys Capital Partne..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Veralox%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Hematology (non-cancer)"]}, {"company": "Verastem Inc.", "city": "Needham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VS-4718", "phase": "Phase I", "indication": "Cancer (unspecified)"}], "ceo": "Dan Paterson", "employees": 78, "founded": 2010, "website": "http://www.verastem.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 138072210.0, "evFmt": "$138M", "ticker": "VSTM", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Verastem", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Verge Analytics Inc. (Verge Genomics)", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 10, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VRG50635", "phase": "Phase I", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "Verge Genomics-COVID-19 antiviral PIKFYVE-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Verge Genomics-ALS-unknown", "phase": "Research", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "Verge Genomics-dementias-unknown", "phase": "Research", "indication": "Frontotemporal dementia"}, {"name": "Verge Genomics-frontotemporal dementia-unknown", "phase": "Research", "indication": "Frontotemporal dementia"}, {"name": "Verge Genomics-Parkinson's disease program 1-unknown", "phase": "Research", "indication": "Parkinson's disease"}, {"name": "Verge Genomics-Parkinson's disease program 2-unknown", "phase": "Research", "indication": "Parkinson's disease"}, {"name": "Verge Genomics-Parkinson's disease program 3-unknown", "phase": "Research", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.vergegenomics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "2023-07-01", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "", "date": "2023-07-01", "investors": "Tenmile"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Verge%20Analytics%20Inc.%20(Verge%20Genomics)", "hasDealsFin": true, "diseaseGroups": ["Alzheimer's / Dementia", "Infectious Disease", "Neurodegeneration / NMD", "Parkinson's"]}, {"company": "Vericel Corp.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cardiovascular", "Dermatology", "Musculoskeletal"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Epicel", "phase": "Marketed", "indication": "Burns"}, {"name": "MACI", "phase": "Marketed", "indication": "Cartilage repair"}, {"name": "Expanded autologous mixed cell therapy", "phase": "Phase II", "indication": "Cardiomyopathy"}], "ceo": "Dominick C. Colangelo", "employees": 357, "founded": 1999, "website": "http://vcel.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 2810793890.0, "evFmt": "$2.8B", "ticker": "VCEL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vericel", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Musculoskeletal", "Supportive / Other"]}, {"company": "Verimmune Inc.", "city": "Washington", "state": "DC", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VERI-101", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.verimmune.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-05-20", "recentDeals": [{"headline": "Fosun Pharma and VerImmune enter into an Exclusive License and Option Agreement for VerImmune\u2019s Virus-inspired Particle (ViP) platform as Novel Immunotherapies in China", "date": "2022-05-20", "value": ""}], "totalRaised": 10125000.0, "totalRaisedFmt": "$10M", "latestFinDate": "2024-09-23", "latestFinType": "Uncategorized venture rounds", "nRounds": 3, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$4M", "date": "2024-09-23", "investors": "Beiley Biofund, John Ballantyne, Proxima Ventures Ltd., Mana Ventures, Gaingels, Undisclosed Investors"}, {"type": "Seed financings", "amount": "$3M", "date": "2023-09-20", "investors": "Proxima Ventures (\u6bd4\u90bb\u661f\u521b\u6295), Gaingels, Mana Ventures, Undisclosed Investors"}, {"type": "Seed financings", "amount": "$2M", "date": "2022-07-27", "investors": "Seedfolio, Ulu Ventures, Proxima Ventures (\u6bd4\u90bb\u661f\u521b\u6295), Nufund Venture Group, Gaingels, Mana Ventures, Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Verimmune", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Verisim Life Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": true, "pipeline": [{"name": "(VeriSIM life) PT001", "phase": "Preclinical", "indication": "Hypertension"}, {"name": "(VeriSIM life) PT002", "phase": "Preclinical", "indication": "Pulmonary fibrosis"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://verisimlife.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 15000000.0, "totalRaisedFmt": "$15M", "latestFinDate": "2022-01-06", "latestFinType": "Series A rounds", "nRounds": 1, "recentFinancing": [{"type": "Series A rounds", "amount": "$15M", "date": "2022-01-06", "investors": "Morpheus Ventures, Debiopharm Innovation Fund, Colorcon Ventures, Oca Ventures, Intel Capital, Serra Ventures, Susa Vent..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Verisim%20Life", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular", "Respiratory / Allergy"]}, {"company": "Verismo Therapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "SynKIR-110", "phase": "IND", "indication": "Biliary cancer"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://verismotherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Verismo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Verndari Inc.", "city": "Sacramento", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Verndari-COVID-19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.verndariinc.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Verndari", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Vero Biotech Inc.", "city": "Atlanta", "state": "GA", "country": "United States", "diseaseCats": ["Cardiovascular", "Diagnostic", "Pulmonary"], "modalityGroups": ["Digital / Device"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Genosyl inhaled nitric oxide delivery system (genosyl delivery system", "phase": "Marketed", "indication": "Pulmonary (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "https://www.vero-biotech.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vero%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Veroscience LLC", "city": "Tiverton", "state": "RI", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Cycloset", "phase": "Marketed", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.veroscience.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Veroscience", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Verrica Pharmaceuticals Inc.", "city": "West Chester", "state": "PA", "country": "United States", "diseaseCats": ["Dermatology", "Infectious"], "modalityGroups": ["Digital / Device", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Ycanth", "phase": "Marketed", "indication": "Infectious (unspecified)"}, {"name": "VP-103", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}], "ceo": "Jayson M. Rieger, PhD, MBA", "employees": 71, "founded": 2013, "website": "https://www.verrica.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 35875759.6, "evFmt": "$36M", "ticker": "VRCA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Verrica%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease"]}, {"company": "Versatope Therapeutics Inc.", "city": "Lowell", "state": "MA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VT-105", "phase": "Phase I", "indication": "Influenza virus"}, {"name": "Versatope-COVID 19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Versatope-COVID 19-unknown2", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "VT-104", "phase": "Preclinical", "indication": "Influenza virus"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.versatope.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Versatope%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Verseau Therapeutics Inc.", "city": "Bedford", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "PSGL-1 (VTX-0811)", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "VTX-1849", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.verseautx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Verseau%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Verseon International Corp.", "city": "Fremont", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Inflammation", "Neurology", "Ophthalmic"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 9, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VE-1902", "phase": "Phase I", "indication": "Stroke"}, {"name": "VE-2851", "phase": "Preclinical", "indication": "Stroke"}, {"name": "VE-3539", "phase": "Preclinical", "indication": "Diabetic retinopathy"}, {"name": "VE-3771", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "VE-4054", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "VE-4062", "phase": "Preclinical", "indication": "Angioedema"}, {"name": "VE-4666", "phase": "Preclinical", "indication": "Angioedema"}, {"name": "VE-4840", "phase": "Preclinical", "indication": "Diabetic retinopathy"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.verseon.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Verseon%20International", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Other Inflammation", "Other Neurology", "Solid Tumors (General)"]}, {"company": "Vertero Therapeutics Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VT-5006", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://vertero.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 20000000.0, "totalRaisedFmt": "$20M", "latestFinDate": "2025-10-21", "latestFinType": "Series D rounds", "nRounds": 1, "recentFinancing": [{"type": "Series D rounds", "amount": "$20M", "date": "2025-10-21", "investors": "Oneventures, Seventure Partners, Private Investors, Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vertero%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Parkinson's"]}, {"company": "Vertex Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Endocrine/Metabolic", "Hematology", "Infectious", "Inflammation", "Neurology", "Pulmonary", "Renal"], "modalityGroups": ["Cell Therapy", "Protein / Biologic", "Small Molecule"], "nProducts": 22, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Alyftrek", "phase": "Marketed", "indication": "Cystic fibrosis (CF)"}, {"name": "Incivek", "phase": "Marketed", "indication": "Hepatitis C virus (HCV)"}, {"name": "Journavx", "phase": "Marketed", "indication": "Pain"}, {"name": "Kaftrio", "phase": "Marketed", "indication": "Cystic fibrosis (CF)"}, {"name": "Kalydeco", "phase": "Marketed", "indication": "Cystic fibrosis (CF)"}, {"name": "Lexiva", "phase": "Marketed", "indication": "HIV/AIDS"}, {"name": "Orkambi", "phase": "Marketed", "indication": "Cystic fibrosis (CF)"}, {"name": "Symdeko", "phase": "Marketed", "indication": "Cystic fibrosis (CF)"}], "ceo": "Reshma Kewalramani, MD", "employees": 6100, "founded": 1989, "website": "http://www.vrtx.com", "companyType": "Large-Cap Biopharma (>=$50 billion)", "ownership": "Public", "enterpriseValue": 99487330000.0, "evFmt": "$99.5B", "ticker": "VRTX", "exchange": "NASDAQ", "nDeals": 5, "totalDealValue": 2045000000.0, "totalDealFmt": "$2.0B", "latestDealDate": "2025-09-02", "recentDeals": [{"headline": "Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases", "date": "2025-09-02", "value": "$2.0B"}, {"headline": "Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)", "date": "2025-01-07", "value": ""}, {"headline": "Vertex and TreeFrog Therapeutics announce licensing agreement and collaboration to optimize production of Vertex's cell therapies for type 1 diabetes", "date": "2024-04-23", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vertex%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease", "Pain / Migraine", "Rare / Genetic"]}, {"company": "Veru Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic", "Genitourinary", "Infectious", "Pulmonary"], "modalityGroups": ["Small Molecule"], "nProducts": 9, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Entadfi", "phase": "Approved", "indication": "Benign prostatic hyperplasia (BPH)"}, {"name": "Tamsulosin DRS", "phase": "Registration", "indication": "Benign prostatic hyperplasia (BPH)"}, {"name": "sabizabulin (VERU-111)", "phase": "Phase III", "indication": "Respiratory distress syndrome (RDS)"}, {"name": "VERU-100", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "Zuclomiphene citrate", "phase": "Phase II", "indication": "Prostate cancer"}, {"name": "APP-111", "phase": "Preclinical", "indication": "Breast cancer"}, {"name": "APP-112", "phase": "Preclinical", "indication": "Hyperuricemia/gout"}, {"name": "APP-944", "phase": "Preclinical", "indication": "Menopause"}], "ceo": "Mitchell Shuster Steiner, MD", "employees": 20, "founded": 1996, "website": "https://verupharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 40453014.2, "evFmt": "$40M", "ticker": "VERU", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Veru", "hasDealsFin": false, "diseaseGroups": ["Breast Cancer", "GU / Gynecologic Cancers", "Obesity / Metabolic", "Other Specialties", "Respiratory / Allergy", "Women's Health"]}, {"company": "Vg Life Sciences Inc.", "city": "Santa Barbara", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Peptide", "Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "HCQ", "phase": "Phase I", "indication": "Ovarian cancer"}, {"name": "VG1177", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "William P. Farrand", "employees": 0, "founded": 1995, "website": "http://www.vglifesciences.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 2912569.2991, "evFmt": "$3M", "ticker": "VGLS", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vg%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Infectious Disease"]}, {"company": "Viatris Inc.", "city": "Canonsburg", "state": "PA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Dermatology", "Endocrine/Metabolic", "Genitourinary", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Ophthalmic", "Pulmonary"], "modalityGroups": ["Combination", "Digital / Device", "Gene Therapy", "Other", "Small Molecule", "Undisclosed"], "nProducts": 36, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Tyrvaya", "phase": "Marketed", "indication": "Dry eye"}, {"name": "simpinicline (OC-02)", "phase": "Phase II", "indication": "Dry eye"}, {"name": "Acnex", "phase": "Marketed", "indication": "Acne"}, {"name": "Aldara", "phase": "Marketed", "indication": "Basal cell carcinoma (BCC)"}, {"name": "Allopurinol sodium", "phase": "Marketed", "indication": "Leukemia"}, {"name": "Anzavir-R", "phase": "Marketed", "indication": "HIV/AIDS"}, {"name": "astepro azelastine hcl 0.1% nasal spray (Astelin", "phase": "Marketed", "indication": "Rhinitis"}, {"name": "astepro azelastine hcl nasal spray 0.15%", "phase": "Marketed", "indication": "Allergy"}], "ceo": "Scott Andrew Smith", "employees": 32000, "founded": 2020, "website": "https://www.viatris.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 28340585000.0, "evFmt": "$28.3B", "ticker": "VTRS", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2022-01-26", "recentDeals": [{"headline": "Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of Valtoco", "date": "2022-01-26", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Viatris", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Hematologic Cancers", "Infectious Disease", "Ophthalmology", "Respiratory / Allergy", "Skin Cancer / Melanoma"]}, {"company": "Vibrant Therapeutics (Guangzhou) Co. Ltd. (\u4fe1\u534e\u751f\u7269)", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VIB305", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.vibrantx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vibrant%20Therapeutics%20(Guangzhou)%20Co.%20Ltd.%20(\u4fe1\u534e\u751f\u7269)", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Vicero Inc.", "city": "Shrewsbury", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VCR-027", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "VCR-054", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "VCR-072", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "VCR-108", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://www.vicerobio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vicero", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Vicus Therapeutics LLC", "city": "Morristown", "state": "NJ", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Inflammation"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "VT-122HCC", "phase": "Phase II", "indication": "Cachexia"}, {"name": "VT-122PC", "phase": "Phase II", "indication": "Inflammation (unspecified)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vicus%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic", "Other Inflammation"]}, {"company": "Vigeo Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Peptide"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "VT1021", "phase": "Phase II/III", "indication": "Brain cancer"}, {"name": "VT200X", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.vigeotherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vigeo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Brain / CNS Tumors", "Solid Tumors (General)"]}, {"company": "Viking Therapeutics Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Hepatic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VK2735", "phase": "Phase I", "indication": "Metabolic (unspecified)"}], "ceo": "Brian Lian, PhD, MBA", "employees": 36, "founded": 2012, "website": "http://www.vikingtherapeutics.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 3486155880.0, "evFmt": "$3.5B", "ticker": "VKTX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Viking%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Vima Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VIM0423", "phase": "Phase I", "indication": "Hyperkinetic movement disorder"}], "ceo": "", "employees": 0, "founded": 2023, "website": "https://vimatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vima%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Vincerx Pharma Inc.", "city": "Santa Clara", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VIP236", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://vincerx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vincerx%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Vir Biotechnology Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Antibody", "Vaccine"], "nProducts": 7, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Ebanga", "phase": "Marketed", "indication": "Ebola"}, {"name": "Xevudy", "phase": "Marketed", "indication": "Coronavirus disease (COVID-19)"}, {"name": "tobevibart (BRII-877", "phase": "Phase II", "indication": "Hepatitis B virus (HBV)"}, {"name": "VIR-1111", "phase": "Phase I", "indication": "HIV/AIDS"}, {"name": "VIR-2020", "phase": "Preclinical", "indication": "Tuberculosis"}, {"name": "Vir-HIV-unknown", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "Vir-malaria-unknown", "phase": "Preclinical", "indication": "Malaria"}], "ceo": "Marianne de Backer, PhD, MBA", "employees": 408, "founded": 2017, "website": "http://www.vir.bio", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 103209989.1, "evFmt": "$103M", "ticker": "VIR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vir%20Biotechnology", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Liver Disease"]}, {"company": "Viridian Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Ophthalmic"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "VRDN-003", "phase": "Phase III", "indication": "Thyroid eye disease"}, {"name": "VRDN-006", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "VRDN-008", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}], "ceo": "Stephen Frank Mahoney, MBA", "employees": 143, "founded": 2007, "website": "https://www.viridiantherapeutics.com/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 795767380.27, "evFmt": "$796M", "ticker": "VRDN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Viridian%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Ophthalmology"]}, {"company": "Viriom Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Approved", "hasOrphan": false, "pipeline": [{"name": "Elpida", "phase": "Approved", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.viriom.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-02-13", "recentDeals": [{"headline": "Lomond Therapeutics grants Viriom an exclusive license agreement for BCL-2 in the Russian Federation", "date": "2025-02-13", "value": ""}, {"headline": "Lomond Therapeutics grants Viriom an exclusive license agreement for FLT-3 in the Russian Federation", "date": "2025-02-13", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Viriom", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Virion Therapeutics LLC", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VRON-0200", "phase": "Phase I", "indication": "Hepatitis B virus (HBV)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.viriontx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Virion%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Liver Disease"]}, {"company": "Viromissile Inc.", "city": "La Jolla", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "IDOV-Immune", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "IDOV-Safe", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "IDOV-Immune+AntiAngio", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "IDOV-Immune+Stealth", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2016, "website": "https://viromissile.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Viromissile", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Vironexis Biotherapeutics Inc.", "city": "Columbus", "state": "OH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 6, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "VNX-101", "phase": "IND", "indication": "Acute lymphoblastic leukemia (ALL)"}, {"name": "VNX-1011", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "VNX-102", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "VNX-1021", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "VNX-103", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "VNX-1031", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://vironexis.com/about.html", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vironexis%20Biotherapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Virpax Pharmaceuticals Inc.", "city": "Malvern", "state": "PA", "country": "United States", "diseaseCats": ["Infectious", "Neurology"], "modalityGroups": ["Other", "Peptide", "Small Molecule", "Undisclosed"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AnQlar", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Envelta", "phase": "Preclinical", "indication": "Pain"}, {"name": "Epoladerm", "phase": "Preclinical", "indication": "Pain"}, {"name": "Probudur", "phase": "Preclinical", "indication": "Pain"}], "ceo": "Jay Dhaliwal", "employees": 2, "founded": 2016, "website": "http://www.virpaxpharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 103190.6997, "evFmt": "$103K", "ticker": "VRPX", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Virpax%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Pain / Migraine"]}, {"company": "Virxsys Corp.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Gene Therapy"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Lexgenleucel-T (VRX496)", "phase": "Phase II", "indication": "HIV/AIDS"}, {"name": "VRX1023", "phase": "Preclinical", "indication": "HIV/AIDS"}, {"name": "VRX1273", "phase": "Preclinical", "indication": "HIV/AIDS"}], "ceo": "", "employees": 0, "founded": 1998, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Virxsys", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Visgenx Inc.", "city": "Santa Cruz", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VGX-0111", "phase": "Preclinical", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://visgenx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Visgenx", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Vision Medicines Inc.", "city": "", "state": "", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VM100", "phase": "Phase I", "indication": "Dry age-related macular degeneration (dry AMD)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.visionmedicines.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vision%20Medicines", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Visioncare Ophthalmic Technologies Inc.", "city": "Saratoga", "state": "CA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "implantable miniature telescope", "phase": "Marketed", "indication": "Wet age-related macular degeneration (wet AMD)"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.visioncareinc.net", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Visioncare%20Ophthalmic%20Technologies", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Vistagen Therapeutics Inc.", "city": "South San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Nanoparticle / Delivery", "Small Molecule", "Undisclosed"], "nProducts": 6, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "aloradine (PH94B", "phase": "Phase III", "indication": "Anxiety"}, {"name": "4-CI-KYN", "phase": "Phase II", "indication": "Depression"}, {"name": "Itruvone (PH10)", "phase": "Phase II", "indication": "Depression"}, {"name": "PH80", "phase": "Phase II", "indication": "Premenstrual syndrome (PMS)"}, {"name": "PH15", "phase": "Phase I", "indication": "Cognitive dysfunction"}, {"name": "PH284", "phase": "Preclinical", "indication": "Cachexia"}], "ceo": "Shawn K. Singh", "employees": 57, "founded": 1998, "website": "http://www.vistagen.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -1780427.5, "evFmt": "", "ticker": "VTGN", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vistagen%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Obesity / Metabolic", "Other", "Psychiatry / Behavioral"]}, {"company": "Vita Therapeutics Inc.", "city": "Baltimore", "state": "MD", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Cell Therapy"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VTA-100", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "VTA-200", "phase": "Preclinical", "indication": "Muscular dystrophy"}, {"name": "VTA-120", "phase": "Research", "indication": "Muscular dystrophy"}, {"name": "VTA-220", "phase": "Research", "indication": "Solid tumors"}, {"name": "VTA-300", "phase": "Research", "indication": "Solid tumors"}, {"name": "VTA-310", "phase": "Research", "indication": "Solid tumors"}], "ceo": "", "employees": 0, "founded": 2018, "website": "https://www.vitatx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-04-08", "recentDeals": [{"headline": "Synthego and Vita Therapeutics Announce Strategic Licensing Agreement for hfCas12Max CRISPR Nuclease", "date": "2025-04-08", "value": ""}], "totalRaised": 31000000.0, "totalRaisedFmt": "$31M", "latestFinDate": "2022-10-12", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$31M", "date": "2022-10-12", "investors": "Cambrian Biopharma Inc., Solve Fshd Holdings Ltd., Riptide Ventures, Cedars Sinai Medical Center, Tedco, Existing Invest..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vita%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Neurodegeneration / NMD", "Solid Tumors (General)"]}, {"company": "Vitabolus Inc.", "city": "New Orleans", "state": "LA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Neurology"], "modalityGroups": ["Cell Therapy"], "nProducts": 2, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "Antimunocel", "phase": "Phase I", "indication": "Rheumatoid arthritis (RA)"}, {"name": "Proimunocel", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2010, "website": "https://www.vitabolus.co/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vitabolus", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Vitalis LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "VTS-72", "phase": "Phase I", "indication": "Multiple sclerosis (MS)"}, {"name": "VTS-63", "phase": "Preclinical", "indication": "Dyslipidemia"}, {"name": "VTS-K", "phase": "Preclinical", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.vitalispharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vitalis", "hasDealsFin": false, "diseaseGroups": ["MS / Neuroimmune", "Obesity / Metabolic", "Pain / Migraine"]}, {"company": "Vitality Biopharma Inc.", "city": "Los Angeles", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Gastrointestinal", "Infectious"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VBX-100", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "VITA-210", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "Michael Cavanaugh, MBA", "employees": 15, "founded": 2007, "website": "http://www.vitality.bio", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 26429850.863832, "evFmt": "$26M", "ticker": "VBIO", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vitality%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Vitro Biopharma Inc.", "city": "Golden", "state": "CO", "country": "United States", "diseaseCats": ["Autoimmune", "Infectious", "Musculoskeletal", "Neurology", "Other"], "modalityGroups": ["Cell Therapy"], "nProducts": 11, "mostAdvanced": "Phase III", "hasOrphan": true, "pipeline": [{"name": "Vitro Biopharma-osteoarthritis-unknown", "phase": "Phase III", "indication": "Osteoarthritis"}, {"name": "AlloRx Stem Cells", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Vitro Biopharma-Crohn's disease-unknown", "phase": "Phase I/II", "indication": "Crohn's disease"}, {"name": "Vitro Biopharma-multiple sclerosis-unknown", "phase": "Phase I", "indication": "Multiple sclerosis (MS)"}, {"name": "Vitro Biopharma-Alzheimer's disease-unknown", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "Vitro Biopharma-autism-unknown", "phase": "Preclinical", "indication": "Autism"}, {"name": "Vitro Biopharma-lupus-unknown", "phase": "Preclinical", "indication": "Lupus"}, {"name": "Vitro Biopharma-meniscus tears-unknown", "phase": "Preclinical", "indication": "Tissue damage"}], "ceo": "", "employees": 0, "founded": 1986, "website": "http://www.vitrobiopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vitro%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Autoimmune / Rheumatology", "IBD / GI Inflammatory", "Infectious Disease", "MS / Neuroimmune", "Musculoskeletal", "Psychiatry / Behavioral", "Supportive / Other"]}, {"company": "Vitruvian Biomedical Inc.", "city": "Addison", "state": "TX", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "AB42 vaccine (NU 700)", "phase": "Preclinical", "indication": "Alzheimer's disease"}, {"name": "YM7555", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.vitruvianbiomedical.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vitruvian%20Biomedical", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia"]}, {"company": "Vittoria Biotherapeutics Inc.", "city": "Philadelphia", "state": "PA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VIPER-101", "phase": "Phase I", "indication": "T cell lymphoma"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://vittoriabio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2023-07-10", "recentDeals": [{"headline": "MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to\u00a0Advance Next Generation Cellular Therapies", "date": "2023-07-10", "value": ""}], "totalRaised": 35000000.0, "totalRaisedFmt": "$35M", "latestFinDate": "2024-11-12", "latestFinType": "Uncategorized venture rounds", "nRounds": 3, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$10M", "date": "2024-11-12", "investors": "Valley Forge Investment Corp., Global Bioaccess Fund, Hatch Biofund, Agent Capital, Tellus Bioventures, Nybc Ventures, U..."}, {"type": "Uncategorized venture rounds", "amount": "$15M", "date": "2023-11-14", "investors": "Valley Forge Investment Corp., Agent Capital, Tellus Bioventures, University of Pennsylvania, Bioadvance, Nybc Ventures,..."}, {"type": "Seed financings", "amount": "$10M", "date": "2022-06-07", "investors": "Tellus Bioventures, Sv Health Investors LLP, Penn Medicine Co-investment Fund, Agent Capital"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vittoria%20Biotherapeutics", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Vivace Therapeutics Inc.", "city": "San Mateo", "state": "CA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VT3989", "phase": "Phase I", "indication": "Mesothelioma"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.vivacetherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vivace%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Lung Cancer"]}, {"company": "Vivacelle Bio Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Cardiovascular", "Inflammation", "Pulmonary"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "VBI-S", "phase": "Phase II/III", "indication": "Hypotension"}, {"name": "VBI-1", "phase": "Preclinical", "indication": "Shock/trauma"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.vivacellebio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vivacelle%20Bio", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Supportive / Other"]}, {"company": "Vivaldi Biosciences Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Pandemic deltaFLU (deltaflu panvax)", "phase": "Phase II", "indication": "Influenza virus"}, {"name": "Seasonal deltaFLU (deltaflu envax", "phase": "Phase II", "indication": "Influenza virus"}], "ceo": "", "employees": 0, "founded": 2007, "website": "http://www.vivaldibiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vivaldi%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Vivani Medical Inc.", "city": "Alameda", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "NPM-119 (Exenatide)", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "Adam Mendelsohn, PhD", "employees": 42, "founded": 2009, "website": "https://vivani.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 64975960.0, "evFmt": "$65M", "ticker": "VANI", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vivani%20Medical", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Vivasor Holding Co.", "city": "Rancho Santa Fe", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Cardiovascular", "Diagnostic", "Endocrine/Metabolic", "Infectious", "Neurology", "Pulmonary"], "modalityGroups": ["ADC", "Antibody", "Cell Therapy", "Diagnostics", "Digital / Device", "Oncolytic / Microbiome", "Other", "Protein / Biologic", "RNA Therapeutics", "Small Molecule", "Undisclosed", "Vaccine"], "nProducts": 30, "mostAdvanced": "Registration", "hasOrphan": true, "pipeline": [{"name": "anti-CD38 CAR T", "phase": "Phase I", "indication": "Multiple myeloma (MM)"}, {"name": "COVI-STIX", "phase": "Registration", "indication": "Infectious, Diagnostic"}, {"name": "Fujovee", "phase": "Phase III", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "Ovydso", "phase": "Phase III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "socazolimab (ZKAB001", "phase": "Phase III", "indication": "Small cell lung cancer"}, {"name": "COVI-DROPS (intranasal STI-2020", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "COVI-MSC (PSC-04)", "phase": "Phase II", "indication": "Respiratory distress syndrome (RDS)"}, {"name": "resiniferatoxin (RTX", "phase": "Phase II", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2024, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vivasor%20Holding", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Infectious Disease", "Lung Cancer", "Pain / Migraine", "Respiratory / Allergy"]}, {"company": "Vivreon Biosciences LLC", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VV2003", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.vivreonbiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vivreon%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory"]}, {"company": "Vivus LLC", "city": "Campbell", "state": "CA", "country": "United States", "diseaseCats": ["Cardiovascular", "Endocrine/Metabolic"], "modalityGroups": ["Combination", "Macrocycle", "Other"], "nProducts": 5, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Qsiva", "phase": "Marketed", "indication": "Obesity"}, {"name": "tacrolimus (VI-0106", "phase": "Phase II", "indication": "Hypertension"}, {"name": "Ascomycin", "phase": "Preclinical", "indication": "Hypertension"}, {"name": "SPI-054", "phase": "Preclinical", "indication": "Hypertension"}, {"name": "SPI-183", "phase": "Preclinical", "indication": "Hypertension"}], "ceo": "", "employees": 0, "founded": 1991, "website": "https://www.vivus.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vivus", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Obesity / Metabolic"]}, {"company": "Vm Pharma LLC", "city": "Fremont", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VM-902A", "phase": "Phase I", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.vmpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vm%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Volastra Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VLS-1488", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://volastratx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 1130000000.0, "totalDealFmt": "$1.1B", "latestDealDate": "2023-03-07", "recentDeals": [{"headline": "Amgen grants Volastra Therapeutics an exclusive worldwide license to develop and commercialize sovilnesib", "date": "2023-03-07", "value": ""}, {"headline": "Volastra Therapeutics announces drug discovery collaboration with Bristol Myers Squibb", "date": "2022-03-21", "value": "$1.1B"}], "totalRaised": 105099998.0, "totalRaisedFmt": "$105M", "latestFinDate": "2025-09-08", "latestFinType": "Series A rounds", "nRounds": 3, "recentFinancing": [{"type": "Series A rounds", "amount": "$30M", "date": "2025-09-08", "investors": "Undisclosed Investors"}, {"type": "Uncategorized venture rounds", "amount": "$15M", "date": "2024-05-17", "investors": "Undisclosed Investors"}, {"type": "Series A rounds", "amount": "$60M", "date": "2023-03-07", "investors": "Polaris Partners, Arch Venture Partners, Eli Lilly and Co., Droia Oncology Ventures, Catalio Capital Management, Vida Ve..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Volastra%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Voltron Therapeutics Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Voltron-COVID-19-Unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://voltrontx.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Voltron%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Vor Biopharma Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Trem-cel", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "VCAR33 (CD33CART)", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "VOR33/VCAR33", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}], "ceo": "Jean-Paul Kress, MD", "employees": 159, "founded": 2016, "website": "http://www.vorbiopharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 16167259.29, "evFmt": "$16M", "ticker": "VOR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vor%20Biopharma", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "Voyager Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Gene Therapy"], "nProducts": 4, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VY9323 (VY-SOD101)", "phase": "Preclinical", "indication": "Amyotrophic lateral sclerosis (ALS)"}, {"name": "VY-FXN01", "phase": "Preclinical", "indication": "Friedreich ataxia"}, {"name": "VY-NAV01", "phase": "Preclinical", "indication": "Pain"}, {"name": "VY-TAU01", "phase": "Preclinical", "indication": "Alzheimer's disease"}], "ceo": "Alfred W. Sandrock, Jr., MD", "employees": 172, "founded": 2014, "website": "http://www.voyagertherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 104016968.81, "evFmt": "$104M", "ticker": "VYGR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Voyager%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Neurodegeneration / NMD", "Pain / Migraine"]}, {"company": "Vrise Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VRTX126", "phase": "Preclinical", "indication": "Colorectal cancer"}], "ceo": "", "employees": 0, "founded": 2021, "website": "https://www.vrisetx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vrise%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Vtv Therapeutics Inc.", "city": "High Point", "state": "NC", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Dermatology", "Endocrine/Metabolic", "Infectious", "Neurology", "Pulmonary", "Renal"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "Phase II/III", "hasOrphan": true, "pipeline": [{"name": "mavodelpar (HPP593", "phase": "Phase I", "indication": "Mitochondrial disease"}, {"name": "azeliragon (TTP488", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "cadisegliatin (TTP399", "phase": "Phase II", "indication": "Diabetes"}, {"name": "HPP737", "phase": "Phase II", "indication": "Psoriasis"}, {"name": "TTP273", "phase": "Phase II", "indication": "Diabetes"}, {"name": "ANT-401 (HPP971)", "phase": "Phase I", "indication": "Renal (unspecified)"}], "ceo": "Paul Jai Sekhri", "employees": 23, "founded": 1999, "website": "http://vtvtherapeutics.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 45215725.7524, "evFmt": "$45M", "ticker": "VTVT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vtv%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Dermatology", "Diabetes", "Infectious Disease", "Kidney Disease", "Rare / Genetic"]}, {"company": "Vycellix Inc.", "city": "Tampa", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "CD38-GEAR-NK", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.vycellix.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vycellix", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Vyera Pharmaceuticals LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular", "Infectious"], "modalityGroups": ["Other"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "VYR 008", "phase": "Phase I", "indication": "Hypertension"}, {"name": "VYR-006", "phase": "Phase I", "indication": "Toxoplasmosis"}, {"name": "VYR-007", "phase": "Preclinical", "indication": "Toxoplasmosis"}], "ceo": "", "employees": 0, "founded": 2014, "website": "http://www.vyera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vyera%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Infectious Disease"]}, {"company": "Vyne Therapeutics Inc.", "city": "Bridgewater", "state": "NJ", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Repibresib (VYN201)", "phase": "Preclinical", "indication": "Dermatology (unspecified)"}], "ceo": "David Domzalski", "employees": 13, "founded": 2011, "website": "https://vynetherapeutics.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 81256150.0, "evFmt": "$81M", "ticker": "VYNE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vyne%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Vyome Holdings Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Dermatology", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "VB 1953", "phase": "Phase II", "indication": "Acne"}, {"name": "VT1908", "phase": "Preclinical", "indication": "Uveitis"}], "ceo": "Venkateswarlu Nelabhotla, MBA", "employees": 18, "founded": 2010, "website": "http://www.vyometx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 2473424.36, "evFmt": "$2M", "ticker": "HIND", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vyome%20Holdings", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Ophthalmology"]}, {"company": "Vyriad Inc.", "city": "Rochester", "state": "MN", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome", "Protein / Biologic"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "vesicular stomatitis virus", "phase": "Phase II", "indication": "Head and neck cancer"}, {"name": "MV-NIS", "phase": "Phase I", "indication": "Bladder cancer"}, {"name": "VSV-E6/7", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2016, "website": "http://www.vyriad.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-09-02", "recentDeals": [{"headline": "Vyriad and Weizmann Institute of Science Enter Exclusive License Agreement for In Vivo Gene Delivery Technology", "date": "2025-09-02", "value": ""}, {"headline": "Vyriad Announces Strategic Collaboration with Novartis to Develop in vivo CAR-T Cell Therapies", "date": "2024-11-20", "value": ""}], "totalRaised": 54500000.0, "totalRaisedFmt": "$54M", "latestFinDate": "2025-12-23", "latestFinType": "Series B rounds", "nRounds": 2, "recentFinancing": [{"type": "Series B rounds", "amount": "$25M", "date": "2025-12-23", "investors": "Stine Seed Farms Inc., Undisclosed Investors"}, {"type": "Series B rounds", "amount": "$30M", "date": "2022-05-17", "investors": "Stine Seed Farms Inc., Mayo Clinic, Mirae Asset Global Investments, Regeneron Pharmaceuticals Inc., Southeast Minnesota ..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vyriad", "hasDealsFin": true, "diseaseGroups": ["GU / Gynecologic Cancers", "Head & Neck Cancer", "Solid Tumors (General)"]}, {"company": "Vytacera Pharma Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Other"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Sulfanegen", "phase": "Preclinical", "indication": "Poisoning"}], "ceo": "", "employees": 0, "founded": 2011, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Vytacera%20Pharma", "hasDealsFin": false, "diseaseGroups": ["Supportive / Other"]}, {"company": "Walden Biosciences Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Renal"], "modalityGroups": ["Antibody", "Protein / Biologic", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "WAL0921", "phase": "Phase I", "indication": "Renal (unspecified)"}, {"name": "Walden-anti-fibrotic biologic-unknown", "phase": "Preclinical", "indication": "Renal (unspecified)"}, {"name": "Walden-proteinuria-unknown", "phase": "Preclinical", "indication": "Renal (unspecified)"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.waldenbiosciences.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Walden%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Kidney Disease"]}, {"company": "Walking Fish Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal"], "modalityGroups": ["Cell Therapy"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "WFT-1", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "WFT-2", "phase": "Preclinical", "indication": "Solid tumors"}, {"name": "WFT-3", "phase": "Preclinical", "indication": "Tissue damage"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://walkingfishtherapeutics.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Walking%20Fish%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)", "Supportive / Other"]}, {"company": "Wave Life Sciences Ltd.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Musculoskeletal", "Neurology", "Ophthalmic"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 6, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "WVE-003", "phase": "Phase I/II", "indication": "Huntington disease (HD)"}, {"name": "WVE-N531", "phase": "Phase I/II", "indication": "Muscular dystrophy"}, {"name": "GSK5462688", "phase": "Phase I", "indication": "Alpha-antitrypsin (AAT) deficiency"}, {"name": "WVE-007", "phase": "Phase I", "indication": "Obesity"}, {"name": "Wave Life Sciences-ATXN3-unknown", "phase": "Preclinical", "indication": "Ataxia"}, {"name": "Wave Life Sciences-USH2A RhoP23H-unknown", "phase": "Preclinical", "indication": "Ophthalmic (unspecified)"}], "ceo": "Paul B. Bolno, MD, MBA", "employees": 288, "founded": 2012, "website": "http://wavelifesciences.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1441692279.16, "evFmt": "$1.4B", "ticker": "WVE", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Wave%20Life%20Sciences", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD", "Obesity / Metabolic", "Ophthalmology", "Rare / Genetic"]}, {"company": "Wavodyne Therapeutics Inc.", "city": "Rochester", "state": "NY", "country": "United States", "diseaseCats": ["Cardiovascular", "Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "URMC-099", "phase": "Preclinical", "indication": "Cognitive dysfunction"}, {"name": "URMC-214", "phase": "Preclinical", "indication": "Heart failure"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://wavodyne.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Wavodyne%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Alzheimer's / Dementia", "Cardiovascular"]}, {"company": "Wellesley Pharmaceuticals LLC", "city": "Newton", "state": "PA", "country": "United States", "diseaseCats": ["Genitourinary"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Nocturol", "phase": "Phase II", "indication": "Nocturia"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://wellesleypharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Wellesley%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other"]}, {"company": "Werewolf Therapeutics Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "WTX-124", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "WTX-330", "phase": "Phase I", "indication": "Non-Hodgkin lymphoma (NHL)"}, {"name": "JZP898", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "WTX-712", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Dan Hicklin, PhD", "employees": 46, "founded": 2017, "website": "https://werewolftx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -8995697.28, "evFmt": "", "ticker": "HOWL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Werewolf%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Solid Tumors (General)"]}, {"company": "Western Oncolytics Ltd.", "city": "Westlake", "state": "OH", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Oncolytic / Microbiome"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "WO-12", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://westernoncolytics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Western%20Oncolytics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Whitehawk Therapeutics Inc.", "city": "Morristown", "state": "NJ", "country": "United States", "diseaseCats": ["Autoimmune", "Ophthalmic"], "modalityGroups": ["Antibody", "Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "AKB-4924 (GB004)", "phase": "Phase II", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "Razuprotafib (AKB-9778)", "phase": "Phase II", "indication": "Diabetic macular edema (DME)"}, {"name": "ARP-1536", "phase": "Preclinical", "indication": "Diabetic retinopathy"}], "ceo": "David Lennon, PhD", "employees": 40, "founded": 2011, "website": "https://www.whitehawktx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 38875467.01, "evFmt": "$39M", "ticker": "WHWK", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Whitehawk%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "IBD / GI Inflammatory"]}, {"company": "Wilmington Pharmaceuticals", "city": "Wilmington", "state": "NC", "country": "United States", "diseaseCats": ["Gastrointestinal"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "Metozolv ODT", "phase": "Marketed", "indication": "Gastroesophageal reflux disease (GERD)"}], "ceo": "", "employees": 0, "founded": 2002, "website": "http://www.wilmingtonpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Wilmington%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GI Cancers"]}, {"company": "Windtree Therapeutics Inc.", "city": "Warrington", "state": "PA", "country": "United States", "diseaseCats": ["Cancer", "Cardiovascular", "Pulmonary"], "modalityGroups": ["Digital / Device", "Peptide", "Small Molecule"], "nProducts": 5, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "Aerosurf (lucinactant)", "phase": "Phase II", "indication": "Respiratory distress syndrome (RDS)"}, {"name": "KL4 Surfactant (lucinactant)", "phase": "Phase II", "indication": "Acute lung injury"}, {"name": "VAR-101", "phase": "Preclinical", "indication": "Basal cell carcinoma (BCC)"}, {"name": "VAR-102", "phase": "Preclinical", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "Windtree-SERCA2a-unknown", "phase": "Preclinical", "indication": "Heart failure"}], "ceo": "Jed Andrew Latkin, MBA", "employees": 14, "founded": 1992, "website": "http://www.windtreetx.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 4142362.095, "evFmt": "$4M", "ticker": "WINT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Windtree%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Cardiovascular", "Hematologic Cancers", "Respiratory / Allergy", "Skin Cancer / Melanoma"]}, {"company": "Wings Therapeutics", "city": "Berkeley", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology"], "modalityGroups": ["RNA Therapeutics"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "QR-313", "phase": "Phase I/II", "indication": "Epidermolysis bullosa"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.wings-tx.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Wings%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Dermatology"]}, {"company": "Winsantor Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Undisclosed"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "WST-057", "phase": "Phase II", "indication": "Neuropathy"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.winsantor.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Winsantor", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Winston Pharmaceuticals Inc.", "city": "Vernon Hills", "state": "IL", "country": "United States", "diseaseCats": ["Autoimmune", "Neurology", "Ophthalmic"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Civamide nasal spray (WL-1001)", "phase": "Phase III", "indication": "Migraine"}, {"name": "Dolorac Nasal Solution (WL-1017", "phase": "Phase II", "indication": "Pain"}, {"name": "Civamide Capsule", "phase": "Phase I", "indication": "Crohn's disease"}], "ceo": "", "employees": 0, "founded": 1997, "website": "http://www.winstonlabs.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 0, "evFmt": "", "ticker": "WPHM", "exchange": "Pink", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Winston%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["IBD / GI Inflammatory", "Pain / Migraine"]}, {"company": "Woolsey Pharmaceuticals Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "Bravyl", "phase": "Phase II", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2019, "website": "https://www.woolseypharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Woolsey%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}, {"company": "Wugen Inc.", "city": "St. Louis", "state": "MO", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Cell Therapy", "Other"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "soficabtagene geleucel (WU-CART-007", "phase": "Phase II", "indication": "Leukemia"}, {"name": "WU-NK-101", "phase": "Phase I/II", "indication": "Acute myelogenous leukemia (AML)"}, {"name": "WU CART 002", "phase": "Preclinical", "indication": "Leukemia"}], "ceo": "", "employees": 0, "founded": 2018, "website": "http://www.wugen.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Wugen", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers"]}, {"company": "X-vax Technology Inc.", "city": "Jupiter", "state": "FL", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Vaccine"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "delta gD-2", "phase": "Preclinical", "indication": "Herpes simplex virus (HSV)"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.x-vax.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=X-vax%20Technology", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "X4 Pharmaceuticals Inc.", "city": "Boston", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Small Molecule"], "nProducts": 3, "mostAdvanced": "Approved", "hasOrphan": true, "pipeline": [{"name": "Xolremdi", "phase": "Approved", "indication": "Immunodeficiency"}, {"name": "X4P-002", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "X4P-003", "phase": "Preclinical", "indication": "Neutropenia"}], "ceo": "Paula S. Ragan, PhD", "employees": 143, "founded": 2014, "website": "http://www.x4pharma.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 123525237.9896, "evFmt": "$124M", "ticker": "XFOR", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=X4%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Hematology (non-cancer)", "Other Inflammation", "Solid Tumors (General)"]}, {"company": "Xalud Therapeutics Inc.", "city": "San Francisco", "state": "CA", "country": "United States", "diseaseCats": ["Dermatology", "Gastrointestinal", "Musculoskeletal", "Neurology", "Ophthalmic"], "modalityGroups": ["Gene Therapy"], "nProducts": 1, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "XT-150", "phase": "Phase II/III", "indication": "Pain"}], "ceo": "", "employees": 0, "founded": 2009, "website": "http://www.xaludthera.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xalud%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine"]}, {"company": "Xbiotech Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Neurology"], "modalityGroups": ["Antibody"], "nProducts": 9, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "514G3", "phase": "Phase II", "indication": "Staphylococcus"}, {"name": "Natrunix (XB2001)", "phase": "Phase I/II", "indication": "Pancreatic cancer"}, {"name": "CAR90972", "phase": "Preclinical", "indication": "Stroke"}, {"name": "Fluvid", "phase": "Preclinical", "indication": "Influenza virus"}, {"name": "RHE 70202", "phase": "Preclinical", "indication": "Psoriatic arthritis"}, {"name": "Xbiotech- C. difficile-unknown", "phase": "Preclinical", "indication": "Clostridium"}, {"name": "XBiotech-COVID 19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}, {"name": "Xbiotech-influenza-unknown", "phase": "Preclinical", "indication": "Influenza virus"}], "ceo": "Sushma Shivaswamy, PhD", "employees": 92, "founded": 2005, "website": "http://www.xbiotech.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -42106129.0, "evFmt": "", "ticker": "XBIT", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xbiotech", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "GI Cancers", "Infectious Disease", "Other Neurology"]}, {"company": "Xcovery Holding Co. LLC", "city": "Palm Beach Gardens", "state": "FL", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 5, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "ensartinib (X-396)", "phase": "Registration", "indication": "Non-small cell lung cancer (NSCLC)"}, {"name": "MRX-2843", "phase": "Phase I", "indication": "Solid tumors"}, {"name": "MRX-6313", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "X-339", "phase": "Preclinical", "indication": "Chronic lymphocytic leukemia (CLL)"}, {"name": "X-379", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.xcovery.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xcovery%20Holding%20Co.", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Lung Cancer", "Solid Tumors (General)"]}, {"company": "Xencor Inc.", "city": "Monrovia", "state": "CA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Hematology", "Infectious", "Inflammation", "Neurology"], "modalityGroups": ["Antibody", "Bispecific Antibody", "Other", "Protein / Biologic"], "nProducts": 23, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "obexelimab (XmAb5871", "phase": "Phase III", "indication": "IgG4-related disease"}, {"name": "Minjuvi", "phase": "Marketed", "indication": "B cell lymphoma"}, {"name": "Quellor (XPro1595)", "phase": "Phase II/III", "indication": "Coronavirus disease (COVID-19)"}, {"name": "AIMab7195 (IV XmAb7195)", "phase": "Phase II", "indication": "Allergy"}, {"name": "AIMab7195 (Subcutaneous XmAb7195)", "phase": "Phase II", "indication": "Allergy"}, {"name": "plamotamab (XmAb13676)", "phase": "Phase II", "indication": "B cell lymphoma"}, {"name": "Vudalimab (XmAb20717", "phase": "Phase II", "indication": "Cancer (unspecified)"}, {"name": "Tidutamab (XmAb18087)", "phase": "Phase I/II", "indication": "Skin cancer"}], "ceo": "Bassil I. Dahiyat, PhD", "employees": 250, "founded": 1997, "website": "http://www.xencor.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 1225241269.7, "evFmt": "$1.2B", "ticker": "XNCR", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 187000000.0, "totalDealFmt": "$187M", "latestDealDate": "2022-08-02", "recentDeals": [{"headline": "Caris Life Sciences partners with Xencor to develop and commercialize novel bispecific antibodies to treat cancer", "date": "2022-08-02", "value": "$187M"}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xencor", "hasDealsFin": true, "diseaseGroups": ["Hematologic Cancers", "Infectious Disease", "Other", "Respiratory / Allergy", "Skin Cancer / Melanoma", "Solid Tumors (General)"]}, {"company": "Xenetic Biosciences Inc.", "city": "Framingham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer", "Hematology"], "modalityGroups": ["Cell Therapy", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase II/III", "hasOrphan": false, "pipeline": [{"name": "ErepoXen", "phase": "Phase II/III", "indication": "Anemia"}, {"name": "Xenetic-Non-Hodgkin Lymphoma-Unknown", "phase": "Preclinical", "indication": "B cell lymphoma"}], "ceo": "James F. Parslow, MBA, CPA", "employees": 2, "founded": 1997, "website": "http://www.xeneticbio.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -13821.39, "evFmt": "", "ticker": "XBIO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xenetic%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Hematologic Cancers", "Hematology (non-cancer)"]}, {"company": "Xeno Biosciences Inc.", "city": "Somerville", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "XEN-101", "phase": "Phase I", "indication": "Obesity"}], "ceo": "", "employees": 0, "founded": 0, "website": "http://www.xenobiosciences.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xeno%20Biosciences", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Xentria Inc.", "city": "Chicago", "state": "IL", "country": "United States", "diseaseCats": ["Inflammation"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": true, "pipeline": [{"name": "XTMAB-16", "phase": "Phase I", "indication": "Sarcoidosis"}], "ceo": "", "employees": 0, "founded": 2020, "website": "https://www.xentria.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 80000000.0, "totalDealFmt": "$80M", "latestDealDate": "2023-06-27", "recentDeals": [{"headline": "Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America", "date": "2023-06-27", "value": "$80M"}], "totalRaised": 25000000.0, "totalRaisedFmt": "$25M", "latestFinDate": "2022-10-18", "latestFinType": "Uncategorized venture rounds", "nRounds": 1, "recentFinancing": [{"type": "Uncategorized venture rounds", "amount": "$25M", "date": "2022-10-18", "investors": "Undisclosed Investors"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xentria", "hasDealsFin": true, "diseaseGroups": ["Other Inflammation"]}, {"company": "Xequel Bio Inc.", "city": "Mount Pleasant", "state": "SC", "country": "United States", "diseaseCats": ["Dermatology", "Infectious"], "modalityGroups": ["Other", "Vaccine"], "nProducts": 2, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Granexin Gel (act 1)", "phase": "Phase III", "indication": "Dermal ulcers"}, {"name": "FirstString Research-COVID 19-unknown", "phase": "Preclinical", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "", "employees": 0, "founded": 2005, "website": "http://www.firststringresearch.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xequel%20Bio", "hasDealsFin": false, "diseaseGroups": ["Dermatology", "Infectious Disease"]}, {"company": "Xeris Biopharma Holdings Inc.", "city": "Austin", "state": "TX", "country": "United States", "diseaseCats": ["Endocrine/Metabolic", "Neurology"], "modalityGroups": ["Other", "Protein / Biologic", "Small Molecule"], "nProducts": 8, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Gvoke", "phase": "Marketed", "indication": "Diabetes"}, {"name": "Recorlev", "phase": "Marketed", "indication": "Cushing disease"}, {"name": "CSI Glucagon", "phase": "Phase II", "indication": "Hypoglycemia"}, {"name": "G-Pen Mini", "phase": "Phase II", "indication": "Hypoglycemia"}, {"name": "G-Pump", "phase": "Phase II", "indication": "Diabetes"}, {"name": "veldoreotide", "phase": "Phase II", "indication": "Acromegaly"}, {"name": "XP-3924", "phase": "Phase II", "indication": "Diabetes"}, {"name": "Xerisol diazepam", "phase": "Phase I", "indication": "Dravet syndrome"}], "ceo": "John Patrick Shannon, Jr.", "employees": 394, "founded": 2005, "website": "http://www.xerispharma.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 697385649.62, "evFmt": "$697M", "ticker": "XERS", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-05-06", "recentDeals": [{"headline": "Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics", "date": "2024-05-06", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xeris%20Biopharma%20Holdings", "hasDealsFin": true, "diseaseGroups": ["Diabetes", "Epilepsy / Seizures", "Other", "Other Specialties"]}, {"company": "Xfibra Inc.", "city": "San Diego", "state": "CA", "country": "United States", "diseaseCats": ["Pulmonary"], "modalityGroups": ["Peptide"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "XFB19 (XFB-19)", "phase": "Phase I", "indication": "Pulmonary fibrosis"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://xfibra.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xfibra", "hasDealsFin": false, "diseaseGroups": ["Respiratory / Allergy"]}, {"company": "Xilio Therapeutics Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody", "Protein / Biologic"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "XTX101", "phase": "Phase I/II", "indication": "Solid tumors"}, {"name": "XTX301", "phase": "Phase I", "indication": "Solid tumors"}], "ceo": "Ren\u00e9 Russo, PharmD", "employees": 64, "founded": 2016, "website": "http://www.xiliotx.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 3954409.92, "evFmt": "$4M", "ticker": "XLO", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xilio%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Xoc Pharmaceuticals Inc.", "city": "Los Gatos", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "XC101", "phase": "Preclinical", "indication": "Migraine"}, {"name": "XC130", "phase": "Preclinical", "indication": "Parkinson's disease"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.xocpharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xoc%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Pain / Migraine", "Parkinson's"]}, {"company": "Xtalpi Holdings Ltd. (Xtalpi)", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Small Molecule"], "nProducts": 6, "mostAdvanced": "IND", "hasOrphan": false, "pipeline": [{"name": "XBD-101", "phase": "IND", "indication": "Cancer (unspecified)"}, {"name": "XBD-207", "phase": "IND", "indication": "Autoimmune (unspecified)"}, {"name": "XTN003", "phase": "IND", "indication": "Solid tumors"}, {"name": "XBD-105", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "XBD-201", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "XBD-202", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "Jian Ma, PhD", "employees": 809, "founded": 2014, "website": "http://www.xtalpi.com", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": 1085160540.14837, "evFmt": "$1.1B", "ticker": "2228", "exchange": "HKEX", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xtalpi%20Holdings%20Ltd.%20(Xtalpi)", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Solid Tumors (General)"]}, {"company": "Xwpharma Ltd.", "city": "Redwood City", "state": "CA", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Small Molecule", "Undisclosed"], "nProducts": 3, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "valiloxybate (XW10172)", "phase": "Phase II", "indication": "Cataplexy"}, {"name": "XW10508", "phase": "Phase I", "indication": "Depression"}, {"name": "XWPharma-other programs-unknown", "phase": "Preclinical", "indication": "Epilepsy"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://www.xwpharma.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xwpharma", "hasDealsFin": false, "diseaseGroups": ["Epilepsy / Seizures", "Other", "Psychiatry / Behavioral"]}, {"company": "Xylocor Therapeutics Inc.", "city": "Wayne", "state": "PA", "country": "United States", "diseaseCats": ["Cardiovascular"], "modalityGroups": ["Gene Therapy"], "nProducts": 2, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "encoberminogene rezmadenovec (XC001", "phase": "Phase I/II", "indication": "Angina"}, {"name": "XC002", "phase": "Research", "indication": "Cardiovascular (unspecified)"}], "ceo": "", "employees": 0, "founded": 2013, "website": "https://xylocor.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 1, "totalDealValue": 130000000.0, "totalDealFmt": "$130M", "latestDealDate": "2024-07-10", "recentDeals": [{"headline": "XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart", "date": "2024-07-10", "value": "$130M"}], "totalRaised": 67500000.0, "totalRaisedFmt": "$68M", "latestFinDate": "2025-01-07", "latestFinType": "Series B rounds", "nRounds": 1, "recentFinancing": [{"type": "Series B rounds", "amount": "$68M", "date": "2025-01-07", "investors": "Jeito Capital, Eqt Life Sciences, Fountain Healthcare Partners, Lumira Ventures"}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Xylocor%20Therapeutics", "hasDealsFin": true, "diseaseGroups": ["Cardiovascular"]}, {"company": "Yamo Pharmaceuticals LLC", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Other"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "L1-79", "phase": "Phase II", "indication": "Autism"}], "ceo": "", "employees": 0, "founded": 2015, "website": "http://www.yamopharma.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Yamo%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Psychiatry / Behavioral"]}, {"company": "Yd Bio Ltd.", "city": "Bothell", "state": "WA", "country": "United States", "diseaseCats": ["Ophthalmic"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "LSC Exosome Eye Drops", "phase": "Preclinical", "indication": "Dry eye"}, {"name": "LSC Exosome Eye Injection", "phase": "Preclinical", "indication": "Dry eye"}], "ceo": "Hsieh-Tsung Shen, PhD, EMBA", "employees": 4, "founded": 2013, "website": "https://ir.ydesgroup.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 45627426.52, "evFmt": "$46M", "ticker": "YDES", "exchange": "NASDAQ", "nDeals": 1, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2024-09-30", "recentDeals": [{"headline": "YD Bio signed an exclusive license for breast cancer detection across the U.S., Europe, and Asia with EG BioMed", "date": "2024-09-30", "value": ""}], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Yd%20Bio", "hasDealsFin": false, "diseaseGroups": ["Ophthalmology"]}, {"company": "Yiviva Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer", "Infectious", "Pulmonary"], "modalityGroups": ["Undisclosed"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "YIV-906", "phase": "Phase II", "indication": "Liver cancer"}, {"name": "YIV-006", "phase": "Preclinical", "indication": "Inflammatory bowel disease (IBD)"}, {"name": "YIV-111", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "YIV-201", "phase": "Preclinical", "indication": "Hepatitis"}], "ceo": "", "employees": 0, "founded": 2014, "website": "https://yiviva.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Yiviva", "hasDealsFin": false, "diseaseGroups": ["GI Cancers", "IBD / GI Inflammatory", "Liver Disease", "Solid Tumors (General)"]}, {"company": "Zabbio Inc.", "city": "Del Mar", "state": "CA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I", "hasOrphan": false, "pipeline": [{"name": "ZB-06", "phase": "Phase I", "indication": "Contraception"}], "ceo": "", "employees": 0, "founded": 2017, "website": "https://www.zabbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zabbio", "hasDealsFin": false, "diseaseGroups": ["Women's Health"]}, {"company": "Zag Bio Inc.", "city": "Cambridge", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ZAG-101", "phase": "Preclinical", "indication": "Diabetes"}], "ceo": "", "employees": 0, "founded": 2022, "website": "https://zagbio.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zag%20Bio", "hasDealsFin": false, "diseaseGroups": ["Diabetes"]}, {"company": "Zalgen Labs LLC", "city": "Germantown", "state": "MD", "country": "United States", "diseaseCats": ["Diagnostic", "Infectious"], "modalityGroups": ["Antibody", "Diagnostics"], "nProducts": 2, "mostAdvanced": "Marketed", "hasOrphan": false, "pipeline": [{"name": "ReEBOV Antigen Rapid Test", "phase": "Marketed", "indication": "Infectious, Diagnostic"}, {"name": "Arevirumab-3", "phase": "Preclinical", "indication": "Viral hemorrhagic fever"}], "ceo": "", "employees": 0, "founded": 2011, "website": "http://www.zalgenlabs.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zalgen%20Labs", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other"]}, {"company": "Zenas Biopharma Inc.", "city": "Waltham", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Ophthalmic"], "modalityGroups": ["Antibody"], "nProducts": 6, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ZB002", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "ZB003", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "ZB004", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "ZB005", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "ZB006", "phase": "Preclinical", "indication": "Autoimmune (unspecified)"}, {"name": "ZB011", "phase": "Preclinical", "indication": "Thyroid eye disease"}], "ceo": "Lonnie Moulder, Jr., MBA", "employees": 130, "founded": 2021, "website": "https://zenasbio.com/about/", "companyType": "Mid-Cap Biopharma ($1-$50 billion)", "ownership": "Public", "enterpriseValue": -7564955.72, "evFmt": "", "ticker": "ZBIO", "exchange": "NASDAQ", "nDeals": 2, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "2025-10-07", "recentDeals": [{"headline": "Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis", "date": "2025-10-07", "value": ""}, {"headline": "Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia", "date": "2023-09-05", "value": ""}], "totalRaised": 318000000.0, "totalRaisedFmt": "$318M", "latestFinDate": "2024-05-07", "latestFinType": "Series C rounds", "nRounds": 2, "recentFinancing": [{"type": "Series C rounds", "amount": "$200M", "date": "2024-05-07", "investors": "Sr One, New Enterprise Associates, Norwest Venture Partners, Delos Capital, Enavate Sciences, Longitude Capital, Federat..."}, {"type": "Series B rounds", "amount": "$118M", "date": "2022-11-07", "investors": "Enavate Sciences, Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal Bio..."}], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zenas%20Biopharma", "hasDealsFin": true, "diseaseGroups": ["Autoimmune / Rheumatology", "Ophthalmology"]}, {"company": "Zentalis Pharmaceuticals Inc.", "city": "New York", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Endocrine/Metabolic"], "modalityGroups": ["Small Molecule"], "nProducts": 4, "mostAdvanced": "Phase II", "hasOrphan": true, "pipeline": [{"name": "azenosertib (ZN-c3)", "phase": "Phase II", "indication": "Endometrial cancer"}, {"name": "ZN-d5", "phase": "Phase I/II", "indication": "Amyloidosis"}, {"name": "Zentalis-hematologic cancer-unknown", "phase": "Preclinical", "indication": "Hematologic malignancies"}, {"name": "Zentalis-solid tumors-unknown", "phase": "Preclinical", "indication": "Solid tumors"}], "ceo": "Julia Marie Eastland, MBA", "employees": 166, "founded": 2014, "website": "http://www.zentalis.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -113062600.0, "evFmt": "", "ticker": "ZNTL", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zentalis%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers", "Hematologic Cancers", "Solid Tumors (General)", "Supportive / Other"]}, {"company": "Zeo Scientifix Inc.", "city": "Miami", "state": "FL", "country": "United States", "diseaseCats": ["Infectious"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": false, "pipeline": [{"name": "Zofin (organicell flow)", "phase": "Phase I/II", "indication": "Coronavirus disease (COVID-19)"}], "ceo": "Ian T. Bothwell", "employees": 20, "founded": 2011, "website": "https://organicell.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 12137612.11, "evFmt": "$12M", "ticker": "BPSR", "exchange": "OTCQB", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zeo%20Scientifix", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease"]}, {"company": "Zetagen Therapeutics Inc.", "city": "Syracuse", "state": "NY", "country": "United States", "diseaseCats": ["Cancer", "Musculoskeletal", "Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 4, "mostAdvanced": "Registration", "hasOrphan": false, "pipeline": [{"name": "ZetaBase", "phase": "Registration", "indication": "Musculoskeletal (unspecified)"}, {"name": "ZetaMet", "phase": "Phase II", "indication": "Bone cancer"}, {"name": "ZetaFuse", "phase": "Phase I", "indication": "Spinal cord injury (SCI)"}, {"name": "ZetaMAST", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2015, "website": "https://www.zetagen.com/", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zetagen%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Musculoskeletal", "Other Neurology", "Other Solid Tumors", "Solid Tumors (General)"]}, {"company": "Zevra Therapeutics Inc.", "city": "Celebration", "state": "FL", "country": "United States", "diseaseCats": ["Autoimmune", "Endocrine/Metabolic", "Infectious", "Neurology", "Other"], "modalityGroups": ["Cell Therapy", "Combination", "Other", "Small Molecule"], "nProducts": 14, "mostAdvanced": "Marketed", "hasOrphan": true, "pipeline": [{"name": "Azstarys (serdexmethylphenidate/ dexmethylphenidate", "phase": "Marketed", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "Apadaz", "phase": "Approved", "indication": "Pain"}, {"name": "Olpruva", "phase": "Approved", "indication": "Urea cycle disorder (UCD)"}, {"name": "Edsivo", "phase": "Phase III", "indication": "Genetic disorders"}, {"name": "Emetine hydrochloride (ACER-2820)", "phase": "Phase II", "indication": "Coronavirus disease (COVID-19)"}, {"name": "serdexmethylphenidate (KP1077)", "phase": "Phase II", "indication": "Hypersomnia"}, {"name": "KP484", "phase": "Phase I", "indication": "Attention deficit hyperactivity disorder (ADHD)"}, {"name": "KP511", "phase": "Phase I", "indication": "Pain"}], "ceo": "Neil F. McFarlane", "employees": 59, "founded": 2006, "website": "https://zevra.com/", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": 376535333.26, "evFmt": "$377M", "ticker": "ZVRA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zevra%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Infectious Disease", "Other", "Pain / Migraine", "Psychiatry / Behavioral", "Rare / Genetic"]}, {"company": "Zielbio Inc.", "city": "Charlottesville", "state": "VA", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Antibody"], "nProducts": 1, "mostAdvanced": "Phase I/II", "hasOrphan": true, "pipeline": [{"name": "ZB131", "phase": "Phase I/II", "indication": "Ovarian cancer"}], "ceo": "", "employees": 0, "founded": 2010, "website": "http://www.zielbio.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zielbio", "hasDealsFin": false, "diseaseGroups": ["GU / Gynecologic Cancers"]}, {"company": "Zinfandel Pharmaceuticals Inc.", "city": "Durham", "state": "NC", "country": "United States", "diseaseCats": ["Diagnostic"], "modalityGroups": ["Diagnostics"], "nProducts": 1, "mostAdvanced": "Phase III", "hasOrphan": false, "pipeline": [{"name": "Biomarker risk assignment algorithm", "phase": "Phase III", "indication": "Neurology, Diagnostic"}], "ceo": "", "employees": 0, "founded": 0, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zinfandel%20Pharmaceuticals", "hasDealsFin": false, "diseaseGroups": ["Other Neurology"]}, {"company": "Zumutor Biologics Inc.", "city": "Woburn", "state": "MA", "country": "United States", "diseaseCats": ["Autoimmune", "Cancer"], "modalityGroups": ["Antibody"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ZM008", "phase": "Preclinical", "indication": "Rheumatoid arthritis (RA)"}, {"name": "ZM012", "phase": "Preclinical", "indication": "Lymphoma"}, {"name": "ZM014", "phase": "Preclinical", "indication": "Lymphoma"}], "ceo": "", "employees": 0, "founded": 2013, "website": "http://www.zumutor.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zumutor%20Biologics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Hematologic Cancers"]}, {"company": "Zwi Therapeutics Inc.", "city": "Watertown", "state": "MA", "country": "United States", "diseaseCats": ["Endocrine/Metabolic"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "ZWI-001", "phase": "Preclinical", "indication": "Hyperuricemia/gout"}], "ceo": "", "employees": 0, "founded": 2019, "website": "", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zwi%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Obesity / Metabolic"]}, {"company": "Zylo Therapeutics Inc.", "city": "Greenville", "state": "SC", "country": "United States", "diseaseCats": ["Autoimmune", "Dermatology", "Genitourinary", "Infectious", "Neurology"], "modalityGroups": ["Nanoparticle / Delivery"], "nProducts": 5, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "HT-005 (anandamide-loaded Z-pod)", "phase": "Preclinical", "indication": "Lupus"}, {"name": "curcumin-loaded Z-pod", "phase": "Preclinical", "indication": "Osteoarthritis"}, {"name": "endocannabinoid-loaded Z-pod", "phase": "Preclinical", "indication": "Lupus"}, {"name": "lidocaine-loaded Z-pod", "phase": "Preclinical", "indication": "Pain"}, {"name": "nitric oxide-loaded Z-pod", "phase": "Preclinical", "indication": "Acne"}], "ceo": "", "employees": 0, "founded": 2017, "website": "http://www.zylotherapeutics.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zylo%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Autoimmune / Rheumatology", "Dermatology", "Musculoskeletal", "Pain / Migraine"]}, {"company": "Zyngenia Inc.", "city": "Gaithersburg", "state": "MD", "country": "United States", "diseaseCats": ["Cancer"], "modalityGroups": ["Bispecific Antibody"], "nProducts": 2, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "Cetuximab-based bispecific zybody", "phase": "Preclinical", "indication": "Cancer (unspecified)"}, {"name": "Trastuzumab-based bispecific zybody", "phase": "Preclinical", "indication": "Cancer (unspecified)"}], "ceo": "", "employees": 0, "founded": 2008, "website": "http://www.zyngenia.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zyngenia", "hasDealsFin": false, "diseaseGroups": ["Solid Tumors (General)"]}, {"company": "Zyversa Therapeutics Inc.", "city": "Weston", "state": "FL", "country": "United States", "diseaseCats": ["Other", "Renal"], "modalityGroups": ["Macrocycle"], "nProducts": 3, "mostAdvanced": "Preclinical", "hasOrphan": false, "pipeline": [{"name": "VAR 200", "phase": "Preclinical", "indication": "Focal segmental glomerulosclerosis (FSGS)"}, {"name": "VAR 300", "phase": "Preclinical", "indication": "Alport syndrome"}, {"name": "VAR 400", "phase": "Preclinical", "indication": "Diabetic nephropathy"}], "ceo": "Stephen C. Glover", "employees": 7, "founded": 2014, "website": "https://www.zyversa.com", "companyType": "Small-Cap Biopharma (<$1 billion)", "ownership": "Public", "enterpriseValue": -354288.02, "evFmt": "", "ticker": "ZVSA", "exchange": "NASDAQ", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zyversa%20Therapeutics", "hasDealsFin": false, "diseaseGroups": ["Diabetes", "Kidney Disease"]}, {"company": "Zz Biotech LLC", "city": "Houston", "state": "TX", "country": "United States", "diseaseCats": ["Neurology"], "modalityGroups": ["Protein / Biologic"], "nProducts": 1, "mostAdvanced": "Phase II", "hasOrphan": false, "pipeline": [{"name": "3K3A-APC", "phase": "Phase II", "indication": "Amyotrophic lateral sclerosis (ALS)"}], "ceo": "", "employees": 0, "founded": 2006, "website": "http://www.zzbiotech.com", "companyType": "Private Biopharma", "ownership": "Private", "enterpriseValue": 0, "evFmt": "", "ticker": "", "exchange": "", "nDeals": 0, "totalDealValue": 0, "totalDealFmt": "", "latestDealDate": "", "recentDeals": [], "totalRaised": 0, "totalRaisedFmt": "", "latestFinDate": "", "latestFinType": "", "nRounds": 0, "recentFinancing": [], "linkedinUrl": "https://www.linkedin.com/search/results/companies/?keywords=Zz%20Biotech", "hasDealsFin": false, "diseaseGroups": ["Neurodegeneration / NMD"]}];
const ALL_TAS=["Autoimmune", "Cancer", "Cardiovascular", "Dental", "Dermatology", "Diagnostic", "Endocrine/Metabolic", "Gastrointestinal", "Genitourinary", "Hematology", "Hepatic", "Infectious", "Inflammation", "Musculoskeletal", "Neurology", "Ophthalmic", "Other", "Otologic", "Pulmonary", "Renal", "Transplant"];
const ALL_MODS=["ADC", "Antibody", "Bispecific Antibody", "Cell Therapy", "Combination", "Diagnostics", "Digital / Device", "Gene Therapy", "Macrocycle", "Nanoparticle / Delivery", "Oncolytic / Microbiome", "Other", "Peptide", "Protein / Biologic", "RNA Therapeutics", "Radiopharmaceutical", "Small Molecule", "Undisclosed", "Vaccine"];
const ALL_DGS=["Alzheimer's / Dementia", "Autoimmune / Rheumatology", "Brain / CNS Tumors", "Breast Cancer", "Cardiovascular", "Dermatology", "Diabetes", "Epilepsy / Seizures", "GI Cancers", "GU / Gynecologic Cancers", "Head & Neck Cancer", "Hematologic Cancers", "Hematology (non-cancer)", "IBD / GI Inflammatory", "Infectious Disease", "Kidney Disease", "Liver Disease", "Lung Cancer", "MS / Neuroimmune", "Musculoskeletal", "Neurodegeneration / NMD", "Obesity / Metabolic", "Ophthalmology", "Other", "Other Inflammation", "Other Neurology", "Other Solid Tumors", "Other Specialties", "Pain / Migraine", "Parkinson's", "Psychiatry / Behavioral", "Rare / Genetic", "Respiratory / Allergy", "Skin Cancer / Melanoma", "Solid Tumors (General)", "Supportive / Other", "Transplant", "Women's Health"];
const ALL_CITIES=[" Barrington", "Abbott Park", "Acton", "Addison", "Agoura Hills", "Alachua", "Alameda", "Aldie", "Allston", "Alpharetta", "Alpine", "Amarilla", "Anaheim", "Andover", "Ann Arbor", "Arcadia", "Ardsley", "Arlington", "Ashburn", "Athens", "Atlanta", "Auburn", "Auburndale", "Aurora", "Austin", "Bala Cynwyd", "Baltimore", "Baskin Ridge", "Basking Ridge", "Baudette", "Bayville", "Bedford", "Bedminster", "Bellaire", "Bellevue", "Belmont", "Beltsville", "Berkeley", "Berkeley Heights", "Bernardsville", "Berwyn", "Bethesda", "Bethesda, MD", "Bethlehem", "Beverly", "Billerica", "Birchwood", "Birmingham", "Blacksburg", "Bloomington", "Blue Ash", "Boca Raton", "Bohemia", "Bonita Springs", "Boonton", "Boston", "Bothell", "Boulder", "Branford", "Brentwood", "Bridgewater", "Brisbane", "Bristol", "Brookline", "Brooklyn", "Broomfield", "Bryn Mawr", "Bryn-Mawr", "Buffalo", "Burlingame", "Burlington", "Calabasas", "Camarillo", "Cambridge", "Campbell", "Canonsburg", "Canton", "Cape Canaveral", "Carlsbad", "Carmel", "Carrboro", "Cartersville", "Cary", "Celebration", "Centennial", "Champaign", "Chandler", "Chapel Hill", "Chappaqua", "Charleston", "Charlestown", "Charlotte", "Charlottesville", "Chatham", "Chesterbrook", "Chesterland", "Chevy Chase", "Cheyney", "Chicago", "Chicago, IL", "Cincinnati", "Claremont", "Clarksville", "Clearwater", "Cleveland", "Clifton", "Coconut Grove", "College Station", "Columbia", "Columbus", "Concord", "Conshohocken", "Coral Gables", "Coral Springs", "Corte Madera", "Coverntry", "Covington", "Cranbury", "Cranford", "Culver City", "Cumberland", "Cumming", "Dallas", "Danville", "Darien", "Davis", "Dayton", "Deer Park", "Deerfield", "Del Mar", "Delaware", "Delray Beach", "Denver", "Detroit", "Dover", "Doylestown", "Dublin", "Duluth", "Durham", "Eagan", "Easely", "East Palo Alto", "East Stroudsburg", "Edgewater", "Edina", "Edison", "Elk Grove Village", "Elkins Park", "Elmhurst", "Emeryville", "Encinitas", "Encino", "Englewood", "Evanstan", "Evanston", "Exton", "Fairfield", "Fargo", "Farmingdale", "Farmington", "Farmington Hills", "Farmville", "Fayetteville", "Ferndale", "Fishers", "Floresville", "Florham Park", "Florida", "Foothill Ranch", "Forest", "Fort Collins", "Fort Lauderdale", "Fort Lee", "Fort Worth", "Foster City", "Foxboro", "Framingham", "Frederick", "Freehold", "Fremont", "Gainesville", "Gaithersburg", "Galveston", "Garden Grove", "Garretson", "Germantown", "Glen Allen", "Glen Rock", "Golden", "Grand Forks", "Greensboro", "Greenville", "Greenwich", "Greenwood Village", "Grosse Pointe Farms", "Groton", "Guilford", "Haddonfield", "Halethorpe", "Half Moon Bay", "Hallandale Beach", "Hamden", "Hartford", "Hatfield", "Hauppauge", "Hayward", "Henderson", "Henrico", "High Point", "Hillsborough", "Holliston", "Honolulu", "Horsham", "Houston", "Hummelstown", "Huntington", "Huntsville", "Huston", "Indianapolis", "Inglewood", "Irvine", "Irving", "Iselin", "Isle Of Palms", "Jericho", "Jersey City", "Johnson City", "Jupiter", "Kalamazoo", "Kansas City", "Kensington", "King Of Prussia", "Kirkland", "Knoxville", "La Habra", "La Jolla", "La Mesa", "La Palma", "Lafayette", "Laguna Hills", "Lake Forest", "Lancaster", "Langhorne", "Lansdale", "Las Vegas", "Lawrence", "Lawrenceville", "Lebanon", "Lehi", "Lehigh Valley", "Lenexa", "Lenoir", "Lexington", "Lincoln", "Lisle", "Little Rock", "Livermore", "Locust Valley", "Loma Linda", "Long Beach", "Los Altos", "Los Angeles", "Los Gatos", "Louisburg", "Louisville", "Lowell", "Lubbock", "Lutz", "Madison", "Malvern", "Manassas", "Manhattan", "Marietta", "Marina del Rey", "Marlborough", "Mason", "Maynard", "Mclean", "Medfield", "Medford", "Melville", "Memphis", "Menlo Park", "Mequon", "Mercer Island", "Miami", "Mill Valley", "Millbrae", "Milpitas", "Milwaukee", "Minneapolis", "Miramar", "Miramar Beach", "Mission Viejo", "Missoula", "Moline", "Monmouth Junction", "Monrovia", "Montvale", "Montville", "Moorpark", "Morgantown", "Morris Hills", "Morristown", "Morrisville", "Mount Arlington", "Mount Pleasant", "Mount Prospect", "Mountain View", "Mt Pleasant", "Naples", "Nashville", "Natick", "Nazareth", "Needham", "Neenah", "New Brunswick", "New Castle", "New Haven", "New Orleans", "New York", "New York City", "Newark", "Newport Beach", "Newton", "Newton Centre", "Newtown Square", "Nissequogue", "Norcross", "Norfolk", "North Andover", "North Bethesda", "North Billerica", "North Brunswick", "North Chicago", "North Miami", "Northbrook", "Northvale", "Northville", "Norwood", "Novato", "Oakland", "Ocala", "Oceanside", "Oklahoma City", "Oldsmar", "Omaha", "Orange", "Orem", "Orlando", "Palatine", "Palm Beach", "Palm Beach Gardens", "Palo Alto", "Paramus", "Parsippany", "Pasadena", "Pendleton", "Philadelphia", "Phoenix", "Phoenixville", "Piscataway", "Pisgah Forest", "Pittsburgh", "Pittsford", "Plainsboro", "Plano", "Platte City", "Pleasanton", "Plymouth", "Plymouth Meeting", "Pomona", "Pompano Beach", "Port Washington", "Portland", "Portola Valley", "Poway", "Powell", "Princeton", "Providence", "Provo", "Purchase", "Quincy", "Radnor", "Radnor Township", "Rahway", "Raleigh", "Ramsey", "Rancho Cucamonga", "Rancho Santa Fe", "Redmond", "Redwood", "Redwood City", "Reno", "Rensselaer", "Research Triangle Park", "Reston", "Richmond", "River Forest", "Riviera Beach", "Rochester", "Rockville", "Roswell", "Rye", "Sacramento", "Saddle Brook", "Saint Paul", "Salem", "Salt Lake City", "San Antonio", "San Bruno", "San Carlos", "San Diego", "San Francisco", "San Jose", "San Juan Capistrano", "San Marino", "San Mateo", "San Rafael", "Santa Ana", "Santa Barbara", "Santa Clara", "Santa Cruz", "Santa Fe", "Santa Monica", "Sarasota", "Saratoga", "Sausalito", "Savannah", "Scarsdale", "Scottsdale", "Seattle", "Secaucus", "Shelton", "Sherman Oaks", "Shrewsbury", "Silver Spring", "Simpsonville", "Skokie", "Solana Beach", "Solon", "Somerset", "Somerville", "Souderton", "South Plainfield", "South San Francisco", "Southborough", "Southfield", "Southlake", "Southport", "Spring House", "Springfield", "St Louis", "St. Louis", "Stafford", "Stamford", "Stanford", "State College", "Stony Brook", "Stoughton", "Stuart", "Sudbury", "Sugarland", "Summerville", "Summit", "Sunnyvale", "Sunrise", "Surfside", "Syracuse", "Tacoma", "Tallahassee", "Tampa", "Tarrytown", "Teaneck", "Temecula", "Tempe", "The Woodlands", "Thousand Oaks", "Tiverton", "Topsfield", "Torrance", "Tucker", "Tucson", "Tuscon", "University Park", "Vallejo", "Vancouver", "Vernon Hills", "Vero Beach", "Vienna", "Villanova", "Wakefield", "Walnut Creek", "Waltham", "Warminster", "Warren", "Warrington", "Washington", "Watertown", "Wauwatosa", "Wayne", "Wellesley", "West Chester", "West Conshohocken", "West Haven", "West Lafayette", "West Palm Beach", "Westfield", "Westlake", "Westlake Village", "Westminster", "Weston", "Wexford", "White Plains", "Williamsville", "Willowbrook", "Wilmette", "Wilmington", "Wilmington, MA", "Winchester", "Winston Salem", "Winston-Salem", "Wixom", "Woburn", "Woodbury", "Woodcliff Lake", "Woodinville", "Woodland Hills", "Woodridge", "Woodstock", "Worcester", "Yonkers", "albuquerque"];
const ALL_STATES=["AL", "AR", "AZ", "BC", "CA", "CO", "CT", "DC", "DE", "FL", "GA", "HI", "IL", "IN", "KS", "KY", "LA", "MA", "MD", "ME", "MI", "MN", "MO", "MS", "MT", "NC", "ND", "NE", "NH", "NJ", "NM", "NV", "NY", "OH", "OK", "OR", "PA", "RI", "SC", "SD", "TN", "TX", "UT", "VA", "WA", "WI", "WV"];
const STATE_CITIES={"CA": ["Agoura Hills", "Alameda", "Anaheim", "Arcadia", "Belmont", "Berkeley", "Brisbane", "Burlingame", "Calabasas", "Camarillo", "Campbell", "Carlsbad", "Claremont", "Corte Madera", "Culver City", "Danville", "Davis", "Del Mar", "East Palo Alto", "Emeryville", "Encinitas", "Encino", "Foothill Ranch", "Foster City", "Fremont", "Garden Grove", "Half Moon Bay", "Hayward", "Hillsborough", "Inglewood", "Irvine", "La Habra", "La Jolla", "La Mesa", "La Palma", "Laguna Hills", "Lake Forest", "Lancaster", "Livermore", "Loma Linda", "Long Beach", "Los Altos", "Los Angeles", "Los Gatos", "Marina del Rey", "Menlo Park", "Mill Valley", "Millbrae", "Milpitas", "Mission Viejo", "Monrovia", "Moorpark", "Mountain View", "Newark", "Newport Beach", "Novato", "Oakland", "Oceanside", "Orange", "Palo Alto", "Pasadena", "Pleasanton", "Pomona", "Portola Valley", "Poway", "Rancho Cucamonga", "Rancho Santa Fe", "Redwood", "Redwood City", "Richmond", "Sacramento", "San Bruno", "San Carlos", "San Diego", "San Francisco", "San Jose", "San Juan Capistrano", "San Marino", "San Mateo", "San Rafael", "Santa Ana", "Santa Barbara", "Santa Clara", "Santa Cruz", "Santa Monica", "Saratoga", "Sausalito", "Sherman Oaks", "Solana Beach", "South San Francisco", "Stanford", "Sunnyvale", "Surfside", "Temecula", "Thousand Oaks", "Torrance", "Vallejo", "Walnut Creek", "Westlake Village", "Woodland Hills"], "OR": ["Portland"], "MA": ["Acton", "Allston", "Andover", "Arlington", "Auburndale", "Bedford", "Belmont", "Beverly", "Billerica", "Boston", "Brookline", "Burlington", "Cambridge", "Canton", "Charlestown", "Concord", "Foxboro", "Framingham", "Frederick", "Holliston", "Lexington", "Lowell", "Marlborough", "Maynard", "Medfield", "Medford", "Natick", "Needham", "Newton", "Newton Centre", "North Andover", "North Billerica", "Norwood", "Quincy", "Salem", "Shrewsbury", "Somerville", "Southborough", "Stoughton", "Sudbury", "Topsfield", "Wakefield", "Waltham", "Watertown", "Wellesley", "Wilmington", "Winchester", "Woburn", "Worcester"], "TX": ["Addison", "Amarilla", "Austin", "Bedford", "Bellaire", "College Station", "Dallas", "Floresville", "Fort Worth", "Galveston", "Houston", "Huston", "Irving", "Lubbock", "Plano", "San Antonio", "Southlake", "Stafford", "Sugarland", "The Woodlands"], "NJ": ["Baskin Ridge", "Basking Ridge", "Bedminster", "Berkeley Heights", "Bernardsville", "Boonton", "Bridgewater", "Chatham", "Clifton", "Cranbury", "Cranford", "Edgewater", "Edison", "Fairfield", "Florham Park", "Fort Lee", "Freehold", "Glen Rock", "Haddonfield", "Hillsborough", "Iselin", "Jersey City", "Lawrenceville", "Monmouth Junction", "Montvale", "Montville", "Morris Hills", "Morristown", "Mount Arlington", "New Brunswick", "Newark", "North Brunswick", "Northvale", "Paramus", "Parsippany", "Piscataway", "Plainsboro", "Princeton", "Rahway", "Ramsey", "Saddle Brook", "Secaucus", "Somerset", "South Plainfield", "Summit", "Teaneck", "Warren", "Westfield", "Woodcliff Lake"], "DC": ["Washington"], "SC": ["Charleston", "Easely", "Greenville", "Isle Of Palms", "Lexington", "Mount Pleasant", "Mt Pleasant", "Simpsonville", "Summerville"], "NC": ["Carrboro", "Cary", "Chapel Hill", "Charlotte", "Durham", "Farmville", "Greensboro", "Greenville", "High Point", "Hillsborough", "Lenoir", "Morrisville", "Pisgah Forest", "Raleigh", "Research Triangle Park", "Wilmington", "Winston Salem", "Winston-Salem"], "NY": ["Ardsley", "Bayville", "Bohemia", "Brooklyn", "Buffalo", "Chappaqua", "Farmingdale", "Hauppauge", "Huntington", "Jericho", "Locust Valley", "Manhattan", "Melville", "New York", "New York City", "Nissequogue", "Pittsford", "Port Washington", "Purchase", "Rensselaer", "Rochester", "Rye", "Scarsdale", "Stony Brook", "Syracuse", "Tarrytown", "White Plains", "Williamsville", "Yonkers"], "UT": ["Alpine", "Lehi", "Orem", "Providence", "Provo", "Salt Lake City"], "MD": ["Baltimore", "Beltsville", "Bethesda", "Cambridge", "Chevy Chase", "Clarksville", "Cumberland", "Frederick", "Gaithersburg", "Germantown", "Halethorpe", "Kensington", "North Bethesda", "Rockville", "Silver Spring"], "IL": ["Abbott Park", "Champaign", "Chicago", "Deer Park", "Deerfield", "Elk Grove Village", "Elmhurst", "Evanstan", "Evanston", "Forest", "Lake Forest", "Lisle", "Moline", "Mount Prospect", "Nazareth", "North Chicago", "Northbrook", "Palatine", "River Forest", "Skokie", "Springfield", "Vernon Hills", "Willowbrook", "Wilmette", "Woodridge"], "FL": ["Alachua", "Boca Raton", "Bonita Springs", "Cape Canaveral", "Celebration", "Clearwater", "Coconut Grove", "Coral Gables", "Coral Springs", "Delray Beach", "Florida", "Fort Lauderdale", "Gainesville", "Hallandale Beach", "Jupiter", "Lutz", "Miami", "Miramar", "Miramar Beach", "Naples", "North Miami", "Ocala", "Oldsmar", "Orlando", "Palm Beach", "Palm Beach Gardens", "Pompano Beach", "Riviera Beach", "Sarasota", "Stuart", "Sunrise", "Surfside", "Tallahassee", "Tampa", "University Park", "Vero Beach", "West Palm Beach", "Weston"], "NV": ["Henderson", "Las Vegas", "Reno"], "DE": ["Dover", "New Castle", "Newark", "Wilmington"], "GA": ["Alpharetta", "Athens", "Atlanta", "Cartersville", "Cumming", "Duluth", "Norcross", "Roswell", "Savannah", "Tucker", "Woodstock"], "MO": ["Columbia", "Kansas City", "Platte City", "St Louis", "St. Louis"], "PA": ["Bala Cynwyd", "Berwyn", "Bethlehem", "Bristol", "Bryn Mawr", "Bryn-Mawr", "Canonsburg", "Chesterbrook", "Cheyney", "Conshohocken", "Doylestown", "East Stroudsburg", "Elkins Park", "Exton", "Hatfield", "Horsham", "Hummelstown", "King Of Prussia", "Langhorne", "Lansdale", "Lehigh Valley", "Malvern", "Newton", "Newtown Square", "Philadelphia", "Phoenixville", "Pittsburgh", "Plymouth Meeting", "Radnor", "Radnor Township", "Souderton", "Spring House", "State College", "Villanova", "Warminster", "Warrington", "Wayne", "West Chester", "West Conshohocken", "Wexford"], "CO": ["Aurora", "Boulder", "Broomfield", "Centennial", "Denver", "Englewood", "Fort Collins", "Golden", "Greenwood Village", "Louisville", "Westminster"], "WA": ["Auburn", "Bellevue", "Bothell", "Kirkland", "Mercer Island", "Redmond", "Seattle", "Tacoma", "Vancouver", "Woodinville"], "MN": ["Baudette", "Birchwood", "Eagan", "Edina", "Minneapolis", "Plymouth", "Rochester", "Saint Paul", "Woodbury"], "VA": ["Aldie", "Ashburn", "Blacksburg", "Charlottesville", "Glen Allen", "Henrico", "Manassas", "Mclean", "Norfolk", "Reston", "Richmond", "Vienna"], "NH": ["Lebanon"], "IN": ["Bloomington", "Carmel", "Fishers", "Indianapolis", "Lafayette", "West Lafayette"], "NE": ["Lincoln", "Omaha"], "KY": ["Covington", "Lexington", "Louisville"], "CT": ["Branford", "Darien", "Fairfield", "Farmington", "Greenwich", "Groton", "Guilford", "Hamden", "Hartford", "New Haven", "Shelton", "Southport", "Stamford", "West Haven"], "ME": ["Portland"], "OH": ["Blue Ash", "Chesterland", "Cincinnati", "Cleveland", "Columbus", "Dayton", "Delaware", "Dublin", "Marietta", "Mason", "Powell", "Solon", "Washington", "Westlake"], "MS": ["Canton"], "ND": ["Fargo", "Grand Forks"], "AL": ["Birmingham", "Huntsville"], "TN": ["Brentwood", "Johnson City", "Knoxville", "Memphis", "Nashville"], "AZ": ["Chandler", "Phoenix", "Scottsdale", "Tempe", "Tucson", "Tuscon"], "MI": ["Ann Arbor", "Birmingham", "Detroit", "Farmington Hills", "Ferndale", "Grosse Pointe Farms", "Kalamazoo", "Northville", "Plymouth", "Southfield", "Wixom"], "WI": ["Madison", "Mequon", "Milwaukee", "Neenah", "Wauwatosa"], "RI": [" Barrington", "Coverntry", "Cumberland", "Lincoln", "Providence", "Tiverton"], "AR": ["Fayetteville", "Little Rock"], "SD": ["Garretson"], "OK": ["Oklahoma City"], "HI": ["Honolulu"], "KS": ["Kansas City", "Lawrence", "Lenexa", "Louisburg", "Manhattan"], "LA": ["New Orleans"], "BC": ["Vancouver"], "MT": ["Missoula"], "NM": ["Santa Fe", "albuquerque"], "WV": ["Morgantown"]};
const PO={'Marketed':10,'Approved':9,'Registration':8,'Phase IV':10,'Phase III':7,'Phase II/III':6.5,'Phase II':6,'Phase I/II':5.5,'Phase I':5,'Phase 0':4.5,'IND':4,'Preclinical':3,'Research':2,'Market (diagnostic)':9,'Market (device)':9,'Development (diagnostic)':3,'Pilot':3,'Pilot (device)':3,'Pivotal':7,'Pivotal (device)':7};
let sortCol='company',sortDir='asc',currentPage=1,pageSize=100;

const allMsels=[];
function createMultiSelect(cid,label,items,onChange){
  const c=document.getElementById(cid);
  let selected=new Set(items);
  let currentItems=[...items];
  const st={q:''};
  function build(){
    let h='<div class="msel-btn">'+label+'</div><div class="msel-drop">';
    if(currentItems.length>8)h+='<div class="msel-search"><input type="text" placeholder="Search..."></div>';
    h+='<div class="msel-actions"><button data-action="all">Select All</button><button data-action="none">Deselect All</button></div><div class="msel-list">';
    currentItems.forEach(i=>{const ck=selected.has(i);h+='<div class="msel-item'+(ck?' checked':'')+'" data-value="'+i.replace(/"/g,'&quot;')+'"><span class="msel-cb">'+(ck?'\u2713':'')+'</span><span class="msel-label">'+i+'</span></div>'});
    h+='</div></div>';c.innerHTML=h;
    const btn=c.querySelector('.msel-btn'),drop=c.querySelector('.msel-drop'),si=c.querySelector('.msel-search input');
    ul();
    btn.addEventListener('click',e=>{e.stopPropagation();document.querySelectorAll('.msel-drop.open').forEach(d=>{if(d!==drop)d.classList.remove('open')});document.querySelectorAll('.msel-btn.open').forEach(b=>{if(b!==btn)b.classList.remove('open')});const o=drop.classList.toggle('open');btn.classList.toggle('open',o);if(o&&si){si.value='';st.q='';rl();si.focus()}});
    if(si){si.addEventListener('input',()=>{st.q=si.value;rl()});si.addEventListener('click',e=>e.stopPropagation())}
    c.querySelector('[data-action="all"]').addEventListener('click',e=>{e.stopPropagation();currentItems.forEach(i=>selected.add(i));rl();ul();onChange(selected)});
    c.querySelector('[data-action="none"]').addEventListener('click',e=>{e.stopPropagation();selected.clear();rl();ul();onChange(selected)});
    c.querySelectorAll('.msel-item').forEach(i=>{i.addEventListener('click',e=>{e.stopPropagation();const v=i.dataset.value;if(selected.has(v))selected.delete(v);else selected.add(v);i.classList.toggle('checked');i.querySelector('.msel-cb').textContent=selected.has(v)?'\u2713':'';ul();onChange(selected)})});
  }
  function ul(){const b=c.querySelector('.msel-btn');if(!b)return;const n=selected.size;b.innerHTML=n===currentItems.length?label:label+' <span class="cnt">'+n+'</span>'}
  function rl(){const q=st.q.toLowerCase();c.querySelectorAll('.msel-item').forEach(i=>{const v=i.dataset.value;i.classList.toggle('hidden',q&&!v.toLowerCase().includes(q));i.classList.toggle('checked',selected.has(v));i.querySelector('.msel-cb').textContent=selected.has(v)?'\u2713':''})}
  build();
  const obj={
    getSelected:()=>selected,
    rebuild:(newItems)=>{currentItems=[...newItems];selected=new Set(newItems);st.q='';build()},
    reset:(items)=>{currentItems=[...items];selected=new Set(items);st.q='';build()}
  };
  allMsels.push({obj,defaultItems:items});
  return obj;
}
document.addEventListener('click',()=>{document.querySelectorAll('.msel-drop.open').forEach(d=>d.classList.remove('open'));document.querySelectorAll('.msel-btn.open').forEach(b=>b.classList.remove('open'))});

const mselTA=createMultiSelect('mselTA','Therapeutic Areas',ALL_TAS,()=>{currentPage=1;render()});
const mselDG=createMultiSelect('mselDG','Disease Focus',ALL_DGS,()=>{currentPage=1;render()});
const mselMod=createMultiSelect('mselMod','Modalities',ALL_MODS,()=>{currentPage=1;render()});
const mselState=createMultiSelect('mselState','State',ALL_STATES,(selStates)=>{
  const cities=new Set();
  for(const st of selStates){if(STATE_CITIES[st])STATE_CITIES[st].forEach(c=>cities.add(c))}
  mselCity.rebuild([...cities].sort());
  currentPage=1;render();
});
const mselCity=createMultiSelect('mselCity','City',ALL_CITIES,()=>{currentPage=1;render()});

// Reset button
document.getElementById('resetBtn').addEventListener('click',()=>{
  document.getElementById('search').value='';
  document.getElementById('fPhase').value='';
  document.getElementById('fMoney').value='';
  allMsels.forEach(m=>m.obj.reset(m.defaultItems));
  sortCol='company';sortDir='asc';currentPage=1;
  document.querySelectorAll('thead th .sa').forEach(s=>s.textContent='');
  document.querySelector('[data-col="company"] .sa').textContent='\u25B2';
  render();
});

function esc(s){const d=document.createElement('div');d.textContent=s;return d.innerHTML}
function pc(p){const o=PO[p]||0;return o>=7?'phl':o>=4.5?'phm':'phe'}

function getFiltered(){
  const q=document.getElementById('search').value.toLowerCase(),phase=document.getElementById('fPhase').value,money=document.getElementById('fMoney').value;
  const sTA=mselTA.getSelected(),sMod=mselMod.getSelected(),sDG=mselDG.getSelected(),sSt=mselState.getSelected(),sCi=mselCity.getSelected();
  const aTA=sTA.size===ALL_TAS.length,aMod=sMod.size===ALL_MODS.length,aDG=sDG.size===ALL_DGS.length,aSt=sSt.size===ALL_STATES.length;
  return DATA.filter(d=>{
    if(q&&!d.company.toLowerCase().includes(q))return false;
    if(!aTA&&!d.diseaseCats.some(c=>sTA.has(c)))return false;
    if(!aDG&&!d.diseaseGroups.some(g=>sDG.has(g)))return false;
    if(!aMod&&!d.modalityGroups.some(m=>sMod.has(m)))return false;
    if(!aSt&&!sSt.has(d.state))return false;
    if(d.city&&!sCi.has(d.city))return false;
    if(phase){const o=PO[d.mostAdvanced]||0;if(phase==='marketed'&&o<9)return false;if(phase==='late'&&(o<7||o>=9))return false;if(phase==='mid'&&(o<4.5||o>=7))return false;if(phase==='early'&&o>=4.5)return false}
    if(money==='financed'&&d.totalRaised<=0)return false;
    if(money==='deals'&&d.nDeals<=0)return false;
    if(money==='both'&&(d.totalRaised<=0||d.nDeals<=0))return false;
    if(money==='enriched'&&!d.hasDealsFin)return false;
    return true;
  });
}
function getSorted(arr){
  return[...arr].sort((a,b)=>{
    let va=a[sortCol],vb=b[sortCol];
    if(sortCol==='mostAdvanced'){va=PO[va]||0;vb=PO[vb]||0}
    if(sortCol==='_ta'){va=(a.diseaseCats||[]).join(',').toLowerCase();vb=(b.diseaseCats||[]).join(',').toLowerCase()}
    if(sortCol==='_dg'){va=(a.diseaseGroups||[]).join(',').toLowerCase();vb=(b.diseaseGroups||[]).join(',').toLowerCase()}
    if(sortCol==='_mod'){va=(a.modalityGroups||[]).join(',').toLowerCase();vb=(b.modalityGroups||[]).join(',').toLowerCase()}
    if(typeof va==='string')va=va.toLowerCase();
    if(typeof vb==='string')vb=vb.toLowerCase();
    if(va<vb)return sortDir==='asc'?-1:1;if(va>vb)return sortDir==='asc'?1:-1;return 0;
  });
}
function render(){
  const filtered=getFiltered(),sorted=getSorted(filtered);
  window._allSorted=sorted;
  const tp=Math.max(1,Math.ceil(sorted.length/pageSize));
  if(currentPage>tp)currentPage=tp;
  const s=(currentPage-1)*pageSize,e=Math.min(s+pageSize,sorted.length),page=sorted.slice(s,e);
  window._s=page;
  const ec=filtered.filter(d=>d.hasDealsFin).length;
  document.getElementById('stats').textContent=filtered.length+' companies ('+ec+' enriched)';
  document.getElementById('tbody').innerHTML=page.map((d,i)=>{
    const taTags=d.diseaseCats.map(c=>'<span class="tag tt">'+esc(c)+'</span>').join('');
    const dgTags=d.diseaseGroups.map(g=>'<span class="tag td2">'+esc(g)+'</span>').join('');
    const modTags=d.modalityGroups.map(m=>'<span class="tag tm">'+esc(m)+'</span>').join('');
    const badge=d.hasDealsFin?'<span class="badge-e">E</span>':'';
    return '<tr>'+
      '<td><div class="cc"><span class="cn" onclick="showPopup('+i+')" title="'+esc(d.company)+'">'+esc(d.company)+'</span>'+badge+'<a href="'+d.linkedinUrl+'" target="_blank" rel="noopener" class="li" title="LinkedIn">in</a></div></td>'+
      '<td class="tc">'+taTags+'</td>'+
      '<td class="tc">'+dgTags+'</td>'+
      '<td class="tc">'+modTags+'</td>'+
      '<td><span class="pb '+pc(d.mostAdvanced)+'">'+esc(d.mostAdvanced)+'</span></td>'+
      '<td>'+d.nProducts+'</td>'+
      '<td class="dc" ondblclick="showFB(event,'+i+')">'+(d.totalRaisedFmt?'<span class="money">'+d.totalRaisedFmt+'</span>':'<span class="mn">\u2014</span>')+'<span class="dh">dbl-click</span></td>'+
      '<td>'+(d.latestFinDate?'<span class="date">'+d.latestFinDate+'</span>':'<span class="mn">\u2014</span>')+'</td>'+
      '<td class="dc" ondblclick="showDB(event,'+i+')">'+(d.totalDealFmt?'<span class="money">'+d.totalDealFmt+'</span>':'<span class="mn">\u2014</span>')+'<span class="dh">dbl-click</span></td>'+
      '<td>'+(d.latestDealDate?'<span class="date">'+d.latestDealDate+'</span>':'<span class="mn">\u2014</span>')+'</td>'+
      '<td><span class="loc">'+esc(d.state)+'</span></td>'+
      '<td><span class="loc">'+esc(d.city)+'</span></td>'+
    '</tr>';
  }).join('');
  let ph='<button onclick="goPage(1)" '+(currentPage===1?'disabled':'')+'>&#x00AB;</button>';
  ph+='<button onclick="goPage('+(currentPage-1)+')" '+(currentPage===1?'disabled':'')+'>&#x2039;</button>';
  const mx=7;let ps2=Math.max(1,currentPage-3),pe2=Math.min(tp,ps2+mx-1);if(pe2-ps2<mx-1)ps2=Math.max(1,pe2-mx+1);
  for(let p=ps2;p<=pe2;p++)ph+='<button onclick="goPage('+p+')" '+(p===currentPage?'class="active"':'')+'>'+p+'</button>';
  ph+='<button onclick="goPage('+(currentPage+1)+')" '+(currentPage===tp?'disabled':'')+'>&#x203A;</button>';
  ph+='<button onclick="goPage('+tp+')" '+(currentPage===tp?'disabled':'')+'>&#x00BB;</button>';
  ph+='<span class="pager-info">'+(s+1)+'–'+e+' of '+sorted.length+'</span>';
  ph+='<select onchange="changePageSize(this.value)">';
  [50,100,200].forEach(n=>{ph+='<option value="'+n+'"'+(pageSize===n?' selected':'')+'>'+n+'/page</option>'});
  ph+='</select>';document.getElementById('pager').innerHTML=ph;
}
function goPage(p){currentPage=p;render();window.scrollTo({top:document.querySelector('.table-wrap').offsetTop-10,behavior:'smooth'})}
function changePageSize(n){pageSize=parseInt(n);currentPage=1;render()}
function showPopup(idx){
  const d=window._s[idx];if(!d)return;
  let h='<div class="ph"><div><div class="pt">'+esc(d.company)+(d.hasDealsFin?' <span class="badge-e">Enriched</span>':'')+'</div>';
  let sub=[];
  if(d.city)sub.push(d.city+(d.state?', '+d.state:''));
  if(d.companyType)sub.push(d.companyType);
  if(d.ownership)sub.push(d.ownership);
  if(d.hasOrphan)sub.push('Orphan Designation');
  h+='<div class="ps">'+esc(sub.join(' \u00b7 '))+'</div>';
  h+='<div class="pa"><a href="'+d.linkedinUrl+'" target="_blank" rel="noopener" class="pl2"><svg viewBox="0 0 24 24"><path d="M20.5 2h-17A1.5 1.5 0 002 3.5v17A1.5 1.5 0 003.5 22h17a1.5 1.5 0 001.5-1.5v-17A1.5 1.5 0 0020.5 2zM8 19H5v-9h3zM6.5 8.25A1.75 1.75 0 118.3 6.5a1.78 1.78 0 01-1.8 1.75zM19 19h-3v-4.74c0-1.42-.6-1.93-1.38-1.93A1.74 1.74 0 0013 14.19a.66.66 0 000 .14V19h-3v-9h2.9v1.3a3.11 3.11 0 012.7-1.4c1.55 0 3.36.86 3.36 3.66z"/></svg>LinkedIn</a>';
  if(d.website)h+='<a href="'+(d.website.startsWith('http')?d.website:'https://'+d.website)+'" target="_blank" rel="noopener" class="pw2">&#x1F310; Website</a>';
  h+='</div></div><button class="px" onclick="closePopup()">&times;</button></div>';
  const mi=[];
  if(d.founded)mi.push(['Founded',''+d.founded]);
  if(d.ceo)mi.push(['CEO',d.ceo]);
  if(d.employees)mi.push(['Employees',d.employees.toLocaleString()]);
  if(d.evFmt)mi.push(['Enterprise Value',d.evFmt]);
  if(d.ticker)mi.push(['Ticker',d.ticker+(d.exchange?' ('+d.exchange+')':'')]);
  if(d.totalRaisedFmt)mi.push(['Total Raised',d.totalRaisedFmt]);
  if(mi.length>0){h+='<div class="pse"><div class="pst">Company Details</div><div class="meta-grid">';mi.forEach(m=>{h+='<div class="meta-item"><div class="meta-label">'+m[0]+'</div><div class="meta-val">'+esc(m[1])+'</div></div>'});h+='</div></div>'}
  h+='<div class="pse"><div class="pst">Focus Areas &amp; Modalities</div><div class="tr" style="margin-bottom:8px">';
  d.diseaseCats.forEach(c=>{h+='<span class="tag tt">'+esc(c)+'</span>'});
  h+='</div><div class="tr" style="margin-bottom:8px">';d.diseaseGroups.forEach(g=>{h+='<span class="tag td2">'+esc(g)+'</span>'});
  h+='</div><div class="tr">';d.modalityGroups.forEach(m=>{h+='<span class="tag tm">'+esc(m)+'</span>'});h+='</div></div>';
  if(d.pipeline&&d.pipeline.length>0){
    h+='<div class="pse"><div class="pst">Pipeline ('+d.nProducts+' assets)</div>';
    d.pipeline.forEach(p=>{h+='<div class="pi"><span class="pn" title="'+esc(p.name)+'">'+esc(p.name)+'</span><span class="pind">'+esc(p.indication)+'</span><span class="pb '+pc(p.phase)+'">'+esc(p.phase)+'</span></div>'});h+='</div>';
  }
  if(d.recentDeals&&d.recentDeals.length>0){
    h+='<div class="pse"><div class="pst">Recent Deals ('+d.nDeals+' total'+(d.totalDealFmt?' \u00b7 '+d.totalDealFmt:'')+')</div>';
    d.recentDeals.forEach(dl=>{h+='<div class="di"><div class="dhl">'+esc(dl.headline)+'</div><div class="dm">'+dl.date+(dl.value?' \u00b7 '+dl.value:'')+'</div></div>'});h+='</div>';
  }
  if(d.recentFinancing&&d.recentFinancing.length>0){
    h+='<div class="pse"><div class="pst">Recent Financing'+(d.totalRaisedFmt?' \u00b7 '+d.totalRaisedFmt+' total':'')+'</div>';
    d.recentFinancing.forEach(f=>{h+='<div class="fi"><div><span class="fa">'+f.amount+'</span></div><div><div class="fd">'+esc(f.type)+' \u00b7 '+f.date+'</div>'+(f.investors?'<div class="fv">'+esc(f.investors)+'</div>':'')+'</div></div>'});h+='</div>';
  }
  document.getElementById('popup').innerHTML=h;document.getElementById('popupOverlay').classList.add('a');document.body.style.overflow='hidden';
}
function closePopup(){document.getElementById('popupOverlay').classList.remove('a');document.body.style.overflow=''}
document.getElementById('popupOverlay').addEventListener('click',function(e){if(e.target===this)closePopup()});
function pos(evt){const b=document.getElementById('miniBubble');let x=evt.clientX+12,y=evt.clientY+12;if(x+420>window.innerWidth)x=evt.clientX-432;if(y+300>window.innerHeight)y=window.innerHeight-320;if(x<8)x=8;if(y<8)y=8;b.style.left=x+'px';b.style.top=y+'px'}
function showDB(evt,idx){evt.preventDefault();const d=window._s[idx];if(!d)return;let h='<div class="mbh"><div><div class="mbt">Deal Details</div><div class="mbc">'+esc(d.company)+(d.totalDealFmt?' \u00b7 '+d.totalDealFmt:'')+'</div></div><button class="mbx" onclick="closeBubble()">&times;</button></div><div class="mbb">';if(d.recentDeals&&d.recentDeals.length>0)d.recentDeals.forEach(dl=>{h+='<div class="di"><div class="dhl">'+esc(dl.headline)+'</div><div class="dm">'+dl.date+(dl.value?' \u00b7 '+dl.value:'')+'</div></div>'});else h+='<div class="mbe">No deal data</div>';h+='</div>';const b=document.getElementById('miniBubble');b.innerHTML=h;pos(evt);b.classList.add('a');document.getElementById('miniScrim').classList.add('a')}
function showFB(evt,idx){evt.preventDefault();const d=window._s[idx];if(!d)return;let h='<div class="mbh"><div><div class="mbt">Financing Details</div><div class="mbc">'+esc(d.company)+(d.totalRaisedFmt?' \u00b7 '+d.totalRaisedFmt:'')+'</div></div><button class="mbx" onclick="closeBubble()">&times;</button></div><div class="mbb">';if(d.recentFinancing&&d.recentFinancing.length>0)d.recentFinancing.forEach(f=>{h+='<div class="fi"><div><span class="fa">'+f.amount+'</span></div><div><div class="fd">'+esc(f.type)+' \u00b7 '+f.date+'</div>'+(f.investors?'<div class="fv">'+esc(f.investors)+'</div>':'')+'</div></div>'});else h+='<div class="mbe">No financing data</div>';h+='</div>';const b=document.getElementById('miniBubble');b.innerHTML=h;pos(evt);b.classList.add('a');document.getElementById('miniScrim').classList.add('a')}
function closeBubble(){document.getElementById('miniBubble').classList.remove('a');document.getElementById('miniScrim').classList.remove('a')}
document.getElementById('miniScrim').addEventListener('click',closeBubble);
document.addEventListener('keydown',function(e){if(e.key==='Escape'){closeBubble();closePopup()}});
document.querySelectorAll('thead th').forEach(th=>{th.addEventListener('click',()=>{const col=th.dataset.col;if(!col)return;if(sortCol===col)sortDir=sortDir==='asc'?'desc':'asc';else{sortCol=col;sortDir=th.dataset.dir||'desc'}document.querySelectorAll('thead th .sa').forEach(s=>s.textContent='');th.querySelector('.sa').textContent=sortDir==='asc'?'\u25B2':'\u25BC';currentPage=1;render()})});
document.getElementById('search').addEventListener('input',()=>{currentPage=1;render()});
document.getElementById('fPhase').addEventListener('change',()=>{currentPage=1;render()});
document.getElementById('fMoney').addEventListener('change',()=>{currentPage=1;render()});
render();
</script>
</body>
</html>